Date;Close;AMGN_Summary;Close;GILD_Summary;Close;REGN_Summary;Close;BNTX_Summary;Close;ILMN_Summary;Close;VRTX_Summary;Close;BIIB_Summary;Close;BGNE_Summary;Close;SGEN_Summary;Close;ALNY_Summary;Close;TECH_Summary;Close;DNA_Summary;Close;BMRN_Summary;Close;TXG_Summary;Close;INCY_Summary;Close;EXAS_Summary;Close;NVAX_Summary;Close;NTLA_Summary;Close;NBIX_Summary;Close;SRPT_Summary;Close;MRTX_Summary;Close;ARWR_Summary;Close;BPMC_Summary;Close;CRSP_Summary;Close;ZLAB_Summary;Close;FATE_Summary;Close;EXEL_Summary;Close;BBIO_Summary;Close;BEAM_Summary;Close;DNLI_Summary;Close;RARE_Summary;Close;HALO_Summary;Close;ARNA_Summary;Close;VIR_Summary;Close;ABCM_Summary;Close;KOD_Summary;Close;PACB_Summary;Close;IONS_Summary;Close;ARVN_Summary;Close;ITCI_Summary;Close;ABCL_Summary;Close;TWST_Summary;Close;ACAD_Summary;Close;ALKS_Summary
2022-01-03;226.69000244140625;;72.58000183105469;;627.0999755859375;;231.85000610351562;;380.8699951171875;;222.52999877929688;;244.13999938964844;;269.55999755859375;;157.85000610351562;;173.91000366210938;CAMBRIDGE, Mass., January 03, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually, on Monday, January 10, 2022 at 9:45 am ET. This presentation will include an update on unaudited fourth quarter and full year 2021 global net product revenues. In addition, the Company will webcast the Q&A breakout session immediately foll;487.7900085449219;Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 4:30 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;8.6899995803833;;89.36000061035156;;145.7899932861328;;73.97000122070312;;81.5199966430664;Exact Sciences Corp. (NASDAQ: EXAS) today announced that company management will participate in the following virtual conference and invited investors to participate by webcast.;142.89999389648438;;118.98999786376953;Gene editing has attracted a lot of attention in recent years. That's because of the incredible potential if companies can make the technology work in various disease areas. The idea is to cut a genome in a particular location, and add, change, or remove a gene responsible for disease.;88.47000122070312;;90.41999816894531;;150.97000122070312;;69.97000122070312;;110.08000183105469;;79.23999786376953;Gene editing has attracted a lot of attention in recent years. That's because of the incredible potential if companies can make the technology work in various disease areas. The idea is to cut a genome in a particular location, and add, change, or remove a gene responsible for disease.;64.4000015258789;;60.279998779296875;;19.18000030517578;;17.15999984741211;BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.;82.16000366210938;CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 2:15 p.m. ET. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the present;47.27000045776367;;84.4000015258789;;41.060001373291016;;93.19000244140625;Investors need to pay close attention to Arena (ARNA) stock based on the movements in the options market lately.;39.400001525878906;;23.889999389648438;;89.44999694824219;;20.899999618530273;;32.599998474121094;;81.56999969482422;;52.02000045776367;"NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 am ET. The live and archived webcast can be accessed under ""Events & Presentati";14.140000343322754;;83.2699966430664;;24.389999389648438;;24.149999618530273;
2022-01-04;227.83999633789062;;72.20999908447266;;616.8200073242188;;224.08999633789062;;372.3599853515625;;221.86000061035156;;241.72999572753906;;246.22000122070312;;152.6699981689453;;165.22999572753906;CAMBRIDGE, Mass., January 04, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President. Dr. Vaishnaw joined Alnylam in 2006 as Vice President, Clinical Research with roles of increasing responsibility, ultimately serving as President of Research and Development (R&D). In this new role, Dr. Vaishnaw will serve as the key scientific leader of Alnylam and will advance the Company’s R&D s;468.0199890136719;;7.980000019073486;;87.22000122070312;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at two virtual conferences in January. To access the live webcasts, please visit: https://investors.biomarin.com/. An archived version of the presentations will also be available through the Company's website for a limited time following the conference.;141.30999755859375;;71.80999755859375;;80.01000213623047;;138.4499969482422;;113.54000091552734;;86.69000244140625;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual 40th Annual J.P. Morgan Healthcare Conference at 11:15 a.m. Eastern Time on Monday Jan. 10, 2022. Kevin Gorman, Chief Executive Officer, will present at the conference.;89.16000366210938;;141.7899932861328;;65.04000091552734;;107.0;;73.25;;59.599998474121094;;55.939998626708984;;18.75;ALAMEDA, Calif., January 04, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced the appointment of Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Goodman has more than 20 years of oncology experience as a drug development leader at global biopharmaceutical organizations, regulator and clinician. She joins Exelixis from Merck, where she served as Vice President, Clinical Research and Therapeutic Area Head, Late Stage Onc“Buy low, sell high” is the mantra for success in the investing world. Consequently, investors are always looking for opportunities to scoop up cheap stocks that could offer incredible value over the long run. As Warren Buffet said, “It’s far better to buy a wonderful company at a fair price than a fair company at a wonderful price.” We have seen many beaten-down stocks without much promise get a bump in share price. Additionally, some promising stocks haven’t been able to win over the stock mar;16.290000915527344;;78.30999755859375;;45.68000030517578;;83.19000244140625;NOVATO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the 40th Annual JP Morgan Healthcare Conference on Monday, January 10, 2022 at 3:45 PM ET. The live and archived webcast of the presentati;40.04999923706055;Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at the 40th Annual J.P. Morgan Health Care Conference on Monday, January 10, 2022 at 7:30 a.m. PT/ 10:30 a.m. ET. The virtual conference will be held from January 10-13, 2022.;93.20999908447266;;37.11000061035156;;21.75;Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of the human proteome.;85.55999755859375;Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 11:15 a.m. Pacific Time (2:15 p.m. Eastern Time).;18.979999542236328;;31.360000610351562;BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervalsBiogen paid Ionis a $60 million one-time upfront payment CAMBRIDGE, Mass. and CARLSBAD, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306. The;78.91000366210938;;44.68000030517578;NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shar;13.270000457763672;;77.1500015258789;SOUTH SAN FRANCISCO, Calif., January 04, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10 at 4:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time.;23.6200008392334;;23.139999389648438;
2022-01-05;225.13999938964844;;72.18000030517578;;595.1199951171875;;211.42999267578125;;367.8800048828125;;221.4199981689453;;239.27000427246094;;221.5800018310547;;145.64999389648438;;155.08999633789062;;434.7300109863281;Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced a partnership to develop the first single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples.Akoya’s powerful new PhenoCycler™-Fusion system combined with Bio-Techne’s proven and established RNAScope® technology will enable comprehensive spatial phenotyping of RNA and protein biomarkersMARLBOROUGH, Mass. and MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, and Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities,Investment company Lvm Capital Management Ltd (Current Portfolio) buys Medtronic PLC, Zoetis Inc, Eaton Corp PLC, Norfolk Southern Corp, Qualcomm Inc, sells AT&T Inc, Activision Blizzard Inc, SPDR Gold Shares ETF, Conagra Brands Inc, Twilio Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Lvm Capital Management Ltd.;6.989999771118164;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that Co-Founder and CEO Jason Kelly is scheduled to participate in a presentation at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022 at 3:45 p.m. Eastern Time.;84.33000183105469;"Emil Kakkis' book documenting the development of the rare disease drug Aldurazyme went on sale Jan. 1. It was published by the media company he set up with his brother to tell ""impossible, positive"" stories.";131.3000030517578;;70.44999694824219;;75.05000305175781;;122.41000366210938;;103.3499984741211;"— Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune diseases — — Kyverna to lead and fund preclinical and clinical development; Intellia to receive option to co-develop and co-promote with lead U.S. commercialization rights — CAMBRIDGE, Mass. and EMERYVILLE, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clA key clinical trial, an enormous market opportunity, and breakthrough biotechnology could drive returns for shareholders this year.";83.25;;84.08999633789062;;137.63999938964844;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will present at the J.P. Morgan 40th Annual Virtual Healthcare Conference, on Monday, January 10, 2022. David Meek, chief executive officer, will make a formal presentation and answer questions about the Company at 2:15 p.m. P.T. / 5:15 p.m. E.T.;60.18000030517578;;93.30000305175781;Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that its Board of Directors has appointed Kate Haviland to succeed Jeff Albers as Chief Executive Officer (CEO), effective April 4, 2022. At that time, Mr. Albers will transition from his current role as Chairman, President and CEO to Executive Chairman of the Board of Directors and Ms. Haviland will transition from her current role as Chief Operating Officer (COO) to President and CEO. In addition, Ms. Haviland will be appointed to;69.01000213623047;;54.150001525878906;;51.86000061035156;;18.030000686645508;ALAMEDA, Calif., January 05, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is complete for CONTACT-03, the global, phase 3 pivotal trial evaluating the efficacy and safety of cabozantinib (CABOMETYX®) in combination with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic clear cell or non-clear cell (papillary or unclassified only) renal cell carcinoma (RCC) who progressed during or following treatment with an immune checkpoint inhibitorALAMEDA, Calif., January 04, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 5:15pm ET / 2:15pm PT.;14.930000305175781;;71.56999969482422;;44.54999923706055;;83.55999755859375;"SARASOTA, Fla. and NOVATO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman syndrome, today announced that the first four patients in the Phase 1/2 study have received multiple doses of GTX-102 and regular assessments for safety. To date three have also received a preliminary assessment of clinical response. There have been no treatmeEmil Kakkis' book documenting the development of the rare disease drug Aldurazyme went on sale Jan. 1. It was published by the media company he set up with his brother to tell ""impossible, positive"" stories.";38.25;;92.97000122070312;;33.86000061035156;SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 1:30 p.m. ET. The conference will be held virtually. A live webcast of the call can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About Vir BiotechnologyVir;21.5;;77.9000015258789;;17.0;The study will evaluate the impact of high-resolution genomes generated on PacBio technology in studying unsolved rare disease casesMENLO PARK, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- PacBio, a leading provider of high-quality, long-read sequencing platforms, and the Care4Rare Canada Consortium (Care4Rare) announce today they are collaborating to study some of the most complex unexplained rare disease cases within Canada. Care4Rare, led out of the CHEO Research Institute affiliated with the UnMENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that its executives will be speaking virtually at the following investor conference: 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 pm Eastern Time (9:00 am Pacific Time) The live webcast can be accessed at the company’s investors page at https://investor.pacificbiosciences.com . A replay of the webcast will be available for at least 30 days following the presentation. About PacBio Pacific B;30.450000762939453;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the virtual 40th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. ET on Wednesday, January 12, 2022.;71.04000091552734;;45.33000183105469;NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds toIntra-Cellular Therapies' (NASDAQ: ITCI) stock could have used a little financial therapy on Tuesday.  The neurologic drugs-focused biotech saw its shares decline by over 14% on the day, following news that it is entering a new round of capital-raising.  After market hours on Monday, Intra-Cellular announced that it is floating a $400 million issue of its common stock.;12.260000228881836;;71.80000305175781;BETHESDA, Md. & SOUTH SAN FRANCISCO, Calif., January 05, 2022--Revelar Biotherapeutics, Inc. and Twist Bioscience Corporation (Nasdaq: TWST) today announced that RBT-0813 binds to and neutralizes the Omicron and Delta variants of SARS-CoV-2 in live virus studies. RBT-0813 is an innovative bispecific antibody discovered by Twist Biopharma and licensed to Revelar Biotherapeutics that targets epitopes on the SARS-CoV-2 spike protein. Revelar continues to advance preclinical development of RBT-0813;23.110000610351562;;23.299999237060547;
2022-01-06;225.1699981689453;;71.58999633789062;;598.4400024414062;;214.74000549316406;;378.92999267578125;;221.64999389648438;;237.3000030517578;;225.33999633789062;"CAMBRIDGE, Mass. & BEIJING, January 06, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the J.P. Morgan 40th Annual Healthcare Conference on Tuesday, January 11, 2022 at 5:15 p.m. ET.CAMBRIDGE, Mass. & BEIJING, January 06, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has approved BeiGene’s anti-PD-1 antibody tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell";144.82000732421875;;151.0;CAMBRIDGE, Mass., January 06, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a collaboration with Novartis to leverage Alnylam’s proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.;426.5400085449219;;6.900000095367432;Optimvia, a biotechnology company specializing in engineering enzymes and their cofactors to synthesize complex therapeutic molecules, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to improve the manufacturing efficiency of biosynthetic heparin, an essential medicine currently produced from industrial animal agriculture. Under the partnership, Optimvia seeks to leverage Ginkgo's cell and enzyme engineering platform, as well a;85.19000244140625;;130.77000427246094;;72.62999725341797;;74.5999984741211;;121.5;;104.56999969482422;"With every new year comes a clean slate. For Cathie Wood’s Ark Invest, that doesn’t seem to be the case. The firm’s beaten-down Ark Innovation Fund fund has hit a new low in 2022 – already.Advance clinical development of NTLA-2001, a potential single-dose therapy for transthyretin (ATTR) amyloidosis; on track to present additional data from Phase 1 study in Q1 2022Achieve preliminary proof-of-concept for NTLA-2002 in patients with hereditary angioedema (HAE) based on ongoing first-in-human study; anticipate presenting interim data in 2H 2022Establish initial safety and activity profile of NTLA-5001 for acute myeloid leukemia (AML) in Phase 1/2a study Progress in vivo and ex vivo rCAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET. A live audio webcast of Intellia’s presentation can be accessed under the Events and Presentations page of";82.52999877929688;;86.9000015258789;Presentation on Monday, Jan. 10, 2022, to include topline results from Part 2 of Study SRP-9001-102 CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2022 at 10:30 a.m. E.T. / 7:30 a.m. P.T. Following the presentation there will be a Q&A session starting at 10:;137.0500030517578;;60.900001525878906;;93.23999786376953;;67.18000030517578;;54.040000915527344;"SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for margetuximab, an investigational, Fc-engineered monoclonal antibody that targets HER2. The margetuximab NDA is for the treatment of adult patients with metastatic";49.380001068115234;;18.290000915527344;Investment company Tarbox Family Office, Inc. (Current Portfolio) buys iShares Core Total USD Bond Market ETF, iShares Core MSCI Total International Stock ETF, BTC iShares International Aggregate Bond Fund, IGM Biosciences Inc, Fisker Inc, sells Alphabet Inc, AT&T Inc, Meta Platforms Inc, Trex Co Inc, JPMorgan Chase during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Tarbox Family Office, Inc..ALAMEDA, Calif. & SOUTH SAN FRANCISCO, Calif., January 06, 2022--Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics, Inc. (Iconic) today announced that the companies have amended the terms of their May 2019 exclusive option and license agreement for XB002 (formerly ICON-2), a next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC). Under the amended agreement announced today, Exelixis has acquired broad rights to use the anti-TF antibody incorporated into XB002, for any app;14.920000076293945;"Every investor knows that the path toward profits lies in buying low and selling high. That’s a basic precept of any economic trading system. The trick, however, is recognizing when the stock is low enough to buy in. The prime moment to buy is when the stock hits bottom; that will maximize returns when the share price starts to rise again. There are a multitude of possible clues investors can use to find the price bottom; today, we’ll be looking at insider buying trends. Insiders – the corporate";70.91000366210938;;43.959999084472656;;79.38999938964844;;38.59000015258789;;93.0;;33.86000061035156;;21.110000610351562;;76.7300033569336;;17.170000076293945;PacBio’s Sequel IIe devices will support genomic researchers around the worldMENLO PARK, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB) today announced an expansion of its extensive suite of HiFi applications with Azenta Life Sciences, formerly GENEWIZ. The deal will increase PacBio’s HiFi sequencing platforms across Azenta’s newly combined company and support Azenta’s mission to enable life science companies to deliver impactful breakthroughs and therapies to market faster. Pac;30.940000534057617;While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings.Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.;71.27999877929688;;45.36000061035156;;12.09000015258789;;72.63999938964844;SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass., January 06, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced today an agreement with the Broad Institute to make available a whole exome target enrichment panel to enable next-generation sequencing (NGS) in canine genomics research. The panel, known as the Twist Alliance Canine Exome Panel, is available for order today;23.389999389648438;;24.190000534057617;Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 40th Annual J.P. Morgan Healthcare Conference. The presentation will take place virtually on Wednesday, Jan. 12, 2022 at 11:15 a.m. EST (4:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
2022-01-07;227.2899932861328;;71.26000213623047;;603.72998046875;;211.83999633789062;;370.3599853515625;;221.85000610351562;;232.60000610351562;;229.52000427246094;;143.72000122070312;;148.1300048828125;Here's why you'll want to keep both eyes open for upcoming announcements from Alnylam Pharmaceuticals (NASDAQ: ALNY), Intercept Pharmaceuticals (NASDAQ: ICPT), and Karuna Therapeutics (NASDAQ: KRTX).  Shares of Alnylam recently slipped around 15% overnight in response to a surprising clinical-trial flop for a drug it isn't even developing.  Recently, BridgeBio Pharma told investors that people with heart damage caused by transthyretin amyloidosis (ATTR) who received acoramidis failed to outperform the placebo group on the six-minute walking test.;415.2799987792969;;6.820000171661377;The BBJ's list of the largest commercial property managers is out. If you're thinking about life sciences properties, you might have to look beyond Boston or Cambridge, where vacancy is near zero.;84.25;;127.79000091552734;Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can...;73.19000244140625;Fort Collins, CO, based Investment company Tributary Capital Management, LLC (Current Portfolio) buys LHC Group Inc, Cambium Networks Corp, Avanos Medical Inc, Integer Holdings Corp, Natus Medical Inc, sells Medpace Holdings Inc, Omnicell Inc, Boot Barn Holdings Inc, Onto Innovation Inc, AMN Healthcare Services Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Tributary Capital Management, LLC.;75.66000366210938;Investment company Canton Hathaway, LLC (Current Portfolio) buys Amplify Lithium & Battery Technology ETF, Raytheon Technologies Corp, Salesforce.com Inc, ETFMG Prime Cyber Security ETF, Snowflake Inc, sells Amgen Inc, Palantir Technologies Inc, iShares MSCI Emerging Markets ETF, Bristol-Myers Squibb Co, The Kraft Heinz Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Canton Hathaway, LLC.;126.69999694824219;;105.73999786376953;Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.;75.31999969482422;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product sales results of INGREZZA® (valbenazine) for 2021, and key clinical development milestones for 2022 and 2023. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will discuss these updates as part of a webcast presentation at the 40th Annual J.P. Morgan Healthcare Conference to be held virtually on Monday, January 10 at 11:15 a.m. Eastern Time, followed;85.5;;132.61000061035156;;58.95000076293945;;91.44999694824219;Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on January 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 9,725 shares of its common stock and an aggregate of 4,862 restricted stock units (RSUs) to seven new employees under Blueprint Medicines' 2020 Inducement Pla;67.66000366210938;;55.08000183105469;;48.310001373291016;;18.739999771118164;;14.649999618530273;Here's why you'll want to keep both eyes open for upcoming announcements from Alnylam Pharmaceuticals (NASDAQ: ALNY), Intercept Pharmaceuticals (NASDAQ: ICPT), and Karuna Therapeutics (NASDAQ: KRTX).  Shares of Alnylam recently slipped around 15% overnight in response to a surprising clinical-trial flop for a drug it isn't even developing.  Recently, BridgeBio Pharma told investors that people with heart damage caused by transthyretin amyloidosis (ATTR) who received acoramidis failed to outperform the placebo group on the six-minute walking test.;70.36000061035156;;41.560001373291016;;73.79000091552734;;37.290000915527344;;93.18000030517578;;33.630001068115234;GlaxoSmithKline PLC announced Thursday an agreement to supply the Government of Canada with 20,000 doses of Sotrovimab, the COVID-19 monoclonal antibody therapy the company developed with Vir Biotechnology Inc. . The agreement follows Canada's initial order of 10,000 doses of Sotrovimab announced in October, which included options for additional purchases. Sotrovimab was authorized for injection by Health Canada in July 2021 to treat mild to moderate COVID-19 in adults and adolescents 12 years o;20.959999084472656;;72.20999908447266;;16.760000228881836;Added whole genome sequencing capacity enables the SOLVE-RD research program to significantly increase sample throughputMENLO PARK, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced Radboud University Medical Center (Radboudumc) in Nijmegen, the Netherlands will increase their SMRT sequencing capacity with the addition of two new PacBio Sequel IIe Systems. Radboudumc has been using PacBio loPacBio's (PACB) recent partnership with Care4Rare, with regard to a study, has the potential to enhance rare disease diagnosis within Canada.;30.3799991607666;;68.95999908447266;Investment company Canton Hathaway, LLC (Current Portfolio) buys Amplify Lithium & Battery Technology ETF, Raytheon Technologies Corp, Salesforce.com Inc, ETFMG Prime Cyber Security ETF, Snowflake Inc, sells Amgen Inc, Palantir Technologies Inc, iShares MSCI Emerging Markets ETF, Bristol-Myers Squibb Co, The Kraft Heinz Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Canton Hathaway, LLC.;43.029998779296875;;11.819999694824219;;66.73999786376953;There's something especially alluring about the potential to achieve a 10x return. Mutual-fund manager Peter Lynch called such investments 10-baggers. He found quite a few of them during his time leading Fidelity Investments' Magellan Fund.;22.59000015258789;;24.010000228881836;
2022-01-10;230.3699951171875;;72.08999633789062;;621.27001953125;;230.0;;362.2799987792969;;223.9600067138672;;235.30999755859375;;239.16000366210938;;145.0800018310547;;150.16000366210938;(Bloomberg) -- Yvonne Greenstreet was sitting on a plane at Boston Logan International Airport waiting to take off in 2018 when U.S. regulators approved Alnylam Pharmaceuticals Inc.’s first drug, Onpattro. The chief operating officer grabbed her carry-on from the overhead bin, ran off the plane and bolted to the office so she could celebrate the accomplishment with her colleagues. Most Read from BloombergCypriot Scientist Says Deltacron Covid Variant Isn’t ErrorWorld’s Biggest Crypto Fortune BegCAMBRIDGE, Mass., January 09, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2021 global net product revenues for ONPATTRO, GIVLAARI and OXLUMO and provided additional updates on the products’ commercial launches.;427.7699890136719;;6.710000038146973;BOULDER, Colo., January 10, 2022--Inscripta said Ginkgo Bioworks has adopted the Onyx genome engineering platform as part of its commitment to cutting-edge tech in its foundries.Leveraging Ginkgo’s high throughput screening and cell engineering capabilities and Selecta’s ImmTOR platform to advance gene therapy delivery with the goal of improved transduction, enhanced tissue tropism and reduced immunogenicityWATERTOWN, Mass. and BOSTON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses,;84.38999938964844;The lack of major biotech acquisitions could be a disappointment to investors, who had been hoping for a busy 2022 for mergers.Shares of BioMarin Pharmaceutical Inc. gained 5.6% in premarket trading on Monday, the day after the company announced promising data from a Phase 3 clinical study of its investigational gene therapy for adults with severe hemophilia A. Biomarin said the treatment reduced the annualized bleeding rate among the 134 participants in the study. Biomarin said it plans to use the data from this trial as part of its submission to the Food and Drug Administration, with a goal of resubmitting valoctocogeBioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A. Annualized Bleeding Rate (ABR) was significantly reduced by 4.1 treated bleeds per year in the pre-specified primary analysis in participants from a prior non-interventional study. Valoctocogene roxaparvovec also significantly reduced the mean annualized Factor VIII infusion rate in the rollover population by 133BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in hemophilia, with 134 participants.;127.72000122070312;;74.66000366210938;;74.41999816894531;Exact Sciences Corp. (NASDAQ: EXAS) and OncXerna Therapeutics, Inc., a precision medicine company, announced today they have entered an exclusive license agreement to bring OncXerna's Xerna TME Panel lab services to more U.S. patients. The Xerna TME (tumor microenvironment) Panel is an innovative gene expression score that helps identify patients likely to respond to anti-angiogenic and immunotherapies. The agreement allows Exact Sciences to provide more critical answers to cancer patients and pExact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $472 million and $475 million for the fourth quarter ended Dec. 31, 2021.Exact Sciences Corp. (NASDAQ: EXAS) announced today it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases.;134.99000549316406;;104.2300033569336;;76.44000244140625;;76.1500015258789;Participants from the placebo crossover group in Part 2 of Study SRP-9001-102 , scored 2.0 points higher on the mean North Star Ambulatory Assessment (NSAA) 48 weeks after treatment with SRP-9001 compared to pre-specified matched external control cohort ( p value=0.0009)Results continue to reinforce the tolerability profile of SRP-9001 with no new safety signals identified CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision geneti;124.55000305175781;Amgen's (AMGN) Lumykras is the first targeted therapy approved for patients with KRAS G12C mutation in Europe.;59.529998779296875;;87.22000122070312;Blueprint Medicines Corporation (NASDAQ: BPMC) today outlined upcoming portfolio milestones that are anticipated to extend its position as a leading precision therapy company.;69.08999633789062;The two companies will develop three treatments for genetic disease by correcting errors in our genes, using base-editing technology.;58.560001373291016;;49.310001373291016;Multiplexed-engineered CAR NK Cell Product Candidate derived from Clonal Master iPSC Line that incorporates Four Functional Elements, including a Novel CAR Targeting the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Antigen Binding Domain of FT536 has been Shown to Overcome MICA/B Shedding, a Common Mechanism of Tumor Cell Escape Broadly Observed Across Solid Tumors Six-arm Phase 1 Clinical Study to Evaluate Multi-dose, Multi-cycle Treatment Schedule of FT536 as Monotherapy and;18.270000457763672;ALAMEDA, Calif., January 09, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2021, provided financial guidance for full year 2022, and delivered an update on its business. Exelixis expects 2022 to be a year of financial, pipeline and corporate growth as it rapidly builds out its portfolio of promising small molecules and biologics, maximizes near-term opportunities for CABOMETYX through four ongoing phase 3 pivo;14.210000038146973;;68.45999908447266;"The two companies will develop three treatments for genetic disease by correcting errors in our genes, using base-editing technology.Shares of Pfizer Inc. gained 0.2% in premarket trading on Monday after the company announced a deal with Beam Therapeutics Inc. worth up to $1.3 billion. Beam's stock was up 4.9% before the market opened. As part of the four-year agreement, the companies will use Beam's vivo base editing technology to develop drugs that treat rare genetic diseases of the liver, muscle, and central nervous system. Pfizer will pay Beam $300 million upfront; including milestone payments, the deal could be worth upPfizer Inc Chief Executive Albert Bourla on Monday said a redesigned COVID-19 vaccine that specifically targets the Omicron coronavirus variant is likely needed and his company could have one ready to launch by March.  Bourla said Pfizer and partner BioNTech SE are working on both an Omicron-targeted vaccine version as well as a shot that would include both the previous vaccine as well as one targeted at the fast-spreading variant.  ""I think it is the most likely scenario,"" Bourla said, speaking at J.P. Morgan's annual healthcare conference, which is being held virtually this year.Bourla said Pfizer and partner BioNTech SE are working on both an Omicron-targeted vaccine version as well as a shot that would include both the previous vaccine as well as one targeted at the fast-spreading variant.  ""I think it is the most likely scenario,"" Bourla said, speaking at J.P. Morgan's annual healthcare conference, which is being held virtually this year.  Bourla said Pfizer could be ready to file for U.S. regulatory approval for a redesigned vaccine and launch it as soon as March.The Cambridge-based gene-editing firm has signed a four-year deal worth up to $1.35 billion with pharmaceutical giant Pfizer Inc.Boston-based Beam Therapeutics has agreed to a potential $1.35 billion drug development deal with pharma giant Pfizer.Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologiesBeam will receive an upfront payment of $300 million, be eligible to receive future milestone payments of up to $1.05 billion for a potential total consideration of up to $1.35 billion Beam may opt into a global co-development and co-coDrugmaker Pfizer will collaborate with gene-editing specialist Beam Therapeutics in a deal worth as much as $1.35 billion to develop therapies for rare genetic diseases.  Beam will receive $300 million in upfront payment and lead research activities till three new therapy targets are selected for development from outside the firm's existing programs, the companies said on Monday.  Pfizer will then be responsible for development and regulatory activities for the targets, with the option to opt in on exclusive, worldwide licenses for each.Biotech stocks haven't been at their best of late.  Investors have been backing away from biotech stocks over the past year for many reasons, including inflationary pressures, the risk of rising interest rates, the threat of fundamental drug pricing reform in the U.S., and the appeal of other high-growth asset classes like cryptocurrency.  Savvy investors, in turn, would be wise to take advantage of this broad selloff in biotech.";40.40999984741211;"Key data readouts to include additional Phase 1/2 data on DNL310 (ETV:IDS) in MPS II (Hunter syndrome) and the first clinical data on DNL919 (ATV:TREM2), both potentially further validating Denali’s Transport Vehicle (TV) platform; in addition, first Phase 1b data in ALS on DNL343, Denali’s small molecule eIF2B activatorCommencing late-stage clinical trials designed to potentially support registration for DNL310 (ETV:IDS) in MPS II and LRRK2 inhibitor BIIB122 (DNL151) in Parkinson’s disease RIPK";73.0999984741211;Regeneron (REGN) teams up with Ultragenyx Pharmaceutical to commercialize and distribute Evkeeza (evinacumab) outside the United States.Preliminary 2021 Crysvita revenue in Ultragenyx territories of $191 million to $193 million and Dojolvi revenue of $38 million to $40 million 2022 Crysvita revenue in Ultragenyx territories expected in the range of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million Year-end 2021 cash balance of approximately $1.0 billion NOVATO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the developme;35.9900016784668;Halozyme Therapeutics, Inc. (NASDAQ: HALO) today introduced 2022 financial guidance and commented on its outlook for the upcoming year.;94.08000183105469;These are the marijuana stocks on the Nasdaq with the best value, fastest growth, and most momentum for January 2022.;33.41999816894531;;20.34000015258789;;69.41999816894531;;16.579999923706055;PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.;30.510000228881836;;69.7699966430664;;41.0;;11.880000114440918;;66.4800033569336;SOUTH SAN FRANCISCO, Calif., January 10, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has developed an innovative, low cost, scarless and scalable enzymatic DNA synthesis process. With these comprehensive capabilities in synthesis, Twist offers multiple approaches to serve the growing number of markets leveraging synthetic DNA. Emily M. Leproust, Ph;22.709999084472656;SAN DIEGO & BEDFORD, Mass., January 10, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Stoke Therapeutics, Inc. (Nasdaq: STOK) announced today that the companies have entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS). The collaboration includes SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mu;24.25;Regeneron (REGN) teams up with Ultragenyx Pharmaceutical to commercialize and distribute Evkeeza (evinacumab) outside the United States.Amgen's (AMGN) Lumykras is the first targeted therapy approved for patients with KRAS G12C mutation in Europe.
2022-01-11;232.3800048828125;;72.37000274658203;;626.0900268554688;;215.8000030517578;;423.79998779296875;By Peter NurseIRVINE, Calif. & AMSTERDAM, January 10, 2022--Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced a multi-year partnership with Illumina, Inc. (NASDAQ: ILMN), to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina’s approach to IVD partnerships in oncology. Agendia joins Illumina’s growinIllumina Inc on Monday forecast 2022 revenue above Wall Street estimates, counting on strong demand for its genetic sequencing products, and said it had signed collaboration agreements with four healthcare companies.  It also posted a preliminary revenue estimate of about $4.52 billion for 2021 and announced a series of deals.  It also signed a deal with drugmaker Boehringer Ingelheim to identify which patients are best suited to its new medicines, and a collaboration agreement with UnitedHealth Group Inc's health services unit, Optum.;226.14999389648438;;241.52000427246094;;241.63999938964844;;144.3699951171875;;148.02999877929688;;432.30999755859375;;6.829999923706055;;88.98999786376953;;121.93000030517578;;74.44000244140625;;79.37999725341797;;130.67999267578125;;105.23999786376953;;75.44999694824219;;76.33999633789062;Sarepta's (SRPT) DMD gene therapy candidate achieves statistically significant improvement in patients but the data fails to meet market expectations. Stock down.;127.27999877929688;;60.220001220703125;;85.86000061035156;;72.70999908447266;;58.7400016784668;ClearBridge Investments, an investment management firm, published its “International Growth EAFE Strategy” third quarter 2021 investor letter – a copy of which can be downloaded here. During the third quarter, the ClearBridge International Growth EAFE Strategy underperformed its MSCI EAFE Index benchmark. The Strategy delivered gains across two of the 10 sectors in which it […];47.540000915527344;;18.270000457763672;Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.The bloodbath continued for biotech stocks Monday despite massive deals for Pfizer and Bayer in gene-editing technology.Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.;14.300000190734863;;75.68000030517578;Pfizer (PFE) collaborates with Beam Therapeutics (BEAM) to advance the next generation of gene-editing therapies.Pfizer is entering the CRISPR space through a $1.35 billion deal with Beam, the companies said Monday. But Beam stock fell in response.;41.7400016784668;;72.76000213623047;;36.59000015258789;;93.25;;34.77000045776367;– 600,000 additional doses to be supplied to the US government for distribution in Q1 2022, enabling further access to sotrovimab nationwide – – Brings total number of doses secured to date through binding agreements to approximately 1.7 million globally – – Preclinical data generated through both pseudo-virus and live virus testing demonstrate sotrovimab retains activity against all tested SARS-CoV-2 variants of concern including Delta and Omicron – LONDON and SAN FRANCISCO, Jan. 11, 2022 (GLOB;20.0;;67.41000366210938;;14.699999809265137;Investors have been surprised by the way 2022 has started, with steep drops on most stock market indexes.  Wall Street tried to mount a comeback on Tuesday morning, though, in the hopes of getting back on a bullish path.  S&P 500 (SNPINDEX: ^GSPC) futures had picked up 15 points to 4,678, while Nasdaq Composite (NASDAQINDEX: ^IXIC) futures had risen 79 points to 15,687.New collaboration builds on existing relationship between the two companies to develop desktop systems for the clinical market in China Berry Genomics to purchase at least 50 instruments at product launch MENLO PARK, Calif. and BEIJING, Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, and Berry Genomics, a leading company in clinical genomics and life science in China, today announced a collaboration to provide PaPilot project designed to demonstrate the power of HiFi sequencing to effectively and efficiently identify novel variants following short-read genome sequencingMENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a collaboration with Genomics England to study PacBio’s technology for identifying genetic variants in unexplained rare disease cases. Genomics England was initially createdInitial proof-of-concept work suggests strong potential to further improve PacBio’s highly accurate HiFi Sequencing with Google deep learning technologiesMENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced a research collaboration with Google. Under the terms of the collaboration, PacBio will explore the use of Google’s genomic analysis, machine learning and algorithm development tMENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue of approximately $36.0 million for its fourth quarter ended December 31, 2021. The Company’s full financial results for the fourth quarter and the fiscal year ended December 31, 2021, are not yet available. Business Updates: Expect preliminary fourth quarter revenue of approximately $36.0 million, rep;31.350000381469727;;70.83000183105469;;40.380001068115234;New York, NY, based Investment company Penbrook Management LLC (Current Portfolio) buys Cohu Inc, Kulicke & Soffa Industries Inc, PubMatic Inc, Chevron Corp, Intra-Cellular Therapies Inc, sells Nuance Communications Inc, Aspen Group Inc, The One Group Hospitality Inc, Landmark Infrastructure Partners LP, Global Partners LP during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Penbrook Management LLC.;12.0600004196167;;67.11000061035156;;22.75;Bedford RNA firm Stoke Therapeutics Inc. has signed a collaboration agreement potentially worth nearly $1 billion with San Diego-based Acadia Pharmaceuticals Inc.;25.020000457763672;
2022-01-12;231.75999450683594;;72.25;;631.4400024414062;;220.8699951171875;;413.3699951171875;"Companies in The News Are: ACCD,PACB,BIG,ILMNIn this article, we discuss 10 biotech stocks to buy according to Chinese billionaire Lei Zhang. If you want to skip our detailed analysis of these stocks, go directly to 5 Biotech Stocks To Buy According To Chinese Billionaire Lei Zhang. Hillhouse Capital Management was founded by Chinese billionaire investor and hedge fund manager Lei […]Illumina's (ILMN) preliminary fourth-quarter results, latest partnership deals and a robust pipeline of technologies instill investor optimism.SAN DIEGO, January 11, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed the company's strong growth trajectory, including 2021 results and 2022 g...The Nasdaq indexes outperformed as beaten down stocks scored the biggest gains. The Dow Jones lagged, hurt by a sell-off in IBM.The stock market hasn't been all that strong so far this year, but the Nasdaq Composite (NASDAQINDEX: ^IXIC) managed to rebound somewhat from its recent woes.  As of noon ET, the Nasdaq was up 172 points to 15,115, rising more than 1% to try to recover some of its lost ground in the first week of 2022.  Illumina (NASDAQ: ILMN) was sharply higher, as its business has been doing better than many had expected, while China's JD.com (NASDAQ: JD) managed to overcome selling pressure from one of the most-followed buyers of high-growth stocks.Fourth-quarter 2021 results hit a ""record,"" and Illumina's gearing up to report a big beat in 2022.At the annual healthcare conference hosted virtually by JPMorgan Chase yesterday, Illumina said sales grew 39% in 2021 and that analysts' forecasts for 2022 revenue were too low.";226.13999938964844;;225.33999633789062;;249.69000244140625;;141.02999877929688;;147.5399932861328;;428.3699951171875;;6.260000228881836;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today preliminary performance updates for the year ended December 31, 2021. Among the results, Ginkgo highlighted that it expects to meet or exceed its key 2021 full year targets for the commencement of new cell programs and revenue from its cell programming and biosecurity offerings based on its preliminary unaudited estimates. The results, along with a broader business review, will be featured in a preSelecta Biosciences Inc. has chosen Ginkgo Bioworks Holdings Inc. to develop new viral capsids for gene therapies.;88.0999984741211;"For his second ""Executive Decision"" segment of Tuesday's Mad Money program, Jim Cramer spoke with J.J. Bienaime, chairman and CEO of BioMarin Pharmaceutical  , which presented this week at the JP Morgan Healthcare Conference.  Bienaime said things are progressing very well for its treatment for Hemophilia A, Roctovian.  Bienaime said it just introduced a new growth treatment for children with a rare condition called achondroplasia (a hereditary condition in which the growth of long bones by ossification of cartilage is retarded).";118.80999755859375;;73.62000274658203;;75.81999969482422;Shares of medical diagnostic company Exact Sciences (NASDAQ: EXAS) fell by a jaw-dropping 41% over the whole of 2021, according to data provided by S&P Global Market Intelligence.  Although the novel cancer diagnostic company saw a healthy rise in sales last year, and this sales growth is widely expected to continue in 2022, Exact's staggering losses haven't been sitting well with shareholders of late.  During the first nine months of 2021, for instance, Exact lost a noteworthy $634 million.;130.1699981689453;;97.95999908447266;Companies like Intellia Therapeutics and Editas Medicine are saying that this year will bring exciting developments.;76.48999786376953;Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory milestone, triggering a payment of .0 million to Xenon. The FDA accepted Neurocrine's protocol amendment that expands the study population to include subjects between 2 and 11 years in the ongoing Phase 2 study of NBI-921352 in pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). Under the agreement, Xeno;73.94999694824219;Oslo, Q8, based Investment company DnB Asset Management AS (Current Portfolio) buys Check Point Software Technologies, Apple Inc, Accenture PLC, Western Digital Corp, Wells Fargo, sells Meta Platforms Inc, International Business Machines Corp, Micron Technology Inc, JPMorgan Chase, Cisco Systems Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, DnB Asset Management AS.;122.55999755859375;;58.220001220703125;PASADENA, Calif., January 12, 2022--Arrowhead initiates Phase 3 PALISADE study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome;81.5;;69.86000061035156;;56.29999923706055;"SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase 3 pivotal trial of Tumor Treating Fields in patients with pancreatic cancer. “Pancreatic cancer is a common, highly aggressive form of gastrointestinal cancer, with an estimated five-year survival";45.04999923706055;;17.959999084472656;;13.600000381469727;;70.23999786376953;In this article, we discuss 10 biotech stocks to buy according to Chinese billionaire Lei Zhang. If you want to skip our detailed analysis of these stocks, go directly to 5 Biotech Stocks To Buy According To Chinese Billionaire Lei Zhang. Hillhouse Capital Management was founded by Chinese billionaire investor and hedge fund manager Lei […];38.54999923706055;;71.20999908447266;;35.47999954223633;;92.7699966430664;;40.0099983215332;After losing some value lately, a hammer chart pattern has been formed for Vir Biotechnology, Inc. (VIR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.The U.S. government enters into an agreement with Glaxo (GSK) and Vir Biotechnology (VIR) to procure an additional 600,000 doses of sotrovimab for early treatment of COVID-19.;19.780000686645508;;65.19999694824219;;14.449999809265137;Companies in The News Are: ACCD,PACB,BIG,ILMNThe stock of Pacific Biosciences of California (NASDAQ: PACB), a company developing DNA sequencing machines, is losing ground after an investor update.  Preliminary fourth-quarter sales figures missed expectations, driving the stock 11.8% lower as of 12:54 p.m. ET on Tuesday.  Preliminary sales figures from the fourth quarter weren't bad, but they were slightly less than the market was expecting.;31.850000381469727;;66.86000061035156;;39.720001220703125;;11.670000076293945;;62.970001220703125;;22.139999389648438;Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.;24.229999542236328;BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.
2022-01-13;230.85000610351562;;71.87999725341797;;616.1099853515625;;202.99000549316406;;399.510009765625;We are honored to be recognized as #32 by CNBC and JUST Capital in the Americas Most JUST rankings and #1 for customers in the Pharmaceuticals and Biotech industry.Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing and to bring improved insights to patients with breast cancer globally;226.5800018310547;;236.6699981689453;;236.17999267578125;;136.7899932861328;;148.0;;397.67999267578125;;6.139999866485596;;88.16000366210938;BioMarin CEO JJ Bienaimé joins Yahoo Finance Live’s Julie Hyman and Anjalee Khemlani to discuss the company's first gene therapy product targeted to patients dealing with hemophilia, the future of biotechnology, biotech stocks, and key takeaways from JPMorgan’s annual health care conference.;104.81999969482422;;73.6500015258789;;75.4000015258789;;112.37999725341797;;89.3499984741211;Intellia Therapeutics Inc. made history last summer when it became the first biotech company to successfully edit DNA inside the human body using CRISPR. Now, the company is planning to build on that momentum.;79.22000122070312;Investment company Harbour Capital Advisors, LLC (Current Portfolio) buys Diamondback Energy Inc, Realty Income Corp, Axalta Coating Systems, Centene Corp, Unity Software Inc, sells Global Payments Inc, Neurocrine Biosciences Inc, Teladoc Health Inc, Altice USA Inc, Zendesk Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Harbour Capital Advisors, LLC.;72.38999938964844;;118.73999786376953;;57.58000183105469;;75.88999938964844;;66.4000015258789;;51.63999938964844;;42.20000076293945;;17.770000457763672;;12.989999771118164;- First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation PALO ALTO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a non-exclusive clinical collaboration with Amgen Inc. (Amgen) to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibit;66.12999725341797;;33.86000061035156;SOUTH SAN FRANCISCO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that after the close of business (Eastern Time) on Wednesday, January 12, 2022, the company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) that the DNL919 (ATV:TREM2) Investigatio;69.88999938964844;;35.5099983215332;CP, HALO, AMX, ESTA, and GEO have been added to the Zacks Rank #5 (Strong Sell) List on January 13, 2021.;92.47000122070312;;37.650001525878906;Vaxxinity (VAXX) starts dosing patients in part B of a phase I study on its investigational Parkinson's disease vaccine candidate.Shares of Vir Biotechnology Inc. were up 1.0% in trading on Thursday after the company and GlaxoSmithKline formally asked the Food and Drug Administration to update the authorization for their COVID-19 treatment to include intramuscular administration. GSK's stock was up 0.1% after the news was announced. The therapy, sotrovimab, is a monoclonal antibody used to treat some teens and adults who are at high risk for severe COVID-19. The therapy was originally authorized for single-dose intravenous– New commitment from the Bill & Melinda Gates Foundation supports the development of Vir’s novel “vaccinal antibody” technology as another important step in the fight to address global infectious diseases – SAN FRANCISCO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an expansion of its partnership with the Bill & Melinda Gates Foundation to include the advancement of innovative platform technologies in the development of broadly neutralizing antibodies– If authorized, would provide the option for intramuscular administration of sotrovimab, in addition to currently authorized intravenous administration – – Submission follows COMET-TAIL Phase 3 data demonstrating that intramuscular administration of sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations – PHILADELPHIA and SAN FRANCISCO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (NasVir Biotechnology, Inc. (VIR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.;18.450000762939453;;62.81999969482422;;13.199999809265137;Industry Veteran Will Lead Company’s Commercial Growth Strategy in Americas RegionMENLO PARK, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate, sequencing platforms, welcomes Lara Toerien, Ph.D., as Vice President and General Manager for the company’s Americas region. Lara will be responsible for leading and developing PacBio’s commercial organization within North and South America while furthering its growth and market presenc;32.130001068115234;;65.04000091552734;;40.970001220703125;;10.859999656677246;After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […];59.40999984741211;;22.139999389648438;;24.8700008392334;Vaxxinity (VAXX) starts dosing patients in part B of a phase I study on its investigational Parkinson's disease vaccine candidate.IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with KeytrudaAlkermes is committed to researching and developing potential new cancer treatment options that may help address unmet patient needs. Clinical trials are an important step in evaluating the safety ...
2022-01-14;235.36000061035156;;71.7699966430664;;615.239990234375;;196.0;;405.1400146484375;Investors are optimistic about Illumina (ILMN) owing to its strength in international markets and notable strategic partnerships.Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.;234.05999755859375;;239.3000030517578;;238.63999938964844;;137.08999633789062;;148.5;CAMBRIDGE, Mass., January 14, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 18-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, at the Société Francophone du Nerf Périphérique (SFNP) Annual Meeting. The meeting will be held January 21-22 in Pa;390.1099853515625;;5.789999961853027;;90.22000122070312;;104.0;;74.87999725341797;;78.43000030517578;;110.81999969482422;;91.37000274658203;CRISPR stocks will face make-or-break moments in 2022 as Big Pharma joins their quest to cure serious diseases with gene editing technology.Investment company Marotta Asset Management (Current Portfolio) buys General Dynamics Corp, iShares iBoxx USD Investment Grade Corporate Bond , Caterpillar Inc, Pfizer Inc, Deere, sells Generac Holdings Inc, Moderna Inc, Global X FTSE Nordic Region ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Marotta Asset Management.;78.36000061035156;;71.0999984741211;;124.30999755859375;A rival to the company's leading pipeline drug wins conditional marketing authorization in a big market abroad.;57.810001373291016;;78.0;;67.7699966430664;CRISPR stocks will face make-or-break moments in 2022 as Big Pharma joins their quest to cure serious diseases with gene editing technology.Investment company McGuire Investment Group, LLC (Current Portfolio) buys SPDR Bloomberg 1-3 Month T-Bill ETF, WisdomTree Floating Rate Treasury Fund, BTC iShares Floating Rate Bond ETF, SPDR Bloomberg Investment Grade Floating Rate ETF, Global X Genomics & Biotechnology ETF, sells Sangamo Therapeutics Inc, ARK Genomic Revolution ETF, Editas Medicine Inc, Boston Scientific Corp, United Rentals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, M;49.779998779296875;;43.279998779296875;;18.1200008392334;;12.75;;67.81999969482422;Pfizer (PFE) inks research collaboration with Beam Therapeutics. Merck's (MRK) Keytruda improves survival in adjuvant lung cancerCRISPR stocks will face make-or-break moments in 2022 as Big Pharma joins their quest to cure serious diseases with gene editing technology.;34.84000015258789;The FDA placed a hold on the company's planned clinical trial of an experimental Alzheimer's disease drug.The Food and Drug Administration placed Denali's Alzheimer's test on hold Thursday, sending DNLI stock into a dive.;72.05000305175781;;35.560001373291016;;92.6500015258789;;38.70000076293945;Glaxo (GSK) and Vir are looking to get authorization for the intramuscular administration of their COVID-19 drug candidate, sotrovimab, which is currently authorized for intravenous administration.;17.84000015258789;;65.12999725341797;;12.430000305175781;;33.08000183105469;;67.41999816894531;;43.06999969482422;;10.050000190734863;;59.81999969482422;;23.049999237060547;Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.;25.25;DUBLIN, January 14, 2022 /3BL Media/ - Results from a newly released survey provide insights from adults living with bipolar I disorder (BD-I)* in the United States (U.S.) on the burden of living w...Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.
2022-01-18;233.8300018310547;;70.43000030517578;;611.219970703125;;169.22999572753906;;383.1300048828125;SAN DIEGO, January 18, 2022 /3BL Media/ -- Illumina Inc. (NASDAQ: ILMN) announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer I...;231.07000732421875;;233.80999755859375;;239.6300048828125;;130.2899932861328;BOTHELL, Wash., January 18, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2021 financial results on Wednesday, February 9, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.;139.19000244140625;;379.0;Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, released its Stellar NIR / IR™ Detection Modules for Jess. Stellar fluorescence modules enable detection of low abundance proteins while multiplexing multiple analytes within the same detection lane, setting a new industry standard for western blotting fluorescence detection sensitivity. Multi-color immunoassays can also be run alongside total protein staining using Stellar detection modules.;5.300000190734863;Investment company Gleason Group, Inc. (Current Portfolio) buys Herc Holdings Inc, DocuSign Inc, Arhaus Inc, YETI Holdings Inc, Alight Inc, sells Centene Corp, AT&T Inc, Boeing Co, BHP Group, Citigroup Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Gleason Group, Inc..Los Angeles, CA, based Investment company Guild Investment Management, Inc. (Current Portfolio) buys The Mosaic Co, ProShares S&P 500 Dividend Aristocrats ETF, General Motors Co, Ares Acquisition Corp, Vanguard S&P 500 ETF, sells ProShares UltraShort S&P500, PowerShares UltraShort Lehman 20+ Year Treasury Pr, Cognyte Software, Cognyte Software, VPC Impact Acquisition Holdings during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Guild Investment Manage;86.70999908447266;;92.69000244140625;;75.01000213623047;WILMINGTON, Del., January 18, 2022--Incyte to Report Fourth Quarter and Year-End 2021 Financial Results;77.41999816894531;;98.44000244140625;;85.80000305175781;;74.5;;66.12000274658203;Every investor in Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) should be aware of the most powerful shareholder groups...;115.9800033569336;;54.130001068115234;;73.1500015258789;;65.05000305175781;Investment company Arlington Financial Advisors, LLC (Current Portfolio) buys FIRST TR EXCHANGE, Apple Inc, iShares MSCI All Country Asia ex Japan Index Fund, iShares MSCI World ETF, iShares U.S.;52.540000915527344;;40.619998931884766;;17.3799991607666;;11.760000228881836;;62.150001525878906;;31.420000076293945;;67.66999816894531;;34.130001068115234;;91.9800033569336;;35.7400016784668;;17.639999389648438;;62.77000045776367;;11.119999885559082;PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.;30.1200008392334;Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that its partner, Roche, is designing a new Phase 2 trial to evaluate tominersen in Huntington's disease (HD). After halting dosing in the Phase 3 GENERATION HD1 study, exploratory post-hoc analyses suggest tominersen may benefit younger adult patients with lower disease burden. These results require confirmation in a randomized, placebo-controlled study.;64.61000061035156;;40.34000015258789;;9.710000038146973;;57.11000061035156;;20.940000534057617;;25.219999313354492;Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place Jan. 20-22, 2022. The poster highlights clinical data related to advanced GI cancers from ARTISTRY-1, a phase 1/2 study evaluating the tolerability and efficacy of nemvaleukin administered
2022-01-19;231.3000030517578;;69.06999969482422;;618.1099853515625;;161.66000366210938;;384.3599853515625;London, X0, based Investment company Sarasin & Partners LLP (Current Portfolio) buys National Instruments Corp, Illumina Inc, Splunk Inc, Entegris Inc, Charter Communications Inc, sells The Home Depot Inc, Welbilt Inc, Apple Inc, iShares Core U.S.Investment company Foster Victor Wealth Advisors, LLC (Current Portfolio) buys Vanguard Value ETF, Schwab U.S.Opening Doors for Students and the Possibilities of a STEM Career;230.83999633789062;;230.80999755859375;;236.85000610351562;;132.5500030517578;BOTHELL, Wash., January 18, 2022--Seagen Reports Data From SEA-CD40 in Combination with Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma at the ASCO GI Symposium;138.6199951171875;;379.8299865722656;;5.039999961853027;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the acquisition of Project Beacon COVID-19 LLC (Project Beacon), a Boston-based social benefit organization focused on helping to increase the capacity, availability, accessibility and affordability of COVID-19 testing. Under the terms of the deal, Ginkgo acquired Project Beacon's assets and will assume responsibility for Project Beacon's ongoing operations, providing COVID-19 monitoring tools to c;86.0;Investment company Asymmetry Capital Management, L.P. (Current Portfolio) buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, AbbVie Inc, IQVIA Holdings Inc, Centene Corp, sells Alkermes PLC, Medtronic PLC, Insulet Corp, Hologic Inc, Sage Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Asymmetry Capital Management, L.P..In this article, we discuss the 10 Jim Cramer stocks to buy in Q1 2022. If you want to skip our detailed analysis of these stocks, go directly to the 5 Jim Cramer Stocks to Buy in Q1 2022. Investors have been scrambling to identify the “real value” of stocks as reports suggest that as […];89.63999938964844;;74.77999877929688;;76.12999725341797;"Exact Sciences Corp. (NASDAQ: EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing overall sensitivity of 95.2% for colorectal cancer (CRC) at specificity of 92.4% for negative samples confirmed by colonoscopy. Subgroup analyses showed 83.3% sensitivity for high-grade dysplasia, the most dangerous precancerous lesions, and 57.2% for all advanced precancerous lesions. These data will be presented January 22 at ASCO GI in a poster titled, ""Investment company CHICAGO TRUST Co NA (Current Portfolio) buys Mastercard Inc, The Home Depot Inc, Boston Scientific Corp, Keysight Technologies Inc, Exact Sciences Corp, sells Wintrust Financial Corp, Biogen Inc, Activision Blizzard Inc, Boeing Co, Teladoc Health Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CHICAGO TRUST Co NA.";92.33000183105469;;83.66999816894531;Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.;72.83000183105469;;63.150001525878906;;120.80999755859375;;53.790000915527344;;72.51000213623047;;64.19000244140625;Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.Shares of clinical-stage biotech companies can skyrocket in a short period based on positive clinical and regulatory news.  With that said, let's look at two clinical-stage biotechs that currently boast significant upside potential if we go by average price targets assigned by Wall Street analysts: CRISPR Therapeutics (NASDAQ: CRSP) and Axsome Therapeutics (NASDAQ: AXSM).;51.970001220703125;;39.310001373291016;;17.079999923706055;ALAMEDA, Calif., January 18, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from cohort 16 of the phase 1b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-containing chemotherapy. Results from cohort 2 of the phase 2 CAMILLA trial of c;11.699999809265137;;62.369998931884766;;33.16999816894531;;66.75;;33.75;;91.51000213623047;"Investment company Asymmetry Capital Management, L.P. (Current Portfolio) buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, AbbVie Inc, IQVIA Holdings Inc, Centene Corp, sells Alkermes PLC, Medtronic PLC, Insulet Corp, Hologic Inc, Sage Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Asymmetry Capital Management, L.P..PARK CITY, Utah, January 18, 2022--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement restricted stock units (""RSUs"") to new employees. The inducement RSUs have a grant date and vesting commencement date of January 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). These grants included:";34.0;;17.729999542236328;;62.720001220703125;;10.65999984741211;;30.31999969482422;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced two appointments that strengthen its leadership team and further position it to become a leading, fully integrated biotechnology company. Joseph T. Baroldi will assume the role of executive vice president and chief business officer, effective Jan. 31, 2022. He will serve as a member of Ionis' executive leadership team and report to Brett P. Monia, Ph.D., Ionis' chief executive officer. In his role, Mr. Baroldi will provide strategic guid;64.41999816894531;;38.7400016784668;;9.420000076293945;;55.209999084472656;Business is booming for these life science businesses, but their stock prices have been slashed to bargain prices.;21.8700008392334;;25.0;Investment company Asymmetry Capital Management, L.P. (Current Portfolio) buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, AbbVie Inc, IQVIA Holdings Inc, Centene Corp, sells Alkermes PLC, Medtronic PLC, Insulet Corp, Hologic Inc, Sage Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Asymmetry Capital Management, L.P..Here are four top-ranked liquid stocks, Alkermes (ALKS), Tesla (TSLA), Nucor (NUE) and GoPro (GPRO), which investors can tap for healthy returns.
2022-01-20;228.89999389648438;;67.80999755859375;;614.3800048828125;Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.;156.52999877929688;;380.44000244140625;Collaboration will transform new insights into drug discovery and therapy development through large-scale genomicsSanta Barbara, CA, based Investment company West Coast Financial LLC (Current Portfolio) buys Schwab Short-Term U.S.Providence, RI, based Investment company Blue Fin Capital, Inc. (Current Portfolio) buys PowerShares NASDAQ Internet Portfolio, Advanced Micro Devices Inc, iShares Biotechnology ETF, Blackstone Inc, Chipotle Mexican Grill Inc, sells Boeing Co, Alibaba Group Holding, AT&T Inc, Cognex Corp, Zoom Video Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Blue Fin Capital, Inc..Manchester, NH, based Investment company Curbstone Financial Management Corp (Current Portfolio) buys Vanguard Extended Market Index ETF, Schwab U.S.;228.61000061035156;;225.91000366210938;;251.3699951171875;CAMBRIDGE, Mass., & BEIJING, January 20, 2022--BeiGene announces acceptance of a supplemental New Drug Application in China for BRUKINSA in Waldenström’s macroglobulinemia based on the ASPEN trial.Shares of Leap Therapeutics (NASDAQ: LPTX), a clinical-stage biopharmaceutical company, are surging in response to positive clinical results from a stomach cancer study.  Last September, Leap Therapeutics stock more than doubled overnight after the company reported impressive response rate data for its lead candidate DKN-1 plus tislelizumab from BeiGene (NASDAQ: BGNE).  The experimental combination treatment was tested among patients newly diagnosed with advanced-stage stomach cancer.;133.05999755859375;;138.30999755859375;;377.2200012207031;While Bio-Techne Corporation ( NASDAQ:TECH ) shareholders are probably generally happy, the stock hasn't had...;5.099999904632568;;84.44999694824219;Investment company Lion Street Advisors, LLC (Current Portfolio) buys Compass Minerals International Inc, First Trust NASDAQ Rising Dividend Achievers ETF, Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, Schwab Fundamental U.S.;93.02999877929688;;74.76000213623047;Incyte Corporation ( NASDAQ:INCY ) shareholders should be happy to see the share price up 14% in the last quarter. But...;76.02999877929688;;90.36000061035156;;82.62000274658203;Investment company Aevitas Wealth Management, Inc. (Current Portfolio) buys Enbridge Inc, Mastercard Inc, Exxon Mobil Corp, Truist Financial Corp, NVIDIA Corp, sells ARK Innovation ETF, ARK Genomic Revolution ETF, ARK Fintech Innovation ETF, Invesco BulletShares 2021 Corporate Bond ETF, CRISPR Therapeutics AG during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Aevitas Wealth Management, Inc..;72.80000305175781;;64.58999633789062;Investment company Financial Management Network Inc (Current Portfolio) buys BTC iShares MSCI EAFE Min Vol Factor ETF, Healthcare Trust of America Inc, Alger Mid Cap 40 ETF, SPDR Portfolio Short Term Corporate Bond ETF, Realty Income Corp, sells iShares 1-3 Year Credit Bond ETF, Becton, Dickinson and Co, iShares 1-3 Year Treasury Bond ETF, , iShares ESG Aware U.S.;118.33999633789062;GuruFocus data shows that EVP Chief Commercial Officer Benjamin Hickey has sold 627 shares in Mirati Therapeutics Inc ( NA:MRTX), on 2022-01-18.;52.5099983215332;;72.69999694824219;Blueprint Medicines Corporation (NASDAQ: BPMC) today announced two executive leadership changes highlighting the company's commitment to developing exceptional leaders. Effective April 4, 2022, Philina Lee, Ph.D. will be promoted to Chief Commercial Officer, succeeding Christina Rossi as she transitions to Chief Operating Officer. With her promotion, Dr. Lee will become an officer of the company and assume responsibility for Blueprint's global commercial strategy and U.S. operations. In an expan;64.36000061035156;New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.Investment company Aevitas Wealth Management, Inc. (Current Portfolio) buys Enbridge Inc, Mastercard Inc, Exxon Mobil Corp, Truist Financial Corp, NVIDIA Corp, sells ARK Innovation ETF, ARK Genomic Revolution ETF, ARK Fintech Innovation ETF, Invesco BulletShares 2021 Corporate Bond ETF, CRISPR Therapeutics AG during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Aevitas Wealth Management, Inc..;52.20000076293945;;38.29999923706055;;17.030000686645508;For more than a decade, growth stocks have been the talk of Wall Street.  Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work.  Below are five value stocks that could make you richer in 2022.;11.460000038146973;;62.84000015258789;;32.84000015258789;;68.97000122070312;;33.560001373291016;;91.01000213623047;;33.13999938964844;The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.;17.56999969482422;;60.439998626708984;;10.390000343322754;;30.010000228881836;Investment company Mitchell & Pahl Private Wealth, Llc (Current Portfolio) buys Fair Isaac Corp, Aspen Technology Inc, Interactive Brokers Group Inc, NVIDIA Corp, HSBC Holdings PLC, sells DocuSign Inc, Ionis Pharmaceuticals Inc, Terminix Global Holdings Inc, Discovery Inc, Teleflex Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Mitchell & Pahl Private Wealth, Llc.;67.33000183105469;;38.869998931884766;;9.079999923706055;;53.880001068115234;SOUTH SAN FRANCISCO, January 20, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 first quarter ended December 31, 2021, before the opening of the market on Friday, February 4, 2022. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time;21.489999771118164;;24.31999969482422;Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.Alkermes, Tesla, Nucor Corp. and GoPro are highlighted in this Screen of the Week article.The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.Phillips (PHG) integrates AI and 3D mapping capabilities it its Mobile C-Arm System, Zenition, enhancing its diagnostic imaging portfolio.
2022-01-21;227.72000122070312;;68.51000213623047;;621.4000244140625;Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.Investment company Harvest Group Wealth Management, Llc (Current Portfolio) buys Real Estate Select Sector SPDR Fund (The), iShares MSCI Global Impact ETF, ARK Innovation ETF, Hartford Total Return Bond ETF, NuShares ESG U.S.Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.Mobile, AL, based Investment company Leavell Investment Management, Inc. (Current Portfolio) buys Quadratic Interest Rate Volatility And Inflation H, Schwab US Dividend Equity ETF, iShares iBonds Dec 2025 Term Muni Bond ETF, Horizon Kinetics Inflation Beneficiaries ETF, PIMCO Dynamic Income Fund, sells iShares iBonds Dec 2021 Term Muni Bond ETF, iShares iBonds Dec 2021 Term Corporate ETF, iShares 1-3 Year Treasury Bond ETF, Alphabet Inc, Regeneron Pharmaceuticals Inc during the 3-months ended 20Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors. Program alumni include recipients of the world's most coveted science and math honors, including 13 Nobel Prizes and 22 MacArthur Foundation Fellowships, as well as the founders of many important science-based companies, including Regeneron.;147.5;ASLAN (ASLN) screens the first patient in the phase II dose ranging study evaluating its investigational monoclonal antibody in patients with atopic dermatitis.;365.94000244140625;San Diego, CA, based Investment company Telos Capital Management, Inc. (Current Portfolio) buys Illumina Inc, United Parcel Service Inc, Newell Brands Inc, Williams-Sonoma Inc, iShares MSCI Emerging Markets ex China ETF, sells Activision Blizzard Inc, iShares Biotechnology ETF, Merck Inc, Aflac Inc, Caterpillar Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Telos Capital Management, Inc..Investment company First United Bank & Trust (Current Portfolio) buys BTC iShares Core MSCI EAFE ETF, Invesco Preferred ETF, FIRST TR EXCH VII, Vanguard ESG International Stock ETF, Altria Group Inc, sells Invesco National AMT-Free Municipal Bond ETF, iShares 1-3 Year Credit Bond ETF, Alibaba Group Holding, Vanguard Intermediate-Term Corporate Bond ETF, ARK Innovation ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First United Bank & Trust.Investment company Encompass Wealth Advisors, Llc (Current Portfolio) buys AbbVie Inc, Coca-Cola Co, Freeport-McMoRan Inc, American Express Co, Sherwin-Williams Co, sells Tesla Inc, iShares Core 1-5 Year USD Bond ETF, Avaya Holdings Corp, Kyndryl Holdings Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Encompass Wealth Advisors, Llc.Illumina, Inc. (NASDAQ: ILMN) today announced that it will issue results for the fourth quarter and full year 2021 following the close of market on Thursday, February 10, 2022.;228.0800018310547;Corning's (GLW) performance in the fourth quarter of 2021 is likely to have been primarily driven by growth in the Optical Communications business.;220.52000427246094;;251.4499969482422;;127.55000305175781;;136.41000366210938;Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-mediated (ATTR) amyloidosis. Transthyretin amyloidosis is characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. The details follow topline data announced in October 2021, showing that the Phase 3 trial met all secondary endpoints measured at 18 months. Vutrisiran treatmeCAMBRIDGE, Mass., January 21, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, met all secondary endpoints measured at 18 months in patients with hATTR amyloidosis with polyneuropathy, including statistically significant improvements in neuropathy impairment, quality of life (QoL;367.1000061035156;;5.28000020980835;;84.6500015258789;;89.29000091552734;10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the expansion of its 10x Certified Service Provider (CSP) Network to include three leading clinical research organizations (CROs). The organizations will partner with 10x Genomics to support global biopharmaceutical companies seeking to leverage 10x Genomics' robust single-cell and spatial technologies to power new therapeutic discoveries and accelerate drug development. The t;74.79000091552734;;74.02999877929688;;84.6500015258789;;81.5199966430664;;75.0999984741211;;63.470001220703125;;114.02999877929688;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in patients with pretreated pancreatic ductal adenocarcinoma and other gastrointestinal (GI) tumors harboring a KRASG12C mutation, including cancers of the biliary tract, appendix, small bowel, gastro-esophageal junction, and esophagus. Results showed that adagrasib demonstrated significant c;50.84000015258789;;68.91000366210938;New York, NY, based Investment company Sib Llc (Current Portfolio) buys FIGS Inc, sells Blueprint Medicines Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Sib Llc.;62.61000061035156;;50.58000183105469;There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Hong Kong, K3, based Investment company Segantii Capital Management Ltd (Current Portfolio) buys Nuance Communications Inc, Cerner Corp, KraneShares CSI China Internet ETF, Pretium Resources Inc, Zai Lab, sells Alibaba Group Holding, , Five9 Inc, NIO Inc, JD.com Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Segantii Capital Management Ltd.;37.150001525878906;;17.31999969482422;;10.300000190734863;;62.86000061035156;;32.36000061035156;;67.16999816894531;;33.88999938964844;;90.4800033569336;;33.459999084472656;;16.799999237060547;;57.79999923706055;;10.050000190734863;;29.8799991607666;;67.08999633789062;;42.65999984741211;;8.640000343322754;;52.88999938964844;;21.18000030517578;;24.0;BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.
2022-01-24;226.0800018310547;AbbVie's blockbuster anti-inflammatory Humira could see eight biosimilars launch next year. Bernstein analyst Ronny Gal is still bullish on AbbVie stock.Investment company Dagco, Inc. (Current Portfolio) buys BTC iShares U.S. Treasury Bond ETF, Schwab US Aggregate Bond ETF, ISHARES TRUST, Vanguard High Dividend Yield Indx ETF, iShares 0-5 Year TIPS Bond ETF, sells Vanguard Intermediate-Term Government Bond ETF, VANGUARD BD IDX FD, iShares Core U.S.Investment company Lincoln Capital Corp (Current Portfolio) buys Textron Inc, Meta Platforms Inc, Verizon Communications Inc, iShares Core S&P 500 ETF, Peloton Interactive Inc, sells iShares 0-3 Month Treasury Bond ETF, GoDaddy Inc, T-Mobile US Inc, Visa Inc, Illumina Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Lincoln Capital Corp.;68.56999969482422;Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.;621.47998046875;;150.97999572753906;A third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac's CoronaVac shot, a study has found.  The study found that CoronaVac received the strongest boost from a viral vector or RNA shot, including against the Delta and Omicron coronavirus variants, researchers from Brazil and Oxford University said https://www.ox.ac.uk/news/2022-01-24-mixed-vaccine-schedules-offer-strong-booster-responses-after-two-doses-coronavac on Monday.  China-based Sinovac's vaccine uses an inactivated version of a coronavirus strain that was isolated from a patient in China.As half of the duo behind one of the world's most widely used and effective COVID-19 vaccines, BioNTech (NASDAQ: BNTX) is well on its way to enduring stardom in the healthcare sector.  Far from content to keep playing second fiddle to collaborator Pfizer (NYSE: PFE), the biotech looks to be on a path toward ever-greater independence.;364.9599914550781;Japan’s Kazusa DNA Research Institute leads an effort to collect plant genomes and make them available to everyoneInvestment company Lincoln Capital Corp (Current Portfolio) buys Textron Inc, Meta Platforms Inc, Verizon Communications Inc, iShares Core S&P 500 ETF, Peloton Interactive Inc, sells iShares 0-3 Month Treasury Bond ETF, GoDaddy Inc, T-Mobile US Inc, Visa Inc, Illumina Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Lincoln Capital Corp.Illumina, Inc. (NASDAQ: ILMN) and the National Cancer Center Japan have announced an international joint research project that will use Illumina's high-throughput DNA sequencing to analyse the blood-based genomic profile and clinical information of patients living with Nasopharyngeal Carcinoma. The study will be known as a part of the Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing (A-TRAIN).Genomic sequencing leader Illumina (NASDAQ: ILMN) recently provided guidance for 2022 and revealed some of its plans for the year.  In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss the outlook for Illumina going forward.  Keith Speights: Hey, there's a company that you and I haven't talked about very much, at least, I'm going to say at least over the last seven or eight months and maybe longer than that.;229.67999267578125;Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.Intel's (INTC) performance in fourth-quarter 2021 is likely to reflect headwinds in the enterprise business of the data center segment.Silicon Motion's (SIMO) performance in the fourth quarter of 2021 is likely to have benefited from increased sales of SSD and eMMC and UFS controllers.PTC is likely to have reported higher year-over-year revenues in first-quarter fiscal 2022, driven by significant growth across all product segments and regions.;224.69000244140625;Investment company Wedge Capital Management L L P (Current Portfolio) buys Fidelity National Financial Inc, Arista Networks Inc, Cognizant Technology Solutions Corp, Seagate Technology Holdings PLC, HP Inc, sells Adobe Inc, Fair Isaac Corp, Corning Inc, Evergy Inc, Biogen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Wedge Capital Management L L P.The Centers for Medicare and Medicaid may ensure the commercial death of Biogen’s controversial Alzheimer’s drug. And that leads at least one analyst to wonder if more radical steps need to be taken.;248.85000610351562;"CAMBRIDGE, Mass. & BEIJING, January 24, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced positive findings from the global Phase 3 RATIONALE 305 trial of tislelizumab versus placebo in combination with chemotherapy as a first-line treatment for patients with locally advanced, unresectable or metastatic gas";129.5500030517578;;136.52999877929688;CAMBRIDGE, Mass., January 24, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2021 on Thursday, February 10, 2022, before the U.S. financial markets open.;381.8900146484375;;5.130000114440918;;86.22000122070312;;94.66000366210938;;75.33999633789062;;74.66000366210938;;79.47000122070312;;88.20999908447266;;75.86000061035156;Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 27%. However, a closer look...;67.30000305175781;;115.7699966430664;;52.790000915527344;PASADENA, Calif., January 24, 2022--Arrowhead Pharmaceuticals closes agreement with GlaxoSmithKline for ARO-HSD, RNAi therapeutic for patients with nonalcoholic steatohepatitis (NASH);72.27999877929688;;60.2599983215332;;49.86000061035156;;39.52000045776367;;18.520000457763672;;10.479999542236328;;67.98999786376953;Pfizer (NYSE: PFE) recently announced a collaboration with Beam Therapeutics (NASDAQ: BEAM) to develop gene-editing therapies targeting rare genetic diseases.  In this Motley Fool Live video, recorded on Jan. 12., Fool contributors Keith Speights and Brian Orelli discuss why Pfizer's deal with Beam appears to be a smart move.  Keith Speights: We mentioned this on Monday I believe, that Pfizer had announced a collaboration with Beam Therapeutics to develop therapies targeting rare genetic diseases.;34.7599983215332;;67.95999908447266;;34.70000076293945;;89.94999694824219;;32.880001068115234;;16.559999465942383;;62.099998474121094;;10.670000076293945;;31.399999618530273;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to eplontersen, an investigational antisense medicine for the treatment of people living with transthyretin-mediated amyloidosis, a systemic, progressive and fatal condition. Orphan drug designation is granted by the FDA to drugs and biologics intended for treatment, prevention or diagnosis of a rare disease or cond;68.4800033569336;;44.34000015258789;Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;8.569999694824219;;55.869998931884766;;22.450000762939453;;25.559999465942383;Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.
2022-01-25;225.0399932861328;Investment company Exeter Financial, LLC (Current Portfolio) buys Amgen Inc, Vanguard S&P 500 ETF, Dimensional International Value ETF, Dimensional U.S.Novato, CA, based Investment company Hennessy Advisors Inc (Current Portfolio) buys ONEOK Inc, ArcBest Corp, Alcoa Corp, Jabil Inc, Goodyear Tire & Rubber Co, sells Vista Outdoor Inc, LPL Financial Holdings Inc, Jefferies Financial Group Inc, Quanta Services Inc, Valmont Industries Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hennessy Advisors Inc.Portland, OR, based Investment company Vision Capital Management, Inc. (Current Portfolio) buys Pinterest Inc, Schlumberger, Amgen Inc, iShares MSCI USA ESG Optimized ETF, Schwab 1-5 Year Corporate Bond ETF, sells Verizon Communications Inc, Tesla Inc, Comcast Corp, Haverty Furniture Inc, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Vision Capital Management, Inc..;68.83999633789062;Gilead Sciences (GILD) closed the most recent trading day at $68.57, moving +0.09% from the previous trading session.Hood River, OR, based Investment company Northside Capital Management, LLC (Current Portfolio) buys Snowflake Inc, Datadog Inc, Procore Technologies Inc, Planet Labs PBC, Trane Technologies PLC, sells Vir Biotechnology Inc, Roblox Corp, Oracle Corp, Abbott Laboratories, Johnson & Johnson during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Northside Capital Management, LLC.;603.1900024414062;Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.Investment company Railway Pension Investments Ltd (Current Portfolio) buys Abbott Laboratories, Alphabet Inc, Advanced Micro Devices Inc, Merck Inc, Qualcomm Inc, sells Morgan Stanley, Amazon.com Inc, Oracle Corp, Nike Inc, Goldman Sachs Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Railway Pension Investments Ltd.COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant that now accounts for nearly all U.S. infections, U.S. health regulators said Monday.Kansas City, MO, based Investment company Atwood & Palmer Inc (Current Portfolio) buys Regeneron Pharmaceuticals Inc, FIRST TR ETF VI, AAM Low Duration Preferred and Income Securities E, INVESCO EXCHANGE T, Goldman Sachs Access Ultra Short Bond ETF, sells First Trust Technology AlphaDEX Fund, Sempra Energy, Check Point Software Technologies, Alerian MLP ETF, SelectQuote Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Atwood & Palmer Inc.The U.S. health regulator revised on Monday the emergency use authorizations for COVID-19 antibody treatments from Regeneron and Eli Lilly to limit their use, as the drugs are unlikely to work against the Omicron coronavirus variant.  The Food and Drug Administration (FDA) said the treatments are currently not cleared for use in any U.S. states or territories, but may be authorized in certain regions if they work against potential new variants.The U.S. Food and Drug Administration (FDA) is likely to restrict the use of COVID-19 antibody treatments from Regeneron and Eli Lilly as they are ineffective against the Omicron variant, the Washington Post reported on Monday.  The FDA action will involve revising the emergency use authorizations for the monoclonal antibodies, the report said https://wapo.st/3KDk1YI, citing two senior administration health officials.Investment company AustralianSuper Pty Ltd (Current Portfolio) buys ICL Group, Apple Inc, Taiwan Semiconductor Manufacturing Co, Ferrari NV, Qualcomm Inc, sells Dollar General Corp, Eli Lilly and Co, CBRE Group Inc, Citigroup Inc, Aon PLC during the 3-months ended 2021Q4, according to the most recent filings of the investment company, AustralianSuper Pty Ltd.;156.49000549316406;"One day after the U.S. Food and Drug Administration said it's halting the use of antibody drugs as COVID-19 treatments because they don't work on the highly contagious omicron variant, Pfizer and German partner BioNTech announced they are launching a trial to evaluate an omicron-based vaccine in healthy adults aged 18 to 55.Drug companies and regulators are making adjustments to cope with the challenges posed by the Covid-19 variant.The firm has already signed a partnership with Covid vaccine developer BioNTech to build an early-warning system for spotting new Covid variants.Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant. Pfizer has said that a two-dose regimen of the original vaccine may not be sufficient to protect against infection from the omicron variant. Related: Pfizer/BioNTech COVID-19 Shot Provides Partial Protection Against Omicron, Study Shows. The companies plan to test the immune response generated by the Omicron-basedBioNTech said it and partner Pfizer may not be able to stick with their plan to launch an Omicron-targeting vaccine by the end of March, depending on how much clinical trial data regulators will require.  Pfizer and BioNTech said earlier they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.  Banking on volunteers in the United States, the companies plan to test the immune response generated by the Omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot for people who already received two doses of their original vaccine.  The companies plan to study the safety and tolerability of the shots in the more than 1,400 people who will be enrolled in the trial.Pfizer Inc. and German partner BioNTech SE said Tuesday they are launching a trial to evaluate an omicron-based COVID-19 vaccine in healthy adults aged 18 to 55. ""While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future,"" said Kathrin U.First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age. The study will have three cohorts examining different regimens of thPfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.  ""While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future,"" Pfizer's head of vaccine research and development, Kathrin Jansen, said in a statement.";344.760009765625;EU antitrust regulators have extended the deadline for their decision on U.S. life sciences company Illumina's bid for $8 billion cash-and-stock takeover of Grail to March 4, according to a European Commission filing.  The deal, unveiled in September 2020, would give Illumina access to Grail's flagship Galleri blood test used to diagnose cancers at early stages when the disease is easier to treat.  Illumina however has rejected such concerns, saying that Menlo Park, California-based Grail has no presence in Europe and has no plans to enter the region for the foreseeable future.;227.11000061035156;When you're looking for stalwart stocks to preserve your portfolio's value while also providing exposure to long-term growth, healthcare businesses can be quite appealing.  More importantly, they're both absolutely indispensable for their customers, which gives them staying power.  Thermo Fisher Scientific (NYSE: TMO) is a healthcare sector juggernaut, earning its market cap of around $253 billion by producing a galaxy of critical goods and hardware for hospitals, diagnostic clinics, and research institutions.AmerisourceBergen has pulled back and is now holding near its 129.64 buy point, although market risk remains high.  The wholesale generic-drug company will kick off fiscal 2022 when it reports first-quarter earnings on Feb. 2.  Past growth for AmerisourceBergen has been steady.Tesla Inc., Steel Dynamics Inc., United Rentals Inc., Freeport-McMoRan Inc. and Vertex Pharmaceuticals Inc. are included in this blog.;222.30999755859375;San Rafael, CA, based Investment company Private Ocean, LLC (Current Portfolio) buys Regal Rexnord Corp, T-Mobile US Inc, Vanguard Total Bond Market ETF, WisdomTree U.S.Biogen Inc. (BIIB) closed at $224.69 in the latest trading session, marking a +1.89% move from the prior day.Investment company LCM Capital Management Inc (Current Portfolio) buys Southern Co, Advanced Micro Devices Inc, Diageo PLC, Duke Energy Corp, Xcel Energy Inc, sells Tesla Inc, Biogen Inc, Yum China Holdings Inc, UiPath Inc, CymaBay Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, LCM Capital Management Inc.;233.47000122070312;;125.0999984741211;Miami, FL, based Investment company EFG Asset Management (Americas) Corp. (Current Portfolio) buys Tesla Inc, Microsoft Corp, Dick's Sporting Goods Inc, iShares MSCI All Country Asia ex Japan Index Fund, UnitedHealth Group Inc, sells TJX Inc, S&P Global Inc, Norfolk Southern Corp, Booking Holdings Inc, Heico Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, EFG Asset Management (Americas) Corp..;130.94000244140625;;368.0;;4.829999923706055;;84.86000061035156;;90.62999725341797;;74.1500015258789;;69.18000030517578;Investment company Orgel Wealth Management, LLC (Current Portfolio) buys Vanguard S&P Small-Cap 600 ETF, iShares Core S&P 500 ETF, Vanguard Mid-Cap Value ETF, Schwab International Equity ETF, Vanguard Mid-Cap Growth ETF, sells Vanguard International High Dividend Yield ETF, ProShares Short S&P500, Trane Technologies PLC, iShares MSCI USA ESG Optimized ETF, Exact Sciences Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Orgel Wealth Management;77.20999908447266;To say that Novavax (NASDAQ: NVAX) investors haven't had a smooth ride recently is a massive understatement.  Amid a string of successes (and a few setbacks) in getting its coronavirus vaccine, Nuvaxovid approved by regulators in the European Union, South Korea, and with the World Health Organization, the company's stock has plummeted, falling around 55% compared to its price six months ago and 57% since a mere 30 days ago.  Has the stock fallen enough to be worth a purchase based on the expectation of future jab sales and vaccine development, or should investors stay away for the time being?If memory serves me correctly, the last time I mentioned Novavax (NASDAQ:NVAX) was in November. At the time, I didn’t have much good things to say about it other than the spike higher from international regulatory developments presented an ideal opportunity to consider exiting NVAX stock. Source: Vladimka production / Shutterstock.com As someone who has never had a position (neither bullish nor bearish) in Novavax, I hope you took the deal the market was giving you then. Right now, the situation;84.7699966430664;;75.93000030517578;;68.70999908447266;;114.04000091552734;;50.9900016784668;;73.62000274658203;;62.540000915527344;;48.13999938964844;;39.869998931884766;;18.209999084472656;;10.25;Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D. as General Counsel and Corporate Secretary. Lori Kunkel, M.D. and Ron Dror, Ph.D. have also joined the company's Scientific Advisory Board.;66.61000061035156;;33.72999954223633;Investment company Arthur M. Cohen & Associates, Llc (Current Portfolio) buys Invesco NASDAQ 100 ETF, General Electric Co, RingCentral Inc, Ford Motor Co, S&P MidCap 400 ETF, sells Ansys Inc, BTC iShares MSCI USA Momentum Factor ETF, Wynn Resorts, Church & Dwight Co Inc, The Trade Desk Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Arthur M.;69.06999969482422;Miami, FL, based Investment company EFG Asset Management (Americas) Corp. (Current Portfolio) buys Tesla Inc, Microsoft Corp, Dick's Sporting Goods Inc, iShares MSCI All Country Asia ex Japan Index Fund, UnitedHealth Group Inc, sells TJX Inc, S&P Global Inc, Norfolk Southern Corp, Booking Holdings Inc, Heico Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, EFG Asset Management (Americas) Corp..;33.529998779296875;;89.88999938964844;;31.360000610351562;Hood River, OR, based Investment company Northside Capital Management, LLC (Current Portfolio) buys Snowflake Inc, Datadog Inc, Procore Technologies Inc, Planet Labs PBC, Trane Technologies PLC, sells Vir Biotechnology Inc, Roblox Corp, Oracle Corp, Abbott Laboratories, Johnson & Johnson during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Northside Capital Management, LLC.;17.170000076293945;;59.959999084472656;;10.239999771118164;;31.479999542236328;Investment company Bard Financial Services, Inc. (Current Portfolio) buys Edison International, Ionis Pharmaceuticals Inc, Omnicom Group Inc, Vanguard International High Dividend Yield ETF, Uber Technologies Inc, sells Templeton Global Income Fund, Welltower Inc, Sprott Physical Gold Trust, Truist Financial Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bard Financial Services, Inc..;67.08000183105469;;46.63999938964844;;8.369999885559082;One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...;53.220001220703125;Investment company Newton One Investments LLC (Current Portfolio) buys Zillow Group Inc, Splunk Inc, Pinterest Inc, Mandiant Inc, Peloton Interactive Inc, sells Automatic Data Processing Inc, JPMorgan BetaBuilders Canada ETF, AllianceBernstein Holding LP, Bank of America Corp, Consumer Portfolio Services Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Newton One Investments LLC.SAN FRANCISCO, January 25, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Artisan Development Labs Inc. (DBA Artisan Bio), an immune cell engineering company developing next-generation cell therapies, today announced a collaboration to discover novel antibodies against five undisclosed targets, with an option to expand with additional targets.;21.93000030517578;;25.190000534057617;The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.
2022-01-26;222.5399932861328;Pittsford, NY, based Investment company LVW Advisors, LLC (Current Portfolio) buys Vanguard FTSE Pacific ETF, Vanguard FTSE Emerging Markets ETF, iShares MSCI Global Min Vol Factor ETF, Xtrackers MSCI EAFE Hedged Equity ETF, Amgen Inc, sells Vanguard S&P 500 ETF, AT&T Inc, BTC iShares U.S.Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;67.33999633789062;FOSTER CITY, Calif., January 25, 2022--Gilead Sciences Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on studies evaluating the combination of magrolimab plus azacitidine due to an apparent imbalance in investigator-reported suspected unexpected serious adverse reactions (SUSARs) between study arms. While no clear trend in the adverse reactions or new safety signal has been identified by Gilead at this time, the partial cliGilead Sciences, which sold the drug for $3 million less than three years ago, still could come out a winner if the drug is approved by the FDA for patients with the blood cancer myelofibrosis.Sierra Oncology reported a late-stage win Tuesday for a bone cancer drug it acquired at a discount — and the biotech stock catapulted.Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Boston, MA, based Investment company Albert D Mason Inc (Current Portfolio) buys PagSeguro Digital, Gilead Sciences Inc, Walgreens Boots Alliance Inc, National Retail Properties Inc, Freeport-McMoRan Inc, sells Verizon Communications Inc, The Kraft Heinz Co, SFL Corp, Martin Midstream Partners LP during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Albert D Mason Inc.;605.25;Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck are included in this blog.Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.Leawood, KS, based Investment company Convergence Investment Partners, LLC (Current Portfolio) buys Chevron Corp, Exelon Corp, Extra Space Storage Inc, Juniper Networks Inc, Moelis, sells Bank of New York Mellon Corp, Avnet Inc, Williams Inc, MDU Resources Group Inc, Brandywine Realty Trust during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Convergence Investment Partners, LLC.Among the top stocks to watch, top biotech stock Regeneron Pharmaceutical shows a new buy point in the current market weakness.The FDA modifies EUA for COVID-19 antibody cocktail drugs of Regeneron (REGN) and Lilly (LLY), limiting their use to treat individuals with COVID-19 infection from non-Omicron variants.;160.6999969482422;Gregory Zuckerman, author of ‘A Shot to Save the World’, joins Yahoo Finance's Editor-in-Chief, Andy Serwer, for a discussion about what COVID-19 will look like in the future.Moderna's (MRNA) stock has been on a declining trend since August 2021 after a strong rally since the beginning of 2020.Yahoo Finance's Anjalee Khemlani details the record-breaking daily COVID-19 deaths as the Omicron wave continues and the beginning of Pfizer and BioNTech's clinical trial for an Omicron vaccine.(Bloomberg) -- Pfizer Inc. and BioNTech SE are starting a study of a Covid-19 vaccine that targets the omicron variant, enrolling participants in a clinical trial that will evaluate the shot’s ability to prompt an immune response in adults.Most Read from BloombergStock Rebound Fails and Futures Plunge on Earnings: Markets WrapNvidia Quietly Prepares to Abandon $40 Billion Arm BidMark Zuckerberg’s Stablecoin Ambitions Unravel With Diem Sale TalksStocks Storm Back From 4% Rout to Close Higher: MarBioNTech (NASDAQ:BNTX) stock is rising higher on news it and Pfizer (NYSE:PFE) can test a new Covid-19 vaccine for Omicron. Source: Shutterstock According to a press release, BioNTech and Pfizer can move forward with plans to evaluate this vaccine in adults ranging from 18 to 55 years in age. This has cohorts examining three regimens of the current Covid-19 vaccine or the new Omicron version. This study will include a total of 1,420 participants. The first batch has two doses of the current vacc;331.7799987792969;We are proud to announce the 2022 winner of our annual Greater Good Initiative grant – Dr. Ranjana Bhattacharjee and the International Institute of Tropical Agriculture (IITA).Ensemble Capital, an investment management firm, published its fourth-quarter 2021 investor letter – a copy of which can be downloaded here. In the letter, the fund has focused on economic and COVID-related commentary. The fund also covered the notable detractors and contributors to its fourth-quarter investment performance and offered a discussion of an aspect of […];226.5800018310547;Vertex Pharmaceuticals Inc., Marten Transport, Nucor, Seagate Technology and Sanderson Farms are included in this blog.It has positive clinical results in hand, a healthy balance sheet, and a strong teammate on its side.Investment company SWS Partners (Current Portfolio) buys Abbott Laboratories, Cognizant Technology Solutions Corp, American Homes 4 Rent, Tapestry Inc, Stitch Fix Inc, sells Medtronic PLC, International Business Machines Corp, Zillow Group Inc, Kohl's Corp, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, SWS Partners.The Zacks Rank and ESP are still a solid combination to predict earnings beats.;219.60000610351562;Investment company Optas, LLC (Current Portfolio) buys Vanguard Small Cap ETF, Vanguard ESG U.S. Stock ETF, Vanguard ESG International Stock ETF, Schwab Emerging Markets Equity ETF, Discovery Inc, sells Vanguard Extended Market Index ETF, Verizon Communications Inc, Moderna Inc, Novartis AG, Biogen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Optas, LLC.Investment company Covenant Asset Management, LLC (Current Portfolio) buys Marvell Technology Inc, Zebra Technologies Corp, Staar Surgical Co, Canadian Pacific Railway, Vanguard Short-Term Inflation-Protected Securities, sells Mastercard Inc, DocuSign Inc, The Walt Disney Co, , during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Covenant Asset Management, LLC.In the latest trading session, Biogen Inc. (BIIB) closed at $222.31, marking a -1.06% move from the previous day.The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.;224.50999450683594;"Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own pancreatic cancer and have an intact immune system. Historically, 42-days is the median survival produced by a 4-drug combination: 2 chemotherapies and two immunotherapies in the same genetic pancreatic cancer mouse model. ""This data highlights why we are excited to collaborate with BeiGene on our planned 2022 Phase 1b/2a combination";123.55000305175781;;130.1199951171875;;363.80999755859375;;4.769999980926514;;83.69999694824219;Investment company 180 Wealth Advisors, Llc (Current Portfolio) buys TJX Inc, UiPath Inc, Lockheed Martin Corp, Energy Transfer LP, Twilio Inc, sells Dollar General Corp, Intuitive Surgical Inc, Royal Bank of Canada, Direxion Daily Financial Bull 3x Shares, Baxter International Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, 180 Wealth Advisors, Llc.;88.44999694824219;Radnor, PA, based Investment company Lincoln National Corp (Current Portfolio) buys 10x Genomics Inc, Invesco Emerging Markets Sovereign Debt ETF, Belpointe PREP LLC, Innovator U.S.;73.5199966430664;Incyte Corporation (NASDAQ: INCY) is withdrawing the New Drug Application for parsaclisib in relapsed/refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). Parsaclisib is the Company's next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ). The decision impacts only the FL, MZL, and MCL indications in the U.S. and does not affect other ongoing clinical trials in the U.S. or other countries. Related: Gilead Withdraws Use Of ZydelWILMINGTON, Del., January 25, 2022--Incyte Provides Update on Parsaclisib and MCLA-145UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a rangCase in point: Last year Cathie Wood, CEO of the asset management company ARK Invest, was one big name in the investing world whose actively managed, exchange-traded funds (ETFs) lagged the broad indices.  Let's consider two Cathie Wood stocks that have been hammered recently but still look like excellent stocks to buy and hold through the next decade: Exact Sciences (NASDAQ: EXAS) and Incyte (NASDAQ: INCY).  Exact Sciences' selling point is simple: its most important product, Cologuard, helps save lives.;68.88999938964844;Case in point: Last year Cathie Wood, CEO of the asset management company ARK Invest, was one big name in the investing world whose actively managed, exchange-traded funds (ETFs) lagged the broad indices.  Let's consider two Cathie Wood stocks that have been hammered recently but still look like excellent stocks to buy and hold through the next decade: Exact Sciences (NASDAQ: EXAS) and Incyte (NASDAQ: INCY).  Exact Sciences' selling point is simple: its most important product, Cologuard, helps save lives.;79.18000030517578;Yahoo Finance's Anjalee Khemlani details the record-breaking daily COVID-19 deaths as the Omicron wave continues and the beginning of Pfizer and BioNTech's clinical trial for an Omicron vaccine.Last week Novavax (NASDAQ:NVAX) received an emergency use authorization (EUA) for its Covid-19 vaccine candidate in Australia. That news catalyst subsequently pushed NVAX stock approximately 6% higher. Source: Ascannio/Shutterstock.com However, the negative market sentiment weighing down the market proved too much to overcome. As the week ended, the stock had lost all of those gains, ending close to a 52-week low. This is the latest episode in a continual “yeah, but” narrative that has plagued NRoughly a month ago, when I last wrote about Novavax (NASDAQ:NVAX), I thought NVAX stock was sure to move upward. This stock was fresh on the heels of news that the World Health Organization (WHO) had granted the firm two Emergency Use Listings (EULs) for its Covid-19 vaccine. Novavax was also planning to reapproach the U.S. Food an Drug Administration (FDA) and begin submitting data by the year’s end. Source: vovidzha / Shutterstock.com Ultimately, Novavax was successful in submitting that data;85.22000122070312;;75.51000213623047;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on Friday, February 11, 2022.;70.23999786376953;;112.94999694824219;Berwyn, PA, based Investment company Kistler-Tiffany Companies, LLC (Current Portfolio) buys Vanguard S&P 500 ETF, PowerShares QQQ Trust Ser 1, Global X U.S.;50.529998779296875;;72.61000061035156;;61.84000015258789;It has positive clinical results in hand, a healthy balance sheet, and a strong teammate on its side.Investment company Moseley Investment Management Inc (Current Portfolio) buys Berkshire Hathaway Inc, Liberty Broadband Corp, Brookfield Asset Management Inc, CarMax Inc, Cable One Inc, sells Vanguard Total World Bond ETF, PayPal Holdings Inc, Direxion Daily Financial Bull 3x Shares, CRISPR Therapeutics AG, Dover Motorsports Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Moseley Investment Management Inc.Yahoo Finance's Jared Blikre examines markets heading into the final trading hour, the U.S. dollar, tech performers in the Nasdaq, and the sector action across industries and travel stocks.;46.59000015258789;;39.27000045776367;;17.920000076293945;;9.739999771118164;;64.97000122070312;;33.25;;68.11000061035156;;32.349998474121094;;89.62999725341797;;32.310001373291016;Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.;17.0;;55.15999984741211;;9.789999961853027;;31.440000534057617;The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.;68.51000213623047;;47.72999954223633;;7.809999942779541;;52.2599983215332;;21.93000030517578;;25.010000228881836;Investment company Hardman Johnston Global Advisors LLC (Current Portfolio) buys Sea, Alkermes PLC, Howmet Aerospace Inc, Applied Materials Inc, Paychex Inc, sells NVIDIA Corp, Vipshop Holdings during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hardman Johnston Global Advisors LLC.Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.
2022-01-27;224.0;Earlier this month, the European Commission gave Lumykras the go-ahead as a treatment for lung cancer.Corning, NY, based Investment company John G Ullman & Associates Inc (Current Portfolio) buys Fiserv Inc, Skanska AB, Chewy Inc, Mandiant Inc, Vontier Corp, sells Verizon Communications Inc, AT&T Inc, Algonquin Power & Utilities Corp, Flowserve Corp, Synaptics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, John G Ullman & Associates Inc.Investment company Franklin Street Advisors Inc (Current Portfolio) buys Lowe's Inc, Genuine Parts Co, Dollar General Corp, Activision Blizzard Inc, Laboratory Corp of America Holdings, sells ViacomCBS Inc, AT&T Inc, NVIDIA Corp, McDonald's Corp, Sysco Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Franklin Street Advisors Inc .;67.2699966430664;Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.(Bloomberg) -- More than 20 years ago, Paul Stoffels helped form Belgian biotechnology company Galapagos NV. Now he’s headed back to lead an effort to revive it.Most Read from BloombergApple to Rival Square by Turning iPhones Into Payment TerminalsStocks Drop in Roller-Coaster Ride for Wall Street: Markets WrapPowell Backs March Liftoff, Won’t Rule Out Hike Every MeetingA Nor’easter Approaching New York Risks Becoming a Bomb CycloneJeremy Grantham Has an Even Scarier Prediction Than His Crash CaGilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.Investment company Strategic Investment Advisors (Current Portfolio) buys iShares 1-3 Year Treasury Bond ETF, BTC iShares Core MSCI EAFE ETF, Target Corp, CVS Health Corp, Capital One Financial Corp, sells iShares J.P.Investment company Polaris Wealth Advisory Group, LLC (Current Portfolio) buys iShares 7-10 Year Treasury Bond ETF, PulteGroup Inc, AT&T Inc, Invesco Senior Loan ETF, Cisco Systems Inc, sells iShares iBoxx USD Investment Grade Corporate Bond , SPDR Bloomberg Convertible Securities ETF, Westlake Chemical Corp, Citigroup Inc, ViacomCBS Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Polaris Wealth Advisory Group, LLC.Investment company Econ Financial Services Corp (Current Portfolio) buys Vanguard Short-Term Bond ETF, Vanguard Long-Term Corporate Bond ETF, Vanguard Intermediate-Term Corporate Bond ETF, Vanguard Total International Bond ETF, SPDR Portfolio S&P 500 Value ETF, sells Schwab International Equity ETF, Schwab U.S.Telehealth has transformed HIV service delivery during the COVID-19 pandemic. But as a new Gilead policy paper explains, it’s critical that telehealth programs are designed to promote health equity...San Francisco, CA, based Investment company Violich Capital Management, Inc. (Current Portfolio) buys Amazon.com Inc, Technology Select Sector SPDR ETF, ConocoPhillips, Cisco Systems Inc, Duke Energy Corp, sells Intel Corp, Vanguard Long-Term Government Bond ETF, Gilead Sciences Inc, Vanguard FTSE Emerging Markets ETF, TotalEnergies SE during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Violich Capital Management, Inc..With a beefed up team of experts and a fresh $85 million from investors and partners such as Gilead Sciences Inc., an Emeryville cell therapy company is seeking to pioneer treatments to reset a patient's immune system to defeat a range of autoimmune diseases.  Kyverna Therapeutics Inc., which emerged from stealth two years ago, now has 50 full-time-equivalent employees and looks to take its lead therapy into a mid-stage clinical trial this year.  The company isn't saying which specific diseases it is targeting but autoimmune diseases can include lupus nephritis and systemic sclerosis, rare chronic diseases that lead to abnormalities in the skin, joins and internal organs, and inflammatory conditions that involve chronic muscle inflammation and muscle weakness.;608.719970703125;Investment company First Quadrant L P (Current Portfolio) buys Innoviva Inc, NOW Inc, General Electric Co, CF Industries Holdings Inc, JPMorgan Chase, sells , Brookfield Asset Management Inc, , Roku Inc, Cardiovascular Systems Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Quadrant L P.Minneapolis, MN, based Investment company Foundry Partners, LLC (Current Portfolio) buys Cisco Systems Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Quest Diagnostics Inc, C.H.Investment company Moody Lynn & Lieberson, Llc (Current Portfolio) buys AbbVie Inc, Pfizer Inc, Northrop Grumman Corp, PepsiCo Inc, American International Group Inc, sells PayPal Holdings Inc, iShares MSCI Japan ETF, Intuitive Surgical Inc, Block Inc, Uber Technologies Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Moody Lynn & Lieberson, Llc.;154.5399932861328;Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.Moderna has begun testing an omicron-specific COVID-19 booster in healthy adults, following in the wake of a study announced earlier this week by Pfizer and German partner BioNTech ,the Associated Press reported. The original vaccines still offer good protection against death and severe illness. Studies in the U.S. and elsewhere show a booster dose strengthens that protection and improves the chances of avoiding even a milder infection. The U.S. is averaging 618,231 cases a day, according to a NShares of coronavirus vaccine makers generally had a good Wednesday on the back of a coming push on additional jabs, plus a notable recommendation boost by a prominent investment bank.  In contrast to the day's dip in the S&P 500 index, Moderna (NASDAQ: MRNA) stock enjoyed a 1.6% lift, Comirnaty vaccine co-developers Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) respectively rose by 0.9% and 2.7%, and perennial underdog Novavax (NASDAQ: NVAX) gained 2.6%.Dr. Elizabeth Clayborne, Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance Live to discuss the staffing shortage in hospitals handling COVID patients, testing, masking, the importance of vaccines, long COVID symptoms, and re-infection rates.;324.3599853515625;Investment company Liontrust Investment Partners LLP (Current Portfolio) buys PayPal Holdings Inc, DocuSign Inc, Illumina Inc, NVR Inc, Otis Worldwide Corp, sells Moderna Inc, Brookfield Infrastructure Corp, 3M Co, Mobile TeleSystems PJSC, Twilio Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Liontrust Investment Partners LLP.;228.22000122070312;Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.The Dow Jones Industrial Average surged Thursday, as Tesla stock skidded on earnings results. Apple earnings are due after the market close.Dow Jones futures tilted higher early Friday, while S&P 500 futures and Nasdaq futures rose further, amid volatile overnight trading. Tesla headlined key earnings after hours, while investors continue to mull a hawkish Fed.Vertex (VRTX) delivered earnings and revenue surprises of 2.74% and 4.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?BOSTON, January 26, 2022--Vertex Reports Fourth Quarter 2021 and Full Year Financial Results;218.94000244140625;Black and Latino people were underrepresented in the trials on which approval of the Alzheimer's drug was based.CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer’s disease, including details of the study’s goal for diverse enrollment and primary endpoint. Biogen aims to enroll 18 percent of U.S. participants in ENVISION from Black/African American and LatinxInvestment company Resonant Capital Advisors, LLC (Current Portfolio) buys Marqeta Inc, Vanguard Tax-Exempt Bond ETF, iShares National Muni Bond ETF, Apple Inc, Amazon.com Inc, sells Xilinx Inc, Biogen Inc, Citrix Systems Inc, Exelixis Inc, Citigroup Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Resonant Capital Advisors, LLC.Boston, MA, based Investment company Eastern Bank (Current Portfolio) buys Eastman Chemical Co, Vanguard S&P 500 ETF, Honeywell International Inc, Vanguard Total Bond Market ETF, PayPal Holdings Inc, sells Invesco BulletShares 2021 Corporate Bond ETF, Autodesk Inc, Ashland Global Holdings Inc, FedEx Corp, Akamai Technologies Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Eastern Bank.;202.89999389648438;;122.91000366210938;;127.18000030517578;;353.8500061035156;It didn't take long for the Bio-Techne CEO to know the life sciences company he took over in April 2013 was ailing.;4.650000095367432;;83.05000305175781;;85.86000061035156;10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 after market close on Wednesday, February 16, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.;71.58999633789062;Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.;68.91000366210938;Exact Sciences (EXAS) closed the most recent trading day at $68.89, moving -0.42% from the previous trading session.Investment company Patten & Patten Inc (Current Portfolio) buys JPMorgan Equity Premium Income ETF, Delta Air Lines Inc, Lincoln Electric Holdings Inc, Planet Fitness Inc, Exact Sciences Corp, sells AT&T Inc, Hologic Inc, General Electric Co, SPDR Gold Shares ETF, NovoCure during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Patten & Patten Inc.Investment company Resonant Capital Advisors, LLC (Current Portfolio) buys Marqeta Inc, Vanguard Tax-Exempt Bond ETF, iShares National Muni Bond ETF, Apple Inc, Amazon.com Inc, sells Xilinx Inc, Biogen Inc, Citrix Systems Inc, Exelixis Inc, Citigroup Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Resonant Capital Advisors, LLC.Investment company Berger Financial Group, Inc (Current Portfolio) buys Hartford Core Bond ETF, Apple Inc, Independence Realty Trust Inc, Amazon.com Inc, Mastercard Inc, sells , Exact Sciences Corp, Nuveen Municipal Credit Opps Fund, American Airlines Group Inc, Cardiovascular Systems Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Berger Financial Group, Inc.Grand Rapids, MI, based Investment company LaFleur & Godfrey LLC (Current Portfolio) buys Medtronic PLC, Goldman Sachs Group Inc, Alcon Inc, Micron Technology Inc, Exxon Mobil Corp, sells Zillow Group Inc, Zscaler Inc, Lockheed Martin Corp, Zimmer Biomet Holdings Inc, ProShares Short S&P500 during the 3-months ended 2021Q4, according to the most recent filings of the investment company, LaFleur & Godfrey LLC.;72.91999816894531;The road to FDA approval can be long, and in the case of COVID-19 vaccines, there is no time for delays and no room for error.  One company that has come to understand this very well is Novavax (NASDAQ: NVAX).  Since 2020, the company has been developing a vaccine to help prevent and fight the impact of COVID-19.Novavax (NASDAQ: NVAX) and Teladoc Health (NYSE: TDOC) both were stock market superstars in 2020.  As the pandemic deepened, investors bet on Novavax's coronavirus-vaccine program and Teladoc's ability to bring medical visits right into people's homes.  As a result, Novavax shares surged 2,700% and Teladoc stock climbed 138%.‘A Shot to Save the World’ author, Gregory Zuckerman joins 'Influencers with Andy Serwer' to discuss the Trump Administration's role in developing the COVID-19 vaccines.As has been the case over the past two years, pretty much anything tied to treating COVID-19 has the potential to generate serious revenue growth this year.  According to the consensus estimate from Wall Street, biotech stock Novavax (NASDAQ: NVAX) is expected to bring in $4.62 billion in sales in 2022.  This would mark a 236% improvement over the $1.38 billion in sales forecast for 2021.Shares of coronavirus vaccine makers generally had a good Wednesday on the back of a coming push on additional jabs, plus a notable recommendation boost by a prominent investment bank.  In contrast to the day's dip in the S&P 500 index, Moderna (NASDAQ: MRNA) stock enjoyed a 1.6% lift, Comirnaty vaccine co-developers Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) respectively rose by 0.9% and 2.7%, and perennial underdog Novavax (NASDAQ: NVAX) gained 2.6%.Dr. Elizabeth Clayborne, Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance Live to discuss the staffing shortage in hospitals handling COVID patients, testing, masking, the importance of vaccines, long COVID symptoms, and re-infection rates.;82.4000015258789;With a beefed up team of experts and a fresh $85 million from investors and partners such as Gilead Sciences Inc., an Emeryville cell therapy company is seeking to pioneer treatments to reset a patient's immune system to defeat a range of autoimmune diseases.  Kyverna Therapeutics Inc., which emerged from stealth two years ago, now has 50 full-time-equivalent employees and looks to take its lead therapy into a mid-stage clinical trial this year.  The company isn't saying which specific diseases it is targeting but autoimmune diseases can include lupus nephritis and systemic sclerosis, rare chronic diseases that lead to abnormalities in the skin, joins and internal organs, and inflammatory conditions that involve chronic muscle inflammation and muscle weakness.;72.44999694824219;;66.87999725341797;;107.83000183105469;;48.20000076293945;;70.11000061035156;;58.7599983215332;CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $61.84, moving -1.12% from the previous trading session.Investment company Boyd Watterson Asset Management Llc (Current Portfolio) buys iShares Core U.S. Aggregate Bond ETF, Plug Power Inc, Qualcomm Inc, iShares 0-5 Year TIPS Bond ETF, Bloom Energy Corp, sells Fiserv Inc, Intel Corp, WEX Inc, CRISPR Therapeutics AG, Citigroup Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Boyd Watterson Asset Management Llc.;42.0099983215332;;35.779998779296875;Baltimore, MD, based Investment company Brown Advisory Inc (Current Portfolio) buys Visa Inc, Alphabet Inc, Mastercard Inc, Taiwan Semiconductor Manufacturing Co, The Estee Lauder Inc, sells Chegg Inc, Fair Isaac Corp, Accenture PLC, Lattice Semiconductor Corp, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Brown Advisory Inc.;17.420000076293945;Investment company Resonant Capital Advisors, LLC (Current Portfolio) buys Marqeta Inc, Vanguard Tax-Exempt Bond ETF, iShares National Muni Bond ETF, Apple Inc, Amazon.com Inc, sells Xilinx Inc, Biogen Inc, Citrix Systems Inc, Exelixis Inc, Citigroup Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Resonant Capital Advisors, LLC.;8.949999809265137;- If successful, BridgeBio’s investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body’s hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone -Initial Phase 1/2 data readout anticipated in the second half of 2022 -BridgeBio’s gene therapy portfolio also includes a clinical stage program for Canavan disease and preclinical programs for classic galactosemia, TMC1 hearing loss, tuberous sclerosis types 1 and 2, cystinur;59.689998626708984;;31.450000762939453;;64.33000183105469;;31.969999313354492;;89.79000091552734;;31.260000228881836;;16.989999771118164;;51.880001068115234;;9.420000076293945;;30.139999389648438;;65.27999877929688;;45.459999084472656;;7.769999980926514;;51.34000015258789;;21.530000686645508;;24.559999465942383;Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.
2022-01-28;229.13999938964844;Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.Los Angeles, CA, based Investment company Bank Of The West (Current Portfolio) buys Citigroup Inc, Goldman Sachs Group Inc, First Republic Bank, Teradyne Inc, The Walt Disney Co, sells Caesars Entertainment Inc, Bristol-Myers Squibb Co, CVS Health Corp, Activision Blizzard Inc, T-Mobile US Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bank Of The West.Is Amgen (AMGN) a great pick from the value investor's perspective right now? Read on to know more.Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (FB), UnitedHealth Group Incorporated (UNH), and salesforce.com, inc. (CRM).In the latest trading session, Amgen (AMGN) closed at $224, marking a +0.66% move from the previous day.Passive-income seekers see the start of a given year as an opportunity to participate in the “Dogs of the Dow” strategy. What’s that investment method? Well, investors buy the 10 highest-yielding stocks from the Dow Jones Index — say at the start of 2022 — and hold them for 12 months. Then, in 2023, they invest in the next set of 10 highest-yielding stocks and rebalance their portfolios. While this may look like a dividend strategy, its roots are actually based on value investing. Put another waInvestment company Morgan Jess S & Co Inc (Current Portfolio) buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Microsoft Corp, Vanguard Total International Stock, sells Amgen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Morgan Jess S & Co Inc.;68.86000061035156;Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.Five corporate behemoths will report fourth-quarter 2021 earnings results next week. These are: TMO, FB, GOOGL, GILD and UPS.;624.9199829101562;"Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have voluntarily withdrawn their application with the FDA for the expanded use of Libtayo in patients with advanced cervical cancer. The application for the monoclonal antibody as the second-line of treatment in the patients was withdrawn ""after the companies and the FDA were not able to align on certain post-marketing studies."" The FDA had accepted the supplemental application for priority review in September,Regeneron Pharmaceuticals Inc and its partner Sanofi voluntarily withdrew their application with the U.S. drug regulator for the expanded use of their anti-cancer drug Libtayo in patients with advanced cervical cancer.  The application for the monoclonal antibody as the second-line of treatment in the patients was withdrawn ""after the companies and the U.S. Food and Drug Administration were not able to align on certain post-marketing studies"", the companies said on Friday.  The FDA had accepted the supplemental application for priority review in September.Shares of Regeneron Pharmaceuticals Inc. were down 0.1% in premarket trading on Friday after the company and Sanofi said they will no longer seek Food and Drug Administration approval for Libtaya as a second-line treatment for cervical cancer. The therapy is currently approved to treat two forms of skin cancer and a type of lung cancer. The companies said they made the decision to withdraw the application for Libtaya because they were not able to ""align"" on post-marketing studies with the FDA; hRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the voluntary withdrawal of the supplemental Biologics License Application (sBLA) for Libtayo® (cemiplimab-rwlc) as a second-line treatment for patients with advanced cervical cancer. The decision was made after the companies and the U.S. Food and Drug Administration (FDA) were not able to align on certain post-marketing studies. Discussions with regulatory authorities outside of the U.S. are ongoing.";162.22000122070312;The head of Germany's vaccines regulator said he supported the decision by BioNTech Pfizer to conduct pivotal tests on their adapted vaccine to target the COVID-19 Omicron variant in the United States.  Pfizer and Germany-based BioNTech said on Tuesday they started a clinical trial in the United States to test the new version of their vaccine as Omicron eludes some of the protection provided by the original two-dose vaccine regimen.Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.;331.9599914550781;Illumina has offered to cut prices and continue to allow rivals access to its technologies in a bid to allay EU antitrust concerns about its proposed takeover of cancer detection test maker Grail, a European Commission filing showed on Friday.  The $8 billion cash-and-stock deal, unveiled in September 2020, would give Illumina access to Grail's flagship Galleri blood test used to diagnose cancers at early stages when the disease is easier to treat.  However, the European Commission has warned that the acquisition could curb innovation and competition.Illumina has offered to cut prices and continue to allow rivals access to its technologies in a bid to allay EU antitrust concerns about its proposed takeover of cancer detection test maker Grail, a European Commission filing showed on Friday.  The $8 billion cash-and-stock deal, unveiled in September 2020, would give Illumina access to Grail's flagship Galleri blood test used to diagnose cancers at early stages when the disease is easier to treat.  However, the European Commission has warned that the acquisition could curb innovation and competition.Illumina included in the Bloomberg Gender-Equality Index and the Human Rights Campaign Corporate Equality Index;243.02000427246094;The past two years have brought stock market investors great gains. The S&P 500 rose 47% over that time period, while the Dow Jones Industrial Average increased 27%. That's even as the pandemic worsened and worries about the economy multiplied.Despite the S&P 500 undergoing 38 double-digit percentage declines since the beginning of 1950, every single one of these drops was eventually erased by a bull-market rally and proved to be a buying opportunity.  In other words, there's no such thing as a bad time to put money to work in the stock market, as long as your holding time frame is measured in years.  What makes Sea such an incredible gem of a company is that it has not one or two, but three rapidly growing, diverse operating segments.Vertex Pharmaceuticals issued a bullish 2022 outlook, leading VRTX stock to approach a 12-month high early Thursday.Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.;225.2100067138672;Stocks are down after yesterday's volatile session. Apple is rising after it reported record revenue. Chevron dropped on its earnings report.Biogen will be selling its stake in a biosimilars joint venture to partner Samsung Biologics for up to $2.3 billion.Biogen Inc (NASDAQ: BIIB) is selling its stake in a pharmaceutical joint venture with the South Korean conglomerate Samsung for $2.3 billion. Under the agreement, Samsung Biologics is acquiring Biogen’s ownership in Samsung Bioepis, which manufactures off-patent versions of biologic medicines called biosimilars. Under the agreement terms, Biogen will receive billion in cash upon closing, followed by $1.25 billion paid out over two years. Biogen is also eligible to receive up to $50 million contiBy Sam Boughedda(Bloomberg) -- Samsung Biologics Co. will buy 49.9% of Samsung Bioepis from Biogen Inc., according to a regulatory filing, giving the South Korean drugmaker full ownership of the joint venture. Most Read from BloombergApple to Rival Square by Turning iPhones Into Payment TerminalsStocks Drop in Roller-Coaster Ride for Wall Street: Markets WrapCrypto Secrecy Makes DeFi a Financial Felon’s WonderlandHow a Fox News Interview Threw the Antiwork Subreddit Into ChaosAmericans’ Gas Stoves Are as Bad foBiogen Inc. shares jumped in after-hours trading Thursday following an announcement that it is selling its part of a joint venture to Samsung Electronics Co. Ltd. Biogen has been working with Samsung Bioepis since 2012, according toThe companies will continue with their exclusive agreements, including for commercialization of their current portfolioCAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that they have entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to USD $2.3 billion.Biogen and Samsung Bioepis have built the industry leading anti-TNF portfolio in Europe1.Denver, CO, based Investment company Cambiar Investors Llc (Current Portfolio) buys iShares MSCI EAFE ETF, Barclays PLC, Constellation Brands Inc, Activision Blizzard Inc, iShares Russell 1000 Value ETF, sells Itau Unibanco Holding SA, ASML Holding NV, Biogen Inc, 3M Co, Banco Santander SA during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Cambiar Investors Llc.Investment company Nbt Bank N A (Current Portfolio) buys Vanguard High Dividend Yield Indx ETF, Dow Inc, Global X U.S.The Cambridge drugmaker has laid out ambitious plans for its FDA-required confirmatory trial of its Alzheimer's drug, Aduhelm. The plans include a diverse patient cohort, as well as new endpoints designed to rate patients' levels of cognitive impairment.Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Investment company Oxler Private Wealth LLC (Current Portfolio) buys Ford Motor Co, Verizon Communications Inc, Zoom Video Communications Inc, Shake Shack Inc, Royalty Pharma PLC, sells AT&T Inc, Newmont Corp, Biogen Inc, Barrick Gold Corp, Beyond Meat Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Oxler Private Wealth LLC.;212.92999267578125;CAMBRIDGE, Mass. & BEIJING, January 28, 2022--BeiGene announces an sNDA for BRUKINSA in first-line chronic lymphocytic leukemia has been accepted in China with breakthrough therapy designation.;127.62000274658203;;132.08999633789062;;367.0899963378906;;4.96999979019165;;86.16000366210938;;87.4000015258789;The Tri-Valley has a regional gross domestic product of nearly $42 billion.  “I really feel like the best days of the Tri-Valley are ahead of us,” said Naylor, the CEO of Innovation Tri-Valley Leadership Group.  In June 2021, ITV launched its Tri-Valley 2040 Vision Plan — a roadmap of sorts, Naylor said — toward those better days.In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.;74.2300033569336;Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT® (baricitinib) in adults with active systemic lupus erythematosus (also referred to as SLE and lupus) and the status of the U.S. atopic dermatitis supplemental new drug application (sNDA).;70.18000030517578;;82.91999816894531;"The world reached a COVID-19 vaccination milestone Friday of 10 billion doses administered globally, according to Our World in Data, but wealthier countries account for the vast majority, while poorer ones have been left behind.Novavax Inc. said Friday it will supply 5 million doses of its protein-based COVID-19 vaccine to Israel as part of an advance purchase agreement, with the Israeli Ministry of Health also taking an option to buy an additional 5 million doses. ""Novavax will work with the Ministry of Health to obtain the necessary authorizations and finalize plans for distribution in Israel pending regulatory approval,"" the company said in a statement. Novavax is currently conducting two Phase 3 trials of the vacciNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Israel's Ministry of Health today announced an agreement for the purchase of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.Israel has signed a deal to buy 5 million COVID-19 vaccine doses from Novavax, the Health Ministry said on Friday.  The vaccines are due to arrive in Israel in the coming months, pending regulatory approval.  Novavax's protein-based vaccine will be administered in two doses and has been found effective against a number of variants, the ministry said.Investors appear to be concerned about Pfizer's and BioNTech's head start in developing an omicron-specific vaccine.";86.0199966430664;;76.7300033569336;;69.69000244140625;;112.94999694824219;;50.09000015258789;;71.63999938964844;Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending to expand the current indication for AYVAKYT® (avapritinib) to include monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN) or mast cell leukemia (MCL), after at least one systemic th;59.0;Both companies' technologies appear to have tremendous potential.  For our Motley Fool members who are considering buying only one of these two biotech stocks, which do you think is the better pick and why?;43.41999816894531;;36.630001068115234;;17.770000457763672;;9.039999961853027;;64.11000061035156;;32.369998931884766;;66.0;Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Ultragenyx...;32.560001373291016;;91.23999786376953;;33.970001220703125;Investment company Cypress Point Wealth Management, LLC (Current Portfolio) buys Brooklyn ImmunoTherapeutics Inc, Robinhood Markets Inc, Vanguard Ultra-Short Bond ETF, Blend Labs Inc, Upstart Holdings Inc, sells Airbnb Inc, Unity Software Inc, Affirm Holdings Inc, ContextLogic Inc, Matador Resources Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Cypress Point Wealth Management, LLC.;17.510000228881836;;54.650001525878906;;10.0600004196167;;31.68000030517578;;65.9000015258789;;45.7400016784668;Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...;8.59000015258789;VANCOUVER, British Columbia, January 27, 2022--AbCellera to Report Full Year 2021 Financial Results on February 24, 2022;52.18000030517578;Both companies' technologies appear to have tremendous potential.  For our Motley Fool members who are considering buying only one of these two biotech stocks, which do you think is the better pick and why?;22.110000610351562;;25.079999923706055;
2022-01-31;227.13999938964844;Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.Over the 13-year period covering the end of the 2008 financial crisis until the fourth quarter of 2021, the biotech industry as a whole crushed the performance of most major U.S. stock indexes.  This prolonged bull market was fueled by a mix of tailwinds such as record low interest rates, massive fiscal stimulus by the U.S. government, and the insights and discoveries flowing out of the human genome project.Investment company Capital Planning LLC (Current Portfolio) buys PIMCO Enhanced Short Maturity Active Exchange-Trad, Schwab U.S.Westlake Village, CA, based Investment company One Capital Management, LLC (Current Portfolio) buys PowerShares QQQ Trust Ser 1, Microsoft Corp, iShares Core S&P 500 ETF, Mastercard Inc, iShares Core Dividend Growth ETF, sells Apple Inc, Amazon.com Inc, Bank of America Corp, Amgen Inc, American Express Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, One Capital Management, LLC.Just because a company is a massive household name doesn't always mean investors should jump in after its stock takes a sizable dip.;68.68000030517578;Over the 13-year period covering the end of the 2008 financial crisis until the fourth quarter of 2021, the biotech industry as a whole crushed the performance of most major U.S. stock indexes.  This prolonged bull market was fueled by a mix of tailwinds such as record low interest rates, massive fiscal stimulus by the U.S. government, and the insights and discoveries flowing out of the human genome project.Stamford, CT, based Investment company ARGA Investment Management, LP (Current Portfolio) buys Petroleo Brasileiro SA Petrobras, Trip.com Group, Alibaba Group Holding, II-VI Inc, RenaissanceRe Holdings, sells Canadian Natural Resources, AerCap Holdings NV, Nutrien, Weibo Corp, 3M Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, ARGA Investment Management, LP.SANTA MONICA, Calif., January 31, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Yescarta® (axicabtagene ciloleucel) to include use of prophylactic corticosteroids across all approved indications. Yescarta is now the first and only chimeric antigen receptor (CAR) T-cell therapy with information in the label to help physicians manage, and potentially prevent, treatment side effects.Let's dig in and decide whether Gilead Sciences is as attractive an investment as it seems.  The ongoing coronavirus pandemic has positively affected Gilead Sciences' financial performance.  Including the COVID-19 therapy, Gilead Sciences' revenue increased by 13% to $7.4 billion during the quarter.;608.5900268554688;Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.Investment company Hussman Strategic Advisors, inc (Current Portfolio) buys Pfizer Inc, Regeneron Pharmaceuticals Inc, Invesco, Dell Technologies Inc, Juniper Networks Inc, sells , Meridian Bioscience Inc, Triton International, Celanese Corp, C.H.The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending expanding the use of Dupixent (dupilumab). The positive opinion covers Dupixent as an add-on maintenance treatment for severe asthma children aged 6 to 11 years with type 2 inflammation who are inadequately controlled on two maintenance therapies. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. RelatedRecommendation based on pivotal trial that showed Dupixent significantly reduced severe asthma attacks and improved lung function in children aged 6 to 11 years;172.0800018310547;;348.82000732421875;;243.0500030517578;From Peru to Palo Alto, our Roundtable panelists see plenty of opportunities in increasingly challenging markets.;226.0;Stamford, CT, based Investment company ARGA Investment Management, LP (Current Portfolio) buys Petroleo Brasileiro SA Petrobras, Trip.com Group, Alibaba Group Holding, II-VI Inc, RenaissanceRe Holdings, sells Canadian Natural Resources, AerCap Holdings NV, Nutrien, Weibo Corp, 3M Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, ARGA Investment Management, LP.CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner will retire from Biogen’s Board of Directors, effective at the time of the Company’s 2022 annual meeting of stockholders. Ms. Leaming, who joined the Biogen Board in 2008, was previously the Chief Executive Officer and President of Tufts Health Plan, a provider of healthcare insurance. Mr. Posner, who also joined the Biogen Board in 2008, is a private investor and fo;242.5800018310547;;134.50999450683594;;137.60000610351562;;376.4100036621094;;5.980000019073486;;88.62999725341797;;96.2699966430664;;74.33000183105469;;76.36000061035156;;93.69999694824219;By Dhirendra Tripathi;94.56999969482422;;79.0199966430664;;71.56999969482422;;119.30000305175781;;52.7599983215332;;77.0999984741211;;63.75;Investment company Ariose Capital Management Ltd (Current Portfolio) buys Qualcomm Inc, The Estee Lauder Inc, NVIDIA Corp, Roblox Corp, CRISPR Therapeutics AG, sells Daqo New Energy Corp, Phoenix New Media during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Ariose Capital Management Ltd.;49.66999816894531;;41.5099983215332;;18.100000381469727;;9.869999885559082;;69.20999908447266;;34.220001220703125;;69.93000030517578;;34.61000061035156;;91.9800033569336;;34.33000183105469;;17.90999984741211;;58.70000076293945;;11.180000305175781;;31.799999237060547;"Pfizer Inc (NYSE: PFE) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) will discontinue the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy. A little over two years after Pfizer paid Ionis $250 million cash to in-license rights to vupanorsen (AKCEA-ANGPTL3-LRx), now the pharma giant has decided to ax late-stage work on the drug and hand it all back to Ionis. The decision follows a thorough review of data from the Phase 2b trial of vupanorseShares of Ionis Pharmaceuticals Inc. fell 7.9% in premarket trading on Monday after the company and Pfizer Inc. said they discontinued a program testing an experimental treatment for cardiovascular risk reduction and severe hypertriglyceridemia. The companies said that although the drug, vupanorsen, met the primary endpoint in a Phase 2b study, there was concern about its viability as a treatment for those indications. Pfizer had licensed the drug from Ionis in 2019; those rights have now been rPfizer Inc. (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG).";71.48999786376953;"The stock market’s recent meltdown has been based on a potent combination of omicron fears, rising inflation, and the prospect of the Fed hiking rates at a rapid pace in an effort to curb the surge. As such, the real prospect of a bear market has reared its ugly head. However, Goldman Sachs’ chief global equity strategist Peter Oppenheimer does not think it is time to sound the alarm; Oppenheimer believes any rate hikes this year won’t be too steep. This should mark the current period as a corre";47.4900016784668;;8.989999771118164;;59.41999816894531;SOUTH SAN FRANCISCO, Calif., January 31, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today released its inaugural environmental social and governance (ESG) report highlighting Twist’s approach to sustainability, social responsibility and commitment to ethics. The full report is available to view at https://www.twistbioscience.com/company/esg.;22.489999771118164;;25.5;
2022-02-01;228.67999267578125;Investment company NewEdge Wealth, LLC (Current Portfolio) buys Blackstone Inc, Zillow Group Inc, Vanguard Small Cap ETF, ISHARES TRUST, iShares MSCI United Kingdom ETF, sells Dun & Bradstreet Holdings Inc, Lennar Corp, Ryman Hospitality Properties Inc, Dolby Laboratories Inc, TJX Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, NewEdge Wealth, LLC.Highland, NY, based Investment company Focused Wealth Management, Inc (Current Portfolio) buys PIMCO Active Bond ETF, iShares Core U.S.Investment company Bristol John W & Co Inc (Current Portfolio) buys Nestle SA, Ross Stores Inc, The Chemours Co, sells Verisk Analytics Inc, Waters Corp, S&P Global Inc, Costco Wholesale Corp, Amgen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bristol John W & Co Inc .Chevy Chase, MD, based Investment company Carderock Capital Management Inc (Current Portfolio) buys PerkinElmer Inc, Edwards Lifesciences Corp, TE Connectivity, Extra Space Storage Inc, Fortinet Inc, sells Becton, Dickinson and Co, AptarGroup Inc, Fair Isaac Corp, T-Mobile US Inc, Fiserv Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Carderock Capital Management Inc.Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.;68.47000122070312;Is Gilead Sciences (GILD) a great pick from the value investor's perspective right now? Read on to know more.What goes into making innovative new medicines? In the second installment of our “Inside the Innovation” series, Gilead’s Ken Kent and Monica Tijerina discuss our patient-focused approach to develo...Rotterdam, P7, based Investment company Robeco Institutional Asset Management B.V. (Current Portfolio) buys Accenture PLC, Block Inc, Visa Inc, Gilead Sciences Inc, Avantor Inc, sells Activision Blizzard Inc, Mastercard Inc, The Walt Disney Co, Chewy Inc, DaVita Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Robeco Institutional Asset Management B.V..Investment company Dfpg Investments, Llc (Current Portfolio) buys Occidental Petroleum Corp, ESS U.S.Global Jets ETF, Citigroup Inc, Airbnb Inc, Caterpillar Inc, sells Moderna Inc, Oatly Group AB, Pinterest Inc, Bumble Inc, Valaris during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Dfpg Investments, Llc.;613.3599853515625;Investment company Wakefield Asset Management LLLP (Current Portfolio) buys ProShares Short S&P500, Regeneron Pharmaceuticals Inc, Goldman Sachs Group Inc, ONEOK Inc, Tapestry Inc, sells ProShares Short QQQ, DTE Energy Co, Restaurant Brands International Inc, Huntington Bancshares Inc, Activision Blizzard Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Wakefield Asset Management LLLP.Investment company Cozad Asset Management Inc (Current Portfolio) buys First Trust Lunt U.S. Factor Rotation ETF, S&P Global Inc, iShares S&P Mid-Cap 400 Value ETF, Regeneron Pharmaceuticals Inc, First Trust NASDAQ Rising Dividend Achievers ETF, sells FedEx Corp, DaVita Inc, Hanesbrands Inc, Newell Brands Inc, SPDR Portfolio S&P 500 Value ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Cozad Asset Management Inc.Investment company Jackson Creek Investment Advisors LLC (Current Portfolio) buys ITeos Therapeutics Inc, Extreme Networks Inc, SMART Global Holdings Inc, BlueLinx Holdings Inc, Newmark Group Inc, sells OptimizeRx Corp, Ranger Oil Corp, Ranger Oil Corp, Ranger Oil Corp, Digital Turbine Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Jackson Creek Investment Advisors LLC.New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.Biotech is big business. And getting bigger. That’s good news if you’re investing in biotech stocks. According to market research firm Grand View Research, the global biotechnology industry is expected to reach $2.44 trillion by 2028, giving it a compound annual growth rate (CAGR) of 16% over the next seven years. Driving that huge growth is demand for new medications and therapeutics to treat a range of both common and rare diseases. Add to that supportive government policies and new technologiRegeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.;179.60000610351562;Federal regulators are expected to be asked as soon as Tuesday to authorize Pfizer's COVID-19 vaccine for children as young as 6 months old, and the first shots could come by the end of February, according to news reports Monday night.Federal regulators are expected to be asked as soon as Tuesday to authorize Pfizer's COVID-19 vaccine for children as young as six months old, and the first shots could come by the end of February, according to news reports Monday night.Pfizer Inc and Germany's BioNTech SE are expected to submit an emergency use authorization request as early as Tuesday to the U.S. Food and Drug Administration (FDA) for vaccines for children aged six months to 5 years, the Washington Post reported https://wapo.st/3rfjDrC on Monday.  Coronavirus vaccines for children younger than 5 could be available as soon as end-February under a plan that would lead to the potential authorization of a two-shot regimen in the coming weeks, the Post reported, citing people briefed on the situation.  The report says that the FDA urged the companies to submit the application so that regulators could begin reviewing the two-shot data.Pfizer Inc and Germany's BioNTech SE are expected to submit an emergency use authorization request on Tuesday to the U.S. Food and Drug Administration (FDA) for vaccines for children aged six months to 5 years, the Washington Post reported https://wapo.st/3rfjDrC on Monday.  Coronavirus vaccines for children younger than 5 could be available as soon as end-February under a plan that would lead to the potential authorization of a two-shot regimen in the coming weeks, the Post reported, citing people briefed on the situation.  The report says that the FDA urged the companies to submit the application so that regulators could begin reviewing the two-shot data.Dr. Shikha Jain, Assistant Professor of Medicine at University of Illinois Chicago, joins Yahoo Finance Live to discuss hospitals dealing with COVID surges and staff shortages, medical supply shortages, COVID misinformation from media figures such as Joe Rogan, and vaccine mandates issued by private companies.The company's long-awaited application for its U.S. launch follows several months of manufacturing delays and buildup, as well as a flurry of similar submissions in other countries.Dr. Howard Forman, Yale professor and 'Health & Veritas' podcast co-host, joins Yahoo Finance Live to discuss the COVID-19 'stealth' variant, vaccination in the U.S., the rise in coronavirus cases among athletes ahead of the Olympics in China, and the outlook for the pandemic.;356.45001220703125;Investment company Equitable Trust Co (Current Portfolio) buys Horizon Kinetics Inflation Beneficiaries ETF, Amazon.com Inc, FlexShares Global Upstream Natural Resources Index, HCA Healthcare Inc, Crown Castle International Corp, sells iShares Gold Trust, iShares 1-3 Year Credit Bond ETF, MercadoLibre Inc, Invesco Optimum Yield Diversified Commodity, HDFC Bank during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Equitable Trust Co.;245.66000366210938;The Dow Jones Industrial Average rose Tuesday. Tech titans Advanced Micro Devices, Alphabet and PayPal will report earnings late Tuesday.Vertex Pharmaceuticals (NASDAQ: VRTX) reported its fourth-quarter earnings for 2021 on January 26, and there's quite a bit for investors to analyze.  In the last three months, Vertex's shares have grown by more than 31%, compared to the market's contraction of around 3.4%, and the earnings report looks like it was an inflection point for the stock.  Vertex has four approved drugs on the market, all of which are designed to treat cystic fibrosis (CF), a rare hereditary lung disease.New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.Dow Jones futures were lower after Monday's stock market surge. Three tech titans are set to report earnings late Tuesday.Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are DAC, ESTE, HAFC, ADM and VRTX.Vertex Pharmaceuticals  posted strong earnings numbers last week but the stock has been strong since bottoming out in October-November.  In the updated daily bar chart of VRTX, below, we can see that the shares have climbed strongly and have yet to reach our target area.  The On-Balance-Volume (OBV) shows strength from early December and helps to confirm the price gains so far.From industrial giants to tech stars to a big biotech, these stocks look like great picks to buy now.In this article, we will take a look at the 10 stocks that beat the quarterly expectations. You can skip our detailed analysis of these companies and go directly to the 5 Stocks That Beat the Quarterly Expectations. Notable stocks from the tech sector, including Intel Corporation (NASDAQ:INTC), ServiceNow, Inc. (NYSE:NOW) and Xilinx, Inc. (NASDAQ:XLNX), […]A Biomed Stock Well Positioned for Outperformance and a Building Materials Company Befitting From a Robust Demand Environment.Meriden, NH, based Investment company Loudon Investment Management, LLC (Current Portfolio) buys Comcast Corp, Verizon Communications Inc, Vertex Pharmaceuticals Inc, ConocoPhillips, Hormel Foods Corp, sells Lockheed Martin Corp, AT&T Inc, Valero Energy Corp, Vanguard Intermediate-Term Bond ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Loudon Investment Management, LLC.;229.3699951171875;Biogen Inc (NASDAQ: BIIB) has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody for B-cell non-Hodgkin's lymphoma (NHL), including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Biogen will pay a $30 million one-time option fee to Genentech, a member of the Roche Holdings AG (OTC: RHHBY), as part of the companies' long-standing collaboration on antibodies targeting CD20. Biogen will hMosunetuzumab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other therapeutic areas CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it exercised its option to participate in the development and commercialization of mosunetuzumab. Biogen will pay a $30 million one-time option fee to Genentech, a member of the Roche Group, as part of the companies’ long-standiInvestment company High Note Wealth, LLC (Current Portfolio) buys The Walt Disney Co, Uber Technologies Inc, Block Inc, VanEck Investment Grade Floating Rate ETF, iShares iBoxx $ High Yield ex Oil & Gas Corporate, sells AdvisorShares Pure US Cannabis ETF, Biogen Inc, Citrix Systems Inc, , Intel Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, High Note Wealth, LLC.Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.;254.44000244140625;CAMBRIDGE, Mass. & BEIJING, February 01, 2022--BeiGene announces the appointment of Margaret Dugan, M.D., and Alessandro Riva, M.D., to its Board of Directors.;137.75;BOTHELL, Wash., February 01, 2022--Seagen appoints Heeson EVP;144.92999267578125;;401.57000732421875;View more earnings on TECHSee more from BenzingaValneva Kickstarts Phase 3 Trial Of Chikungunya Vaccine Candidate In AdolescentsSio Gene Terminates Parkinson's Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2021. The quarterly dividend will be payable February 25, 2022, to all common shareholders of record on February 11, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis.Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2021.;6.21999979019165;;89.44000244140625;;99.45999908447266;;75.19000244140625;While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.;77.4000015258789;Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.Springfield, MO, based Investment company SignalPoint Asset Management, LLC (Current Portfolio) buys Exact Sciences Corp, iShares Russell 1000 Value ETF, Ncino Inc, Invesco Variable Rate Preferred ETF, Advanced Micro Devices Inc, sells Invesco S&P 500 Equal Weight Technology ETF, Invesco S&P 500 Equal Weight Health Care ETF, Invesco S&P 500 Equal Weight Financials ETF, Invesco S&P 500 Equal Weight Consumer Discretionar, Invesco S&P 500 Equal Weight Industrials ETF during the 3-months ended 2021Q;95.18000030517578;"Moderna hit a 'momentous milestone' after its Covid vaccine won full approval from the FDA on Monday.The earnings season has picked up momentum, with many stocks reporting over the next few weeks. Analysts predict to see robust earnings growth in old economy stocks that include cyclical sectors, energy, materials, industrials, and consumer discretionary names. Meanwhile, following recent price declines, many tech shares are also offering better value. Therefore, today’s article introduces seven stocks to watch in February. Corporate announcements also reveal how companies have been coping withNovavax (NASDAQ: NVAX) soared a jaw-dropping 7,900% from the start of 2020 through its peak last February.  Today, Novavax's situation has changed dramatically.  First, let's talk about why investors have been worrying about Novavax.(Bloomberg) -- Novavax Inc. and Beyond Meat Inc. jumped alongside other growth-oriented stocks in Monday trading after an Evercore ISI strategist suggested some of the battered meme stocks could rebound in coming weeks. Most Read from BloombergTeen Who Demanded $50,000 From Elon Musk Is Now Targeting More Billionaire JetsCovid-Infected HIV Patient Developed Mutations, Study ShowsAn Army of Faceless Suits Is Taking Over the $4 Trillion Hedge Fund WorldNasdaq 100 Notches Best Two-Day Rally Since 2Dr. Shikha Jain, Assistant Professor of Medicine at University of Illinois Chicago, joins Yahoo Finance Live to discuss hospitals dealing with COVID surges and staff shortages, medical supply shortages, COVID misinformation from media figures such as Joe Rogan, and vaccine mandates issued by private companies.Yahoo Finance's Anjalee Khemlani gives an update on FDA authorization for COVID-19 vaccines from Moderna and Novavax.As we know, the Covid-19 pandemic is far from over. For major vaccine players, this has proven to be a good thing. For investors in smaller, less-established vaccine players such as Novavax (NASDAQ:NVAX) and NVAX stock, it’s been a bit more of a rocky ride of late. Source: vovidzha / Shutterstock.com As far as smaller vaccine stocks go, Novavax is a company with a relatively robust track record. This company’s Covid-19 vaccine, named NVX-CoV2373, is produced using “small, laboratory-built piecesNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2.The company's long-awaited application for its U.S. launch follows several months of manufacturing delays and buildup, as well as a flurry of similar submissions in other countries.If you bought Novavax (NASDAQ:NVAX) stock two years ago, before the Covid-19 pandemic, your investment has scored a 857% gain. Source: vovidzha / Shutterstock.com If you bought it on Dec. 17, you’re down 58%. Novavax should get approval on its Covid-19 vaccine, now called Nuxavoid, in 10 countries over the next few months. It will be available in Australia starting on February 21. It has a supply deal with Israel, one of the world’s most vaccinated nations.InvestorPlace - Stock Market News, StocNovavax Inc said on Monday it has filed for emergency use authorization of its COVID-19 vaccine for U.S. adults, a long-awaited step for the company following months of struggles with development and manufacturing problems.  The filing is based on data provided to the U.S. Food and Drug Administration last month and results of two late-stage trials in the United States, Mexico and the UK that showed the protein-based vaccine had an overall efficacy of about 90%, the company said.  ""We believe our vaccine offers a differentiated option... that can be an alternative to the portfolio of available vaccines to help fight the COVID-19 pandemic,” said Novavax Chief Executive Officer Stanley Erck in a statement.Shares of Novavax Inc. rallied 10.0% in trading on Monday after the company said it filed for authorization of its experimental COVID-19 shot in the U.S. Novavax's COVID-19 vaccine candidate is protein-based, meaning it's a different type of vaccine than the mRNA shots developed by BioNTech SE /Pfizer Inc. and Moderna Inc. or the Johnson & Johnson viral vector vaccine. Novavax said it is seeking authorization for its two-dose vaccine in adults, based on two clinical studies. One Phase 3 trial asNovavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.";99.80000305175781;;79.22000122070312;;74.25;Collaboration combines Sarepta’s proprietary gene editing technologies and GenEdit’s non-viral delivery platform to create new genetic medicines for patients with neuromuscular diseasesInitial results from the ongoing research collaboration have demonstrated delivery to muscle tissue after systemic administrationSarepta and GenEdit will work together to identify development candidates for further testing CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- SareptaCAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 35 individuals hired by Sarepta in January 2022. The equity awards were approved in accordance with Nasdaq Listing;123.0199966430664;;55.099998474121094;;79.16000366210938;;65.52999877929688;;53.59000015258789;;41.11000061035156;;18.420000076293945;;10.8100004196167;;69.16000366210938;;35.349998474121094;SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced upcoming presentations from the DNL310 (ETV:IDS) clinical development program to be given at the 18th Annual WORLDSymposium™, which will be held February 7-11, 2022, in San Diego, California, and virtually. DNL310 is an;72.04000091552734;;35.13999938964844;Garden City, NY, based Investment company United Asset Strategies, Inc. (Current Portfolio) buys Belpointe PREP LLC, ISHARES TRUST, The Walt Disney Co, Communication Services Select Sector SPDR Fund, Invesco S&P 500 Pure Value ETF, sells iShares Russell 2000 ETF, WisdomTree Floating Rate Treasury Fund, iShares Core MSCI Emerging Markets ETF, Comcast Corp, Altice USA Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, United Asset Strategies, Inc.;92.69999694824219;New York, NY, based Investment company Havens Advisors Llc (Current Portfolio) buys BHP Group PLC, CyrusOne Inc, NeoPhotonics Corp, Rogers Corp, Triple-S Management Corp, sells , , , Cloudera Inc, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Havens Advisors Llc.;35.18000030517578;;17.59000015258789;"CAMBRIDGE, England & SOUTH SAN FRANCISCO, Calif., February 01, 2022--Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic an";62.27000045776367;;11.4399995803833;;31.510000228881836;Pfizer backed out of a deal to co-develop an Ionis Pharmaceuticals heart-disease drug on Monday. But IONS stock pared its losses.What happened Shares of Pfizer (NYSE: PFE) were sliding 3.1% lower as of 12:54 p.m. ET on Monday. The decline came after the big drugmaker announced that it is discontinuing the clinical development of vupanorsen.;70.0999984741211;;48.43000030517578;;9.3100004196167;;62.349998474121094;"CAMBRIDGE, England & SOUTH SAN FRANCISCO, Calif., February 01, 2022--Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic an";23.84000015258789;;25.270000457763672;Techne (TECH) delivered earnings and revenue surprises of 3.30% and 0.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Schizophrenia is a complex brain disorder that can significantly impact patients. Fortunately, there are treatment options that may help.
2022-02-02;228.92999267578125;Investment company American Financial Advisors, LLC (Current Portfolio) buys First Trust NASDAQ CEA Cybersecurity ETF, First Trust Low Duration Mortgage Opportunities ET, Vanguard Short-Term Corporate Bond ETF, Aflac Inc, Qualcomm Inc, sells First Trust SSI Strategic Convertible Securities E, SPDR S&P Aerospace & Defense ETF, iShares iBoxx USD Investment Grade Corporate Bond , Welltower Inc, iShares 7-10 Year Treasury Bond ETF during the 3-months ended 2021Q4, according to the most recent filingRaleigh, NC, based Investment company Capital Investment Counsel, Inc (Current Portfolio) buys Citrix Systems Inc, FedEx Corp, Cracker Barrel Old Country Store Inc, Martin Marietta Materials Inc, KraneShares CSI China Internet ETF, sells Target Corp, Ollie's Bargain Outlet Holdings Inc, Tenable Holdings Inc, Intuitive Surgical Inc, NetApp Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Capital Investment Counsel, Inc.Houston, TX, based Investment company Eagle Global Advisors Llc (Current Portfolio) buys Energy Transfer LP, Charles Schwab Corp, Qualcomm Inc, Pfizer Inc, Equitrans Midstream Corp, sells Amgen Inc, Boeing Co, Genesis Energy LP, Truist Financial Corp, PowerShares QQQ Trust Ser 1 during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Eagle Global Advisors Llc.Investment company Ellis Investment Partners, LLC (Current Portfolio) buys JPMorgan Equity Premium Income ETF, Pfizer Inc, Independence Realty Trust Inc, Amgen Inc, Fidelity Blue Chip Growth ETF, sells BorgWarner Inc, Kinder Morgan Inc, Jazz Pharmaceuticals PLC, SPDR Portfolio TIPS ETF, SPDR Gold Shares ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Ellis Investment Partners, LLC.Investment company First Bank & Trust (Current Portfolio) buys Daktronics Inc, Amgen Inc, Bristol-Myers Squibb Co, Realty Income Corp, British American Tobacco PLC, sells Pfizer Inc, Canadian Imperial Bank of Commerce, Cisco Systems Inc, , Electronic Arts Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Bank & Trust.Tokyo, M0, based Investment company Nomura Asset Management Co Ltd (Current Portfolio) buys Blackstone Secured Lending Fund, Thermo Fisher Scientific Inc, Eli Lilly and Co, Amgen Inc, Fortinet Inc, sells BTC iShares MSCI USA Value Factor ETF, Chegg Inc, Alibaba Group Holding, Pinterest Inc, Johnson Controls International PLC during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Nomura Asset Management Co Ltd.Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q4 earnings.;65.81999969482422;In this article, we examined billionaire Kerr Neilson’s portfolio management strategy and approach to investing in stocks. We also reviewed 10 stocks to invest in today according to billionaire Kerr Neilson’s portfolio. You can skip our detailed discussion about Kerr Neilson’s investment philosophy and portfolio management strategies and jump directly to 5 Stocks to Invest […]Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.Gilead (GILD) delivered earnings and revenue surprises of -54.90% and 9.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Gilead Sciences reported lighter-than-expected fourth-quarter earnings late Tuesday, leading GILD stock to tumble in after-hours action.Britain's GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.  The settlement, announced by GSK on Tuesday, relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018  infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds.  HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.(Reuters) -Gilead Sciences Inc on Tuesday posted lower-than-expected fourth-quarter earnings, citing a $1.25 billion legal settlement involving HIV drug patents and a charge related to its collaboration with Arcus Biosciences Inc , sending the company's shares down nearly 4%.  Gilead reported adjusted quarterly earnings of 69 cents per share, down from $2.19 a year earlier.  Wall Street analysts had forecast $1.60 per share, as compiled by Refinitiv.FOSTER CITY, Calif., February 01, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.8% in the company’s quarterly cash dividend, beginning in the first quarter of 2022. The increase will result in a quarterly dividend of $0.73 per share of common stock. The dividend is payable on March 30, 2022, to stockholders of record at the close of business on March 15, 2022. Future dividends will be subject to Board approval.FOSTER CITY, Calif., February 01, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2021.Gilead Sciences Inc's COVID-19 drug remdesivir last year overtook AbbVie Inc's 20-year-old arthritis drug Humira as the medicine that U.S. hospitals spent the most on, according to Vizient Inc, a purchasing group used by about half the nation's hospitals.  Remdesivir, an intravenous antiviral approved early in the pandemic for hospitalized COVID patients and authorized last month for high-risk outpatients, could retain the top spot through mid-2023, according to Vizient's projections.  The group purchasing organization said Gilead's drug, sold as Veklury, made up 3.42% of total member spending on pharmaceuticals during October 2020 to September 2021.;622.8499755859375;Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen are highlighted in this Industry Outlook article.Syracuse, NY, based Investment company Lipe & Dalton (Current Portfolio) buys Lockheed Martin Corp, Douglas Elliman Inc, The Kraft Heinz Co, Rogers Corp, Regeneron Pharmaceuticals Inc, sells Martin Marietta Materials Inc, AT&T Inc, Dominion Energy Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Lipe & Dalton.Late-breaking pivotal data show significant disease improvements in eosinophilic esophagitis and also in chronic spontaneous urticariaInvestment company Gitterman Wealth Management, LLC (Current Portfolio) buys Independence Realty Trust Inc, NextEra Energy Inc, Digital Realty Trust Inc, Intuit Inc, Crown Castle International Corp, sells iShares Core S&P 500 ETF, Vanguard Short-Term Corporate Bond ETF, BTC iShares Core MSCI EAFE ETF, Vanguard Mortgage-Backed Securities ETF, Vanguard Growth ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Gitterman Wealth Management, LLC.Decatur, GA, based Investment company Decatur Capital Management, Inc. (Current Portfolio) buys Regeneron Pharmaceuticals Inc, Rockwell Automation Inc, Albemarle Corp, Advanced Micro Devices Inc, sells Gentex Corp, Exxon Mobil Corp, WestRock Co, AECOM during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Decatur Capital Management, Inc..Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.;180.14999389648438;View more earnings on ABCSee more from BenzingaFerrari Races With 14% Jump In Q4 Profit Amid F8 Model BoostFDA Asks Pfizer - BioNTech To Submit For COVID-19 Vaccine Emergency Use Nod For Youngest Children© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.View more earnings on RACESee more from BenzingaFDA Asks Pfizer - BioNTech To Submit For COVID-19 Vaccine Emergency Use Nod For Youngest ChildrenHumana Q4 Bottom-Line Beats Expectations, Plans Cost Savings© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Children as young as 6 months could be vaccinated. The FDA's vaccines advisory committee will meet on Feb. 15.Pfizer Inc. and BioNTech SE have asked the FDA to authorize the emergency use of their COVID-19 vaccine for children under 5, saying that three doses of the vaccine will be needed.With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy of two 3 µg doses as part of a three-dose primary series for this age group to address the urgent public health needCompanies plan to submit additional data on a third 3 µg dose in this age group in the coming months If authorization is granted, the Pfizer-BioNTech vaccine would be the first COVID-19 vaccine available for pediatric populationsThe FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.What happened Shares of BioNTech (NASDAQ: BNTX) had climbed 4.3% as of 11:54 a.m. ET on Tuesday. The gain came after multiple news organizations reported that BioNTech and its big partner, Pfizer (NYSE: PFE), are expected to soon file for U.;356.2300109863281;Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the third quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]How two US Navy retirees transitioned into the private sector—and discovered meaningful work in the life sciencesToday we're going to take a look at the well-established Illumina, Inc. ( NASDAQ:ILMN ). The company's stock saw...;253.57000732421875;We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.Danaos Corp., Earthstone Energy Inc., Hanmi Financial Corp., Archer-Daniels-Midland Co. and Vertex Pharmaceuticals Inc are highlighted in this Screen of the Week article.Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen are highlighted in this Industry Outlook article.Little Rock, AR, based Investment company Ifrah Financial Services, Inc. (Current Portfolio) buys Janus Henderson AAA CLO ETF, Janus Henderson Mortgage-Backed Securities ETF, Vanguard Short-Term Inflation-Protected Securities, Vertex Pharmaceuticals Inc, BTC iShares U.S.;224.9600067138672;When Biogen cut the price of its Alzheimer's drug in half, it exposed the arbitrary nature of drug pricing.Investment company Traynor Capital Management, Inc. (Current Portfolio) buys Advanced Micro Devices Inc, Vale SA, Intuitive Surgical Inc, Vanguard Real Estate Index Fund ETF, Activision Blizzard Inc, sells Biogen Inc, CRISPR Therapeutics AG, Boeing Co, Quidel Corp, SPDR Portfolio S&P 500 ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Traynor Capital Management, Inc..;245.60000610351562;;137.1999969482422;;145.25999450683594;;417.8599853515625;;6.139999866485596;;88.44000244140625;;96.95999908447266;;74.38999938964844;;75.83999633789062;Exact Sciences Corp.  is a molecular diagnostics company specializing in the detection of early stage cancers like colorectal cancer.  Perhaps you have seen their commercials on TV for the Cologuard test?  The On-Balance-Volume (OBV) has been in a decline the past year telling us that sellers have been more aggressive than buyers.Exact Sciences (EXAS) closed the most recent trading day at $77.40, moving +1.36% from the previous trading session.;89.44000244140625;Vaccine maker Novavax (NASDAQ: NVAX) has fallen harder than the broader market of late, dropping by 36% in the past three months alone.  Meanwhile, Novavax's shares are trading at $95.22.  Although Novavax's stock has been somewhat affected by factors outside of its control, the company also made several blunders of its own.Novavax (NVAX) closed the most recent trading day at $95.18, moving +1.58% from the previous trading session.(Bloomberg) -- U.S. hospital admissions for Covid-19 are receding in 34 states and the nation’s capital, easing the health-care staffing crises that were widespread at the start of the year. The World Health Organization warned countries not to ease restrictions prematurely.Most Read from BloombergTeen Who Demanded $50,000 From Elon Musk Is Now Targeting More Billionaire JetsAlphabet Stock Split Aimed at Bringing Google Shares to MassesSeaWorld Makes $3.4 Billion Takeover Bid for Cedar FairCovidWhat happened Shares of Novavax (NASDAQ: NVAX) were rising 4.2% as of 11:27 a.m. ET on Tuesday. The gain came after the company announced on Monday that it had submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of COVID-19 vaccine NVX-CoV2373.After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.Every investor in Novavax, Inc. ( NASDAQ:NVAX ) should be aware of the most powerful shareholder groups. Institutions...;95.38999938964844;;78.75;Investment company Mount Yale Investment Advisors, LLC (Current Portfolio) buys Discover Financial Services, Phillips 66, BTC iShares MSCI EAFE Growth ETF, iShares Core S&P 500 ETF, iShares S&P 500 Value ETF, sells Marathon Petroleum Corp, Chubb, MercadoLibre Inc, HDFC Bank, Ulta Beauty Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Mount Yale Investment Advisors, LLC.;71.41999816894531;;118.08999633789062;Gilead (GILD) delivered earnings and revenue surprises of -54.90% and 9.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?;52.630001068115234;;77.97000122070312;Investment company AGF Investments LLC (Current Portfolio) buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The Energy Select Sector SPDR Fund, Paratek Pharmaceuticals Inc, Hello Group Inc, sells Industrial Select Sector SPDR, Consumer Staples Select Sector SPDR, Utilities Select Sector SPDR ETF, Microsoft Corp, UnitedHealth Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, AGF Investments LLC.;62.119998931884766;Shares of Crispr Therapeutics gained 3.1% in premarket trading on Wednesday after the company said the first patient had been dosed in a Phase 1 clinical trial evaluating the experimental type 1 diabetes treatment it developed with the privately held ViaCyte Inc. The investigational treatment uses ViaCyte's stem cell-derived therapy in combination with Crispr's gene-editing technology to generate pancreatic cells. Crispr's stock has tumbled 61.0% over the past year, while the S&P 500 has gainedZUG, Switzerland, and CAMBRIDGE, Mass., and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced the first patient has been dosed in the Phase 1 clinical trial of VCTX210 for the treatmentInvestment company Traynor Capital Management, Inc. (Current Portfolio) buys Advanced Micro Devices Inc, Vale SA, Intuitive Surgical Inc, Vanguard Real Estate Index Fund ETF, Activision Blizzard Inc, sells Biogen Inc, CRISPR Therapeutics AG, Boeing Co, Quidel Corp, SPDR Portfolio S&P 500 ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Traynor Capital Management, Inc..;53.31999969482422;;39.59000015258789;SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences: 4th Annual Guggenheim Oncology Day available on demand on Wednesday, February 9, 2022 at 11:00 AM ETSVB Leerink 2022 Global Healthcare Conference;17.920000076293945;;10.25;;62.70000076293945;;34.0099983215332;Denali Therapeutics (NASDAQ:DNLI) has had a rough three months with its share price down 34%. But if you pay close...;69.91000366210938;;35.0099983215332;;92.94999694824219;;33.02000045776367;;18.25;;60.150001525878906;;11.40999984741211;MENLO PARK, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022, at 4:30 pm Eastern Time. The call will be webcast live and may be accessed at Pacific Biosciences’ website at: https://investor.pacificbiosciences.com/. Date: Tuesday, February 15, 2022 Time: 4:30pm ET Listen via Internet: https://investor.pacificbiosciences.comThe Medical Device companies' Q4 results are likely to reflect base business recovery. Let's see how IDXX, ABC, and ALGN are poised ahead of their earnings releases.;31.5;Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.;70.44000244140625;;48.060001373291016;;9.279999732971191;;61.43000030517578;;23.40999984741211;;24.59000015258789;
2022-02-03;228.0;Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets. The multi-year collaboration supports the discovery of novel molecular glue therapeutics leveraging insights from Amgen's expertise in developing multispecific molecules.Amgen (AMGN) closed at $228.93 in the latest trading session, marking a +0.11% move from the prior day.How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]Investment company HC Advisors, LLC (Current Portfolio) buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, Amgen Inc, Dyne Therapeutics Inc, UnitedHealth Group Inc, sells Netflix Inc, Invesco S&P 500 Equal Weight ETF, PIMCO Energy & Tactical Credit Opportunities, Pinduoduo Inc, Alphabet Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HC Advisors, LLC.AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.;65.61000061035156;Gilead's success could be inversely proportional to Pfizer's success with its COVID-19 pill.King Of Prussia, PA, based Investment company Girard Partners Ltd. (Current Portfolio) buys Vanguard Total International Stock, The Toronto-Dominion Bank, SPDR Bloomberg High Yield Bond ETF, Vanguard Total International Bond ETF, BTC iShares MSCI EAFE Value ETF, sells Fidelity National Information Services Inc, Leidos Holdings Inc, Lamb Weston Holdings Inc, Tesla Inc, Activision Blizzard Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, GirardIn this article, we will take a look at the 10 stocks drawing attention on earnings reports. You can skip our detailed analysis of these companies and go directly to the 5 Stocks Drawing Attention on Earnings Reports. Some of the most valuable companies, including Alphabet Inc. (NASDAQ:GOOG), Advanced Micro Devices, Inc. (NASDAQ:AMD), PayPal Holdings, […]The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of September 30th, when the S&P 500 Index was trading around the […]Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.Sales of Veklury hit $5.6 billion last year — an increase of 98% from an abbreviated 2020, when the drug was approved — and Gilead is studying an oral drug for use outside hospitals.;618.530029296875;Investment company Integral Health Asset Management, LLC (Current Portfolio) buys McKesson Corp, Centene Corp, Abbott Laboratories, Biogen Inc, Amedisys Inc, sells Arena Pharmaceuticals Inc, Medtronic PLC, Hologic Inc, Zimmer Biomet Holdings Inc, Acadia Healthcare Co Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Integral Health Asset Management, LLC.In this article we are going to estimate the intrinsic value of Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) by...Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.;172.85499572753906;Dr. Ezekiel Emanuel, former White House Health Policy Adviser, joins Yahoo Finance Live to discuss the United States' COVID-19 vaccination and infection rates, anti-viral therapeutics, testing resources, hospitalizations, and China's zero-COVID strategy.Sorrento Therapeutics Chairman and CEO Henry Ji joins Yahoo Finance Live to discuss the Covishield antibody Sorrento is developing, the timeline for getting FDA approval, cancer treatment research, and the pharmaceutical biotech sectors.The European Commission proposed on Thursday a change to rules on COVID-19 certificates that would allow participants in vaccine trials to get a valid pass despite having received unapproved shots.  The move follows concerns raised by Germany's BioNTech and Spain's Hipra about difficulties in enrolling volunteers for their COVID-19 vaccine trials because participants could face limitations to access public spaces and to travel.  The changes to the rules, which also extend by one year the validity of the EU COVID pass until the end of June 2023, will certify that EU countries can issue vaccination certificates to participants in trials.Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.;347.32000732421875;Illumina, Inc. (NASDAQ:ILMN), today announced an agreement with the Jean Perrin Center at the Clermont-Ferrand University Hospital in France to assess the clinical value of comprehensive genomic profiling (CGP) in cancer therapy options in patients with late-stage disease compared to use of current standard of care, including small panel tests. Evidence from the CELIA (comprehensive genomic profiling impact) research study will be used to support a precision medicine approach for patients with lInvestment company Buckley Wealth Management, LLC (Current Portfolio) buys Campbell Soup Co, Caterpillar Inc, NVIDIA Corp, PayPal Holdings Inc, 3M Co, sells AT&T Inc, Illumina Inc, Fidelity National Information Services Inc, Teladoc Health Inc, American Express Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Buckley Wealth Management, LLC.Investment company Davidson Capital Management Inc. (Current Portfolio) buys Kinsale Capital Group Inc, Williams-Sonoma Inc, Western Alliance Bancorp, PayPal Holdings Inc, PowerShares QQQ Trust Ser 1, sells iShares 1-3 Year Credit Bond ETF, MarketAxess Holdings Inc, Primoris Services Corp, Amedisys Inc, Verizon Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Davidson Capital Management Inc..;248.64500427246094;Boston, MA, based Investment company Birch Hill Investment Advisors LLC (Current Portfolio) buys Vertex Pharmaceuticals Inc, iShares Core S&P Small-Cap ETF, NVIDIA Corp, The Hershey Co, Lowe's Inc, sells Meta Platforms Inc, Organon, Boston Scientific Corp, Berkshire Hathaway Inc, Walmart Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Birch Hill Investment Advisors LLC.Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.Investors have been taking money out of growth stocks recently in recognition that rising interest rates in the U.S. will likely sap some value from those companies' future profits.  Vertex Pharmaceuticals (NASDAQ: VRTX) fits that description -- a solid growth stock that still boasts excellent long-term prospects despite recent struggles.  Vertex's difficulties predate the stock market's recent issues.;216.4499969482422;"Biogen stock tumbled Thursday after the company's 2022 guidance lagged forecasts. Biogen expects ""minimal"" sales of Aduhelm for Alzheimer's treatment.Management said it would deepen planned cost cuts if the CMS doesn't change a draft decision limiting Medicare payments for Aduhelm to patients in a clinical trial.Shares of Biogen Inc. were down 3.7% in premarket trading on Thursday after the company issued new guidance for 2022. Biogen had earnings of $368.2 million, or $2.50 per share, in the fourth quarter of 2021, compared with $357.9 million, or $2.33 per share, in the fourth quarter a year ago. It had adjusted earnings per share of $3.39, against a FactSet consensus of $3.37. Biogen reported revenue of $2.7 billion in the final three months of the year, down from $2.8 billion a year ago. The FactSetThe drugmaker's shares fell 3% before the opening bell as the company also said it expects ""minimal"" sales from the treatment, Aduhelm, which was once touted as a potential blockbuster but now faces weak uptake after its controversial approval and a lack of clarity over coverage.  Analysts' on average had expected $2.8 million in fourth-quarter sales of Aduhelm.  The U.S. Centers for Medicaid and Medicare Services (CMS) in January proposed to severely restrict coverage for Alzheimer's drugs including Aduhelm to patients taking part in approved clinical trials.Biogen Inc reported just $1 million in quarterly sales of its Alzheimer's disease drug and forecast 2022 earnings well below analysts' estimates, following a proposal last month by the U.S. Medicare regulator to limit coverage of drug.  Analysts' on average had expected $2.8 million in fourth-quarter sales of Aduhelm.  The U.S. Centers for Medicaid and Medicare Services (CMS) in January proposed to severely restrict coverage for Alzheimer's drugs including Aduhelm to patients taking part in approved clinical trials.Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January. We aren’t certain about the bubbly technology stocks that trade for ridiculously high multiples of their revenues, but we believe top hedge fund stocks will deliver positive returns for the rest […]Investment company Integral Health Asset Management, LLC (Current Portfolio) buys McKesson Corp, Centene Corp, Abbott Laboratories, Biogen Inc, Amedisys Inc, sells Arena Pharmaceuticals Inc, Medtronic PLC, Hologic Inc, Zimmer Biomet Holdings Inc, Acadia Healthcare Co Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Integral Health Asset Management, LLC.Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.";237.97000122070312;;136.99000549316406;BOTHELL, Wash., February 03, 2022--ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin LymphomaSeattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Investment company Integral Health Asset Management, LLC (Current Portfolio) buys McKesson Corp, Centene Corp, Abbott Laboratories, Biogen Inc, Amedisys Inc, sells Arena Pharmaceuticals Inc, Medtronic PLC, Hologic Inc, Zimmer Biomet Holdings Inc, Acadia Healthcare Co Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Integral Health Asset Management, LLC.;143.22999572753906;;402.2749938964844;In this article, we will take a look at the 10 stocks drawing attention on earnings reports. You can skip our detailed analysis of these companies and go directly to the 5 Stocks Drawing Attention on Earnings Reports. Some of the most valuable companies, including Alphabet Inc. (NASDAQ:GOOG), Advanced Micro Devices, Inc. (NASDAQ:AMD), PayPal Holdings, […];5.75;;87.43000030517578;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Company will be presenting data in several presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A at the 15th Annual Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 2-4. Notably, there will be an oral presentation of data from the two-year analysis of an ongoing global Phase 3 study, GENEr8-1, the largesInvestment company Integral Health Asset Management, LLC (Current Portfolio) buys McKesson Corp, Centene Corp, Abbott Laboratories, Biogen Inc, Amedisys Inc, sells Arena Pharmaceuticals Inc, Medtronic PLC, Hologic Inc, Zimmer Biomet Holdings Inc, Acadia Healthcare Co Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Integral Health Asset Management, LLC.;94.7699966430664;;73.55999755859375;WILMINGTON, Del., February 03, 2022--Incyte to Present at Upcoming Investor Conference;75.32499694824219;Investment company C WorldWide Group Holding A (Current Portfolio) buys Adobe Inc, Align Technology Inc, NovoCure, Axonics Inc, Exact Sciences Corp, sells Visa Inc, DexCom Inc, Quidel Corp, Xylem Inc, Fidelity National Information Services Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, C WorldWide Group Holding A.;90.45999908447266;Dr. Ezekiel Emanuel, former White House Health Policy Adviser, joins Yahoo Finance Live to discuss the United States' COVID-19 vaccination and infection rates, anti-viral therapeutics, testing resources, hospitalizations, and China's zero-COVID strategy.Sorrento Therapeutics Chairman and CEO Henry Ji joins Yahoo Finance Live to discuss the Covishield antibody Sorrento is developing, the timeline for getting FDA approval, cancer treatment research, and the pharmaceutical biotech sectors.Shares of Novavax Inc. gained 0.9% in premarket trading on Thursday after the company said its COVID-19 vaccine received conditional authorization in the U.K. The protein-based vaccine, which is called Nuvaxovid, requires two shots spaced 21 days apart and can be used in adults. The U.K. has already ordered up to 60 million doses of Novavax's vaccine. The company announced that it filed for authorization in the U.S. on Monday. Novavax's stock has tumbled 68.5% over the past year, while the S&P 5Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older in Great Britain. The vaccine, also knownBritain has approved Novavax's COVID-19 vaccine for use in those 18 years of age and older, the country's medicines regulator said on Thursday, bringing a fifth coronavirus shot to its roster amidst the rapid spread of the Omicron variant.  The vaccine, Nuvaxovid, was approved as a first and second dose as it met the required safety, quality and effectiveness standards, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) said https://www.gov.uk/government/news/novavax-covid-19-vaccine-nuvaxovid-approved-by-mhra in a statement.  Novavax's Nasdaq-listed shares reversed course to trade 3.7% higher at $92.76 in premarket trading by 1146 GMT.Germany's expert panel on vaccine use on Thursday recommended Novavax's protein-based COVID-19 vaccine for basic immunisation for people over 18, in a push to win over the more than 15% of German adults still not fully vaccinated.  The high-profile advisory group known as STIKO said a booster shot should still be given with an mRNA vaccine, and particularly vulnerable people should also receive a second booster with an mRNA vaccine.  Novavax's recombinant protein vaccine uses a more established technology than mRNA, the novel method behind the two most commonly used COVID-19 vaccines in Germany - from Pfizer/BioNTech and Moderna.Is Novavax stock a buy or a sell after asking the FDA to authorize its Covid shot for emergency use? Is NVAX stock a buy or sell?;93.34500122070312;Rewrite Therapeutics’ proprietary and versatile DNA writing platform enables a range of novel genome editing strategiesAcquisition further expands Intellia’s industry-leading genome editing toolbox by adding a platform that is highly complementary to its existing CRISPR/Cas9 and base editing technologies CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveragLuxembourg, N4, based Investment company Pictet & Cie (Europe) SA (Current Portfolio) buys Thermo Fisher Scientific Inc, Air Products & Chemicals Inc, EOG Resources Inc, Mastercard Inc, Intercontinental Exchange Inc, sells Johnson & Johnson, Chevron Corp, Fidelity National Information Services Inc, Exact Sciences Corp, SPDR Biotech ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Pictet & Cie (Europe) SA.;78.20999908447266;;70.54499816894531;;117.30999755859375;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.;49.09000015258789;PASADENA, Calif., February 02, 2022--Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results and hold conference call;76.55500030517578;;61.459999084472656;Investment company HC Advisors, LLC (Current Portfolio) buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, Amgen Inc, Dyne Therapeutics Inc, UnitedHealth Group Inc, sells Netflix Inc, Invesco S&P 500 Equal Weight ETF, PIMCO Energy & Tactical Credit Opportunities, Pinduoduo Inc, Alphabet Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HC Advisors, LLC.;52.39500045776367;;39.0;Investment company Emerald Advisers, Llc (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, HireRight Holdings Corp, Arhaus Inc, sells Chegg Inc, ORIC Pharmaceuticals Inc, BellRing Brands Inc, Trex Co Inc, Arena Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Advisers, Llc.;17.850000381469727;ALAMEDA, Calif., February 02, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the virtual Guggenheim Healthcare Talks Oncology Day on Wednesday, February 9, 2022 at 1:30pm ET / 10:30am PT.If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: Bluebird Bio (NASDAQ: BLUE) and Exelixis (NASDAQ: EXEL).  To say that Bluebird Bio has lagged the market in the past year would be an understatement.  The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.;10.109999656677246;;62.94499969482422;;33.470001220703125;Investment company Clarius Group, LLC (Current Portfolio) buys BTC BlackRock Ultra Short-Term Bond ETF, , Vanguard Ultra-Short Bond ETF, Vanguard FTSE Emerging Markets ETF, iShares Core U.S.;68.81999969482422;NOVATO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 16,050 shares of common stock of the company and 5,350 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company. The awards were approveLeola, PA, based Investment company Emerald Mutual Fund Advisers Trust (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, Karuna Therapeutics Inc, HireRight Holdings Corp, sells Chegg Inc, BellRing Brands Inc, Echo Global Logistics Inc, Tetra Tech Inc, ORIC Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Mutual Fund Advisers Trust.;35.0;Halozyme Therapeutics, Inc. ( NASDAQ:HALO ) shareholders might be concerned after seeing the share price drop 15% in...Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Nicole LaBrosse has been promoted to the position of senior vice president, chief financial officer, effective immediately. Ms. LaBrosse will succeed Elaine Sun, who is stepping down to pursue another opportunity.;92.9800033569336;Investment company Integral Health Asset Management, LLC (Current Portfolio) buys McKesson Corp, Centene Corp, Abbott Laboratories, Biogen Inc, Amedisys Inc, sells Arena Pharmaceuticals Inc, Medtronic PLC, Hologic Inc, Zimmer Biomet Holdings Inc, Acadia Healthcare Co Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Integral Health Asset Management, LLC.;33.505001068115234;;17.770000457763672;;60.380001068115234;"Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its GLEAM and GLIMMER Phase 3 clinical trials of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with diabetic macular edema (""DME"").";11.128999710083008;Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;31.530000686645508;;69.4800033569336;;47.84989929199219;;9.300000190734863;;60.029998779296875;;23.540000915527344;Investment company Emerald Advisers, Llc (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, HireRight Holdings Corp, Arhaus Inc, sells Chegg Inc, ORIC Pharmaceuticals Inc, BellRing Brands Inc, Trex Co Inc, Arena Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Advisers, Llc.Leola, PA, based Investment company Emerald Mutual Fund Advisers Trust (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, Karuna Therapeutics Inc, HireRight Holdings Corp, sells Chegg Inc, BellRing Brands Inc, Echo Global Logistics Inc, Tetra Tech Inc, ORIC Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Mutual Fund Advisers Trust.;24.25;Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 16, 2022 to discuss the company's fourth quarter and year-end 2021 financial results. Management will also discuss financial expectations for 2022 and provide an update on the company.
2022-02-14;224.27000427246094;At this point, it makes sense to start to consider some defensive growth stocks. Inflation, rising interest rates, and the COVID-19 pandemic have hit many growth stocks hard. U.S. inflation hit a 39-year high of 7%, and to curb this inflation, the Federal Reserve might raise interest rates as many as seven times in 2022, according to Wall Street. These measures may bring inflation down to 4.6% this year, but will have adverse effects on the stock market. In a situation of rising interest rates,Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals are highlighted in this Industry Outlook article.;61.11000061035156;Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.;623.530029296875;Lilly's (LLY) new antibody-drug, bebtelovimab is authorized to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 who are at high risk of progressing to severe diseaseFutures rose with Russia/Ukraine tensions in focus after the stock market rally sold off Friday. Tesla China sales were strong.;154.52999877929688;Pfizer (PFE) and its partner BioNTech are planning to extend their rolling submission to the FDA for the authorization of Comirnaty for use in children 6 months through 4 years of age to include the three-dose data.The FDA has postponed the Advisory Committee meeting scheduled for Pfizer Inc (NASDAQ: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine in children six months through 4 years of age, initially scheduled for February 15. The decision comes after a preliminary assessment of data submitted by Pfizer / BioNTech to request emergency authorization, and the agency thinks it needed more data before weighing in on approval. The extension allows the FDA time to receive updated data on the two and thre;329.45001220703125;Today, the Montreal Neurological Institute-Hospital at McGill University (The Neuro) announced a new research collaboration with Illumina, along with Takeda Development Center Americas, Inc., and p...;231.22999572753906;;214.1199951171875;;205.3000030517578;;124.51000213623047;;148.66000366210938;;413.6400146484375;Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in World Journal of Urology, entitled Pre–diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post–prostatectomy pathology outcome. Principal investigator Dr. Alexander Kretschmer, urologist from Ludwig Maximilian University of Munich, Germany, and colleagues demonstrated utility of the ExoDx™ Prostate test, or EPI, to address limitations related to prostate biopsy sampling error, prostate biopsy bias as;5.170000076293945;;90.01000213623047;;89.41999816894531;;66.0199966430664;;78.33000183105469;;80.11000061035156;;90.30999755859375;;86.5199966430664;;78.62999725341797;;101.47000122070312;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the fourth quarter and full year of 2021 along with recent corporate updates on February 28, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on February 28, company executives will provide company updates and review financial results.;49.79999923706055;;81.44999694824219;;58.61000061035156;;52.5;;36.38999938964844;;18.59000015258789;;8.539999961853027;;67.7300033569336;;34.880001068115234;As previously announced, Denali Therapeutics Inc (NASDAQ: DNLI) was informed via e-mail communication from the FDA that DNL919 (ATV:TREM2) Investigational New Drug (IND) application was placed on clinical hold. Denali has now received a formal clinical hold letter and is moving forward to address the FDA's observations related to the preclinical toxicology assessment. The Company will also provide the information requested to initiate clinical studies, including proposed changes to the clinical;71.25;;33.63999938964844;;93.44999694824219;;30.079999923706055;Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.;16.81999969482422;;53.369998931884766;;10.979999542236328;;32.59000015258789;;75.54000091552734;;53.0;;9.5;;55.2599983215332;;26.190000534057617;SAN DIEGO, February 14, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 28, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.;23.06999969482422;
2022-02-15;223.94000244140625;Global pharmaceutical spending is positioned to keep growing. These three companies can profit from the trend.Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced pancreatic cancer who received LUMAKRAS® (sotorasib)*. The data will be presented at the monthly American Society of Clinical Oncology (ASCO) Plenary Series on Feb. 15, 2022. Data show encouraging and clinically meaningful anticancer activity and a positive benefit:risk profile.;61.33000183105469;"In this clip from ""The Pharma & Biotech Show"" on Motley Fool Live, recorded on Feb. 2, Motley Fool contributors Brian Orelli and Keith Speights discuss the major lawsuit between Gilead (NASDAQ: GILD) and [GlaxoSmithKline (LSE: GSK) majority-owned] ViiV Healthcare and analyze what effects the resulting settlement might have on future profits.  Brian Orelli: I think four things to watch in 2022 is Trodelvy, which has four Phase III clinical trials happening, three in breast cancer and one in lung cancer.";630.1500244140625;;163.44000244140625;"MAINZ, Germany, February 15, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will welcome project partners, among them official representatives, in Marburg to conduct a high-level meeting on sustainable vaccine manufacturing in the African Union. The meeting initiated by the kENUP foundation will be followed by public statements on February 16, 2022 at approx. 11.30 CET / 05.30 ET from the following participants: H.E. President Macky Sall of Senegal, President of the African UnionPfizer's (PFE) COVID-19 vaccine and its oral antiviral pill for COVID-19, Paxlovid are expected to generate a combined $54 billion in sales in 2022.In this clip from ""The Pharma & Biotech Show"" on Motley Fool Live, recorded on Feb. 2, Motley Fool contributors Keith Speights and Brian Orelli discuss the recently announced rolling EUA submission from Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) regarding the vaccine for children ages six months to five years and the upcoming meeting with the FDA.  Keith Speights: Brian, another big story this week is that Pfizer and BioNTech have announced that they've initiated their rolling EUA submission for their vaccine in younger kids.Dr. Jeremy Faust, Brigham and Women’s Hospital Emergency Medicine Physician & Editor-in-chief of MedPage Today, joins Yahoo Finance Live to discuss Walmart pulling back its mask mandate for employees, herd immunity myths, boosters and vaccinations, and keeping hospitals safe through vaccine mandates.Shares of Pfizer (NYSE: PFE) were sliding 3.9% as of 10:57 a.m. ET on Monday.  Pfizer's partner, BioNTech (NASDAQ: BNTX), was getting hit even harder with its stock falling 8.3%.  Shares of rival Moderna (NASDAQ: MRNA) were sinking 12.24%.";342.1199951171875;On National Inventors Day, two employees talk about getting “hooked” on sequencing and the importance of being wrong (sometimes);233.41000366210938;;217.3699951171875;;219.88999938964844;;128.72000122070312;"BOTHELL, Wash. & TOKYO, February 14, 2022--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas"") today announced the initial results from Cohort H of the EV-103 trial investigating PADCEV® (enfortumab vedotin-ejfv) as a monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. Data from this late-breaking abstract will be included in an oral presentation (Abstract 435) at tAstellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas"") and Seagen Inc. (Nasdaq:SGEN) today announced the initial results from Cohort H of the EV-103 trial investigating PADCEV® (enfortumab vedotin-ejfv) as a monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. Data from this late-breaking abstract will be included in an oral presentation (Abstract 435) at the 2022 ASCO Genitourinary Cancers Symposiu";153.3000030517578;We feel now is a pretty good time to analyse Alnylam Pharmaceuticals, Inc.'s ( NASDAQ:ALNY ) business as it appears the...;412.75;;5.550000190734863;;92.06999969482422;;95.30000305175781;Despite U.S. inflation, America’s economy is still the best house on the worst block. According to the latest data points, consumer prices surged more than 7% in January, the highest gain since February 1982, per a CNBC report. Despite the obvious jitters, it is important not to forget about stocks to love. In reality, it is during bear markets where people can potentially accrue the greatest wealth. Should the equities sector tumble, you may be able to pick up incredible discounts. And with the;67.5;WILMINGTON, Del., February 15, 2022--Incyte to Present at Upcoming Investor Conference;81.27999877929688;;87.12999725341797;;98.5199966430664;Collaboration combines Intellia’s genome editing platform with ONK’s optimized natural killer (NK) cell therapy platform Intellia grants ONK non-exclusive rights to its ex vivo genome editing and LNP delivery technologies and exclusive rights to certain guide RNAs for up to five allogeneic CRISPR-edited NK cell therapies ONK is responsible for the research, clinical development and commercialization of engineered NK cell therapies derived from collaboration Intellia to receive global co-developm;86.48999786376953;;81.3499984741211;;107.38999938964844;;50.220001220703125;;83.20999908447266;;60.970001220703125;;56.959999084472656;"-- Company to Host Conference Call and Webcast on March 2, 2022, at 8:00 a.m. ETSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the twelve months ended December 31, 2021, after the closing of the U.S. equity markets on March 1, 2022. The Company will host a";37.880001068115234;;19.18000030517578;Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma. The updated results will be featured at the American Society of Clinical Oncology (ASCO) 2022 Genitourinary Cancers Symposium. With a median follow-up of 32.9 months, Opdivo/Cabometyx combo continued to show meaningful improvem;8.90999984741211;BridgeBio Pharma (BBIO) closed the most recent trading day at $8.54, moving -1.61% from the previous trading session.;73.87000274658203;;35.63999938964844;Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.;73.55000305175781;;34.43000030517578;;94.25;;32.2400016784668;ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.;17.600000381469727;;56.2400016784668;;11.380000114440918;;33.65999984741211;;72.94000244140625;– Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations – – Arvinas plans to initiate a pivotal trial by year end 2022 evaluating bavdegalutamide in patients with mCRPC who have progressed on or after novel hormonal agents (NHAs) and have tumors that harbor AR T878X/H875Y mutations – – Updated data to be presented in a rapid abstract session and a poster session at ASCO GU and;56.0;;9.979999542236328;;59.75;;27.280000686645508;;23.309999465942383;
2022-02-16;222.66000366210938;Japan's regulatory agency recently authorized Lumakras as a treatment for a type of lung cancer.Amgen Inc (NASDAQ: AMGN) announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in KRAS G12C-mutated advanced pancreatic cancer patients who received Lumakras (sotorasib). The data will be presented at the American Society of Clinical Oncology (ASCO) Plenary Series. Data show encouraging and clinically meaningful anticancer activity and a favorable benefit-risk profile. The Company posted a new Lumakras data, spotlighting a 21% objective response rate among;61.900001525878906;Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.Children are being hospitalized with COVID 19 at increasingly high rates, and those younger than 5 aren't eligible to receive a vaccine. We’re committed to helping in this area by investing in rese...Don't think the slump for biotech stocks that began last year will go on forever.  Here's why they chose Gilead Sciences (NASDAQ: GILD), Novavax (NASDAQ: NVAX), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski (Gilead Sciences): This month is a good time to buy up shares of drugmaker Gilead.;630.9000244140625;;165.49000549316406;"BioNTech SE (NASDAQ: BNTX), which developed the first widely approved COVID-19 shot together with Pfizer Inc (NYSE: PFE), unveiled plans to establish manufacturing facilities in Africa to boost the availability of much-needed medicines on the continent. The manufacturing solution consists of one drug substance and one formulation module, allowing for mRNA vaccine production in bulk (mRNA manufacturing and formulation). Local partners will take over fill-and-finish. The first turnkey facility wilBioNTech's co-founder and top executive said the vaccine maker has no plans to enforce its intellectual property rights should organisations in Africa strike out on their own to produce unauthorised versions of the company's shot.  The remarks come after the company, which developed the western world's most widely used COVID-19 shot with U.S. drugmaker Pfizer, mapped out a plan to enable African countries to produce its Comirnaty-branded shot under BioNTech's supervision.Germany's BioNTech, which is preparing to produce its COVID-19 vaccine or other disease-preventing shots in Africa, said that novel cancer therapies it is working on will in future be available on the continent at affordable prices.  ""We pledge as BioNTech to develop our cancer medicines also according to the needs of the African people and enable affordable access to our immunotherapies to African states and African people,"" the company's chief executive said at a news conference on Wednesday.  BioNTech earlier unveiled a vaccine factory made from shipping containers that it plans to ship to Africa as assembly kits to ease disparities in global COVID-19 vaccine access.BioNTech SE said Wednesday it is developing turkey mRNA manufacturing facilities based on a container solution in an effort to promote scalable vaccine production in Africa. The company is expecting to deliver the first BioNTainer in the second half, comprising one drug substance and one formulation module. ""Each module is built of six ISO sized containers (2.6m x 2.4m x 12m). This allows for mRNA vaccine production in bulk (mRNA manufacturing and formulation), while fill-and-finish will be takeDeveloping turnkey solution to enable mRNA-based vaccine production in modular and scalable sites installed by BioNTech Presidents of Ghana, Rwanda, Senegal, the Director-General of the World Health Organization, the Director of the Africa CDC and the Federal Minister of Economic Cooperation and Development of Germany met in Marburg to jointly discuss the infrastructure, regulatory and technological requirements to establish end-to-end manufacturing network for mRNA-based vaccines in AfricaFirst";333.8599853515625;RiverPark Funds, an investment management firm, published its “RiverPark Large Growth Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. The RiverPark Large Growth Fund (the “Fund”) returned -3.23% for the third quarter of 2021, while its benchmarks, the S&P 500 Total Return Index (“S&P”) advanced 0.58%, the Russell […]GRAIL, LLC, a health care company with a mission of detecting cancer early when it can be cured, today announced an agreement with Point32Health, the combined organization of Harvard Pilgrim Health Care and Tufts Health Plan, to collaborate on a two-phased pilot of Galleri®, GRAIL's groundbreaking multi-cancer early detection blood test. Point32Health is the first commercial health plan in the U.S. to work with GRAIL on its Galleri multi-cancer early detection (MCED) test as a complement to reco;235.77000427246094;;214.5500030517578;"Pioneering neuroscience and driving innovation comes from a truly diverse workforce. Our partnership with HBCUs and student internship program helps drive our efforts to ensure our future leaders c...Shares of Sage Therapeutics Inc. tumbled 11.2% in premarket trading on Wednesday after Wall Street raised questions about the durability of the experimental treatment for major depressive disorder that Sage is developing with Biogen Inc. . Biogen's stock was up 0.7% in premarket trading. The companies had announced Monday morning that zuranolone met the primary endpoint in a Phase 3 clinical trial; however, some analysts still have concerns about the commercial appeal of the drug, if it is approIf you're a former Biogen (NASDAQ: BIIB) investor like me, you might feel compelled to warn other people away from the stock.  Since the U.S. Food and Drug Administration (FDA) approved its controversial Alzheimer's drug Aduhelm in mid-2021, very little has gone right for the pharma company.  When Aduhelm was approved on June 7, Biogen's stock shot up wildly, as the market expected that the FDA would decline to let it proceed.Sage Therapeutics Inc said on Wednesday its drug along with an antidepressant helped improve depressive symptoms after three days in a late-stage study, paving way for the drug developer to submit data for U.S. approval this year.  The company and partner Biogen Inc said the drug, zuranolone, met the study's secondary goal of showing an improvement in symptoms over a two-week period.  Major depressive disorder (MDD) is a common but serious mood disorder in which people experience depressive symptoms and it affects over 16 million American adults every year.";220.1999969482422;;128.6699981689453;One thing we could say about the analysts on Seagen Inc. ( NASDAQ:SGEN ) - they aren't optimistic, having just made a...;153.27999877929688;;412.0299987792969;;5.440000057220459;;92.69000244140625;;94.9800033569336;;67.83000183105469;;78.37999725341797;RiverPark Funds, an investment management firm, published its “RiverPark Large Growth Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. The RiverPark Large Growth Fund (the “Fund”) returned -3.23% for the third quarter of 2021, while its benchmarks, the S&P 500 Total Return Index (“S&P”) advanced 0.58%, the Russell 1000 […];86.55000305175781;;95.86000061035156;Intellia stock surged Tuesday after the CRISPR gene-editing company forged a cancer deal with Onk Therapeutics worth nearly $1 billion.;85.87000274658203;;79.98999786376953;;93.5999984741211;The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lung cancer (NSCLC). The application covers NSCLC patients harboring the KRASG12C mutation who have received at least one prior systemic therapy. The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022. The adagrasib NDA is being reviewed by the FDA for Accelerated Approval (Subpart H) and is being reviewed under the FDA ReThe analysts covering Mirati Therapeutics, Inc. ( NASDAQ:MRTX ) delivered a dose of negativity to shareholders today...Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy. The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022.;49.27000045776367;Investors are used to hearing about the S&P 500 and the Dow Jones Industrial Average. Both of these indices track highly prominent companies whose stock prices factor heavily into the U.S. and global economy. The S&P 500 tracks the performance of 500 large companies listed on stock exchanges across the United States while the DJIA tracks 30. These stocks are highly capitalized. But investors are also interested in small-cap equities as well. For that, the Russell 2000 is a great place to look. T;74.8949966430664;Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2021.;61.970001220703125;"CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.75% and 139.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?- More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began dosing patients in the pivotal trial of CTX110™, targeting CD19+ B-cell malignancies; additional data expected to report in 2022- -Top-line data expected to report in 1H2022 for ongoing CTX120™ and CTX130™ clinical trials- -First patient dosed in Phase 1 clinical trial of VCTX210 for the treatment of type";58.75;;36.0099983215332;SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Monday, February 28, 2022 at 5:00 PM ET to report its fourth quarter and full year 2021 financial results and provide a corporate update. In order to pa;19.079999923706055;Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.;8.84000015258789;;73.58000183105469;;35.33000183105469;;71.16999816894531;;34.36000061035156;Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;93.5;;32.90999984741211;;17.549999237060547;;55.40999984741211;;11.880000114440918;PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.PacBio HiFi Sequencing Technology Will Be Used to Investigate Effect on Diagnostic Yield of Unresolved Rare Diseases in ChildrenSINGAPORE and MENLO PARK, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- KK Women’s and Children’s Hospital (KKH) and PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a collaboration to leverage PacBio technology in understanding the genetic causes of neurodevelopmental disorders. As part of the Bringing ResearcView more earnings on PACBSee more from BenzingaDid Umbilical Cord Blood Transplant Help Cure A Woman's HIV infection?AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Pacific Biosciences (PACB) delivered earnings and revenue surprises of -7.14% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2021. Updates since our last earnings release Achieved record fourth quarter revenues of $36.0 million reflecting growth of 33% compared to the prior year period and grew the Sequel II/IIe installed base by 84% to 374 as of December 31, 2021.Launched the HiFiViral SARS-CoV-2 Kit – a fully kitted end-to-end solution for COVID-19 surveilla;33.400001525878906;;71.94999694824219;Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110). The data were shared at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium. The data showed that bavdegalutamide continues to provide evidence of anti-tumor activity and patient benefit in metastatic castration-resistant prostate cancer (mCRPC). Bavdegalutamide reduced prostate-sp;55.810001373291016;;9.800000190734863;;58.439998626708984;SOUTH SAN FRANCISCO, Calif., February 15, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the closing of its upsized underwritten public offering of 5,227,272 shares of its common stock at a public offering price of $55.00 per share, including the exercise in full by the underwriters of their option to purchase up to an additional 681,818 shares of common stoc;27.5;SAN DIEGO, February 16, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has resubmitted its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) to the U.S. Food and Drug Administration (FDA).Holding on to popular or trending stocks for the long-term can make your portfolio a winner.;26.790000915527344;Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2021 and provided financial expectations for 2022.
2022-02-17;221.67999267578125;"On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.Rating Action: Moody's assigns Baa1 rating to Amgen's notes; stable outlookGlobal Credit Research - 17 Feb 2022New York, February 17, 2022 -- Moody's Investors Service (""Moody's"") assigned a Baa1 rating to the new senior unsecured note offering of Amgen Inc. (""Amgen"").  There are no changes to Amgen's existing ratings including the Baa1 senior unsecured long-term rating and the Prime-2 short-term rating, and the outlook remains stable.  Assignments:  ..Issuer: Amgen Inc.  ....Senior Unsecured Notes, assigned Baa1RATINGS RATIONALEAmgen's credit profile reflects its sizeable revenue base and significant biotechnology presence, high margins and good cash flow.Amgen (NASDAQ:AMGN) today announced that it has been named to Newsweek magazine's list of ""America's Most Responsible Companies"" for the third consecutive year; JUST Capital's list of ""America's Most JUST Companies"" for the fifth consecutive year; Barron's list of ""America's Most Sustainable Companies"" for the second consecutive year; and the Human Rights Campaign Foundation's list of ""Best Places to Work for LGBTQ+ Equality"" for the sixth consecutive year. These rankings reflect the company's eA longer-than-expected regulatory review for the company's lung cancer drug is weighing on its shares today.";61.290000915527344;FOSTER CITY, Calif., February 16, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV. The findings demonstrated that lenacapavir, administered subcutaneously every six months in combination with other antiretrovirals, achieved high rates of virologic suppression;626.719970703125;There are more New York manufacturers racing to gain market share and increase production through large capital expenditures than at any time over the past 15 years.Vertex Pharmaceuticals (NASDAQ: VRTX) is the leader in cystic fibrosis (CF) treatments.  Gains were led by its blockbuster Trikafta.  The only threat to Trikafta's market share is another Vertex candidate in development.Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.;157.36000061035156;"When most of us think of mRNA technology, we probably think of Moderna (NASDAQ: MRNA).  The biotech company put messenger RNA on the map when it brought the first coronavirus vaccine candidate into human testing.  Big-pharma rival Pfizer (NYSE: PFE) has been expanding its abilities with the technology.BioNTech SE Sponsored ADR (BNTX) closed at $165.49 in the latest trading session, marking a +1.25% move from the prior day.Delivery of Pfizer and BioNTech SE's vaccine to combat the Omicron COVID-19 variant was delayed by several weeks due to a slower-than expected data gathering process, BionTech Chief Executive Ugur Sahin told Germany's Bild on Thursday.  Once the vaccine is ready, the company would assess whether it was still needed, Sahin said.  ""If the wave ends, that does not mean it can't begin again,"" he told Bild in a video interview, adding that BioNTech was in a position to continue creating new vaccines as variants emerged if needed.Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pneumococcal conjugate vaccine, Apexxnar, in Europe.";317.8399963378906;As part of the support, Illumina pledged $20 million over four years to help strengthen sequencing technology for 20 African countries. This in-kind donation includes next-generation sequencing pla...Bionano (NASDAQ:BNGO) stock has tumbled, but it will come back big. Source: Dennis Diatel / Shutterstock.com As Cathie Wood and many others know, owning growth stocks over the last year has not been easy. Amid fears about inflation and rising interest rates, many such equities have tumbled.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Famously, the Street and many retail investors tend to give up on companies that face tough issues but wind up becoming great. For example, I remeIllumina's (ILMN) GRAIL Galleri MCED test detects more than 50 types of cancer and can predict the origin of the cancer signal with high accuracy across multiple cancer types.;232.77000427246094;;210.60000610351562;Investors questioned the durability of Sage's depression treatment on Wednesday, and Sage stock collapsed to a nearly two-year low.The late-stage trial results for the company's major depressive disorder drug aren't impressing investors today.;205.19000244140625;BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING, February 17, 2022--BeiGene announces approval for BRUKINSA (zanubrutinib) by Swissmedic for the treatment of adult patients with Waldenström’s Macroglobulinemia;124.16000366210938;;149.9499969482422;;398.19000244140625;;4.940000057220459;;90.30000305175781;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.;80.98999786376953;Shares of the lab tools firm  10x Genomics  slid by nearly a quarter in premarket trading on Thursday, the day after the company reported financial results and issued guidance that fell well short of Wall Street expectations.  Late Wednesday, the company reported revenue of $143.5 million for the fourth quarter of 2021, short of the $148.5 million FactSet consensus estimate.  The big disappointment for investors, however, was in the company’s guidance for 2022:  10x Genomics  now says it expects revenue between $600 million and $630 million, short of the FactSet consensus estimate of $678.8 million, as of Wednesday.View more earnings on TXGSee more from BenzingaMerck Inks Oncology, Neurology Drug Discovery Pact With British Biotech, Curve TherapeuticsICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.10x Genomics (TXG) delivered earnings and revenue surprises of -166.67% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided outlook for 2022.;67.83000183105469;;74.7699966430664;;83.44000244140625;;90.4000015258789;The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.Fourth quarter and full-year 2021 financial results – February 24, at 8:00 a.m. ETUpdated interim clinical data from the ongoing Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis – February 28, at 4:30 p.m. ET CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that it will be hoIntellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.;84.68000030517578;;76.63999938964844;;91.0199966430664;(Bloomberg) -- Former high flying biotechnology favorites Mirati Therapeutics Inc. and Sage Therapeutics Inc. have lost more than half their value from record highs, hurt by growing pessimism on new medicines as well as the higher rate environment damaging most stocks. Most Read from BloombergStocks Edge Higher With Fed Hiking Bets Steady: Markets WrapHong Kong to Mass Test Whole City for Covid With Beijing’s HelpJho Low’s Wild Nights on Display: $250,000 for DiCaprio, FoxFed Eyes Rate Hike SoonA longer-than-expected regulatory review for the company's lung cancer drug is weighing on its shares today.;45.18000030517578;PASADENA, Calif., February 17, 2022--Arrowhead presented clinical data on ARO-HIF2 in patients with renal cell carcinoma at 2022 ASCO GU;69.08999633789062;;58.61000061035156;CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.;56.68000030517578;"--- Potential best-in-class therapy for ROS1-positive metastatic NSCLC and advanced solid tumorsSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for investigational repotrectinib for th";33.709999084472656;;18.34000015258789;;8.359999656677246;On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.;69.0199966430664;In this article, we will discuss the top 10 biotech stocks to buy according to Jeremy Green’s Redmile Group. If you want to skip our detailed analysis of Green’s history, investment philosophy performance, you can go directly to the Top 5 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group. Jeremy Green is the […];33.439998626708984;;67.2300033569336;"2022 has started out with a marked increase in market volatility, accompanied by a sharp reversal of last year’s bullish trend. The sudden correction, and the shift to a more downbeat investor sentiment, are generally attributed to a series of increased risk factors. On the international front, these tensions include geopolitical tensions on the Russia-Ukraine border and around China’s belligerence. Domestically, factors impacting the markets include the inflation that is both high and rising; a";33.02000045776367;;93.30999755859375;;30.950000762939453;;17.200000762939453;;54.08000183105469;;11.029999732971191;;32.7400016784668;A good alternative is to consider buying exchange-traded funds (ETFs) that will do the job for you and allow you to diversify into multiple different holdings without needing to pick any stocks.  Two funds that aim to focus on these sectors are the Alps Medical Breakthroughs ETF (NYSEMKT: SBIO) and the Amplify Transformational Digital Sharing ETF (NYSEMKT: BLOK).  Buying and holding these ETFs can be a solid way to benefit from the growth of the two sectors while keeping your overall risk low.;69.37999725341797;– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA50 rate and durable RECIST responses – – Data support the potential for an accelerated approval pathway in a molecularly defined patient population, and the Company intends to initiate a pivotal trial by year end 2022 – – Anti-tumor activity seen across all subgroups of the ongoing Phase 2 ARDENT trial in patients who had progressed after treatment with novel hormIt might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...;57.4900016784668;;9.300000190734863;;55.2400016784668;;26.6299991607666;ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders will doubtless be very grateful to see the share price up 45...;25.350000381469727;"Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.Alkermes plc (Nasdaq: ALKS) today presented new data from the ongoing phase 1/2 ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy. The data were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place Feb. 17-19, 2022.Such was the case on Wednesday with biotech Alkermes (NASDAQ: ALKS), which crushed analysts' projections like a grape with its fourth-quarter fundamentals.  For its final quarter of 2021, Alkermes posted revenue of $324.5 million.  In the earnings release, Alkermes quoted CEO Richard Pops as saying that the improvements were due to ""growing our commercial business, expanding and advancing our development pipeline, and driving profitability.""We're committed to understanding the unique needs of people living with mental illness and supporting disease awareness and education. We know there’s much to be done."
2022-02-18;220.77000427246094;The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.;61.04999923706055;You don't need to invest in stocks that pay monthly just to collect a recurring dividend income each month.Dr. Porscha Showers’ route to health sciences wasn’t always a sure thing. Porscha, who grew up in Louisiana, wanted to become an attorney – despite having a mother who worked as a registered nurse ...Big names in the food and beverage, industrial, and pharmaceutical sectors are lifting their payouts.If Gilead stock stays above 60 at expiry, the put expires worthless leaving the trader with a 36% annualized return.;615.1300048828125;"Let's see if Regeneron Pharmaceuticals, Inc. (REGN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistical significance in interim analysis despite numeric improvements observed across key endpoints; trial will be stopped due to futilityRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:";156.94000244140625;"Since then, however, this biotech company has been closely linked to a product that has at least been mentioned in every household -- and that's the coronavirus vaccine.  Big-pharma Pfizer joined forces with BioNTech in the early days of the pandemic to develop and commercialize the product.  In fact, it accounts for 70% of vaccine doses distributed in the U.S. and European Union through early February.Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering process, BioNTech Chief Executive Ugur Sahin told Germany's Bild. Once the vaccine is ready, the company would assess whether it was still needed, Sahin said. Related: Pfizer's Omicron-Targeted Vaccine Expected To Be Ready In March: CEO Says On CNBC. ""If the wave ends, that does not mean it can't begin again,"" he told Bild in a video intBiotech stocks are down and out right now. But sentiment can turn on a dime. Here are trends to watch in the biotech sector in 2022.";311.9700012207031;;229.61000061035156;;209.7899932861328;Biogen was recently included in S&P Global's Sustainability Yearbook 2022, which assessed over 7,500 companies in the 2021 Corporate Sustainability Assessment (CSA). Only 716 companies with top sco...Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability of the drug.;213.0;;120.26000213623047;;147.5;;401.010009765625;;4.650000095367432;Completed Audit Committee evaluation and restated Q2 2021 unaudited interim financial statements Announces strategic realignment to support future growth strategies Consolidated net revenue increased 80% in the third quarter of 2021 compared to the third quarter of 2020 Launched Cronos Group's first cultured cannabinoid gummy and vape products under Spinach FEELZ™ brand Spinach® held a double-digit market share in the gummies category in Canada in the third quarter of 2021 TORONTO, Feb. 18, 2022;84.86000061035156;BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that the FDA had requested additional information regarding the clinical hold on PHEARLESS Phase 1/2 study of BMN 307 issued in September 2021. BMN 307 is an AAV5-human phenylalanine hydroxylase (hPAH) gene therapy studied in adults with phenylketonuria (PKU). The FDA has requested data from additional non-clinical studies to assess the theoretical oncogenic risk to human study participants, expected to take several quarters. Related: FDA Slaps CliBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on its investigational gene therapy programs in clinical development. In February 2022, the Company received additional requests from the Food and Drug Administration (FDA) for information needed to resolve the clinical hold of the PHEARLESS Phase 1/2 study of BMN 307 issued in September 2021. BMN 307 is an AAV5-human phenylalanine hydroxylase (hPAH) gene therapy being studied in adults with phenylketonuria (PKU). The FDA has requeste;81.55999755859375;What happened Shares of 10x Genomics (NASDAQ: TXG) have sunk 13.9% as of 10:56 a.m. ET on Thursday. The big decline came after the life sciences company announced its 2021 fourth-quarter and full-year results following market close on Wednesday.;68.52999877929688;;74.12999725341797;;81.88999938964844;;86.5199966430664;Yahoo Finance's Jared Blikre breaks down how markets opened on Friday.Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;85.31999969482422;;74.58000183105469;;91.31999969482422;The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.;44.25;PASADENA, Calif., February 18, 2022--Arrowhead Pharmaceuticals doses first subjects in Phase 1/2 Study of ARO-C3, RNAi therapeutic for treatment of complement mediated diseases;66.69000244140625;Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.;58.290000915527344;In this article we are going to estimate the intrinsic value of CRISPR Therapeutics AG ( NASDAQ:CRSP ) by estimating...;59.33000183105469;;33.13999938964844;;19.559999465942383;Exelixis (EXEL) delivered earnings and revenue surprises of 314.29% and 26.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?ALAMEDA, Calif., February 17, 2022--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.;8.079999923706055;BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;67.0199966430664;;32.58000183105469;Baron Funds, an asset management firm, published its “Baron Growth Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. A return of 6.56% was delivered by the fund’s institutional shares for the fourth quarter of 2021 and 15.84% for the year. This exceeded the Fund’s primary benchmark, the Russell […]Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;66.70999908447266;;32.720001220703125;;93.12999725341797;"PARK CITY, Utah, February 17, 2022--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units (""RSUs""). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).";30.1299991607666;Vir Biotechnology, Inc. (VIR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;16.479999542236328;;52.59000015258789;;11.470000267028809;;32.27000045776367;Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;69.0199966430664;;56.630001068115234;Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;9.15999984741211;;53.209999084472656;;25.860000610351562;;25.079999923706055;Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant immunotherapy for advanced renal cell carcinoma (RCC). The data were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium. The presentation includes updated efficacy and safety data from the monotherapy arm of ARTISTRY-1, in which anti-tumor activity was observed in RCC patients, including patients w
2022-02-22;221.41000366210938;;60.97999954223633;Most people are familiar with the hepatitis B (HBV) and hepatitis C (HCV) viruses that attack the liver. But not many have heard of hepatitis D (HDV), the most severe form of viral hepatitis. Peopl...Long before the Covid-19 pandemic, I touted Moderna (NASDAQ:MRNA) as the next wave in biotech. After its Covid-19 vaccine showed effectiveness, I called MRNA stock “the stock of the decade.” Then I bought some shares. After calling them fully valued in October, I sold, booking fat profits. Source: diy13 / Shutterstock But even before my warning, MRNA stock was falling. Shares hit an all-time high close to the $500 level in August. In early October, they were trading closer to $300. Today, they s;602.8900146484375;In this article, we discuss 10 biotech stocks to sell now according to Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to 5 Biotech Stocks to Sell Now According to Cathie Wood. The mass sell-off of stocks in the high growth sector has not been very kind to […]Long before the Covid-19 pandemic, I touted Moderna (NASDAQ:MRNA) as the next wave in biotech. After its Covid-19 vaccine showed effectiveness, I called MRNA stock “the stock of the decade.” Then I bought some shares. After calling them fully valued in October, I sold, booking fat profits. Source: diy13 / Shutterstock But even before my warning, MRNA stock was falling. Shares hit an all-time high close to the $500 level in August. In early October, they were trading closer to $300. Today, they s;149.88999938964844;BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years. Medigene will contribute its proprietary TCR discovery platform to develop TCRs against multiple solid tumor targets nominated by BioNTech. Medigene's automated, high throughput TCR discovery platform is designed to bypass central tolerance to yield high-affinity TCRs. Also See: PCollaboration leverages BioNTech’s multi-platform immunotherapy capabilities and Medigene’s T cell receptor (TCR) discovery platform to discover and develop innovative TCR immunotherapies against targets selected by BioNTechBioNTech to acquire preclinical PRAME TCR and receive licenses to Medigene’s PD1-41BB switch receptor and precision pairing technologiesBioNTech will hold exclusive worldwide development and commercialization rights to all TCR therapies arising from the collaborationMedigene;319.8599853515625;Materials innovation company Checkerspot is using microalgae to create a sustainable alternative to petroleumIllumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:;230.2100067138672;;209.80999755859375;;207.8800048828125;"CAMBRIDGE, Mass. and BEIJING, February 22, 2022--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic LeukemiaBASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING, February 22, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the European Medicines Agency (EMA) has accepted for review two new indication applications for its BTK inhibitor BRUKINSA® (zanubrutinib) for the treatment of patients with chronic lymphocyt";123.44000244140625;;146.80999755859375;;400.1099853515625;Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize the ExoTRU kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand.;4.21999979019165;;85.37000274658203;;78.5999984741211;;68.16999816894531;;73.44999694824219;;79.38999938964844;Recent polls suggest that most Americans have come to terms with living with Covid-19 on an ongoing basis. This means that the headlines from this crisis affect stock prices less than last year. This is bad for Novavax (NASDAQ:NVAX) stock, but good for the health of our citizens. Source: Vladimka production / Shutterstock.com Therefore, it is not a surprise to see NVAX stock touch lows from the pandemic summer. This is a very active stock, so its investors need a high tolerance for risk. Chasing;84.19000244140625;;87.69999694824219;;75.04000091552734;CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2021 financial results after the Nasdaq Global Market closes on Tuesday, March 1, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2021 financial results and to provide a corporate update. The conference call may be accessed by diaWe feel now is a pretty good time to analyse Sarepta Therapeutics, Inc.'s ( NASDAQ:SRPT ) business as it appears the...;90.66000366210938;Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;43.119998931884766;;65.94000244140625;;55.65999984741211;;57.54999923706055;;33.13999938964844;;19.600000381469727;;7.809999942779541;;65.13999938964844;;32.849998474121094;;66.91999816894531;;32.790000915527344;;93.76000213623047;;29.479999542236328;Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.;16.31999969482422;;50.349998474121094;;10.319999694824219;;31.34000015258789;;66.4800033569336;;54.619998931884766;NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, March 1, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2021. To a;8.8100004196167;;52.130001068115234;;26.149999618530273;Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;25.010000228881836;#BlackHistoryMonth represents an opportunity to highlight the disparities within the Black community when it comes to mental health. According to a 2018 survey, 50% of Black adults with serious men...
2022-02-23;221.0;Amgen (NASDAQ:AMGN) today announced the issuance of its inaugural $750 million green bond, with a 3.000% semi-annual coupon and maturing in 2029, to advance the environmental goals that are part of Amgen's environmental, social and governance (ESG) framework.And the stock charts say here comes the sell-off.Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Novartis AG (NVS), and NextEra Energy, Inc. (NEE).;61.349998474121094;Curious just how much cheaper the S&P 500 is now due to the sell-off? It's now a nearly a quarter off in about a year's time.;608.97998046875;;141.16000366210938;;315.2799987792969;;230.69000244140625;;209.0800018310547;;203.3000030517578;The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its first approval in the European Union (EU) for Waldenström's macroglobulinemia (WM), who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy. Additionally, the FDA has als;119.61000061035156;;147.47000122070312;;392.3599853515625;Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi 2022 Virtual Healthcare Conference on Thursday, February 24, 2022, at 10:15 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;4.269999980926514;;82.5199966430664;Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.;70.33000183105469;"10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today unveiled new details about upcoming products and capabilities across its single cell, spatial, and in situ platforms at its second annual Xperience 2022 virtual event. Highlights included the Fixed RNA Profiling Kit, which improves sample preparation workflow and adds flexibility for Chromium single cell experiments; Visium CytAssist, to expand the number of tissue samples accessi";67.98999786376953;;68.98999786376953;Exact Sciences, known for its Cologuard cancer test, reported good revenue growth in its December quarter. The follow-up conference call was spent on initiatives to tap big markets and reverse the stock's yearlong slide.Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.Exact Sciences (EXAS) delivered earnings and revenue surprises of -40.66% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473.8 million for the fourth quarter ended Dec. 31, 2021 and $1,767.1 million for the full year ended Dec. 31, 2021.;73.48999786376953;Novavax Inc said on Wednesday it had started shipping doses of its COVID-19 vaccine to European Union member states, with France, Austria and Germany expected to be the first to receive the shots in the coming days.  Shipments of Nuvaxovid to additional EU member states from the company's Netherlands distribution center are expected to quickly follow, adding to the stockpile of the region as it struggles with a surge in infections due to the Omicron variant.  Novavax's recombinant protein vaccine uses a more established technology than mRNA, the novel method behind the two most commonly used COVID-19 vaccines made by Pfizer /BioNTech and Moderna.As with the other vaccine stocks, most investors seem to have given up on Novavax (NASDAQ:NVAX). But as the crowd abandons NVAX stock in droves, is it a buy? Source: Ascannio/Shutterstock.com InvestorPlace - Stock Market News, Stock Advice & Trading Tips It depends. On the one hand, if analysts’ average earnings projections for 2022 are to be believed, the shares have been oversold. According to Yahoo! Finance, their mean 2022 earnings per share projection for the company is $25.03. Based on tha;80.05000305175781;In this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming. If you want to skip our detailed analysis of these stocks, go directly to 5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming. ARK Investment Management is an innovation-focused hedge fund that is headquartered in St. Petersburg, Florida, with […]State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapiesNew facility in Waltham, Massachusetts expected to be operational in 2024 CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, today announced that it has entered into a lease agreement to develop a 140,000-squ;85.55000305175781;;73.61000061035156;;84.41999816894531;;41.529998779296875;;63.66999816894531;;53.25;In this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming. If you want to skip our detailed analysis of these stocks, go directly to 5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming. ARK Investment Management is an innovation-focused hedge fund that is headquartered in St. Petersburg, Florida, with […];51.220001220703125;;31.829999923706055;;19.420000076293945;;7.340000152587891;;63.61000061035156;In this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming. If you want to skip our detailed analysis of these stocks, go directly to 5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming. ARK Investment Management is an innovation-focused hedge fund that is headquartered in St. Petersburg, Florida, with […];31.260000228881836;;64.79000091552734;;33.7400016784668;Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on its recent corporate activities and outlook.;93.98999786376953;;27.799999237060547;;16.149999618530273;;9.859999656677246;"The broader stock market has entered an official 10% correction, but for investors focusing on the Nasdaq Composite (NASDAQINDEX: ^IXIC), double-digit declines from recent highs are nothing new.  On Wednesday morning, though, Nasdaq investors saw a little light at the end of a long, dark tunnel, with futures on the index rising more than 1% as of 8:30 a.m. ET.  There's even more volatility lurking under the surface of major stock market indexes, with good news celebrated but bad news punished.Shares of Kodiak Sciences Inc. plummeted 76.3% to pace all premarket decliners Wednesday, after the biopharmaceutical company said a Phase 2b/3 trial of its treatment for age-related macular degeneration failed to meet its primary efficacy endpoint. The selloff put the stock on track to open at the lowest price seen during regular-session hours since September 2019. The company said its KSI-301 showed ""strong durability,"" and was safe and well tolerated, but it did not meet the primary endpointKodiak Sciences Inc. (Nasdaq: KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration.";10.039999961853027;In this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming. If you want to skip our detailed analysis of these stocks, go directly to 5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming. ARK Investment Management is an innovation-focused hedge fund that is headquartered in St. Petersburg, Florida, with […]Genomics Industry Veteran to Oversee Development of Robust Computational Biology ProgramMENLO PARK, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, welcomes Michael Eberle, Ph.D., as Vice President of Computational Biology. Michael will be responsible for leading the company’s bioinformatics and data sciences program to enhance PacBio’s genomic analysis offerings. Michael is a genomics industry veteran wi;30.729999542236328;;64.19000244140625;;53.04999923706055;;8.260000228881836;;49.119998931884766;In this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming. If you want to skip our detailed analysis of these stocks, go directly to 5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming. ARK Investment Management is an innovation-focused hedge fund that is headquartered in St. Petersburg, Florida, with […];24.690000534057617;;24.1299991607666;
2022-02-24;219.27000427246094;The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.NVIDIA, Novartis AG, NextEra Energy, The Goldman Sachs Group and Amgen are included in this blog.;60.61000061035156;By Derek Major;609.780029296875;The company — which still has a quartet of late-stage trials with the drug and more than $700 million in cash — saw its stock continue to drop on Thursday.What happened Shares of the clinical-stage biotech Kodiak Sciences (NASDAQ: KOD) are down by a hefty 80.3% as of 2:22 p.m. ET Wednesday afternoon. The drugmaker's stock is plunging today in response to its lead product candidate, KSI-301, failing to meet the primary endpoint of a combined phase 2/3 trial as a treatment for wet age-related macular degeneration (wet AMD).Kodiak Sciences' attempt to improve on Regeneron's blockbuster eye drug backfired on Wednesday — and investors pummeled KOD stock.Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.The drug, for wet age-related macular degeneration, is designed to require less frequent injections into the eye than Regeneron's Eylea, the standard treatment.;154.05999755859375;Buying and holding quality growth stocks can be a surefire way to significantly increase your portfolio's value over the years.  Two growth stocks that show lots of promise and are down more than 60% from their 52-week highs are BioNTech SE (NASDAQ: BNTX) and Matterport (NASDAQ: MTTR).  Healthcare company BioNTech finished last week at less than $157 per share -- down more than 66% from the $464 it peaked at last Aug. 10, which was just after the release of its second-quarter results.;323.9100036621094;Through an organization called ASrid, patient families find connection and hope;230.25;;203.1199951171875;"The approval was controversial, as some argued Biogen's clinical trials failed to prove the treatment's efficacy.  In this video clip from ""The Pharma & Biotech Show,"" recorded on Feb. 9, Motley Fool contributor Taylor Carmichael asks Dr. Frank David, author of , about what Biogen's drug approval means for investors and other biopharma companies.";215.83999633789062;;126.2699966430664;COPENHAGEN, Denmark & BOTHELL, Wash., February 24, 2022--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN) who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. Early results showed tisotumab vedotin demonstrated aBOTHELL, Wash., & COPENHAGEN, Denmark, February 24, 2022--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN) who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. Early results showed tisotumab vedotin demonstrated;152.88999938964844;;412.8999938964844;;4.610000133514404;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in the following upcoming conferences:;77.3499984741211;Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declinesBioMarin (BMRN) delivered earnings and revenue surprises of 250% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Financial Highlights (in millions of U.S. dollars, except per share data, unaudited);77.23999786376953;;67.83999633789062;;75.55999755859375;As with many other instances of investing in uncertain waters, exchange-traded funds (ETFs) can come to the rescue of investors.  Two particularly attractive funds for investors to consider today are the ARK Genomic Revolution ETF (NYSEMKT: ARKG) and the Global X Robotics & Artificial Intelligence ETF (NASDAQ: BOTZ).  Companies in ARK Invest's Genomic Revolution ETF are ones that are working on extending and improving human life.;79.94999694824219;Recent developments for Novavax (NASDAQ:NVAX) stock have been positive. Source: rarrarorro / Shutterstock.com The company finally filed emergency use authorization for its vaccine in America. More filings to come after a late-stage trial indicated 80% effectiveness with this vaccine against symptomatic Covid-19. Nonetheless, the recent sluggish price momentum for NVAX stock is due to several factors.InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a move that will undoubtedly diPharma stocks have taken on a new allure since the onset of the pandemic. The early stages of the health crisis were characterized by a race to ensure that pharma majors were not laggards in vaccine development. There have been few clear winners and these drug makers have witnessed strong revenue and cash flow upside. With expectations that the pandemic might evolve to an endemic in 2022, there has been some correction in pharma stocks. This has created a good opportunity to accumulate some qualNovavax (NASDAQ: NVAX) saw its shares wilt on Wednesday, due in no small part to a fairly deep price-target cut from an analyst.  Mamtani's adjustment comes mere days before Novavax is slated to unveil its Q4 earnings.  On Wednesday, Novavax announced that it has begun shipping the jab to the region.The CEO of the largest vaccine manufacturer in the world says that despite a slowdown in global vaccine uptake, he expects a strong Q2 and Q3.It's been a tough past 12 months for Novavax (NASDAQ: NVAX) as the biotech company saw its shares plummet nearly 70%.  For instance, the company ran into several delays in its quest to apply for Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate, NVX-CoV2373.  Meanwhile, other companies were dominating the coronavirus vaccine market.On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine.;87.45999908447266;Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -19.78% and 33.35%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?On track to present additional interim data from dose-escalation portion of the ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy on February 28, at 4:30 p.m. ETPlans to present interim data from ongoing first-in-human study of NTLA-2002 for hereditary angioedema (HAE) in 2H 2022Nominated two new development candidates – NTLA-6001, its first ex vivo allogeneic CAR-T candidate for CD30+ expressing hematologic cancers, and NTLA-2003, an in vivo knockout caThe company plans to occupy a 140,000-square-foot facility on Winter Street in Waltham, which is being redeveloped by Alexandria Real Estate Equities.;87.12999725341797;;75.81999969482422;;88.02999877929688;Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.;43.720001220703125;PASADENA, Calif., February 24, 2022--Arrowhead reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3 for mixed dyslipidemia;63.029998779296875;;57.15999984741211;This article speculates on a number of takeover targets of 2022. Global mergers and acquisitions (M&A) soared to new highs last year. According to Wall Street Journal, the total value of M&A in 2021 was $5.7 trillion, 64% higher than the previous year. Almost 60,000 deals closed in 2021 through Dec. 21, up 22% year-over-year (YOY). The average value per deal was close to $100 million. Meanwhile, analysts predict another robust year for takeovers and M&A activity in 2022. With billions of dollars;55.25;;33.95000076293945;;20.100000381469727;;8.0;"BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio’s financial runway into 2024 –Dosed first patient in Phase 1/2 trial of investigational gene therapy for congenital adrenal hyperplasia (CAH); initial data readout anticipated in second half of 2022 –Launched clinical collaboration with Amgen to study BBP-398, a potentially best-in-class SHP2 inhibitor, in combination with LUMAKRAS® (sotorasib) in advanced solid tumors with the KRAS G12C mutation –Es";70.36000061035156;;32.91999816894531;;67.81999969482422;;35.279998779296875;Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.;94.0999984741211;PARK CITY, Utah, February 23, 2022--Arena Pharmaceuticals today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021The Serious Fraud Office has opened a criminal investigation into Arena Television, a collapsed broadcaster that worked on the Euro 2020 football tournament and Glastonbury.;28.219999313354492;;16.280000686645508;;9.170000076293945;The company — which still has a quartet of late-stage trials with the drug and more than $700 million in cash — saw its stock continue to drop on Thursday.What happened Shares of the clinical-stage biotech Kodiak Sciences (NASDAQ: KOD) are down by a hefty 80.3% as of 2:22 p.m. ET Wednesday afternoon. The drugmaker's stock is plunging today in response to its lead product candidate, KSI-301, failing to meet the primary endpoint of a combined phase 2/3 trial as a treatment for wet age-related macular degeneration (wet AMD).Kodiak Sciences' attempt to improve on Regeneron's blockbuster eye drug backfired on Wednesday — and investors pummeled KOD stock.;11.0;;32.4900016784668;Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 76.25% and 30.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year ended December 31, 2021, and recent business achievements.;66.33000183105469;Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?;53.56999969482422;;8.449999809265137;VANCOUVER, British Columbia, February 23, 2022--AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools;53.59000015258789;;25.81999969482422;;24.75;Our recent survey conducted with Harris Poll and Depression and Bipolar Support Alliance found that many individuals with Bipolar 1 disorder felt that finding the right treatment can be a long and ...
2022-02-25;227.02999877929688;;61.119998931884766;;618.6599731445312;Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.History has shown us that it’s best to remain invested in the stock market for the long term. The market has recovered from temporary dips to print new all-time highs with 100% precision over the past century. Investors could buy low-volatility stocks to manage the tension triggered by bouts of market turbulence. Once again, turbulence has returned to the stock market in 2022. High inflation, threats of rising interest rates, rising employment costs and rising geopolitical risks trigger market cRegeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.;150.6199951171875;;329.489990234375;In this article, we discuss 10 stocks that billionaire Andreas Halvorsen is selling. If you want to skip our detailed analysis of these stocks, go directly to Billionaire Andreas Halvorsen Is Selling These 5 Stocks. Ole Andreas Halvorsen is a Norwegian billionaire investor who founded Viking Global, a Connecticut-based hedge fund, in 1999. After graduating […];230.3000030517578;Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.In a bad market, what's one of the top Fidelity funds up to? Growth Discovery, one of the best mutual funds anywhere, is making three savvy moves.Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.;207.3800048828125;Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.The topic is much more exciting — and frightening —  in the wake of Aduhelm, a drug developed by Biogen  (BIIB)  to treat early-stage Alzheimer’s disease with an original ask price of $56,000 per patient per year.  Traditional Medicare is composed of two programs (see Table 1).Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.;214.11000061035156;"CAMBRIDGE, Mass. & BEIJING, February 25, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the fourth quarter and full year of 2021, recent business highlights, and anticipated upcoming milestones.";128.3800048828125;;155.0;;422.69000244140625;;4.409999847412109;;78.0;While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.;81.2699966430664;;68.41999816894531;;78.31999969482422;In this article, we will take a look at the 10 stocks in focus after posting their earnings reports. You can skip our detailed analysis of these companies and go directly to the 5 Stocks in Focus After Posting Their Earnings Reports. Recently, stocks from the consumer cyclical and healthcare sectors, including Lowe’s Companies, Inc. […];81.62999725341797;Pharma companies hit gold during this pandemic. While it helped several companies scale and report record revenues, Novavax (NASDAQ:NVAX) is still struggling to make an impact in the market. The vaccine manufacturer suffered several setbacks and NVAX stock disappointed many investors. Source: Vladimka production / Shutterstock.com The stock is down 66% in the past six months and has gone from $250 to $77 today. Novavax has been waiting for a very long time for the FDA approval and it may still tWith Russia’s attack on Ukraine at the forefront of the current news flow, Covid has been put on the backburner for now. That said, as has been proven before with the emergence of new variants, it is still too early to say with certainty the pandemic is finally behind us. In any case, over the long run, in similar fashion to the flu, annual boosters to protect against Covid will be required. So, there is still room for Covid-19 vaccine makers to make their mark, which bodes well for one of the l;96.36000061035156;Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.;88.86000061035156;;76.02999877929688;;88.54000091552734;Mirati (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;43.9900016784668;;62.18000030517578;;59.72999954223633;;54.060001373291016;;34.93000030517578;;20.18000030517578;Over the past two months, Wall Street and investors have been reminded that crashes and corrections are inevitable.  For patient investors, there's simply no better time to put their money to work in the stock market.  One such bargain-priced company that should thrive long after this correction is over is auto stock General Motors (NYSE: GM).;7.900000095367432;;74.75;;33.029998779296875;;67.44999694824219;;35.529998779296875;;94.62999725341797;Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.;27.829999923706055;"Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 50.77% and 21.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?– Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date – – $917.2 million of sotrovimab collaboration revenue recognized in 2021 – – Multiple commercial and clinical value drivers expected across the portfolio in 2022 – SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.";16.299999237060547;;8.819999694824219;Kodiak Sciences Inc. (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.;11.359999656677246;;31.780000686645508;One thing we could say about the analysts on Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) - they aren't optimistic...Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.Companies in The News Are: AEP,ATHM,IONS,DISH;67.4800033569336;Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.;55.279998779296875;;8.930000305175781;Image source: The Motley Fool.  AbCellera Biologics Inc. (NASDAQ: ABCL)Q4 2021 Earnings CallFeb 24, 2022, 5:00 p.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  OperatorLadies and gentlemen, thank you for standing by, and welcome to the AbCellera full year 2021 earnings results and business update.VANCOUVER, British Columbia, February 24, 2022--AbCellera Reports Full Year 2021 Business Results;54.97999954223633;;25.639999389648438;;24.809999465942383;
2022-02-28;226.47999572753906;Amgen Inc (NASDAQ: AMGN) shared results from a pooled post-hoc analysis of the NAVIGATOR Phase 3 and PATHWAY Phase 2b trials of Tezspire (tezepelumab-ekko) in broad asthma patient population. Tezspire is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. In the pooled analysis, Tezspire, when added to standard of care (SoC), reduced asthma exacerbations in patients, irrespective of baseline blood eosinophil counts, demonstra;60.400001525878906;;618.3599853515625;Dow Jones futures signal a market rally reversal as the West ramps up sanctions vs. Russia banks amid the ongoing Ukraine invasion.;150.80999755859375;Today we will run through one way of estimating the intrinsic value of BioNTech SE ( NASDAQ:BNTX ) by taking the...;326.6000061035156;NoRo pilots the country’s first and only patient-run reference center for rare diseases;230.02000427246094;Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.;211.00999450683594;;210.52000427246094;;128.8699951171875;"TOKYO & BOTHELL, Wash., February 28, 2022--Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas"") and Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed its previously adopted positive opinion, recommending approval of PADCEV™ (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have";157.85000610351562;CAMBRIDGE, Mass., February 28, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today on Rare Disease Day announced the premiere of its new documentary, Two of Me: Living with Porphyria, a film chronicling the lives of seven people around the world living with acute hepatic porphyria (AHP), a family of debilitating, rare genetic diseases. Directed by Emmy-nominated filmmaker Cynthia Lowen, Two of Me: Living with Porphyria is a story of human strength, pe;419.4100036621094;Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 11:10 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;4.5;Phytolon, a growing startup company making natural food colorants, announced a partnership today with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, to produce vibrant cultured food colors via fermentation of yeast. Under this partnership, Phytolon is leveraging Ginkgo's ability to engineer biology at scale to work together on the production of vibrant betalain pigments, the healthy and colorful compounds found in foods like beets and cactus fruit. The project;78.12000274658203;;81.47000122070312;Gold Equivalent Indicated Mineral Resource Increases 24% to 4.39 Moz at 5.38 g/t (All amounts expressed in U.S. Dollars unless otherwise stated) TORONTO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Torex Gold Resources Inc. (the “Company”) (TSX: TXG) announces an updated Mineral Resource estimate for the Media Luna project, which now consists of a gold equivalent1 (“AuEq”) Indicated Resource of 4.39 million ounces (“Moz”) at an average grade of 5.38 grams per tonne (“g/t”). This reflects a 24% increase in;68.30000305175781;;78.05999755859375;Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conferences and invited investors to participate by webcast.;83.37000274658203;;98.8499984741211;;89.87000274658203;NVIDIA and Neurocrine Biosciences highlighted as Zacks Bull and Bear of the Day.Strong growth for Ingrezza meets company investment in the pipeline, sparking lowered EPS estimates;76.61000061035156;Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 96.88% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?;88.29000091552734;;44.0;;60.54999923706055;Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics today announced a strategic collaboration to advance novel targeted protein degrader therapies to address important areas of medical need. Targeted protein degradation harnesses the body's natural protein disposal system and offers the potential to develop new medicines that target historically difficult-to-drug proteins that play an important role in causing serious diseases.;61.369998931884766;In this article, we discuss 10 innovative stocks in Cathie Wood’s portfolio that failed to impress. If you want to skip our detailed analysis of these stocks, go directly to 5 Innovative Stocks in Cathie Wood’s Portfolio That Failed to Impress. Innovative stocks are companies that develop and harness new technologies, allowing for the revolutionization […]ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in March: Cowen 42nd Annual Health Care ConferenceDate: Monday, March 7, 2022 Time: 10:30 a.m. ET. Barclays Global Healthcare ConferenceDate: Thursday, March 1;54.70000076293945;;34.54999923706055;;20.530000686645508;;7.800000190734863;;78.3499984741211;Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 16.67% and 483.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion Executing First Wave of Long-term Strategy for Sickle Cell Disease with Planned Initiation of BEAM-101 Clinical Trial and IND Submission for BEAM-102 in the Second Half of 2022 Strong Cash Position of $1.2 Billion, Including Pfizer Upfront, to Support Robust Set of Milestones Across Ex Vivo and In Vivo Base Editing Programs Anticipated in 2022 and Beyond CAMBRIDGE, Mass., Feb. 28, 20;32.560001373291016;Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to ad;67.31999969482422;;35.470001220703125;Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here. A return of -6.99% was recorded by its Investor Class: ARTSX, -6.93% by its Advisor Class: APDSX, and -6.93% by its Institutional Class: APHSX for the fourth […];94.97000122070312;;25.190000534057617;;16.68000030517578;;8.640000343322754;;11.920000076293945;SickKids will use HiFi Sequencing to explore potential genetic causes of a range of medical and developmental conditionsMENLO PARK, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- PacBio, a leading provider of high-quality, highly accurate sequencing platforms, today announced it will be supporting The Hospital for Sick Children (SickKids) in Toronto, Canada in using HiFi whole genome sequencing (HiFi WGS) to potentially identify genetic variants that may be associated with medical and developmental cIn this article, we discuss 10 innovative stocks in Cathie Wood’s portfolio that failed to impress. If you want to skip our detailed analysis of these stocks, go directly to 5 Innovative Stocks in Cathie Wood’s Portfolio That Failed to Impress. Innovative stocks are companies that develop and harness new technologies, allowing for the revolutionization […];33.380001068115234;;64.80999755859375;Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “It has been an exciting time for Arvinas over the past 12 months, including the beginning of a transformational collaboration with Pfizer, and compelling clinical updates supporting;55.47999954223633;Intra-Cellular Therapies (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 16.67% and 483.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?;8.710000038146973;;55.939998626708984;SOUTH SAN FRANCISCO, Calif., February 28, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has become a part of the Digital Preservation Coalition’s (DPC) Supporter Program, where members and solution providers can collaborate.SOUTH SAN FRANCISCO, Calif., February 28, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the following upcoming virtual investor conferences:;25.40999984741211;;24.860000610351562;
2022-03-01;225.2100067138672;;60.2599983215332;"Shares of Gilead Sciences Inc. were down 1.0% in premarket trading on Tuesday after the company said it received a complete response letter from the Food and Drug Administration regarding its application for an experimental HIV drug. Gilead is seeking FDA approval for lenacapavir, a long-acting HIV-1 capsid inhibitor, for people with multi-drug resistant HIV. The FDA raised questions about the use of a specific type of vial and whether it's compatible with the drug solution. Gilead said it willThe U.S health regulator has declined to approve Gilead Sciences' injectable drug for the treatment of HIV-1 infection over concerns related to the vials meant for the drug, the company said on Tuesday.  In a so-called complete response letter, the U.S. Food and Drug Administration (FDA) cited issues related to the compatibility of the drug, lenacapavir, with the proposed borosilicate vial.  ""Gilead intends to provide FDA with a comprehensive plan and corresponding data to use a different vial type,"" said Merdad Parsey, chief medical officer of Gilead in a statement.FOSTER CITY, Calif., March 01, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor under review for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.";607.030029296875;Eight months after delivering promising biomarker data from one of the first CRISPR trials, Intellia Therapeutics Inc (NASDAQ: NTLA) presented additional data from the Phase 1 trial for NTLA-2001 in transthyretin, or ATTR, amyloidosis. In the initial study, Intellia showed that a single infusion of its gene-editing therapy could lower the amount of toxic protein in six patients by an average of 52% or 87%, depending on the dose. The new results showed that a slightly higher dose produced similarAchieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsAchieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsDurable serum TTR reductions observed with patient follow-up ranging from 2 to 12 monthsNTLA-2001 was generally well tolerated at all dose levels On track to initiate polyneuropathy dose-expansion cohort (Part 2) in Q1 2022 Intellia to host investor event today, Monday, February 28, at 4:30 p.m. ET CAMBRIDGE, Mass. and TARRYTOW;146.72999572753906;The COVID-19 vaccine developed by Pfizer and German partner BioNTech SE is much less effective in preventing infection in children aged 5 to 11 than in older people, according toThe COVID-19 vaccine developed by Pfizer and German partner BioNTech SE is much less effective in preventing infection in children aged 5 to 11 than in older people, according toOvid Pharmaceuticals CEO Jeremy Levin joins Yahoo Finance Live to discuss biotech industry leaders pledging to cut ties with Russia and how sanctions financially target key Russian officials.Two doses of the Pfizer Inc and BioNTech SE COVID-19 vaccine was protective against severe disease in children aged 5 to 11 during the recent Omicron variant surge, but quickly lost most of its ability to prevent infection in the age group, according to a study by New York State researchers.  The vaccine's efficacy against infection among those children declined to 12% at the end of January from 68% in mid-December compared to kids who did not get vaccinated, according the study https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1, which has not yet been peer reviewed.  For those aged 12 to 17, the vaccine's protection against infection fell to 51% in late January from 66% in mid-December.;330.25;;230.69000244140625;Riding out the storm and perhaps even adding to your positions in excellent companies is the right course of action during market downturns.  With that in mind, let's look at two stocks that are worth buying no matter what transpires in the next few weeks: Vertex Pharmaceuticals (NASDAQ: VRTX) and Airbnb (NASDAQ: ABNB).  Biotech giant Vertex Pharmaceuticals has performed better than most this year with the company's shares rising by about 5% since the beginning of the year vs. a nearly 10% drop for the S&P 500.Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.Buffett's latest letter to Berkshire Hathaway shareholders revealed the legendary investor's present mindset.;210.33999633789062;Aduhelm, a drug developed recently by Biogen  (BIIB)  has raised enormously important issues for Medicare.  Biogen’s initial proposed price for Aduhelm was $56,000 per patient per year.  Because Aduhelm is administered intravenously by physicians, it would be covered under Medicare Part B. (Medicare Part D covers retail prescription drugs.) While, to date, Medicare has covered virtually all drugs approved by the Food and Drug Administration (FDA), officials issued a draft decision in January 2022 to limit coverage of Aduhelm to those in clinical trials.;216.2100067138672;"CAMBRIDGE, Mass. & BEIJING, March 01, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:50 a.m. ET.";129.4600067138672;BOTHELL, Wash., March 01, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 11:10 a.m. Eastern Time. The presentation will be webcast live and available for replay from the investor section of Seagen’s website at investor.seagen.com.;162.50999450683594;CAMBRIDGE, Mass., March 01, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s supplemental New Drug Application (sNDA) for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1 (PH1)CAMBRIDGE, Mass., February 28, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:;420.17999267578125;;4.289999961853027;;77.37000274658203;;80.91000366210938;;68.69999694824219;Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitorsCHICAGO and FORT WORTH, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2 study of elraglusib (9-ING-41) plus retifanlimab combined with gemcitabine/nab-paclitaxel fo;76.48999786376953;FORT MILL, S.C., March 01, 2022 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. (NASDAQ: DSEY), a leading provider of hygiene, infection prevention and cleaning solutions, has appointed Katherine S. Zanotti to the company’s board of directors, effective March 1, 2022. This appointment will bring the total number of directors to eleven. “We are delighted to welcome Katherine (‘Kay’) to our board. Kay’s long history of leadership coupled with her extensive experience in sales and marketing within the;83.73999786376953;"The COVID-19 vaccine developed by Pfizer and German partner BioNTech is much less effective in preventing infection in children aged 5 to 11 than in older people, according to a new data set from health officials in New York state.Shares of Novavax Inc. were down 6.7% in premarket trading on Tuesday, the day after the company fell short of revenue expectations for the fourth quarter of 2021. Novavax on Monday reported $222.2 million in revenue in the fourth quarter of 2021. The FactSet consensus was $331.8 million. The company's protein-based COVID-19 vaccine is its only authorized or approved therapy; it recently received authorization in several regions, including the European Union, New Zealand, and the U.K. (The shotThe Covid-19 vaccine maker Novavax expects revenue of between $4 billion and $5 billion in 2022, That compares with $1.1 billion for 2021.By Dhirendra TripathiNovavax Inc said on Monday it would pursue full approval of its COVID-19 vaccine in the second half of this year and forecast total revenue of between $4 billion and $5 billion for 2022.  ""We expect to gain additional authorizations where we have already filed, including in the U.S. We will pursue full approval of our vaccine including filing our BLA (biologics license application), in the second half of 2022,"" Chief Executive Officer Stanley Erck said during a post-earnings call.  Novavax said it has completed delivery of around 9 million vaccine doses to Indonesia, 6 million to Australia and 2 million to South Korea and expects to supply 69 million doses to Europe in the first half of this year.The company also said Monday that its protein-based vaccine showed efficacy of 82.5% in protection against all Covid infection over a six-month period as part of a phase 3 clinical trial in the U.K.  The Gaithersburg biotech received $948.71 million in grants across fiscal 2021 that it said related to funding from both the U.S. government and the Coalition for Epidemic Preparedness Innovations for its Covid vaccine candidate.  Novavax said the jump in R&D grew from manufacturing its Covid vaccine and working to build up an inventory of 2 million doses annually in advance of regulatory authorizations.  For the fourth quarter of 2021, Novavax reported $222 million in revenue — down from $280 million from the fourth quarter of 2020.Novavax (NVAX) delivered earnings and revenue surprises of -681.82% and 42.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?NVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the world, including the European Union, Australia, Canada, and Great Britain; authorizations granted by 12 regulatory agencies and emergency use listing from the WHONovavax Inc said on Monday that an extended analysis of a late-stage study conducted in the United Kingdom showed that its COVID-19 vaccine provided long-term protection against the coronavirus.  Additionally, vaccine efficacy of 82.5% was maintained against both symptomatic and asymptomatic infection, while vaccine efficacy against severe disease was 100%.  Novavax is working on developing an Omicron-specific vaccine and said on Monday it expects to begin manufacturing doses of the shot at a commercial scale in the first quarter.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today shared extended analysis from its pivotal Phase 3 clinical trial conducted in the United Kingdom (UK), showing that a high level of efficacy for its protein-based COVID-19 vaccine, NVX-CoV2373, was maintained over a 6-month period of surveillance. Additionally, the analysis showed vaccine efficacy of 82.5% (95% CI: 75.0, 87.7) in protecOvid Pharmaceuticals CEO Jeremy Levin joins Yahoo Finance Live to discuss biotech industry leaders pledging to cut ties with Russia and how sanctions financially target key Russian officials.";79.8499984741211;The decision is a setback for Intellia Therapeutics, Crispr Therapeutics, and Caribou Biosciences, and a win for Editas Medicine and Beam Therapeutics.NTLA-5001 is a novel investigational T cell receptor (TCR)-T cell therapy which leverages Intellia’s proprietary cell engineering platform NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen frequently found in acute myeloid leukemia (AML) and other hematologic and solid tumors CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeEight months after delivering promising biomarker data from one of the first CRISPR trials, Intellia Therapeutics Inc (NASDAQ: NTLA) presented additional data from the Phase 1 trial for NTLA-2001 in transthyretin, or ATTR, amyloidosis. In the initial study, Intellia showed that a single infusion of its gene-editing therapy could lower the amount of toxic protein in six patients by an average of 52% or 87%, depending on the dose. The new results showed that a slightly higher dose produced similarThe decision — centering on the gene-editing technology CRISPR and its initial cutting protein, called Cas9 — shifts the invention of the system to two other institutions.Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsAchieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsDurable serum TTR reductions observed with patient follow-up ranging from 2 to 12 monthsNTLA-2001 was generally well tolerated at all dose levels On track to initiate polyneuropathy dose-expansion cohort (Part 2) in Q1 2022 Intellia to host investor event today, Monday, February 28, at 4:30 p.m. ET CAMBRIDGE, Mass. and TARRYTOW;91.88999938964844;;76.0199966430664;CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 14 individuals hired by Sarepta in January 2022. The equity awards were approved in accordance with Nasdaq Listing;90.20999908447266;Mirati Therapeutics (MRTX) reports wider-than-expected fourth-quarter loss. Sales miss estimates.Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year 2021 and recent corporate updates.;44.310001373291016;;61.310001373291016;Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies. The collaboration will bring Proteovant's Artificial Intelligence (AI)-enhanced targeted protein degradation (TPD) platform and Blueprint Medicine's precision medicine expertise to discover novel targeted protein degraders. The companies will jointly research important targets and advance up to two novel protein degrader therapies into develop;57.439998626708984;The decision is a setback for Intellia Therapeutics, Crispr Therapeutics, and Caribou Biosciences, and a win for Editas Medicine and Beam Therapeutics.;52.54999923706055;;34.41999816894531;"Fate Therapeutics (FATE) delivered earnings and revenue surprises of -5.88% and 30.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose for R/R BCL; Interim Phase 1 Data of 16 Patients Showed 69% ORR and 56% CR in Single-dose Escalation Cohorts of FT596+R at ≥90 Million Cells Granted RMAT Designation for FT516 in R/R DLBCL; Enrollment Ongoing in Multi-dose, Multi-cycle Expansion Cohorts at 900 Million Cells per Dose in Disease-specific Indications, including Aggressive BCL in Patients Previously Treated with Autologous CD19-t";20.889999389648438;;8.359999656677246;Today is shaping up negative for BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) shareholders, with the analysts delivering a...;73.5;;32.099998474121094;Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -51.22% and 67.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided business highlights. “Denali is now transitioning to a late-stage development company, having made significant progress in advancing;67.37000274658203;;35.630001068115234;;94.69000244140625;These are the marijuana stocks with the best value, fastest growth, and most momentum for March 2022.;24.0;Vir Biotechnology, Inc. (VIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.;16.309999465942383;;8.84000015258789;;12.15999984741211;;34.08000183105469;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a panel discussion on orphan neurological disease therapeutics at the virtual Cowen 42nd Annual Health Care Conference at 9:10 a.m. ET on Monday, March 7, 2022.;65.73999786376953;;56.5;Intra-Cellular (ITCI) delivered earnings and revenue surprises of 0% and 3.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Received FDA approval for CAPLYTA® (lumateperone) for the treatment of bipolar depression in adults. CAPLYTA is the first and only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. Total revenues for the fourth quarter were $25.7 million, compared to $12.5 million for the same period in 2020, representing a 106% increase. Total revenues for the year were $83.8;9.039999961853027;;55.5;;25.06999969482422;Acadia (ACAD) posts a wider-than-expected loss for the fourth quarter of 2021. Shares fall during the after-hours trading.Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?SAN DIEGO, February 28, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2021.;23.93000030517578;Alkermes plc (Nasdaq: ALKS) today announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women's Cancer, taking place March 18-21, 2022. New data in patients with platinum-resistant ovarian cancer from ARTISTRY-1, a phase 1/2 study evaluating the safety, tolerability and efficacy of intravenously administered (IV) nem
2022-03-02;228.58999633789062;;61.2400016784668;Featured articles and commentaries explore social, cultural and economic factors related to HIV/AIDS in the Black CommunityThe FDA has issued a complete response letter (CRL) for Gilead Sciences Inc's (NASDAQ: GILD) application for lenacapavir for heavily treated multi-drug resistant (MDR) HIV-1 infection. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor. In the CRL, the FDA has cited Chemistry Manufacturing and Controls (CMC) issues relating to the compatibility of lenacapavir with the proposed container vial. The FDA raised questions about vials made of borosilicate glass and their compatibili;616.8699951171875;Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.;146.9499969482422;Novavax (NVAX) reports a wider-than-expected loss for the fourth quarter of 2021. Also, revenues miss estimates. Its shares decline in after-market trading following the announcement.;330.19000244140625;Recognizing and supporting rare disease organizations and families around the worldVIR vs. ILMN: Which Stock Is the Better Value Option?;234.11000061035156;ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the United States.Horizon's (HZNP) revenues beat estimates in the fourth quarter of 2021. Shares rise following the results.Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.BOSTON, March 01, 2022--Vertex to Present at Cowen’s 42nd Annual Health Care Conference on March 8FATE reports a wider loss on increased R&D expenses in the fourth quarter.Endo (ENDP) tops Q4 earnings and sales estimates. However, Vasostrict faces generic competition, and the ongoing COVID-19 driven market conditions affect specialty product office-based procedures.;207.7899932861328;"Longleaf Partners Fund, a Memphis-based fund under Southeastern Asset Management, published its “Longleaf Partners Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. Longleaf Partners Fund added 6.18% in the fourth quarter, taking returns for the full year to 23.58%, well ahead of its absolute return goal. However, the S&P […]Rating Action: Moody's confirms Alkermes' Ba3 CFR; outlook stableGlobal Credit Research - 01 Mar 2022New York, March 01, 2022 -- Moody's Investors Service (""Moody's"") confirmed the ratings of Alkermes, Inc., a subsidiary of Alkermes plc (collectively ""Alkermes"").  The confirmed ratings include the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, and the Ba3 senior secured term loan rating.  There is no change to Alkermes' SGL-1 Speculative Grade Liquidity Rating.Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.";214.1999969482422;;126.68000030517578;;163.1999969482422;;423.67999267578125;;4.25;;78.1500015258789;;76.8499984741211;10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming Cowen 42nd Annual Health Care Conference.;69.58000183105469;;75.31999969482422;;86.38999938964844;"Pity the poor Novavax (NASDAQ:NVAX) investor. The stock’s down more than 40% so far this year. And while there’s some legitimate analyst momentum that NVAX stock will rebound in the next nine months, geopolitical tensions pose a new risk. Source: rarrarorro / Shutterstock.com NVAX has emergency use authorizations to distribute its Covid-19 vaccine in more than 30 countries. Australia granted approval on Jan. 19 for the company’s branded Nuvaxovid shot. And the European Commission authorized NovaNovavax (NASDAQ: NVAX) missed Wall Street's revenue estimate in the fourth quarter of 2021.  As proof, the vaccine maker's shares rose on Tuesday after Novavax's Q4 update following the market close on Monday.  Here are two numbers that should especially make Novavax shareholders smile.Investors have a reason to be optimistic about Novavax's fortunes -- at least over the near term.Novavax's highly anticipated Covid vaccine lagged sales expectations in its first quarter on the market, but NVAX stock reversed on Tuesday.In this article, we will take a look at the 10 companies under investors’ radar after releasing their earnings reports. You can skip our detailed analysis of these companies and go directly to the 5 Companies Under Investors’ Radar After Releasing their Earnings Reports. Leading stocks from the technology sector, including HP Inc. (NYSE:HPQ), Workday, […]Investors might have been disappointed with Novavax’s (NVAX) latest quarterly results, but Jefferies analyst Roger Song thinks a “transformational year” could be in the cards for the vaccine maker. “While next few Q's commercial/regulatory/clinical execution remains key, we could start to see big promise coming to fruition,” the analyst opined following the Q4’s print. That is despite misses on both the top-and bottom-line. Revenue declined 20.5% year-over-year to $222.2 million, falling $109.59After a busy final quarter of 2021, Novavax's CEO said he expects the Maryland company's ""momentum will only accelerate"" this year.Shares of Novavax (NASDAQ: NVAX) were jumping 3.2% higher as of 11:45 a.m. ET on Tuesday after rising as much as 9.2% earlier in the day.  Investors weren't all that concerned with Novavax's fourth-quarter revenue of $222 million and net loss of $846 million.  Instead, they were pleased with the company's 2022 revenue guidance of $4 billion to $5 billion.Novavax (NVAX) reports a wider-than-expected loss for the fourth quarter of 2021. Also, revenues miss estimates. Its shares decline in after-market trading following the announcement.";84.38999938964844;Imagine winning a Nobel Prize for something and then your institution loses the patent rights. This researcher's greatest nightmare became...The University of California will lose a little money in the short term, but as CRISPR-Cas9 therapies make their way through clinical trials and toward commercialization, the licensing fees it would have collected would have been based on sales potentially in the billions of dollars.Intellia successfully lowered a problematic protein in patients with a liver disease on Monday, but NTLA stock fell on a patent decision.(Bloomberg) -- Intellia Therapeutics Inc. fell by the most in more than five years after the gene-editing company suffered a significant legal setback on the same day it unfurled promising early data on its leading drug candidate.Most Read from BloombergTeen Who Tracked Elon Musk’s Jet Is Now Chasing Russian TycoonsChina Spy Think Tank Advising Xi Predicts Russia Sanctions Will BackfireMicrosoft Says Son of CEO Satya Nadella Has Died at 26Russia Steps Up Aerial Campaign Against Cities: Ukraine U;91.86000061035156;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:;79.55999755859375;"Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the fourth quarter. The company also raises revenue guidance for the year. Stock down in after-market trading.Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 5.96% and 6.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Total revenues, which consist primarily of net product revenues and collaboration revenues, for the fourth quarter and full-year 2021 totaled $201.5 million and $701.9 million, respectivelyNet product revenues for the fourth quarter and full-year 2021 totaled $178.7 million and $612.4 million, respectively Fourth quarter 2021 net product revenues increased approximately 46% over the fourth quarter of 2020; full-year 2021 net product revenues increased approximately 34% over the prior year CAMBRI";89.1500015258789;;45.540000915527344;;61.290000915527344;;58.779998779296875;Imagine winning a Nobel Prize for something and then your institution loses the patent rights. This researcher's greatest nightmare became...;52.529998779296875;"Company to Host Conference Call and Webcast on March 2, 2022, at 8:00 a.m. ESTSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the twelve months ended December 31, 2021, along with recent product highlights and corporate updates. “2021 marked another year of strong growth and execution for Zai Lab i";34.970001220703125;FATE reports a wider loss on increased R&D expenses in the fourth quarter.;20.979999542236328;The shine has come off biotech stocks.  For example, the exchange-traded fund SPDR S&P Biotech ETF (NYSEMKT: XBI) is down more than 20% so far in 2022, and more than 41% over the past 12 months.  Biotech stocks still hold plenty of attraction, though, because the right ones can make investors wealthy.;8.260000228881836;;74.19999694824219;Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders should be happy to see the share price up 15% in the last month...;32.220001220703125;Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.;67.41999816894531;;36.0;;94.41999816894531;;24.1299991607666;Now is a great time to buy stocks. The market has been super-negative over the last couple of months. The war in the Ukraine and rising interest rates are two of the primary culprits, along with our COVID-19 malaise.VIR vs. ILMN: Which Stock Is the Better Value Option?;16.709999084472656;;8.850000381469727;Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.Kodiak Sciences (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2021.;11.699999809265137;;33.150001525878906;;68.04000091552734;;57.04999923706055;;9.430000305175781;;55.209999084472656;;24.65999984741211;;23.65999984741211;"Rating Action: Moody's confirms Alkermes' Ba3 CFR; outlook stableGlobal Credit Research - 01 Mar 2022New York, March 01, 2022 -- Moody's Investors Service (""Moody's"") confirmed the ratings of Alkermes, Inc., a subsidiary of Alkermes plc (collectively ""Alkermes"").  The confirmed ratings include the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, and the Ba3 senior secured term loan rating.  There is no change to Alkermes' SGL-1 Speculative Grade Liquidity Rating."
2022-03-03;232.63999938964844;Amgen (AMGN) closed the most recent trading day at $228.59, moving +1.5% from the previous trading session.Amgen (NASDAQ:AMGN) will virtually present at the 42nd Annual Cowen Healthcare Conference at 11:10 a.m. ET on Tuesday, March 8, 2022. Murdo Gordon, executive vice president of Global Commercial Operations and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the second quarter of 2022. The dividend will be paid on June 8, 2022, to all stockholders of record as of the close of business on May 17, 2022.;61.709999084472656;;611.1500244140625;Kodiak Sciences (KOD) is developing its lead candidate, KSI-301, for treating various retinal vascular diseases. The recent setback for KSI-301 has hurt the stock.;142.25999450683594;"The European Medicines Agency's leading vaccine expert said he was not concerned over recent data from New York state on a decline of protection from the Pfizer and BioNTech SE COVID-19 vaccine in children aged 5 to 11.  ""This study somehow showed lower protection from symptomatic COVID-19 but it is still within the frame of the level of protection that we are seeing overall with the vaccines that we have against Omicron and after a primary series,"" EMA's head of vaccines strategy, Marco Cavaleri, said in a media briefing, adding the regulator would assess the data in more detail.As exemplified by Shiba Inu's explosive debut in 2021, cryptocurrencies are one area where investors can find tremendous growth.  Another such area is biotech, where surging share prices are (usually) driven by clinical trial results and regulatory decisions rather than memes and out of control hype.  It goes without saying that biotech stocks and cryptocurrencies are poor places for risk-averse investors to tread.Although shares of biotech company BioNTech (NASDAQ: BNTX) have recently fallen along with most other stocks, the vaccine maker's performance over the past 12 months remains above that of the broader market.  BioNTech has one thing to thank for this performance: the COVID-19 vaccine Comirnaty, which it developed in collaboration with Pfizer.  Based in Germany, BioNTech was originally founded in 2008 and made its debut on the stock market in the U.S. in late 2019.";331.95001220703125;;235.69000244140625;Kodiak Sciences (KOD) is developing its lead candidate, KSI-301, for treating various retinal vascular diseases. The recent setback for KSI-301 has hurt the stock.Harding Loevner, an investment management firm, published its “Global Equity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. A net return of 4.35% was recorded by the fund for the fourth quarter of 2021, trailing its Benchmarks, the MSCI All Country World Index, and the MSCI World Index […]Vertex Pharmaceuticals' (NASDAQ:VRTX) stock is up by a considerable 15% over the past three months. Given the company's...;211.22999572753906;;185.19000244140625;"MISSISSAUGA, Ontario & CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland, March 03, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BRUKINSA® (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.";126.83999633789062;;165.07000732421875;;419.82000732421875;;3.859999895095825;;75.43000030517578;;74.04000091552734;;69.45999908447266;;71.2699966430664;;80.52999877929688;In this article, we discuss 10 pandemic stocks that are losing value. If you want to skip our detailed analysis of these stocks, go directly to 5 Pandemic Stocks That Are Losing Value. The outbreak of the COVID-19 pandemic in the beginning of 2020 triggered a freefall in share prices and the stock market saw […]Novavax (NASDAQ: NVAX) has reached a major milestone.  Novavax and rival Moderna (NASDAQ: MRNA) are each working on one, but Novavax is farthest ahead so far.  April could be a critical month for the program -- and therefore, for Novavax.Novavax (NASDAQ: NVAX) was an early leader in the coronavirus vaccine race.  Novavax fell behind in its regulatory authorization requests, and share gains turned modest compared to the previous year's mind-boggling increase.  Today, the situation has changed once again for Novavax -- for the positive.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Cowen's 42nd Annual Healthcare Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.;70.97000122070312;The race to develop a new gene therapy with CRISPR took some interesting turns recently.  On the same day that Intellia Therapeutics (NASDAQ: NTLA) dazzled the medical community with clinical trial results for its lead candidate, the fight for intellectual property rights related to all its candidates took a sharp turn for the worse.  Do solid clinical trial results make Intellia a good stock to buy now?;87.62000274658203;;81.47000122070312;CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at three upcoming virtual investor conferences: Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 2:10 p.m. E.T.Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 3:20 p.m. E.T.Guggenheim 3rd Annual Genomic Medicines and Rar;87.48999786376953;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Cowen Healthcare Conference, which will be webcast on March 9 at 10:30 a.m. P.T. / 1:30 p.m. E.T. David Meek, chief executive officer, will represent the company.;43.619998931884766;;58.880001068115234;The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.;54.189998626708984;;41.86000061035156;;33.04999923706055;SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences: Cowen 42nd Annual Health Care Conference available on demand on Wednesday, March 9, 2022 at 11:10 AM ETBarclays Global Healthcare Conference ava;21.059999465942383;ALAMEDA, Calif., March 02, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March:;7.889999866485596;;67.80000305175781;;31.030000686645508;;64.08000183105469;NOVATO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will participate in the Orphan CNS Panel at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 2:10 PM ET. The live and archived w;35.619998931884766;;94.02999877929688;These are the marijuana stocks on the Nasdaq with the best value, fastest growth, and most momentum for March 2022.;24.299999237060547;SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in an infectious disease panel discussion at the 42nd Annual Cowen Healthcare Conference on Wednesday, March 9, at 10:30 a.m. ET. The conference will be held virtually. A live webcast of the panel discussion can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About Vir;16.190000534057617;;8.649999618530273;Kodiak Sciences (KOD) is developing its lead candidate, KSI-301, for treating various retinal vascular diseases. The recent setback for KSI-301 has hurt the stock.;11.300000190734863;;33.2400016784668;;63.939998626708984;Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.;55.9900016784668;;9.039999961853027;;52.369998931884766;;24.360000610351562;SAN DIEGO, March 03, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 2:50 p.m. Eastern Time.;23.489999771118164;Our recent survey conducted with Harris Poll and Depression and Bipolar Support Alliance found that a vast majority of respondents who live with bipolar I disorder experienced medication side effec...
2022-03-04;232.91000366210938;;61.86000061035156;Appointment furthers ASCPT's commitment to diversity, equity, and inclusionModerna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;620.4099731445312;Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...;136.25999450683594;Investors were spooked by the government's plan to share certain COVID treatment technologies with international health organizations.;323.57000732421875;"The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...U.S. life sciences company Illumina's offer to cut prices and allow rivals continued access to its technologies has ""yet to convince"" EU antitrust regulators scrutinising its $8 billion cash-and-stock bid for Grail Inc, people familiar with the matter said.  Such doubts could mean that Illumina may have to sweeten its package of proposed remedies if it wants to win EU approval for the acquisition of the cancer detection test maker which it completed last August but is keeping as a separate company prior to regulatory approval.  The European Commission declined to comment, saying its investigation was ongoing.";238.66000366210938;Experts predict 40,000 more jobs coming to the state's life sciences industry. Here's how companies are trying to fill them.Intercept (ICPT) posts a narrower loss in the fourth quarter and sales beat estimates.;209.4499969482422;"RBC Capital Markets analyst Brian Abrahams upgraded the biotech stock to Outperform from Sector Perform, raising his target for the price.Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, ""Biogen"") announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401). The lecanemab Clarity AD Phase 3 clinical stuBiogen stock popped Thursday after an analyst suggested it could reap $8 billion in sales of its Alzheimer's treatments.Shares of Biogen Inc. were up 1.0% in trading on Thursday after the company confirmed to media outlets that it is laying off some U.S. employees as part of an effort to secure $500 million in annual cost savings.Biogen Inc. has begun eliminating positions as part of a long-promised cost-saving measure in the wake of the fallout from its Alzheimer's drug.";176.3699951171875;;131.99000549316406;;164.44000244140625;;417.5899963378906;;3.430000066757202;Experts predict 40,000 more jobs coming to the state's life sciences industry. Here's how companies are trying to fill them.;76.31999969482422;;69.7699966430664;;70.05000305175781;A new study found that baricitinib, a rheumatoid arthritis drug developed by Eli Lilly & Co. and Incyte Corp. , reduced the risk of death among patients who have been hospitalized with severe COVID-19. The newA large randomized trial found that adding the drug to the standard of care treatment reduced the risk of death by 13%.According to a British study, Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients in the standard of care group died within 28 days, compared to 513 patients in the baricitinib group who died where they were also given;70.7300033569336;;71.72000122070312;The stocks of both Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) have lost about 40% since the start of the year.  This is even as both companies predict billions of dollars in coronavirus vaccine revenue over the coming months.  In fact, both Moderna and Novavax make good buys after their recent earnings reports.;65.04000091552734;;88.19000244140625;;79.36000061035156;;83.01000213623047;;42.91999816894531;;57.040000915527344;;53.189998626708984;;40.5;;32.470001220703125;;20.700000762939453;;7.510000228881836;Helsinn Group and BridgeBio Pharma Inc (NASDAQ: BBIO) have updated their existing strategic collaboration to develop, manufacture, and commercialize infigratinib for oncology indications. Under the amended and restated agreement terms, Helsinn will gain an exclusive license to commercialize infigratinib in the U.S. Helsinn will be responsible for developing, manufacturing, and commercializing infigratinib in oncology indications except for achondroplasia or any other skeletal dysplasias except i;64.05000305175781;;30.450000762939453;;62.779998779296875;;35.11000061035156;;93.91999816894531;;23.200000762939453;;16.299999237060547;;7.699999809265137;Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.;10.680000305175781;;32.29999923706055;;64.54000091552734;NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences: Cowen & Co. 42nd Annual Health Care Conference on Monday, March 7. Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on th;55.09000015258789;;8.529999732971191;;48.150001525878906;;24.040000915527344;;23.18000030517578;
2022-03-07;234.36000061035156;;60.2599983215332;FOSTER CITY, Calif., March 07, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. The study met its primary endpoint with a statistically significant improvement in progression-free survival (PFS) versus physician’s choice of chemotherapy. The trial tar;618.5900268554688;Futures fell while crude oil prices skyrocketed on Russia oil embargo risks. The stock market rally is nearing February lows as Russia's Ukraine invasion continues.;126.25;;316.3299865722656;By Ryan Taft;235.5399932861328;The ideal scenario for this Vertex stock option trade is a rise up to 260 around April 14 with stable or rising implied volatility.Occidental Petroleum (OXY), Northrop (NOC), Hershey (HSY), Commercial Metals (CMC) and Vertex Pharma (VRTX) are among the stocks that are outperforming the market this year and are headed by female CEOs.Futures fell while crude oil prices skyrocketed on Russia oil embargo risks. The stock market rally is nearing February lows as Russia's Ukraine invasion continues.Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.;205.77999877929688;In this article, we will share the insights on 10 large-cap stocks hedge funds are talking about. You can skip the first five stocks and our comprehensive analysis of the background for these companies by going go directly to 5 Large-Cap Stocks Hedge Funds Are Talking About. The S&P 500, the benchmark for large-cap US stocks, […];179.72999572753906;David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...;134.38999938964844;;163.0;Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating;401.32000732421875;;3.450000047683716;;74.27999877929688;;68.54000091552734;;70.62000274658203;;71.08000183105469;Katie Couric, award winning journalist and colorectal cancer advocate who normalized talking about colon cancer more than two decades ago, today announced she has teamed up with Exact Sciences (NASDAQ: EXAS), the maker of Cologuard®, to highlight the urgent need for people to get screened.;69.7300033569336;Slow and steady wins the race, right? Well, not when it comes to a finite pandemic. Nearly fifteen months after the first coronavirus vaccine...;62.86000061035156;;87.94999694824219;;80.41999816894531;;81.45999908447266;In this article, we will discuss the 10 latest stock picks of billionaire Steve Cohen. You can skip our detailed analysis of Steve Cohen’s investment philosophy and his hedge fund performance over the years, and go directly to 5 Latest Stock Picks of Billionaire Steve Cohen. Steven A. Cohen is an American billionaire hedge fund […];41.97999954223633;;54.099998474121094;;55.20000076293945;;37.22999954223633;;31.860000610351562;;20.700000762939453;;7.510000228881836;;62.810001373291016;;30.90999984741211;;63.0;;34.75;;93.62000274658203;;22.469999313354492;;16.0;;7.429999828338623;;10.430000305175781;PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.;32.16999816894531;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it is now accepting applications for the Janice Wiesman Young Investigator Grant Program, which honors Janice Wiesman, M.D. (1958-2020), a leading global expert on the neurological impact of amyloidosis. The program awards $50,000 annually for up to two years to U.S.-based researchers whose work advances the understanding of transthyretin amyloidosis (ATTR). The deadline for applications is April 4, 2022.;61.22999954223633;;53.22999954223633;;8.279999732971191;;47.66999816894531;;24.399999618530273;;23.559999465942383;
2022-03-08;231.10000610351562;The company has said jobs at the $550 million facility will pay average salaries of more than $119,000 per year.Amgen (NASDAQ:AMGN) today announced the groundbreaking of its newest biomanufacturing facility, located in Holly Springs, North Carolina. The facility, expected to be operational by 2025, will support the growing demand for Amgen's medicines that treat serious illnesses such as cancer and heart disease.;59.540000915527344;Election to the NAE is among the highest professional distinctions in the field, and we're very proud.Gilead unveiled mixed results for its drug Trodelvy in women with breast cancer on Monday — and GILD stock sank at the close.;614.739990234375;BioNTech SE and Regeneron Pharmaceuticals Inc. said they plan to test an experimental BioNTech cancer vaccine in combination with Regeneron's Libtayo in patients with advanced non-small cell lung cancer, starting with a Phase 1/2 clinical trial. Libtayo is approved in the U.S. to treat advanced basal cell carcinoma. The companies already have an agreement evaluating this combination in patients with advanced melanoma. Both companies have generated billions of dollars in revenue from COVID-19 vac;128.16000366210938;BioNTech SE and Regeneron Pharmaceuticals Inc. said they plan to test an experimental BioNTech cancer vaccine in combination with Regeneron's Libtayo in patients with advanced non-small cell lung cancer, starting with a Phase 1/2 clinical trial. Libtayo is approved in the U.S. to treat advanced basal cell carcinoma. The companies already have an agreement evaluating this combination in patients with advanced melanoma. Both companies have generated billions of dollars in revenue from COVID-19 vacBioNTech and Regeneron plan to jointly conduct clinical trials evaluating FixVac candidate BNT116 in combination with Libtayo for the treatment of advanced non-small cell lung cancer (NSCLC)The development costs for the trials will be equally shared between the partiesThe companies advance clinical development of FixVac and Libtayo combination to third tumor type building on their existing agreements in melanoma and prostate cancer by combining their complementary immunotherapies to pave the wayInvestors are concerned that the company's revenue will plunge as the need for its COVID-19 vaccine diminishes.The FDA turns down an emergency use authorization request from Ocugen (OCGN) to use its COVID-19 vaccine Covaxin in pediatric population. Stock depreciates.;313.5199890136719;Geraldine Pittman Woods was a neuroembryologist who dedicated much of her life to expanding opportunities for people of color in STEM and education. Here is a small piece of her story.;238.7100067138672;The FDA grants priority review to Horizon's (HZNP) sBLA for Krystexxa plus methotrexate to treat people living with uncontrolled gout. A decision is due on Jul 7, 2022.AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.;202.00999450683594;Stifel analyst Paul Matteis downgraded shares of the company, best known for its Alzheimer's treatment Aduhelm, to Hold from Buy,President Biden, in his State of the Union speech, proposed giving Medicare the ability to negotiate lower prices for prescription drugs.  While Medicare’s decision to limit the coverage of Aduhelm to clinical trials will hold costs in check for a while, the bigger issue is the financial implications of an effective drug for early Alzheimer’s in an environment where Medicare has no ability to negotiate prices.  While Biogen  (BIIB)  originally priced Aduhelm at $56,000, it reduced the price, in response to weak sales, to $28,200.;184.72000122070312;;137.22999572753906;;162.0;;393.7200012207031;;3.4800000190734863;;76.26000213623047;;67.66999816894531;;71.1500015258789;;71.68000030517578;;72.79000091552734;;63.650001525878906;;87.9800033569336;;83.18000030517578;Application website is now open for the 2022 Scholarship ProgramFor the 2022-2023 academic year, the scholarship program has expanded to include two groups: one for individuals living with Duchenne and another for siblings in Duchenne families. CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route 79, The Duchenne Scholarship Program, is officially open;83.19999694824219;;41.33000183105469;;55.54999923706055;;60.349998474121094;;36.709999084472656;;32.77000045776367;;20.43000030517578;;7.829999923706055;BridgeBio Pharma Inc (NASDAQ: BBIO) has agreed to sell Nulibry (fosdenopterin) for injection to Sentynl Therapeutics Inc, owned by Zydus Lifesciences Ltd. Sentynl will provide cash payments upon the achievement of certain regulatory milestones. BridgeBio will be eligible to receive commercial milestone payments and tiered sales-based royalties. Specific terms were not disclosed. FDA-approved Nulibry is used to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) TyPALO ALTO and SOLANA BEACH, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced the execution of an asset purchase;62.470001220703125;CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president and chief scientific officer, will participate in a fireside chat during the Barclays 2022 Global Healthcare Conference on Tuesday, March 15, 2022 at 8:30 a.m. ET. The conference will be held in Miami, FL from March 15-17, 2022. A live webcast will be available in;30.15999984741211;;66.8499984741211;;34.27000045776367;;98.63999938964844;;22.549999237060547;;15.5;;7.659999847412109;;10.649999618530273;;32.349998474121094;;64.08999633789062;;53.939998626708984;;8.1899995803833;;47.369998931884766;;23.399999618530273;;23.8799991607666;
2022-03-09;231.4600067138672;Amgen (AMGN) closed the most recent trading day at $231.10, moving -1.39% from the previous trading session.Amgen (NASDAQ: AMGN) today announced that new data from across its oncology portfolio and pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13 in New Orleans, Louisiana.;59.0;While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results.;623.4299926757812;;140.2100067138672;BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $128.16, moving +1.51% from the previous trading session.;324.7099914550781;Illumina honored for developing several innovative technologies, including COVID-19 sequencing tests to track the spread of variants even at smaller labs;239.24000549316406;While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results.While companies with poor financials can shine during bull markets, in times of distress fundamentals are crucial.;202.27000427246094;;195.47000122070312;;140.4600067138672;;162.22999572753906;;418.29998779296875;Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022, at 8:30 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;3.4700000286102295;;78.87000274658203;;70.4800033569336;;72.01000213623047;;72.26000213623047;;79.06999969482422;It's been more than a month since the company filed for Emergency Use Authorization of its COVID-19 vaccine.After several delays and setbacks, Novavax (NVAX) finally filed an EUA request for its Covid-19 vaccine with the FDA at the end of January. Given precedents and the company’s recent comments, Jefferies’ Roger Song thinks a decision is due shortly. “We see the decision as a near-term stock-moving catalyst, and high likelihood of positive outcome, providing upside potential to the current share price,” Song opined. That could come in handy right now. Like most of the market, the stock has retreate;65.98999786376953;;89.87999725341797;;84.44999694824219;;87.0;;44.58000183105469;;58.61000061035156;Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new clinical and preclinical data for multiple programs across its precision therapy portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, April 8 to 13. The presentations highlight Blueprint Medicines' next wave of therapeutic candidates in its growing pipeline. These investigational treatments could bring the promise of precision medicine to broad patient populations w;62.41999816894531;"The broader market started the week with a brutal sell-off, but the biotech gained ground Monday thanks in part to an interview given by CEO Sam Kulkarni at Cowen's 42nd annual Health Care Conference.  Should investors pounce on this biotech stock?  Speaking at Cowen's conference, Kulkarni provided updates on CTX001, a treatment for beta thalassemia and sickle cell disease; CTX110, a treatment for malignant tumors; and other aspects of the business.ZUG, Switzerland and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present an e-poster at the American Association for Cancer Research (AACR) 2022 Annual Meeting, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online. Title: CBLB, CISH and CD70 multiplexed gene knoDespite big gains today, the biotech specialist's share price is still down roughly 46% over the past year of trading.";39.02000045776367;;35.40999984741211;;20.860000610351562;;8.569999694824219;;65.11000061035156;;32.619998931884766;SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that dosing has begun in a Phase 1/2 clinical trial of DNL593 (PTV:PGRN) for the potential treatment of frontotemporal dementia (FTD) caused by mutations in the granulin gene (GRN). Pending initial clinical data from t;67.66000366210938;;35.720001220703125;;99.93000030517578;Investors need to pay close attention to Arena (ARNA) stock based on the movements in the options market lately.;23.229999542236328;;16.25;;8.34000015258789;;11.229999542236328;;33.33000183105469;;68.0;;57.13999938964844;Wasatch Global Investors, an investment management firm, published its “Wasatch Small Cap Growth Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. During the fourth quarter, the benchmark Russell 2000® Growth Index rose 0.01% while the Russell 2000 Index increased 2.14%. Underperforming its benchmark, the Wasatch Small Cap Growth […];8.539999961853027;;50.83000183105469;SOUTH SAN FRANCISCO, Calif. & REDWOOD CITY, Calif., March 09, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today announced an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology ap;25.780000686645508;SAN DIEGO, March 09, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has received a target action date of August 4, 2022 from the U.S. Food and Drug Administration (FDA) for its resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The FDA’s Division of Psychiatry has also advised the company that it is planning to hold an Advisory Committee meeting in c;24.709999084472656;
2022-03-10;226.9499969482422;Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;57.91999816894531;By Andrew Hexter, Lisa LamGilead Sciences, Inc.'s ( NASDAQ:GILD ) dividend will be increasing to US$0.73 on 30th of March. This will take the...The changes come as Gilead tries to push on with clinical trials of its cancer-fighting drug Trodelvy, part of its $21 billion buyout of New Jersey-based Immunomedics 17 months ago.Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.;630.3599853515625;Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.;137.27000427246094;Pfizer's (PFE) Paxlovid is the first oral antiviral pill to be studied in a pediatric clinical study.Vaccine stocks popped Wednesday, but remain broadly under pressure. Their Covid wares are predicted to fall as the virus becomes endemic.Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.;316.0400085449219;;241.92999267578125;Pfizer's (PFE) Paxlovid is the first oral antiviral pill to be studied in a pediatric clinical study.Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.Voyager (VYGR) stock rises on the license option agreement with Novartis to get a target-specific access to next-generation TRACER AAV capsids for gene therapy programs.BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.;198.63999938964844;;184.0;;140.8300018310547;;160.55999755859375;;415.0899963378906;;3.369999885559082;;77.88999938964844;Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia A;67.1500015258789;;73.47000122070312;;68.55999755859375;Exact Sciences (EXAS) closed at $72.26 in the latest trading session, marking a +0.81% move from the prior day.;77.7699966430664;Novavax (NASDAQ: NVAX) has reported a string of good news since late last year.  Novavax has shipped doses, and healthcare facilities around the world are administering them.  The vaccine is showing efficacy against omicron and other variants.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the launch of its global unbranded 'We Do Vaccines' and 'Know Our Vax' programs, educational efforts aimed to help protect the health of people everywhere in the fight against COVID-19 and other deadly infectious diseases, such as influenza.Is Novavax stock a buy on expectations for at least $4 billion in sales this year? Is NVAX stock a buy right now?;65.91000366210938;Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has received an FDA orphan drug designation. The autologous T cell receptor therapy, dubbed NTLA-5001, is being evaluated in a Phase 1/2a trial in acute myeloid leukemia, the white blood cell cancer that affects blood and bone marrow. A week ago, the company dosed the first patient in the NTLA-5001 Phase 1/2a trial in AML after receiving standard first-line therapy. The trial will enroll 54 patients. Read Next: Intellia ShaNTLA-5001, a novel T cell receptor (TCR)-T cell therapy, is currently being evaluated in a Phase 1/2a study in adults with persistent or recurrent acute myeloid leukemiaCAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug desiIntellia stock has plunged since the trademark office decided not to grant patents the company had relied on in developing treatments for diseases like sickle cell and cancer.;90.91000366210938;;82.29000091552734;;84.6500015258789;;43.31999969482422;;57.040000915527344;;62.43000030517578;The two key moments we are going to review for CRISPR Therapeutics AG (NASDAQ:CRSP) are their latest annual report and the ruling of the U.S. Patent and Trademark Office. At the end of the day, the technology has a lot of value creation potential, but investors should know the downsides just as well.They’re a dime a dozen. They’re risk assets of all shapes and sizes rocketing higher out of a bearish debris field on Wall Street in Wednesday’s session. Even those dreaded, down-and-out Cathie Wood stocks. But could there be more to it? In Cathie Wood stocks, that is. With knowledge that one day doesn’t necessarily make a trend, let’s look at three of Cathie’s Ark ETF stocks that have been left to their own devices on the monthly price charts and now readying for purchase, no matter tomorrow’sIntellia stock has plunged since the trademark office decided not to grant patents the company had relied on in developing treatments for diseases like sickle cell and cancer.;35.5;;35.47999954223633;;21.329999923706055;;8.569999694824219;;65.72000122070312;;31.170000076293945;;67.5199966430664;;35.869998931884766;;99.98999786376953;;22.43000030517578;;15.930000305175781;While Abcam plc ( LON:ABC ) shareholders are probably generally happy, the stock hasn't had particularly good run...;8.279999732971191;;10.9399995803833;;33.16999816894531;;68.56999969482422;;56.72999954223633;;8.380000114440918;;49.36000061035156;CANTON, Mass., March 10, 2022--The Business Intelligence Group today announced that it has awarded Abveris, a division of Twist Bioscience, a Best Places to Work 2022. The organization sought to identify companies that are actively working to improve their own performance through efforts to challenge employees in environments that make work fun and engaging.;24.559999465942383;;24.8799991607666;
2022-03-11;228.85000610351562;Amgen (NASDAQ:AMGN) will virtually present at the 32nd Annual Oppenheimer Healthcare Conference at 11:20 a.m. ET on Wednesday, March 16, 2022. Rob Lenz, M.D., Ph.D., senior vice president of Global Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.;58.0;Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.;642.5800170898438;Futures jumped early Friday as Putin cited positive shifts in Russia-Ukraine talks. The market rally showed resilience Thursday.Regeneron Pharmaceuticals rejoins the IBD 50 hot stocks to watch as it builds a new base and could break out.Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.;135.63999938964844;Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.Yale's Dr. Howard Forman says the U.S. has an important window to address the current pandemic — and those in the future — as COVID-19 cases decline around the world.;303.8699951171875;Announcement of Periodic Review: Moody's announces completion of a periodic review for a group of North America Medical Products and Device issuersGlobal Credit Research - 10 Mar 2022New York, March 10, 2022 -- Moody's Investors Service (Moody's) has completed a periodic review of the ratings -and other ratings that are associated with the same analytical units for the rated entity(entities) listed below.The review was conducted through a portfolio review discussion held on 3 March 2022 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.  A possible outcome from periodic reviews is a referral of a rating to a rating committee.This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.Announcement of Periodic Review: Moody's announces completion of a periodic review for a group of North America Medical Products and Device issuersGlobal Credit Research - 10 Mar 2022New York, March 10, 2022 -- Moody's Investors Service (Moody's) has completed a periodic review of the ratings -and other ratings that are associated with the same analytical units for the rated entity(entities) listed below.The review was conducted through a portfolio review discussion held on 3 March 2022 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.  A possible outcome from periodic reviews is a referral of a rating to a rating committee.This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.;236.47999572753906;ARK Invest exchange-traded funds launched by Cathie Wood, CEO and chief investment officer of ARK Investment Management, made the headlines in 2020 due to their stellar performance that year. These funds typically focus on disruptive technologies or themes that are likely to become part of high-growth stories over the next decade. And as a part of the success of these funds, so-called “Cathie Wood stocks” came to fruition. However, ARK Invest ETFs were hit hard in the past year. Investor rotatioIn this article, we present the list of the 10 biotech stocks hedge funds are talking about. You can skip our comprehensive analysis of the biotech industry, and go directly to 5 Biotech Stocks Hedge Funds Are Talking About. A broader exodus of investors from growth stocks, rising inflation and an expected hike in interest […]Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.;197.6699981689453;In the latest trading session, Biogen Inc. (BIIB) closed at $198.64, marking a -1.79% move from the previous day.In this article, we present the list of the 10 biotech stocks hedge funds are talking about. You can skip our comprehensive analysis of the biotech industry, and go directly to 5 Biotech Stocks Hedge Funds Are Talking About. A broader exodus of investors from growth stocks, rising inflation and an expected hike in interest […]Since the beginning of February, Sandrock has joined the boards of directors of four biotech startups, most recently Boston-based central nervous system company Atalanta Therapeutics.Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.;161.52999877929688;"CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland, March 11, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has granted conditional approval to BeiGene’s anti-PD-1 antibody, tislelizumab, for the treatment of adult patients with advancedThe SEC named Chinese companies that could face delisting under the Holding Foreign Companies Accountable Act.Regulators started a two-year clock Thursday to force China-based companies to comply with U.S. trading rules — leading three biotech stocks to crumble.";137.97000122070312;;154.9600067138672;;400.8399963378906;;3.049999952316284;;75.9800033569336;;61.66999816894531;;73.94000244140625;Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;62.75;;72.98999786376953;Novavax (NASDAQ: NVAX) is waiting for the U.S. to authorize its coronavirus vaccine.  Exelixis' (NASDAQ: EXEL) cabozantinib franchise could make it a superstar in tomorrow's world of oncology treatment.Yale's Dr. Howard Forman says the U.S. has an important window to address the current pandemic — and those in the future — as COVID-19 cases decline around the world.President Joe Biden's COVID-19 program faced some uncertainty Thursday, after U.S. lawmakers passed a massive new bill that would fund the federal government for the remainder of the fiscal year, as well as further aid Ukraine, but a last-minute snag resulted in COVID-19 money being dropped.;61.290000915527344;;89.29000091552734;;77.8499984741211;;80.77999877929688;;41.779998779296875;;57.099998474121094;;61.41999816894531;In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $62.43, marking a +0.02% move from the previous day.;29.780000686645508;The SEC named Chinese companies that could face delisting under the Holding Foreign Companies Accountable Act.By Gina LeeRegulators started a two-year clock Thursday to force China-based companies to comply with U.S. trading rules — leading three biotech stocks to crumble.;33.54999923706055;;20.989999771118164;Novavax (NASDAQ: NVAX) is waiting for the U.S. to authorize its coronavirus vaccine.  Exelixis' (NASDAQ: EXEL) cabozantinib franchise could make it a superstar in tomorrow's world of oncology treatment.;8.579999923706055;PALO ALTO, Calif., March 11, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it will host an investor call on March 14, 2022, at 8:00 AM ET to discuss data from its Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i). The results will be featured at the Muscular Dystrophy Association (MDA) 2022 Annual Meeti;60.90999984741211;;30.389999389648438;Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.;65.41000366210938;;34.720001220703125;;99.98999786376953;;21.84000015258789;"According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) monoclonal antibody with COVID-19 infection. Data shows that the mutations have been associated with a reduction by a factor of 100 to 297 in neutralization by sotrovimab. ""These data show the persistence of viable SARS-CoV-2 in patients after sotrovimab infusions and the rapid development of spike g";15.640000343322754;;7.980000019073486;;9.899999618530273;;32.189998626708984;;68.20999908447266;;58.63999938964844;;7.75;;43.790000915527344;;23.18000030517578;SAN DIEGO, March 10, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 1st Annual Needham Virtual Neuroscience Forum on Wednesday, March 16, 2022 at 3:20 p.m. Eastern Time.Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.;24.3799991607666;
2022-03-14;229.2100067138672;;58.150001525878906;;656.4099731445312;Russia's Ukraine invasion, a looming Fed rate hike and the return of Covid are big headwinds as the major indexes near their Feb. 24 lows.;151.9199981689453;Yahoo Finance's Anjalee Khemlani discusses the current outbreak of COVID-19 in China and what it means for the country's zero-COVID policy.;306.1099853515625;Investors are optimistic about Illumina's (ILMN) better-than-expected results and strategic collaborations.Illumina, Inc. (NASDAQ: ILMN) announced today that Carissa Rollins will join the company as Chief Information Officer on March 14, 2022. Rollins brings over 30 years of business technology transformation and digital and consumerization strategy experience. Rollins will report to Chief Executive Officer, Francis deSouza.;241.67999267578125;AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.The Dow Jones Industrial Average rallied Monday, as Russia-Ukraine talks continue. The 10-year Treasury yield surged, while oil prices tumbled.;193.77000427246094;"Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and NURTURE studies. The first patient treated in the ASCEND study is evaluating the higher dose nusinersen in children, teens, and adults previously treated with Roche Holdings AG's (OTC: RHHBY) Evrysdi (risdiplam). ASCEND aims to enroll approximately 135 children. Biogen will also present baseline characteristics from the RESPFirst patient treated in the ASCEND study evaluating the potential benefit of investigational higher dose nusinersen in children, teens and adults previously treated with Evrysdi® (risdiplam)Baseline characteristics indicate all nine infants and toddlers enrolled in RESPOND had suboptimal clinical status in ≥2 areas after receiving Zolgensma® (onasemnogene abeparvovec); there were no new safety findings with subsequent SPINRAZA® (nusinersen) treatmentNew NURTURE results continue to show the pote";146.72999572753906;Yahoo Finance's Jared Blikre breaks down how Chinese stocks are trading.By Dhirendra Tripathi;136.86000061035156;;151.8000030517578;;392.2099914550781;;2.8299999237060547;"Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the entry into a definitive agreement to acquire FGen AG (""FGen""), a Swiss company specializing in strain development and optimization. FGen has developed an ultra-high-throughput (uHT) screening platform built on nanoliter reactor technology. Ginkgo believes that FGen's technology will significantly enhance Ginkgo's cell screening capabilities and enable Ginkgo to explore wider expanses of genetic";76.01000213623047;;55.70000076293945;;72.19000244140625;WILMINGTON, Del., March 14, 2022--Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for Vitiligo;58.709999084472656;;71.93000030517578;Yahoo Finance's Anjalee Khemlani discusses the current outbreak of COVID-19 in China and what it means for the country's zero-COVID policy.Demand for the COVID-19 vaccine produced by U.S. biotech firm Novavax has been underwhelming in the European Union's main countries in the early rollout, so far undermining hopes that it could convince vaccine sceptics to get a shot.  The Novavax vaccine, the latest to receive the EU regulators' approval under the trade name of Nuvaxovid, was expected to persuade some sceptics because it is based on a more conventional technology than the other four vaccines authorised so far in the EU.Demand for the COVID-19 vaccine produced by U.S. biotech firm Novavax has been underwhelming in the European Union's main countries in the early rollout, so far undermining hopes that it could convince vaccine sceptics to get a shot.  The Novavax vaccine, the latest to receive the EU regulators' approval under the trade name of Nuvaxovid, was expected to persuade some sceptics because it is based on a more conventional technology than the other four vaccines authorised so far in the EU.  In Germany, the EU's most populous country and home to more than 10 million unvaccinated people, only about 36,000 Novavax doses were administered in the first two weeks since the start of the rollout on Feb. 24, according to data from the Robert Koch Institute.;58.79999923706055;;90.0;;74.54000091552734;;75.81999969482422;;39.619998931884766;;55.91999816894531;;58.060001373291016;;27.770000457763672;By Dhirendra Tripathi;29.670000076293945;;20.59000015258789;;8.25;BridgeBio Pharma Inc (NASDAQ: BBIO) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), a group of conditions that cause weakness and wasting of the muscles in the arms and legs. The Company plans to engage with regulatory health bodies in 2022 to discuss potential paths to approval and intends to initiate a Phase 3 trial in 2H of 2022. At the Muscular Dystrophy Association (MDA) 2022, BridgeBio is also presenting Phase 1 trial d- 43% increase in the ratio of glycosylated alpha-dystroglycan (αDG) to total αDG from baseline were measured across all three dosing cohorts, signifying the oral therapy has the potential to address both the root cause of LGMD2i and drive functional improvements for patients- Average of 70% reduction in creatine kinase (CK), a key marker of muscle breakdown, after 90 days of treatment and average 77% reduction after 180 days- Increase in velocity in the 10-meter walk test (10MWT) at day 90 and;53.72999954223633;;29.0;;62.20000076293945;;34.56999969482422;;;;22.09000015258789;;16.170000076293945;"Growing demand for Abcam’s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its final results for the 18-month period ended 31 December 2021 (the ‘period’). The Group’s accounting refe";7.090000152587891;;8.430000305175781;;32.68000030517578;;63.91999816894531;;56.93000030517578;A look at the shareholders of Intra-Cellular Therapies, Inc. ( NASDAQ:ITCI ) can tell us which group is most powerful...;7.460000038146973;;38.58000183105469;;22.270000457763672;;23.56999969482422;
2022-03-15;231.55999755859375;In this article, we discuss 10 ETFs to buy and hold for the next 10 years. If you want to skip our detailed analysis of these exchange traded funds, go directly to 5 ETFs to Buy and Hold for the Next 10 Years. Exchange traded funds are fast becoming a trade instrument of choice for […];58.31999969482422;By Manika Lall;665.9299926757812;;145.0399932861328;On BioNTech's (BNTX) fourth-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.Novavax fans, investors and patients alike, are frustrated by FDA's delays in authorizing COVID-19 vaccine.What happened Shares of several COVID-19 vaccine companies were jumping as of 11:43 a.m. ET on Monday. BioNTech (NASDAQ: BNTX) was the biggest mover, with its shares soaring 14.7%. Dynavax Technologies (NASDAQ: DVAX) was vaulting 5.;312.6099853515625;Partnership will expand use of next-generation sequencing (NGS) to help diagnose patients quickly and more accurately.Illumina Inc (NASDAQ: ILMN) has launched TruSight Oncology (TSO) Comprehensive (EU), a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. With its global launch first taking place in Europe, the in vitro diagnostic (IVD) kit will help inform precision medicine decisions for cancer patients. Illumina's TruSight Oncology Comprehensive test kit scans for 517 cancer-relevant genes across nearly 30 solid tumor types by evaluatGenome sequencing group Illumina on Tuesday launched a cancer test in Europe that checks for a wide range of tumour genes in one tissue sample, potentially helping patients with rare diseases to be matched up with treatment options.  The test, which Illumina says scans for more mutations than any available kits, comes amid drug industry efforts to develop precision oncology drugs for ever smaller patient groups defined by a genetic profile.  Illumina's TruSight Oncology Comprehensive test kit scans for 517 cancer-relevant genes across nearly 30 solid tumour types, it said in a statement.;246.99000549316406;Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.The FDA gives CRL to AstraZeneca's (AZN) sBLA for Fasenra for chronic rhinosinusitis with nasal polyps (CRSwNP) for want of additional clinicalModerna (MRNA) starts dosing in an mRNA-based HIV vaccine study.AstraZeneca's (AZN) stock has risen 26.9% in the past year compared with an increase of 22.3% for the industry.Dow Jones futures rose Tuesday ahead of the Federal Reserve's two-day meeting. Tesla stock rallied after the company raised car prices.China's Covid shutdowns slammed tech stocks and oil prices. The Nasdaq broke below its Feb. 24 lows, but the S&P 500 hasn't yet.Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.Novartis (NVS) reports positive data on SMA treatment from a phase III study. It also acquires Coalesce Product Development Limited to strengthen its respiratory and complex generics business.;197.36000061035156;"Eisai Co Ltd (OTC: ESALY) is giving up its right to share in profits from Aduhelm (aducanumab-avwa), which was developed in partnership with Biogen Inc (NASDAQ: BIIB). Biogen and Eisai have amended their agreement to give Biogen full authority to make regulatory and sales decisions regarding Aduhelm. From 2023, Eisai will receive royalties starting at 2% of Aduhelm's global sales, increasing as sales rise, reaching 8% when Aduhelm's sales exceed $1 billion annually. In December, Biogen reduced tJapan's Eisai Co Ltd will surrender its rights to share profit from Aduhelm, the Alzheimer's treatment drug jointly developed with U.S. partner Biogen Inc, and instead receive sales royalties, the companies said on Monday.  Beginning January next year, Eisai will receive royalties from Aduhelm, which starts at 2% and reaches 8% when annual sales exceed $1 billion, the companies said in a joint statement, adding that Biogen now had ""sole decision making"" and commercialization rights for the drug.  The U.S. Food and Drug Administration (FDA) in June last year approved Aduhelm - the first treatment for Alzheimer's in decades - despite one of its two large-scale clinical trials failing to show a benefit to patients.Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023Lecanemab collaboration to continue unchanged globallyLecanemab supply agreement to extend to 10 years from 5 years for commercial manufacturing by BiogenBoth companies will continue to collaborate together with the goal of bringing more options to patients and maximizing the value of both products CAMBRIDGE, Mass. and TOKYO, March 14, 2022 (GLOBE NEWSWIRE";146.52000427246094;"PETACH TIKVA, Israel & CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland, March 15, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160, SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and Medison Pharma Ltd. a global pharma company focused on providing access to highly innovative therapies to patients in international markets (""Medison""), today announced that the State of I";137.60000610351562;;152.9199981689453;;405.6000061035156;;2.9100000858306885;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in a fireside chat at Jefferies Virtual Synthetic Biology Week, on March 22, 2022, at 10:00 a.m. Eastern Time.;78.2699966430664;;56.20000076293945;;73.30999755859375;Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.;57.560001373291016;Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.;73.80000305175781;Novavax fans, investors and patients alike, are frustrated by FDA's delays in authorizing COVID-19 vaccine.There's a simple reason why: The vaccine hasn't received U.S. Emergency Use Authorization (EUA) yet.  The company launched two websites this month that don't refer at all to the brand name of its COVID-19 vaccine (Nuvaxovid).What happened Shares of several COVID-19 vaccine companies were jumping as of 11:43 a.m. ET on Monday. BioNTech (NASDAQ: BNTX) was the biggest mover, with its shares soaring 14.7%. Dynavax Technologies (NASDAQ: DVAX) was vaulting 5.;58.27000045776367;;91.05999755859375;;76.16999816894531;;77.31999969482422;;40.720001220703125;PASADENA, Calif., March 15, 2022--Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma;58.560001373291016;;60.040000915527344;;29.059999465942383;"SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Josh Smiley as its Chief Operating Officer (COO). Mr. Smiley brings over 26 years of experience working within the biopharmaceutical industry, including experience leading finance, corporate strategy, business development, venture capital and the GlobalIt is now my pleasure to introduce your host, Sarah Higgins, vice president of finance, controller, and principal accounting officer.  Participants on today's call are Evan Loh, chief executive officer; Adam Woodrow, president and chief commercial officer; and Randy Brenner, chief development and regulatory officer.";31.309999465942383;;20.299999237060547;Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus atezolizumab versus sorafenib in untreated hepatocellular carcinoma (HCC). The final analysis showed neither improvement nor detriment in OS for cabozantinib/atezolizumab combo versus sorafenib. Bayer AG's (OTC: BAYRY) sorafenib is marketed as Nexavar and Roche Holdings AG's (OTC: RHHBY) atezolizumab as TeALAMEDA, Calif., March 14, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial, which evaluated cabozantinib (CABOMETYX®) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC). The final analysis showed neither improvement nor detriment in OS for cabozantinib in combination with atezolizumab versus sora;8.510000228881836;;55.2400016784668;;29.610000610351562;;63.689998626708984;;35.36000061035156;;;;22.989999771118164;;16.530000686645508;;7.28000020980835;;9.15999984741211;;32.70000076293945;;60.27000045776367;;58.369998931884766;;7.769999980926514;;40.40999984741211;;23.049999237060547;;24.8700008392334;
2022-03-16;231.6699981689453;Pharma stock Amgen (NASDAQ: AMGN) appears to fit these requirements.  Let's dig deeper into four reasons why this stock is one that income investors can buy and hold forever.  Amgen recorded $6.85 billion in revenue in the fourth quarter, which represents a 3.2% growth rate over the year-ago period.Sanofi (SNY) is developing a subcutaneous formulation of its myeloma drug, Sarclisa. A pivotal study is expected to start in the second half of 2022.;57.970001220703125;;677.97998046875;Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced the top ten winners headed by Christine Ye, 17, of Sammamish, Wash., who won the top award in the 2022 Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.Regeneron (REGN) closed the most recent trading day at $665.93, moving +1.45% from the previous trading session.;163.9199981689453;MAINZ, GERMANY, March 16, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2021 on Wednesday, March 30th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the fourth quarter and full year 2021. The slide presePfizer (PFE) and BioNTech (BNTX) believe that for individuals to be adequately protected, additional booster doses of COVID vaccines are needed.By Dhirendra TripathiThe vaccine makers asked regultors to authorize another booster shot of their Covid-19 vaccine for adults aged 65 and older who have already gotten one booster dose of an approved vaccine.Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who received an additional booster dose of Pfizer-BioNTech COVID-19 Vaccine compared to individuals who received only an initial booster NEW YORK and MAINZ, GERMANY, March 15, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have submitted an application to the UPfizer Inc and its German partner BioNTech SE on Tuesday filed an application with U.S. regulators seeking emergency use authorization for a second booster shot of their COVID-19 vaccine for people aged 65 and older.  The submission to the U.S. Food and Drug Administration includes data collected in Israel, where a second booster is authorized for many people over age 18.  An analysis of data from over a million adults 60 years and older showed rates of confirmed infections and severe illness were lower among individuals who received an additional booster dose of the vaccine administered at least four months after an initial booster (third) dose compared to those who received only one booster dose, the companies said.;326.6000061035156;;248.52000427246094;"AbbVie (ABBV) joins Scripps Research in the latter's SARS-CoV-2 research program to accelerate the development of new antiviral therapies for COVID-19.Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.At first glance, stocks like CRISPR Therapeutics (NASDAQ: CRSP) would seem like the kind to avoid right now given the current uncertain state of equity markets.  After all, the biotech company currently has no products on the market and remains deeply unprofitable.  With investors shifting away from speculative stocks recently, CRISPR could still see dark days ahead, even after dropping by more than 50% in the past year.The Dow Jones Industrial Average jumped Wednesday, as Ukrainian President Zelenskyy said peace talks were becoming ""more realistic.""Dow Jones futures were higher after Tuesday's stock market surge. The Federal Reserve's interest-rate decision is due out Wednesday.Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.";203.8000030517578;"CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer’s disease. The publication includes results from the primary, secondary and tertiary endpoints in the trials, as well as safety data and biomarker sub-Biogen Inc said on Wednesday patients in a long-term trial of its Alzheimer's drug Aduhelm experienced reductions in two key disease indicators after nearly two and a half years of treatment.  Biogen said that Aduhelm ""significantly reduced"" amyloid beta plaque levels out to week 132 of treatment and also decreased plasma levels of a protein called p-tau181 at week 128, Biogen said.  Biogen did not provide the details of its findings.Shares of Biogen Inc. gained 4.3% in premarket trading on Wednesday after the company announced new data for its Alzheimer's disease drug demonstrating reductions in amyloid beta plaques for 132 weeks and plasma p-tau181 for 128 weeks. The company also said in a news release that the clinical-trial data show that patients with lower plasma p-tau181 levels had less clinical decline. Adoption of Aduhelm has been low since it was approved in June. The drug generated $3 million in the six months ofADUHELM continued to reduce two key Alzheimer’s disease pathologies, amyloid beta plaques and p-tau181, in patients treated for up to two and a half yearsData from both Phase 3 studies also show that clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeksThese data further inform the scientific evidence for amyloid as a surrogate biomarker and the importance of continuation of treatment CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: B";183.3300018310547;;141.74000549316406;BOTHELL, Wash. & PARIS, March 16, 2022--Seagen Inc. (Nasdaq:SGEN) and Sanofi today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and Sanofi currently has o;158.97000122070312;CAMBRIDGE, Mass., March 16, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2021 Corporate Responsibility Report. This year’s edition, which is the company’s first full report, presents findings from its inaugural materiality assessment, enhances transparency with environmental disclosures aligned to GRI and SASB frameworks, highlights how the structure of corporate responsibility has strengthened across the company, and details prog;423.4200134277344;;2.990000009536743;;80.72000122070312;;63.380001068115234;;74.5999984741211;;61.43000030517578;In the latest trading session, Exact Sciences (EXAS) closed at $57.56, marking a -1.96% move from the previous day.;77.48999786376953;Novavax’s (NASDAQ:NVAX) Covid-19 shot is reportedly progressing towards an emergency use approval (EUA). The company is also making significant progress on other fronts, so I remain very bullish on NVAX stock. Source: Vladimka production / Shutterstock.com Also importantly, the valuation of NVAX stock is still very attractive. Finally, although fears of the coronavirus have dropped sharply, I still expect meaningful demand for Novavax’s shot from governments and consumers going forward. On March;65.91999816894531;;92.16000366210938;;76.5;;81.1500015258789;;43.720001220703125;;60.400001525878906;;65.54000091552734;At first glance, stocks like CRISPR Therapeutics (NASDAQ: CRSP) would seem like the kind to avoid right now given the current uncertain state of equity markets.  After all, the biotech company currently has no products on the market and remains deeply unprofitable.  With investors shifting away from speculative stocks recently, CRISPR could still see dark days ahead, even after dropping by more than 50% in the past year.;35.810001373291016;;34.04999923706055;;20.649999618530273;Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.;9.34000015258789;;59.84000015258789;;30.950000762939453;SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that Steve Krognes will transition from his role as Chief Financial Officer (CFO) and join the company’s Board of Directors on May 1, 2022. Denali’s Chief Operating Officer Alexander Schuth, M.D., will add the Chief Fi;67.76000213623047;;36.06999969482422;Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Moni Miyashita to its board of directors. Ms. Miyashita is an accomplished executive with over 25 years of global strategic, mergers & acquisitions and business transformation expertise.;;;24.84000015258789;;17.170000076293945;;8.010000228881836;;10.260000228881836;;33.97999954223633;;61.90999984741211;;59.72999954223633;;8.5;;45.83000183105469;;23.600000381469727;;25.389999389648438;
2022-03-17;235.86000061035156;;59.20000076293945;Gilead Sciences (GILD) closed the most recent trading day at $57.97, moving -0.6% from the previous trading session.;685.22998046875;The Dow Jones Industrial Average dropped Thursday following Wednesday's stock market surge. U.S. oil prices jumped back above $100 a barrel.;165.0;Yahoo Finance's Anjalee Khemlani discusses the spread of the BA.2 coronavirus subvariant and President Biden appointing a new COVID czar.Moderna's (MRNA) shares are rising presumably in anticipation of rising demand for its COVID-19 vaccine amid authorization for younger population and the fear of another global infection wave.;338.260009765625;The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey;250.0;Catalyst's (CPRX) fourth-quarter 2021 earnings miss estimates while revenues slightly beat the mark.The Dow Jones Industrial Average dropped Thursday following Wednesday's stock market surge. U.S. oil prices jumped back above $100 a barrel.;205.32000732421875;Scientists are criticizing the publication of results from late-stage trials of Aduhelm in a small and relatively unknown journal.Biogen Inc on Wednesday published long-awaited results of studies supporting approval of its Alzheimer's drug in a lesser-known medical journal whose editor was a leader on the research, adding controversy to the already troubled treatment.  The data on the drug Aduhelm - the first treatment for the mind-wasting disease to win U.S. approval in 20 years - was published in the Journal of Prevention of Alzheimer's Disease, for which Dr. Paul Aisen, who is also a second author on the studies, serves at editor-in-chief.  The company has been under pressure to publish its results to allow the wider scientific community to view the data.Patients who received Biogen's Alzheimer's drug for over two years showed slower cognitive decline — leading Biogen stock to tick higher.Biogen Inc (NASDAQ: BIIB) has announced new data from the long-term extension phase of the Phase 3 trials of Aduhelm (aducanumab-avwa) in Alzheimer's disease. The data exhibited that after nearly two and a half years of treatment (128 weeks) with Aduhelm, patients continued to experience significant reductions in two key Alzheimer's disease pathologies, amyloid-beta plaques, and plasma p-tau181. The data also show that in both Phase 3 trials, at 78 weeks, patients with reduced levels of plasma p;189.0399932861328;BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.BeiGene (NASDAQ: BGNE), a Chinese biopharmaceutical company, saw its shares rise 33.7% on Wednesday.  There were three reasons for the bounce, one related to the overall market and the other two associated directly with BeiGene.  Last week, the Securities and Exchange Commission named BeiGene as one of five Chinese stocks that faced being delisted because the company was not complying with the Holding Foreign Companies Accountable Act by refusing to make its financials available for U.S. regulators.;142.92999267578125;;163.0800018310547;"Alnylam Pharmaceuticals Inc on Thursday filed lawsuits  in Delaware federal court against Pfizer Inc and Moderna Inc, claiming their multibillion-dollar mRNA COVID-19 vaccines infringe one its patents.  Alnylam said it was seeking damages over the use of lipid nanoparticle (LNP) technology used in the Pfizer/BioNTech and Moderna vaccines to carry and deliver genetic material into the body.  Representatives for Pfizer and Moderna did not immediately respond to requests for comment on the lawsuits.Alnylam said it was seeking damages over the use of lipid nanoparticle (LNP) technology used in the Pfizer/BioNTech and Moderna vaccines to carry and deliver genetic material into the body.  Representatives for Pfizer and Moderna did not immediately respond to requests for comment on the lawsuits.  Shares of Moderna, whose lone commercial product is its COVID vaccine, were off about 4%.CAMBRIDGE, Mass., March 17, 2022--Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) the leading RNAi therapeutics company, announced today that it has separately filed suit in United States District Court for the District of Delaware against Pfizer, Inc. and Moderna, Inc., seeking damages for infringement of U.S. Patent No. 11,246,933 (the ""’933 Patent"") in the parties’ manufacture and sale of their messenger RNA (mRNA) COVID-19 vaccines. The patent relates to Alnylam’s biodegradable cationic lipidsWhen most companies spotlight record revenue growth, that means they’ve sold more product than ever before. But for pharmaceutical companies, that isn’t necessarily the case.";431.7300109863281;Stop fearing what rising interest rates might mean for your S&P 500 stocks. In fact, many thrive when rates move higher.Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022, at 11:15 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;2.9700000286102295;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2021, on Monday, March 28, 2022, beginning at 4:30 p.m. ET.;80.27999877929688;"BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced publication of results from the Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in the New England Journal of Medicine (NEJM). The article titled, ""Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A,"" reports one year or more of follow-up data from the study and is referenced in an editorial published in the same issue of the Journal acknow";67.05000305175781;;74.3499984741211;Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.;64.16999816894531;;79.2300033569336;Novavax (NASDAQ: NVAX) started the year with plenty of good news. So far, more than 35 countries have authorized the biotech company's very first product -- its coronavirus vaccine. Novavax has shipped its product to various areas, such as the European Union.Biotech Novavax (NASDAQ: NVAX) was one of the better-performing stocks in its sector on Wednesday.  China-based CFRA chopped its price target by over 20%, reducing it to $83 per share from the preceding $107.  In the past, like other notable biotechs, Novavax has been rather susceptible to analyst adjustments such as this one.Rising Covid-19 cases in China have sent Shenzhen and other cities back into lockdown and there have also been newly confirmed cases in other countries/regions such as the UK, Australia and the EU. This is bad news for everyone, except of course for the makers of Covid-19 vaccines. The UK, Australia and the EU also happen to be places where Novavax (NVAX) has already signed APAs (advanced purchase agreements). Jefferies analyst Roger Song thinks this could naturally work to the vaccine maker’s a;69.05000305175781;Certara, Inc. (CERT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.;93.68000030517578;;79.12999725341797;When most companies spotlight record revenue growth, that means they’ve sold more product than ever before. But for pharmaceutical companies, that isn’t necessarily the case.;84.91000366210938;;46.689998626708984;;62.81999969482422;;67.45999908447266;CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.;35.349998474121094;;36.06999969482422;;20.75;Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.;10.760000228881836;BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) shareholders will have a reason to smile today, with the analysts making...;62.290000915527344;;32.68000030517578;;68.86000061035156;;36.779998779296875;;;;25.1200008392334;;17.6299991607666;;8.3100004196167;;10.930000305175781;Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;34.7599983215332;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapies, today announced the publication of positive Phase 2 data for donidalorsen (formerly IONIS-PKK-LRx) in the New England Journal of Medicine (NEJM) available at NEJM.org. Donidalorsen is an investigational antisense medicine Ionis is evaluating for treating patients with hereditary angioedema (HAE). In the Phase 2 study, donidalorsen demonstrated a 90% reduction in angioedema attacks compared with placebo at the 80 mg;65.6500015258789;;60.380001068115234;These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q2 2022.;8.819999694824219;;49.58000183105469;;23.860000610351562;;25.889999389648438;
2022-03-18;236.25;;59.41999816894531;By Daniel O’Day;685.9400024414062;The Dow Jones Industrial Average dropped Friday ahead of a call between President Biden and Chinese leader Xi Jinping.Yahoo Finance reporter Anjalee Khemlani details the latest news on COVID-19 and how cases are expected to rise due to the emergence of a new variant in Europe.;174.4600067138672;What happened Shares of BioNTech (NASDAQ: BNTX) were jumping 6% as of 11:22 a.m. ET on Friday. The gain continued momentum from earlier this week with COVID-19 cases soaring in China and Europe. And on Tuesday, BioNTech and its big partner, Pfizer (NYSE: PFE), applied for Food and Drug Administration authorization of an additional booster dose of their COVID  vaccine for adults 65 or older.J&J's (JNJ) Pharma unit is performing above market levels. The Consumer unit is improving. The Medical Devices unit is being hurt by soft recovery trends in medical procedures.BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $165, moving +0.66% from the previous trading session.Yahoo Finance reporter Anjalee Khemlani details the latest news on COVID-19 and how cases are expected to rise due to the emergence of a new variant in Europe.;346.1099853515625;Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.;249.0800018310547;Here is how BioDelivery Sciences International (BDSI) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.The Dow Jones Industrial Average dropped Friday ahead of a call between President Biden and Chinese leader Xi Jinping.;208.57000732421875;Canonsburg-based pharmaceutical company Viatris Inc. said it prevailed in federal court against Biogen over a patent for a drug that had been launched as a generic in August 2020.;192.97000122070312;;142.80999755859375;;165.25;A new set of patent lawsuits over the technology behind the messenger RNA-based Covid-19 vaccines increases risks for Moderna stock, but could take years to play out.;445.6000061035156;;3.049999952316284;;81.66999816894531;;69.83000183105469;Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.;75.19999694824219;WILMINGTON, Del., March 18, 2022--Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming American Academy of Dermatology (AAD) Annual Meeting, held March 25-29, 2022, in Boston.FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate-to-severe ulcerative colitis in adults. This is the fourth indication for Rinvoq in the United States.The recent pipeline setbacks will weigh on Incyte's (INCY) growth trajectory and jeopardize its plans to diversify its revenue base.;66.9800033569336;;82.30000305175781;Yahoo Finance reporter Anjalee Khemlani details the latest news on COVID-19 and how cases are expected to rise due to the emergence of a new variant in Europe.;72.33000183105469;;93.12999725341797;;81.04000091552734;;87.66999816894531;;47.380001068115234;;65.05999755859375;Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;67.88999938964844;Cathie Wood's ARK family of ETFs might induce a shudder from investors who have seen big losses from those holdings.  UiPath (NYSE: PATH) is a tech stock that's helping to launch the artificial intelligence revolution.  The company's software platform enables enterprises to automate numerous functions.;38.72999954223633;;37.75;;21.389999389648438;;11.140000343322754;;63.11000061035156;;35.130001068115234;;69.77999877929688;;37.310001373291016;;;;26.1200008392334;;18.0;The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Abcam PLC Sponsored ADR (ABCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.;8.40999984741211;;10.720000267028809;LHC Group's (LHCG) latest joint venture with Archbold Medical Center to enhance home health services in Thomasville and across South Georgia.Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.;35.25;;68.75;;61.04999923706055;;8.829999923706055;;50.56999969482422;;25.3799991607666;;26.1200008392334;
2022-03-21;236.32000732421875;Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.;59.65999984741211;Atea Pharmaceuticals, Inc. (AVIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.;693.2000122070312;The Dow Jones Industrial Average fell Monday, as oil prices jumped above $108 a barrel. Boeing slumped after a Boeing 737 crashed in China.;170.1199951171875;J&J, Pfizer, BioNTech, and Moderna have been highlighted in this Analyst Blog.;347.0;;250.25999450683594;Bristol Myers (BMY) gets FDA approval for a fixed-dose combination of Opdivo (nivolumab) and relatlimab to treat patients 12 years of age or older with unresectable or metastatic melanoma.The Dow Jones Industrial Average fell Monday, as oil prices jumped above $108 a barrel. Boeing slumped after a Boeing 737 crashed in China.Tweedy, Browne Company LLC, an investment management firm, published its “International Value Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. A portfolio quarterly return of 5.14% was recorded by the fund for the fourth quarter of 2021, while its benchmark, the MSCI EAFE Index, by comparison, returned 4.21% […];206.80999755859375;;179.6199951171875;;141.5500030517578;;162.42999267578125;Healthcare stocks have had a weird run over the last couple of years.  Seasoned healthcare investors know that their favorite businesses continue growing steadily even when their stock prices take a turn for the worse.  Here are three healthcare stocks that Wall Street analysts expect to put up gains of 28% or better in the near term.;438.239990234375;;2.9700000286102295;;81.16000366210938;;66.56999969482422;TORONTO, March 21, 2022 (GLOBE NEWSWIRE) -- Torex Gold Resources Inc. (the “Company” or “Torex”) (TSX: TXG) announces that it plans to release the results of an updated technical report (the “Technical Report”) for the Morelos Complex after market close on Thursday, March 31, 2022. A technical session (the “Technical Session”) to discuss the results of the Technical Report will be held on Friday, April 1, 2022. The live webcast is scheduled to start at 8:30 AM ET and will last approximately 3 hoHere are three stocks down 50% or more that Wall Street thinks could double within the next 12 months.  Sea Limited (NYSE: SE) has lost roughly two-thirds of its market cap since October 2021.  Wall Street expects a big comeback for the stock, though, with a 12-month price target reflecting an upside potential of around 95%.;76.58000183105469;;63.900001525878906;;78.55999755859375;The past couple of months have been a reminder to new and tenured investors that stock market corrections are a normal part of the investing cycle and the price of admission to one of the world's greatest wealth creators.  While big moves lower in the stock market can be scary -- especially when they occur in such a short time frame -- they're the ideal time to put your money to work.  After all, every notable stock market decline throughout history has eventually been put into the rearview mirror by a bull market rally.;69.95999908447266;;94.16000366210938;;80.97000122070312;;83.08000183105469;Baron Funds, an asset management firm, published its “Baron Opportunity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. An increase of 3.16% was delivered by the fund’s institutional shares for the fourth quarter of 2021 but trailed the Russell 3000 Growth Index, which increased 10.89%, and the S&P […];45.400001525878906;;63.56999969482422;;65.66000366210938;;38.43000030517578;PRIME study demonstrates that niraparib treatment had a statistically significant and clinically meaningful improvement in progression-free survival in the overall study population regardless of biomarker status when compared to placeboThe primary endpoint of the trial was met, with median progression-free survival of 24.8 months for niraparib patients versus 8.3 months for patients taking placeboTreatment was tolerable in the population studied and showed a safety profile consistent with previo;37.709999084472656;;21.25;;10.4399995803833;;59.130001068115234;;33.34000015258789;;68.77999877929688;;37.20000076293945;;;;25.329999923706055;;17.899999618530273;;8.260000228881836;;9.9399995803833;;34.91999816894531;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the following investor conferences:;66.58999633789062;;58.619998931884766;Have the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for oil, and disruptions in the global commodity markets, Wall Street just finished its best week since November of 2020. Between March 14 and March 18, the S&P 500 rose ~6%, while the NASDAQ was up ~9%. Investors were clearly in a buying mood, and the indexes reflected it. However, some Wall Street pros are un;8.819999694824219;;47.119998931884766;Twist Bioscience Corporation (NASDAQ: TWST) has launched specific synthetic RNA positive controls for SARS-CoV-2 encapsulated in stainless steel mini capsules that Imagene SA provided. The airtight mini capsules provide a stable environment for the RNA controls, allowing cost-effective shipping and storage at room temperature of fragile RNA for an extended period. In particular, the product enhancement will enable Twist to serve customers in regions that do not have an effective cold chain systeSOUTH SAN FRANCISCO, Calif., March 21, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated in proprietary stainless steel minicapsules provided by Imagene SA. The airtight minicapsules provide a stable environment for the RNA controls, allowing cost-effective shipping and storage at;25.549999237060547;;25.889999389648438;
2022-03-22;236.47000122070312;Amgen (AMGN) closed the most recent trading day at $236.32, moving +0.03% from the previous trading session.;59.97999954223633;By Harald Nusser, head of global patient solutions at Gilead Sciences;692.6400146484375;In the latest trading session, Regeneron (REGN) closed at $693.20, marking a +1.06% move from the previous day.;174.6300048828125;Pfizer (PFE) is recalling six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets.The FDA advisory committee meeting on Apr 6 is likely to give an insight into how the regulatory agency feels about the need for additional boosters of COVID-19 vaccines.Yahoo Finance Live details the spread of a new COVID variant in the U.S., health experts' predictions on the scale of an outbreak, renewed discussions around future booster shots and mask mandates, and Shanghai Disney closing down.The FDA will discuss Covid booster shots from Pfizer and Moderna next month — possibly giving vaccine stocks another chance to shine.Moderna (MRNA) seeks the FDA's authorization for a fourth dose of its COVID vaccine in adults who already got an initial authorized booster dose of the same in the United States.;350.20001220703125;;251.8800048828125;BOSTON, March 22, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has advanced VX-147 into pivotal development for people living with proteinuric kidney disease mediated by two mutations in the APOL1 gene (AMKD), which affects approximately 100,000 people in the U.S. and Europe. VX-147 is the first investigational therapy aimed at treating the underlying cause of AMKD. The pivotal study will open for enrollment later this month.The Nasdaq Composite Index (NASDAQINDEX: ^IXIC) is no longer in a bear market.  The good news is that Nasdaq's correction could nearly be over, too.  While the Nasdaq isn't in a bear market anymore, some individual stocks in the index are.Moderna (MRNA) seeks the FDA's authorization for a fourth dose of its COVID vaccine in adults who already got an initial authorized booster dose of the same in the United States.;210.9199981689453;"Biotech giant Biogen (NASDAQ: BIIB) has generated many headlines in the past couple of years, largely due to its Alzheimer's disease (AD) therapy, Aduhelm, and that drug's controversial path to approval in the U.S. However, this landmark regulatory win hasn't been enough to save Biogen's performance.  Let's look at two red flags that Biogen is currently facing and discuss whether it is worth it to purchase the company's shares right now.  Drugmakers typically benefit from patents that allow them to sell their products on the market without worrying about cheaper generic competition, at least for a set period.Months after exiting the embattled Biogen Inc., Al Sandrock has stepped into the chief executive role at gene therapy firm Voyager Therapeutics Inc.After a two-year, pandemic-induced hiatus, our meal program – Heat-n-Eats – is back in action!Shares of Voyager Therapeutics Inc. gained 2.9% in premarket trading on Tuesday after the gene therapy company said it hired former Biogen Inc. executive Dr. Alfred Sandrock Jr. as its CEO. Sandrock replaces interim CEO Michael Higgins, who will remain board chair. Sandrock is the former chief medical officer at Biogen; he left that company in November. Voyager's stock has soared 208.8% so far this year, while the broader S&P 500 is down 6.4%.Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, ""Biogen"") announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Aβ) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Aβ Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's DiseIn the latest trading session, Biogen Inc. (BIIB) closed at $206.81, marking a -0.84% move from the previous day.";186.3300018310547;Revance Therapeutics, Inc. (RVNC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.;142.92999267578125;;163.8300018310547;CAMBRIDGE, Mass., March 22, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2022 CNS Days, being held virtually, on Monday, March 28, 2022 at 2:00 pm ET;442.1400146484375;;3.190000057220459;;82.1500015258789;;69.55999755859375;;78.05000305175781;;67.83000183105469;;83.80000305175781;Novavax (NVAX) stock has tumbled from its peak price of more than $300. The market doesn’t seem to appreciate the company’s progress in getting its Covid-19 vaccine approved abroad. Investors should stay the course as the conditions are right for Novavax shares to move higher. Novavax (NASDAQ:NVAX) seeks to provide novel products to prevent a broad range of infectious diseases. Yet, as many NVAX stock holders are probably aware, the company is best known in the U.S. for developing Covid-19 vacciShares of Novavax (NASDAQ: NVAX) were slipping 3% as of 11:21 a.m. ET on Monday after falling as much as 6.3% earlier in the day.  The decline appeared to be linked to a disappointing uptake for the company's COVID-19 vaccine in Germany.  European news organization The Local reported Monday morning that Germans who are skeptical about vaccination haven't been won over by Novavax's vaccine, branded as Nuvaxovid.;73.54000091552734;In this article, we discuss Cathie Wood’s 10 stock picks for the next 5 years. If you want to read about some more stocks in Wood’s portfolio, go directly to Cathie Wood’s 5 Stock Picks for the Next 5 Years. Cathie Wood of ARK Investment Management was one of the most successful investors of the […];94.80999755859375;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2022 CNS Days virtual conference at 3:30 p.m. Eastern Time on Monday, March 28, 2022. Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the conference.;82.16000366210938;;85.48999786376953;;47.529998779296875;;66.5;;67.5;In this article, we discuss Cathie Wood’s 10 stock picks for the next 5 years. If you want to read about some more stocks in Wood’s portfolio, go directly to Cathie Wood’s 5 Stock Picks for the Next 5 Years. Cathie Wood of ARK Investment Management was one of the most successful investors of the […];42.650001525878906;;37.90999984741211;;21.6200008392334;;11.039999961853027;;61.68000030517578;;34.040000915527344;Denali Therapeutics Inc. (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.;70.77999877929688;;37.630001068115234;Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that data from argenx's Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod (1000mg efgartigimod-PH20) for the treatment of generalized myasthenia gravis (gMG) achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical non-inferiority to VYVGART® (efgartigimod alfa-fcab) intravenous (IV) formulation in gMG patients. Based on these results, argenx has stated it plans to submit a Bi;;;26.399999618530273;;18.100000381469727;;8.489999771118164;;10.180000305175781;;36.279998779296875;;67.41999816894531;;60.369998931884766;;9.40999984741211;;49.2599983215332;;26.389999389648438;SAN DIEGO, March 22, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced a late-breaking oral presentation on the efficacy and safety data from the Phase 3 Lavender study of trofinetide, an investigational treatment for Rett syndrome (RTT), will be presented at the 2022 American Academy of Neurology Annual Meeting (AAN), held in Seattle, WA, April 2-7, and virtually April 24-26, 2022.;26.100000381469727;
2022-03-23;234.17999267578125;;58.849998474121094;A couple of the more attractive income investments you can buy today are Gilead Sciences (NASDAQ: GILD) and Unilever (NYSE: UL).  Gilead Sciences doesn't have a long track record of paying dividends --  it's only been distributing them since 2015 -- but it still has some qualities that could make it an appealing income investment.In the latest trading session, Gilead Sciences (GILD) closed at $59.98, marking a +0.54% move from the previous day.;669.219970703125;;166.3300018310547;Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day;339.7900085449219;Biobot Analytics is using wastewater data to predict COVID surges and other outbreaksShannon Whitmore is a Real Time Revolutionary who has been driving the field of scientific computing ever since developing a tool for visualizing the secondary structure of rRNA for her master's th...;248.1300048828125;ORIC declines on discontinuation of pipeline candidate ORIC-101 following planned interim analyses of two phase Ib studies.Vertex's (VRTX) pivotal phase III study on VX-147 targeting a broad patient population with proteinuric kidney disease mediated by two mutations in the APOL1 gene (AMKD) is expected to begin later this month.Moderna (NASDAQ: MRNA) has seen its stock price soar nearly 800% over the past two years.  And they can be reached as Vertex wins approvals in more age groups and reimbursements by healthcare systems in additional countries.Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.;209.6199951171875;In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have released more data on lecanemab, another anti-Alzheimer's drug. The lecanemab's Phase 2b study data were presented at the annual AD/PD meeting. The ratio of amyloid-related imaging abnormality (ARIA) in the Core study was 9.9% (16/161) of patients treated with the drug's 10 mg/kg dose biweekly, compared with 0.8% (2/245) of placebo patients. Over 40% of approximately 12 treatment-naïve patien;187.3000030517578;;138.72999572753906;;162.35000610351562;;429.0199890136719;;3.5199999809265137;Concentric by Ginkgo, the public health and biosecurity initiative of Ginkgo Bioworks (NYSE: DNA), today released new findings from its joint SARS-CoV-2 monitoring program with the Centers for Disease Control and Prevention (CDC) and XpresCheck®, a subsidiary of XpresSpa Group, Inc (Nasdaq: XSPA). The findings, published in a preprint yesterday on medRxiv, outline how this voluntary Traveler-Based SARS-CoV-2 Genomic Surveillance program operates as an early warning system and closes a gap in natMassVentures plans to expand its investment reach beyond Boston and Cambridge thanks to new federal funds.;80.86000061035156;;68.33000183105469;;77.0999984741211;The Swiss agency for therapeutic products has granted temporary approval for MorphoSys AG (NASDAQ: MOR) and Incyte Corp's (NASDAQ: INCY) Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval comes for Minjuvi combined with lenalidomide, followed by Minjuvi monotherapy for adult patients, after at least one prior line of systemic therapy, who are not eligible for autologous stem cell transplant (ASCT). The approval is based on the results from the L-;66.0199966430664;;80.18000030517578;Novavax (NASDAQ:NVAX) could have become the biggest stock of the year but just one hold up and it is right where it started. The company started the year with big news and massive potential but it is still awaiting the U.S. Food and Drug Administration approval for its Covid-19 vaccine. This is significantly affecting the stock’s growth prospects. NVAX stock has gone from $270 to $84 today. It is down more than 65% in the past year and has seen a major dip since the beginning of this month. SourThe FDA certainly doesn't seem to be in a hurry to grant Emergency Use Authorization to NVX-CoV2373.It’s the first country to approve Novavax’s COVID vaccine for those ages 12 through 18.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' protein-based COVID-19 vaccine for adolescents aged ≥12 to <18 years in India. The vaccine, also known as NVX-CoV2373, is manufNovavax Inc said on Tuesday its COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years.  The authorization is a global first for the age group for the vaccine, which is manufactured and marketed in India by the Serum Institute of India under the brand name Covovax.  Novavax last month said its vaccine was 80% effective against COVID-19 in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years.Is Novavax stock a buy on expectations for at least $4 billion in sales this year? Is NVAX stock a buy right now?;70.23999786376953;;92.69999694824219;;80.12000274658203;;82.4000015258789;;45.58000183105469;;64.37999725341797;;63.56999969482422;Vertex's (VRTX) pivotal phase III study on VX-147 targeting a broad patient population with proteinuric kidney disease mediated by two mutations in the APOL1 gene (AMKD) is expected to begin later this month.;43.81999969482422;"SHANGHAI and SAN FRANCISCO, and CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and the recent pandemic-related restrictions in Shanghai, the format of the extraordinary general meeting of shareholders (EGM) of Zai Lab Limited has been changed and will be held in a virtual m";36.95000076293945;;21.299999237060547;;10.760000228881836;;56.779998779296875;;33.43000030517578;;68.7699966430664;;37.58000183105469;argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.Argenx SE (NASDAQ: ARGX) ) has announced topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod for generalized myasthenia gravis (gMG). Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles. SC efgartigimod achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical noninferiority to Vyvgart (efgartigimod alfa-fcab) intravenous (IV) formulation. Argenx plans to subm;;;24.760000228881836;;17.899999618530273;;8.109999656677246;;9.880000114440918;PacBio Logo in New London Office PacBio opens new office in London. Company Announces New European Headquarters to Serve Growing Customer Demand in Europe, Middle East and Africa Region Also Announces First Commercial Services Provider in Europe MENLO PARK, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate, sequencing platforms, today announced the company’s expansion to better serve customers in the Europe, Middle East and Afr;35.66999816894531;;65.37999725341797;;59.5;;9.420000076293945;;46.97999954223633;;25.68000030517578;;26.09000015258789;
2022-03-24;236.8699951171875;Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.Comcast, Danaher, Amgen, Boeing and Canadian Pacific Railway have been included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), Danaher Corporation (DHR), and Amgen Inc. (AMGN).;59.13999938964844;;679.760009765625;"Amazon recently announced a stock split, its first since 1999.  The benefit of a stock split is that it can make a high-priced stock feel more accessible, especially to investors who can't or don't want to buy fractional shares.  A stock split also puts a company into the news for positive reasons -- namely that its business is doing well and its share price has risen enough where a split makes sense; you wouldn't expect to see a stock split from a company whose shares are trading at just $100.";170.41000366210938;Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.Moderna CEO Stéphane Bancel joins Yahoo Finance Live to discuss FDA authorization for the company's COVID-19 vaccine for children under 6, the outlook for an Omicron-specific vaccine, and the path forward for company growth after the pandemic.It nearly seems like a distant memory now, but the stocks of COVID-19 vaccine makers were once sizzling hot.  In 2020, shares of Novavax (NASDAQ: NVAX) skyrocketed 2,700%.  Moderna (NASDAQ: MRNA) stock more than quadrupled that year and soared even more at one point in 2021.Dr. Jeremy Faust, Brigham and Women’s Hospital emergency medicine physician and MedPage Today editor-in-chief, joins Yahoo Finance Live to discuss Moderna's vaccine for kids under 6 and the outlook for the COVID-19 BA.2 variant.Moderna stock tumbled Wednesday despite promising test results that could help it beat Pfizer to the finish line with a pediatric Covid shot.Here's why Moderna's stock isn't reacting more favorably to a potential COVID-19 vaccine breakthrough.Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.;343.04998779296875;;251.6999969482422;;213.00999450683594;;202.4199981689453;;141.27000427246094;;163.6999969482422;;435.05999755859375;"Evolve Funds Group Inc. (""Evolve"") is pleased to announce the distribution amounts per unit (the ""Distributions"") for certain funds (the ""Evolve Funds""), for the period ending March 31, 2022, as indicated in the table below.";3.7200000286102295;;80.87999725341797;;68.98999786376953;;78.19000244140625;Second, the need for lifesaving medicines won't have subsided 10 years from today.  Let's consider two excellent candidates: Novo Nordisk (NYSE: NVO) and Incyte (NASDAQ: INCY).  Denmark-based Novo Nordisk delivered a strong performance last year.;67.11000061035156;Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;81.44999694824219;Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.;72.01000213623047;;94.05000305175781;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders program and telemedicine research at the American Academy of Neurology (AAN) Annual Meeting being held in person April 2–7, 2022 in Seattle and virtually April 24–26.;80.44000244140625;;82.18000030517578;;47.11000061035156;PASADENA, Calif., March 24, 2022--Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases;66.08999633789062;;64.4000015258789;;46.90999984741211;;38.689998626708984;;21.530000686645508;;10.75;;58.68000030517578;;34.09000015258789;;69.12000274658203;;38.720001220703125;Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Halozyme Therapeutics Inc (NASDAQ: HALO) has announced a collaboration and license agreement with Chugai Pharmaceutical Co Ltd for exclusive access to Halozyme's ENHANZE drug delivery technology for an undisclosed target. The ENHANZE drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics delivered subcutaneously. Using rHuPH20, some biologics and compounds administeredHalozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that gives exclusive access to Halozyme's ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for an undisclosed target. Chugai intends to explore the potential use of ENHANZE® for a Chugai drug candidate.;;;25.229999542236328;;18.020000457763672;;8.15999984741211;Short-term investors could be interested in these businesses;9.670000076293945;;36.91999816894531;;66.48999786376953;;59.38999938964844;;9.710000038146973;;47.52000045776367;;27.149999618530273;;26.56999969482422;
2022-03-25;238.7899932861328;Amgen (NASDAQ: AMGN) today announced that new Otezla (apremilast) data, along with findings on the unmet need for patients with plaque psoriasis, will be presented at the American Academy of Dermatology (AAD) congress in Boston, Massachusetts, March 25-29, 2022. These data presentations follow the recent U.S. Food and Drug Administration (FDA) expanded Otezla label approval in December 2021.;58.90999984741211;From the age of four, LaToya Bolds-Johnson knew she wanted to be a healer. For more than ten years she’s been fulfilling that mission by working as an ER physician assistant in Maryland. But the sc...;680.030029296875;These companies haven't said they'll split their stocks, but the topic should be on their minds.;161.10000610351562;;341.7200012207031;Which infectious disease kills more people in the world than any other? It mutates, mostly impacts your lungs, very contagious in a close household setting, can be asymptomatic and hard to eradicat...;253.9499969482422;Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.Vertex Pharmaceuticals (Canada) Incorporated (NASDAQ: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of PrKALYDECO® (ivacaftor) in patients from 4 months to 18 years of age and weighing at least 5 kg with the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.Creative Medical Technology (CELZ) reports positive follow-up data from a pilot study evaluating StemSpine, a patented stem cell treatment for chronic lower back pain.Pfizer's (PFE) late-stage candidate etrasimod achieves statistical significance in its primary endpoint of clinical remission in an ulcerative colitis study.The FDA okays Novartis' (NVS) targeted radioligand therapy Pluvicto to treat PSMA-positive metastatic castration-resistant prostate cancer.;210.97000122070312;;192.6199951171875;;138.3300018310547;;163.80999755859375;;435.45001220703125;;3.6600000858306885;;79.0199966430664;BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;67.79000091552734;;78.45999908447266;WILMINGTON, Del., March 25, 2022--Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease;66.66999816894531;;74.12999725341797;"An airport-based COVID-19 surveillance program detected the first known U.S. case of the highly transmissible omicron BA.2 subvariant in December, according to a new study that was funded by the Centers for Disease Control and Prevention.Novavax Inc. said Friday that its experimental COVID-19 booster is being tested in a Phase 1/2 clinical trial sponsored by the National Institutes of Health. This study is evaluating Novavax's protein-based booster candidate in people who have already received the primary series of shots developed by BioNTech SE and Pfizer Inc. , Johnson & Johnson , or Moderna Inc. . (Novavax's COVID-19 vaccine has not been authorized in the U.S.; it is currently being reviewed by the Food and Drug AdministratioNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine, is included in two trials now underway to evaluate its vaccine's safety, immunogenicity, and reactogenicity as a booster amidst the ongoing COVID-19 pandemic. Both studies have initiated participant enrollment and will help to extend knowledge of how a range of vaccines, inIn the latest trading session, Novavax (NVAX) closed at $81.45, marking a +1.58% move from the previous day.";70.6500015258789;;93.72000122070312;;77.2699966430664;;80.1500015258789;;44.11000061035156;;64.44000244140625;Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Commission (EC) has expanded the current indication for AYVAKYT® (avapritinib) to include monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN) or mast cell leukemia (MCL), after at least one systemic therapy.;62.13999938964844;CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $64.40, moving +1.31% from the previous trading session.;42.310001373291016;;38.0;;21.8799991607666;ALAMEDA, Calif., March 25, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during;10.359999656677246;;58.029998779296875;CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, and Giuseppe Ciaramella, Ph.D., president and chief scientific officer, will participate in a fireside chat during the virtual Guggenheim Genomic Medicines and Rare Disease Conference on Friday, April 1, 2022 at 9:00 a.m. ET. A live webcast will be available in the;33.20000076293945;;68.87000274658203;;38.08000183105469;Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.;;;21.809999465942383;;18.040000915527344;"Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance discoveries and deliver faster breakthroughs.";7.699999809265137;;9.239999771118164;;36.66999816894531;;64.61000061035156;;60.779998779296875;;9.539999961853027;;45.40999984741211;;26.889999389648438;;27.43000030517578;
2022-03-28;240.47000122070312;;59.18000030517578;FOSTER CITY, Calif., March 28, 2022--Gilead Sciences, Inc., (Nasdaq: GILD) today announced $24 million in grants to help reduce health disparities, improve access to quality healthcare, advance medical education and support local communities most impacted by the HIV epidemic and COVID-19 pandemic. The Zeroing In: Ending the HIV Epidemic program, will support 116 organizations in 41 countries. The funding recipients will focus on advancing at least one of three focus areas: Comprehensive HIV Inno;693.4000244140625;The market rally has been strong despite surging bond yields, but for now. Tesla popped on plans for a stock split.;166.35000610351562;;347.0799865722656;;255.72000122070312;Bristol Myers (BMY) application seeking label expansion of Reblozy extended by three months by the FDA.;211.67999267578125;"Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx) for C9orf72-associated amyotrophic lateral sclerosis (ALS). In this Phase 1 study, BIIB078 was generally well-tolerated. The adverse events (AEs) were mostly mild to moderate in severity and occurred similarly across BIIB078 and placebo groups. The most common AEs were falls, procedural pain, and headache. BIIB078 did not meet any secondary efficacyBIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinuedBiogen and Ionis remain committed to their decade-long pursuit of advancing ALS research and developing therapies for all forms of this progressive and fatal neurodegenerative disease CAMBRIDGE, Mass. and CARLSBAD, Calif. , March 28, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc.";196.4199981689453;;139.6999969482422;;161.64999389648438;;437.32000732421875;;3.740000009536743;;78.36000061035156;;70.41000366210938;;78.94999694824219;Incyte Corporation (NASDAQ: INCY) announced new 52-week results from its Phase 3 TRuE-V trial of ruxolitinib cream (Opzelura) in nonsegmental vitiligo. The data were presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting. The 52-week results build on the previously announced positive 24-week results and include data from the 24-week double-blind and 28-week treatment extension periods of the Phase 3 TRuE-V1 and TRuE-V2 studies. The Week 52 analysis showed that patients applyi;67.81999969482422;;73.8499984741211;Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have dominated the U.S. market since they became the first to launch their vaccines.  Today, Pfizer has fully vaccinated more than 124 million Americans.  Does this mean these players are a step ahead of Pfizer and Moderna?;73.08000183105469;;93.58999633789062;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment patterns and unmet needs in adult and pediatric patients with classic congenital adrenal hyperplasia (CAH) at the Academy of Managed Care Pharmacy (AMCP) 2022 annual meeting in Chicago on March 29–April 1. The three studies being presented evaluate the treatment patterns, healthcare-related costs, medication preferences, and unmet needs of patients with classic CAH.;76.06999969482422;;79.75;;44.779998779296875;;65.41000366210938;;62.83000183105469;;41.31999969482422;;38.0;;21.75;;10.430000305175781;PALO ALTO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that updated data from its ongoing Phase 2 open-label extension (OLE) study of acoramidis (AG10) in patients with symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) will be featured in an oral presentation at the American College of Cardiology (ACC) Annual Sci;59.060001373291016;;33.0;;67.97000122070312;;39.16999816894531;;;;21.190000534057617;The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK and Vir said they are preparing a data package to support a higher dose for sotrovimab for the BA.2 subvariant. Related: AstraZeneca;18.56999969482422;;7.769999980926514;;9.539999961853027;;35.880001068115234;"BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinuedBiogen and Ionis remain committed to their decade-long pursuit of advancing ALS research and developing therapies for all forms of this progressive and fatal neurodegenerative disease CAMBRIDGE, Mass. and CARLSBAD, Calif. , March 28, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc.";64.30999755859375;;61.47999954223633;;9.489999771118164;;47.04999923706055;;24.649999618530273;;27.479999542236328;
2022-03-29;241.5399932861328;;60.529998779296875;;698.4299926757812;The stock market opened higher Tuesday, with cease-fire talks between Russia and Ukraine underway in Turkey. Treasury yields inched slightly lower, while U.S. oil prices leaned lower following Monday's dive.The European Commission approves AstraZeneca's (AZN) Evusheld for the pre-exposure prophylaxis of COVID-19 infection in a broad patient population.;172.38999938964844;;357.3500061035156;;257.9800109863281;;214.9499969482422;Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.Biogen will stop developing a drug to treat a severe neurodegenerative disease, as it did not show sufficient benefit when tested in trials.;207.5399932861328;;143.1699981689453;;166.74000549316406;;446.0199890136719;;4.590000152587891;"Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, ""Ginkgo""), the leading horizontal platform for cell programming, today announced its results for the fourth quarter and year ended December 31, 2021. The update, including a webcast slide presentation with additional details on the fourth quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.";79.55999755859375;;77.25;;79.70999908447266;;71.87999725341797;;78.83000183105469;;76.2300033569336;;92.86000061035156;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL® capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia from the Japanese Ministry of Health, Labour and Welfare on March 28, 2022.;78.72000122070312;;84.76000213623047;;46.720001220703125;;66.55999755859375;The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.;65.94999694824219;Kala Pharma (KALA) delivered earnings and revenue surprises of -58.14% and 45.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?;45.189998626708984;;41.939998626708984;;21.989999771118164;It's safe to say that the stock market hasn't had the best year so far.  Drugmakers Bristol-Myers Squibb (NYSE: BMY) and Exelixis (NASDAQ: EXEL) are two prime examples.  Are these healthcare companies worth considering as they continue to outperform the market this year?;10.859999656677246;;62.029998779296875;;34.470001220703125;;71.48999786376953;;40.31999969482422;;;;22.579999923706055;;18.729999542236328;;7.980000019073486;;10.319999694824219;;36.47999954223633;;67.58000183105469;;62.09000015258789;;9.779999732971191;;51.09000015258789;;25.31999969482422;;27.989999771118164;While not a mind-blowing move, it is good to see that the Alkermes plc ( NASDAQ:ALKS ) share price has gained 16% in...As we approach the second anniversary of the COVID-19 pandemic, our Head of Human Resources, Steve Schiavo, took time to reflect on the appreciation we have for all our employees – especially those...
2022-03-30;242.57000732421875;(Bloomberg) -- Pharmaceutical giant Amgen Inc. plans to sell more bonds to benefit the environment and society after its debut green-bond got a warm reception from investors.Most Read from BloombergUkraine Update: U.S. Skeptical After Russia Vows Kyiv PullbackUkraine Update: Kyiv Seeks Cease-Fire Deal in Russia TalksWorld’s Longest Passenger Flight Plans to Avoid Russian SkiesAbramovich Suffered Suspected Poisoning During Ukraine TalksThe Fed Has Made a U.S. Recession InevitableThe maker of the;59.65999984741211;Dr. Dwaun Warmack was just miles from the town of Ferguson, Missouri in 2014 when the police shooting death of teenager Mike Brown ignited unrest and sparked national debate about the relationship ...;692.3800048828125;;174.77999877929688;;352.0400085449219;;256.5199890136719;;211.02999877929688;"Biogen Inc. said Wednesday it submitted the study protocol to the Food and Drug Administration for a confirmatory clinical trial for Aduhelm, its Alzheimer's disease drug. The regulator approved Aduhelm a year ago under the condition that a confirmatory trial would be conducted. Biogen said it expects to complete the placebo-controlled Phase 4 study in four years; the study is designed to enroll 1,500 patients. Biogen's stock has declined 10.4% so far this year, while the broader S&P 500 is 2.8%Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening to start in MayMultiple strategies in place to enroll patients that are representative of diverse American population CAMBRIDGE, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has submitted the final study protocol for the confirmatory Phase 4 ENVISION trial to the U.S. Food and Drug Administration (FDA) for review and approval. This is in line with the company’s commBiogen  has filed the final design for the required post-approval study of Aduhelm, its Alzheimer’s disease drug, with the Food and Drug Administration, the company said Wednesday.  The FDA approved Aduhelm last June through the agency’s accelerated approval program, under which drugmakers are required to run an additional study of the drug after it is approved for use.  Immediately after Aduhelm’s approval,  Biogen  CEO made public comments that suggested that the company felt no urgency to move quickly on the confirmatory trial.Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.";206.0;;141.55999755859375;;165.24000549316406;;442.3800048828125;;4.21999979019165;Two years into the pandemic, Ginkgo Bioworks is still relying on Covid-19 testing for most of its revenue — and as its partners scale back testing budgets and operations, it's unclear how steady that stream of income will be.;77.88999938964844;;74.73999786376953;;79.66999816894531;;71.31999969482422;;74.75;;72.18000030517578;;92.44999694824219;;78.58999633789062;;83.20999908447266;Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;45.59000015258789;;65.05999755859375;;64.08000183105469;;45.5099983215332;;39.86000061035156;Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;22.440000534057617;;10.369999885559082;;59.45000076293945;;32.400001525878906;Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;71.36000061035156;;40.220001220703125;"Halozyme Therapeutics  is a biopharmaceutical company ""bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies"".  In this daily Point and Figure chart of HALO, below, we can see a potential upside price target of $56.";;;25.90999984741211;"Shares of Vir Biotechnology Inc. were up 12.8% in premarket trading on Wednesday, the day after it was announced that the stock will join the S&P SmallCap 600 , effective April 4. The company is led by George Scangos, the former CEO of Biogen Inc. ; it has one authorized therapy, the COVID-19 monoclonal antibody, sotrovimab. Vir's stock is down 46.0% so far this year, while the S&P SmallCap 600 has declined 2.9%.S&P MidCap 400 constituent Camden Property Trust (NYSE: CPT) will replace People's United Financial Inc. (NASD: PBCT) in the S&P 500, S&P SmallCap 600 constituent Matador Resources Co. (NYSE: MTDR) will replace Camden Property Trust in the S&P MidCap 400 and Vir Biotechnology, Inc. (NASD: VIR) will replace Matador Resources in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 4. S&P 500 constituent M&T Bank Corp. (NYSE: MTB) is acquiring People's United Financial in";18.440000534057617;;7.730000019073486;;9.649999618530273;;35.689998626708984;Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.;63.86000061035156;;60.31999969482422;;9.75;;50.25;;24.40999984741211;Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;26.56999969482422;
2022-03-31;241.82000732421875;;59.45000076293945;Vir Biotechnology (VIR) shares gain as the company is set to join the S&P SmallCap 600 effective prior to the opening of trading on Monday, Apr 4.;698.4199829101562;The Dow Jones Industrial Average fell Thursday. Oil prices dived on news that the Biden administration is planning to tap U.S. oil reserves.;170.55999755859375;The highly transmissible newer version of the coronavirus can more easily evade the current portfolio of vaccines.Companies In The News Are: FIVE, MSM, BNTX, AER.MAINZ, Germany, March 31, 2022 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a share repurchase program (the “Program”), pursuant to which the Company may purchase American depositary shares (ADSs) in the amount of up to $1.5 billion over the next two years. BioNTech expects to use all or a portion of the ADSs to satisfy upcoming settlement obligations under the Company’s share-based payment arrangements. “We would like our s;349.3999938964844;;260.9700012207031;;210.60000610351562;Phreesia (PHR) delivered earnings and revenue surprises of 14.29% and 3.93%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?Acquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.;188.60000610351562;;144.0500030517578;;163.2899932861328;;433.0400085449219;;4.03000020980835;Shareholders will be ecstatic, with their stake up 44% over the past week following Ginkgo Bioworks Holdings, Inc. 's...;77.0999984741211;;76.06999969482422;;79.41999816894531;;69.91999816894531;Investors are optimistic about Exact Sciences (EXAS) on strong buoyed by Cologuard volume growth.In the latest trading session, Exact Sciences (EXAS) closed at $71.32, marking a -0.78% move from the previous day.;73.6500015258789;;72.66999816894531;;93.75;;78.12000274658203;Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.It hasn't been the best quarter for Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shareholders, since the share price has...;82.22000122070312;;45.9900016784668;;63.880001068115234;;62.77000045776367;;43.97999954223633;;38.77000045776367;;22.670000076293945;;10.149999618530273;;57.29999923706055;;32.16999816894531;;72.62000274658203;;39.880001068115234;;;;25.719999313354492;Vir Biotechnology (VIR) shares gain as the company is set to join the S&P SmallCap 600 effective prior to the opening of trading on Monday, Apr 4.Adagio Therapeutics Inc. (Nasdaq: ADGI) share prices shot up after the startup said its antibody was effective at preventing and treating Covid-19 — reducing symptomatic illness by more than one-third — even in the face of the omicron variant.What happened Shares of Vir Biotechnology (NASDAQ: VIR) were skyrocketing 19.4% higher as of 12:33 p.m. ET on Wednesday. The big jump came after S&P Global announced that Vir will replace Matador Resources on the S&P SmallCap 600 index effective before the market open on April 4.;18.290000915527344;;7.71999979019165;Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;9.100000381469727;;37.040000915527344;;67.30000305175781;;61.189998626708984;;9.75;;49.380001068115234;;24.219999313354492;;26.309999465942383;
2022-04-01;243.1199951171875;Dividend stocks are a great way to grow your money over time.  Which dividend stocks should investors have on their radars right now?  Two Fool.com contributors picked Amgen (NASDAQ: AMGN) and National Research Corporation (NASDAQ: NRC).;59.66999816894531;Ricki Fairley thought her annual checkup would be a breeze. For the mom and marketing professional, the appointment was just one item to cross off on a long to-do list. That visit eight years ago, ...;694.8300170898438;The Dow Jones Industrial Average rallied Friday after the March jobs report miss. The 10-year Treasury yield surged.Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.;178.77999877929688;;363.8999938964844;;266.1499938964844;In a rising interest rate economy, risk-averse investors need to be paying attention to companies with high debt loads.  The good news is that you don't have to sacrifice investing in growth stocks altogether and just load up on ultra-conservative investments to battle interest rate increases.  A couple of fast-growing companies that aren't saddled with much debt are Vertex Pharmaceuticals (NASDAQ: VRTX) and Alphabet (NASDAQ: GOOG).The Dow Jones Industrial Average rallied Friday after the March jobs report miss. The 10-year Treasury yield surged.Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.Vertex Pharmaceuticals has been highlighted in this Investment Ideas article.;210.64999389648438;Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.;197.10000610351562;;148.88999938964844;;169.2899932861328;;433.2699890136719;;4.199999809265137;;79.2699966430664;;81.12000274658203;"Figure 1 Annualized AuEq sold of 374 koz estimated over the life of mine; Annual AuEq sold through 2027 is expected to average 450 koz when the capacity of the processing plant is to be fully utilized Figure 2 ML Project expected to be the sole source of ore post 2027 based on current Mineral Reserves Figure 3 Credible ramp-up period of 3 years assumed for the ML Project Figure 4 Exploration and drilling key to ensuring full capacity utilization in the processing plant post 2027 Figure 5 Debt fi";79.94000244140625;;75.61000061035156;;74.31999969482422;;76.12999725341797;;95.56999969482422;"Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from the Phase 3 KINECT-HD study, which demonstrated once-daily administration of valbenazine was associated with significant improvement in chorea associated with Huntington disease (HD) compared with placebo. These data (abstract #1199) will be shared as an oral presentation Tuesday, April 5th during the Emerging Science Session at the American Academy of Neurology (AAN) 2022 ""Great Neuro Reunion"" annual meeting in Seattle, Wa";82.55999755859375;CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in March 2022. The equity awards were approved in accordance with Nasdaq Listing Rul;85.44000244140625;;49.20000076293945;PASADENA, Calif., April 01, 2022--Arrowhead Pharmaceuticals will present at April 2022 conferences including APASL 2022, AACR 2022, and Oligo22;65.4000015258789;;66.1500015258789;;45.470001220703125;;41.31999969482422;;22.889999389648438;A tumbling market is the perfect opportunity to buy into these highly profitable and attractively priced stocks.;10.850000381469727;;59.95000076293945;The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions.  This means that investors may wait for years before knowing whether a drug under development will pay off.  The industry includes smaller start-up companies with recent traction as well as large, well-established corporations that aim to develop a range of drugs and technologies.;35.0099983215332;;77.37000274658203;;41.61000061035156;"Halo Collective Inc. (""Halo"" or the ""Company"") (NEO: HALO) (OTCQB: HCANF) (Germany: A9KN) today announced its financial and operational results for the fourth quarter (""Q4 2021"") and full year ended December 31, 2021 (""FYE 2021"").";;;25.299999237060547;The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions.  This means that investors may wait for years before knowing whether a drug under development will pay off.  The industry includes smaller start-up companies with recent traction as well as large, well-established corporations that aim to develop a range of drugs and technologies.Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;18.719999313354492;;7.880000114440918;;9.479999542236328;Science magazine publication details how the human genome was finally completed with the help of PacBio long-read technology Where will we go in the future? The complete, telomere-to-telomere assembly of a human genome marks a new era of genomics. MENLO PARK, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, announced today PacBio’s essential contribution to the completion of the first truly complete human;38.900001525878906;;70.0199966430664;;62.68000030517578;;10.130000114440918;;52.90999984741211;;25.559999465942383;;28.059999465942383;
2022-04-04;244.8699951171875;;60.66999816894531;;698.4099731445312;The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.The Dow Jones Industrial Average fell Monday, as Tesla climbed after the company reported record vehicle deliveries.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis (EoE), a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow. The target action date for the FDA deci;186.24000549316406;;365.54998779296875;;268.6400146484375;The Dow Jones Industrial Average fell Monday, as Tesla climbed after the company reported record vehicle deliveries.;211.63999938964844;Generic sales hit MS franchise and Alzheimer's treatment is slow starter: EPS forecasts down 20%;216.0500030517578;In this article, we discuss the 10 best non-tech Chinese stocks to buy now. If you want to read about some more non-tech Chinese stocks, go directly to 5 Best Non-Tech Chinese Stocks to Buy Now. Chinese stocks have been hammered in the past few months due to factors like concerns around delistings in the […];149.91000366210938;;161.77000427246094;CAMBRIDGE, Mass., April 04, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline of the New Drug Application (NDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, to allow for the review of newly added information related to the new secondary packaging and labeling facility. Alnylam rec;432.0400085449219;;4.130000114440918;;80.27999877929688;;82.41000366210938;;80.91000366210938;;76.2300033569336;;75.29000091552734;;76.20999908447266;;97.5;;85.62000274658203;;88.70999908447266;;50.61000061035156;;67.19000244140625;;69.51000213623047;;49.68000030517578;;42.38999938964844;;23.15999984741211;;12.020000457763672;;62.36000061035156;;35.189998626708984;;78.1500015258789;;41.83000183105469;;;;25.329999923706055;;19.15999984741211;;7.900000095367432;;10.430000305175781;The companies will leverage high-throughput whole genome HiFi sequencing for advanced plant biotechnology, breeding and crop protection product developmentMENLO PARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, announced today a new collaboration with global agriculture company, Corteva Agriscience, to develop custom, end-to-end workflows for plant, pest and microbial sequencing. The project focuses o;38.72999954223633;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its partner, AstraZeneca, today announced positive data from the ETESIAN Phase 2b study of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with hypercholesterolemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). These data were presented at the American College of Cardiology's 71st Annual Scientific Session & Expo.;73.33999633789062;;63.09000015258789;;10.40999984741211;;54.0;;26.219999313354492;;28.709999084472656;Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2022-04-05;244.55999755859375;;59.75;;691.469970703125;In this article, we discuss the 10 most profitable biotech companies in the world. You can skip our comprehensive analysis of the biotech industry, its history, performance, and outlook for future growth, and go directly to 5 Most Profitable Biotech Companies in the World. The biotechnology sector is estimated to grow from approximately $500 billion […]The Dow Jones Industrial Average dropped Tuesday. Tesla CEO Elon Musk is set to join Twitter's board of directors.;180.82000732421875;;363.8399963378906;Immunodiagnostics company Verici Dx leverages AI workflows in Illumina Connected Analytics for transplant prognosisSOUTH SAN FRANCISCO, Calif., April 05, 2022--The DNA Data Storage Alliance, an organization formed in 2020 by Illumina, Inc. (NASDAQ: ILMN), Microsoft (Nasdaq: MSFT), Twist Bioscience Corporation (NASDAQ: TWST) and Western Digital (NASDAQ: WDC) to create and promote an interoperable storage ecosystem based on DNA as a data storage medium, today announced that the organization has expanded to more than 50 members with the recent addition of FUJIFILM Recording Media U.S.A., Inc. The Fujifilm Group;269.9599914550781;Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $268.64, moving +0.94% from the previous trading session.;207.61000061035156;Biogen Inc. (BIIB) closed the most recent trading day at $211.64, moving +0.47% from the previous trading session.Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm high rates of persistence and adherence for VUMERITY® (diroximel fumarate)Early research investigates the potential of machine learning to predict MS disease progression from brain MRI scans CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from itAdvanced Micro Devices and Biogen are part of Zacks Bull and Bear of the Day article.;211.38999938964844;Facing the prospect of being booted off U.S. stock exchanges, several Chinese companies have come up with a way to keep their U.S. listings, while Beijing seeks to resolve a long-running audit standoff with Washington.A handful of tech stocks popped Monday after Chinese regulators axed an auditing hurdle for China-based companies trading in the U.S.;150.7899932861328;;159.91000366210938;The FDA needs time to review new information incorporated into Alnylam's (ALNY) vutrisiran NDA related to a new secondary packaging and labeling facility, which has been cited as a reason for the delay;433.04998779296875;;3.609999895095825;SOUTH SAN FRANCISCO, Calif. & BOSTON, April 05, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem. The four-year agreement inBRISBANE, Australia & BOSTON, April 04, 2022--Microba Life Sciences (ASX: MAP), a precision microbiome science company, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to identify single-strain, live bacteria product (LBP) candidates against autoimmune diseases. The collaboration aims to build on Microba’s precision approach to LBP development with an in-depth evaluation of the company’s strains using Ginkgo's high throughput,;79.44999694824219;;76.37999725341797;ClearBridge Investments, an investment management firm, published its “All Cap Growth Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge All Cap Growth Strategy underperformed its Russell 3000 Growth Index benchmark in the fourth quarter. On an absolute basis, the Strategy generated gains across seven of the […];80.69999694824219;;71.58000183105469;;65.2300033569336;;70.16000366210938;;97.05000305175781;;86.66999816894531;;88.38999938964844;;48.400001525878906;;66.51000213623047;Blueprint Medicines (NASDAQ:BPMC): initial data from a Phase 1/2 study of a lung cancer drug candidate for patients with certain types of mutation Bristol-Myers Squibb (NYSE:BMY): Food and Drug Administration (FDA) decision on a potentially blockbuster heart disease drug Coherus (NASDAQ:CHRS): several impending catalysts over next 15 months, with one coming up as early as April Tarsus Pharma (NASDAQ:TARS): key data readout is due which will determine the fate of the NDA filing for what could pot;67.4800033569336;;48.0;Facing the prospect of being booted off U.S. stock exchanges, several Chinese companies have come up with a way to keep their U.S. listings, while Beijing seeks to resolve a long-running audit standoff with Washington.;40.08000183105469;;22.899999618530273;;12.100000381469727;;56.45000076293945;;33.2599983215332;;80.69999694824219;;41.459999084472656;;;;22.420000076293945;The U.S. government is distributing fewer doses of an experimental Covid-fighting drug from Vir Biotechnology Inc. after raising doubts about its effectiveness against the latest variant of the deadly viral disease.  Vir and GSK have said they are assembling data to show that a higher dose of sotrovimab would work against BA.2.  Until then, however, the FDA is excluding sotrovimab's use in states and territories where BA.2 represents more than 50% of new SARS-CoV-2 infections, including California.SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the 21st Annual Needham Healthcare Conference on Monday, April 11, at 11:00 a.m. ET. The conference will be held virtually. A live webcast of the panel discussion can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About Vir BiotechnologyVir Biotec;18.8700008392334;;7.539999961853027;;9.460000038146973;;38.27000045776367;;74.23999786376953;;63.209999084472656;"NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 11:00 am ET. The live and archived webcast can be accessed under ""Events & Prese";10.0600004196167;;51.2599983215332;SOUTH SAN FRANCISCO, Calif., April 05, 2022--The DNA Data Storage Alliance, an organization formed in 2020 by Illumina, Inc. (NASDAQ: ILMN), Microsoft (Nasdaq: MSFT), Twist Bioscience Corporation (NASDAQ: TWST) and Western Digital (NASDAQ: WDC) to create and promote an interoperable storage ecosystem based on DNA as a data storage medium, today announced that the organization has expanded to more than 50 members with the recent addition of FUJIFILM Recording Media U.S.A., Inc. The Fujifilm GroupSOUTH SAN FRANCISCO, Calif. & BOSTON, April 05, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem. The four-year agreement in;25.75;;28.56999969482422;
2022-04-06;249.92999267578125;In this article, we discuss 10 biotech penny stocks with growth catalysts. If you want to see some more stocks in this selection, check out 5 Biotech Penny Stocks with Growth Catalysts. According to Global Market Insights, the market for biotech in 2020 was valued at $497 billion, and it is forecasted to grow to […]Amgen (AMGN) closed the most recent trading day at $244.56, moving -0.13% from the previous trading session.;60.81999969482422;As the founder and director of BCN Checkpoint, a community HIV program geared toward gay men and transgender women in Barcelona, Ferran Pujol has helped provide hope to those living with HIV for ne...ClearBridge Investments, an investment management firm, published its “Sustainability Leaders Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge Sustainability Leaders Strategy outperformed its Russell 3000 Index benchmark during the fourth quarter. On an absolute basis, the Strategy had gains in nine of 10 sectors in which […]In the latest trading session, Gilead Sciences (GILD) closed at $59.75, marking a -1.52% move from the previous day.Chairman and CEO Dan O'Day made $91 for every $1 in median Gilead employee compensation last year.;708.3599853515625;The Dow Jones Industrial Average slid Wednesday, extending losses from Tuesday's stock market sell-off, as the 10-year Treasury yield surged.Regeneron (REGN) closed at $691.47 in the latest trading session, marking a -0.99% move from the prior day.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.;166.64999389648438;A fourth dose of the Pfizer/BioNTech vaccine lowered rates of COVID-19 among the elderly but the protection against infection appeared short-lived, a large study https://www.nejm.org/doi/full/10.1056/NEJMoa2201570 in Israel has found.;358.5199890136719;An Illumina iConserve project is mapping genetic diversity to identify where confiscated gorillas come from and boost survival rates;272.3900146484375;In 2022, Vertex (VRTX) expects continued revenue growth as there are more than 25,000 patients who are addressable with Vertex's CF therapies.;209.7100067138672;;212.19000244140625;"BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING, April 06, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that marketing authorization applications (MAA) for tislelizumab, submitted by Novartis, the license holder in Europe, have been validated for regulatory review by the European Medicines Agency";151.89999389648438;;158.47000122070312;CAMBRIDGE, Mass., April 05, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that Steven Paul, M.D. is retiring from the Board of Directors effective April 16, 2022.;434.20001220703125;;3.5299999713897705;;80.16000366210938;;73.56999969482422;;81.87000274658203;Incyte Corp. has opened a six-story research and development building in Wilmington, a project that allows it to move staff members from nearby rented space to its main headquarters campus in Delaware.  Incyte CEO Herve Hoppenot said only that the building was delivered on time and under budget.  The company for years has leased space in Chadds Ford, Pennsylvania, and elsewhere in Wilmington to go along with the three buildings totaling 544,000 square feet in laboratory and office space at its headquarters.;68.70999908447266;;62.439998626708984;;67.55000305175781;;98.54000091552734;;88.12999725341797;;87.08000183105469;;48.13999938964844;"PASADENA, Calif., April 06, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 1, 2022, the Compensation Committee of the Company’s Board of Directors approved ""inducement"" grants to 23 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 53,000 restricted stock units. The grants are outside the Company’s stockholder-approved equi";69.87000274658203;;66.12000274658203;In 2022, Vertex (VRTX) expects continued revenue growth as there are more than 25,000 patients who are addressable with Vertex's CF therapies.;47.0;"ClearBridge Investments, an investment management firm, published its “International Growth ACWI ex-U.S. Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here. During the fourth quarter, the ClearBridge International Growth ACWI ex-U.S. Strategy outperformed its MSCI ACWI Ex-U.S. benchmark. The Strategy delivered gains across seven of the 10 sectors in […]- First preview of preclinical data for ZL-1218, an anti-CCR8 antibody, in an oral presentation - Poster presentations will feature three additional candidates of Zai Lab’s internal immuno-oncology/oncology pipeline: ZL-1201 (anti-CD47 antibody) for advanced hematologic malignancies and solid tumors, ZL-1211 (anti-CLDN18.2 antibody) for gastric and pancreatic cancer and ZL-2201 (DNA-PK inhibitor) for solid tumors - Abstracts: Oral presentation 3590; poster presentations: 3425, 5234 and 2594 SHAN";40.72999954223633;;23.079999923706055;;12.140000343322754;;54.79999923706055;;33.41999816894531;;82.8499984741211;;42.310001373291016;Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive revenues.;;;22.329999923706055;The monoclonal antibody has been used in hospitalized Covid patients following its emergency use authorization last spring, but it has been ineffective in its current form against the latest Covid subvariant, BA.2.;18.950000762939453;;7.510000228881836;;8.800000190734863;;38.75;;70.04000091552734;;65.63999938964844;ClearBridge Investments, an investment management firm, published its “Small Cap Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge Small Cap Strategy outperformed the Russell 2000 Index, the Strategy’s benchmark, during the fourth quarter. On an absolute basis, the Strategy posted gains in nine of 11 sectors […];9.930000305175781;;48.81999969482422;;27.219999313354492;;29.530000686645508;
2022-04-07;251.63999938964844;;60.9900016784668;Gilead's board as recently as eight years ago had one Black member and two women. Now, times have changed.;721.7999877929688;Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) for use in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation. The inflammation is characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), inadequately controlled with medium to high dose inhaled corticosteroids (ICS) and another medicinal product for maintenance treatment. The approval is based on Phase 3 VORegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent® (dupilumab) in the European Union. Dupixent is now also approved in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled coThis maker of drugs to treat eye and inflammatory diseases as well as cancer remains in a buy zone even as the stock market rally struggles.Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.;169.11000061035156;The European health agencies agreed that the fourth dose of mRNA-based COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) may be given to adults 80 years and above.Vaccine stocks toppled Wednesday after an Israeli study suggested immunity wanes quickly following a second Covid booster shot.;368.0;Illumina (NASDAQ: ILMN) is a giant in the world of next-generation sequencing (NGS).  The first chart breaks down the global market for next-generation sequencing -- also known as massively parallel gene sequencing -- by the types of end-users, for 2017 and forecasting out to 2028.  Given that, more companies can be expected to acquire Illumina sequencers as they work to develop their products.;275.8299865722656;;211.63999938964844;;213.58999633789062;;156.1199951171875;BOTHELL, Wash., April 07, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2022 financial results on Thursday, April 28, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.;162.25;;449.6499938964844;;3.4100000858306885;;83.3499984741211;;73.30000305175781;10x Genomics, Inc. ( NASDAQ:TXG ) is possibly approaching a major achievement in its business, so we would like to...;82.18000030517578;;68.56999969482422;Repligen and Exact Sciences have a proven track record with significant opportunities for continued growth.;59.5;;65.95999908447266;;98.48999786376953;;88.44000244140625;;85.86000061035156;In this article we present the list of top 10 stocks billionaire Mets owner Steve Cohen just added to his portfolio. You can skip our comprehensive analysis of Steve Cohen’s history, investment philosophy, and hedge fund performance and go directly to Top 5 Stocks Billionaire Mets Owner Steve Cohen Just Added to His Portfolio. Micron […];49.0099983215332;;68.36000061035156;Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on April 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 13,337 shares of its common stock and an aggregate of 6,665 restricted stock units (RSUs) to thirteen new employees under Blueprint Medicines' 2020 Inducement P;63.939998626708984;;46.650001525878906;;39.56999969482422;;22.93000030517578;;11.5;;53.369998931884766;;32.20000076293945;;82.16000366210938;;41.869998931884766;;;;22.829999923706055;VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.SAN FRANCISCO, April 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that a team of three company scientists were named one of the winners of the Pediatric COVID-19 Data Challenge, sponsored by the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Health and Human Services (HHS). The challenge asked participants to develop, train and validate computational models that could help healthcare providers predict which of their;19.25;;7.369999885559082;;8.770000457763672;;39.33000183105469;;70.16000366210938;;64.4000015258789;;9.75;;48.29999923706055;SOUTH SAN FRANCISCO, April 07, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MediSix Therapeutics, a cell therapy company creating novel therapeutics to target T-cell leukemia and lymphoma, today announced a collaboration to discover novel antibodies against five undisclosed targets.;27.059999465942383;;29.610000610351562;Alkermes plc (Nasdaq: ALKS) today presented new research from its psychiatry portfolio at the 2022 Congress of the Schizophrenia International Research Society (SIRS), taking place April 6-10, 2022 in Florence, Italy and virtually.
2022-04-08;252.02000427246094;;62.29999923706055;Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals are part of top Analyst article.Regulatory and pipeline news from Vir Biotechnology (VIR) and Bristol Myers (BMY) are a few key highlights from the biotech sector during the past week.;738.8400268554688;Regeneron and Bristol-Myers Squibb are part of today's Investment Idea article.With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.Passive investing in index funds can generate returns that roughly match the overall market. But in our experience...;170.25999450683594;"Centennial Resource Development and ShotSpotter are part of Zacks Bull and Bear of the Day article.BioNTech has won a five-year contract with the German health ministry to produce and supply mRNA vaccines in emergency situations in the country, the Germany-based biotechnology company said on Friday.  Under the framework agreement, BioNTech would reserve and maintain manufacturing capabilities to produce at least 80 million mRNA-based vaccine doses each year to address potential public health threats, the company said in a statement.  ""There is growing evidence that viral pandemics will continue to pose a public health challenge for years,"" said Sean Marett, BioNTech's chief business and chief commercial officer.MAINZ, Germany, April 8, 2022 — BioNTech SE (Nasdaq: BNTX) today announced that it is one of the companies in Germany to be granted a pandemic preparedness contract by the Federal Republic of Germany. The framework agreement is aimed at pandemic preparedness including manufacturing and supply of mRNA vaccines in emergency situations in Germany. “There is growing evidence that viral pandemics will continue to pose a public health challenge for years. This contract with the German government will";362.67999267578125;Report highlights contributions of genomics to advances in public health and overall health of our planet;280.2799987792969;Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals are part of top Analyst article.Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) insiders who bought shares over the past year were rewarded...Regulatory and pipeline news from Vir Biotechnology (VIR) and Bristol Myers (BMY) are a few key highlights from the biotech sector during the past week.;214.75;A decision from the Centers for Medicare and Medicaid Services effectively closed the door on the commercial future of Biogen’s Alzheimer's drug, Aduhelm.Biogen (NASDAQ:BIIB) stock is trending lower today on news that Medicare will limit coverage of its Aduhelm drug for Alzheimer’s. Source: PictureDesignSwiss / Shutterstock.com In an announcement, Medicare said that it will restrict coverage of Aduhelm, a controversial and expensive Alzheimer’s drug, to patients who are enrolled in clinical trials. The decision effectively ends an intense lobbying campaign on the part of prescription drug makers who wanted Medicare to cover the cost of the AlzheiYahoo Finance Live’s Julie Hyman discusses Biogen shares amid news that Medicare will restrict coverage of the pharmaceutical company's Alzheimer’s drug.Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.By Peter NurseThe Centers for Medicare and Medicaid Services on Thursday confirmed it will limit routine payment for Biogen’s Aduhelm--designed to treat early-stage Alzheimer’s disease--to patients enrolled in approved clinical trials.The Centers for Medicare and Medicaid Services are sticking to their January decision to limit coverage of Aduhelm to patients enrolled in randomized clinical trials.The projected cost of the new Alzheimer's drug was a major driver behind a $22 increase in Medicare's Part B premium this yearThe U.S. government health plan for people age 65 and over on Thursday issued its final coverage policy for Biogen Inc's Alzheimer's drug, Aduhelm, moving forward with an unusually strict plan limiting it to patients in clinical trials.  For drugs similar to Aduhelm, the Centers for Medicare and Medicaid Services (CMS) said it would allow coverage if the medication is approved after a standard review by the Food and Drug Administration.  The FDA approved Aduhelm last June under an accelerated approval pathway, finding that the drug's ability to clear amyloid plaque from the brain offered enough evidence that it would likely help slow cognitive decline for Alzheimer's patients.Shares of Biogen Inc. fell 0.3% in the extended session Thursday after the Centers for Medicare and Medicaid Services, which oversees the Medicare program, said they had finalized their policies about covering the biotech's controversial Alzheimer's drug Aduhelm and future others. As it signaled in January, CMS said that Food and Drug Administration-approved monoclonal antibodies such as Aduhelm and others in its class would be covered for people with Medicare only if they are enrolled in clinic;196.57000732421875;"CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland, April 08, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that clinical results, as well as biomarker data, from its immuno-oncology program in solid tumors will be presented at the American Academy for Cancer Research (AACR) Annual Meeting 2022. The AACR mNovartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.";151.83999633789062;;163.4199981689453;;433.1700134277344;;3.5299999713897705;;85.98999786376953;;71.5;These shares are down significantly from all-time highs, but the businesses have plenty of room for growth.10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.;83.18000030517578;;67.30999755859375;Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company plans to release its first quarter 2022 financial results after the close of the U.S. financial markets on April 26, 2022. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.;60.630001068115234;Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the Thailand Food and Drug Administration (Thai FDA) has granted emergency use authorization (EUA) for Novavax' protein-based vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severeNovavax (NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration (FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to. The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would furthe;63.0;;100.06999969482422;;87.94000244140625;When looking for the best stocks to buy and watch, focus on those with rising relative price strength.  One stock that fits that bill is Sarepta Therapeutics stock, which had its Relative Strength (RS) Rating upgraded from 80 to 85 Thursday.  When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.;85.37000274658203;;48.25;;69.58999633789062;;61.619998931884766;ZUG, Switzerland and CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in April: 21st Annual Needham Virtual Healthcare ConferenceDate: Tuesday, April 12, 2022Time: 12:45 PM ET Canaccord Genuity Horizons in Oncology Virtual Confe;43.5099983215332;;37.97999954223633;;23.020000457763672;If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...;10.9399995803833;;51.77000045776367;;30.700000762939453;;81.88999938964844;;41.93000030517578;;;;22.170000076293945;Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals are part of top Analyst article.With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.Regulatory and pipeline news from Vir Biotechnology (VIR) and Bristol Myers (BMY) are a few key highlights from the biotech sector during the past week.;19.1299991607666;;7.210000038146973;;8.489999771118164;;40.119998931884766;;66.41999816894531;;64.5999984741211;;9.039999961853027;;45.95000076293945;Twist Bioscience Corporation (NASDAQ: TWST) and MediSix Therapeutics have collaborated to discover novel antibodies against five undisclosed targets. Under the terms of the collaboration, Twist will leverage its proprietary Library of Libraries to discover five novel antibodies directed against MediSix's targets. MediSix will use its platform technologies to develop novel CAR T-cell therapies targeting malignancies and autoimmune diseases without any CAR T-cell fractricide. Twist will receive an;26.0;;29.6299991607666;
2022-04-11;250.8699951171875;Amgen (NASDAQ: AMGN) today announced the presentation of long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who received LUMAKRAS® (sotorasib)*. The two-year follow-up data will be presented orally as part of a clinical trials plenary session at the American Association for Cancer Research (AACR) annual meeting on April 10, 2022. LUMAKRAS is the first and only KRASG12C inhibitor to-date to show;61.88999938964844;;722.3699951171875;Regeneron (REGN) gains 17% YTD on the back of Eylea, Dupixent and good pipeline progress.;170.5500030517578;"BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC platform technology. The companies will collaborate on formulation, optimization, and in vitro testing. ""We are thrilled to partner with this world-class organization to demonstrate the capabilities of our LNC platform further and potentially provide an opportunity for the oral administration of vAround three million COVID-19 vaccine doses are expected to expire in Germany by the end of June, a spokesperson for the health ministry said on Monday, as supply outstrips demand because a declining number of people are being vaccinated.  After a shortage in vaccine doses at the beginning of the vaccine campaign in early 2021, Germany stepped up its deliveries to meet growing demand, but a lower inoculation rate means Germany has more vaccine than it needs or can donate.  Around 76% of the population has received at least one dose, less than the level of more than 80% in western European countries including France, Italy and Spain.BioNTech  on Monday touted what it called positive early data from a trial of a combination cancer therapy that involves a messenger RNA cancer vaccine in an early test of mRNA applicability in cancer.  Shares of  BioNTech  (ticker: BNTX) were down 1.7% in premarket trading.  Before the Covid-19 pandemic, much of the focus of biotechnology companies working on mRNA technology—including BioNTech,  Moderna  (MRNA), and  CureVac  (CVAC)—was on applications in cancer.Exclusive collaboration combines BioNTech’s mRNA vaccine development expertise and Matinas’ Lipid Nanocrystal (LNC) Delivery Platform Technology to advance novel formulations for mRNA vaccines, including a potential formulation for oral vaccinesMatinas will receive an upfront exclusive access fee from BioNTech, as well as additional research funding BioNTech and Matinas have commenced license agreement discussions for Matinas’ LNC Delivery Platform Technology MAINZ, Germany and BEDMINSTER, N.J.,BNT211 combines two innovative approaches in one regimen, an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac) to improve persistence and functionality of the adoptively transferred cellsTreatment with BNT211 alone or in combination with CARVac, currently being tested in a Phase 1/2 Trial in patients with advanced solid tumors, was well tolerated across multiple tumor indications in preliminary data fro";351.2799987792969;;281.0899963378906;;210.6199951171875;;184.41000366210938;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, April 11, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced results from the Phase 3 ALPINE trial showing BTK inhibitor BRUKINSA® (zanubrutinib) demonstrated superiority versus ibrutinib in overall response rate (ORR) as assessed by an Independent Review Committee (IRC) in adult patients with relapsed or refractory (";144.2899932861328;;157.42999267578125;;422.510009765625;;3.3499999046325684;Elanco Animal Health Incorporated (NYSE: ELAN), a leading global animal health company, and Ginkgo Bioworks, the leading horizontal platform for cell programming, today announced the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.;83.2699966430664;;72.55000305175781;;80.94999694824219;;66.54000091552734;;57.540000915527344;Novavax (NASDAQ:NVAX) seeks to provide novel products to prevent a broad range of infectious diseases. The company is best known in the U.S. for developing Covid-19 vaccine NVX-CoV2373. However, a recent development highlights Novavax’s global ambitions in combating infectious diseases. Sometimes, it’s tempting to just focus on how vaccine makers are faring in the U.S. Clearly, Novavax wasn’t first to market with a Covid-19 vaccine for distribution to the American public. Yet, investors should b;61.66999816894531;Regeneron (REGN) gains 17% YTD on the back of Eylea, Dupixent and good pipeline progress.;98.47000122070312;;84.33999633789062;;82.68000030517578;;46.790000915527344;;66.37000274658203;Investing in biotechnology companies is both difficult and incredibly exciting.  Watching as a company goes through the regulatory approval process, from a fledgling early-stage clinical trial biotech to an industry juggernaut, can be exhilarating.  While positive outcomes aren't guaranteed in clinical trials, let's look at two promising companies at different stages of development.Blueprint Medicines Corp (NASDAQ: BPMC) announced proof-of-concept data from the Phase 1/2 SYMPHONY trial of BLU-945 for advanced EGFR-mutant non-small cell lung cancer (NSCLC). The data were shared at the American Association for Cancer Research (AACR) Annual Meeting 2022. The early readout from the phase 1/2 Symphony trial shows the first safety and clinical activity data. Results from the higher dose group hint at tumor shrinkage too. One patient treated with 400 mg once daily experienced a p;61.45000076293945;;42.88999938964844;;35.83000183105469;;22.389999389648438;;10.829999923706055;;49.0099983215332;;30.020000457763672;;79.2699966430664;;41.380001068115234;;;;21.75;;18.969999313354492;;7.059999942779541;;8.210000038146973;;39.61000061035156;;66.2699966430664;;62.7599983215332;;8.829999923706055;;43.95000076293945;;23.6200008392334;;28.690000534057617;
2022-04-12;250.0399932861328;BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.Amgen (AMGN) closed the most recent trading day at $250.87, moving -0.46% from the previous trading session.Biomea Fusion Inc (NASDAQ: BMEA) presented new preclinical data at the American Association of Cancer Research (AACR) Annual Meeting for BMF-219 in liquid cancers and solid tumors. BMF-219 exhibited cytotoxic activity as a single agent at similar concentrations across multiple preclinical patient-derived (PDX) models ex vivo, including diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer. In addition, the;61.630001068115234;"Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.The Food and Drug Administration's decision on Monday to lift the partial hold on Gilead Sciences Inc.'s magrolimab for two indications is ""good news"" for the company, according to RBC Capital Markets analysts. ""While GILD still has much to prove around its emerging oncology franchise, we see this as a much-needed piece of good news,"" analysts wrote in a note to investors on Monday. Magrolimab is being tested as a treatment for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), botFOSTER CITY, Calif., April 11, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination with azacitidine. The FDA removed the partial clinical hold after a review of the comprehensive safety data from each trial.";715.7899780273438;;169.1300048828125;Demand for Covid boosters is waning, according to a recent IBD/TIPP Poll, which sheds some light on continued pressure for vaccine stocks.BioNTech SE (NASDAQ: BNTX) presented data from its ongoing Phase 1/2 trial of its CAR-T cell therapy candidate, BNT211, in advanced solid tumors. The preliminary results demonstrated a favorable safety profile and antitumor activity in testicular cancer patients. BNT211 comprises an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac). The presentation included data from 16 patients who received CLDN6 CAR-;344.5899963378906;;281.1499938964844;If so, there are some increasingly popular entrees on the biopharmaceutical industry's menu that deserve your attention.  Bristol Myers Squibb shares have risen 25% this year to reach an all-time high water mark for this well-established pharmaceutical giant.  New safety and efficacy results from a clinical trial with an experimental drug for patients with abnormally thick hearts called mavacamten have been pushing the stock higher this month.;208.05999755859375;Thank you to all the women who took chances and paved the way so we could forge our own paths today. This past Women’s History Month, we honored women in science by continuing our commitment to mak...;182.4199981689453;BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.;142.22999572753906;;159.5800018310547;;412.75;Bio-Techne Corporation (NASDAQ: TECH) and Cygnus Technologies, part of Maravai LifeSciences (NASDAQ: MRVI), announced today the launch of the Simple Plex™ HEK 293 HCP 3G assay for automated process impurity testing on the Ella™ immunoassay platform.Bio-Techne's (NASDAQ:TECH) stock is up by a considerable 5.4% over the past month. Given that stock prices are usually...;3.450000047683716;Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to develop a novel therapeutics based on the bacterial genus Bacteroides.;82.58999633789062;;71.4800033569336;;80.06999969482422;WILMINGTON, Del., April 12, 2022--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 3, 2022.;67.4000015258789;;58.099998474121094;Like a fad that arrived and left, Covid-19 vaccine stocks are out of favor now. Novavax (NASDAQ:NVAX) is facing tremendous selling pressure compared to its peers. Unlike its competitors that received approval for its vaccines and sold them to global markets, Novavax barely started. NVAX stock is either a bargain of the century temping bottom-fishers to buy the dip. Alternatively, its slumping stock price may continue. 7 Cloud Computing Stocks to Buy for April 2022 Biotechnology investors are wel;61.349998474121094;;98.01000213623047;;82.33999633789062;;79.61000061035156;;46.84000015258789;;67.01000213623047;;64.55000305175781;In this article, we discuss the 10 undervalued mid-cap stocks that hedge funds love. If you want to read about some more undervalued mid-cap stocks, go directly to Hedge Funds Love These 5 Undervalued Mid-Cap Stocks. Fears of a recession in the United States economy are growing again, merely a couple of years after the […];42.45000076293945;;36.939998626708984;;22.3700008392334;The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.;10.779999732971191;;50.06999969482422;;30.209999084472656;;80.83999633789062;;41.619998931884766;;;;21.84000015258789;;18.899999618530273;;6.960000038146973;;8.119999885559082;The three purest plays on the science are Illumina (NASDAQ: ILMN), Pacific Biosciences of California (NASDAQ: PACB) -- also known as PacBio -- and Oxford Nanopore Technologies (LSE: ONT).  For shareholders of PacBio, it has never been about sales and profit.;39.630001068115234;;65.7300033569336;;63.33000183105469;;8.65999984741211;;44.91999816894531;;23.399999618530273;;28.719999313354492;
2022-04-13;253.50999450683594;When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...;62.060001373291016;Growing up in Nigeria offered Anu Osinusi her first glimpse of the devastating effects viral hepatitis can have on people’s lives. The country’s large population, coupled with a relatively high pre...GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.;731.8900146484375;;179.3800048828125;Ocugen (OCGN) is conducting the OCU-002 study to support its BLA for the approval of Covaxin in the United States. The FDA places a clinical hold on this study.Children under five in the U.S. aren’t yet eligible for a Covid-19 vaccine after efforts to get the shots to market have hit setbacks. WSJ’s Peter Loftus explains what we know about the vaccines and when they might become available. Photo composite: Todd JohnsonMatinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.;343.3500061035156;A look at the shareholders of Illumina, Inc. ( NASDAQ:ILMN ) can tell us which group is most powerful. Institutions...Illumina's (ILMN) customers and partners in Brazil currently span basic research, applied markets to clinical labs and healthcare institutions.Regional Solution Center in São Paulo, Brazil will enable customer access to next-generation sequencing training and expertise to improve patient outcomesSAN DIEGO, April 12, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of John Frank as the Company'...;290.92999267578125;We have narrowed our search to five Nasdaq listed stocks that have witnessed double-digit rally year to date. These are: VRTX, SPLK, HSIC, CHKP and JKHY.The most recent bear market for the Nasdaq Composite Index lasted only a few days.  The Nasdaq Composite Index only has to drop another 4% to again enter bear territory.  Alphabet's (NASDAQ: GOOG) (NASDAQ: GOOGL) share price has held up better than many other Nasdaq stocks.;213.97999572753906;Biogen’s (BIIB) Aduhelm looks like a market failure Approvals on treatments that don’t cure are now under challenge There can be no unlimited draw from a limited pool of funds Source: PictureDesignSwiss / Shutterstock.com When Biogen (NASDAQ:BIIB) stock got its Alzheimer’s drug Aduhelm approved last June, the stock spiked to nearly $420/share. It was due to open April 11 at $213. As I wrote recently, the whole biotech sector has gone into a spin. It’s not a coincidence. The way I see it, Biogen;187.66000366210938;The Chautauqua International Growth fund has outperformed its peers amid market turmoil by sticking with its strategy and favored stocks, particularly in China and Canada.;147.44000244140625;"TOKYO & BOTHELL, Wash., April 13, 2022--Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas"") and Seagen Inc. (Nasdaq:SGEN) today announced that the European Commission (EC) has approved PADCEV™ (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor. The EC approval is supported by data from the global phase";168.4600067138672;;419.3999938964844;Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. CDT to review third quarter fiscal 2022 financial results.;3.8299999237060547;FREDsense Technologies Corp, a next generation water quality platform company leveraging synthetic biology to build field kits for faster, cheaper, and more efficient analysis, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to build biosensors for water quality monitoring and detection. Through this partnership, Ginkgo seeks to build four distinct microbial strain biosensors, compatible with FREDsense's field-ready hardware fo;84.0;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 27th, at 4:30 p.m. ET to discuss first quarter 2022 financial results and provide a general business update.;68.4000015258789;;81.98999786376953;;69.9000015258789;;62.16999816894531;Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. The vaccine, also known as NVX-CoV2373, i;63.0;;98.95999908447266;;83.23999786376953;;81.56999969482422;;49.2400016784668;;70.1500015258789;;65.83999633789062;There's nothing in biopharma that's quite like CRISPR, the mysterious and powerful gene-editing system that has long captured the imaginations of serious researchers and fantastical hype purveyors alike.  It's a truism to say that it'll be a major area of drug development for years to come as a result of its ability to precisely remodel genetic code.ZUG, Switzerland and CAMBRIDGE, Mass., April 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Maria Fardis, Ph.D., MBA, to its Board of Directors at the Company’s upcoming annual general of shareholders meeting to be held later this year. “We are very pleased to invite Maria to join our Board of Directors,” said Samarth Kulkarni, Ph.D., Ch;44.650001525878906;SHANGHAI, April 13, 2022 /PRNewswire/ – Forbes released the 2022 Midas List on April 12, a ranking of the world's top 100 venture capitalists. Nisa Leung, Managing Partner of Qiming Venture Partners, and Duane Kuang, Founding Managing Partner of Qiming Venture Partners, ranked on the list.;38.93000030517578;;22.989999771118164;Things have been even more challenging for the technology-focused Nasdaq Composite (NASDAQINDEX: ^IXIC).  Between mid-November and mid-March, the Nasdaq lost 22% of its value, thereby pushing it into a bear market.  Superficially speaking, bear markets can, at times, be scary.;11.619999885559082;;51.52000045776367;;31.040000915527344;;84.58000183105469;;41.459999084472656;"Shares of  Antares Pharma  surged 49% Wednesday after the specialty pharmaceutical company agreed to be bought by  Halozyme Therapeutics   in a cash deal valued at $960 million.  Under terms of the deal, Halozyme (ticker:  HALO) will pay $5.60 a share to buy Antares (ATRS), the company said in a statement.  Halozyme said that it expects the deal, which is expected to close in the first half of 2022, to immediately add to 2022 revenue and adjusted earnings per share, and accelerate revenue and earnings growth through 2027.The deal, which values Antares at roughly $960 million, deepens Halozyme’s focus on drug delivery.By Sam BougheddaShares of the drug delivery specialist Antares Pharma (NASDAQ: ATRS) jumped by as much as 49.2% in premarket action Wednesday morning.  The company's stock is bolting higher in response to a $960 million definitive merger agreement with Halozyme (NASDAQ: HALO).  Per the terms of the deal, Halozyme will pay $5.60 per share in cash to acquire Antares, which amounts to a 49.7% premium compared to the drug delivery company's closing price Tuesday afternoon.Halozyme Therapeutics Inc (NASDAQ: HALO) will acquire Antares Pharma Inc (NASDAQ: ATRS) for $5.60 per share, valuing Antares at approximately 0 million. The transaction is expected to be accretive to Halozyme's 2022 revenue and adjusted earnings and accelerate top-and bottom-line growth through 2027, with multiple growth drivers beyond 2027. Antares' suite of FDA-approved and partner products utilizing the Antares auto-injector technology have already demonstrated commercial success and are posiHalozyme Therapeutics Inc will buy specialty pharmaceutical company Antares Pharma Inc in a $960 million all-cash deal, the companies said on Wednesday.  Halozyme will pay $5.60 for each share of Antares Pharma, a premium of 49.7% to the company's last closing price.  San Diego-based Halozyme offers a delivery technology that enables high volumes of a drug to be injected under the skin, potentially reducing the need for multiple injections.Shares of Antares Pharma Inc. rocketed 46.3% in premarket trading Wednesday toward a two-decade high, after the specialty pharmaceutical company agreed to be acquired by Halozyme Therapeutics Inc. in a cash deal valued at $960 million. Halozyme's stock was still inactive ahead of the open. Under terms of the deal, Halozyme will pay $5.60 for each Antares share outstanding, which represents a 49.7% premium to Tuesday's closing price of $3.74. Halozyme expects the deal, which is expected to closeHalozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") and Antares Pharma, Inc. (NASDAQ: ATRS) (""Antares"") today announced that the companies have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for $5.60 per share in cash. The transaction, which values Antares at approximately $960 million, was unanimously approved by both the Halozyme and Antares Boards of Directors.";;;23.18000030517578;;18.670000076293945;;7.199999809265137;;8.149999618530273;;40.63999938964844;;68.4800033569336;;64.69999694824219;;9.010000228881836;VANCOUVER, British Columbia, April 12, 2022--AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022;45.150001525878906;;24.43000030517578;;28.739999771118164;
2022-04-14;254.02000427246094;In this article, we will discuss 10 dividend stocks to buy now according to Kerr Neilson’s hedge fund. If you want to skip reading about dividend investing, Kerr Neilson’s investment philosophy, and his hedge fund’s past performance, you can continue to 5 Dividend Stocks to Buy Now According to Kerr Neilson’s Hedge Fund. Kerr Neilson, […]Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.In the latest trading session, Amgen (AMGN) closed at $253.51, marking a +1.39% move from the previous day.;61.81999969482422;Gilead Sciences (GILD) closed at $62.06 in the latest trading session, marking a +0.7% move from the prior day.;733.02001953125;"The FDA has extended its review of Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) marketing application of REGEN-COV (casirivimab and imdevimab) for non-hospitalized COVID-19 patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure prophylactic use. Regeneron has submitted additional data from its completed prophylaxis trial that the FDA has accepted for review. The FDA has provided a new target action date of July 13, 2022, andRegeneron Pharmaceuticals Inc. said Thursday that the Food and Drug Administration extended the review time by three months on whether to fully approve Regen-Cov as a treatment for non-hospitalized COVID-19 patients and as a prophylactic. Regeneron said the extension has to do with using Regen-Cov to prevent COVID-19 infections. Regen-Cov, which is a monoclonal antibody, was authorized as a COVID-19 treatment in November 2020; however, the therapy is not in use anywhere in the U.S. at this timeRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended by three months its review of the Biologics License Application (BLA) for REGEN-COV® (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure prophylactic use, for which Regeneron has submitted additional data from its completed prophylaxis";175.2899932861328;"Pfizer and  BioNTech  booster dose increased antibody levels in children aged 5 through 11, the companies announced early Thursday morning.  Analyzed data from 140 healthy children who received the booster shot about six months after the second dose of Covid-19, showed there was a sixfold increase in antibodies one month after the additional shot.  The trial looked at children who had no evidence of prior Covid-19 infection.NEW YORK & MAINZ, Germany, April 14, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. These data demonstrate an increase in SARS-CoV-2 Omicron variant and wild-type strain neutralizing titers following a booster dose of the Pfizer-BioNTech COVID-19Pfizer Inc. and German partner BioNTech SE said Thursday a Phase 2/3 trial of their COVID-19 vaccine booster showed a high immune response in children aged 5-to-11-years old. Data from a sub-analysis of 30 sera from the trial showed a 36-fold increase in neutralizing titers against the omicron variant, which has become dominant globally. ""These data demonstrate an increase in SARS-CoV-2 Omicron variant and wild-type strain neutralizing titers following a booster dose of the Pfizer-BioNTech COVID";336.489990234375;Regulatory complications are raising the legal expenses for Illumina (ILMN), thereby building pressure on the bottom line.;287.9700012207031;Scientists have been talking about and working on CRISPR gene editing for years.  CRISPR Therapeutics (NASDAQ: CRSP), which uses the CRISPR technique, plans on submitting its candidate for blood disorders for regulatory approval at the end of this year.  CRISPR Therapeutics and its partner Vertex Pharmaceuticals have reported favorable data from clinical trials in sickle cell disease and beta thalassemia.Splunk, Vertex Pharmaceuticals, Henry Schein, Jack Henry & Associates, and Check Point Software Technologies are part of Top Analyst Blog.Biotech stocks have put plenty of investors on the road to riches in recent years.  Or we can refer to a smaller player like Novavax, which soared 2,700% in one year on optimism about its coronavirus vaccine program.  Investors already know Moderna (NASDAQ: MRNA) for its blockbuster coronavirus vaccine, and that's why it might be overlooked right now.;212.5500030517578;;182.36000061035156;;149.72000122070312;;167.33999633789062;We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.CAMBRIDGE, Mass., April 14, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2022 on Thursday, April 28, 2022, before the U.S. financial markets open.A Relative Strength Rating upgrade for Alnylam Pharmaceuticals shows improving technical performance. Will it continue?;418.0799865722656;;3.8399999141693115;;82.94999694824219;;64.87999725341797;10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the commercial availability of two new products designed to improve sample preparation workflow and broaden the adoption of the company's leading Chromium platform for single cell analysis: Fixed RNA Profiling and Nuclei Isolation Kits. Together, these kits will enable easier single cell multiomic analysis of fragile human tissue samples and make frozen sample analysis, which;81.73999786376953;;69.61000061035156;;58.54999923706055;Novavax (NASDAQ: NVAX) helped make a lot of investors richer in the early days of the coronavirus pandemic.  Today, more than 35 countries have authorized the Novavax vaccine.  Investors aren't happy about the time it's taking the FDA to review Novavax's EUA submission.Swiss officials authorized Novavax's Covid vaccine on Wednesday, and NVAX stock popped, though it remains below its key lines.What happened Always a bit of an underdog coronavirus stock, Novavax (NASDAQ: NVAX) over-performed on Wednesday. The biotech's shares were trading over 8% higher in late afternoon action, following yet another authorization from a healthcare regulator for the company's COVID-19 vaccine.Novavax (NASDAQ:NVAX) got good news Wednesday morning. Swissmedic, the Swiss Agency for Therapeutic Products, gave Nuvaxovid, the company’s protein-based Covid-19 vaccine, conditional marketing authority (CMA). As a result, NVAX stock is 5% in early trading. “We are proud that Switzerland is part of the growing list of countries to authorize Nuvaxovid and that people in Switzerland will have a protein-based COVID-19 vaccine option,” said Stanley C. Erck, President and Chief Executive Officer, No;59.93000030517578;;99.2699966430664;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 4, 2022.;81.44999694824219;;81.94000244140625;;46.869998931884766;;68.0199966430664;;62.189998626708984;We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.Scientists have been talking about and working on CRISPR gene editing for years.  CRISPR Therapeutics (NASDAQ: CRSP), which uses the CRISPR technique, plans on submitting its candidate for blood disorders for regulatory approval at the end of this year.  CRISPR Therapeutics and its partner Vertex Pharmaceuticals have reported favorable data from clinical trials in sickle cell disease and beta thalassemia.;44.40999984741211;In this article, we will look at 10 pharmaceutical stocks to buy now according to billionaire Kerr Neilson. If you want to skip reading about Kerr Neilson’s investment philosophy and Platinum Asset Management’s past performance, you can go directly to 5 Pharmaceutical Stocks to Buy Now According to Billionaire Kerr Neilson. Kerr Neilson is an Australian […];37.77000045776367;;23.09000015258789;"ALAMEDA, Calif., April 14, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of the first-in-human phase 1 trial of XL114, a novel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 complex, as a monotherapy in patients with non-Hodgkin’s lymphoma (NHL) who have received prior standard therapies. The objectives of the study are to determine the recommended dose and/or the maximum tolerated dose of XL114 and to evaluate the safety and preliminary eALAMEDA, Calif., April 13, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that Charles Cohen, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors. Dr. Cohen will not stand for re-election to the Board at the company’s 2022 Annual Meeting of Stockholders, which has been tentatively scheduled for Wednesday, May 25, 2022; his resignation from the Board will take effect that same day.";10.979999542236328;;46.400001525878906;;30.110000610351562;;85.4000015258789;It started with hearing a podcast about Duchenne muscular dystrophy and progressed through an 11th grade biology class project. Now Shivin Kumar and Malyka Ram's Uplands Med is starting experiments at a San Carlos incubator.;42.27000045776367;Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying.Antares, which was originally founded in Exton, is a specialty pharmaceutical company that develops, manufactures and commercializes therapeutic products using its advanced drug delivery systems.;;;23.93000030517578;SAN FRANCISCO, April 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will host a virtual Hepatitis Portfolio R&D Day for the investment community on Wednesday, April 27, from 12:00 – 2:00 p.m. ET. Vir’s Hepatitis Portfolio R&D Day will review the Company’s robust hepatitis pipeline and multiple clinical value drivers in 2022. The event will include presentations from Vir’s senior leadership team, as well as a hepatitis overview by Jordan Feld,;18.360000610351562;;6.940000057220459;;7.539999961853027;;40.970001220703125;;66.95999908447266;;64.30000305175781;;8.989999771118164;;42.59000015258789;;23.469999313354492;;29.360000610351562;
2022-04-18;251.92999267578125;;61.58000183105469;When Cristina Herrera was 15 years old, she traveled alone from Southern California to the Bronx in pursuit of new life experiences. A native of El Salvador, Cristina thought as a teenager that she...;723.2000122070312;Here's why they chose Novartis (NYSE: NVS), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski (Novartis): Regardless of whether you value growth, dividends, or just want a reasonably priced investment that you can hang on to for years, Novartis is a stock that you should consider adding to your portfolio.  The company has 20 assets that it believes could each generate at least $1 billion in annual revenue for the business.;159.57000732421875;Talks on Taiwan buying the child version of the Pfizer/BioNTech COVID-19 vaccine have stalled as Pfizer does not have the right to sell it and BioNTech and its Chinese partner do not make it, a Taiwanese minister said on Monday.  The sales rights for the vaccine in Greater China, including Taiwan, belong to BioNTech and its Chinese sales agent, Shanghai Fosun Pharmaceutical Group.Talks on Taiwan buying the child version of the Pfizer/BioNTech COVID-19 vaccine have stalled as Pfizer does not have the right to sell it, and BioNTech and its Chinese partner do not make it, a Taiwan minister said on Monday.  The sales rights for the vaccine in Greater China, including Taiwan, belong to BioNTech and its Chinese sales agent, Shanghai Fosun Pharmaceutical Group, which snarled a deal for the main version of the vaccine last year after Taiwan accused China of political interference, which Beijing denied.;335.8500061035156;;282.989990234375;Here's why they chose Novartis (NYSE: NVS), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski (Novartis): Regardless of whether you value growth, dividends, or just want a reasonably priced investment that you can hang on to for years, Novartis is a stock that you should consider adding to your portfolio.  The company has 20 assets that it believes could each generate at least $1 billion in annual revenue for the business.;212.5399932861328;;172.13999938964844;;144.38999938964844;;156.67999267578125;;412.05999755859375;;3.630000114440918;;81.18000030517578;;62.189998626708984;;80.33000183105469;;67.83999633789062;;55.15999984741211;The stock is trying to settle below $55.50.By Sam BougheddaNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will provide a first look at data from its COVID-19 influenza combination vaccine and seasonal influenza vaccine trials, at the World Vaccine Congress (WVC) in Washington, DC, April 18 - 21, 2022. In addition, the latest data on its protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be presented at both WVC and the 32nd European CongShares of Novavax (NASDAQ:NVAX) stock showed impressive volatility around April 13. At that time, Swiss officials authorized Novavax’s Nuvaxovid vaccine for conditional use against Covid-19. That news sent NVAX stock upward for the day by roughly 5%. A day later, the stock had given back those gains. So what gives? It’s probably a combination of a few factors. The most prevalent of which is that its vaccine still lacks U.S. Food and Drug Administration (FDA) approval. While Nuvaxovid has gainedA Japanese Health Ministry committee said on Monday it has approved Novavax Inc's COVID-19 vaccine, setting the stage for full approval of the country's fourth shot for the coronavirus.  The Japanese government has agreed to purchase 150 million doses of Novavax's recombinant protein type vaccine, which is to be manufactured domestically by Takeda Pharmaceutical Co. .  Most of Japan's COVID vaccinations have been carried out with the mRNA types made by Pfizer Inc and Moderna Inc .Novavax (NASDAQ: NVAX) has been one of the more promising COVID-19 vaccine stocks to invest in since the pandemic began.  There's still hope for Novavax to grab some market share, especially with the Food and Drug Administration (FDA) recently permitting a second booster shot for individuals 50 and over and those with weakened immune systems.  As Novavax's share price continues falling to new lows, investors may see the risk-reward ratio become a bit more tenable.Novavax (NVAX) still has an opportunity to grow. It has approvals for its Covid-19 vaccine in 36 countries, where revenue could show upside potential. NVAX stock might never reach all-time highs again, but a comeback isn’t out of the question. Source: Vladimka production / Shutterstock.com Despite reporting high efficacy in its Covid-19 vaccine and having filed for Food and Drug Administration (FDA) approval, Novavax (NASDAQ:NVAX) hasn’t inched closer to its best days yet. It received U.S. gover;56.619998931884766;;97.30000305175781;;80.0199966430664;;76.91999816894531;;44.33000183105469;;64.94000244140625;;58.7400016784668;;42.79999923706055;;35.47999954223633;;22.850000381469727;;10.210000038146973;;43.97999954223633;;28.530000686645508;;78.44000244140625;;41.7400016784668;;;;23.020000457763672;;18.09000015258789;;6.46999979019165;;7.340000152587891;;41.0099983215332;;64.87000274658203;;60.61000061035156;;8.40999984741211;;40.720001220703125;SOUTH SAN FRANCISCO, Calif., April 18, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 second quarter ended March 31, 2022, after the closing of the market on May 5, 2022. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discus;22.40999984741211;;28.899999618530273;
2022-04-19;253.3699951171875;The proposal by an order of Roman Catholic nuns and a social-activist shareholder organization comes as biopharma spending on lobbying reaches into the tens of millions of dollars per year.Initial data from a late-stage study comparing Amgen's (AMGN) Stelara biosimilar candidate with the original Stelara drug showed no clinically meaningful differences in treating plaque psoriasis.Amgen (NASDAQ:AMGN): Generated $2.5 billion of free cash flow, and has significant drugs in the pipeline for 2023. CrowdStrike (NASDAQ:CRWD): Free cash flow in fiscal 2022 increased 51% to a record $442 million. Walgreens Boots Alliance (NASDAQ:WBA): Retail comparable sales growth of 14.7% stateside was the highest in 20 years. Now may be one of the best times to invest in long-term stocks. Tax season has arrived for around 170 million Americans. As of March 25, the IRS has issued 58 million refAmgen (NASDAQ:AMGN) today announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA® (ustekinumab) in adult patients with moderate to severe plaque psoriasis. The study met the primary efficacy endpoint, demonstrating no clinically meaningful differences between ABP 654 and STELARA.A deep dive into why I'm confident in the company's dividend;62.779998779296875;The proposal by an order of Roman Catholic nuns and a social-activist shareholder organization comes as biopharma spending on lobbying reaches into the tens of millions of dollars per year.SANTA MONICA, Calif., April 19, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland. The site will produce Kite’s FDA approved CAR T-cell therapy used to treat blood cancer.;716.219970703125;Initial data from a late-stage study comparing Amgen's (AMGN) Stelara biosimilar candidate with the original Stelara drug showed no clinically meaningful differences in treating plaque psoriasis.By Sam BougheddaProposed ~$250 million all-cash acquisition strengthens Regeneron’s portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 19, 2022 (GLOBERegeneron Pharmaceuticals  is a biotechnology company whose drugs have helped countless people.  In this daily bar chart of REGN, below, we can see that prices made a large equilateral triangle formation and broke out on the upside in early March.  Trading volume has not been particularly strong the past six weeks as prices rallied to new highs.Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.;159.74000549316406;A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.Shares of BioNTech (NASDAQ: BNTX) were sinking 8.2% as of 12:27 p.m. ET on Monday.  Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) stocks were down 5.3% and 6.4%, respectively.  There are different reasons behind each of these stocks sliding today.;342.2699890136719;Congratulations and thank you to the Illumina Singapore team on having Illumina ranked #1 Best Employer in our industry, and #17 overall, in Singapore by The Straits Times!Congratulations to Sam Samad, Illumina’s Chief Financial Officer (CFO), on being selected San Diego Business Journal’s 2022 CFO of the Year!;282.5199890136719;Today's Research Daily features Q1 earnings season scorecard and fresh reports on UnitedHealth(UNH), Danaher (DHR), Wells Fargo (WFC) & others.J&J (JNJ) reports mixed first-quarter results. It beats estimates for earnings but misses the same for sales. It cuts full-year outlook.;223.02000427246094;"Biogen stock looks ""too good to ignore,"" an analyst said Monday as he argued for the value of Biogen's base business.";176.9600067138672;"BeiGene Ltd (NASDAQ: BGNE) shared updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab combined with chemotherapy versus chemotherapy plus placebo in first-line recurrent or metastatic nasopharyngeal cancer. Updated efficacy analyses showed that, at a median follow-up of 15.5 months, tislelizumab/chemotherapy combo demonstrated a clinically significant progression-free survival (PFS) benefit over chemotherapy alone. The safety profile of the tislelizumab and chemotherapy coCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, April 19, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the presentation of updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab, a humanized anti-PD-1 monoclonal antibody, in combination with chemotherapy versus chemotherapy plus pl";144.2899932861328;;161.1999969482422;;413.25;;3.819999933242798;;80.58000183105469;;63.709999084472656;;79.47000122070312;;68.9800033569336;;54.59000015258789;Biotech giant Novavax (NASDAQ:NVAX) notched up another regulatory win for its coronavirus jab. The company’s protein-based vaccine, Nuvaxovid, was greenlit by regulators in Switzerland just days after it was approved in Thailand. Another approval is always good news for NVAX stock but the stock’s overall story is complicated. Swissmedic, the national surveillance authority for drugs in Switzerland, granted a conditional marketing authorization (CMA) to Nuvaxovid for those aged 18 or older. It’sNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that its partner, Takeda, received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare for its Nuvaxovid™ Intramuscular Injection (Nuvaxovid), Novavax' novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older. Nuvaxovid (NVX-CInvestors worry Novavax's protein-based vaccine, an alternative to mRNA jabs, is too late to the market.Is Novavax stock a buy on expectations for at least $4 billion in sales this year? Is NVAX stock a buy right now?Shares of BioNTech (NASDAQ: BNTX) were sinking 8.2% as of 12:27 p.m. ET on Monday.  Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) stocks were down 5.3% and 6.4%, respectively.  There are different reasons behind each of these stocks sliding today.;57.040000915527344;;97.77999877929688;;81.66999816894531;;76.80000305175781;;45.4900016784668;;67.23999786376953;;58.959999084472656;Investing in biotech companies can be risky. Biotechs are often a corporation wrapped around a hypothesis. If the hypothesis works out, riches can follow. But if not, the company can go bankrupt or be sold for pennies after years of frustration.;45.119998931884766;"Partners with One Tree Planted and Donates at least $25,000SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today, in celebration of Earth Day 2022, a partnership with the global charity One Tree Planted, to plant one tree in recognition of each one of its nearly 2,000 employees worldwide. “Planting a tree in honor of each one o";36.77000045776367;;22.760000228881836;Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.;10.800000190734863;;44.70000076293945;;28.309999465942383;;78.0999984741211;;42.5099983215332;;;;23.25;Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.;18.1200008392334;;6.739999771118164;;7.429999828338623;;40.959999084472656;;66.45999908447266;;61.099998474121094;;8.670000076293945;;41.68000030517578;;21.719999313354492;Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. The primary endpoint, a comparison of cumulative pain intensity scores over 24 hours between the ACP-044 1600 mg once daily, ACP-044 400 mg four times daily, and placebo treatment arms, was not met. A trend favoring the ACP-044 400 mg once every six hours treatment group was observed on the primary endpoint, a differSAN DIEGO, April 18, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. The primary endpoint, a comparison of cumulative pain intensity scores over 24 hours between the ACP-044 1600 mg once daily, ACP-044 400 mg four times daily and placebo treatment arms, was not met.;28.479999542236328;"Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. (""Janssen""), a subsidiary of Johnson & Johnson. Under these agreements, Janssen received access and rights to Alkermes' small particle pharmaceutical compound technology, known as NanoCrystal® Technology, which enabled a number of successful products, such as INVEGA SUSTENNA®, INVEGA TRINZA®, INVEGA HAFYERA® and CABENUVA®. Janssen part"
2022-04-20;255.3800048828125;Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.Amgen (AMGN) closed at $253.37 in the latest trading session, marking a +0.57% move from the prior day.Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;63.599998474121094;Big healthcare firms such as Bristol-Meyers, Cardinal Health, and AbbVie offer stability in this volatile market and, in some cases, steady dividends.Julie and her husband Bob were enjoying being empty nesters and getting ready to head on a beach vacation when Julie started feeling sick. A few weeks before the trip, Julie’s symptoms – a dry coug...;719.6199951171875;Regeneron (REGN) is set to acquire Checkmate Pharmaceuticals for $250 million to broaden its portfolio of diverse immuno-oncology candidates.Biotech stocks are down big since last summer.  The media's focus on gene editing, messenger RNA (mRNA), and monoclonal antibodies may have waned, but some patients are already benefiting.  Admittedly, shares of Regeneron are doing just fine.Shares of the clinical-stage cancer specialist Checkpoint Pharmaceuticals (NASDAQ: CMPI) are up by a handsome 328% as of 1:41 p.m. ET Tuesday afternoon.  The drugmaker's shares are racing higher today in response to a $250 million all-cash buyout offer from Regeneron Pharmaceuticals (NASDAQ: REGN).  Regeneron's tender offer of $10.50 per share represents a whopping 332% premium relative to Checkpoint Pharmaceuticals' closing price Monday afternoon.;153.67999267578125;Moderna's (MRNA) bivalent COVID booster candidate creates superior neutralizing antibodies compared to its currently authorized COVID vaccine mRNA-1273's booster dose against all variants of concern.Biotech stocks are down big since last summer.  The media's focus on gene editing, messenger RNA (mRNA), and monoclonal antibodies may have waned, but some patients are already benefiting.  Admittedly, shares of Regeneron are doing just fine.Arcus Biosciences (NYSE:RCUS): Cancer biotech having multiple big-pharma collaborations that ensure revenue streams Vir Biotechnology (NASDAQ:VIR): Diversified infectious disease play BioNTech (NASDAQ:BNTX): Potential for replicating its Covid-19 success with its rich oncology pipeline Beam Therapeutics (NASDAQ:BEAM): Gene-editing platform technology company has high-profile collaborations The overall market mood is risk averse, influenced by the macroeconomic uncertainty and intensification ofBioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $159.74, moving +0.11% from the previous trading session.;344.1700134277344;Investors are optimistic about Illumina's (ILMN) strategic collaborations and strong international sales.;285.29998779296875;Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone to treat schizophrenia faces rejection from the FDA.Moderna's (MRNA) bivalent COVID booster candidate creates superior neutralizing antibodies compared to its currently authorized COVID vaccine mRNA-1273's booster dose against all variants of concern.FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).Right now, I'm thinking of a biotech company that's a leader in its field, a healthcare services company that could represent the future of medical visits -- and a pharma player that's gaining in prescription drug market share.  Vertex Pharmaceuticals (NASDAQ: VRTX) recently did something it hasn't done in a long time.  The company's shares surpassed Wall Street's average 12-month forecast.UnitedHealth Group, Danaher, Wells Fargo, Vertex Pharmaceuticals and Canadian Pacific Railway have been included in this Analyst Blog.;220.42999267578125;Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.;172.00999450683594;;143.88999938964844;BOTHELL, Wash., April 20, 2022--Seagen Inc. (Nasdaq: SGEN) today announced plans to build a new facility in Everett, Washington, to expand the company’s biomanufacturing capacity and enable the company greater control and flexibility over the production of its medicines to treat cancer. The 270,000-square-foot facility will be built north of the company’s U.S. headquarters in Bothell, Washington. Seagen expects to have the facility operational in 2024 and ultimately employ up to 200 highly skill;167.9499969482422;Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...;424.6099853515625;;3.640000104904175;;80.61000061035156;;61.58000183105469;While Wall Street has been busy punishing the stock, which is down over 50% year to date, the total number of publications has skyrocketed.  The number of papers using the company's toolset has more than tripled since the start of 2020 and is up more than 50% over the last four quarters.  Maker of biotech instruments and associated consumables, 10x Genomics allows scientists to evaluate what is going on within a single cell.;78.70999908447266;Incyte's (NASDAQ:INCY) stock up by 6.3% over the past three months. Given its impressive performance, we decided to...;65.55999755859375;;53.689998626708984;By Sam BougheddaJapan’s health ministry on Tuesday formally approved Novavax's COVID-19 vaccine, a fourth foreign-developed tool to combat the infections as the country sees signs of a resurgence led by a subvariant of fast-spreading omicron.In the latest trading session, Novavax (NVAX) closed at $54.59, marking a -1.03% move from the previous day.;54.84000015258789;Biotech stocks are down big since last summer.  The media's focus on gene editing, messenger RNA (mRNA), and monoclonal antibodies may have waned, but some patients are already benefiting.  Admittedly, shares of Regeneron are doing just fine.;98.12000274658203;Mid-cap healthcare companies have built up a combination of competitive advantages. This article looks at several top stocks in the segment.;81.06999969482422;;76.38999938964844;;45.7599983215332;;67.55000305175781;;57.58000183105469;;45.0;"-- Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ETSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the three months ended March 31, 2022, after the closing of the U.S. equity markets on May 10, 2022. The Company will host a live";36.599998474121094;;22.989999771118164;;10.779999732971191;;43.77000045776367;;28.270000457763672;;78.72000122070312;Global study will evaluate UX143 in pediatric and young adult patients ages 5 to <26 years of ageNOVATO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the first patient has been dosed in a clinical study for the treatment of Osteogenesis Imperfecta (OI) in patients ages 5 to <26 years of age. T;43.310001373291016;;;;22.899999618530273;;18.170000076293945;;6.75;;7.010000228881836;;43.0;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 4th at 11:30 a.m. Eastern Time to discuss its first quarter financial results and report on pipeline and business progress.;66.22000122070312;;60.029998779296875;;8.460000038146973;;39.689998626708984;;22.31999969482422;In this article, we will discuss some of the popular stocks trending on Tuesday. To take a look at some more stocks that are moving, go to 5 Trending Stocks to Watch Today. The US stock market is on the rise today as all the 11 major S&P Sectors are in the green. Bank of […]Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced the primary endpoint miss of the phase 2 POC study of ACP-044 in acute postoperative pain following bunionectomy, a surgical procedure that moves toes back into the correct position. RBC Capital Markets writes that although trends of pain reduction were observed in the 400 mg QID ACP-044 arm compared to the placebo, the difference was not statistically significant. While disappointed, the analysts believe the low expectations should limit the sAcadia's (ACAD) phase II study, evaluating ACP-044 for treating acute pain following bunionectomy surgery, misses the primary endpoint. Stock down.;29.450000762939453;Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone to treat schizophrenia faces rejection from the FDA.In a recent article for Boston Business Journal, our head of Medical Affairs, Dr. Kanchan Relwani highlights the importance of patient-focused drug development and how we seek to incorporate the pa...
2022-04-21;255.4600067138672;Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.;63.75;NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a new Breakthrough Therapy designation request with the FDA for Zyesami focused on a subgroup of critical COVID-19 patients. The subgroup includes patients who were also treated with Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) in addition to aviptadil or placebo. The request includes safety data on approximately 750 patients treated with intravenous Zyesami for Critical COVID-19. NRx Pharmaceuticals submitted a Breakthrough Therapy d;706.1099853515625;Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.;147.83999633789062;Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.;335.7900085449219;;281.7099914550781;Centene's (CNC) first-quarter results are likely to reflect growing revenues attributable to a rise in premiums and membership, partly offset by lower investment income.Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. With this announcement, approximately 500 Canadians with CF ages 6-11 are now eligible for TRIKAFTA®. As a resulIn the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $285.30, marking a +0.98% move from the previous day.Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.;218.39999389648438;Biogen (NASDAQ: BIIB) has been a volatile investment over the past year.  From highs of more than $460 to lows of less than $193, investors have both made and lost a lot of money from the stock.  Since the start of the year, shares of Biogen are down around 7%.Since Biogen (NASDAQ: BIIB) got regulatory approval last year to sell its Alzheimer's disease drug, Aduhelm, things have gone from bad to worse.  Now, Biogen's shares are down more than 16% in the last six months, and if you bought this stock at practically any time in the last five years, you've lost (at least) some money.  The first reason to suspect that Biogen will eventually make a turnaround is that there is a massive market waiting to be penetrated if it does eventually commercialize an Alzheimer's therapy that's popularly recognized as being safe and effective.Prothena (PRTA) has had a phenomenal run in the past year, primarily due to its promising pipeline for AD.;164.72000122070312;"HOPEWELL, N.J. & CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, April 21, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, and Crossroads4Hope, A Network of Cancer Support, a 501(c)(3) organization committed to transforming the cancer experience for patients and their families across New Jersey, today announced a grant from BeiGene that will enable Crossroads4Hope to expand the reac";141.44000244140625;;168.75;;412.0899963378906;;3.450000047683716;;80.5;;55.709999084472656;;76.86000061035156;;60.97999954223633;;48.79999923706055;Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.In January, biotech company Novavax (NASDAQ: NVAX) finally completed its application for an emergency use authorization (EUA) for its coronavirus vaccine, NVX-CoV2373, in the U.S. The much-anticipated application came after the company ran into delays that pushed back its timeline to submit the EUA in the country.  Should investors give up on Novavax?  Novavax announced that it had completed its regulatory application to the U.S. Food and Drug Administration (FDA) for its COVID shot on Jan. 31.Novavax signaled a positive outlook for its vaccine pipeline Wednesday with announcements at the World Vaccine Congress and an update on its COVID-19 vaccine.Preliminary results from an early clinical study show the combined shot could be safe and effective.Anyone who bought Novavax (NASDAQ: NVAX) stock prior to 2020 and sold at the end of last year scored a big win.  The stock surged more than 3,400% over the past two years because investors bet on the company's coronavirus vaccine candidate.  Today, Novavax is back on the right track.Novavax (NASDAQ: NVAX), the vaccine specialist whose stock has been quite a seesaw at times, saw its share price dip by nearly 2% on Wednesday.  This was despite some good news in the clinical space announced by the company this morning.  Novavax unveiled the initial results from a phase 1/2 trial of its COVID-Influenza Combination (CIC) vaccine.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination Vaccine (CIC). The CIC combines Novavax' COVID-19 vaccine, NVX-CoV2373, and its quadrivalent influenza vaccine candidate. The CIC trial demonstrated that formulating the combination vaccine is feasible, well-tolerated and immunogenic.Novavax, which is still awaiting a federal decision for its stand-alone Covid vaccine, received early results that suggest it can move forward with its testing for the single shot for both viruses.Novavax has published the first clinical data for a combined Covid-19 and flu vaccine, with promising initial findings that a two-in-one shot could be safe and effective.  An initial analysis found that their immune responses were similar to that for Novavax’s standalone Covid-19 vaccine and its flu vaccine candidate, which is waiting for regulatory approval.  Novavax said that it expected to start a bigger phase 2 trial before the end of the year and the vaccine could be ready for rollout by the end of 2023.;50.5099983215332;;95.76000213623047;;77.3499984741211;;71.43000030517578;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the first quarter of 2022 along with recent corporate updates on May 4, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on May 4, company executives will provide company updates and review financial results.;42.7400016784668;PASADENA, Calif., April 20, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 10, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 second quarter ended March 31, 2022.;64.55000305175781;;55.529998779296875;;42.209999084472656;"Zai Lab’s engagement of an audit firm located in the United States is expected to facilitate the Company’s continued listing on Nasdaq because KPMG is subject to inspection by the PCAOBSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today that the Audit Committee of its Board of Directors has approved the engagement of KPMG aIn this piece, we will take a look at the ten biotechnology stocks to buy today according to Kerr Neilson’s Platinum Asset Management. If you want to skip the details about Mr. Neilson and his hedge fund, then jump ahead to the top five stocks in this list by heading to 5 Biotech Stocks to […]";34.52000045776367;;22.559999465942383;The company selected the Philadelphia area over Boston and expects to hire several hundred employees locally.;10.010000228881836;;42.099998474121094;;27.239999771118164;;75.22000122070312;;43.56999969482422;;;;21.90999984741211;;17.399999618530273;;6.420000076293945;;6.670000076293945;Every investor in Pacific Biosciences of California, Inc. ( NASDAQ:PACB ) should be aware of the most powerful...MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration with Children’s Mercy Kansas City, one of the nation’s top pediatric medical systems, to use the multi-omics capabilities of PacBio’s Sequel IIe system in the study of genetic disease. The research will apply direct methylation detection and Iso-Seq™ full-length RNA sequencing in their study. A bSignificant enhancements to the Sequel II/IIe platform include methylation calling in native DNA, greatly accelerated sample preparation, and support for gene therapy applicationsMENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the release of a transformative capability to detect DNA methylation using the Sequel IIe and Sequel II Systems. This extends PacBio’s unique and highlyMENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022, at 5:00 pm Eastern Time. The call will be webcast live and may be accessed at PacBio’s website at: https://investor.pacificbiosciences.com/. Date: Wednesday, May 4, 2022 Time: 5:00pm ET (2:00pm PT) Listen via Internet: https://investor.pacificbiosciences.com/ Toll-free: 866-652-5;43.0;;64.12999725341797;;55.75;NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the appointment of E. Rene Salas to the Intra-Cellular Therapies Board of Directors. Mr. Salas will serve as a member of the audit committee. “We are pleased to welcome Rene Salas to the Intra-Cellular Therapies Board,” said Dr. Sharon Mates, Chairman and;8.170000076293945;;35.41999816894531;SOUTH SAN FRANCISCO, Calif., April 21, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has joined the Storage Networking Industry Association (SNIA www.snia.org) as a voting member. SNIA is a nonprofit organization made up of storage professionals and is the globally recognized and trusted authority for storage leadership, standards and technology expertiseSOUTH SAN FRANCISCO, Calif., April 21, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Tracey Mullen, MBA to senior vice president of operations and Nimisha Srivastava, Ph.D. to senior vice president of research and development. In addition, Patrick Weiss will step down from his role as chief operating officer into a strategic advisor role for;21.34000015258789;In this piece, we will take a look at the nine healthcare stocks to invest in today according to Stanley Druckenmiller. If you want to jump ahead to the top five stocks in this list, then take a look at 5 Healthcare Stocks to Invest In Today According to Stanley Druckenmiller. Stanley Druckenmiller is a […]SAN DIEGO, April 21, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 4, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.;29.260000228881836;Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 27, 2022 to discuss the company's first quarter financial results. Management will also provide an update on the company.
2022-04-22;250.35000610351562;Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others and the biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.Set yourself up to collect a little extra cash while waiting for the market to figure out where it wants to go next.Amgen (AMGN) closed at $255.46 in the latest trading session, marking a +0.03% move from the prior day.;62.25;Gilead Sciences (GILD) closed the most recent trading day at $63.75, moving +0.24% from the previous trading session.Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;688.0800170898438;Regeneron (REGN) closed at $706.11 in the latest trading session, marking a -1.88% move from the prior day.These are the healthcare stocks with the best value, fastest growth, and most momentum for May 2022.;145.07000732421875;With coronavirus vaccine maker BioNTech (NASDAQ: BNTX) announcing  March 31 that it plans to conduct share repurchases of up to $1.5 billion over the next two years, investors are right to wonder whether the company is starting a new phase of its life.  Given that share repurchases are typically the purview of mature companies, the move is somewhat of a surprise for the biotech's investors.  It also opens the question of whether now is the right time to invest as the buybacks will push the stock a bit higher over time.;322.6700134277344;Ensemble Capital, an investment management firm, published its fourth-quarter 2021 investor letter – a copy of which can be seen here. While this recent quarter represents the fund’s largest degree of underperformance, so too did its 2020 results. In 2020 the Fund was up 30.89% vs the S&P 500 up 18.39% for 12.51% outperformance. It […]A raft of multicancer blood tests are under development that promise early detection. Our verdict on Grail’s Galleri: An exciting innovation that’s far from routine use.;270.4200134277344;"Intercept (ICPT) lead drug Ocaliva holds ground amid challenges. A positive readout from the NASH studies will be a good boost for the stock in the year ahead.Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals have been included in this Analyst Blog.Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $281.71, moving -1.26% from the previous trading session.BOSTON, April 21, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1 (412) 902-6510 (International) and reference the ""Vertex Pharmaceuticals First Quarter 2022 Earnings Call"".";209.99000549316406;"Biogen Inc. shares fell 2% Friday, after the company said it has withdrawn the marketing authorization application for its controversial Alzheimer's treatment aducanumab with the European regulator because early communications suggest the data is not sufficient to gain a positive opinion. ""We stand by the safety and efficacy of aducanumab, and we look forward to upcoming data readouts to continue to provide important information on the science of this new class of compound,"" Priya Singhal, headBiogen Inc said on Friday it will withdraw the marketing application for its controversial Alzheimer's drug, aducanumab, in Europe after the U.S. biotech company failed to convince the European regulator of the treatment's benefits.  Biogen shares were down $7.54, or 3.5%, at $210.86.  The drugmaker said the move follows interactions with the European Medicines Agency that suggested data provided so far would not be enough to support an approval.By Sam BougheddaIn the latest trading session, Biogen Inc. (BIIB) closed at $218.40, marking a -0.92% move from the previous day.";163.77999877929688;;138.0;The Bothell-based company expects the 270,000-square-foot project to open in 2024 and employ up to 200 workers.Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;167.0;Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;402.989990234375;;3.4000000953674316;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced plans to significantly expand its platform capabilities in agricultural biologicals, from discovery to field. These capabilities will be built through a series of transactions, in which Ginkgo will acquire Bayer's 175,000-square-foot West Sacramento Biologics Research & Development site, team, and internal discovery and lead optimization platform as well as integrate the R&D platform assets from Jo;80.5;;53.900001525878906;;76.58000183105469;WILMINGTON, Del., April 22, 2022--Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer;60.68000030517578;A raft of multicancer blood tests are under development that promise early detection. Our verdict on Grail’s Galleri: An exciting innovation that’s far from routine use.;46.650001525878906;Novavax Inc (NASDAQ: NVAX) has initiated the administration of the first booster doses of NVX-CoV2373 in the pediatric expansion of the PREVENT-19 pivotal Phase 3 trial. The study will evaluate the safety and immunogenicity of a third dose of NVX-CoV2373 among trial participants aged 12 through 17. All PREVENT-19 trial participants aged 12 through 17 are now eligible to receive a third booster dose of NVX-CoV2373. Related: Novavax's COVID-19/Influenza Combo Vaccine Shows Immunogenicity In Early-Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, has initiated administration of the first booster doses of NVX-CoV2373, the company's protein-based COVID-19 vaccine, in the pediatric expansion of the PREVENT-19 pivotal Phase 3 clinical trial. The study will evaluate the safety and immunogenicity of a third dose of NVX-CoV2373 among trial participants aged 12 through 17.;50.65999984741211;While CRISPR has come of age in one sense, gene-editing is still a nascent science, with broad potential as well as challenges. Nessan Bermingham spoke with the Business Journal about the future of the field.;93.62000274658203;;76.4000015258789;;69.68000030517578;;42.65999984741211;;63.52000045776367;;55.68000030517578;;43.38999938964844;;34.630001068115234;SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 4, 2022 at 5:00 PM ET to report its first quarter 2022 financial results and provide a corporate update. In order to participate in the;22.420000076293945;;10.020000457763672;;42.13999938964844;;26.75;;75.05999755859375;Physician researcher and biopharmaceutical executive to join R&D Committee Amrit Ray, M.D., M.B.A. Amrit Ray, M.D., M.B.A. NOVATO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the appointment of Amrit Ray, M.D., M.B.A. to the company’s Board of Directors. Dr. Ray will serve on the Board’s ReseUltragenyx (RARE) doses the first patient in a pivotal phase II/III study evaluating setrusumab (UX143) for the treatment of osteogenesis imperfecta.;43.529998779296875;Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.;;;21.459999084472656;SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022. The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir BiotechnologyVir Biotechnology is a commercial-stage immunology company;16.950000762939453;;6.360000133514404;;6.820000171661377;;41.72999954223633;;62.400001525878906;;52.439998626708984;;7.980000019073486;;34.209999084472656;;20.43000030517578;;28.200000762939453;April marks National Minority Health Month, a time for us to reflect on the work still needed to address and break down existing barriers that keep minority communities from seeking mental health c...
2022-04-25;252.1699981689453;Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) first-quarter 2022 results.Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Five Dow stocks with positive Earnings ESP will report earnings results this week. These are: V, Ko, MRK, CVX and AMGN.;62.650001525878906;Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) first-quarter 2022 results.Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.FOSTER CITY, Calif., April 24, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced findings from two studies, which provide further insights on the use of Veklury® (remdesivir) for the treatment of hospitalized and non-hospitalized patients with COVID-19. The first study is a retrospective observational analysis of the real-world treatment data from the Premier Healthcare Database consisting of 853,219 patients hospitalized with COVID-19 across the United States. This analysis found that;690.3300170898438;Roche (RHHBY) performance in the first quarter was encouraging, driven by demand for COVID-19 tests and contribution from newer drugs.;155.10000610351562;;319.1000061035156;QGEN vs. ILMN: Which Stock Is the Better Value Option?Anderson, a partner at Baillie Gifford, is one of the preeminent growth-stock investors of his time. As he prepares to step down, he’s more optimistic than ever.;271.67999267578125;Roche (RHHBY) performance in the first quarter was encouraging, driven by demand for COVID-19 tests and contribution from newer drugs.Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.;214.5399932861328;;162.8000030517578;Yahoo Finance Live’s Julie Hyman joins the Live show to discuss the COVID-19 wave concerns in China that have prompted a sell-off in global markets.;138.5399932861328;;162.07000732421875;;400.9100036621094;;3.880000114440918;;81.87999725341797;;55.04999923706055;;76.55999755859375;;62.63999938964844;;50.209999084472656;;53.59000015258789;;93.76000213623047;;76.69999694824219;;70.54000091552734;;43.90999984741211;PASADENA, Calif., April 25, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines in Greater China. The company also announced that it has entered into a license agreement with Visirna, pursuant to which Visirna will have exclusive rights to develop and commercialize four of Arrowhead’s investigational RNA interference (RNAi) therapeutics for cardiometabolic disea;65.0999984741211;;57.27000045776367;;45.88999938964844;;35.45000076293945;;22.84000015258789;;10.09000015258789;;44.22999954223633;;27.100000381469727;;75.66000366210938;;44.61000061035156;;;;22.920000076293945;Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.;17.200000762939453;;6.309999942779541;;7.190000057220459;;42.34000015258789;;63.33000183105469;;53.18000030517578;"CAPLYTA label now includes dosage recommendations for specific patient populations; those with moderate or severe hepatic impairment and patients who are concomitantly taking moderate or strong CYP3A4 inhibitors.NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration";8.0600004196167;;34.22999954223633;;20.260000228881836;;28.469999313354492;
2022-04-26;249.8699951171875;Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.Amgen, Chevron, Coca-Cola, Visa and Merck have been included in this Analyst Blog.;61.77000045776367;"The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.Today we announced our support of the Robert A. Winn Diversity in Clinical Trials Award Program, a five-year initiative launched by the Bristol Myers Squibb Foundation to increase diversity in clin...The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental marketing application for Veklury (remdesivir) for pediatric COVID-19 patients older than 28 days. The approval covers patients weighing at least 3 kg and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe infection. This approval follows the recent FDA nod for Veklury for non-hospitalized adult and adolescent patients at high risk of progression to sFOSTER CITY, Calif., April 25, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Veklury® (remdesivir) for the treatment of pediatric patients who are older than 28 days, weighing at least 3 kg, and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe COVID-19, including hospitalization or death. This approThe U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences Inc's drug remdesivir.  The move comes months after the agency expanded the drug's emergency use authorization to also include children below 12 years of age weighing at least 3.5 kilograms.  The Food and Drug Administration's (FDA) decision makes the drug the first approved COVID-19 treatment for children less than 12 years of age, the agency said.The Food and Drug Administration said Monday it expanded the approval of Gilead Sciences Inc.'s Veklury to include pediatric patients between the ages of four weeks and 12 years old. (Infants must also weigh at least seven pounds.) Veklury is a COVID-19 treatment for patients who have been hospitalized or who have mild or moderate infections but are at high risk of severe COVID-19. The drug previously received emergency authorization for this group of pediatric patients. ""As COVID-19 can cause s";674.8200073242188;Regeneron (REGN) closed at $690.33 in the latest trading session, marking a +0.33% move from the prior day.;147.9499969482422;Mainz, Germany, April 26, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2022 on Monday, May 9th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2022. The slide presentation and audio of the webcast wilNovavax's (NVAX) begins administering a third/booster dose of its COVID-19 vaccine in adolescents aged between 12 years and 17 years in a pivotal late-stage study.;301.44000244140625;How genomics provided critical answers—and in record time—to transform outcomes for a newborn and his family;267.69000244140625;Quidel's (QDEL) first-quarter results are likely to reflect continued strength across its SARS-related products.Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.AbbVie's (ABBV) first-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to focus on any update related to Humira LOE.The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.;206.99000549316406;It's been a forgettable year for Biogen (NASDAQ: BIIB).  Total revenue is down year over year from $13.4 billion to $11 billion, and the company is guiding even lower for 2022.  Just last week, the company announced it had officially withdrawn its Alzheimer's drug, Aduhelm, from consideration for authorization in Europe.;152.57000732421875;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, April 26, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today introduced the Company’s global environmental, social, and governance (ESG) strategy.Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (""Biocytogen"") reached an agreement with BeiGene (Beijing) Co., Ltd. (""BeiGene"") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen's fully human antibody RenMab™/RenLite™ mice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.";131.58999633789062;;155.0;;382.1300048828125;Bio-Techne Corporation (NASDAQ: TECH) today announced that it has been included on the Forbes list of Best Employers for Diversity 2022. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list can currently be viewed on the Forbes website.;3.690000057220459;;79.29000091552734;Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.;52.400001525878906;;74.1500015258789;The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.;58.630001068115234;;47.41999816894531;Novavax's (NVAX) begins administering a third/booster dose of its COVID-19 vaccine in adolescents aged between 12 years and 17 years in a pivotal late-stage study.;49.849998474121094;;91.80000305175781;;72.80999755859375;;65.93000030517578;;40.90999984741211;PASADENA, Calif., April 26, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). ARO-ANG3 is the company’s investigational RNA interference (RNAi) therapeutic designed to silence the hepatic expression of angiopoietin-like protein 3 (ANGPTL3), a liver synthesized inhibitor of lipoprotein lipase an;61.380001068115234;Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 3, 2022 to report its first quarter 2022 financial results and provide a corporate update.;52.79999923706055;;41.220001220703125;;32.439998626708984;Stock jumps 140% on news of positive outcomes;22.25;Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe, who most recently served as President and Chief Financial Officer of Myovant Sciences, Inc. (NYSE:MYOV), brings over twenty-five years of financial and life-sciences expertise to Phathom. “We areExelixis is the IBD Stock Of The Day as it adds onto a lengthy consolidation ahead of a key test for its headliner cancer treatment.;9.170000076293945;;40.16999816894531;;24.700000762939453;Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;70.73999786376953;Ultragenyx 2021 ESG report - title page Ultragenyx 2021 ESG report - title page NOVATO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today issued its inaugural ESG report. The new report provides an overview of the Company's ESG milestones, commitments and aspirations. “From the earliest days at Ultragenyx we;42.97999954223633;"Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. (""Purchaser""), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ: ATRS) (""Antares"") for $5.60 per share in cash. The offer is being made pursuant to the previously announced Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme, Purchaser and Antares (the ""Merger Agre";;;21.959999084472656;;16.100000381469727;;5.889999866485596;;6.670000076293945;;40.119998931884766;;58.36000061035156;;51.7400016784668;;7.559999942779541;The big shareholder groups in AbCellera Biologics Inc. ( NASDAQ:ABCL ) have power over the company. Large companies...;31.290000915527344;;18.940000534057617;;27.139999389648438;Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.Alcohol use disorder is a debilitating disease that impacts millions of people every day, and the stigma surrounding it prevents people from seeking help. This Alcohol Awareness Month, we encourage...
2022-04-27;248.7899932861328;Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER cardiovascular outcomes trial. The studies were designed to assess the long-term safety and tolerability of Repatha over five years in adults with clinically evident atherosclerotic cardiovascular disease.Shares of Molecular Partners Inc. slid 37.3% in premarket trading on Wednesday, the day after the company said Amgen Inc. returned the global rights to an investigational oncology therapy currently in a Phase 1 clinical trial targeting solid tumors. Amgen's stock was up 0.3% in the premarket on Wednesday. Molecular said it will seek new partners. Molecular's stock is down 55.4% this year, while the broader S&P 500 has declined 12.4%.Molecular Partners AG's (NASDAQ: MOLN) collaborating partner Amgen Inc (NASDAQ: AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners following a strategic pipeline review. MP0310 is a dual-targeted compound targeting both FAP and 4-1BB that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming to avoid systemic side effects associated with 4-1BB activation. Given this mode of action, future development;61.59000015258789;A report from the Centers for Disease Control and Prevention is highlighting just how many Americans have been infected with COVID-19, and how much the number increased since the arrival of the highly infectious omicron variant late last year.Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.FOSTER CITY, Calif., April 26, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:Johnson & Johnson has filed a lawsuit against drug distributors and a pharmacy seeking to stop the sale of counterfeit versions of its HIV drugs, months after a similar case brought by Gilead Sciences Inc.  In a complaint filed April 7 and made public on Tuesday, J&J said it had learned of widespread counterfeiting through complaints from patients who received the wrong pills in their prescription bottle, and from the voluntary return of hundreds of bottles of counterfeit drugs from one of the defendants, distributor ProPharma Distribution LLC.  The company also said that distribution of counterfeit versions of its HIV pills had come to light through Gilead's lawsuit https://www.reuters.com/article/gilead-sciences-hiv-idCNL4N2TY48H, filed in January.;673.510009765625;;144.44000244140625;BioNTech SE and Pfizer Inc. said Tuesday that they expect to share data from a clinical trial evaluating their COVID-19 vaccines in children between the ages of 6 months and 5 years old sometime before the end of June. The announcement was included in a news release stating that the companies requested Food and Drug Administration authorization for a COVID-19 booster dose in children between the ages of 5 and 11 years old. Back in February, BioNTech and Pfizer said that they amended their FDA auBioNTech SE and Pfizer Inc. said Tuesday that they asked the Food and Drug Administration to authorize a COVID-19 booster dose for children between the ages of 5 and 11 years old. Boosters are already authorized for teens and adults. The companies said data from a Phase 2/3 clinical trial yielded no new safety concerns when children in this age group received a booster six months after completing the primary series of shots. So far this year, BioNTech's stock has tumbled 43.6% and Pfizer sharesPfizer  and  BioNTech  are seeking emergency use authorization for Covid-19 booster shots for use in five- to 11-year-olds, the companies said in a press release.  The request included data from Phase 2 and 3 trials, data which “demonstrated a strong immune response in this age group following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine with no new safety signals.”  Pfizer stock has declined 0.4% in after-hours trading, while BioNTech is unchanged.Pfizer Inc and its partner BioNTech SE said on Tuesday that they had submitted an application to the U.S. health regulator for the authorization of a booster dose of their COVID-19 vaccine for children aged 5 to 11 years.  The companies earlier this month reported data from a mid-to-late stage study showing a third dose of their shot increased protection against the original coronavirus version and the Omicron variant among children in the age group.  Just 28% of children aged 5 to 11 years - around 8.2 million - are fully vaccinated, according to data from the U.S. Centers for Disease Control and Prevention.;297.5400085449219;Hannover Medical School study will evaluate the use of whole-genome sequencing to show positive impact of earlier diagnosis and treatment for children with suspected genetic disorders;267.25;;206.94000244140625;Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the first quarter.Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;157.8000030517578;"CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland, April 27, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced presentations from the Company’s global clinical development programs in hematologic malignancies and solid tumors at the 2022 Annual Meeting of the American Society of Cancer Oncology (ASCO) being hNovartis AG (NYSE: NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic ESCC, regardless of PD-L1 expression. Novartis intends to submit these data to regulatory autCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, April 27, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the Independent Data Monitoring Committee (IDMC) determined at a pre-planned interim analysis that RATIONALE 306, a global Phase 3 trial of tislelizumab in combination with chemotherapy, had met the";130.44000244140625;;154.9199981689453;;380.92999267578125;;3.430000066757202;;80.30999755859375;;50.790000915527344;10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.;74.43000030517578;Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;62.52000045776367;Robust performances by the Screening and Precision Oncology segments drove Exact Sciences' (EXAS) first-quarter top line.View more earnings on EXASSee more from BenzingaNovartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer TrialAchieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking CessationDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Exact Sciences raised its sales guidance for 2022 and said its Cologuard colon cancer test will prove more accurate than rival's blood-based cancer DNA screens.Ladies and gentlemen, thank you for standing by, and welcome to the Exact Sciences Corp. first quarter 2022 earnings call.  Megan Jones, senior director of investor relations, you may begin your conference.  Thank you for joining us for Exact Sciences' first quarter 2022 conference call.Exact Sciences (EXAS) delivered earnings and revenue surprises of 7.14% and 5.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;46.459999084472656;;49.34000015258789;;91.52999877929688;;74.0;CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, May 4, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2022 financial results and to provide a corporate update. The conference call may be accessed by dialing (800) 895-3361 for domes;64.6500015258789;;41.61000061035156;PASADENA, Calif., April 27, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a pulmonary research & development (R&D) day to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates from 10:00 a.m. to 1:00 p.m. ET on May 26, 2022, in New York City. The R&D day will feature presentations from key opinion leaders, Mario Castro, M.D., MPH (University of Kansas Medical Center) and Matthias Salathe, M.D. (University of Kan;59.72999954223633;;51.959999084472656;Stocks with huge growth potential usually come with additional risk.  Stock valuations usually reflect potential gains, but companies with fantastic upside potential usually face tons of uncertainty.  Every investor needs to figure out their ideal balance of risk and reward and allocate accordingly.;42.77000045776367;;31.8700008392334;;22.600000381469727;ALAMEDA, Calif., April 26, 2022--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.;8.770000457763672;;39.83000183105469;;25.09000015258789;;70.9800033569336;Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;41.9900016784668;;;;21.3700008392334;Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 – – Virtual R&D Day webcast scheduled for today, Wednesday, April 27, at 12:00 pm ET / 9:00 am PT – SAN FRANCISCO, April 27, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will review its robust hepatitis portfolio, including initial data from the first cohort of the MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial evaluating;15.449999809265137;;5.840000152587891;;6.639999866485596;;39.86000061035156;;57.59000015258789;Arvinas, Inc. (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;53.04999923706055;;7.760000228881836;VANCOUVER, British Columbia, April 26, 2022--AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022;30.219999313354492;;18.989999771118164;;30.3799991607666;
2022-04-28;238.1300048828125;Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.The Dow Jones Industrial Average jumped Thursday, as Facebook soared 18% on earnings results. Apple earnings are due after the market closes.View more earnings on AMGNSee more from BenzingaThe Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In ZentalisMolecular Partners Regains Rights To Early-Stage Cancer Asset From AmgenDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Biotech firm Amgen is disputing the claims, which relate to how it accounts for profits from its Puerto Rico operations.The following are the top stories in the Wall Street Journal.  - Archegos Capital Management founder Bill Hwang and its former chief financial officer, Patrick Halligan, were indicted on securities fraud and racketeering charges Wednesday in what prosecutors said was a massive fraud and manipulation scheme that nearly jeopardized the U.S. financial system.  - SpaceX blasted four astronauts to the International Space Station on Wednesday morning in a mission that comes as billionaire founder Elon Musk prepares to add Twitter Inc to the roster of companies he runs.Amgen stock fell late Wednesday on a surprise in its 2022 outlook despite a strong first-quarter showing with earnings and sales above views.Amgen (AMGN) delivered earnings and revenue surprises of 0.71% and 2.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Amgen Inc. on Wednesday logged better-than-expected revenue and a decline in profit in the first quarter.Amgen Inc on Wednesday said the U.S. Internal Revenue Service (IRS) is seeking additional back taxes of $5.1 billion, plus interest and penalties, related to the drugmaker's 2013 to 2015 accounting for profits between the United States and Puerto Rico, the location of most of its manufacturing operations.  Shares of Amgen, which also reported higher first-quarter revenue and earnings, were down more than 6% at $233 in extended trading.  Amgen was already in the process of disputing a previous IRS decision to increase the company's taxable income for 2010-2012 by an amount that would result in additional federal tax of around $3.6 billion, plus interest.(Reuters) -Amgen Inc on Wednesday said the U.S. Internal Revenue Service (IRS) is seeking additional back taxes of $5.1 billion, plus interest and penalties, related to the drugmaker's 2013 to 2015 accounting for profits between the United States and Puerto Rico, the location of most of its manufacturing operations.  Shares of Amgen, which also reported higher first-quarter revenue and earnings, were down more than 6% at $233 in extended trading.  Amgen was already in the process of disputing a previous IRS decision to increase the company's taxable income for 2010-2012 by an amount that would result in additional federal tax of around $3.6 billion, plus interest.Amgen Inc on Wednesday said the U.S. Internal Revenue Service (IRS) is seeking additional back taxes of $5.1 billion, plus interest and penalties, related to the drugmaker's 2013 to 2015 accounting for profits between the United States and Puerto Rico, the location of most of its manufacturing operations.  Amgen is already in the process of disputing a previous IRS decision to increase the company's taxable income for 2010-2012 by an amount that would result in additional federal tax of around $3.6 billion, plus interest.  Also on Wednesday, Amgen said its first quarter revenue rose 6% to $6.2 billion as product sales increased 2%, and it posted higher revenue from an agreement to manufacture COVID treatments sold by Eli Lilly and Co.Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2022. Key results include:;61.560001373291016;Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.;675.5800170898438;Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines. Consumer healthcare sales remain strong.Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;143.39999389648438;Moderna starts its filing for an emergency use authorization of its COVID-19 vaccine in kids under 6 years.Former U.S. Surgeon General Dr. Jerome Adams joins Yahoo Finance Live to discuss the potential end to the pandemic, COVID-19 application submissions, and the availability of quality masks.Europe says pandemic is entering a new phase where it must respond flexibly, but Brussels warns “we must not lower our guard.”;303.05999755859375;Illumina (NASDAQ: ILMN) leads the genome sequencing industry with a 90% market share in the U.S. and a 75% share globally.  Here are a couple of reasons why investors might want to pick up shares of Illumina, and one issue that might give them pause.  You might expect a company that dominates the genome sequencing market would invest heavily in research and development.;268.6400146484375;;210.41000366210938;Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.In the latest trading session, Biogen Inc. (BIIB) closed at $206.94, marking a -0.02% move from the previous day.Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.;158.4499969482422;"MONTEVIDEO, Uruguay & CAMBRIDGE, Mass & BEIJING, April 28, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the BTK inhibitor BRUKINSA (zanubrutinib) has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma (MCL), relapsed or refractory marginal zon";130.22999572753906;BOTHELL, Wash., April 28, 2022--Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its expanding pipeline of marketed and investigational therapies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022 in Chicago. The accepted abstracts demonstrate the growth of Seagen’s portfolio and clinical progress across multiple cancer types, including cervical and urothelial cancers and pediatric and adult Hodgkin lymphoma. Ground;143.16000366210938;Alnylam (ALNY) delivered earnings and revenue surprises of -3.63% and 12.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?CAMBRIDGE, Mass., April 28, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2022 and reviewed recent business highlights.;386.8900146484375;;3.119999885559082;;82.63999938964844;BioMarin (BMRN) delivered earnings and revenue surprises of 44.74% and 2.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (BioMarin or the Company) today announced financial results for the first quarter ended March 31, 2022.;49.9900016784668;10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;75.4000015258789;Incyte's (INCY) top line is likely to have been driven in the first quarter by the sales of its lead drug, Jakafi.;57.529998779296875;Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence Score® test in early-stage breast cancer patients has been expanded by the American Society of Clinical Oncology (ASCO) in its 2022 Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer guideline update.i;44.27000045776367;Former U.S. Surgeon General Dr. Jerome Adams joins Yahoo Finance Live to discuss the potential end to the pandemic, COVID-19 application submissions, and the availability of quality masks.;50.290000915527344;CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2022 financial results and operational highlights in a conference call on May 5, 2022, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five;91.68000030517578;Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;74.16000366210938;Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;64.2699966430664;Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibitor, adagrasib, in a study of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 to 7, 2022 in Chicago, IL.;42.310001373291016;;60.22999954223633;;51.619998931884766;;39.93000030517578;91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the duration of response (DOR) range was 3.6+-7.5+ months with median DOR follow-up of 3.7 months 36-67% cORR by BICR in China subpopulation across three TKI-pretreated cohorts (EXP-2, EXP-3, and EXP-4)Zai Lab plans to discuss topline TKI-naïve data with Chinese health authority in the fourth quarter of91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the duration of response (DOR) range was 3.6+-7.5+ months with median DOR follow-up of 3.7 months 36-67% cORR by BICR in China subpopulation across three TKI-pretreated cohorts (EXP-2, EXP-3, and EXP-4)Zai Lab plans to discuss topline TKI-naïve data with Chinese health authority in the fourth quarter of;31.649999618530273;Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;22.770000457763672;;8.65999984741211;;39.56999969482422;;25.040000915527344;;71.16999816894531;NOVATO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 5:00pm ET to discuss its financial results and corporate update for the quarter ended March 31, 2022. The live and replayed webcast of the call will be available through the com;41.5;;;;21.600000381469727;;15.5;;6.050000190734863;;6.550000190734863;Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;39.54999923706055;Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;56.2400016784668;;51.63999938964844;;7.880000114440918;;30.200000762939453;SOUTH SAN FRANCISCO, Calif., April 28, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of synthetic DNA using its silicon platform, today announced the launch of the Twist High Throughput Antibody Production, a gene-to-antibody production platform that enables customers to turn candidate DNA sequences into purified antibodies for therapeutic discovery and screening applications.;18.959999084472656;Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;29.790000915527344;
2022-04-29;233.19000244140625;AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.Yahoo Finance's Ines Ferre joins the Live show to look at markets closing ahead of the bell, as well as the sector action, Nasdaq leaders, and the semiconductor industry.In this article, we will take a look at the 11 stocks making big moves on earnings reports. You can skip our detailed analysis of these companies and go directly to the 5 Stocks Making Big Moves on Earnings Reports. Social network giant Meta Platforms, Inc. (NASDAQ:FB), semiconductor giant QUALCOMM Incorporated (NASDAQ:QCOM) and online payments […](Bloomberg) -- Shares of Amgen Inc. fell the most in a year after the company disclosed that it is facing a potential tax bill of at least $7.1 billion from the U.S. Internal Revenue Service.Most Read from BloombergFour European Gas Buyers Made Ruble Payments to RussiaPutin Is Losing So Here’s How He’ll Make the War WorseElon Musk Offloads $4 Billion of Tesla Shares, Pledges No More SalesU.S. Economy Posts Surprise Contraction, Belying Solid Consumer PictureStocks Surge Before Amazon Casts Shado;59.34000015258789;Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.This Earth Day, we’re highlighting our longstanding commitment to environmental stewardship. We’ll continue to accelerate our efforts to reduce greenhouse gas emissions, minimize waste generation a...Thank you for standing by, and welcome to the Gilead Sciences first quarter 2022 earnings conference call.  The press release, slides and supplementary data are available on the Investors section of our website at gilead.com.  The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day, our chief commercial officer, Johanna Mercier, our chief medical officer, Merdad Parsey, and our chief financial officer, Andrew Dickinson.Gilead (GILD) delivered earnings and revenue surprises of 19.77% and 6.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Gilead beat first-quarter estimates on Thursday, though offered a profit view that was a penny light at the midpoint, and GILD stock fell.Gilead Sciences Inc on Thursday said its first-quarter revenue rose 3%, helped by sales of HIV drug Biktarvy and COVID antiviral Veklury, but the company reported a net loss as it wrote down the value of its 2020 acquisition of Immunomedics following recent trial results for cancer drug Trodelvy.  The biotech company said adjusted earnings rose 4% from a year ago to $2.12 per share, topping the average analyst estimate of $1.81, as compiled by Refinitiv.  Revenue for the quarter rose to $6.6 billion from $6.4 billion, ahead of Wall Street estimates of $6.27 billion.Gilead Sciences Inc on Thursday said its first-quarter revenue rose 3%, helped by sales of HIV drug Biktarvy and COVID antiviral Veklury, but the company reported a net loss as it wrote down the value of its 2020 acquisition of Immunomedics following recent trial results for cancer drug Trodelvy.  The biotech company said adjusted earnings rose 4% from a year ago to $2.12 per share, topping the average analyst estimate of $1.81, as compiled by Refinitiv.  Revenue for the quarter rose to $6.6 billion from $6.4 billion, ahead of Wall Street estimates of $6.27 billion.FOSTER CITY, Calif., April 28, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2022.;659.1099853515625;Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.;138.77999877929688;Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the first quarter.The coronavirus vaccine race might be over, but that doesn't make BioNTech (NASDAQ: BNTX) any less relevant.  With more than 2.6 billion doses delivered in 2021 and more than $20.2 billion in sales, the Comirnaty COVID-19 vaccine it developed jointly with Pfizer is BioNTech's only source of revenue.For most investors, the story of BioNTech (NASDAQ: BNTX) will always start with the pandemic and its partnership with Pfizer (NYSE: PFE) to deliver Comirnaty, the messenger RNA (mRNA) vaccine for COVID-19.  The coronavirus vaccine and its history of cancer research are a combination that could produce blockbusters, making its shares worth much more than the market is pricing in.  Here's more on these three things smart investors already know about BioNTech.BioNTech SE Sponsored ADR (BNTX) closed at $143.40 in the latest trading session, marking a -0.72% move from the prior day.Yahoo Finance's Anjalee Khemlani details the latest information surrounding Moderna's FDA filing to authorize a COVID vaccine for children, as well as looking at Merck's Q1 earnings beat attributed to its COVID treatment pill.;296.6499938964844;Illumina’s Open Innovation programs work with partners to change livesIllumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:;273.2200012207031;;207.44000244140625;AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.Biogen Inc. (BIIB) closed at $210.41 in the latest trading session, marking a +1.68% move from the prior day.;160.0;HOPEWELL, N.J. & CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, April 29, 2022--BeiGene announced the groundbreaking of its flagship U.S. manufacturing, clinical R&D center at the Princeton West Innovation Campus in Hopewell, N.J.;131.00999450683594;Seattle Genetics (SGEN) delivered earnings and revenue surprises of 24.49% and 4.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?BOTHELL, Wash., April 28, 2022--Seagen Inc. (Nasdaq:SGEN) reported financial results today for the first quarter ended March 31, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline.;133.42999267578125;Eighteen of the 40 people in the first section of Vir's midstage clinical trial are enrolled in Ukraine or neighboring Moldova.;379.69000244140625;;2.9000000953674316;;81.3499984741211;Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.Alkermes (ALKS) rides high on both earnings and sales beating estimates in the first quarter of 2022.;47.7599983215332;;74.95999908447266;WILMINGTON, Del. & OSAKA, Japan, April 28, 2022--Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan;55.04999923706055;;45.06999969482422;Novavax could know more about the fate of its experimental Covid-19 vaccine in a little more than a month.  The Food and Drug Administration said Friday it plans to hold a Vaccines and Related Biological Products Advisory Committee meeting June 7 to discuss the Gaithersburg biotech’s emergency use authorization request for the candidate.  Then the Advisory Committee on Immunization Practices, part of the Centers for Disease Control and Prevention, would issue policy recommendations on how the vaccine should be used, the company confirmed to the Washington Business Journal.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) will review NVX-CoV2373 COVID-19 Vaccine (recombinant, adjuvanted) for active immunization against SARS-CoV-2 at a meeting scheduled for June 7, 2022. VRBPAC reviews and evaluates data regarding the safety anSan Francisco's Bay Area Rapid Transit system is reinstating a face-mask mandate for riders, making it the only big transit system in the region to do so, as it moves to protect at-risk individuals including children.Shares of Novavax Inc. jumped 10.8% in trading on Friday after the Food and Drug Administration announced that an advisory committee is set to meet June 7 to examine the benefits and risks of the company's experimental COVID-19 vaccine. Novavax's protein-based vaccine has been authorized in several countries, including by the U.K. and the European Commission, but is still being reviewed by the FDA. The company's stock has tumbled 65.6% this year, while the broader S&P 500 is down 10.0%.Yahoo Finance's Anjalee Khemlani details the latest information surrounding Moderna's FDA filing to authorize a COVID vaccine for children, as well as looking at Merck's Q1 earnings beat attributed to its COVID treatment pill.;49.029998779296875;;90.02999877929688;;72.31999969482422;;61.790000915527344;;41.11000061035156;;58.349998474121094;;49.619998931884766;;39.959999084472656;;28.559999465942383;;22.34000015258789;Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.;8.020000457763672;In the latest trading session, BridgeBio Pharma (BBIO) closed at $8.66, marking a -1.25% move from the previous day.;37.529998779296875;;23.799999237060547;;70.69000244140625;Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...;39.900001525878906;;;;20.350000381469727;Eighteen of the 40 people in the first section of Vir's midstage clinical trial are enrolled in Ukraine or neighboring Moldova.Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;15.520000457763672;;6.019999980926514;Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that presentations of clinical study data on its investigational therapy KSI-301 will be made at two upcoming vision research conferences: the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting in Denver, Colorado, and Retina World Congress 2022 in Fort Lauderdal;6.340000152587891;;36.7599983215332;;54.970001220703125;;50.61000061035156;;7.670000076293945;;28.84000015258789;Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;18.440000534057617;;28.850000381469727;
2022-05-02;230.9199981689453;Amgen (NASDAQ:AMGN) today released its 2021 Environmental, Social & Governance (ESG) report, providing a comprehensive overview of the many ways the Company is doing its part to build a better, healthier world.;60.310001373291016;FOSTER CITY, Calif. & WALTHAM, Mass., May 02, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications. NK cell engagers represent a novel mechanism with the potential to address a broad range of cancers, including potential for activity in checkpoint resistant and refractory tumors, as well as other diseas;652.02001953125;Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.;146.0399932861328;Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 products are likely to have driven sales in the first quarter.;300.8500061035156;Strategic Dx partnering allows for innovation and value at scale;261.9599914550781;(Bloomberg) -- Vertex Pharmaceuticals Inc. tumbled after U.S. regulators placed its study of a key new treatment for type 1 diabetes on clinical hold.Most Read from BloombergBiggest Treasury Buyer Outside U.S. Quietly Selling BillionsEnd of Easy Money Brings a $410 Billion Global Financial ShockCiti Says Trader Made Error Behind Flash Crash in Europe StocksDip Buyers Save the Day as Stocks Finish Higher: Markets WrapUkraine Latest: Johnson to Evoke ‘Finest Hour’ in Speech to KyivThe Food and DruZoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 products are likely to have driven sales in the first quarter.Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the first-quarter earnings call that can help it to reduce its dependence on Spikevax.;207.32000732421875;Sage Therapeutics Inc. and Biogen Inc. said Monday that they started a rolling submission to the Food and Drug Administration for zuranolone, a treatment they are developing for major depressive disorder. The full application, including clinical data, is set to be submitted in the second half of this year. The experimental therapy is also being tested as a treatment for postpartum depression, with plans to submit an application to the FDA for this indication in the first half of next year. Sage'CAMBRIDGE, Mass., May 02, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD). Zuranolone is an investigational two-week, once-daily oral drug being developed for MDD and postpartum depression (PPD). The companies have submitted the nonclinical module of the NDA to the FDA and plan to submit the reNovo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.;166.52999877929688;;130.4499969482422;;139.0500030517578;;382.5799865722656;Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 2:40 p.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;3.130000114440918;;83.30999755859375;Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.;50.849998474121094;;76.05000305175781;;57.45000076293945;Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conference and invited investors to participate by webcast.;53.75;What happened Shares of Novavax (NASDAQ: NVAX) were soaring 12.9% as of 11:24 a.m. ET on Monday. The gain continues the momentum that started on Friday after the Food and Drug Administration (FDA) announced plans to convene an advisory committee to review the Emergency Use Authorization (EUA) filing for Novavax's COVID-19 vaccine.Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.Yahoo Finance's Julie Hyman and Brian Sozzi discuss Pfizer saying its COVID-19 treatment pill has failed as a preventive therapy in a clinical trial.;51.61000061035156;Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell therapyFindings support recent development candidate initiation of NTLA-6001, an investigational allogeneic CAR-T therapy, for the treatment of CD30-expressing hematologic cancers CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative the;91.22000122070312;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its support of Mental Health Awareness Month and commitment to raising awareness of and supporting people living with tardive dyskinesia (TD) through Tardive Dyskinesia Awareness Week. TD is a persistent and often irreversible movement disorder associated with prolonged use of certain mental health medicines (antipsychotics) to treat bipolar disorder, depression, schizophrenia, or schizoaffective disorder.1,2-5 This year marks the fifth;73.77999877929688;;64.37999725341797;;43.04999923706055;The big shareholder groups in Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) have power over the company. Institutions...PASADENA, Calif., May 02, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Victoria Vakiener, as an independent director of the company, with a term beginning effective May 2, 2022.PASADENA, Calif., May 02, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:;59.720001220703125;;51.97999954223633;"Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Ginkgo Bioworks Holdings (NYSE: DNA), and Novocure (NASDAQ: NVCR).  Prosper Junior Bakiny (CRISPR Therapeutics): ""Beaten-down"" doesn't begin to describe what has happened to CRISPR Therapeutics in the past year on the market.  CRISPR Therapeutics has several promising pipeline candidates.";39.54999923706055;;29.770000457763672;;22.65999984741211;;8.420000076293945;;40.779998779296875;;25.149999618530273;Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with amyotrophic lateral sclerosis (ALS)Denali to receive a milestone payment of $40 million from Sanofi for Phase 2 clinical trial initiationDevelopment of RIPK1 inhibitor program continues in a broad range of CNS and peripheral inflammatory indications SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a;72.29000091552734;;40.849998474121094;;;;20.860000610351562;;15.619999885559082;Abcam (LON:ABC) has had a rough month with its share price down 11%. It is possible that the markets have ignored the...;6.440000057220459;;6.849999904632568;;38.369998931884766;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 2, 2022.;56.060001373291016;;51.77000045776367;;8.069999694824219;;31.34000015258789;SOUTH SAN FRANCISCO, Calif., May 02, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced six poster presentations at PEGS (The Essential Protein Engineering & Cell Therapy Summit) Boston occurring May 2-6 virtually and in-person at the Hynes Convention Center in Boston, MA. In addition, Aaron Sato, Ph.D., chief scientific officer of Twist Bioscience, will present;19.540000915527344;Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.;28.8799991607666;
2022-05-03;232.19000244140625;Pfizer (PFE) misses estimates for Q1 earnings and sales. It did not raise its sales guidance for 2022. Stock declines.Amid a gloomier performance from the broader market, the healthcare industry has presented a few bright spots for investors.  Amgen (NASDAQ: AMGN), a biotech pioneer that uses living cells to make biologic medicines, has seen its stock rise 10% year-to-date.;60.33000183105469;If 2022 has been a rough year on Wall Street, then April was the cruelest month so far for the Bay Area's biggest public companies. Here's how their shares performed last month and in the year-to-date.By Aida Meskel;660.489990234375;Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ: REGN) from $679 to $647 and maintained a Sector Perform rating. Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment. The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose data, expected in 2H 2022, would need to be impressive to defend fully vs. biosimilars. AcRegeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.;149.22999572753906;On BioNTech's (BNTX) first-quarter earnings call, investors' focus is expected to be on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.Pfizer (PFE) misses estimates for Q1 earnings and sales. It did not raise its sales guidance for 2022. Stock declines.Shares of top coronavirus stock BioNTech (NASDAQ: BNTX) nicely bucked the general downward trend of the market on Monday.  A continued rise in coronavirus cases kept investors interested, but a stronger catalyst was the launch of a stock repurchase program.  In the original press release heralding the move, BioNTech said it would use the repurchased shares to take care of share-based payment obligations it has committed to.;300.70001220703125;Guardant Health launched its first blood-based screening test for colon cancer, creating competition for the blood test sold by the Grail unit of Illumina.By Angelica Peebles;269.1099853515625;Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.The Dow Jones fell as the 10-year treasury yield spiked., A couple of Warren Buffett stocks popped higher. Intel led the blue chips.With the market searching for a bottom, Tesla, Microsoft, Eli Lilly and other leading stocks try to recharge as May kicks off.On Vertex Pharmaceuticals' (VRTX) Q1 earnings call, investors are most likely to focus on the sales performance of its triple combo CF drug Trikafta/Kaftrio and updates on the non-CF pipeline.The Dow Jones was near session lows in afternoon trading Monday, but Buffett stock Chevron was a bright spot, along with Honeywell.The U.S. Food and Drug Administration has hit Vertex Pharmaceuticals Inc. with a clinical hold, ordering a temporary stop to an early-stage study of a Type 1 diabetes drug.The FDA has instituted a clinical hold on Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) VX-880 Phase 1/2 study due to a determination that there is insufficient information to support dose escalation with the product. VX-880 is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for type 1 diabetes (T1D). Three patients have been dosed in the Phase 1/2 study with VX-880. Two patients received half the target dose of cells in Part A of the sAn analyst at Jefferies analyst says the FDA hold on the diabetes treatment is a slight setback and not the 'the primary thesis to the story.';205.6999969482422;"Biogen stock popped Tuesday on its plans to ""substantially eliminate"" commercial efforts for its embattled Alzheimer's drug, Aduhelm.Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.The biopharmaceutical company says it has begun to eliminate commercial infrastructure for Aduhelm, its Alzheimer's medication, after failing to get broad Medicare coverage.Biogen chief executive Michel Vounatsos will step down following the disastrous launch of the company’s Alzheimer’s drug Aduhelm.  The US biotech group said on Tuesday it had begun a search for a successor and would dismantle its global sales infrastructure for Aduhelm in a move that would save $500mn in annual costs.  The management shake-up follows the failed launch of the Alzheimer’s drug, which last year became the first treatment approved by US regulators to combat the disease in almost two decades.After more than five years at the helm of embattled Biogen Inc., Michel Vounatsos is stepping down as CEO.Biogen Inc. (BIIB) delivered earnings and revenue surprises of -17.91% and 1.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Shares of Biogen Inc. fell 2.3% in premarket trading on Tuesday after the company missed Wall Street's expectations for revenue and earnings for the first quarter of 2022. Biogen had net income of $303.8 million, or $2.06 per share, in the first quarter of the year, down from $410.20, or $2.69 per share, in the first quarter of last year. Adjusted earnings per share were $3.62, against a FactSet consensus of $4.34. The company attributed the change in EPS to inventory write-offs for Aduhelm, itsBiogen Inc. said Tuesday that it is conducting a search to replace CEO Michel Vounatsos, who will stay in his role unless a successor is named. The announcement was made in the company's first-quarter earnings, which saw Biogen missing Wall Street's expectations for earnings and revenue. Vounatsos has served as CEO since 2017. Biogen's stock is down 13.4% this year, while the S&P 500 has declined 12.8%.""I will be leaving at a time of promise for Biogen, with noteworthy potential for value creation,"" said departing CEO Michel Vounatsos.(Reuters) -Biogen Inc said on Tuesday that chief executive Michel Vounatsos will step down and that the company is pulling back on selling its controversial Alzheimer's drug Aduhelm, in what appears to be a final blow to its prospect of becoming a big seller.  The future of Aduhelm has been in doubt since the U.S. government's Medicare program restricted coverage of the medicine to patients in clinical trials.  Biogen said on Tuesday https://bit.ly/3LHu8vF it was looking at ""substantially"" eliminating commercial infrastructure related to Aduhelm and plans for more cost cuts, in addition to the current program to save $500 million annually.Biogen Inc said on Tuesday its Chief Executive Officer Michel Vounatsos will step down and the company has started a search for a successor. The company reported a 26% fall in quarterly profit as sales of its blockbuster multiple sclerosis drug Tecfidera continued to be pressured by cheaper versions of the treatment.Biogen Inc said on Tuesday that Chief Executive Michel Vounatsos will step down and that the company is pulling back on selling its controversial Alzheimer's drug Aduhelm, in what appears to be a final blow to its prospect of becoming a big seller.  The future of Aduhelm has been in doubt since the U.S. government's Medicare program restricted coverage of the medicine to patients in clinical trials.  Biogen said on Tuesday https://bit.ly/3LHu8vF it was looking at ""substantially"" eliminating commercial infrastructure related to Aduhelm and plans for more cost cuts, in addition to the current program to save $500 million annually.Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have initiated a rolling submission of a marketing application to the FDA for zuranolone in major depressive disorder (MDD). Zuranolone is an investigational two-week, once-daily oral drug developed for MDD and postpartum depression (PPD). The companies have submitted the nonclinical module and plan to submit the remaining components for the MDD filing in 2H of 2022. Related: Sage Therapeutics - Biogen Partnered Depression Drug M";163.52999877929688;;131.50999450683594;;142.88999938964844;"Recently, Vir Biotechnology Inc (NASDAQ: VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ: ALNY), and VIR-3434, a monoclonal antibody (mAb). The key highlight of the event was the initial data presented from the Phase 2 MARCH trial of VIR-2218 + VIR-3434 in patients with chronic HBV. ""The combination therapy achieved hepatitis B surface antigen (HBsAg) knockdown of more than 3 log10 IU/mL, an";383.42999267578125;;3.2200000286102295;;83.5199966430664;;50.65999984741211;;77.18000030517578;Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.Incyte (INCY) delivered earnings and revenue surprises of -3.51% and 4%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?WILMINGTON, Del., May 03, 2022--Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs.Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.;56.13999938964844;Guardant Health launched its first blood-based screening test for colon cancer, creating competition for the blood test sold by the Grail unit of Illumina.;58.88999938964844;The Food and Drug Administration (FDA) will meet in June to determine approval for Novavax’s (NVAX) Covid-19 vaccine. The early rollout of it in the European Union has been underwhelming. NVAX stock could be severely overvalued as a result. Source: vovidzha / Shutterstock.com In 2019, Novavax (NASDAQ:NVAX) was off to a promising start. It was one of the companies that participated in the federal government’s Operation Warp Speed program along with Moderna (NASDAQ:MRNA). Its differentiating factoNovavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2022 financial results and operational highlights on Monday, May 9, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows:Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;51.779998779296875;Incyte (INCY) delivered earnings and revenue surprises of -3.51% and 4%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. “We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer;88.69999694824219;;73.33000183105469;;64.26000213623047;;42.650001525878906;;62.81999969482422;Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 0% and 45.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2022.;52.619998931884766;;39.09000015258789;DEEP DIVE  A screen of stocks that popped during the coronavirus pandemic highlights dozens that have crashed. But some are considered worthy of purchase by a majority of analysts. You might want to keep an eye on them because every market cycle, even bad ones like today’s, eventually turns around.;28.780000686645508;;22.579999923706055;The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.ALAMEDA, Calif., May 03, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy. This approval allows for the marketing of CABOMETYX in this indication inThe European Commission (EC) has approved Ipsen SA's (OTC: IPSEY) Cabometyx (cabozantinib) as monotherapy in differentiated thyroid carcinoma (DTC) setting. The approval covers adult patients with locally advanced or metastatic DTC, refractory or not eligible for radioactive iodine, who have progressed during or after systemic therapy. This EC approval follows the FDA approval announced by Exelixis Inc (NASDAQ: EXEL) in September 2021 of Cabometyx for adult and pediatric patients with locally ad;8.34000015258789;;40.029998779296875;CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new preclinical data from several programs across its base editing portfolio at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting. The meeting is being held May 16-19, 2022, in Washington, DC. Beam’s presentations showcase a key component of the company’s;25.540000915527344;Investing in stocks comes with the risk that the share price will fall. And unfortunately for Denali Therapeutics Inc...;71.47000122070312;;40.939998626708984;;;;21.43000030517578;"Recently, Vir Biotechnology Inc (NASDAQ: VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ: ALNY), and VIR-3434, a monoclonal antibody (mAb). The key highlight of the event was the initial data presented from the Phase 2 MARCH trial of VIR-2218 + VIR-3434 in patients with chronic HBV. ""The combination therapy achieved hepatitis B surface antigen (HBsAg) knockdown of more than 3 log10 IU/mL, an";15.359999656677246;;6.389999866485596;;6.829999923706055;;38.5;;55.2400016784668;NEW HAVEN, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10 at 7:00 p.m. ET /4:00 p.m. PT in Las Vegas. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Compan;51.09000015258789;NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, May 10, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2022. To access the liveIntra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;8.039999961853027;VANCOUVER, British Columbia & SAN DIEGO, May 03, 2022--AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration;31.920000076293945;;19.809999465942383;SAN DIEGO, May 02, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a virtual meeting of the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee to review the resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) has been scheduled for June 17, 2022. The target action date for the application is August 4, 2022.;29.0;
2022-05-04;236.10000610351562;North Carolina remains in elite status for economic development projects, according to Site Selection magazine.;62.08000183105469;;660.8599853515625;"Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.The pharmaceutical company posts first-quarter revenue of $2.97 billion, up 17% from a year earlier.Dow Jones futures rose modestly early Wednesday, along with S&P 500 futures and Nasdaq futures. Advanced Micro Devices popped and lithium play Livent skyrocketed on after-hours earnings. But investor focus is on the Federal Reserve meeting decision this afternoon.Regeneron (REGN) delivered earnings and revenue surprises of 22.63% and 9.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Regeneron Pharmaceuticals reported better-than-expected revenue aided by sales from its COVID-19 antibody outside the United States and strong demand for its blockbuster drugs Dupixent and Eylea.  About $216 million in first-quarter sales from the intravenous COVID drug through a partnership with Roche, which sells the drug outside the United States under brand name Ronapreve, helped Regeneron limit the setback from no sales in the United States-- its biggest market.  Regeneron in February warned it will record zero sales from the pill in the United States for the first quarter after the U.S. Food and Drug Administration limited its use due to lack of effectiveness against the Omicron coronavirus variant.Regeneron Pharmaceuticals Inc. shares rose 1.4% in premarket trade Wednesday, after the company beat consensus estimates for the first quarter. The company posted net income of $974 million, or $8.61 a share, for the quarter, down from $1.115 billion, or $10.09 a share, in the year-earlier period. Adjusted per-share earnings came to $11.49, ahead of the $9.68 FactSet consensus. Revenue rose 17% to $2.965 billion from $2.529 billion a year ago, also ahead of the $2.690 billion FactSet consensus.About $216 million in first-quarter sales from the intravenous COVID drug through a partnership with Roche, which sells the drug outside the United States under brand name Ronapreve, helped Regeneron limit the setback from no sales in the United States - its biggest market.  Regeneron in February warned it will record zero sales from the intravenous COVID drug in the United States for the first quarter after the U.S. Food and Drug Administration limited its use due to lack of effectiveness against the Omicron coronavirus variant.First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-COV";151.83999633789062;The stock market gained as investors await the outcome of the Fed's two-day meeting and digest a report signaling a tight labor market.;307.67999267578125;;273.70001220703125;Moderna's (MRNA) Spikevax sales beat expectations. The company plans to start late-stage studies for Omicron-containing bivalent booster and seasonal flu vaccines later this year. Stock gains in pre-market.TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.Vertex (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.The company was on a roll when it came to good news.  Vertex said it would apply for the regulatory approval of a potential blockbuster treatment for blood disorders by the end of the year.  The U.S. Food and Drug Administration placed one of Vertex's clinical trials on clinical hold.Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.;210.10000610351562;The following are the top stories on the New York Times business pages.  -  Microsoft Corp's LinkedIn, the professional networking platform, has reached an agreement with the U.S. Department of Labor to pay $1.8 million to female employees who the agency said received far less compensation than their male colleagues from 2015 to 2017, the department said on Tuesday.  - Starbucks Corp announced Tuesday that it was raising pay and expanding training at corporate-owned locations in the United States.Reporters and analysts covering first-quarter earnings from drug companies may have noticed a change in how they account for upfront payments made to finance research and development at companies in which they have acquired equity stakes.;163.0;"Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, May 04, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has granted conditional approval of BLINCYTO® (blinatumomab) for injection for the treatment of pediatric patients with relapsed or refrac";132.64999389648438;;143.42999267578125;CAMBRIDGE, Mass., May 04, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:;395.8399963378906;Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2022.Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2022. The quarterly dividend will be payable May 27, 2022, to all common shareholders of record on May 16, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis.;3.2899999618530273;;84.6500015258789;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the BofA Securities Healthcare Conference on May 12 at 8:40am PT/11:40am ET in Las Vegas. To access the live webcast, please visit the BioMarin website, https://investors.biomarin.com/.;52.4900016784668;;80.72000122070312;View more earnings on INCYSee more from BenzingaThe Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme LayoffsGlobal Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600MDon't miss real-time alerts on your stocks - joinBenzinga Profor free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.;59.34000015258789;;62.72999954223633;"Moderna CEO Stephane Bancel joins Yahoo Finance Live to discuss earnings, COVID-19 vaccine sales growth, creating new boosters for the fall, funding for future sales, and the process for approving a vaccine for young kids.Pharmaceutical company Novavax (NASDAQ:NVAX) had a chance to become a game-changer in the industry, but the delay in U.S. Food and Drug Administration (FDA) approvals has led the stock to suffer. NVAX stock had a tough start to 2022 despite the high hopes of investors. The stock was trading at $277 in September last year when the pandemic was at its peak. However, the decline has been huge. NVAX stock lost 69% of its value over a year to now trade at $58. This has led to frustration amongst inveLike Pfizer (PFE) and Moderna (MRNA), Novavax (NVAX) has Covid-19 vaccine. Unlike Pfizer or Moderna, Novavax's Covid-19 vaccine hasn't yet been approved by the U.S. Food and Drug Administration (FDA) -- not even for restricted ""Emergency Use Authorization,"" or EUA. But it soon might. On Friday last week, the FDA announced that on June 7 it will convene an advisory committee to review Novavax's application for its NVX-CoV2373 vaccine for potential EUA. A positive outcome isn't certain, and even iOn Novavax's (NVAX) first-quarter earnings call, investor focus is likely to be on the sales figures of its COVID-19 vaccine.";55.70000076293945;;88.4000015258789;Neurocrine (NBIX) delivered earnings and revenue surprises of -57.58% and 1.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2022 and reiterated financial guidance for 2022.Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2022 Healthcare Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday, May 10, 2022 in Las Vegas. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.;72.75;CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 9:20 a.m. P.T. / 12:20 p.m. E.T. The fireside chat will be held at the Encore Hotel in Las Vegas, Nev. The presentation will be webcast live under the Events & Presentations section of the inv;64.0199966430664;;43.0099983215332;;63.2599983215332;;55.619998931884766;"ZUG, Switzerland and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 2022 Bank of America Healthcare Conference on Wednesday, May 11, 2022, at 4:40 p.m. PT. A live webcast of the event will be available on the ""Events & Presentations"" page in the Investors sec";37.630001068115234;;30.690000534057617;;22.829999923706055;;8.579999923706055;;43.189998626708984;"Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in fireside chats during the following May investor conferences: BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 2:00 p.m. PT in Las Vegas; and,2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022,";26.709999084472656;;70.93000030517578;NOVATO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 20,480 shares of common stock of the company and 11,620 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company. The awards were approveNOVATO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Camille Bedrosian, M.D., the company’s Chief Medical Officer, and Mardi Dier, the company’s Chief Financial Officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:40 PM ET. The live and arch;41.40999984741211;EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -4% and 10.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 on May 10 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president, and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the first quarter ended March 31, 2022, following the close of trading.;;;22.270000457763672;;15.319999694824219;;6.389999866485596;;7.289999961853027;;39.58000183105469;Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.35% and 9.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the first quarter of 2022 and recent business achievements.;54.630001068115234;;51.16999816894531;;8.279999732971191;AbCellera Biologics Inc. (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;34.849998474121094;;19.889999389648438;SAN DIEGO, May 03, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:;28.950000762939453;
2022-05-05;234.35000610351562;Shares of healthcare company Amgen (NASDAQ: AMGN) have been falling since it released its latest quarterly results on April 27.  Although the company generated positive year-over-year revenue growth, earnings declined during the period.  Amgen's revenue for the first three months of 2022 totaled $6.2 billion and rose 5.7% year over year.Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.;61.349998474121094;Pfizer (PFE) stock looks cheap after reporting record results from its Covid-19 vaccine. The rest of the year should look even better as sales ramp up for its Covid-19. Investors should worry about where its new CFO invests the cash. Source: Manuel Esteban / Shutterstock.com Pfizer (NYSE:PFE) stock rose 2% after earnings beat street estimates. But it remains 20% below its November high. The company reported adjusted income of $9.3 billion, or $1.62 per share, on revenue of $25.7 billion. All theEarnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.;639.3699951171875;"The first quarter could represent a ""high-water mark"" for Regeneron Pharmaceuticals, an analyst said Wednesday.The biotech company tests a key indicator, and here's how investors should proceed, according to the technical readout.";141.9199981689453;BioNTech SE Sponsored ADR (BNTX) closed at $151.84 in the latest trading session, marking a +1.75% move from the prior day.;291.7200012207031;By Tony Quested;266.3699951171875;The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...Most stocks have fallen, with the S&P 500 index in correction territory and the Nasdaq Composite index in bear territory again.  In 2012, Vertex Pharmaceuticals (NASDAQ: VRTX) became the first company to win U.S. approval of a drug that treated the underlying cause of cystic fibrosis (CF).  Vertex has achieved remarkable success in the subsequent years with a virtual monopoly in the CF market.Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.;201.17999267578125;Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Union Pacific Corporation (UNP), and Ford Motor Company (F).The company plans to let go of its CEO and scrap commercial plans for its controversial Alzheimer’s disease drug.The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)MedRhythms to receive a $3 million upfront payment as part of the agreement and is eligible to receive potential development and commercial milestone payments CAMBRIDGE, Mass. and PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and MedRhythms have entered into a license agreement to develop and commercialize MR-004, an inBiogen's (NASDAQ: BIIB) biggest problem a couple of years ago was similar to that of every other biotech that's been around for a while.  The situation didn't turn out as Biogen had hoped, though.  Biogen withdrew its regulatory request in Europe after it became clear it wouldn't win approval there.Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.;159.47999572753906;"Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, May 05, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the first quarter of 2022, recent business highlights, and anticipated upcoming milestones.BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.";128.69000244140625;;136.74000549316406;;386.1499938964844;;2.930000066757202;Marcus Partners is scheduled to formally break ground on Ginkgo Bioworks’ future headquarters in Boston’s Seaport District next month.;81.97000122070312;BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation of Hemophilia (WFH) 2022 World Congress from May 8-11 in Montreal, Canada.;50.40999984741211;View more earnings on TXGSee more from BenzingaPhibro Animal Reports Mixed Q3 Earnings, Lifts FY22 Sales OutlookUS Study Shows Omicron As Severe As Previous COVID Variants: ReutersDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.10x Genomics (TXG) delivered earnings and revenue surprises of -2.70% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2022.;77.27999877929688;WILMINGTON, Del., May 05, 2022--Incyte Announces European Commission Approval of Jakavi (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic GVHD.WILMINGTON, Del., May 04, 2022--Incyte (Nasdaq:INCY) announced today that it will present at the 2022 RBC Capital Markets Healthcare Conference on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York.;56.22999954223633;;58.65999984741211;Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -41.18% and 23.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Ligand (LGND) delivered earnings and revenue surprises of -4.92% and 33.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Novavax Inc said on Wednesday it had filed an application with Britain's drugs regulator for the authorization of its COVID-19 vaccine among adolescents aged 12 and older.  Britain had in February cleared the two-dose vaccine, Nuvaxovid, for use in adults amid a spike in cases fueled by the Omicron variant of the coronavirus.  Novavax's submission includes data from a late-stage trial in the United States, where the vaccine showed 80% efficacy among adolescents when Delta was the dominant variant in the country.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in BofA Securities 2022 Healthcare Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.;50.029998779296875;"Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy, demonstrating a single dose of NTLA-2001 resulted in rapid, deep and sustained reduction in disease-causing proteinInterim readout showed treatment with NTLA-2001 at 1.0 mg/kg dose led to 93% mean and 98% maximum serum TTR reduction by day 28, with durability observed through follow-up period; initiated Part 2 in the polyneuropathy arm, with plans to share additional dLet's look at the five biotech/drug companies, slated to release quarterly results on May 5.";85.27999877929688;"With me as usual are Kevin Gorman, our chief executive officer; Matt Abernethy, our chief financial officer; Eiry Roberts, our chief medical officer; Eric Benevich, our chief commercial officer; and Kyle Gano, our chief business development and strategy officer.  Before we get going, I'll remind everyone that during today's call, we will be making forward-looking statements.";71.69000244140625;Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.At this time, I'll turn the call over to Mary Jenkins, senior manager, investor relations.  Earlier today, we released our financial results for the first quarter of 2022.  Joining us today on the call are Doug Ingram, Ian Estepan, Dallan Murray and Dr.Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 11.11% and 3.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2022 totaled $210.8 million Net product revenues for the first quarter 2022 totaled $188.8 million, a 51% increase over the same quarter of prior year CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2022. “We are pleased to report yet a;62.380001068115234;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the first quarter of 2022 and recent corporate updates.;40.2400016784668;;60.33000183105469;Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.;51.34000015258789;;35.779998779296875;"- Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardless of prior therapy or disease severity - Statistically significant separation from placebo in key platelet-derived secondary endpoints - Safety and tolerability profile of VYVGART is consistent with previous clinical trials; ADVANCE is first registrational trial with chronic dosing out to 24 weeks -";27.190000534057617;FATE reports a narrower loss and higher collaboration revenues in the first quarter.Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?FT596+R Enrollment Ongoing in Single- and Multi-dose, Multi-cycle Cohorts for R/R BCL FT596+R-CHOP Clinical Protocol for First-line Investigation to be Submitted to FDA in 2Q22 FT819 Enrollment Ongoing in Single- and Multi-dose Cohorts for R/R BCL in Landmark Study of Off-the-shelf, iPSC-derived CAR T-cell Therapy FT516 Multi-disciplinary RMAT Meeting with FDA Planned for Mid-2022 Third IND Candidate Nominated under Janssen Collaboration Triggering Preclinical Milestone SAN DIEGO, May 04, 2022 (;22.290000915527344;ALAMEDA, Calif., May 04, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May:;7.510000228881836;"BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?–Completed sale to Sentynl Therapeutics of BridgeBio’s NULIBRY™ (Fosdenopterin) for Injection–Updated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib in oncology indications in the U.S.; BridgeBio is eligible to receive regulatory and commercial milestone payments as well as tiered royalties on adjusted net sales from Helsinn–Released positive data from Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), whiPersonalis (PSNL) delivered earnings and revenue surprises of -10.53% and 2.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?";37.02000045776367;Aeglea (AGLE) delivered earnings and revenue surprises of -5.71% and 6.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;23.969999313354492;AVEO (AVEO) delivered earnings and revenue surprises of -15.38% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;66.43000030517578;;40.290000915527344;;;;20.84000015258789;Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.;14.430000305175781;;5.920000076293945;;6.420000076293945;PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.View more earnings on PACBSee more from BenzingaThe Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study10x Genomics Posts Topline Growth Of 8%, Reaffirms FY22 GuidanceDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Pacific Biosciences (PACB) delivered earnings and revenue surprises of -15.63% and 1.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results Revenue of $33.2 million, a 14% increase compared with $29.0 million in the prior year period.Delivered a record 50 Sequel II/IIe systems during the quarter compared to 41 Sequel II/IIe systems placed in the prior year quarter.Installed base of 424 Sequel II/IIe systems as of March 31, 2022, compared with 244 as of March 31, 2021;38.04999923706055;Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.;49.20000076293945;Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -41.18% and 23.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “It has been a very productive first quarter for Arvinas, as we prepare to initiate three planned pivotal clinical studies in the second half of 2022 for our two lead programs – ARV-471 in metastatic br;48.689998626708984;;7.760000228881836;;31.139999389648438;Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 11.11% and 3.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;18.829999923706055;Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.Acadia (ACAD) delivered earnings and revenue surprises of -42.86% and 6.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?SAN DIEGO, May 04, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2022.;27.899999618530273;Thermo Fisher's (TMO) core business strength was broad-based across segments, end markets, and geographies.Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.
2022-05-06;236.5;Adding defensive healthcare stocks can be a great way to ride out continued volatility in the market. AbbVie (ABBV): Investors are overreacting to this venerable big pharma company’s recent earnings report. Amgen (AMGN): An established biotech company with a high forward dividend yield (3.33%). Baxter International (BAX): A reasonably-priced medical products provider on track to deliver strong results. Quest Diagnostics (DGX): Focus will soon shift to the evergreen nature of its main testing busPerhaps not surprisingly, a greater emphasis on mental and physical health as well as prioritizing time offline were top of mind for companies and HR leaders over the past year.  Here are the 2022 honorees of the Bay Area Workplace Wellness Award, and scroll to the end of page for the methodology.  Salesforce  Location: San Francisco What it does: Provides customer relationship management software and applications focused on sales, customer service, marketing automation, analytics and application development Bay Area employees: 10,580 What makes the company healthy: The complexities of the past two years have meant that the line between professional and personal lives has become blurry.;61.18000030517578;Codion Isom never had any teachers who looked like him growing up, and as a Black man he knows the importance of having Black male role models at a young age. That’s why he answered the call to pla...;623.0499877929688;Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.;136.1699981689453;FDA follows CDC to recommend limitations to J&J COVID-19 vaccine use.;249.0500030517578;The company reaffirmed that it wants to increase sales in blood-based cancer screening and new drug discovery.Illumina (ILMN) ended the first quarter with better-than-expected earnings and revenues on strength in Core Illumina and the GRAIL businesses driving the top line.View more earnings on ILMNSee more from BenzingaFDA Berates Pfizer CEO's Suggestion To Take More Paxlovid If COVID-19 Symptoms ReboundBridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Illumina (ILMN) delivered earnings and revenue surprises of 22.99% and 0.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Illumina crushed earnings forecasts on Thursday, though the next-generation DNA sequencer just met sales views. Illumina stock was unchanged.Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2022, which include consolidated financial results for GRAIL.;253.92999267578125;Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.Strength in Healthcare and AST arms is expected to have driven STERIS' (STE) fourth-quarter revenues.Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.Here is how Lantheus Holdings (LNTH) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.Treasury yields surged in a delayed reaction to the Fed meeting. Stocks dived, wiping out Wednesday's market rally.Most mutual funds have losses this year amid the market's sell-off. But JPMorgan Large Cap Value Fund is in positive territory. Here's why.Image source: The Motley Fool.  Vertex Pharmaceuticals (NASDAQ: VRTX)Q1 2022 Earnings CallMay 05, 2022, 4:30 p.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  Michael Partridge Good evening.Vertex (VRTX) delivered earnings and revenue surprises of -2.22% and 0.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Vertex will need to lean on its pipeline to prop VRTX stock, an analyst said Thursday after the company delivered a mixed report.BOSTON, May 05, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2022 and reiterated full year 2022 product revenue guidance.;193.61000061035156;Oracle, Union Pacific, Ford Motor, Biogen and Expedia Group have been included in this Analyst Blog.;147.2899932861328;;123.44000244140625;;134.75;;372.92999267578125;;2.7100000381469727;;79.26000213623047;BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company hired two pharmaceutical industry leaders in their respective areas of expertise. Humaira Serajuddin was named Senior Vice President, Chief Marketing Officer and Erin Burkhart was named Group Vice President, Chief Accounting Officer, filling two key strategic roles supporting BioMarin's growth goals.;51.189998626708984;;75.19999694824219;;55.0;The company reaffirmed that it wants to increase sales in blood-based cancer screening and new drug discovery.;57.29999923706055;Novavax (NVAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.What happened Novavax (NASDAQ: NVAX) is absolutely crushing it this week. Shares of the vaccine maker were up 29.9% for the week as of the market close on Thursday, according to data from S&P Global Market Intelligence.;47.56999969482422;;79.55000305175781;;70.16000366210938;;56.7400016784668;Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.;36.91999816894531;;56.63999938964844;Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on May 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 40,684 shares of its common stock and an aggregate of 20,335 restricted stock units (RSUs) to twenty-three new employees under Blueprint Medicines' 2020 Inducemen;48.0099983215332;Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.;28.549999237060547;;24.15999984741211;;21.489999771118164;;6.699999809265137;View more earnings on BBIOSee more from BenzingaBioCryst's Voluntary Pause Of Rare Blood Disorder Trial Turns Into FDA Clinical HoldWalgreens Announces $683M Opioid Settlement With FloridaDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.;35.68000030517578;;23.049999237060547;Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.77% and 72.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2022, and provided business highlights. “Recent achievements highlight the broad potential of our BBB-crossing Transport Vehicle (TV) platform and the transition of;57.540000915527344;Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.Ultragenyx (RARE) delivered earnings and revenue surprises of -24.43% and 5.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?First quarter 2022 total revenue of $79.9 million and Crysvita® revenue in Ultragenyx territories1 of $54.6 million Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million Cash balance of approximately $814 million as of March 31, 2022 NOVATO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization;39.2400016784668;;;;21.579999923706055;Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 19.94% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?– $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter – – More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of the first quarter – – Encouraging initial data from MARCH trial evaluating hepatitis B functional cure shared in April – – Multiple value drivers in COVID-19, hepatitis B, hepatitis D, HIV and influenza expected in 2022 – SAN FRANCISCO, May 05, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR)The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...;13.84000015258789;;5.71999979019165;Kodiak (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;6.119999885559082;MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada. PacBio’s management is scheduled to present on Thursday, May 12 at 11:20 a.m. Pacific Time / 2:20 p.m. Eastern Time. The live webcast can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the presentation. Abou;36.29999923706055;David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...;45.68000030517578;;46.20000076293945;;7.440000057220459;;31.389999389648438;Twist Bioscience (TWST) delivered earnings and revenue surprises of 1.59% and 5.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?SOUTH SAN FRANCISCO, Calif., May 05, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2022 ended March 31, 2022.;17.8799991607666;;27.6299991607666;Since the start of fiscal 2022, Medtronic (MDT) has been witnessing a strong recovery and displayed a return to growth.Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.Illumina (ILMN) ended the first quarter with better-than-expected earnings and revenues on strength in Core Illumina and the GRAIL businesses driving the top line.Avanos Medical's (AVNS) first-quarter 2022 results reflect strength in the Pain Management segment.Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.In Q3, Phirbo (PAHC) reports growth in the Animal Health business on higher sales of processing aids, which are used to improve production efficiency in the ethanol fermentation industry.Despite strength in dialysis patient service revenues, DaVita (DVA) records an overall soft Q1 performance.Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.
2022-05-09;239.24000549316406;;61.68000030517578;;599.77001953125;;140.32000732421875;"The German biotech company earned €14.24 a share in the first quarter from revenue of €6.37 billion.BioNTech's first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer , but the German biotech firm is still forecasting a full-year decline in vaccine sales.  ""As a result of an increased order volume initially placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong revenues and earnings, leaving us well-positioned to achieve the 2022 financial guidance,"" finance chief Jens Holstein said.  BioNTech stood by its 2022 vaccine revenue guidance of 13 to 17 billion euros, down from 19 billion last year, implying a decline during the rest of the year.View more earnings on BNTXSee more from BenzingaFDA Limits Use of Johnson & Johnson's COVID-19 Vaccine to Certain Individuals - All You Should KnowArcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster TrialDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.(Bloomberg) -- BioNTech SE’s first-quarter sales soared past expectations as the German biotech said early research hinted that an omicron-adapted booster might provide broader protection than another dose of its original Covid-19 shot. Most Read from BloombergMarcos Jr. Leads With 61% of Votes Counted: Philippines UpdateStocks Slide in Broad-Based Rout Amid Fed Anguish: Markets WrapDay Trader Army Loses All the Money It Made in Meme-Stock EraEU Push to Ban Russian Oil Is Stalled by Hungarian DeBioNTech , the U.S-listed German biotech, said its first-quarter profit more than tripled to €3.7 billion ($3.9 billion), or €14.24 per share, from €1.13 billion, or €4.39 per share, as revenue jumped to €6.38 billion from €2.05 billion, mostly on its share of COVID-19 vaccine sales from Pfizer and Fosun Pharma as well as direct sales to customers in Germany and Turkey. Analysts polled by FactSet had expected earnings of €9.70 per share on sales of €4.59 billion. In the first quarter of 2022, BiFRANKFURT (Reuters) -BioNTech's first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer, but the German biotech firm is still forecasting a full-year decline in vaccine sales.  ""As a result of an increased order volume initially placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong revenues and earnings, leaving us well-positioned to achieve the 2022 financial guidance,"" finance chief Jens Holstein said.  BioNTech stood by its 2022 vaccine revenue guidance of 13 to 17 billion euros, down from 19 billion last year, implying a decline during the rest of the year.First quarter revenues of €6.4 billion1, net income of €3.7 billion and fully diluted earnings per share of €14.24 ($15.972)Reiterates BioNTech COVID-19 2022 vaccine revenue guidance of €13 billion to €17 billionFirst-in-class CAR-T program targeting CLDN-6 (BNT211) in solid tumors showed manageable safety profile and signs of clinical activity; preliminary Phase 1/2 data presented at AACR Annual Meeting 2022Continued pipeline expansion to 16 clinical stage oncology programs in 20 ongoing clinicBioNTech said first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer , but the German biotech firm reaffirmed its forecast for a full-year decline in vaccine sales.  ""As a result of an increased order volume initially placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong revenues and earnings, leaving us well-positioned to achieve the 2022 financial guidance,"" finance chief Jens Holstein said.  BioNTech reiterated its 2022 vaccine revenue guidance of between 13 billion and 17 billion euros, down from 19 billion last year, implying a decline during the rest of the year.By Peter Nurse";220.67999267578125;First-of-its-kind partnership will identify drug targets and accelerate novel therapy development using genomics and artificial intelligence;235.02000427246094;Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.Investors have been focusing on what's next for Vertex Pharmaceuticals (NASDAQ: VRTX) for quite a while. The company's main business of cystic fibrosis (CF) treatments has brought in billions. But everyone wants to see the company expand beyond that specialty.When will the market turmoil end? Unfortunately, no one really knows. There's no end in sight right now to high inflation, rising interest rates, and the continuing conflict in Ukraine. All of these factors are weighing on the stock market.;187.5399932861328;;134.22000122070312;;108.80999755859375;BOTHELL, Wash., May 09, 2022--The Board of Directors of Seagen Inc. (Nasdaq: SGEN) today announced that President, CEO and Chairman Clay Siegall, Ph.D. is on a leave of absence. The company is aware of an alleged incident of domestic violence that occurred recently at Dr. Siegall’s home. Dr. Siegall has denied these allegations and has informed the company that he is engaged in a divorce. The Board of Directors has formed a committee of independent directors and is conducting a thorough investig;122.5199966430664;;347.05999755859375;;2.380000114440918;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2022, on Monday, May 16, 2022, beginning at 4:30 p.m. ET.;74.62000274658203;;47.400001525878906;;72.6500015258789;;50.27000045776367;;53.2599983215332;Novavax is perhaps best known for its coronavirus-related work.  The company's vaccine against the disease, NVX-CoV2373, proved nearly 90% effective against all current COVID strains in a phase 3 clinical trial conducted in the U.K. That is on par with the results some of the leaders in the COVID-19 vaccine market delivered.  Over the past few months, NVX-CoV2373 has earned regulatory approvals or Emergency Use Authorization (EUA) in many countries, including those in the EU.;41.45000076293945;;75.79000091552734;ClearBridge Investments, an investment management firm, published its “SMID Cap Growth Strategy” first quarter 2022 investor letter – a copy of which can be downloaded here. During the first quarter, the ClearBridge SMID Cap Growth Strategy underperformed its Russell 2500 Growth benchmark. On an absolute basis, the Strategy had losses across eight of the 10 […];65.16000366210938;Quite a few insiders have dramatically grown their holdings in Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) over the past...;53.0099983215332;;32.720001220703125;PASADENA, Calif., May 09, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today held a groundbreaking ceremony in Verona, WI, on the site which will house a new approximately 160,000 square foot drug manufacturing facility and an approximately 125,000 square foot laboratory and office facility to support process development and analytical activities. The Company also announced that it received awards for up to $16 million in tax increment financing from the city of Verona, and up to $2.5 mi;51.849998474121094;;43.22999954223633;If you want to know who really controls CRISPR Therapeutics AG ( NASDAQ:CRSP ), then you'll have to look at the makeup...;25.559999465942383;;22.350000381469727;Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders might understandably be very concerned that the share price has...;19.34000015258789;Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;5.659999847412109;;33.290000915527344;Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 8.18% and 89.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022 Natural History Study Initiated in People with Sickle Trait to Provide Insights into Key Characteristics of Sickle Cell Trait and Sickle Cell Disease Manmohan Singh, Ph.D., Appointed to Executive Leadership Team, and Anne Marie Woodland Appointed as Head of Regulatory Ended First Quarter 2022 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securitie;22.799999237060547;;51.79999923706055;Oral presentations include longer term durability data from DTX301 and DTX401, and manufacturing data on the Pinnacle PCL™ (AAV vector Producer Cell Line) platform and technologyNOVATO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that clinical, preclinical and manufacturing data from its investigational gene t;37.349998474121094;Heska (HSKA) delivered earnings and revenue surprises of -34.15% and 3.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;;;20.6200008392334;;12.6899995803833;;5.300000190734863;;5.28000020980835;Advanced Automation Aims to Optimize Service Lab Efficiency and Highly Reproducible Data Production from HiFi Long-Read SequencingMENLO PARK, Calif., TOKYO, May 09, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with genome analysis company iLAC, Inc. (iLAC) and Robotic Biology Institute, Inc. (RBI) to develop fully automated end-to-end workflows for PacBio’s Sequel II and Sequel IIe HiFi;31.709999084472656;;38.540000915527344;"GNS Healthcare, the leader in the use of ""Virtual Patients"", Causal AI and simulation technology for biopharmaceutical companies, today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases.";43.0;;6.5;A favorable commodity pricing scenario is likely to have aided Ring Energy's (REI) earnings in Q1.;28.329999923706055;SOUTH SAN FRANCISCO, Calif., May 09, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc. Under the terms of the agreement, the companies will jointly conduct research activities to identify and optimize proprietary Twist antagonist antibodies, targeting an;16.3799991607666;;26.600000381469727;Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.Robust adoption of Omnipod DASH and record new customer starts have contributed to Insulet's (PODD) Q1 performance.AMN Healthcare's (AMN) robust Q1 results demonstrate its segmental strength.Alkermes plc (Nasdaq: ALKS) today announced the acceptance of four abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually. The final dataset from the phase 1/2 ARTISTRY-1 clinical trial, evaluating the safety, tolerability and efficacy of nemvaleukin administered intravenously as a monot
2022-05-10;240.7100067138672;;61.779998779296875;;615.0900268554688;Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.;144.42999267578125;Vaccine developer BioNTech completed a Phase II clinical trial of its COVID-19 vaccine in China in January but has yet to release its results, a registry of such trials showed on Tuesday.  The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive approval in China, which has vaccinated 89% of its 1.4 billion population with several domestically developed non-mRNA shots.  China's leading medical experts have urged authorities to retain tough zero-COVID measures to buy time, step up vaccination rates and develop new treatments in the battle against the country' biggest outbreak.Companies In The News Are: DUK, BNTX, TSN, HGVVaccine developer BioNTech completed a Phase II clinical trial of its COVID-19 vaccine in China in January but has yet to release its results, a registry of such trials showed on Tuesday.  The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive an approval in China, which has relied only on domestically developed vaccine.Good morning, and good afternoon, and thank you for joining us today to review BioNTech's first quarter 2022 clinical and operational progress and financial results.  As outlined on Slide 2, today's presentation, we'll be making several forward-looking statements.BioNTech's first-quarter revenue tripled on the back of its Pfizer-partnered Covid vaccine, leading BNTX stock to pop Monday.Shares of BioNTech (NASDAQ: BNTX) rose on Monday, following the release of the biotechnology company's first-quarter financial results.  As of 2 p.m. ET, BioNTech's stock price was up more than 3% after rising as much as 7.3% earlier in the day.  BioNTech's revenue surged 211% year over year to 6.4 billion euros ($6.7 billion), driven by sales of the company's COVID-19 vaccine.;219.6699981689453;"A jury in the U.S. District Court for the District of Delaware rendered a verdict that Illumina Inc (NASDAQ: ILMN) willfully infringed the U.S. Patent Nos. 9,222,132 and 10,662,473 owned by Complete Genomics Inc. The jury awarded approximately $334 million to CGI in past damages. The jury also invalidated three patents owned by Illumina, namely, U.S. Patent Nos. 9,217,178; 9,303,290; and 9,970,055. Illumina said it disagrees with the jury's verdict and intends to defend the action, including fil";240.16000366210938;;195.0;"Biogen partner Japanese drug company Eisai said it submitted an application with the FDA for experimental Alzheimer's drug lecanemab.Eisai Co Ltd (OTC: ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. Eisai is collaborating with Biogen Inc (NASDAQ: BIIB) for drug development. Eisai has requested a Priority Review, while the lecanemab Phase 3 Clarity AD trial conducted with 1,795 patients will report out in the Fall of 2022. Also Read: Biogen Fails To Convince BenefEisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, ""Biogen"") announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401) for the treatment of mild cognitive impair";143.67999267578125;BeiGene, Ltd. ( NASDAQ:BGNE ) shareholders might understandably be very concerned that the share price has dropped 33...;120.4800033569336;Seagen Chief Medical Officer Roger Dansey is taking over as interim CEO for the company, which is conducting an investigation with an independent law firm.Seagen CEO Clay Siegall was placed on leave after a domestic abuse allegation, the biotech company said Monday as SGEN stock dropped.;128.17999267578125;;351.5400085449219;"Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, will have a major scientific presence at the annual American Urological Association Conference (AUA) taking place May 13-16 in New Orleans, LA. Exosome Diagnostics will have two poster presentations, including a podium presentation, six in-booth scientific presentations, and a live symposium with American icon, National Baseball Hall of Famer, and former Baltimore Orioles player ""Iron Man"" Cal Ripk";2.4100000858306885;;79.43000030517578;;45.349998474121094;;76.13999938964844;;51.41999816894531;;53.86000061035156;"Novavax reported lighter-than-expected first-quarter sales and profit after launching its Covid vaccine in November. NVAX stock fell.The vaccine maker reports its first profitable quarter but the stock declines after earnings miss Wall Street expectations.Shares of Novavax (NASDAQ: NVAX) were sinking 11.9% as of 10:27 a.m. ET on Tuesday after plunging as much as 21.6% earlier in the morning.  Novavax reported Q1 revenue of $704 million, up 57% year over year.  The company posted its first profitable quarter ever, with Q1 earnings of $203 million, or $2.56 per share.A group of former heads of state led by Gordon Brown, former U.K. Prime Minister, is calling on the U.S. to commit $5 billion to the effort to combat the pandemic globally and urging President Joe Biden to take a more forceful role at a COVID-19 summit planned for Thursday.Yahoo Finance Live anchors discuss first quarter earnings for Novavax. The company said in September it had targeted for the delivery of at least 2 billion doses of its COVID-19 vaccine in 2022.  Novavax said on Monday it delivered about 42 million doses globally in the first quarter.  Serum Institute of India, the world's biggest vaccine maker, also produces the company's COVID-19 vaccine under the brand name Covovax.Novavax could be close to winning a long-awaited U.S. Emergency Use Authorization (EUA) for its vaccine.  With all of that in mind, investors were hopeful that the company's first-quarter results announced after the market closed on Monday would provide a nice catalyst.  The vaccine stock plunged in after-hours trading after Novavax missed Wall Street's Q1 estimates by a mile.These innovative, fast-paced stocks are historically cheap and ripe for the picking by opportunistic investors.By Peter NurseNovavax’s Covid-19 vaccine still isn’t approved for use in the U.S. With the pandemic in full retreat and the majority of people now fully vaccinated, demand for Novavax’s vaccine is likely to be weak. Rival pharmaceutical companies Pfizer and Moderna have beat Novavax to market with multiple Covid-19 treatments. Source: rarrarorro / Shutterstock.com Any hope that pharmaceutical company Novavax (NASDAQ:NVAX) stock will gain widespread approval to bring a Covid-19 vaccine to market is now over. TNovavax (NVAX) delivered earnings and revenue surprises of -23.12% and 19.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Shares of Novavax Inc. dropped more than 6% in the extended session Monday after the biotech company reported its first profitable quarter, but not by as much as Wall Street expected, and its sales were also below estimates.Novavax Inc on Monday revealed a sharp drop in first-quarter COVID-19 research funding and said it shipped less than a fourth of the total vaccine deliveries slated for 2022, dragging shares of the company down nearly 16% after hours.  Still, Novavax reiterated its forecast for total revenue of $4 billion to $5 billion for 2022, saying it expects shipments to key markets and sales to increase in the second quarter.  ""We expect to see additional pull through within these markets in the coming months as demand continues with recent surges of COVID around the world,"" Chief Commercial Officer John Trizzino said.The turnaround in its bottom line follows years in penny stock territory and a dramatic transformation through the pandemic.Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the first quarter ended March 31, 2022.";44.400001525878906;On Wall Street, some things never change. High inflation or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of the industry itself. Healthcare companies are unique in that their financial performances aren’t necessarily the most important piece of the puzzle. Rather, a few key factors like clinical data readouts or regulatory approvals indicate whether or not a particular name will be able to generate sustainable r;82.22000122070312;;65.41999816894531;Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.;55.119998931884766;;34.290000915527344;;53.720001220703125;;47.310001373291016;"CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -21.47% and 83.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?- More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001 Phase 3 clinical trials in pediatric patients with TDT and SCD- -Enrollment and dosing ongoing for CTX110™, targeting CD19+ B-cell malignancies; additional data expected to report in 2022- -Updates from ongoing CTX120™ and CTX130™ clinical trials anticipated in 1H2022- ZUG, Switzerland and CAMBRIDGE, Mass., May 09, 202";26.239999771118164;;23.75;;19.770000457763672;;6.050000190734863;;35.779998779296875;;22.979999542236328;;53.560001373291016;;38.20000076293945;;;;21.959999084472656;;13.4399995803833;;5.449999809265137;;5.329999923706055;;34.150001525878906;;42.310001373291016;On Wall Street, some things never change. High inflation or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of the industry itself. Healthcare companies are unique in that their financial performances aren’t necessarily the most important piece of the puzzle. Rather, a few key factors like clinical data readouts or regulatory approvals indicate whether or not a particular name will be able to generate sustainable r;53.2400016784668;Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?First quarter 2022 results reflect strong CAPLYTA® (lumateperone) launch in bipolar depression First quarter 2022 CAPLYTA new and total prescriptions increased 63% and 45%, respectively, versus the fourth quarter 2021 First quarter 2022 CAPLYTA new and total prescriptions increased 154% and 134%, respectively, versus the same period in 2021 New-to-brand CAPLYTA prescriptions, representing new patient starts, have increased approximately 300% following bipolar depression approval Total revenues fAtyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;6.639999866485596;;29.18000030517578;SOUTH SAN FRANCISCO, Calif., May 10, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will participate in the 2022 Materials Research Society (MRS) Spring Meeting and Exhibit taking place in Honolulu, Hawai’i May 8-13 and virtually May 23-25. Mr. Hellmold will participate as aTwist Bioscience Corporation (NASDAQ: TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC: ALPMF) to conduct research activities to identify and optimize proprietary Twist antagonist antibodies. The antibodies will target an undisclosed checkpoint inhibitor pathway in the tumor microenvironment as potential therapeutic development candidates. Ligands in this pathway are found in relatively high concentrations in the tumor microenvi;16.84000015258789;;26.950000762939453;Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.Allscripts' (MDRX) robust Q1 results demonstrate strength in both segments.Intersect ENT (XENT) records lower-than-expected revenues for the first quarter, with mounting operating costs impacting the bottom line.Glaukos' (GKOS) soft Q1 results fail to impress investors.SmileDirectClub's (SDC) revenues declined year over year in the first quarter due to a drop in unique aligner shipments.Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.DENTSPLY SIRONA's (XRAY) preliminary first-quarter 2022 results reflect weakness in segments.
2022-05-11;240.63999938964844;Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.;60.560001373291016;The data we presented at ECCMID 2022 is part of Gilead’s mission to advance access to effective therapies. We've helped transform the treatment and prevention of HIV and delivered HCV cures as a re...;613.0499877929688;;144.16000366210938;Novavax (NVAX) misses on both earnings and sales for the first quarter of 2022. Its shares decline in after-hours trading following the result announcement.;213.0500030517578;Partnership aims to provide better understanding of common disease risk prediction through their Polygenic Risk Score (PRS) software suite;234.9600067138672;Amicus Therapeutics (FOLD) posts a wider-than-expected loss for the first quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.;191.07000732421875;Biogen stock popped Tuesday after the company's partner, Eisai, finished submitting its application for an experimental Alzheimer's drug.Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.;121.11000061035156;;119.44999694824219;;120.41999816894531;;338.6700134277344;Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...;2.200000047683716;Evo Foods, a consumer packaged goods company creating the next generation of plant-based substitutes for animal products, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to develop a method for producing animal-free egg proteins for use in Evo's products.Better Therapeutics Inc. and Ginkgo Bioworks Holdings Inc. have positive ratings despite falling more than 59% over the past year;75.68000030517578;For many, the main point of investing is to generate higher returns than the overall market. But the main game is to...;39.650001525878906;;73.91000366210938;Eli Lilly & Co. and Incyte said Wednesday the Food and Drug Administration has approved the use of their Olumiant for the treatment of certain adults who are hospitalized with COVID-19. The treatment, also called baricitinib, will be used for patients who require oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first. The treatment has been avaEli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first.;48.20000076293945;;42.91999816894531;Novavax (NASDAQ: NVAX) reached a pretty big milestone in the first quarter: The biotech company posted its first profit as a commercial-stage company.  Novavax's profit fell short of analysts' expectations.  The advance purchase agreement with Gavi calls for Novavax to deliver 350 million doses.Novavax (NVAX) misses on both earnings and sales for the first quarter of 2022. Its shares decline in after-hours trading following the result announcement.Is Novavax stock a sell after its first full quarter of Covid vaccine sales missed estimates? Is NVAX stock a sell now?;39.939998626708984;;81.9000015258789;;62.709999084472656;;52.13999938964844;;28.950000762939453;PASADENA, Calif., May 10, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022. The company is hosting a conference call today, May 10, 2022, at 4:30 p.m. ET to discuss the results.;52.15999984741211;;43.66999816894531;;25.030000686645508;"Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the first quarter of 2022, along with recent product highlights and corporate updates.";21.450000762939453;;19.84000015258789;Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?ALAMEDA, Calif., May 10, 2022--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.;5.210000038146973;PALO ALTO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will participate in the Bank of America Securities Healthcare Conference in Las Vegas, NV on Wednesday, May 11th at 7:40 pm ET. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within th;29.959999084472656;One thing we could say about the analysts on Beam Therapeutics Inc. ( NASDAQ:BEAM ) - they aren't optimistic, having...;20.8799991607666;;50.880001068115234;;38.58000183105469;"Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 7.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today reported financial results for the first quarter ended March 31, 2022 and provided an update on its recent corporate activities and outlook.";;;19.079999923706055;;13.149999618530273;;5.039999961853027;Just because a business does not make any money, does not mean that the stock will go down. For example, although...Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended March 31, 2022.;4.670000076293945;;33.029998779296875;;38.40999984741211;;53.380001068115234;For the quarter, Intra-Cellular booked $35 million in revenue, almost double the $15.9 million the company earned in the same quarter last year.  Caplyta is a relatively new drug on the market, having won Food and Drug Administration (FDA) approval last December.  Intra-Cellular's net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021's $52.7 million deficit.;5.71999979019165;AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?VANCOUVER, British Columbia, May 10, 2022--AbCellera Reports Q1 2022 Business Results;26.6200008392334;;15.289999961853027;;26.399999618530273;Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.Investors are optimistic about Henry Schein (HSIC) on favorable international Dental business trends and bullish guidance.National Vision (EYE) reports better-than-expected earnings and an increase in store count for the first quarter.Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and expansion in gross margin.Amicus Therapeutics (FOLD) posts a wider-than-expected loss for the first quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
2022-05-12;244.72000122070312;Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the campaign, he has created a fun and educational dance to help make it easy for everyone to recognize the early signs and symptoms of psoriatic arthritis, a condition Bass has lived wReaders hoping to buy Amgen Inc. ( NASDAQ:AMGN ) for its dividend will need to make their move shortly, as the stock is...;62.47999954223633;The market’s scary. But dividends can provide some comfort.In this article, we discuss the 15 best income stocks to invest in. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Best Income Stocks To Invest In. Stocks can be incredibly volatile, and 2022 has provided yet another reminder of that fact. With stocks […];633.9600219726562;Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...;158.0;;217.4199981689453;Cancer is the second leading cause of death and cancer care costs $1 trillion annually.;240.85000610351562;Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.;194.32000732421875;Biogen and development partner Eisai are looking to get their next Alzheimer's drug to market using the FDA's accelerated approval pathway.;131.47999572753906;CAMBRIDGE, Mass., BEIJING & BASEL, Switzerland, May 12, 2022--BeiGene announced 20 presentations from the Company’s global clinical development programs in hematologic malignancies at EHA.A Roche failure in lung cancer sent a ripple through biotech stocks on Wednesday, toppling Arcus, BeiGene, Iteos and others.;127.0999984741211;Seagen Inc. ( NASDAQ:SGEN ) shareholders might be concerned after seeing the share price drop 17% in the last month. On...;121.33000183105469;;348.8800048828125;Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria® bladder cancer diagnostic panel using xMAP Luminex® technology.;2.380000114440918;;76.37999725341797;;40.91999816894531;;75.51000213623047;The FDA grants full approval to Lilly (LLY) and Incyte for COVID-19 in certain hospitalized adults. Olumiant is already authorized for emergency use for this indication since November 2020.;48.2599983215332;;47.97999954223633;;42.599998474121094;The last three months have been tough on Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders, who have seen the...;82.83000183105469;;63.279998779296875;;53.349998474121094;;30.309999465942383;;54.029998779296875;;46.540000915527344;ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that an abstract providing safety and efficacy data from the ongoing CTX130™ clinical trial for patients with T-cell lymphoma has been accepted for oral presentation at the Annual European Hematology Association (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022;27.06999969482422;;21.809999465942383;;19.799999237060547;Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.;5.940000057220459;BridgeBio Pharma Inc (NASDAQ: BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE: BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the agreement terms, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in the low- to mid-teens. BridgeBio will retain the option to acquire higher royalties in the U.S. in connectio- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments and royalties -SHP2 inhibitor deal expands earlier agreement between BridgeBio and Bristol Myers Squibb to study BBP-398 in combination with OPDIVO® (nivolumab) in advanced solid tumors with KRAS mutations - BridgeBio will continue to lead its three current Phase 1 monotherapy and BBP-398 combination therapy trials with additional support froMarket forces rained on the parade of BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) shareholders today, when the analysts...;31.440000534057617;;21.829999923706055;Shareholders in Denali Therapeutics Inc. ( NASDAQ:DNLI ) may be thrilled to learn that the analysts have just delivered...;50.41999816894531;;39.040000915527344;"Bernzott Capital Advisors, an investment management firm, published its “US Small Cap Value Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. The portfolio fell -4.6% (gross), modestly below the Russell 2000 Value’s decline of -2.4% and the Russell 2500 Value’s decline of -1.5% for the first quarter of […]Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the ""HSR Act""), applicable to Halozyme's proposed acquisition of Antares Pharma, Inc. (NASDAQ: ATRS) (""Antares"") has expired.";;;20.639999389648438;;12.989999771118164;;5.360000133514404;Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.;4.989999771118164;;35.119998931884766;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022.;40.439998626708984;;55.220001220703125;Intra-Cellular Therapies shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.;6.710000038146973;Shares of contract drug developer AbCellera Biologics (NASDAQ: ABCL) are down 10% as of 12:04 p.m. ET today, according to data from S&P Global Market Intelligence, following Piper Sandler's lowered price target despite a seemingly strong earnings report.  For the three-month stretch ending March 31, biopharma outfit AbCellera Biologics turned $316.6 million worth of revenue into earnings of $0.54 per share.  While AbCellera Biologics' CEO Carl Hansen is unsurprisingly optimistic about the future, that's a future in which the drugs' combined revenue contribution could fade -- significantly.;29.489999771118164;The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...;16.030000686645508;;26.56999969482422;Robust performances across all four reporting segments drive STERIS' (STE) fiscal fourth-quarter revenues.According to Globus Medical (GMED), its Q1 results reflect modest revenue growth against a difficult prior-year comparison, coupled with COVID-related revenue impacts in key countries.Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023. BHVN also reports wider-than-expected Q1 loss.
2022-05-13;243.39999389648438;Amgen, Altria Group, Uber Technologies, Microchip Technology, and Arista Networks are part of Zacks top Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Altria Group, Inc. (MO), and Uber Technologies, Inc. (UBER).;62.369998931884766;One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...Gilead Sciences shows improving price performance, earning an upgrade to its IBD Relative Strength RatingThe day after Lee Raines found out he acquired HIV, he was arrested by police in New York. It was 1989, and he was one of thousands of people who attended a protest against New York City’s policy t...Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.;645.52001953125;Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog;158.83999633789062;;233.55999755859375;;246.72000122070312;;199.11000061035156;;132.8699951171875;;135.6300048828125;;126.47000122070312;;367.7699890136719;;2.6600000858306885;;77.7300033569336;;47.630001068115234;;74.9000015258789;;52.290000915527344;;51.88999938964844;Down more than 68% year to date, Novavax (NASDAQ: NVAX) shares just can't catch a break.  Between interest rate-driven chaos in the market and a slew of regulatory and logistical setbacks for the biotech's attempt to profitably commercialize its coronavirus vaccine candidate, Nuvaxovid, the era of Novavax as a high-flying pandemic stock appears to be over.  Now, investors are once again faced with determining whether the company remains a good investment, given its issues.The big news for Novavax (NASDAQ: NVAX) investors this week was that the company reported its first-ever quarterly profit.  Regardless of whether or not you think Novavax's COVID-19 vaccine will obtain Emergency Use Authorization from the U.S. Food and Drug Administration this year, the business needs to have products that can generate long-term growth beyond just COVID.  There's the possibility that health officials will administer booster shots annually for COVID either by themselves or in conjunction with a flu shot.;48.599998474121094;;84.12000274658203;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valbenazine as a treatment for Huntington disease (HD). The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation. In December 2021, Neurocrine Biosciences reported top-line data from its Phase 3 KINECT-HD study evaluating the efficacy, safety and tolerability of valbenazine, a selective vesicular monoam;65.97000122070312;;56.84000015258789;;31.639999389648438;;54.95000076293945;;52.22999954223633;Shares of Editas Medicine (NASDAQ: EDIT), a genome editing biotech company that uses CRISPR/Cas9 and CRISPR/Cas12a genome editing systems to develop therapies, saw its shares plummet 28.9% this week, according to data from S&P Global Market Intelligence.  Editas' shares have steadily fallen this year, but it is hardly alone among gene-editing companies.  Intellia Therapeutics is down more than 63% so far this year while CRISPR Therapeutics has seen its shares drop more than 38%.Let's look at two stocks that boast significant upside potential, going by average price targets set by analysts on the street: Moderna (NASDAQ: MRNA) and CRISPR Therapeutics (NASDAQ: CRSP).  Biotech giant Moderna fell along with the broader market in recent months.  Moderna currently generates revenue from just one product: its coronavirus vaccine.Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.;33.220001220703125;;24.219999313354492;;20.079999923706055;With its stock down 11% over the past month, it is easy to disregard Exelixis (NASDAQ:EXEL). But if you pay close...;6.619999885559082;Because of this stock market crash, some wonderful stocks are super cheap in 2022. Here's a mini-portfolio of innovative companies trading under $10 a share right now.-Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021 for $110 million -Secured a two-year extension of interest-only period on its existing senior secured credit facility PALO ALTO, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has entered into a definitive agreemen;35.45000076293945;;22.860000610351562;;51.470001220703125;;40.41999816894531;;;;22.6299991607666;Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ: VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline, which includes compounds in development for chronic hepatitis B virus (CHB), human immunodeficiency viru;13.449999809265137;;5.53000020980835;;5.840000152587891;;36.08000183105469;;43.130001068115234;;59.099998474121094;Intra-Cellular Therapies (NASDAQ: ITCI), a biotech that specializes in therapies to treat complex psychiatric and neurologic diseases, saw its shares rise 21.4% this week through today's close, according to data from S&P Global Market Intelligence.  The drug was initially approved by the Food and Drug Administration (FDA) in the first quarter of 2020 as a treatment for adult schizophrenia.  In late December, an additional indication, as a monotherapy or adjunct treatment for bipolar depression, was approved by the FDA.;7.230000019073486;AbCellera Biologics Inc. ( NASDAQ:ABCL ) shareholders will have a reason to smile today, with the analysts making...;34.290000915527344;;16.850000381469727;;26.8799991607666;NEOGEN's (NEOG) recent launch enables simultaneous low-pass whole genome sequencing and high-coverage genotyping at regions of interest.This National Women’s Health Week, Alkermes’ Director of Corporate and R&D Communications, Gretchen Murphy, shares her personal story and why regular cancer screenings are vital. This NWHW, we enco...AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.
2022-05-16;243.8699951171875;;62.2400016784668;;655.010009765625;;151.1999969482422;;233.74000549316406;;254.1699981689453;;198.3800048828125;;129.17999267578125;;142.5399932861328;BOTHELL, Wash., May 16, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger Dansey, M.D., Seagen’s Chief Medical Officer since 2018, will continue as interim CEO until a new CEO is found.;124.87000274658203;;362.1300048828125;;2.430000066757202;;77.31999969482422;;46.29999923706055;;74.51000213623047;;50.54999923706055;;48.0;;45.959999084472656;;84.87999725341797;;67.52999877929688;;56.470001220703125;;32.880001068115234;By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Cardiometabolic Programs Progressing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has two late-stage cardiometabolic programs, ARO-APOC3 and ARO-ANG3. ARO-APOC3 is targeted to apolipoprotein C-III (APOC3), a component of very low-density lipoprotein (VLDL) and an inhibitor of lipoprotein lipase. This program is;56.209999084472656;;51.540000915527344;Despite recent declines in share prices, these Cathie Wood stocks are strong plays on innovation, a key driver of the global economy. Block (SQ) — The launch of Square Loans in Canada as well as the new generation of the Square Stand could provide a significant path to revenue growth. CRISPR Therapeutics (CRSP) — Substantial global investment in genetic engineering is likely to pave the way for tremendous growth. Shopify (SHOP) — The recent acquisition of Deliverr is likely to improve logistics;32.939998626708984;;22.639999389648438;;20.260000228881836;;6.739999771118164;;32.540000915527344;;23.270000457763672;;55.2599983215332;;41.689998626708984;Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.;;;22.280000686645508;;13.520000457763672;;5.699999809265137;;5.510000228881836;;36.599998474121094;;42.45000076293945;;58.91999816894531;;7.809999942779541;;32.29999923706055;;16.600000381469727;;28.93000030517578;
2022-05-17;245.35000610351562;As concerns over a looming recession grow, these are some blue-chip stocks to buy that could help decrease portfolio volatility. 3M (MMM): The recent purchase of LeanTec could improve long-term growth projections Amgen (AMGN): A new manufacturing facility in North Carolina could help expand revenue and drive down costs. Boeing (BA): Relocating headquarters close to Washington, D.C. signals a shift to defense technologies. JP Morgan Chase (JPM): Investments in cloud-based share management technol;63.18000030517578;The FDA has lifted the clinical hold placed on Gilead Sciences Inc's (NASDAQ: GILD) Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis. The agency has removed the clinical hold after reviewing Gilead's comprehensive plan and corresponding data on the storage and compatibility of lenacapavir injection with an alternative vial made from aluminosilicate glass. Related: FDA Slaps Clinical Hold On Gilead's Injectable LenacapavirGilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.FOSTER CITY, Calif., May 16, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP). As previously announced, the FDA had placed a clinical hold on the use of injectable lenacapavir in borosilicate vials due to a vial compatibility issue. FDA removed the clinical;667.5599975585938;Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc. with participation from existing investors. Stine Seed Farms joins Mayo Clinic, Mirae Asset, Regeneron Pharmaceuticals Inc., Southeast Minnesota Capital Fund (SMCF), and several high-net-worth individuals on the Vyriad investment roster. This round adds to a prior closing for Vyriad's Ser;159.8000030517578;NEW YORK & MAINZ, Germany, May 17, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) expanded emergency use authorization (EUA) to include a booster dose after completion of the primary series of the Pfizer-BioNTech COVID-19 Vaccine in children 5 through 11 years of age. The booster dose is given at least five months after the second dose of the two-dose primary series and is the same 10-µg dose of the Pfizer-BioNTech COVID-1The federal government is again offering Americans free COVID-19 test kits through the mail, allowing for up to eight more tests to be ordered through the USPS.The Food and Drug Administration said Tuesday that children between the ages of 5 and 11 years old can get a booster dose of BioNTech SE and Pfizer Inc.'s COVID-19 vaccine. Children in this age group should wait at least five months after getting the primary series of shots. The regulator authorized a booster of the BioNTech/Pfizer vaccine for teens back in January. The FDA's advisory committee did not meet to discuss whether the benefits of a third dose of the BioNTech/Pfizer vaccine outweigh tChildren ages five to 11 can receive the booster at least five months after receiving the first two doses of the Pfizer-BioNTech Covid-19 vaccine.By Liz Moyer;243.22000122070312;MENLO PARK, Calif. & SALT LAKE CITY, May 17, 2022--Intermountain Healthcare will offer Galleri®, GRAIL's multi-cancer early detection blood test, as a complement to existing single cancer screenings.;261.8399963378906;BOSTON, May 17, 2022--At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced plans to build another 344,000 square foot facility in the Seaport to support the company’s continued rapid growth, in particular the expansion of its cell and genetic therapies programs. With the completion of this new site expected in 2025, Vertex will occupy 1.9 million square feet of real estate in the SeBOSTON, May 17, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex and the Vertex Foundation, a nonprofit charitable foundation, have committed $50 million over five years to clinical trial diversity, access to quality care, and education of our health care workforce. The donations are an extension of Vertex’s long-standing commitment to inclusion, diversity and equity and the existing work of the Vertex Foundation to promote these values through education, innoWhile CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.;202.89999389648438;If you want to know who really controls Biogen Inc. ( NASDAQ:BIIB ), then you'll have to look at the makeup of its...;138.5800018310547;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, May 17, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new regional office in Basel, Switzerland. BeiGene has built a European organization, including commercial and clinical teams, and this new location will serve as a hub for the company’s operations in the region.";146.5500030517578;Clay Siegall, who co-founded the Bothell-based biotech in 1998, first took a leave of absence from the company starting May 9, more than two weeks after his arrest.;129.30999755859375;;371.04998779296875;;2.740000009536743;"Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, ""Ginkgo""), the leading horizontal platform for cell programming, today announced its results for the first quarter ended March 31, 2022. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.";79.12000274658203;;49.459999084472656;;75.51000213623047;;54.11000061035156;;51.95000076293945;;48.33000183105469;In this article, we discuss the 10 biggest losers in Cathie Wood’s latest portfolio. If you want to skip our detailed analysis of Wood’s hedge fund performance, history and stock selection, go directly to 5 Biggest Losers in Cathie Wood’s Latest Portfolio. Cathie Wood became a superstar money-manager in 2020, the very year stock markets […];85.80000305175781;;71.30000305175781;;59.9900016784668;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Laurie Stelzer as the Company's Chief Financial Officer (CFO) effective May 16, 2022. Laurie will report to the Company's Chief Executive Officer, David Meek.;35.77000045776367;;58.470001220703125;;54.36000061035156;ZUG, Switzerland and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D., FACP, as Chief Medical Officer, effective May 23, 2022. Dr. Morrow brings more than a decade of leadership experience in global drug development and joins CRISPR Therapeutics to lead the Company’s global clinical deveWhile CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.;35.349998474121094;;23.729999542236328;;20.690000534057617;The stock market is highly volatile now.  Robotic-assisted surgery is the future of surgery, and Intuitive Surgical (NASDAQ: ISRG) is already dominating the space.  Biotech company Exelixis (NASDAQ: EXEL) and internet retail company Etsy (NASDAQ: ETSY) also have remarkable growth prospects that could bring in some exciting long-term returns.;7.429999828338623;PALO ALTO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: Citi Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Panel, Virtual: Wednesday, May 18th at 2:30 pm ETH. C. Wainwright Global Investment Conference, Virtual: Tuesday, May 24th;34.06999969482422;;25.1200008392334;;54.349998474121094;ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy (ASGCT) today NOVATO, Calif. and NEW YORK and CLEVELAND, May 17, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome;44.459999084472656;Community Health (CYH) employs PeriGen's technology to bring about enhanced obstetrics services and assure the safety of mothers as well as babies in the labor and delivery procedures.;;;23.09000015258789;;13.979999542236328;;6.110000133514404;;5.730000019073486;;38.75;;45.33000183105469;;59.40999984741211;;8.149999618530273;;33.90999984741211;●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our N;17.049999237060547;;29.690000534057617;
2022-05-18;243.9600067138672;;63.220001220703125;Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.Joey sold his business and felt like he was living the American dream when his life was turned upside down in 2019. He was diagnosed with metastatic bladder cancer.FOSTER CITY, Calif. & SANTA MONICA, Calif., May 17, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that more than 20 abstracts, including two oral presentations and four poster discussions, will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. These data highlight promising targets across diverse tumor types and blood cancers, including hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER;659.2000122070312;;157.05999755859375;Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.Vaccine stocks Pfizer and BioNTech rose moderately Tuesday after the Food and Drug Administration signed off on Covid boosters for children.The FDA has authorized a booster shot of Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine for children aged 5 to 11. Kids will be eligible for the booster at least five months after completing a primary series with the Pfizer-BioNTech COVID-19 Vaccine. The move makes everyone in the U.S over the age of 5 eligible for a third shot or a booster. The U.S. Centers for Disease Control and Prevention still needs to sign off on the shots before they can be administered. Also ReaWhat happened Shares of BioNTech (NASDAQ: BNTX) were up by 5.6% as of 3:24 p.m. ET Tuesday. The gain came after the Food and Drug Administration (FDA) expanded the Emergency Use Authorization (EUA) for the COVID-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech to include booster doses for 5- through 11-year-olds.;239.80999755859375;SAN DIEGO, May 18, 2022 /3BL Media/ - Illumina has been included for the first time on the 2022 100 Best Corporate Citizens list by 3BL Media, recognizing outstanding environmental, social, and gov...Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.;252.35000610351562;"BOSTON, May 18, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (""Suky"") Upadhyay has been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life sciences sector. He is currently the Executive Vice President and Chief Financial Officer of ZimmeVertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.The new site will be across Northern Avenue from a research and manufacturing facility that it formally dedicated to executive chairman Jeffrey Leiden on Tuesday.";195.7100067138672;;131.08999633789062;;143.0;;128.30999755859375;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing OXLUMO™ (lumasiran) injection for subcutaneous use for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in paediatric and adult patients.1;359.0899963378906;;2.430000066757202;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and First Serv, a Qatari investment holding company, today announced that they have entered into a non-binding Memorandum of Understanding (MOU) to develop and implement new biosecurity capabilities in Qatar. The partners to the MOU recognize the importance of international collaboration and cooperation to effectively prevent and respond to biological threats in this global age. The initial goal of the partnership;78.18000030517578;;47.33000183105469;;73.38999938964844;With that as a backdrop, let's consider two biotech stocks that don't grab a lot of headlines but deserve serious consideration: Incyte (NASDAQ: INCY) and Axsome Therapeutics (NASDAQ: AXSM).  Incyte is a drugmaker with a particular focus on the field of oncology.  Its best-selling product is called Jakafi, which treats some types of bone marrow cancer, among other conditions.;52.0;;52.11000061035156;;46.939998626708984;;84.94999694824219;;68.47000122070312;;57.68000030517578;;34.20000076293945;;55.5;;54.7599983215332;Vertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.;34.5099983215332;;21.829999923706055;;19.489999771118164;The stock market continues to be under pressure due to geopolitical tensions and various economic problems.  For instance, cancer-focused biotech company Exelixis (NASDAQ: EXEL) has run circles around the broader market year to date.  Can Exelixis continue beating the market from here on out?;7.090000152587891;Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.;32.029998779296875;;23.190000534057617;;47.70000076293945;Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.;43.0;;;;22.709999084472656;;13.579999923706055;;6.0;;5.21999979019165;;38.38999938964844;;42.84000015258789;;58.5;;8.029999732971191;;34.279998779296875;SOUTH SAN FRANCISCO, Calif., May 18, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 2022 UBS Global Healthcare Conference on Monday, May 23 at 9:15 a.m. Eastern Time in New York.;16.040000915527344;;28.8700008392334;
2022-05-19;244.77000427246094;Dividend stocks are a great way to buffer your portfolio against the uncertainty in the market, especially when thinking long-term. Bank of New York Mellon (BK) was originally owned by Alexander Hamilton and has been around since 1784. Fifth Third Bancorp (FITB) is one of the top regional banks in the country and continues to drive innovation. Intel (INTC) remains a premier chipmaker and bringing chipmaking back to the U.S. will help its long-term stability. Merck (MRK) may have missed out on th;63.27000045776367;;657.1500244140625;;167.8699951171875;;240.75;Study will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient's cancer, which may influence choice of treatment based on cancer stage and type;255.4499969482422;Alibaba, McDonald, Advanced Micro Devices, Abbott Laboratories, and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.Last year, things couldn't have gone more swimmingly for the stock market.  The Federal Reserve was intent on maintaining its dovish monetary stance, and historically low interest rates were fueling hiring, acquisitions, and innovation throughout the tech sector.  Although some aspects of inflation have been out of the Federal Reserve's control (e.g., Russia invading Ukraine), hindsight has demonstrated that the nation's central bank left its foot on the accelerator for far too long.Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), McDonald's Corporation (MCD), and Advanced Micro Devices, Inc. (AMD).;193.08999633789062;;131.6699981689453;;142.6300048828125;;129.36000061035156;;366.44000244140625;Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022, at 9:30 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;2.5199999809265137;;79.27999877929688;;49.869998931884766;;74.33999633789062;;54.0;;58.43000030517578;;47.709999084472656;;85.37000274658203;;69.22000122070312;;59.61000061035156;;35.150001525878906;;56.959999084472656;;56.4900016784668;;35.720001220703125;;22.399999618530273;;17.440000534057617;;7.389999866485596;;33.939998626708984;;23.770000457763672;;47.0;Durable and clinically meaningful responses sustained for more than three years post-treatment in study of DTX401 for GSDIa and four or more years in study of DTX301 for OTC NOVATO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced positive longer-term efficacy and safety data from Phase 1/2 studies;43.84000015258789;We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.;;;24.93000030517578;SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20, 2022, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast. Vir Biotechnology’s stockholders of record as of March 28, 2022 (the “Record Date”) can attend and vote at the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/VIR2AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.;13.819999694824219;;6.710000038146973;Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, and Lonza announced today the opening of a new, custom-built, bioconjugation facility within Lonza's Ibex® Dedicate manufacturing complex in Visp (CH).;5.599999904632568;;39.130001068115234;;44.06999969482422;;57.72999954223633;;8.300000190734863;;37.45000076293945;;16.829999923706055;With the business potentially at an important milestone, we thought we'd take a closer look at ACADIA Pharmaceuticals...;29.479999542236328;
2022-05-20;247.5;;63.84000015258789;In the winter 2019, Kavita Juneja found herself at the center of a maelstrom. A strange and deadly virus known as SARS-CoV-2 was hurtling across the globe.A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue?;661.1400146484375;;163.0;The Centers for Disease Control and Prevention recommended that children ages 5 to 11 receive the newly authorized COVID-19 booster shot from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX). Following the recommendation, many of the nation's doctors, pharmacies, and other vaccination sites are expected to begin offering the extra doses to the 28 million U.S. children in the age group. The shots are to be given five months after the second dose. The extra dose is one-third of those 12 yearsThe daily average for new COVID-19 cases topped the 100,000 mark of the third straight day and hospitalizations keep rising, but deaths fell to a 10-month low. Meanwhile, advisors to the Centers for Disease Control and Prevention recommended that children aged 5 to 11 receive the COVID-19 booster shot from Pfizer Inc. and BioNTech SE that was cleared by the Food and Drug Administration earlier this week. The seven-day average of new cases was 103,537 on Thursday, up 52% from two weeks ago and thAn overall market rebound and Tuesday's authorization of boosters for kids likely propelled the stock higher.;243.49000549316406;Illumina strives to create a purpose-driven culture with opportunities for employees to volunteer in their community through organizations that matter most to them. Each year, employees at Illumina...;258.5899963378906;;199.64999389648438;The pandemic, inflation, rising interest rates, the war in Ukraine and other factors have made for a bumpy two-plus years for businesses. The largest Massachusetts public companies give insight into which companies have fared best and worst.;137.32000732421875;;139.63999938964844;;132.27000427246094;Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.;366.3500061035156;;2.609999895095825;;79.72000122070312;;50.15999984741211;;74.87999725341797;Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT® (baricitinib) for the treatment of adults with severe alopecia areata (AA).;53.16999816894531;;53.41999816894531;;47.7400016784668;;86.18000030517578;;71.12999725341797;;63.349998474121094;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.;36.209999084472656;;57.369998931884766;;56.34000015258789;;36.790000915527344;;23.100000381469727;;17.760000228881836;;7.610000133514404;- PTR-01 was well-tolerated over a four-month treatment period in RDEB patients - Treatment with PTR-01 led to rapid, consistent, and durable wound healing as observed in reduction of wound surface area and clinician-reported assessments - All patients that completed the study reported a decrease in pain over the course of treatment with PTR-01 PALO ALTO, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair, which is focused o;35.189998626708984;;24.719999313354492;;48.54999923706055;;44.31999969482422;Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.;;;24.360000610351562;;14.510000228881836;;6.960000038146973;;5.610000133514404;;39.4900016784668;;44.63999938964844;;57.880001068115234;;7.900000095367432;;36.9900016784668;;17.110000610351562;;30.0;
2022-05-23;249.0399932861328;Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.J&J's immunology mega-blockbuster loses exclusivity in the U.S. next year -- and Amgen's biosimilar is ready to capitalize.;63.65999984741211;JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical have been included in this Analyst Blog.;681.9099731445312;"The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced positive results from a Phase 3 trial evaluating Evkeeza (evinacumab) in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). HoFH is a disorder where it is hard for the body to remove LDL ""bad"" cholesterol from the blood, raising the chances of a heart attack at an early age. The trial met its primary endpoint. It showed that children who added Evkeeza to other lipid-lowering therapies reduced their low-density lipopr";163.22000122070312;"Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.  The companies said they plan to soon ask global regulators to authorize the shot for the age group, children for whom no vaccine is currently approved in most of the world.  The clinical trial involved giving 1,678 children ages 6 months to under 5 years smaller doses of the vaccine than given to older children and adults.Pfizer releases data on Monday that suggest a three-dose series of its Covid-19 vaccine is highly effective at protecting children aged six months to under five years.Shares of Pfizer Inc. rose 0.3% and BioNTech SE rallied 1.3% in premarket trading, after the drug makers said three doses of it COVID-19 vaccine for children aged six months to five years ""met all immunobridging criteria"" required for Emergency Use Authorization by the U.S. Food and Drug Administration. The companies said the vaccine showed 80.3% efficacy in an analysis of three doses at a time when omicron was the dominant variant, with a favorable safety profile, similar to placebo. ""The studyNEW YORK & MAINZ, Germany, May 23, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. Following a third dose in this age group, the vaccine was found to elicit a strong immune response, with a favorable safety profile similar to placebo.Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under the age of five in their clinical trial.  The companies said the vaccine was safe and well-tolerated by the children, and they plan to soon ask global regulators to authorize the shot for the age group, children for whom no vaccine is currently approved in most of the world.  Pfizer and BioNTech said that three shots of a 3 microgram formulation of their vaccine generated a similar immune response in children aged six months to under five years of age as in 16 to 25-year-olds who had received two doses of the 30 microgram formulation of the vaccine in an earlier clinical trial.";245.07000732421875;;268.3500061035156;SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash. Management Comments“We have been exploring strategic alternatives to monetize our assets and maximize value f;199.39999389648438;As a purpose-driven company, Biogen seeks ways to reinforce our commitment to climate, health and equity. Our newly released 2021 Year in Review reports on our progress on these and other prioritie...With the Triangle boasting one of the hottest job markets in the U.S., commercial real estate investors are holding firm in lease negotiations and banking on a flight to quality among corporate tenants seeking more highly amenitized office spaces to entice employees back to the office.;135.1699981689453;;139.33999633789062;BOTHELL, Wash., May 23, 2022--Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the pivotal phase 2 MOUNTAINEER clinical trial investigating TUKYSA® (tucatinib) in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC). Data from this trial will form the basis of a planned supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) under the FDA’s Accelerated Approval Program. Merck, known as M;129.5800018310547;CAMBRIDGE, Mass., May 23, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new positive results from an 18-month analysis of exploratory cardiac endpoints in the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. The 18-month findings show that in a pre-defined cardiac subpopulation, treatment with vutrisiran was associated with improveme;364.510009765625;;2.680000066757202;;80.36000061035156;;49.7599983215332;;76.91000366210938;The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.;52.0;Investors are optimistic about Exact Sciences (EXAS) on impressive Q1 results and a bullish 2022 outlook.;51.400001525878906;;47.31999969482422;;86.48999786376953;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data on the use of INGREZZA® (valbenazine) capsules for the treatment of tardive dyskinesia (TD) at the American Psychiatric Association (APA) Annual Meeting being held in person May 21-25 in New Orleans and virtually June 7-10.;71.61000061035156;;63.58000183105469;;36.04999923706055;;56.90999984741211;;54.709999084472656;;37.06999969482422;;22.600000381469727;;17.75;;7.340000152587891;;34.9900016784668;;24.399999618530273;;47.939998626708984;;44.33000183105469;;;;24.139999389648438;;14.880000114440918;;6.849999904632568;;5.739999771118164;;39.470001220703125;;43.130001068115234;;58.40999984741211;;7.670000076293945;;37.41999816894531;;16.790000915527344;;29.299999237060547;
2022-05-24;251.88999938964844;;64.3499984741211;;686.02001953125;Regeneron Pharmaceuticals, Inc. (REGN) stock has jumped, rising 34.6% over the past year.Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.;154.5;Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).Pfizer (PFE) and BioNTech (BNTX) state that their three-dose COVID-19 vaccine is 80% effective in children under five years of age.The Food and Drug Administration said Monday an advisory panel would meet June 15 to discuss use of the vaccines developed by Pfizer Inc. and German partner BioNTech SE as well as the one developed by Moderna Inc. in children aged 6 months to four years old. The announcement came after Pfizer and BioNTech said three doses of their vaccine proved 80% effective at preventing symptomatic infections in children in that cohort. If the panel adopts a positive opinion on the shots, the FDA could authorVaccine stocks edged higher Monday after Pfizer said its three-dose Covid vaccine was more than 80% effective in toddlers and infants.;240.25999450683594;"Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS - - DYNS announces effectiveness of registration statement on Form S-4 - - Meeting of DYNS stockholders to approve proposed business combination scheduled for Tuesday, June 7, 2022 at 10:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Senti BioscienFOSTER CITY, Calif., May 24, 2022--Illumina Ventures promotes Malek Faham to Chief Scientist, and adds Charles Lin as Principal and Dave Johnson as Entrepreneur in Residence.";268.4800109863281;;202.5399932861328;The executive who replaces Michel Vounatsos will inherit a large-cap biotech facing significant challenges.;122.98999786376953;;133.47000122070312;;127.05000305175781;CAMBRIDGE, Mass., May 24, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new positive results from the six-month primary analysis period of the ILLUMINATE-C Phase 3 open-label study of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – that is being investigated for the treatment of patients of all ages with advanced primary hyperoxaluria type 1 (PH1). As previously reporte;357.1700134277344;;2.5799999237060547;;78.77999877929688;;45.720001220703125;;75.11000061035156;WILMINGTON, Del., May 24, 2022--Incyte (Nasdaq:INCY) announced today that it will present at the 43rd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 14, 2022 at 8:00 a.m. (PDT) /11 a.m. (EDT) in Rancho Palos Verdes.;47.88999938964844;;46.540000915527344;;42.90999984741211;;84.5999984741211;;68.83999633789062;;58.79999923706055;;33.79999923706055;;55.33000183105469;;52.380001068115234;;34.04999923706055;"SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following investor conferences in June: Jefferies Global Healthcare Conference 2022Presentation: Thursday, June 9, 2022, 9:00 a.m. ET Goldman Sachs 43rd Annual Global Healthcare ConferenceFireside Chat: Thursday, June 16";21.139999389648438;;17.700000762939453;;6.71999979019165;;31.440000534057617;;23.25;;45.79999923706055;;44.81999969482422;"Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today announced the successful completion of its acquisition of Antares Pharma, Inc. (""Antares"").";;;22.81999969482422;;13.979999542236328;;6.519999980926514;;5.389999866485596;;37.11000061035156;;41.279998779296875;;56.959999084472656;;7.260000228881836;;34.939998626708984;;15.979999542236328;;28.350000381469727;
2022-05-25;253.00999450683594;Buying quality retirement stocks can provide both safety and growth to keep savings goals on track AbbVie (ABBV): With revenue concerns abating, it’s time to take a fresh look at this dividend king. Amgen (AMGN): This biotech giant has an ideal combination of in-market products and products in its pipeline. Apple (AAPL): Make this tech giant prove that the bears are right before abandoning its stock. Dollar General (DG): Inflation and a weakening economy will help keep the revenue coming. Wester;65.01000213623047;It is the fourth strike this year against Bay Area drug developers trying to find a potential cure for hepatitis B.FOSTER CITY, Calif., May 25, 2022 /3BL Media/ Gilead Sciences, Inc. (Nasdaq: GILD) was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report ...;690.8800048828125;Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.;154.6699981689453;AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.;242.39999389648438;Illumina's (ILMN) first companion diagnostic claim for TSO Comprehensive (EU) will help identify cancer patients with NTRK gene fusions for a genomically matched treatment.First companion diagnostic claim for Illumina's TruSight™ Oncology Comprehensive (EU) test enables targeted therapy with Bayer's VITRAKVI® (larotrectinib) for patients with NTRK fusion cancer;270.8399963378906;On Tuesday, Vertex Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. Keep an eye out to see if VRTX stock sees more buying action from institutional investors. The new Composite score means the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.;202.36000061035156;;127.41000366210938;;136.47000122070312;;126.75;Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced new results from the six-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran for primary hyperoxaluria type 1 (PH1). PH1 is a rare disorder that mainly affects the kidneys. It results from the buildup of a substance called oxalate, typically filtered through the kidneys and excreted in the urine. Treatment with lumasiran resulted in substantial reductions in plasma oxalate (POx) at six months. Read Next: See Why Di;352.80999755859375;Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a global study in the Journal of Electrophoresis: Global Intercompany Assessment of icIEF Platform Comparability for the Characterization of Therapeutic Proteins. This publication reports the findings of a multi-company study focused on the comparability of the iCE3 and Maurice instruments, two gold standard analytical platforms for charge heterogeneity analysis of therapeutic proteins. Bio-Techne pioneered the use of image;2.880000114440918;;78.93000030517578;;45.869998931884766;;76.51000213623047;;48.43000030517578;;46.130001068115234;;43.810001373291016;;88.37999725341797;"Neurocrine Biosciences, Inc. (Nasdaq: NBIX) (the ""Company"" or ""Neurocrine Biosciences"") today announced that it has entered into separate, privately negotiated transactions (the ""Agreements"") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the ""2024 Notes"") to repurchase approximately $179.4 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of an amount of cash estimated to be the sum of (i) approximately $224.0 million, (ii) an";68.48999786376953;;58.02000045776367;;33.970001220703125;;55.939998626708984;;54.54999923706055;;32.11000061035156;;21.850000381469727;;17.809999465942383;;6.630000114440918;;31.969999313354492;;22.93000030517578;;45.91999816894531;;46.290000915527344;Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.;;;23.65999984741211;;14.260000228881836;;6.679999828338623;;5.369999885559082;In this article, we discuss the 2022 portfolio of Korean-Japanese Billionaire Masayoshi Son and the 10 stocks to watch. If you want to skip our detailed analysis of Son’s stock picks and hedge fund history, go directly to Korean-Japanese Billionaire Masayoshi Son’s 2022 Portfolio: 5 Stocks to Watch. Masayoshi Son is the CEO, Chairman and […];36.86000061035156;;40.84000015258789;;56.66999816894531;;7.5;;35.16999816894531;;15.960000038146973;;28.850000381469727;
2022-05-26;253.0500030517578;Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.With the COVID-19 crisis sending the U.S. economy in a recession, we're looking at what companies managed to thrive during the last recession for guidance.;64.47000122070312;Based on the review of approximately 460 patients, Data Safety and Monitoring Board (DSMB) determined that the evaluation of NRx Pharmaceuticals Inc's (NASDAQ: NRXP) Zyesami (aviptadil) should cease due to futility. Aviptadil was the sole remaining investigational medicine in ACTIV-3b targeted at critical-ill COVID-19 patients. ACTIV-3b study evaluated Zyesami and Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) as monotherapy and in combination against placebo. Also Read: NRx Pharmaceu;683.4400024414062;Biotechnology giant Regeneron's (NASDAQ: REGN) eye medication EYLEA is one of the best-selling blockbuster drugs around, generating $9.4 billion sales globally in 2021.  The drug is approved for a number of eye diseases and has been a mainstay for Regeneron for the past decade.  Although its patents are nearing the end of their lifespan, Regeneron has a number of new treatments that will step in to replace lost revenue.SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.;158.14999389648438;Steep market corrections offer opportune entry points for investors searching some of the best cheap stocks. Alpha and Omega Semiconductor (AOSL): The chipmaker saw 28% annual revenue growth in the computer segment. Bark (BARK): Its Barkbox service continues to add subscribers and generate reliable recurring revenue. BioNTech (BNTX): Anticipates generating significant Covid-19 vaccine-related revenue for fiscal 2022. Daqo New Energy (DQ): Grew top line by 400% year-over-year thanks to a booming;243.57000732421875;A European court will decide on July 13 whether U.S. life sciences company Illumina's $8 billion cash-and-stock takeover of Grail should be scrutinised by EU antitrust regulators, people familiar with the matter said on Wednesday.  The case coincides with the European Commission seeking to expand its power to examine big companies' acquisitions of start-ups aimed at shutting down nascent rivals, with the focus on tech and pharma deals.  The Luxembourg-based General Court, Europe's second-top court, declined to comment on the date of its ruling.;269.6499938964844;A roindup of companies developing drugs and devices, inking new partnership deals, raising money, expanding facilities and more.You know that you can count on them for leadership in their market and earnings growth.  Here, I'll focus on three companies that stand out for their strong market positions: a biotech company and a medical device company that each dominate their fields, and a pharmaceutical player on the way to winning in market share.  Vertex Pharmaceuticals (NASDAQ: VRTX) is the worldwide leader in cystic fibrosis (CF) treatment.With the COVID-19 crisis sending the U.S. economy in a recession, we're looking at what companies managed to thrive during the last recession for guidance.;204.22000122070312;The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.;131.25999450683594;;138.4600067138672;;125.5999984741211;Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders have seen the share price descend 22% over the month. But...In wake of Tuesday's mass shooting at an elementary school in Uvalde, Texas, Massachusetts life sciences leaders are urging the industry to come together to limit access to guns.;365.32000732421875;Bio-Techne Corporation (NASDAQ: TECH) today announced Advanced Cell Diagnostics (ACD), a brand of Bio-Techne, reached an extraordinary milestone of developing over 40,000 unique RNAscope in situ Hybridization (ISH) probes in over 400 species. ACD's broad portfolio of RNAscope probes enables ground-breaking scientific discoveries, accelerates the development of next generation therapeutics, and delivers critical diagnostic applications.Today we're going to take a look at the well-established Bio-Techne Corporation ( NASDAQ:TECH ). The company's stock...;2.9600000381469727;;78.86000061035156;;47.349998474121094;;76.0199966430664;WILMINGTON, Del., May 26, 2022--Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting;49.86000061035156;;47.06999969482422;;45.0099983215332;;89.83999633789062;;70.9000015258789;;58.459999084472656;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.;33.33000183105469;PASADENA, Calif., May 26, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform. The event will feature presentations by Arrowhead's management team and key opinion leaders, Mario Castro, M.D., MPH (University of Kansas Medical Center) and Matthias;55.36000061035156;;55.22999954223633;;30.0;;22.43000030517578;;18.190000534057617;;6.619999885559082;;32.560001373291016;;24.15999984741211;;45.84000015258789;;46.599998474121094;;;;24.459999084472656;;14.539999961853027;;6.71999979019165;;5.409999847412109;In this article, we discuss the 9 stocks Masayoshi Son is selling in 2022. If you wish to skip our detailed analysis of Son’s stock picks and hedge fund history, go directly to Masayoshi Son is Selling These 4 Stocks in 2022. Masayoshi Son is the man behind SoftBank, an investment and telecommunications media giant […];36.650001525878906;;41.29999923706055;;58.720001220703125;;7.5;In this article, we discuss the 9 stocks Masayoshi Son is selling in 2022. If you wish to skip our detailed analysis of Son’s stock picks and hedge fund history, go directly to Masayoshi Son is Selling These 4 Stocks in 2022. Masayoshi Son is the man behind SoftBank, an investment and telecommunications media giant […];34.720001220703125;;16.229999542236328;;29.360000610351562;
2022-05-27;255.25999450683594;Amgen's 3.1% dividend yield is nearly double the S&P 500's -- and that's not the only thing to like about the stock.An experimental Mirati Therapeutics Inc drug that targets a specific genetic mutation shrank tumors in 44% of advanced lung cancer patients in clinical trials, the company said on Thursday.  The 132 patients, who had stopped responding to previous therapy, were given once daily adagrasib in early and mid-stage studies.  The oral medication is designed to target a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers (NSCLC), the most common type of lung cancer.Amgen (NASDAQ: AMGN) will present new data from across its broad oncology innovative medicines and biosimilars portfolio and robust pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago and virtually.;64.80000305175781;When medical student Cátia Seabra talks to high school classes in Portugal about sexually transmitted infections, her goal is to normalize sexual health education and make sure students don’t feel ...;692.7999877929688;;166.9600067138672;European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.In this article, we discuss the 10 stocks that Jim Cramer and hedge funds agree on. If you want to read about some more stocks that Jim Cramer and hedge funds agree on, go directly to Jim Cramer and Hedge Funds Agree on These 5 Stocks. In the past few weeks, Jim Cramer, the journalist […];258.05999755859375;Singapore launches Southeast Asia’s most comprehensive consented population study with 100,000 whole genomes for health and clinical breakthroughs;273.7300109863281;Drug stock Vertex is rounding out a new base and nearing a buy point as it continues to deliver solid earnings growth.;206.1999969482422;;133.9600067138672;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, May 26, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, will present data from its broad solid tumor and hematology portfolios in eight presentations at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting being held in Chicago from June 3-7, 2022. Highli";141.38999938964844;CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash., May 26, 2022--Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association;127.7699966430664;;386.55999755859375;;3.2100000381469727;;80.97000122070312;BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;52.9900016784668;;77.19000244140625;;53.83000183105469;Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and treatment guidance tools will be showcased in nine poster presentations and five e-abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 3-7 in Chicago, Illinois.Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conferences and invited investors to participate by webcast.Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;55.290000915527344;;48.75;;93.0999984741211;;74.6500015258789;;39.810001373291016;The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week’s American Society of Clinical Oncology annual meeting.  Arcellx Inc.’s  (ACLX)  stock jumped 11.9% after an abstract provided updated data for its CART-ddBCMA.  SVB Securities analysts said in a note on Friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsed/refractory patients.”Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID in patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy. Findings will be presented on June 3 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, as an oral presentation duringAn experimental Mirati Therapeutics Inc drug that targets a specific genetic mutation shrank tumors in 44% of advanced lung cancer patients in clinical trials, the company said on Thursday.  The 132 patients, who had stopped responding to previous therapy, were given once daily adagrasib in early and mid-stage studies.  The oral medication is designed to target a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers (NSCLC), the most common type of lung cancer.;34.20000076293945;;56.290000915527344;;58.34000015258789;;29.899999618530273;;23.579999923706055;;18.399999618530273;Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.ALAMEDA, Calif., May 26, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from multiple cohorts of the phase 1b COSMIC-021 trial of cabozantinib (CABOMETYX®) as a monotherapy and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Data from urothelial carcinoma (UC) cohorts 3, 4 and 5 and from non-small cell lung cancer (NSCLC) cohorts 7 and 20 will be presented during oral abstract sessions at the 2022 American Society of Clinical OALAMEDA, Calif., May 26, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a phase 2, investigator-sponsored trial of cabozantinib (CABOMETYX®) in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The data will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting during Oral Abstract Session: Head and Neck Cancer on Friday, June 3 beginning at 2:45 p.m. CT.;7.239999771118164;BridgeBio Pharma Inc (NASDAQ: BBIO) has announced interim Phase 1 data from healthy volunteers, supporting the development of BBP-671 for pantothenate kinase-associated neurodegeneration (PKAN) and organic acidemias. BBP-671 is being developed as a potential therapy for diseases in which coenzyme-A (CoA) metabolism is deficient, including PKAN, propionic acidemia (PA), and methylmalonic acidemia (MMA). BBP-671 was detected in healthy volunteer plasma and cerebrospinal fluid (CSF), which suggests- BBP-671 detected in healthy volunteer plasma and cerebrospinal fluid (CSF), suggesting that BBP-671 is entering the brain, a location critical to target neurological complications of PKAN and organic acidemias at their source - Results showed BBP-671 increased whole blood acetyl-coenzyme-A (CoA) levels, a signal supporting proof of mechanism of the therapy - Based on these data, BridgeBio intends to move forward with the second part of the Phase 1 clinical study in patients with propionic acid;36.06999969482422;;25.229999542236328;;48.63999938964844;;48.29999923706055;;;;26.700000762939453;;14.979999542236328;;6.920000076293945;PALO ALTO, Calif., May 27, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 9, 2022, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time).;6.170000076293945;;37.630001068115234;;43.189998626708984;;58.279998779296875;;7.900000095367432;;35.95000076293945;;17.079999923706055;;30.540000915527344;
2022-05-31;256.739990234375;Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients with Lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA designed to lower the body's production of apolipoprotein(a), a key component of Lp(a) that has been associated with an increased risk of cardiovascular events.;64.8499984741211;Source: iQoncept/shutterstock.com The relative safety of dividend stocks makes them a compelling choice at any time. However, at times when many equities (and entire indexes) are posting negative growth, safe dividend stocks really shine. That’s because these stocks generate regular income that investors can reinvest. This boosts the total return of an investment. Dividend stocks are usually stable companies with reliable earnings that they reinvest for the benefit of shareholders. In bullish ti;664.739990234375;The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully acquired Checkmate Pharmaceuticals, Inc., deepening its commitment to immuno-oncology and adding a new modality to the company's portfolio of potential combination-ready approaches for difficult-to-treat cancers.Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved;163.36000061035156;AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst Blog;239.47999572753906;Investors are optimistic about Illumina's (ILMN) better-than-expected results and revenue contributions from the GRAIL business.MENLO PARK, Calif., May 31, 2022--GRAIL collaborates with the U.S. Department of Veterans Affairs Veterans Health Administration and the Veterans Health Foundation to provide Galleri.;268.6499938964844;BOSTON, May 31, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell‑derived, fully differentiated pancreatic islet cell replacement therapy, have been accepted for presentation during the American Diabetes Association 82nd Annual Scientific Sessions Conference held June 3-7, 2022 in New Orleans, Louisiana.;200.0;"BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s diseasePhase 2b LUMA to enroll approximately 640 participants with early-stage Parkinson’s disease; most advanced clinical study of a LRRK2 inhibitor SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), and Biogen Inc. (NASDAQ:BIIB) today announced that dosing has commenced in the global";137.22000122070312;;135.67999267578125;;125.80000305175781;;369.7300109863281;Aristotle Capital Management, an independent/employee-owned investment management organization, published its “Aristotle Core Equity” first quarter 2022 investor letter – a copy of which can be downloaded here. For the first quarter of 2022, Aristotle Atlantic’s Core Equity Composite posted a total return of -6.79% gross of fees (-6.89% net of fees), underperforming the S&P 500 […];3.0799999237060547;;75.12999725341797;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today updated results from its ongoing open-label Phase 1/2 study, which represents the longest duration of clinical observation for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A. The Company plans to share the data during an oral presentation at the upcoming International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress (July 9-13). Six-year and five-year post-treatment fo;51.189998626708984;;75.88999938964844;;49.810001373291016;;55.33000183105469;;46.13999938964844;;93.48999786376953;;72.81999969482422;;39.15999984741211;;33.36000061035156;;55.0;;58.04999923706055;ZUG, Switzerland and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will host an Innovation Day focused on early research and development on Tuesday, June 21, 2022 at 2:00 PM ET. CRISPR Therapeutics’ Innovation Day will focus on the Company's differentiated genetic engineering platform technologies, novel approach to cell and ge;29.100000381469727;Presentation features a new subgroup analysis of the Phase 3 PRIME study exploring the efficacy of niraparib maintenance therapy for patients in China with advanced ovarian cancer based on their response to first-line platinum-based chemotherapy Results showed a significant extension of progression-free survival compared with placebo, regardless of the response status to prior platinum-based chemotherapy SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Li;23.100000381469727;;18.329999923706055;;6.829999923706055;;35.18000030517578;;24.290000915527344;"BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s diseasePhase 2b LUMA to enroll approximately 640 participants with early-stage Parkinson’s disease; most advanced clinical study of a LRRK2 inhibitor SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), and Biogen Inc. (NASDAQ:BIIB) today announced that dosing has commenced in the global";46.900001525878906;;45.97999954223633;;;;25.809999465942383;;14.859999656677246;;7.239999771118164;;5.630000114440918;;36.52000045776367;;41.689998626708984;;57.400001525878906;;7.619999885559082;;34.040000915527344;SOUTH SAN FRANCISCO, Calif., May 31, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the Twist Human Methylome Panel, a product now available to customers that can advance applications in cancer metastasis, human development and functional genetics. The panel can be used to identify a robust, collated set of CpG sites, methylated cytosine and gua;16.149999618530273;;29.850000381469727;The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.Reata's (RETA) prospects are likely to improve following the potential approval of its lead candidate, omaveloxolone, expected by the end of 2022 is likely driving its share price.Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.Alkermes plc ( NASDAQ:ALKS ) is possibly approaching a major achievement in its business, so we would like to shine...
2022-06-01;253.4199981689453;Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers the body's production of apolipoprotein(a), a key component of Lp(a) which increases the risk of cardiovascular events.;64.7699966430664;As a young girl, Betty Chiang was curious to explore how science affected our wellbeing and health. Growing up, she witnessed some family and friends experiencing health issues that were not as pre...;658.9199829101562;;161.49000549316406;In this article, we discuss the 10 stocks that Jim Cramer was right about. If you want to read about some more stocks that Jim Cramer was right about, go directly to Jim Cramer Was Right About These 5 Stocks. The stock market has been very volatile in the past few weeks as recession fears […]Advisers to the U.S. Food and Drug Administration are due to meet in June to decide on whether to recommend authorizing Moderna Inc's vaccine for children below 6 years old, and Pfizer Inc and BioNTech SE's COVID-19 vaccine for children below 5 years old.  Here is a look at some of the factors expected to be considered in this decision concerning the last age groups not yet covered by previous U.S. regulatory authorizations for COVID-19 vaccines.  Moderna has filed with the FDA seeking authorization for a two-dose regimen of its vaccine, called Spikevax, in children ages 6 months to 6 years old.;235.1999969482422;A Brazilian sequencing program for EB patients brings access to more accurate diagnoses and better treatmentIllumina (ILMN) GRAIL's recent collaboration is part of REFLECTION, a real-world observational study assessing the performance of the Galleri MCED test in clinical settings.In this article, we discuss 10 stocks to buy according to GuardCap Asset Management. If you want to skip our detailed analysis of the hedge fund’s history, investment philosophy, and its performance, go directly to 5 Stocks to Buy According to GuardCap Asset Management. GuardCap Asset Management is a specialized investing hedge fund with headquarters […];269.4100036621094;Vertex Pharmaceuticals  is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases.  The math-driven On-Balance-Volume (OBV) line shows an upward path from early December telling us that buyers of VRTX have been more aggressive.  The Moving Average Convergence Divergence (MACD) oscillator is crossing back above the zero line for a fresh outright buy signal.;200.0;Biogen and Sage Therapeutics said new data allows them to seek approval for their depression medication zuranolone as a treatment for postpartum depression early next year.Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start later in 2022.Sage Therapeutics Inc and Biogen's experimental drug improved symptoms of postpartum depression after 15 days in a late-stage study, the companies said on Wednesday.  Zuranolone, Sage's most advanced drug candidate, is being developed for the treatment of major depressive disorder as well.  It improved depression symptoms in two late-stage studies, but there have been concerns about its effectiveness and durability.;139.02000427246094;;134.16000366210938;Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;123.05000305175781;Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers the body's production of apolipoprotein(a), a key component of Lp(a) which increases the risk of cardiovascular events.;359.95001220703125;;2.9800000190734863;;74.37000274658203;The once-and-done gene therapy, initially rejected by the FDA in summer 2020, could potentially provide a genetic fix for a bleeding disorder that today can require multiple prophylactic injections a week.;46.13999938964844;;74.9800033569336;;48.47999954223633;;53.63999938964844;;42.86000061035156;;92.75;;72.5999984741211;CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 70 individuals hired by Sarepta in May 2022. The equity awards were approved in accordance with Nasdaq Listing Rule 5635;39.93000030517578;;33.04999923706055;;56.040000915527344;;57.869998931884766;;29.5;;22.6299991607666;;18.469999313354492;The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.ALAMEDA, Calif., May 31, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in June:;6.590000152587891;;34.029998779296875;;23.889999389648438;Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start later in 2022.;46.13999938964844;;45.400001525878906;;;;25.520000457763672;;14.899999618530273;;7.53000020980835;;5.130000114440918;;35.90999984741211;;40.95000076293945;-- In honor of 20 years of targeted protein degradation, Arvinas announces $25,000 prize to recognize the efforts of an up-and-coming researcher in the field of targeted protein degradation – -- Global nomination deadline of August 1, 2022 -- NEW HAVEN, Conn., June 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced a global call for entries for their inaugural Early;55.2599983215332;;7.800000190734863;;30.920000076293945;;16.3700008392334;;29.969999313354492;Did you know rates of substance use disorder are rising in the US? The 2020 National Survey on Drug Use and Health reports that 8.3% of American adults, or 20.9 million people, in the United States...Investors are optimistic about Thermo Fisher's (TMO) robust y/y revenue growth in the Analytical Instruments, and the Laboratory Products and Biopharma Services segments.Illumina (ILMN) GRAIL's recent collaboration is part of REFLECTION, a real-world observational study assessing the performance of the Galleri MCED test in clinical settings.Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start later in 2022.Alkermes plc (Nasdaq: ALKS) today announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy. The data will be presented in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually, and in an investor webcast hosted by the company on June 6, 2022.Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.
2022-06-02;248.27999877929688;Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;63.459999084472656;FOSTER CITY, Calif., June 02, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day. Dr. Ma will assume responsibility for Gilead’s Pharmaceutical Development and Manufacturing organization effective July 18, 2022. Dr. Ma will succeed Dr. Yang, who;630.7000122070312;(Bloomberg) -- Regeneron Pharmaceuticals Inc. agreed to buy the immune-oncology drug Libtayo from partner Sanofi for as much as $1.1 billion, revisiting a deal that helped the French company re-enter the field of cancer research. Most Read from BloombergOne-Third of Americans Making $250,000 Live Paycheck-to-Paycheck, Survey FindsElon Musk’s Ultimatum to Tesla Execs: Return to the Office or Get OutApple Plans to Make the iPad More Like a Laptop and Less Like a PhoneJamie Dimon Says JPMorgan Is BRegeneron Pharmaceuticals said on Thursday it would buy the global rights to cancer drug Libtayo from French drugmaker Sanofi SA in a deal that includes an upfront payment of $900 million.  The companies signed a collaboration agreement in 2015 under which they jointly marketed the drug in the United States, while Sanofi was responsible for selling it outside the country.  Worldwide profits from Libtayo were split equally.Regeneron Pharmaceuticals Inc. announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s stake in the Regeneron-Sanofi collaboration on cancer treatment Libtayo. Under terms of the deal, Regeneron will make an upfront payment of $900 million, and Sanofi will be entitled to a $100 million regulatory milestone and up to $100 million in sales-related milestone payments. Sanofi will also receive an 11% royalty on global Libtayo sales. Sanofi's U.S.-listRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its intent to purchase Sanofi's stake in the Regeneron and Sanofi collaboration on Libtayo® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization and manufacturing rights to the medicine. The transaction is subject to merger control clearance outside the United States and is expected to close in the third quarter of 2022. Once the transaction has closed, Regeneron will record 100% of global net salAd-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ: CMPI) by Regeneron Pharmaceuticals (NASDAQ: REGN). The completion triggers a $5 million milestone paymRegulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.;158.36000061035156;Pfizer Inc and partner BioNTech have completed the filing with the U.S. drugs regulator seeking authorization for their COVID-19 vaccine in children under 5 years of age.  The filing with the U.S. Food and Drug Administration (FDA), completed on Wednesday, included data showing three lower-dose shots of the vaccine generated a strong immune response in children as young as 6 months of age.  No COVID-19 shot is yet approved for children in that age group in most parts of the world.Partners Pfizer, Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) urged the FDA to authorize three vaccine doses for children below five, the Wall Street Journal reports. The companies previously asserted that three doses of the shot were 80% effective at preventing symptomatic Covid-19 with robust immune response in children between six months to five years. After mixed results in the children who received two doses, the companies studied three doses to determine the relative efficacy of an extraPfizer Inc. and partner BioNTech SE have asked U.S. health regulators to authorize three doses of their vaccine for children under 5 years, the Wall Street Journal reported. The move comes after the companies said last month that three doses of the shot were 80% effective at preventing symptomatic COVID-19 and generated a robust immune response in children ages 6 months to 5 years old. FDA clearance could come before the end of the month. If the Centers for Disease Control and Prevention signs oNovavax says the FDA has inspected its India manufacturing site, paving the way for COVID-19 vaccine authorization soon.Shareholders reappointed Helmut Jeggle as Chairman of the Supervisory Board Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl will complement the existing Supervisory Board to reflect company growthShareholders followed the proposal of the Management Board and Supervisory Board and resolved to pay a special cash dividend of €2.00 per ordinary share MAINZ, GERMANY, June 1, 2022 (GLOBE NEWSWIRE) — At the Annual General Meeting (“AGM”) of BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”);248.52999877929688;;270.04998779296875;BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass., June 02, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced new late-breaking clinical data accepted for oral presentation at the 2022 European Hematology Association (EHA) Congress. Vertex also announced three abstracts accepted for poster presentation at EHA.Vertex Pharmaceuticals got an upgrade Wednesday on its burgeoning non-cystic fibrosis pipeline — as VRTX stock inched higher.;198.50999450683594;Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.BYOOVIZ™ is the first FDA approved ophthalmology biosimilar BYOOVIZ, priced 40% lower than LUCENTIS®, provides an equally effective and more affordable treatment option to patients suffering from retinal disorders BYOOVIZ will be commercially available through major distributors across the U.S. on July 1, 2022 CAMBRIDGE, Mass. and INCHEON, Korea, June 02, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Samsung Bioepis Co., Ltd. today announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilSage stock popped Wednesday after its Biogen-partnered treatment for postpartum depression met every goal in a final-phase study.Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.;138.80999755859375;;135.1999969482422;;125.5;CAMBRIDGE, Mass., June 02, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that data from its preclinical research on delivery of lipophilic short interfering RNA (siRNA) conjugates to extra-hepatic tissues, including the central nervous system (CNS), were published online in Nature Biotechnology. The published data provide early evidence of a potential role for 2'-O-hexadecyl (C16)-conjugated siRNAs in treating diseases of the CNS, eye,;374.010009765625;;3.4800000190734863;;75.69999694824219;BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.;50.220001220703125;;74.62999725341797;Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;51.220001220703125;;55.970001220703125;;44.66999816894531;;94.41999816894531;;72.58000183105469;CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday June 14, 2022 at 10:00 a.m. P.T./ 1:00 p.m. E.T. The fireside chat will be held at the Terranea Resort, Rancho Palos Verdes, CA. The presentation will be webcast live under the Events & Presentation;40.2599983215332;;33.7599983215332;;56.720001220703125;Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.In this article, we will discuss some of the notable stocks trending today. To take a look at some more stocks that are in the news, go to 5 Stocks Making Headlines Today. US equity market is in the red on Wednesday despite stronger-than-anticipated results from the US manufacturing sector. The S&P 500 Index, the […];61.0;BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass., June 02, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced new late-breaking clinical data accepted for oral presentation at the 2022 European Hematology Association (EHA) Congress. Vertex also announced three abstracts accepted for poster presentation at EHA.;28.700000762939453;;23.360000610351562;;18.739999771118164;;6.71999979019165;;36.849998474121094;;24.270000457763672;;49.959999084472656;NOVATO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022, at 2:30 PM ET in New York. The live and archived webcast of the pre;45.66999816894531;;;;24.979999542236328;;15.149999618530273;;7.849999904632568;;5.599999904632568;;35.86000061035156;;42.689998626708984;;55.65999984741211;;7.71999979019165;;31.8799991607666;SOUTH SAN FRANCISCO, Calif., June 02, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences:;16.209999084472656;;29.75;Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NEOGEN's (NEOG) insect control solution for poultry producers is the latest addition to the company's Prozap product line.The new manufacturing facility by Insulet (PODD) is set to have approximately 400,000 square feet of manufacturing space.Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:30 p.m. ET (7:30 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.IBD's Screen Of The Day features two oil stocks near buy points. Also, this biotech with excellent earnings made the list.
2022-06-03;248.4499969482422;Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;63.45000076293945;Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Congratulations to Michael Elliott, Vice President of Development and Medical Affairs at Gilead, for being named to this year's Empower Advocate Executive Role Model List. The list honors people wh...;630.3499755859375;Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Regeneron Pharmaceuticals (NASDAQ: REGN) had a day to forget, at least as far as its stock was concerned.  Regeneron announced that it's buying out its partner Sanofi's (NASDAQ: SNY) stake in Libtayo, the cancer drug on which they've collaborated.  Under the terms of the arrangement, Regeneron would hold the exclusive development, commercialization, and manufacturing rights to the medication worldwide.Regeneron stock tumbled Thursday after the company announced a deal to acquire the international rights to Sanofi-partnered cancer drug Libtayo.Regeneron will gain exclusive worldwide development, commercialization, and manufacturing rights to the drug Libtayo.;157.6999969482422;The FDA accepts the EUA request from Pfizer (PFE) for its COVID-19 vaccine for use in kids below 5 years of age. The U.S. government plans to start vaccinating these kids in June, following an FDA panel advisory.;232.97000122070312;"Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abstracts authored in collaboration with Illumina at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 3 – June 7 in Chicago. In addition, Illumina will host a related event, ""Unlocking Precision Medicine: The Transformational Impact of Comprehensive Genomic Profiling,"" featuring Chief Medical Officer, Phil FeIt's a bit early for investors to jump the ship regarding Guardant because the biotech stock still has plenty of good long-term prospects.  The test will compete with the Galleri blood-based cancer screening by the Grail unit of Illumina and a the Cologuard fecal screening by Exact Sciences.  Investors are also watching the outcome of a lawsuit, filed in March by Illumina, that claims that Guardant and two of its founders -- former employees of Illumina -- used Illumina's propriety information to help them launch Guardant.";269.44000244140625;Biotech Vertex Pharmaceuticals (NASDAQ: VRTX) is defying the stock market sell-off this year.  While that's great news for shareholders, it's essential to look beyond a mere six months' worth of stock market performances.  Vertex made its fortune by developing and marketing the only therapies on the market that treat the underlying causes of cystic fibrosis (CF).In this article, we discuss the 10 Cathie Wood stocks hedge funds are selling. If you wish to skip our detailed analysis of Wood’s stock picks and the latest market situation, go directly to Hedge Funds are Selling These 5 Cathie Wood Stocks. The market is experiencing a sell-off owing to the current macro outlook. […];200.6199951171875;CAMBRIDGE, Mass. and GUANGZHOU, China, June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 data for BIIB800 (BAT1806), a biosimilar candidate referencing ACTEMRA®/ROACTEMRA® (tocilizumab), anti-interleukin-6 receptor monoclonal antibody, at the Annual European Congress of Rheumatology (EULAR 2022). Data from the Phase 3 comparative clinical trial demonstrated that the investigational biosimilar candidate BIIB80012-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of lifeTofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegeneration SOD1-ALS is a rare, progressive and fatal genetic form of the disease, leading to the loss of everyday functions and affecting approximately 2% of people with ALS CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) todaSage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.;141.91000366210938;;139.94000244140625;Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;131.52000427246094;CAMBRIDGE, Mass., June 02, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:;363.1000061035156;;3.6600000858306885;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in William Blair's 42nd Annual Growth Stock Conference, on June 9, 2022, at 11:20 a.m. CT.;77.48999786376953;;45.27000045776367;Biotech stocks are mired in a historic correction.  Throughout 2020 and 2021 investors were bombarded with hype from trendy thematic exchange-traded funds and short-lived social-media celebrities.  The correction shows that fundamentals still matter, drug development is difficult, and biotech is not tech.;73.95999908447266;Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Intel Corporation (INTC), and Union Pacific Corporation (UNP).;47.54999923706055;;44.7599983215332;;45.310001373291016;;95.54000091552734;;72.9800033569336;Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointments of Michael Chambers and Kathryn Boor, Ph.D., to its Board of Directors. Both Mr. Chambers and Dr. Boor bring distinct and invaluable experience to the Sarepta board that will help guide the company on its mission to change the course of life-threatening rare diseases. “We’re pleased to welcome two new board mem;44.33000183105469;Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;34.86000061035156;;59.349998474121094;;64.20999908447266;;30.389999389648438;"Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass. and ST. HELIER, Jersey, June 03, 2022 (GLOBE NEWSWIRE) -- Zai Lab (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass., June 03, 2022--Novocure and Zai Lab announced that the EF-31 phase 2 pilot study met its primary endpoint as a first-line treatment of gastric cancer.";23.649999618530273;Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the 2022 Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9:00 AM ET in New York, New York. A live webcast, if recorded, of the presentation can be accessed under “Events &;19.040000915527344;;7.21999979019165;;37.279998779296875;CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2022 Jefferies Healthcare Conference on Friday, June 10, 2022 at 9:30 a.m. ET in NYC. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days;24.450000762939453;;51.40999984741211;;45.619998931884766;;;;25.059999465942383;;14.869999885559082;;7.980000019073486;;5.090000152587891;;36.150001525878906;Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Biogen today announced results from the Phase 3 VALOR study and its open-label extension (OLE) of tofersen, an investigational antisense medicine being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The data show that earlier initiation of tofersen, compared to delayed initiation, slowed declines in clinical function, respiratory function, muscle strength and quality of life. At the time of the analy;44.25;NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13 at 4:20 p.m. ET / 1:20 p.m. PT in Rancho Palos Verdes, Calif. A live audio webcast of the presentation will be available here and on the Events + Presentations s;58.349998474121094;;7.539999961853027;;30.459999084472656;;17.899999618530273;Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;29.309999465942383;Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Investors are optimistic about Bruker (BRKR) on strength across the BSI and BEST businesses.The FDA accepts the EUA request from Pfizer (PFE) for its COVID-19 vaccine for use in kids below 5 years of age. The U.S. government plans to start vaccinating these kids in June, following an FDA panel advisory.
2022-06-06;245.44000244140625;Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. RIABNI is already approved for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatos;62.029998779296875;CHICAGO, June 06, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today presented final data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease. In a follow-up analysis from the final database lock, Trodelvy improved median progression-free survival versus physicians’ choice of chemotherapy (4.8 vs.;609.030029296875;Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...;159.30999755859375;BioNTech SE (NASDAQ: BNTX) announced initial data from the Phase 1 study of mRNA-based individualized neoantigen-specific immunotherapy (iNeST), autogene cevumeran. The study assesses cevumeran combined with Tecentriq (atezolizumab) and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC). The preliminary results showed a favorable safety profile and encouraging signs of clinical activity. Autogene cevumeran is the lead candidate from BioNTech's iNeST platform, jointlyPreliminary analysis of data from an ongoing investigator-initiated, single-center Phase 1 study supported by BioNTech and Genentech and conducted at Memorial Sloan Kettering Cancer Center, New York, United States Autogene Cevumeran, a fully individualized mRNA cancer immunotherapy (iNeST) demonstrated that vaccine-induced immunity significantly correlates with delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinomaInitial results suggest sequential combination of ant;226.60000610351562;;268.0;BOSTON, June 06, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided additional data on patients dosed in Part A of its Phase 1/2 clinical trial of VX‑880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with T1D with impaired hypoglycemic awareness and severe hypoglycemia. As reported last month, both patients treated with half the target dose of VX-880 achieved glucose-responsive insulin production, improvement;197.11000061035156;AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s DiseaseAlectos to receive a $15 million upfront payment and is eligible to receive potential future development and commercial milestone payments CAMBRIDGE, Mass. and BURNABY, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) -- Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and comm;138.42999267578125;;142.52000427246094;BOTHELL, Wash. & COPENHAGEN, Denmark, June 06, 2022--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer (r/mCC) who have not received prior systemic therapy, with a confirmed objective response rate (ORR) of 41% (95% Confidence Interval [CI]: 24% to 59%) and median durabilitCOPENHAGEN, Denmark & BOTHELL, Wash., June 06, 2022--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer (r/mCC) who have not received prior systemic therapy, with a confirmed objective response rate (ORR) of 41% (95% Confidence Interval [CI]: 24% to 59%) and median durabilit;131.6300048828125;;363.3999938964844;;3.4700000286102295;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it has acquired certain assets from Bitome, a company pioneering real-time metabolite monitoring for faster biological product development. Bitome has developed technology leveraging machine learning to provide continuous monitoring of cell culture media, illuminating the performance of cells in real-time and enabling faster rates of bioprocess optimization.;76.08000183105469;;44.970001220703125;;73.88999938964844;;46.689998626708984;;47.540000915527344;;45.189998626708984;;94.16000366210938;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) was honored by the CARES Foundation for its ongoing research and development of novel therapies for patients with classic congenital adrenal hyperplasia (CAH). The CARES Foundation, Inc. is the only U.S.-based nonprofit organization solely dedicated to improving the lives of the CAH patient community and seeks to advance quality health care. Neurocrine Biosciences' Chief Research Officer, Dimitri Grigoriadis, Ph.D., accepted the Corporate Partner AwardNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today presents data on sleep disturbances in Parkinson's disease (PD) demonstrating the impact of OFF episodes, or reemergence of symptoms between doses of levodopa, on falling asleep and staying asleep. These data (abstract ID: 0581) are being shared at SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies, LLC (APSS) being held June 4-8 in Charlotte, North Carolina. The oral presentation of these data will take place on June 8;70.01000213623047;;43.15999984741211;Mirati Therapeutics Inc (NASDAQ: MRTX) announced the results of a prospective analysis from the Phase 1b cohort of the KRYSTAL-1 study of intracranial (IC) responses of adagrasib in KRASG12C-mutated non-small cell lung cancer (NSCLC) with active and untreated central nervous system (CNS) metastases. With a median follow-up of 6.6 months (data cutoff date December 2021), 25 patients with active, untreated CNS metastases were enrolled in the study and treated with adagrasib 600 mg BID. Of the radiMirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results of a prospective analysis from the Phase 1b cohort of the KRYSTAL-1 study evaluating intracranial (IC) responses of adagrasib in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) with active and untreated central nervous system (CNS) metastases. This is the first clinical data demonstrating CNS-specific activity of a KRASG12C inhibitor in patients with NSCLC with active aMirati Therapeutics Inc's experimental drug that targets a specific genetic mutation helped about one third of a small subset of patients in a clinical trial whose lung cancer  had spread to their brains, the company said on Monday.  Early data show that out of 19 evaluated patients treated with adagrasib, three had complete resolution of central nervous system metastases, and three had partial tumor shrinkage, Mirati said ahead of a presentation in Chicago at the annual meeting of the American Society of Clinical Oncology.  At the median follow up of 6.6 months, another 10 of the patients achieved stabilization of brain metastases, the company said.;32.959999084472656;;57.939998626708984;;64.22000122070312;;26.829999923706055;;22.0;;18.780000686645508;;7.010000228881836;PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: Jefferies Healthcare Conference, New York, NY: Thursday, June 9th at 4:00 pm ETGoldman Sachs Global Healthcare Conference, Ranchos Palos Verdes, CA: Wednesday, June 15th at 5;35.88999938964844;;23.579999923706055;;49.2599983215332;;44.45000076293945;Halozyme Therapeutics, Inc. (HALO) stock has grown a lot, gaining 11.4% in the last month.;;;24.979999542236328;;15.050000190734863;;7.840000152587891;;4.989999771118164;The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...;34.02000045776367;;42.77000045776367;;58.20000076293945;;7.670000076293945;;30.06999969482422;;16.93000030517578;;28.34000015258789;Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.Boston Scientific (BSX) is currently looking forward to launching its arterial and venous offerings in the second half of 2022.Competitive Grants Program Application Period to Begin on June 15, 2022Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.Abbott's (ABT) FreeStyle Libre 3 system is the first and only 14-day CGM system with an overall MARD of 7.9%.Investors are optimistic about Quest Diagnostics (DGX) on a strong recovery in the base business and the raised 2022 outlook.
2022-06-07;246.41000366210938;The Dow Jones Industrial Average gave up some small gains earlier in the day to finish Monday roughly flat, adding about 16 points on the day. There was little today that could sway investor sentiment firmly one way or the other.;62.540000915527344;;613.97998046875;The stock market gave back most of its early gains and traded near session lows in afternoon trading. Amazon.com rose in the first day of its stock split.;160.1199951171875;In this article, we discuss the 10 stocks to buy before the next pandemic. If you wish to skip our comprehensive review of the biotech firms well-positioned to fight the next pandemic, go directly to 5 Stocks to Buy Before the Next Pandemic. The Covid-19 pandemic tested the world’s readiness to deal with a global health […]Before deciding the fate of Novavax's (NVAX) COVID-19 vaccine, a document issued by the FDA suggests that the vaccine may cause heart problems like myocarditis/pericarditis.;233.07000732421875;The philanthropic grant from Illumina will support clean energy projects in four regions across the U.S., working towards tribal energy sovereignty and lower-cost utility bills for income-qualified homeowners around the nationInvestors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.;271.8599853515625;The Dow Jones Industrial Average sold off Tuesday, as Target dived after warning profits would drop in the current quarter.Dow Jones futures were lower after Monday's stock market action. The 10-year Treasury yield jumped back above 3%.;201.0800018310547;Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disease.;154.57000732421875;;144.36000061035156;;134.00999450683594;In this article, we discuss the 10 stocks to buy before the next pandemic. If you wish to skip our comprehensive review of the biotech firms well-positioned to fight the next pandemic, go directly to 5 Stocks to Buy Before the Next Pandemic. The Covid-19 pandemic tested the world’s readiness to deal with a global health […];366.0;;3.5899999141693115;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo Nordisk, a leading global healthcare company, to create novel expression hosts for pharmaceutical products.;78.19999694824219;;46.349998474121094;10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced a series of product updates that will be presented at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Fla. The latest developments across 10x Genomics' leading Chromium and Visium platforms and the highly anticipated Xenium launch expected later this year showcase the company's leadership and innovation at the forefront of;74.91000366210938;;48.099998474121094;;47.540000915527344;By Liz MoyerBy Yasin EbrahimAdvisers to the U.S. Food and Drug Administration on Tuesday voted overwhelmingly to recommend that the agency authorize Novavax Inc's COVID-19 vaccine for use in adults, which the drugmaker hopes can become the shot of choice among some American vaccine skeptics.  The panel of outside vaccine experts voted 21-0 with one abstention in favor of the vaccine for those 18 and older after discussing whether the shot's benefits outweigh risks, including rare occurrences of heart inflammation that may be associated with the vaccine.  If the FDA follows the recommendation and authorizes the shot, it will be the fourth COVID vaccine available for use in adults in the United States.Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) are both biotechs which rose to prominence as a result of their efforts to develop and commercialize a coronavirus vaccine.  Only Novavax has largely accomplished that goal so far, though its product isn't yet approved for sale in the U.S. But do its recent successes make it a better buy?  The argument for buying Novavax is that in the near term it'll be raking in global sales of its coronavirus vaccine, which will continue to get approved for use in more and more jurisdictions.STOCKSTOWATCHTODAY BLOG  Here are some stocks moving in premarket action Tuesday:  Kohl’s (ticker: KSS) stock has risen 8.6% after the retailer entered into exclusive negotiations with Franchise Group (FRG) over a potential sale of the department store chain that values Kohl’s at nearly $8 billion.In this article, we discuss the 10 stocks to buy before the next pandemic. If you wish to skip our comprehensive review of the biotech firms well-positioned to fight the next pandemic, go directly to 5 Stocks to Buy Before the Next Pandemic. The Covid-19 pandemic tested the world’s readiness to deal with a global health […]By Peter Nurse;48.099998474121094;;95.47000122070312;;71.76000213623047;;58.88999938964844;;34.88999938964844;PASADENA, Calif., June 07, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:;62.619998931884766;;69.04000091552734;;27.790000915527344;;24.290000915527344;;19.469999313354492;;8.050000190734863;;38.52000045776367;;25.110000610351562;Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disease.;53.22999954223633;;46.0099983215332;"Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism). TLANDO™ was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.";;;26.5;If you want to know who really controls Vir Biotechnology, Inc. ( NASDAQ:VIR ), then you'll have to look at the makeup...;15.0600004196167;;9.029999732971191;;4.880000114440918;;35.029998779296875;;44.83000183105469;;58.790000915527344;;7.829999923706055;;30.790000915527344;SOUTH SAN FRANCISCO, Calif., June 07, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the Twist MRD Rapid 500 Panel1, a custom solution that can be added to a standard next generation sequencing (NGS) workflow, offering fully customizable and highly cost effective panels to detect minimal residual disease (MRD) in as few as five days.;18.270000457763672;;28.950000762939453;Data presented at the ADA conference demonstrates Tandem Diabetes' (TNDM) Control-IQ technology's ability to make a positive and sustained impact across a diverse group of people with diabetes.Investors are optimistic about NuVasive (NUVA) on strong sales performance across the U.S. spinal hardware and the U.S. surgical support product lines.Intercept (ICPT) faces yet another setback as its resubmission for NDA for OCA for NASH gets delayed.Emergent (EBS) sends contract breach notice to J&J, following the latter's decision to end their contract for CDMO services for its COVID-19 vaccine. J&J also cites contract breach as the basis for termination.Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disease.Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.
2022-06-08;245.47999572753906;"Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.The ability to diagnose cancers with specific genetic alterations offers new hope for developing targeted treatment options for patients.  For example, an estimated 22% of all solid-tumor cancers harbor a mutation in the KRAS gene.  While there are multiple types of KRAS mutations, Amgen  made history in 2021 by earning the first approval for this high-value target that was once considered ""undruggable.""Shares of MRTX stock rocketed Tuesday after Mirati Therapeutics unveiled early — but promising — test results for a lung cancer treatment.";62.380001068115234;We’re pleased to announce that we're joining the global Access to Oncology Medicines (ATOM) Coalition to help improve care and access to essential cancer medicines in low- and lower middle-income c...Identifying oversold stocks gives investors the opportunity to buy shares of high-quality companies at a discounted price. Long-term InvestorPlace.com readers will surely know that the Street may overreact to news and events in the short run. For instance, the risk-off market sentiment in 2022 has wiped out about $7 trillion from the blue-chip stocks in the S&P 500 index. The Nasdaq 100 index has also plunged 21% year-to-date (YTD), leaving tech investors wondering what may be next. Analysts con;607.760009765625;Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron Pharmaceuticals Inc's anti-inflammation drug Dupixent to treat eczema in young children, the two companies said on Tuesday.  Dupixent is now the first approved treatment for moderate-to-severe eczema in young children, Sanofi and Regeneron said.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Regulatory filings for this age group are underway by the European Medicines Agency and regulatory authorities in additional countries.Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.;161.72999572753906;FDA votes to recommend use of Novavax COVID-19 vaccine in adultsRisk of heart inflammation from mRNA vaccines is being studied, creator says.;233.52999877929688;SAN DIEGO, June 7, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today shared key customer-focused announcements and presentatio...;274.5400085449219;The Dow Jones Industrial Average fell Wednesday, as Treasury yields jumped. Top stocks to buy and watch include cosmetics leader Ulta Beauty.The market rally had a bullish reaction to the new Target warning. China EV giant BYD will supply batteries to Tesla.BOSTON, June 08, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has granted inaxaplin (VX-147) Breakthrough Therapy Designation for APOL1-mediated focal segmental glomerulosclerosis (FSGS) and the European Medicines Agency (EMA) has granted inaxaplin Priority Medicines (PRIME) designation for APOL1-mediated chronic kidney disease (AMKD). Inaxaplin is the first investigational therapy aimed at treating the underlying cause of AOne of them plans to file for regulatory approval of a potentially game-changing candidate.  Vertex Pharmaceuticals (NASDAQ: VRTX) is a champion in the area of cystic fibrosis (CF) treatment.  In spite of that market strength, investors have worried about Vertex's ability to expand beyond CF.;206.72999572753906;Biogen's (NASDAQ:BIIB) stock is up by 3.9% over the past month. Given that stock prices are usually aligned with a...;162.0500030517578;"In this article, we discuss the top Chinese companies on NASDAQ. If you want to skip our analysis of these companies, go directly to the Top 5 Chinese Companies on NASDAQ. There were 261 Chinese firms listed on the three largest US exchanges, namely the New York Stock Exchange, NASDAQ, and NYSE American, as of March […]CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland, June 08, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that Julia Wang, Chief Financial Officer, and Angus Grant, Ph.D., Chief Business Executive, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on TuesdayYahoo Finance's Jared Blikre looks at today's outperformers in the stock market.";144.2899932861328;;139.39999389648438;;364.45001220703125;;3.5799999237060547;;77.56999969482422;;45.369998931884766;;74.98999786376953;Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.;49.4900016784668;;50.11000061035156;"Is Novavax stock a buy now that the Federal Drug Administration's advisory panel endorsed the company's Covid shot?Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Novavax's Covid-19 vaccine is protein-based; others use messenger RNA to boost immunity to the virus.It's the moment Novavax (NASDAQ: NVAX) and its investors have been waiting for. A U.S. Food and Drug Administration (FDA) advisory panel voted for the authorization of Novavax's coronavirus vaccine candidate.The BA.4 and BA.5 subvariants of the highly transmissible omicron variant of the coronavirus that causes COVID-19 are spreading rapidly, according to data from the Centers for Disease Control and Prevention, and may overtake others to dominate in the U.S.NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Novavax (NASDAQ: NVAX), Stealth BioTherapeutics (NASDAQ: MITO) and PharmaDrug (OTC: LMLLF) (CSE: PHRX). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponentiNovavax CEO Stanley Erck joins Yahoo Finance Live to discuss expectations for the upcoming FDA advisory meeting vote regarding the Novavax COVID-19 vaccine, stock data, and the outlook for the future of COVID-19 vaccines.What happened Shares of Novavax (NASDAQ: NVAX) were jumping 3.1% as of 10:01 a.m. ET on Wednesday after rising as much as 11.3% earlier in the day. The move came after a U.S. Food and Drug Administration (FDA) advisory committee voted 21-0 with one abstention on Tuesday in favor of recommending Emergency Use Authorization (EUA) for Novavax's COVID-19 vaccine NVX-CoV2373.(Bloomberg) -- Novavax Inc. shares rose after an advisory panel recommended US approval of the company’s coronavirus vaccine, though the rally will barely make dent in the 85% loss shareholders have endured from the 2021 peak.Most Read from BloombergTarget Tries to Save Itself by Putting Everything on SaleAmazon’s Stock Split Delivers More Than Bargained ForHedge Fund D1 Borrowed Billions for a Hot Bet That Now Faces ReckoningTarget's Oversupply Problem Should Scare All RetailersThese Are the Wo""The advisory committee's positive recommendation acknowledges the strength of our data and the importance of a protein-based Covid vaccine,"" said CEO Stanley Erck.At long last, Novavax (NVAX) may be close to getting its EUA. As the company announced late Tuesday, the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) just voted 21-0 (with one abstention) to recommend that the FDA grant Novavax's ""Nuvaxovid"" coronavirus vaccine (aka NVX-CoV2373) Emergency Use Authorization (EUA) to protect patients aged 18 and older from getting infected with Covid-19. If the FDA agrees with the recommendation, andThe stock tumbled about 20% on Friday after the heath regulator's reviewers flagged concerns of a type of heart inflammation following the vaccination, adding uncertainty over the outcome of Tuesday's meeting.  However, the voting by the outside advisers - 21 for, none against and 1 abstention - indicates that the FDA could soon authorize the fourth vaccine in the United States, where Novavax hopes it would become the shot of choice among vaccine skeptics.  The positive vote ""acknowledges the strength of our data and the importance of a protein-based Covid-19 vaccine"", Novavax Chief Executive Officer Stanley Erck said on Tuesday.Target to slash inventory as consumers shift shopping habits, new bill would give CFTC oversight for cryptocurrency market, FDA advisors back Novavax’s Covid-19 vaccine, and other news to start your day.The Food and Drug Administration’s vaccines advisory panel backed  Novavax  long-delayed Covid-19 vaccine, saying the benefits outweighed the risks.  The panel voted Tuesday 21 to zero in favor of the proposition that the vaccine’s benefits outweighed its risks, with one abstention.  The panel, however, expressed disappointment that more data wasn’t available on the vaccine’s efficacy against more recent variants of the virus.Novavax shares soared 18% premarket Wednesday, after an advisory panel to the U.S. Food and Drug Administration voted in favor of its COVID-19 vaccine, a protein-based one that is made with more conventional technology than the other ones to have been authorized. Novavax shots are already used in Australia, Canada, parts of Europe and dozens of other countries, as the Associated Press reported. But U.S. clearance is a key hurdle for the Maryland-based company. FDA's vaccine chief Dr. Peter MarksBy Geoffrey SmithBy Peter NurseNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 21 to 0, with one abstention, to recommend that the FDA grant Emergency Use Authorization (EUA) for the Novavax COVID-19 vaccine (NVX-CoV2373) for individuals aged 18 years and over.American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.US government advisers have recommended the approval of a fourth Covid-19 jab developed by Novavax, expressing hopes that it can help boost the nation’s flagging immunisation programme as a new wave of infections sweeps across the population.  Scientists on a US Food and Drug Administration advisory panel on Tuesday voted overwhelmingly in favour of authorising the first protein-based Covid vaccine — a type of technology that has been used for decades against diseases including shingles and the flu.  The panel vote represents an important milestone for Novavax, a Maryland-based biotech company which signed a $1.6bn deal with the US government in 2020 to develop a Covid vaccine.Yahoo Finance's Anjalee Khemlani joins the Live show to detail Novavax's FDA approval for its two-dose COVID vaccine for adults.PayPal will allow users to move their crypto to other wallets, Novavax stock is halted ahead of an FDA panel on its COVID vaccine, and Smuckers is expected to take a $125M hit from its Jif peanut butter recall.It marks a crucial win for the Gaithersburg biotech, and brings its vaccine a step closer to authorization.FDA votes to recommend use of Novavax COVID-19 vaccine in adultsRisk of heart inflammation from mRNA vaccines is being studied, creator says.""So all vaccines that are being distributed globally commercially are being made in a single facility by our partners (the Serum Institute in India) that includes the vaccines which are being deployed around the world as well as the ones that will be initially deployed in the U.S.,"" said Chief Medical Officer Filip Dubovsky.An advisory panel to the U.S. Food and Drug Administration is due to meet later Tuesday to review the vaccine developed by Novavax Inc. as a potential fourth shot for American adults and will vote on whether the risks outweigh the benefits.";52.0;Oral presentation to include additional durability data from patients treated with NTLA-2001, the first-ever systemically administered in vivo CRISPR investigational therapyPresentation to include data supporting fixed dose selection in the ongoing single-dose expansion cohort of polyneuropathy arm CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-b;97.86000061035156;;72.26000213623047;;60.45000076293945;"Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.The ability to diagnose cancers with specific genetic alterations offers new hope for developing targeted treatment options for patients.  For example, an estimated 22% of all solid-tumor cancers harbor a mutation in the KRAS gene.  While there are multiple types of KRAS mutations, Amgen  made history in 2021 by earning the first approval for this high-value target that was once considered ""undruggable.""Shares of MRTX stock rocketed Tuesday after Mirati Therapeutics unveiled early — but promising — test results for a lung cancer treatment.The stock market traded mixed as investors worried about the retail sector, and the U.S. trade gap fell. Oil stocks gained.";34.0;;64.5;Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;73.83000183105469;"CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to...ZUG, Switzerland and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022, at 9:20 a.m. Pacific Time (PT). A live webcast of the presentation will be available on the ""Events & PresIdentifying oversold stocks gives investors the opportunity to buy shares of high-quality companies at a discounted price. Long-term InvestorPlace.com readers will surely know that the Street may overreact to news and events in the short run. For instance, the risk-off market sentiment in 2022 has wiped out about $7 trillion from the blue-chip stocks in the S&P 500 index. The Nasdaq 100 index has also plunged 21% year-to-date (YTD), leaving tech investors wondering what may be next. Analysts con";29.43000030517578;;24.260000228881836;;19.219999313354492;You may not realize it, but what's arguably the most important data release of the entire second quarter occurred just a few weeks ago -- and it has nothing to do with inflation or economic growth.  May 16 represented the Form 13F filing deadline for money managers with at least $100 million in assets under management.  If there was one trend that clearly stood out during the first quarter, it's that growth stocks were on the menu for many billionaire money managers.;7.809999942779541;;40.18000030517578;;24.81999969482422;;54.38999938964844;;46.20000076293945;"Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the Goldman Sachs 43rd Annual Global Healthcare Conference being held in Rancho Palos Verdes, CA on June 14-16, 2022.";;;25.0;SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accepted for one oral and two poster presentations at the International Liver Congress™ 2022 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place in London and online June 22-26. The oral presentation will highlight new dose and duration data from a Phase 2;15.1899995803833;;9.479999542236328;;4.710000038146973;;35.0;;44.7599983215332;;57.61000061035156;;7.960000038146973;;31.540000915527344;;18.1200008392334;;28.969999313354492;Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.Bruker's (BRKR) timsTOF HT is enhanced for high-throughput, deep and unbiased plasma proteomics, and liquid biopsy biomarker research.Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.
2022-06-09;241.75;Amgen (AMGN) closed the most recent trading day at $245.48, moving -0.38% from the previous trading session.;61.18000030517578;;575.47998046875;Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.When looking for the best stocks to buy and watch, focus on those with rising relative price strength.  One stock that fits that bill is Regeneron Pharmaceutical stock, which had its Relative Strength (RS) Rating upgraded from 76 to 82 Wednesday.  When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.;149.27000427246094;The White House is readying for distribution of kids' COVID-19 vaccines next week.MAINZ, Germany, June 9, 2022 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) will welcome its African partners for the first time on the African continent and provide an update on the joint establishment of mRNA manufacturing facilities and vaccine development plans. The event will encompass the groundbreaking for BioNTech’s initial African mRNA manufacturing facility in Kigali, Rwanda, where the first BioNTainer modules are planned to be delivered by the end of 2022. Following the invIt’s been a good week for Novavax.  The Gaithersburg biotech is now a step away from potentially getting its first product to market, after the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee gave its nod to Novavax’s experimental Covid-19 vaccine at its meeting Tuesday.  The FDA, which typically listens to the advisory committee’s recommendations, must now decide whether to greenlight the protein-based shot for emergency use authorization for adults in the U.S. The Centers for Disease Control and Prevention would then have to endorse its use.An FDA advisory committee supports granting emergency use authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. Post the news, the stock rallies 20% in pre-market trading.;224.47000122070312;(Bloomberg) -- Illumina Inc.’s lawyers said that its takeover of cancer detection upstart Grail Inc. would not hamper competition in the nascent field of early-stage testing, as the gene sequencing giant sought to overcome a US antitrust challenge.Most Read from BloombergTarget Tries to Save Itself by Putting Everything on SaleHedge Fund D1 Borrowed Billions for a Hot Bet That Now Faces ReckoningAmazon’s Stock Split Delivers More Than Bargained ForMusk’s Twitter Bid Includes Financier Linked to;259.70001220703125;The Dow Jones Industrial Average fell Thursday after unemployment data. Tesla stock raced higher on news that May sales in China rebounded.Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.Recent IBD Stock Of The Day Vertex Pharmaceuticals briefly broke out Wednesday on promising test results in diabetes.BOSTON, June 08, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 1:20 p.m. PT.;202.22000122070312;A lot has changed for Biogen (NASDAQ: BIIB) in just a year's time.  It was June 7, 2021, that the Food and Drug Administration granted accelerated approval for the company's Alzheimer's treatment, Aduhelm.  Since then, multiple experts have resigned from an FDA panel that suggested the agency not approve the drug.Amid brewing economic concerns, investors seeking upside opportunities in the equities sector should consider biotech stocks to buy for one simple reason: extraordinary and permanent relevance. No matter what happens to the global markets, whether continued volatility or a fresh rally, people will always look to medical advancements to maintain and improve their health. Therefore, biotechs are somewhat detached from traditional economic barometers. Another major catalyst for no-brainer biotech s;150.63999938964844;A look at the shareholders of BeiGene, Ltd. ( NASDAQ:BGNE ) can tell us which group is most powerful. Institutions...;141.75;;135.0;CAMBRIDGE, Mass., June 09, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today topline results from the Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway that is in development in collaboration with Regeneron Pharmaceuticals for the treatment of immunoglobulin A nephropathy (IgAN). At Week 32, treatment with cemdisiran resulted in a 37 percent mean reduction from baseline in the 24-hour urine protein to creatinine;355.44000244140625;;3.109999895095825;;76.66000366210938;;42.5;;72.77999877929688;;44.59000015258789;Many of these Cathie Wood stocks have faced significant challenges in the first half of 2022. Wood’s innovation-focused exchange-traded funds (ETFs) were all the rage on Wall Street until the recent market downturn. As Bloomberg recently reported, “Wood and her firm ARK Investment Management have been among the highest-profile victims of a stock selloff that has swept Wall Street as inflation takes off and the Federal Reserve raises borrowing costs.” Investors have been keeping away from riskier;41.47999954223633;Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.Novavax’s Covid-19 vaccine, unlike the Pfizer and Moderna ones, uses a well-established, protein-based approach.By Liz MoyerTuesday was a crucial day for Novavax (NASDAQ: NVAX).  At long last, the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) met to review the company's COVID-19 vaccine data.  A negative recommendation from the FDA advisory committee held the potential to deliver a crushing blow.It’s been a good week for Novavax.  The Gaithersburg biotech is now a step away from potentially getting its first product to market, after the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee gave its nod to Novavax’s experimental Covid-19 vaccine at its meeting Tuesday.  The FDA, which typically listens to the advisory committee’s recommendations, must now decide whether to greenlight the protein-based shot for emergency use authorization for adults in the U.S. The Centers for Disease Control and Prevention would then have to endorse its use.By Peter NurseThe company will struggle to capture a sizable share of the Covid-19 vaccine market in the U.S.An FDA panel voted nearly unanimously in favor of Novavax's Covid shot on Tuesday. After yo-yoing Wednesday, NVAX stock settled up.HC Wainwright says safety concerns were noted for Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, but the strength of data showed that benefit outweighs risks. With a 21-0 vote (one abstention) for Emergency Use Authorization (EUA), moved the first traditional, protein-based COVID-19 vaccine closer to becoming available in the U.S. HC Wainwright believes six cases of heart inflammation observed in clinical studies are notable. The VRBPAC did not conclude that it was a risk that outweighed the benModerna, Novavax, BioNTech, and Pfizer shares are all in the red so far in 2022. Updated vaccines may not have an effect on the share prices.An FDA advisory committee supports granting emergency use authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. Post the news, the stock rallies 20% in pre-market trading.;50.13999938964844;;97.30000305175781;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time) on Wednesday, June 15, 2022 in Rancho Palos Verdes, CA. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.;70.73999786376953;;60.4900016784668;Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.;32.4900016784668;;58.77000045776367;Blueprint Medicines Corporation (NASDAQ: BPMC) today announced updates on the AYVAKIT®/AYVAKYT® (avapritinib) development program in systemic mastocytosis (SM):;71.69999694824219;Amid brewing economic concerns, investors seeking upside opportunities in the equities sector should consider biotech stocks to buy for one simple reason: extraordinary and permanent relevance. No matter what happens to the global markets, whether continued volatility or a fresh rally, people will always look to medical advancements to maintain and improve their health. Therefore, biotechs are somewhat detached from traditional economic barometers. Another major catalyst for no-brainer biotech s;27.0;If you want to know who really controls Zai Lab Limited ( NASDAQ:ZLAB ), then you'll have to look at the makeup of its...;23.479999542236328;Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;18.8799991607666;Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;7.489999771118164;- BridgeBio will host an investor call on June 13, 2022, at 4:30 pm ET to discuss the Phase 2b study results and the planned pivotal Phase 3 study design PALO ALTO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that 24-week Phase 2b data of encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1) will be featured i;37.79499816894531;;24.40999984741211;;51.09000015258789;;44.97999954223633;Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;;;23.829999923706055;;14.8100004196167;;8.510000228881836;Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.The stock market, as measured by the S&P 500 Index  (SPX)  has traded within a small range — these days, 100 points is a small range — in a volatile fashion since May 27.  There has been some deterioration of the internal indicators while SPX has been in this range, but not a lot.  The range is marked with a red square on the accompanying SPX chart.;4.539999961853027;;34.93000030517578;Many of these Cathie Wood stocks have faced significant challenges in the first half of 2022. Wood’s innovation-focused exchange-traded funds (ETFs) were all the rage on Wall Street until the recent market downturn. As Bloomberg recently reported, “Wood and her firm ARK Investment Management have been among the highest-profile victims of a stock selloff that has swept Wall Street as inflation takes off and the Federal Reserve raises borrowing costs.” Investors have been keeping away from riskier;43.029998779296875;;55.47999954223633;;8.390000343322754;;28.799999237060547;;17.43000030517578;;28.1299991607666;PerkinElmer's (PKI) microbial plates minimize human error by providing standardized protocols and offer a small footprint to save space in incubators and storage areas.Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 2:40 p.m. PT (5:40 p.m. ET/10:40 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
2022-06-10;240.00999450683594;A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.;60.7400016784668;We’re honored to be to be a finalist for the PinkNews Awards in the Business Equality category. These UK-based awards recognize the contributions of businesses, individuals and organizations who he...Gilead Sciences, Inc. ( NASDAQ:GILD ) is about to trade ex-dividend in the next three days. The ex-dividend date is one...;571.8099975585938;Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.;143.85000610351562;Novavax's authorization timeline differs from other first-time applicants, and ongoing submission of manufacturing data has given the FDA reason to slow the process.Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.;204.19000244140625;What happened Shares of Illumina (NASDAQ: ILMN) were sinking 9.5% at 11:33 a.m. ET on Friday. The decline came after the company announced the departure of CFO Sam Samad in a press release issued after market close on Thursday.Illumina’s global program aims to inspire the next generation of genomic leadersBy Peter NurseIllumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami, Chief Strategy and Corporate Development Officer, will also serve as interim Chief Financial Officer while the company conducts a search for a permanent CFO. Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.;254.8800048828125;BOSTON, June 10, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that five scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the European Cystic Fibrosis Society's (ECFS) 45th European Cystic Fibrosis Conference held June 8-11, 2022, in Rotterdam, the Netherlands.;197.5;;147.47000122070312;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, June 10, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, presents data from its hematology portfolio at the European Hematology Association (EHA) 2022 Hybrid Congress being held June 9-12, 2022, in Vienna, Austria.CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, June 10, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has approved BeiGene’s anti-PD-1 antibody, tislelizumab, in combination with chemotherapy as a first-line treatment for patients with rec";139.39999389648438;;132.11000061035156;Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.;334.54998779296875;;2.819999933242798;Some real estate firms have proposed creating job-training spaces in the life sciences projects they're building. Marcus Partners wants to take that sort of training on the road.;75.08000183105469;;40.38999938964844;;70.4000015258789;;41.22999954223633;;40.619998931884766;Novavax's authorization timeline differs from other first-time applicants, and ongoing submission of manufacturing data has given the FDA reason to slow the process.On Thursday, the price of one of the more volatile coronavirus vaccine stocks, Novavax (NASDAQ: NVAX),  headed sharply for the ground.  The slump followed the disheartening news that a major regulatory decision on one of the company's products will likely be handed down later than expected.  The Food and Drug Administration (FDA) said Thursday that it must review changes to Novavax's production processes as part of its overall authorization process for the NVX-CoV2373 coronavirus vaccine.Novavax CEO Stanley Erck looked at the clock, in a conference room surrounded by about 30 colleagues, as the Food and Drug Administration advisory committee chairman called for a vote Tuesday afternoon.  Members of the Vaccines and Related Biological Products Advisory Committee started entering their votes into the electronic system.  A recommendation for emergency use authorization for Novavax’s experimental Covid-19 vaccine would be critical to an ultimate green light.;42.45000076293945;;94.30999755859375;;69.1500015258789;;59.06999969482422;Shares of Mirati Therapeutics (NASDAQ: MRTX) were skyrocketing 37.2% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence.  This huge gain came after the company presented data at the 2022 American Society of Clinical Oncology annual meeting on Monday.  For a biotech stock to soar as much as Mirati has on the presentation of clinical data, that data has to be exceptionally positive.;30.520000457763672;;48.06999969482422;The FDA recommended Blueprint Medicines change the ultimate goal of a midstage study, leading BPMC stock to crumble Thursday.;63.7599983215332;;26.610000610351562;"-- Breakthrough Therapy Designations granted for ROS1-positive non-small cell lung cancer (NSCLC) patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor (TKI) with or without prior chemotherapy -- Potential best-in-class therapy for ROS1-positive metastatic NSCLC and NTRK-positive advanced solid tumors SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, g";19.809999465942383;;18.139999389648438;;6.659999847412109;PALO ALTO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and its affiliate company Venthera, Inc. (Venthera), today announced preliminary data from the Phase 1b trial of VT30 topical gel (BBP-681) in patients with venous, lymphatic and mixed venolymphatic lesions of the skin (VM, LM and VLM, respectively), which are rare genetic vascular anomalies driven by dysregulated activation of intracellular PI3K. The data are being shared in a virtual presenta;33.08000183105469;;22.579999923706055;;49.880001068115234;NOVATO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, and Mardi Dier, the company’s Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Thursday, June 16, 2022, at 10:00;43.790000915527344;;;;23.1200008392334;;14.609999656677246;;8.069999694824219;;4.28000020980835;;34.7599983215332;;40.130001068115234;;53.02000045776367;;8.34000015258789;;26.780000686645508;;17.09000015258789;;27.459999084472656;New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.Within Abbott's (ABT) Nutrition arm, while the pediatric nutrition business witnesses a drag, the adult nutrition business continues to perform well.Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.Thermo Fisher's (TMO) RNA Polymerase III and EliA Rib-P blood tests are intended to diagnose systemic sclerosis and systemic lupus erythematosus.Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.
2022-06-13;236.77000427246094;;59.150001525878906;;549.2999877929688;;133.6199951171875;"Per the FDA reviewers, the available data supports Pfizer (PFE) and BioNTech (BNTX) vaccine's effectiveness in preventing COVID infection in kids six months to under five years of age as a three-dose primary series.Is BioNTech a value trap landmine waiting for value-hunters, or is the market getting this one wrong?  Let's start to answer this question by defining the concept of a value trap so that we're on the same page.  Falling for a value trap often means parking your capital somewhere it will decline over time, as the stock becomes a better and better ""bargain"" the lower its price gets, sometimes in the face of rising revenue or earnings.Sanofi SA (NASDAQ: SNY) said the next-gen COVID-19 vaccine candidate it has developed with GSK Plc (NASDAQ: GSK) in two trials showed a potential to protect against the virus's main variants of concern when used as a booster. In the Phase 3 VAT02 Cohort 2 study, the vaccine candidate showed a 15-fold increase against the parent virus and a 30-fold increase against Beta strain in adults previously primed with mRNA COVID-19 vaccines. In particular, against omicron, preliminary data show a 40-foldFrench drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.  While the two companies' first experimental COVID shot is undergoing review by the European Medicines Agency, Sanofi and GSK have continued work on a vaccine that is molded on the now-supplanted Beta variant, hoping still that it will confer broad protection against future viral mutations.  Sanofi said this new vaccine candidate was shown to significantly boost antibody levels against a number of variants of concern, when given to trial participants who had an initial course of mRNA vaccines, a type made by BioNTech-Pfizer and Moderna.";194.30999755859375;;245.38999938964844;;192.16000366210938;;130.3000030517578;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, June 13, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide today announced that its BTK inhibitor BRUKINSA™ (zanubrutinib) has been approved by the Ministry of Health in Kuwait, the National Health Regulatory Authority in Bahrain and the Ministry of Public Health in Qatar forCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, June 13, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date by three months to January 20, 2023 for the supplementary new drug application (sNDA)";139.60000610351562;;127.69999694824219;;324.9800109863281;;2.380000114440918;;71.91000366210938;;36.95000076293945;;67.75;;37.279998779296875;;36.279998779296875;The Australian regulatory authority has conditionally approved Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over. The provisional registration was based on data from Novavax's Phase 2 trial conducted in Australia, wherein a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six months after their primary two-dose vaccination series of Nuvaxovid. The third dose produced increased immune resNovavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Australian Therapeutic Goods Administration (TGA) has granted provisional registration of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over.Novavax (NASDAQ: NVAX) investors were just about to breathe a sigh of relief.  A U.S. Food and Drug Administration (FDA) advisory committee earlier this week recommended that the agency authorize Novavax's coronavirus vaccine.  Novavax initially planned on requesting authorization in the first half of last year -- but challenges in a manufacturing ramp-up slowed things down.;38.959999084472656;;91.44000244140625;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new Phase 2 data on the use of crinecerfont in adolescent patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD), which demonstrated substantial reductions in adrenal androgens and androgen precursors. These data will be shared as an oral presentation by Ron S. Newfield, M.D., University of California, San Diego and Rady Children's Hospital, San Diego on June 13 from 11:;67.0;;53.75;;28.280000686645508;;45.22999954223633;;55.27000045776367;;25.18000030517578;;17.780000686645508;;17.6299991607666;;5.949999809265137;- Treatment with encaleret resulted in rapid and sustained restoration of normal mineral homeostasis, with mean values of blood calcium, urinary calcium, and blood PTH within the normal range by day 5 of therapy and sustained at 24 weeks, and was well-tolerated without any reported serious adverse events - At week 24 of encaleret treatment, 92% (12/13) of participants had achieved normal trough blood calcium levels in the absence of extra-dietary calcium supplements and active vitamin D, and 77%;29.860000610351562;"It’s difficult to put a positive spin on the current state of the stock market. While 2022’s action has seen moments of relief, for the most part, the trend has been resolutely downbeat, as reflected in the main indexes’ performances. All are down by at least double-digits; the tech-heavy NASDAQ’s 27% drop has been the most acute, while the S&P 500 has often flirted dangerously close to bear market territory. That said, while it’s hard to watch any owned stock sink to the bottom, the upside to t";22.059999465942383;;47.68000030517578;;43.099998474121094;;;;22.09000015258789;;14.0;;7.320000171661377;;4.019999980926514;;33.5;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation and rare pediatric disease designation to ION582, an investigational antisense medicine for the treatment of Angelman syndrome, a rare neurogenetic disorder caused by the loss of function of the maternally inherited Ubiquitin Protein Ligase E3A (UBE3A) gene. ION582 targets UBE3A.;36.970001220703125;;53.06999969482422;NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience held virtually June 10-12, 2022. Three posters were presented on Saturday June 11, 2022 during the “In the Spotlight: Live Posters 2” session: Oral Poster titled “;8.199999809265137;;26.200000762939453;;16.770000457763672;;27.34000015258789;Investors are optimistic about SmileDirectClub's (SDC) better-than-expected revenues and new product launches.LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.
2022-06-14;235.6999969482422;;57.790000915527344;;548.3499755859375;;134.82000732421875;Moderna's COVID-19 vaccine may have a higher risk of heart inflammation in young men than the Pfizer/BioNTech shot, according to data presented on Tuesday to U.S. Food and Drug Administration advisers weighing its use for those aged 6 to 17.  An FDA official told the expert panel that while the data showed a higher risk for the Moderna shot, the findings were not consistent across various safety databases and were not statistically significant, meaning they might be due to chance.  The overall incidence is relatively rare and the vast majority who suffer the side effect fully recover, but a comparison showed the risk of myocarditis and pericarditis in young males aged 18-39 was 1.1 to 1.5 times higher after the Moderna shot, the FDA said in its presentation, citing data from three U.S. vaccine safety databases.The World Trade Organization is meeting this week to consider adopting an agreement that would make it easier to produce COVID-19 vaccines and treatments by waiving patent enforcement during health emergencies.(Reuters) -Advisers to the U.S. Food and Drug Administration on Tuesday unanimously recommended that the agency authorize Moderna Inc's COVID-19 vaccine for children and teens aged 6 to 17 years of age.  Around 77 million people in the United States have received at least a two-dose course of Moderna's vaccine, which has long been available for people aged 18 and older.  The committee of outside experts is scheduled on Wednesday to consider the Moderna shot for children under 6, and Pfizer and BioNTech's COVID vaccine for children under 5 - and in both cases as young as 6 months.The FDA announced that COVID vaccines from both Pfizer and Moderna were effective in children under the age of 5, signaling good news for approval.FDA staffers said Pfizer's and Moderna's pediatric Covid vaccines are safe and effective, but both vaccine stocks toppled Monday.;189.41000366210938;How artificial intelligence and automation are enabling precision medicine to become the standard of careBaron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. Baron Opportunity Fund (the “Fund”) fell sharply and significantly lagged the broader market during the first quarter. For the period, the Fund dropped 16.02% (Institutional Shares), trailing the Russell 3000 […]The news that the company's CFO is leaving has spooked investors. The stock has tumbled 15.7% since Thursday morning.At ASCO 2022, an oncology panel discusses the benefits and practices of comprehensive genomic profiling;249.0800018310547;"Crispr Therapeutics could have a ""functional cure"" for two inherited blood diseases, analysts said Monday, but CRSP stock plummeted.";194.17999267578125;;132.00999450683594;;144.63999938964844;;133.52000427246094;The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.CAMBRIDGE, Mass., June 13, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA™ (vutrisiran), an RNAi therapeutic administered via subcutaneous injection once every three months (quarterly) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. hATTR amyloidosis is a rare, inherited, rapidly progressive, and fatal disease w;324.17999267578125;;2.4200000762939453;A meltdown across equity and cryptocurrency markets Monday is dragging Cathie Wood’s flagship Ark Invest down hard.;71.4800033569336;BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) presented data at The Endocrine Society Annual Meeting, ENDO 2022, demonstrating the Company's ongoing commitment to understanding the lifetime impact of achondroplasia, the most common form of disproportionate short stature. The Company provided data from a Phase 2 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of VOXZOGO™ (vosoritide) for Injection in infants and children aged 0 to less than five years;37.04999923706055;;66.18000030517578;MorphoSys (MOR) and Pfizer collaborate to develop a combination of MOR's Monjuvi and Pfizer's checkpoint inhibitor candidate, TTI-622, for treating r/r DLBCL.Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), available as 4-mg, 2-mg and 1-mg tablets.1 The recommended dose is OLUMIANT 2-mg/day, with an increase to 4-mg/day if treatment response is inadequate. For patients with nearly complete or complete scalp hair loss, with or without su;37.13999938964844;Yahoo Finance's Alexandra Semenova joins the Live show to discuss performance for Cathie Wood's ARK Innovation ETF amid the current market meltdown.;38.709999084472656;The World Trade Organization is meeting this week to consider adopting an agreement that would make it easier to produce COVID-19 vaccines and treatments by waiving patent enforcement during health emergencies.;38.4900016784668;;91.22000122070312;;64.52999877929688;;52.5099983215332;;27.889999389648438;Baron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. Baron Opportunity Fund (the “Fund”) fell sharply and significantly lagged the broader market during the first quarter. For the period, the Fund dropped 16.02% (Institutional Shares), trailing the Russell 3000 […];45.599998474121094;;58.11000061035156;"A meltdown across equity and cryptocurrency markets Monday is dragging Cathie Wood’s flagship Ark Invest down hard.Crispr Therapeutics could have a ""functional cure"" for two inherited blood diseases, analysts said Monday, but CRSP stock plummeted.A certain type of cell therapy is easier to manufacture, but may lead to worse long-term outcomes for patients.CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies. CTX130 was well tolerated across all dose levels. There were no cases of Graft versus Host Disease (GvHD), no dose-limiting toxicities (DLTs), and no instances of tumor lysis syndrome (TLS). Needham notes that 95% of beta-thalassemia (TDT) achieved sustained transfusion independence";24.0;;18.6299991607666;;17.670000076293945;;6.510000228881836;;30.829999923706055;;21.43000030517578;;47.40999984741211;Taking the occasional loss comes part and parcel with investing on the stock market. And there's no doubt that...;43.59000015258789;;;;22.260000228881836;;13.430000305175781;;7.179999828338623;;4.099999904632568;Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health CAMBRIDGE, United Kingdom, June 14, 2022 (GLOBE NEWSWIRE) -- Cambridge Epigenetix (CEGX), a l;33.5099983215332;;36.0099983215332;;54.02000045776367;;8.800000190734863;;27.459999084472656;;16.25;;27.190000534057617;Pride Month is a time for us to celebrate the important strides made to support and advance LGBTQIA+ mental health. See the images to learn about several queer mental health trailblazers and keep u...Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.Investors are optimistic about Teleflex's (TFX) better-than-expected results and strong growth within the vascular business.Align (ALGN) competes with products similar to Invisalign Technology, such as the products from Ormco Orthodontics, a division of Sybron Dental Specialties.Strong performance across Chemed's (CHE) Roto-Rooter arm and increased home-based admissions raise investors' confidence.
2022-06-15;235.5800018310547;Microsoft, Amgen, Honeywell International, Booking Holdings and Stryker have been included in this Analyst Blog.A major land deal has gone through in Holly Springs as part of a larger partnership focused on life sciences.In the latest trading session, Amgen (AMGN) closed at $235.70, marking a -0.45% move from the previous day.Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amgen Inc. (AMGN), and Honeywell International Inc. (HON).;58.38999938964844;Finding solutions to complex areas of unmet medical need is fundamental to Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and Program Chair for Gilead’s ...;561.1900024414062;;137.99000549316406;The European Medicines Agency on Wednesday launched a rolling review of a variant-adapted COVID-19 vaccine developed by Pfizer and BioNTech , as cases of new sub-variants of the coronavirus's Omicron lineage are on the rise.  When available, clinical trial data will be added to the rolling submission, which is designed to speed up any approval, BioNTech and Pfizer said in a joint statement.The European Medicines Agency on Wednesday launched a rolling review of a variant-adapted COVID-19 vaccine developed by Pfizer and BioNTech , as cases of new sub-variants of the coronavirus's Omicron lineage rise.  When available, clinical trial data will be added to the rolling submission, which is designed to speed up any approval, BioNTech and Pfizer said in a joint statement.  The pair added they would also begin submitting data on the planned variant-adapted vaccine to the U.S. Food and Drug Administration (FDA) over the next few weeks.Moderna has finally moved one step closer to authorization of its COVID-19 vaccine for two additional age groups, 6-11 years and 12-17 years, after an U.S. Food and Drug Administration advisory committee voted unanimously to recommend the doses Tuesday.Advisers to the U.S Food and Drug Administration on Wednesday will vote on whether to recommend authorization of two COVID-19 vaccines for the millions of children ages five years and under, an important step toward immunizing a group that has not been eligible for the shots during the pandemic.  The U.S. government is planning for a June 21 start to its under-5 vaccination campaign should the vaccines from Moderna Inc and Pfizer/BioNTech receive FDA authorization, White House COVID-19 response coordinator Ashish Jha said last week.  Once the FDA authorizes the vaccines for the age group - 6 months to 4 years old for Pfizer/BioNTech and 6 months to 5 years old for Moderna - the U.S. Centers for Disease Control and Prevention (CDC) will make its recommendations on use of the shots in young children.Advisors to the FDA unanimously Tuesday recommended expanding Moderna's Covid vaccine to children as young as 6.Amid lower demand, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) agreed to delay supplies of their Covid-19 shot to the European Union. Doses to be shipped from June to August would be sent in September and Q4. Reuters reports that the bloc is putting heat on Pfizer to restrict supplies further. The move comes two weeks after the EU agreed with Moderna Inc (NASDAQ: MRNA) to postpone its scheduled delivery of COVID-19 vaccines. Responding to a request for comment, a Pfizer spokesperson reModerna Inc's (NASDAQ: MRNA) COVID-19 vaccine may relate to a higher risk of heart inflammation in some age groups than Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) shot, Reuters reported citing the Centers for Disease Control and Prevention. Citing recent data, CDC said that the findings on myocarditis and pericarditis, types of heart inflammation linked to both the mRNA shots, were inconsistent across all of the U.S. vaccine safety monitoring systems. Related: Moderna's COVID-19 Vacci;193.6300048828125;;253.50999450683594;Let's look at two stocks that could rebound from their recent woes in the market: Axsome Therapeutics (NASDAQ: AXSM) and CRISPR Therapeutics (NASDAQ: CRSP).  Few things can wreak more havoc on biotech companies than regulatory rejections for their leading pipeline candidates.  The company's shares have been hammered over the past year because it failed to earn regulatory approval for its two leading products.;197.25999450683594;"RESPOND study is actively enrolling, with baseline characteristics reporting infants and toddlers have residual unmet medical needs in multiple areas after gene therapy; SPINRAZA treatment following gene therapy was well-tolerated Final safety data from DEVOTE Part A support the continued development of an investigational, higher dose of nusinersen; additional study phases are actively enrolling Biogen’s continued R&D investments, including the ongoing DEVOTE, RESPOND and ASCEND studies, aim toThe FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.CAMBRIDGE, Mass., June 14, 2022 /3BL Media/ - Biogen Inc. (Nasdaq: BIIB) is celebrating 20 years of caring deeply with the 20th anniversary of the Biogen Foundation and the Biogen Community Lab. Th...";136.74000549316406;;147.24000549316406;;135.4499969482422;;330.6600036621094;Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shares), compared with the 4.56% decline for the Russell 3000 Health Care Index […];2.5899999141693115;Cathie Wood weighs in on the current volatile market backdrop. Wood is staying firm in her convictions.;74.1500015258789;;39.619998931884766;;68.55000305175781;;38.689998626708984;;41.22999954223633;Novavax (NASDAQ: NVAX) hasn't yet applied for the use of its vaccine as a booster in the U.S. It's still waiting for regulators to give it the nod for use as a primary series.  Novavax also has applied for booster authorization in the U.K. and European Union.  There, Novavax could carve out share in the booster market.Novavax could struggle to find a U.S. market for its Covid shot, according to the latest IBD/TIPP Poll as NVAX stock continues to flounder.;40.93000030517578;;93.1500015258789;;64.5;;53.95000076293945;;29.190000534057617;;47.970001220703125;;62.65999984741211;Let's look at two stocks that could rebound from their recent woes in the market: Axsome Therapeutics (NASDAQ: AXSM) and CRISPR Therapeutics (NASDAQ: CRSP).  Few things can wreak more havoc on biotech companies than regulatory rejections for their leading pipeline candidates.  The company's shares have been hammered over the past year because it failed to earn regulatory approval for its two leading products.Cathie Wood weighs in on the current volatile market backdrop. Wood is staying firm in her convictions.;24.510000228881836;;19.3799991607666;;17.940000534057617;;6.739999771118164;;31.950000762939453;;22.579999923706055;;50.709999084472656;;44.630001068115234;;;;23.920000076293945;;13.630000114440918;;7.130000114440918;;4.28000020980835;;34.66999816894531;The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.;38.279998779296875;;56.529998779296875;;9.270000457763672;;29.93000030517578;;18.770000457763672;;27.6299991607666;ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in its base business and encouraging 2022 guidance.
2022-06-16;230.7100067138672;;57.720001220703125;;556.75;It recently hit a new 52-week low and trades at an incredibly low earnings multiple.  In 2022's first quarter, Regeneron's sales were down 40% compared to 2021's fourth quarter.  The gaping hole in the company's financials was due to REGEN-COV, its COVID-19 treatment, which didn't generate any revenue in the U.S. in Q1.;129.14999389648438;What happened Shares of the top COVID-19 vaccine makers were sinking on Thursday. Pfizer (NYSE: PFE) stock was down 2% at 11:06 a.m. ET. Shares of Pfizer's partner, BioNTech (NASDAQ: BNTX), were down 6.The FDA VRBPAC committee unanimously recommends the approval of both Pfizer and BioNTech and Moderna's vaccines for young children, saying the benefits of the vaccines outweigh the risks.Pfizer (PFE) and its partner BioNTech initiate rolling submission, seeking authorization of the variant-adapted version of their COVID-19 vaccine.Yahoo Finance senior health care reporter Anjalee Khemlani details the latest FDA advisory panel votes on Pfizer and Moderna's two-dose COVID vaccine for children.FDA's advisory committee checked the first of four boxes that would allow COVID-19 vaccines for kids 5 and under to be authorized in the U.S. Wednesday.Advisers to the U.S Food and Drug Administration on Wednesday unanimously recommended the agency authorize COVID-19 vaccines from Moderna Inc and Pfizer Inc/BioNTech SE for millions of the youngest American children.  The committee's recommendation is an important step toward immunizing children under the age of 5 and as young as 6 months old who have not yet been eligible for the shots.  The FDA is likely to authorize the shots soon.;187.77000427246094;;250.9600067138672;McKesson, Bristol Myers Squibb, Merck, Vertex Pharmaceuticals, and Organon are all sitting on year-to-date gains.;191.52999877929688;Roche's trial aimed at preventing Alzheimer’s disease had failed. That's a bad sign for Biogen and Eli Lilly, which are pushing forward with similar drugs.Biogen Inc. (NASDAQ: BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ: KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of Nuclear Export compound KPT-350 and certain related assets to Biogen. KPTI received an upfront payment of $10 million in 2018 and was eligible to receive additional payments of up to $207 million based on the achievement by Biogen;133.77999877929688;;146.77999877929688;;134.82000732421875;The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.  Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.  Canada approves Amylyx drug  Amylyx Pharmaceuticals Inc. (Nasdaq: AMLX) scored its first-ever approval from Health Canada for its amyotrophic lateral sclerosis (ALS) drug Albrioza.;322.6700134277344;;2.319999933242798;;72.16999816894531;;37.11000061035156;The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...;68.04000091552734;;35.61000061035156;;37.65999984741211;Shares of Novavax (NASDAQ: NVAX) had declined by nearly 11% as of 10:56 a.m. ET on Thursday amid the Nasdaq's broader decline of more than 3.8%.  Its shares are likely falling due to the Federal Reserve's decision yesterday to hike interest rates, which disproportionately hurts growth stocks like Novavax.  Plus, the Food and Drug Administration's (FDA) nonbinding advisory committee also ruled yesterday that the coronavirus shots made by Moderna and Pfizer are likely to be safe and effective for infants, and both are major Novavax competitors in the vaccine market.After an FDA panel “unanimously” voted to recommend that the agency approved Novavax’s (NASDAQ:NVAX) coronavirus vaccine, the outlook of NVAX stock has significantly improved. Nonetheless, I believe that the shares remain risky, and I recommend that only speculative, risk-tolerant investors buy them at this point. An FDA Approval Is Probably Assured, But Other Risks Remain Multiple news outlets have emphasized that the FDA almost always follows the recommendations of its panels. What’s more, sinYahoo Finance senior health care reporter Anjalee Khemlani details the latest FDA advisory panel votes on Pfizer and Moderna's two-dose COVID vaccine for children.;41.439998626708984;;88.93000030517578;;62.689998626708984;;51.040000915527344;;27.790000915527344;We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...;46.779998779296875;;64.63999938964844;;23.139999389648438;;19.360000610351562;;17.56999969482422;"Exelixis Inc (NASDAQ: EXEL) and BioInvent International AB (OTC: BOVNF) have entered into an option and license agreement focused on identifying and developing novel antibodies for use in immuno-oncology therapeutics. Exelixis will pay BioInvent an upfront fee of $25 million in exchange for rights to select three targets identified using BioInvent's proprietary F.I.R.S.T platform and n-CoDeR library. BioInvent will be responsible for initial target and antibody discovery activities and characterALAMEDA, Calif. & LUND, Sweden, June 16, 2022--Exelixis, Inc. (Nasdaq: EXEL) and BioInvent International AB (""BioInvent"") (Nasdaq Stockholm: BINV) today announced that the companies have entered into an option and license agreement focused on the identification and development of novel antibodies for use in IO therapeutics. The collaboration is intended to expand Exelixis’ portfolio of antibody-based therapies and will combine BioInvent’s cancer immunology and antibody biology expertise with Exe";6.510000228881836;;32.22999954223633;The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.  Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.  Canada approves Amylyx drug  Amylyx Pharmaceuticals Inc. (Nasdaq: AMLX) scored its first-ever approval from Health Canada for its amyotrophic lateral sclerosis (ALS) drug Albrioza.;21.3799991607666;;50.02000045776367;;43.11000061035156;;;;23.170000076293945;;13.899999618530273;;7.010000228881836;;4.050000190734863;;33.72999954223633;;36.790000915527344;;53.43000030517578;;9.260000228881836;;29.84000015258789;SOUTH SAN FRANCISCO, Calif., June 16, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Fujifilm 12th Annual Global IT Executive Summit taking place June 22-25, 2022 at the InterContinental Hotel in San Diego, CA. Mr. Hellmold will present on Thursday, June 2;19.510000228881836;The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.There were no surprises in the FDA's assessment of an Alzheimer's drug from Acadia Pharmaceuticals, and ACAD stock surged Wednesday.Ahead of Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) FDA AdComm meeting on Friday, the agency officials released their briefing documents, revealing a mixed bag of opinions. The company's resubmitted supplemental New Drug Application for pimavanserin for hallucinations and delusions associated with Alzheimer's disease psychosis (ADP) has a target action date of August 4. Initially, the FDA considered the Phase 2 trial, dubbed Study 019, insufficiently adequate and well-controlled, one of many reRegulators might be warming to the company's candidate to treat Alzheimer's-associated psychosis.;27.010000228881836;Bruker's (BRKR) NeuraLight 3D Ultra module offers revolutionary 3D holographic photostimulation to support neuroscience and optogenetics research applications.According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.Pfizer (PFE) and its partner BioNTech initiate rolling submission, seeking authorization of the variant-adapted version of their COVID-19 vaccine.
2022-06-17;234.72000122070312;;58.529998779296875;Gilead showcased the strength and diversity of the data science work occurring across the organization at our inaugural Data Science Symposium earlier this month. More than 700 people from around t...This beaten-down biotech is paying a 5.1% dividend -- three times the average dividend on the S&P 500.In the latest trading session, Gilead Sciences (GILD) closed at $57.72, marking a -1.15% move from the previous day.;580.9500122070312;Regeneron (REGN) closed at $556.75 in the latest trading session, marking a -0.79% move from the prior day.;125.13999938964844;The FDA has granted emergency use authorization (EUA) to Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 Vaccine as a three 3-µg dose series for children six months through 4 years of age. Based on safety, tolerability, and immunogenicity data, the 3-µg dose was carefully selected as the preferred dose for children under five. The EUA is based on data from a Phase 2/3 trial that included 4,526 children six months through 4 years of age. In the trial, children received the thirdFDA advisory panel member Dr. Paul Offit says kids vaccines are a game-changer, for the roughly 20% aged 5 and under who are likely to get vaccinated.The Food and Drug Administration announced Friday that it authorized the COVID-19 vaccines developed by BioNTech SE /Pfizer Inc. and Moderna Inc. for children as young as six months old. The regulator said Moderna's two-dose vaccine is now authorized for children between the ages of 6 months old and 17 years old. It was previously authorized and is now fully approved for adults. The BioNTech/Pfizer shot, which had already been authorized for older children and teens, is now authorized in childreNEW YORK & MAINZ, Germany, June 17, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine as a three 3-µg dose series for children 6 months through 4 years of age (also referred to as 6 months to less than 5 years of age). The 3-µg dose was carefully selected as the preferred dose for children under 5 years of age based on safety, tolerability, andFDA panel recommends the use of PFE, MRNA COVID vaccine in kids under five. LLY's Alzheimer's candidate fails to show clinical benefit in study. FDA approves expanded use of LLY's Olumiant.Oxford Industries and Flagstar Bancorp have been highlighted as Zacks Bull and Bear of the Day.Dr. Paul Offit, Children’s Hospital of Philadelphia Vaccine Education Center Director and Professor of Pediatrics, explains the importance of FDA recommending COVID vaccines for children from Pfizer and Moderna and the symptoms parents should expect in vaccinated kids.As Bavarian Nordic A/S (OTC: BVNRY) was in the headlines recently due to the smallpox vaccine amid rising cases of monkeypox, the company is also getting ready to evaluate its COVID-19 booster, ABNCoV2, in a pivotal study. ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark using their proprietary capsid virus-like particle technology. The upcoming Phase 3 trial will include Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 shot in the cThe Swiss parliament failed to finance the government's plan to buy COVID-19 vaccines in 2023, forcing the cabinet to try to renegotiate contracts with Moderna and Pfizer/Biontech  for millions of doses.  With the two houses of parliament split over the funding request, budget rules required the adoption of the cheaper version of draft legislation, the SDA news agency said in a report posted on parliament's website.  Parliament approved spending 560 million Swiss francs ($579 million) instead of the requested 780 million.;187.2899932861328;;263.0899963378906;Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $250.96, moving -1.01% from the previous trading session.;201.74000549316406;Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.;132.13999938964844;;165.4499969482422;Merck & Co Inc (NYSE: MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ: SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion. According to the report, some people said other unnamed suitors are also eying Seagen, a perennially speculated takeover target. Also Read: Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence. Talks ha;137.08999633789062;;327.1499938964844;;2.369999885559082;;76.08000183105469;;38.400001525878906;;71.2699966430664;Syndax Pharmaceuticals has toiled for years toward finding cancer therapies that can improve the lives of patients.;37.02000045776367;;40.2400016784668;Yahoo Finance Live’s Brian Sozzi reports that the FDA has authorized Moderna and Pfizer COVID vaccines for children under the age of 5.Dr. Paul Offit, Children’s Hospital of Philadelphia Vaccine Education Center Director and Professor of Pediatrics, explains the importance of FDA recommending COVID vaccines for children from Pfizer and Moderna and the symptoms parents should expect in vaccinated kids.Is Novavax stock a buy or sell after the FDA's advisors endorsed the company's Covid shot? Is NVAX stock a buy or sell right now?;42.97999954223633;;93.27999877929688;;66.97000122070312;;55.0;;29.1200008392334;;48.630001068115234;Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.;70.0;There are plenty of stocks out there that are $10 or less or have a low price-to-earnings ratio (P/E).  A lot of low-priced stocks deserve to be where they are, and many stocks with low P/Es are downtrodden because their futures aren't that bright.  The best bargains are the ones that will be good stocks to have and hold for the long term, yet are priced to sell right now.;27.729999542236328;;21.040000915527344;;18.559999465942383;Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.;7.650000095367432;Stephen Bardin will join as CFO Designate on June 27, 2022After a transition period, atai’s current CFO Greg Weaver will be moving into a part time strategic advisory role NEW YORK and BERLIN, June 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V., (Nasdaq: ATAI) (“atai” or the “Company”), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today that Stephen Bardin, currently Senior Vice President of Finance and Operations at Bri;35.77000045776367;"A fundamental analyst at a sell-side firm rated Beam Therapeutics  a new ""market perform"" Friday with a $41 price target.  Let's check out the charts of this company that is using CRISPR technology to perform what are known as base edits.  In the daily bar chart of BEAM, below, we can see a long decline in price and a recent stability around $30.";23.899999618530273;;53.290000915527344;;44.13999938964844;;;;24.530000686645508;;14.210000038146973;;7.909999847412109;;4.239999771118164;;35.2599983215332;;38.349998474121094;;54.939998626708984;;10.119999885559082;;31.15999984741211;;19.510000228881836;Acadia Pharmaceuticals Inc. said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The FDA's Psychopharmacologic Drugs Advisory Committee will review Acadia's Nuplazid at a meeting scheduled for 8:45 a.m. Eastern. About six million people living in the U.S. have Alzheimer's disease, according to the AlzheiSAN DIEGO, June 17, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nasdaq has halted trading of the company’s common stock.HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected. It reiterates the stock with a Buy rating and a price target of $36.00. Related: Why ACADIA Pharmaceuticals Shares Are Trading Higher Today? The analysts believe the below points are left open for discussion when the AdCom members meet tomorrow: The closeness between Parkinson's disease dementia (PDD) and Alzheimer's disease dementia (ADD) in terms of disease mechanism argue;28.030000686645508;Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.Henry Schein's (HSIC) widespread network and channel mix along with favorable long-term trends in the dental business look encouraging.Bausch (BHC) suspends its plans for the initial public offering of its Solta Medical business in light of the challenging market conditions and other factors.Hologic's (HOLX) core molecular diagnostics franchise is growing driven by strong uptake in newer assays such as vaginitis panel and menu within the virology product line.Fact: compared to women, men are less likely to seek support and services for mental illness. This Men's Health Month, Alkermes encourages its followers to join the movement to amplify Men's Mental...
2022-06-21;238.41000366210938;In the latest trading session, Amgen (AMGN) closed at $234.72, marking a +1.74% move from the previous day.;60.5099983215332;FOSTER CITY, Calif., June 21, 2022--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that more than 80 abstracts will be presented at the International Liver Congress™ (ILC) 2022, taking place from June 22-26, 2022. Key oral presentations will include Week 48 primary endpoint data from the Pivotal Phase 3 program of Hepcludex® (bulevirtide) evaluating its efficacy and safety for the treatment of hepatitis delta virus (HDV) and the impact of the treatment on patient-reported outcomes. Gilead w;587.6699829101562;;123.25;;183.24000549316406;;270.1700134277344;Futures rose as Bitcoin rebounded. It's a bear market, so stay safe. Tesla rival BYD is among a few stocks setting up.;206.88999938964844;Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).Patent covers approved dosing regimen for TECFIDERA and expires in 2028 CAMBRIDGE, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Patent Office has granted a patent that expires in February 2028 related to TECFIDERA® (dimethyl fumarate). The patent, EP 2 653 873, is directed to treating multiple sclerosis using dimethyl fumarate dosed at 480mg per day, which is the European Medicines Agency (EMA) recommended maintenance dose for TECFIDERA. P;152.6699981689453;"CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING, June 21, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for the company’s anti-PD-1 inh";170.00999450683594;;139.02000427246094;;329.29998779296875;;2.440000057220459;"Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (""Cronos""), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (""Ginkgo""), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo's platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid";78.4000015258789;Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.;40.0;;73.13999938964844;;38.040000915527344;Ultima Genomics, Inc. and Exact Sciences Corporation (Nasdaq: EXAS) have entered a long-term supply agreement for Ultima's next-generation sequencing (NGS) technologies. Under the terms of the supply agreement, Ultima Genomics will provide access to its NGS products, which are based on a new architecture designed to enable sequencing at a fraction of the cost of other commercially available technologies. The companies also plan to develop one or more of Exact Sciences' advanced cancer diagnostic;41.369998931884766;;44.47999954223633;;93.37000274658203;;68.56999969482422;;58.279998779296875;;30.59000015258789;;50.63999938964844;;64.66999816894531;;29.049999237060547;;22.229999542236328;;19.350000381469727;ALAMEDA, Calif., June 21, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-303, a phase 3 pivotal trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer (CRC) that is not microsatellite instability-high or mismatch repair-deficient, who have progressed after or are intolerant to the standard of care therapy. XL092 is a next-generation tyrosine kinase inhibitor (TKI) in development for multiple advanced;7.96999979019165;;38.04999923706055;;26.75;;55.56999969482422;;45.7599983215332;Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.;;;24.700000762939453;;14.359999656677246;;8.100000381469727;;4.610000133514404;;37.40999984741211;"U.S.-listed shares of AstraZeneca were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its primary endpoints in a Phase 3 clinical trial. AstraZeneca is developing eplontersen with Ionis Pharmaceuticals Inc. ; shares in Ionis were up 5.1% on Tuesday. The rare disease can cause nerve damage and motor disability and affects about 40,000 people worldwide, the companies said. They also said they plan to seeIonis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).AstraZeneca plc (NASDAQ: AZN) and partner Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced a positive interim analysis of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). ATTRv-PN is a rare inherited condition characterized by an abnormal build-up of a protein called amyloid in the body's organs and tissues. In Phase 3 NEURO-TTRansform study, eplontersen met the main goals. Read Next: Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary GoIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from a 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). Eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for the co-primary endpoints of percent change in serum transthyretin (TTR) concentration and the modified Neuropathy Imp";38.88999938964844;;54.81999969482422;Wasatch Global Investors, an investment management firm, published its “Wasatch Ultra Growth Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. Growth stocks fared worse than value stocks in the quarter, with the benchmark Russell 2000® Growth Index down -12.63%. The Wasatch Ultra Growth Fund—Investor Class posted a larger […];9.8100004196167;;32.4900016784668;;13.010000228881836;"A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis. The drug, Nuplazid, is already indicated for Parkinson's-related psychosis. Acadia tried and failed last year to get another FDA approval for Alzheimer's psychosis. Related: Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related Psychosis. ""We are disappoinShares of Acadia Pharmaceuticals Inc. were still down 30.5% in premarket trading on Tuesday, days after a Food and Drug Administration advisory committee voted against approval of the company's treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The committee on Friday voted 9-3 that the benefits of pimavanserin do not outweigh the risks. The FDA, which is not required to follow the advice of the committee but often does, is expected to decide whether to app";27.649999618530273;Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.
2022-06-22;240.13999938964844;With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.;61.5099983215332;Dale Cain is known in her community as someone who is an advocate of wellness, but she was not always focused on her own health and wellbeing. Formerly a self-defined “workaholic,” a chance encount...;586.8400268554688;;123.66000366210938;You don't need a fortune to make good money, not when many growth stocks are as cheap as they are right now.  A couple of the most noteworthy deals out there right now are for shares of BioNTech (NASDAQ: BNTX) and Amazon (NASDAQ: AMZN).  Healthcare company BioNTech helped Pfizer develop a highly successful COVID-19 vaccine that has generated tens of billions in revenue.Yahoo Finance's Anjalee Khemlani discusses the rollout of COVID vaccines for kids 6 months to 5 years, plus a new test that could indicate when a person needs a booster shot.BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $123.25, moving -1.51% from the previous trading session.;181.5800018310547;;272.30999755859375;Stocks turned mixed as Fed chief Jerome Powell minimized recession risks before Congress. But crude oil and bond yields tumbled.We've entered the much-dreaded bear market. And studying your portfolio right now may not bring you a lot of joy. But don't worry. History tells us bear markets, downturns, and even crashes don't last forever.;207.0;Armany is a rising junior at Northeastern University majoring in electrical and computer engineering who developed a passion for science during his time as a Biogen Community Lab student and as a R...CAMBRIDGE, Mass. & NEW YORK, June 22, 2022--Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company™, today announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their wellbeing, learn about treatment options,;155.67999267578125;BeiGene, Ltd. (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.BeiGene's (NASDAQ: BGNE) shares were up by more than 13% on Tuesday at 2:50 p.m. ET thanks to a regulatory body in China accepting one of the company's supplemental biologics licensing application filings for a new indication for its drug tislelizumab.  The Center for Drug Evaluation (CDE) will now evaluate whether tislelizumab is sufficiently safe and effective to treat metastatic gastric junction adenocarcinoma in conjunction with chemotherapy for patients whose tumors express the PD-1 biomarker, potentially giving BeiGene the green light for an expansion of its commercialization in China.  If regulators ultimately opt to approve the company's application, it'll be the 10th indication for tislelizumab in China, which speaks to its versatility as a cancer medicine as well as its money-making potential.;169.66000366210938;SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN). The analysts refrain from commenting on the probability of the deal happening. The analysis suggests that the short-term impact on EPS from the potential acquisition will likely be meaningfully dilutive. Related: Merck Shows Takeover Interest In Seagen: WSJ. According to SVB, the deal decreases forecasted GAAP EPS by -12%, -7%, and -2% in;141.55999755859375;;329.70001220703125;Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Namocell, Inc. Bio-Techne anticipates the acquisition to close in the first quarter of its fiscal 2023.;2.490000009536743;;81.31999969482422;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan granted approval of the registration of VOXZOGO® (vosoritide) for injection, indicated for the treatment of achondroplasia in children of all ages, whose growth plates are not closed. Voxzogo, a modified C-type natriuretic peptide (CNP), directly targets the underlying pathophysiology of achondroplasia by down regulating fibroblast growth factor receptor 3 (FGFR3) signaling;41.720001220703125;;73.75;;39.4900016784668;;45.47999954223633;It's never a bad idea to follow advice from Warren Buffett.  The billionaire investor has a wealth of knowledge and advice out there for people willing to listen.  There's one particular piece of his advice that today could prove immensely valuable to investors, one that could save you from incurring significant losses.;45.540000915527344;;94.20999908447266;By scanning for stocks with a relative strength line at new highs in the IBD Stock Screener, we can look for these outperformers.;68.30999755859375;;63.0;;31.56999969482422;;53.029998779296875;;59.939998626708984;;32.540000915527344;;23.610000610351562;;20.190000534057617;;8.449999809265137;- These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with the severity of disease - Initial pharmacodynamic results for two participants show unprecedented decreases in N-acetylaspartate (NAA) in the brain and urine, suggesting the therapy is producing functional ASPA enzyme - If successful, BridgeBio’s gene therapy could be the first therapeutic option for children born with Canavan disease, a devastating and fatal neurodev;39.130001068115234;The Biden administration is pushing hard to promote electric vehicles (EVs). From a $7.5 billion provision in the ‘Build Back Better’ bill to political pressure on automakers to commit to increased production with the goal of converting 40% of car sales to EVs by the end of this decade, it’s clear that under Biden, the government has the will to enforce a major shift in the automotive industry. The Biden administration has also prioritized the production of EV battery systems, to the tune of $3.;27.209999084472656;;56.119998931884766;;45.900001525878906;;;;24.540000915527344;;14.149999618530273;;8.210000038146973;;4.869999885559082;;37.2400016784668;;39.4900016784668;;54.27000045776367;;10.289999961853027;;33.560001373291016;;13.430000305175781;An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.;28.06999969482422;National Vision (EYE) plans to continue executing its core growth initiatives and further investing in strengthening competitive advantages.According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.On the heels of ASCO22, we remain committed to innovating in the oncology space, particularly for cancers with high unmet needs, like platinum-resistant ovarian cancer. Thomas Herzog, M.D. and Crai...Investors are optimistic about National Vision's (EYE) better-than-expected earnings and new store growth.Investors are optimistic about LabCorp's (LH) robust Drug Development business performance and several pandemic-related developments.
2022-06-23;243.08999633789062;;62.58000183105469;Shares of Gilead Sciences (NASDAQ: GILD) and Best Buy (NYSE: BBY) have fallen more than 19% this year.  Are these dividend stocks potential steals right now, or should you be worried about a possible cut to their above-average payouts?  Gilead's 19% year-to-date decline has actually been modest, compared to the S&P 500, which is down 23% over the same time frame.FOSTER CITY, Calif., June 23, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 48 results from the Pivotal Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex® (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. Findings from the study underscore the efficacy and safety of bulevirtide for the treatment of chronic HDV and are being presented today in the International Liver Congress™ (ILC) 2022 Official Press Program. In addiGilead Sciences (GILD) closed the most recent trading day at $61.51, moving +1.65% from the previous trading session.A former corporate communications chief for a New Jersey biotechnology company admitted on Wednesday to illegal trading based on tips about a new breast cancer drug from the company's chief financial officer, who was her boyfriend at the time.  Lauren Wood, 33, of Washington, D.C., pleaded guilty to securities fraud before U.S. District Judge John Michael Vazquez in Newark, New Jersey.  Wood and Usama Malik, the former CFO of Immunomedics Inc, now owned by Gilead Sciences Inc, were charged over the alleged scheme last December.;607.3900146484375;;132.2899932861328;"First BioNTech product candidate to receive priority medicines (PRIME) designation by the European Medicines Agency for enhanced regulatory support facilitating the clinical development of the investigational cell therapy candidate BNT211 in the third- or later-line setting in patients with heavily pretreated testicular cancerDesignation follows positive interim Phase 1/2 data for BNT211 demonstrating an encouraging safety profile and early signs of anti-tumor activity in testicular cancer patieBioNTech SE said Thursday it has broken ground on the construction of the first mRNA manufacturing facility in Africa, a plant in Kigali, Rwanda that is expected to employ about 100 workers by 2024. The first of two BioNTainers are expected to be delivered by year-end and the company's malaria vaccine candidate is expected to enter its first in-human trial later in 2022. ""The company expects to set up additional factories in Senegal and South Africa in close coordination with its partners in theBreaking of Ground for BioNTech’s initial African modular mRNA manufacturing facility in Kigali, Rwanda; delivery of first container modules planned for end of 2022On invitation by H.E. President Paul Kagame of Rwanda, Heads of State and Government from Africa and around the world, highest leadership of African Union, European Union as well as from WHO and WTO joined BioNTech CEO Ugur Sahin on site to mark the establishment of BioNTech’s pan-African end-to-end manufacturing network for mRNA-base";193.5500030517578;Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research test, codeveloped with Merck (known as MSD outside the United States and Canada). The research test builds upon Illumina's commitment to broadly enable comprehensive genomic profiling and enhance research critical to realizing precision medicine in oncology. The test adds assessment of a new genomic signature to the distributed, market leading TruSight™ Oncology;283.5;The market rally rebounded from losses but gains faded. Five stocks from a hot sector are near buy points.Just a few weeks ago, shares of Devon Energy (NYSE: DVN) were skyrocketing more than 75% year to date.  Rising oil prices continue to serve as a massive tailwind for Devon.  In addition to its sizzling stock performance, Devon offers one of the juiciest dividends you'll find.Biotech stock United Therapeutics joins peers Vertex and Harmony Biosciences on the Breakout Stocks Index as it reenters a buy zone.;211.3800048828125;Machelle Sanders, secretary of the Department of Commerce for North Carolina, climbed the corporate ranks before taking charge of the state's thriving economic development prospects. Now, she must keep the momentum going.;156.1999969482422;;174.0;;146.3000030517578;;345.29998779296875;;2.940000057220459;;84.55000305175781;;46.470001220703125;Recent declines on Wall Street have been unnerving for most investors. So far in the year the S&P 500 index has lost around 21%. But you can still find some interesting stocks to buy right now. Investing is a long-term strategy that helps many of us prepare for later years. Metrics suggest between 1991 and 2020, the average return for the S&P 500 index has been well over 10%. For instance, let’s assume you are now 35 with $10,000 in savings and you plan to retire at age 65. You decide to invest;74.77999877929688;;42.2400016784668;;51.810001373291016;Novavax did a few encore presentations of its coronavirus vaccine efficacy and safety data at a conference.;50.7599983215332;;97.4000015258789;;71.81999969482422;Proposed ~US$161 million all-cash acquisition to accelerate invoX’s strategy to build Sino Biopharm’s International Biopharmaceutical R&D Platform outside of China, transforming the lives of patients worldwideThe transaction demonstrates the strength of F-star’s differentiated bispecific antibody technology and provides backing from a top 40 global pharmaceutical company to accelerate growth and unlock potentialF-star’s unique next-generation tetravalent (2+2) bispecific antibody platform comple;65.88999938964844;;34.2599983215332;;56.380001068115234;;65.1500015258789;;33.150001525878906;;25.610000610351562;;21.329999923706055;These phenomenal stocks are begging to be bought following a bear market decline in the Nasdaq and S&P 500.Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.;9.079999923706055;BridgeBio Pharma Inc (NASDAQ: BBIO) announced promising pharmacodynamic data from the first two participants dosed in CANaspire Phase 1/2 trial of BBP-812, gene therapy for Canavan disease. Canavan disease is an ultra-rare inherited disorder that damages the ability of nerve cells (neurons) in the brain to send and receive messages. Data from the first two participants show rapid and robust post-treatment decreases in N-acetylaspartate (NAA) in urine and, significantly, in cerebrospinal fluid (C;41.56999969482422;TELA Bio, Inc. (TELA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.;30.190000534057617;;59.9900016784668;;46.79999923706055;;;;25.889999389648438;;14.600000381469727;;8.989999771118164;;5.460000038146973;;39.02000045776367;;42.41999816894531;;57.189998626708984;;10.550000190734863;Insiders who bought AbCellera Biologics Inc. ( NASDAQ:ABCL ) stock in the last 12 months were richly rewarded last...;38.11000061035156;;14.720000267028809;;29.559999465942383;A survey by the The National Institute on Drug Abuse (NIDA) showed that 32% of lesbian, gay and bisexual adults reported binge drinking versus 26% of non-LGB adults. To learn more about findings fr...Neogen's (NEOG) robust segmental performance and notable product launches instill investors' confidence.Moderna's (MRNA) bivalent COVID booster candidate exhibits a greater than a 5-fold boost in antibody responses against the Omicron subvariants BA.4 and BA.5 in a phase II/III study.Investors are optimistic about Tandem Diabetes' (TNDM) strong pump shipments and ongoing product innovations.Walgreens' (WBA) subsidiary teams up with Buckeye Health Plan to provide wellness services through Walgreens Health Corner locations in Ohio.
2022-06-24;245.3699951171875;;63.08000183105469;Gilead is as passionately committed to championing inclusion and diversity, health equity and social justice issues, as it is to helping improve the lives of people with life-threatening diseases. ...FOSTER CITY, Calif., June 24, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for investigational lenacapavir for the treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.;612.489990234375;Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced additional positive interim data from an ongoing Phase 1 study of their lead investigational in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. The data were presented in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, taking place Jun;134.0399932861328;The CDC recommended use of Moderna’s Covid-19 vaccine in children 6 to 17 years, the final step in allowing the shots to become widely available.A panel of advisers to the Centers for Disease Control and Prevention voted unanimously Thursday to recommend Moderna's COVID vaccine for children and adolescents aged 6 to 17.EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to Novavax's (NVAX) COVID-19 vaccine for use in adolescents. The stock rises 13.9%.A panel of advisers to the Centers for Disease Control and Prevention voted unanimously Thursday to recommend Moderna's COVID vaccine for children and adolescents aged 6 to 17. The move is expected to lead CDC head Dr. Rochelle Walensky to sign off on the vaccine for that age group, offering a second option along with the vaccine developed by Pfizer and German partner BioNTech . The agency authorized the Moderna vaccine for adults in December of 2020 but has been reviewing it for a younger age gYahoo Finance's Rachelle Akuffo looks at Moderna's stock following a CDC panel's endorsement of its latest vaccine.;193.92999267578125;Public/private partnership expands access to comprehensive genomic profiling to improve patient care and advance drug discovery;292.54998779296875;Dow Jones futures rose Friday morning, along with S&P 500 futures and Nasdaq futures. The stock market rally attempt made progress Thursday, especially on the Nasdaq, amid some hints that inflation is peaking.The major stock market indexes are mixed and are trading near or at the lows of the day, with the Nasdaq composite and S&P 500 down from the last hour.  The Nasdaq composite is up 0.3% while the S&P 500 is down 0.3%.  Harmony Biosciences is up 4.8% and now extended from the 47.21 buy point of a cup-with-handle base.;211.92999267578125;Biogen Inc. said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company updated the study's ClinicalTrials.gov;177.99000549316406;;179.3300018310547;;147.5;Foreign direct investments play an important role as an indicator of a healthy economy in terms of economic growth and long-term capital movement.;352.760009765625;;2.859999895095825;;86.8499984741211;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization (CMA) for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. A final approval decision, typically consistent with the CHMP recommendation, is expected from the European Commission in Q3 2022.;49.630001068115234;;78.19000244140625;;45.150001525878906;;51.66999816894531;"EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to Novavax's (NVAX) COVID-19 vaccine for use in adolescents. The stock rises 13.9%.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Taiwan Food and Drug Administration has granted emergency use authorization (EUA) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in individuals aged 18 years and over.What happened Shares of Novavax (NASDAQ: NVAX) were soaring 28.4% higher this week as of the market close on Thursday, according to data from S&P Global Market Intelligence. Much of this big gain came after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended granting expanded conditional marketing authorization for Novavax's COVID-19 vaccine, Nuvaxovid (NVX-CoV2373), in adolescents ages 12 through 17.Yahoo Finance's Rachelle Akuffo looks at Moderna's stock following a CDC panel's endorsement of its latest vaccine.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) for adolescents aged 12 through 17. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its opinion on results from the Phase 3 PShares of Novavax Inc. shot up 9.8% in afternoon trading Thursday, after the biotechnology company said its COVID-19 vaccine Nuvaxovid has been recommended by the Committee for Medicinal Products for Human Use (CHMP) for expanded conditional marketing authorization (CMA) in the European Union for people aged 12 through 17. ""This recommendation brings us closer to offering adolescents in the EU the first protein-based COVID-19 vaccine developed using an innovative approach to traditional technolo";53.40999984741211;Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced additional positive interim data from an ongoing Phase 1 study of their lead investigational in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. The data were presented in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, taking place Jun;98.23999786376953;;75.22000122070312;"The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.Sarepta Therapeutics Inc. shares plummeted as much as 20% in after-hours trading Thursday, after the company reported that a study had been put on hold by the Food and Drug Administration. Sarepta disclosed that a patient in a study of a proposed drug for Duchenne muscular dystrophy suffered a ""serious adverse event of hypomagnesemia,"" or seriously low levels of magnesium in blood. The FDA put the study on clinical hold and requested more information about cases of hypomagnesemia; Sarepta said t- Sarepta to host conference call at 4:15 p.m. Eastern time CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), the Company’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable t";68.16000366210938;;34.459999084472656;;60.150001525878906;Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors. Mr. Dable, who was Chief Executive Officer of Acceleron Pharma from 2016 to 2021, brings nearly 30 years of experience in strategic leadership, commercial growth and organizational scale across global pharmaceutical and emerging biotechnology companies.;66.95999908447266;Crispr Therapeutics Chief Executive Sam Kulkarni says the next two years of clinical trials and data readouts will give investors, and patients, plenty to cheer about.Yahoo Finance's Jared Blikre checks out the market and sector action heading into today's close, software stocks, ARK ETF components, and the travel industry ahead of the close.;34.220001220703125;;26.799999237060547;;22.219999313354492;On Friday, Exelixis got a positive adjustment to its Relative Strength (RS) Rating, from 79 to 90.  When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.  Over 100 years of market history reveals that the best stocks often have an 80 or better RS Rating at the beginning of a new price run.;9.239999771118164;;42.5099983215332;;30.93000030517578;;60.56999969482422;;46.900001525878906;;;;24.84000015258789;;14.880000114440918;;9.039999961853027;;5.610000133514404;;39.25;;45.79999923706055;;55.619998931884766;;10.649999618530273;;41.04999923706055;;14.979999542236328;;29.709999084472656;Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.Tandem Diabetes (TNDM) is witnessing strong customer retention, driven by the impressive positive response from the Control-IQ technology.
2022-06-27;244.85000610351562;Let's look at two companies that fit the bill: Amgen (NASDAQ: AMGN) and Microsoft (NASDAQ: MSFT).  Biotech Amgen has been around since 1980, and in that time the company has survived several recessions.  In the first quarter, Amgen's revenue increased by a respectable 6% year over year to $6.2 billion.;62.83000183105469;FOSTER CITY, Calif., June 27, 2022--Gilead Sciences today announced that the company has signed onto the Kigali Declaration on neglected tropical diseases (NTDs) which succeeds the London Declaration on NTDs. It was launched on the margins of the Commonwealth Heads of Government Meeting (CHOGM), at a high-level session that was attended by Heads of State, other global dignitaries, industry partners and global community as part of a joint malaria and NTDs Summit. This high-level political declaraBiotech stocks have suffered significant setbacks during the first half of the year. Investors had little appetite for innovation-driven companies, seeking safe haven in more traditional stocks delivering steady profits. “Clinical trial failures, regulatory setbacks, drug pricing concerns and a lull in M&A all contributed to the slowdown,” said Brian Abrahams, Co-Head of Biotechnology Research at Endpoints. “On the whole, the sector has slowed too much. There are increasingly compelling valuatio;602.4000244140625;;143.7100067138672;"Pfizer Inc. and partner BioNTech SE said the update to their COVID-19 booster shot showed a ""high immune response"" against the omicron variant, in time for an FDA meeting and as the daily average of COVID-19-related hospitalizations rose to a 3-month high.Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) said the modified vaccine against the omicron coronavirus variant generated a higher immune response. The companies said that 30 µg and 60 µg doses of a shot targeting just the BA.1 omicron subvariant elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against that subvariant. Also Read: Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months. A version of the shot that contained botCongressional gridlock on Covid-19 funding might lead to vaccine inequity, but it won’t be a bad thing for the manufacturers, which will charge a higher price in the private market.Pfizer Inc. and BioNTech SE said over the weekend that the change they made to their COVID-19 vaccine that targets the omicron variant is both safe and effective. The announcement comes as the U.S. Food and Drug Administration considers this week if it should order a formula change for vaccines in hopes that the modified vaccines could protect against another COVID-19 surge that is expected in the fall and the winter. The seven-day average of new daily COVID-19 cases was 102,818 on Sunday, the tBiotech stocks have suffered significant setbacks during the first half of the year. Investors had little appetite for innovation-driven companies, seeking safe haven in more traditional stocks delivering steady profits. “Clinical trial failures, regulatory setbacks, drug pricing concerns and a lull in M&A all contributed to the slowdown,” said Brian Abrahams, Co-Head of Biotechnology Research at Endpoints. “On the whole, the sector has slowed too much. There are increasingly compelling valuatio";193.35000610351562;;287.32000732421875;Of the top 10 stocks with the biggest market caps that have soared 20% or more year to date, seven are energy stocks.  It's much easier to find energy stocks that are in positive territory this year than to find those that aren't.  The second-biggest energy company, Chevron (NYSE: CVX), has also delivered impressive gains.;213.57000732421875;Biotech stocks have suffered significant setbacks during the first half of the year. Investors had little appetite for innovation-driven companies, seeking safe haven in more traditional stocks delivering steady profits. “Clinical trial failures, regulatory setbacks, drug pricing concerns and a lull in M&A all contributed to the slowdown,” said Brian Abrahams, Co-Head of Biotechnology Research at Endpoints. “On the whole, the sector has slowed too much. There are increasingly compelling valuatio;171.27000427246094;;177.72999572753906;;146.49000549316406;;353.3399963378906;;2.7899999618530273;EATV (NYSE: EATV), the VegTech™ Plant-based Innovation & Climate ETF, made history on June 23rd, when its advisor, VegTech™ Invest, threw a party at The New York Stock Exchange celebrating the listing of the world's first Plant-based Innovation ETF.;85.08999633789062;;48.95000076293945;;77.36000061035156;;44.099998474121094;Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.;53.81999969482422;Novavax (NASDAQ: NVAX) is a pandemic stock.  Now it's down to $50, and the company's market cap is under $4 billion.  Here are three arguments for buying Novavax stock and one reason for why you might want to avoid these shares.The early case for the mRNA-based Covid-19 vaccines was that the adaptability of the technology meant they could be updated to match the virus as it evolved.;53.400001525878906;;99.93000030517578;;76.30000305175781;A look at the shareholders of Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) can tell us which group is most powerful...;69.66000366210938;;33.720001220703125;;57.380001068115234;;66.9000015258789;In this article, we will take a look at the 10 stocks that recently received price-target cuts from analysts. You can skip our detailed analysis of these companies and go directly to Analysts Just Decreased Price Targets of These 5 Stocks. Footwear retailer NIKE, Inc. (NYSE:NKE), health care company Baxter International Inc. (NYSE:BAX) and biotechnology firm […];34.33000183105469;"– First company to Convert from Secondary to Primary Listing Status in Hong Kong – Our dual Primary Listing on the Nasdaq and Hong Kong Stock Exchange provides greater access for investors SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it has completed its voluntary conversion of its secondary listing status to a p";26.25;;22.219999313354492;;9.34000015258789;– BBP-711 led to near complete inhibition of glycolate oxidase throughout the dosing period and greater than 10-fold increases in plasma glycolate, suggesting it has the potential to be both a best-in-class therapy and the first oral therapy for PH1 and recurrent kidney stone formers – Based on the tolerability and potency of the oral therapy, BridgeBio has met with regulators and intends to initiate a Phase 2/3 pivotal study by the end of 2022 – At the end of 2022, BridgeBio also intends to lau;43.09000015258789;CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new research highlighting the company’s internal efforts to develop improved transplant conditioning regimens for patients with sickle cell disease (SCD) undergoing hematopoietic stem cell transplantation (HSCT) will be presented today, June 27, 2022, at 4:00 p.m. CEST at the Federation of American Soc;30.75;There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...;61.18000030517578;;47.040000915527344;Biotech stocks have suffered significant setbacks during the first half of the year. Investors had little appetite for innovation-driven companies, seeking safe haven in more traditional stocks delivering steady profits. “Clinical trial failures, regulatory setbacks, drug pricing concerns and a lull in M&A all contributed to the slowdown,” said Brian Abrahams, Co-Head of Biotechnology Research at Endpoints. “On the whole, the sector has slowed too much. There are increasingly compelling valuatio;;;26.649999618530273;Immatics (IMTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.;14.979999542236328;"Abcam plc (""Abcam,"" ""Company,"" ""Group"") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.";8.40999984741211;;5.309999942779541;;39.34000015258789;;45.459999084472656;Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;57.900001525878906;;10.270000457763672;;39.34000015258789;Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.;14.640000343322754;;29.770000457763672;Ipsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in cash, along with a contingent value right of $1 per share. The transaction is likely to close by third-quarter 2022.Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.
2022-06-28;243.50999450683594;Amgen (AMGN) closed the most recent trading day at $244.85, moving -0.21% from the previous trading session.;62.209999084472656;Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.In advance of Juneteenth, our Gilead Leadership Organization of Black Employees (GLOBE) employee resource group gathered to raise the Juneteenth flag on our Foster City campus. With this symbol of ...SANTA MONICA, Calif., June 28, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission (EC) has approved its CAR T-cell therapy Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy. Yescarta has maintained orphan medicinal product designation in this indication.FOSTER CITY, Calif., June 27, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.;594.4199829101562;;139.82000732421875;Companies in The News Are: BNTX,PFE,WBA,HOOD,SAVE,ULCC,JBLUShares of the coronavirus vaccine maker BioNTech (NASDAQ: BNTX) are up by over 7.2% as of 11:28 a.m. ET on Monday.  The rise follows the company's report on June 25 that its updated jab candidate elicits a strong immune response against the omicron BA.1 variant when used as a booster, per its ongoing clinical trial in phase 2/3.  Importantly, it also stated that preliminary preclinical research suggests the candidate can elicit an immune response against the BA.4 and BA.5 viral lineages, which are currently the dominant ones in circulation.;187.42999267578125;How one St. Louis company is using sequencing to identify microbes that naturally control pests and boost agricultural yieldsMENLO PARK, Calif. & INDIANAPOLIS, June 28, 2022--GRAIL and Community Health Network partner to offer Galleri® to individuals at Community Health Network’s sites of care.;276.1700134277344;Vertex Pharmaceuticals  has been knocking on their 52-week highs and the question is whether prices will continue higher or will this company stall out and perhaps turn lower.  Aggressive traders could use available weakness to probe the long side of VRTX.;202.50999450683594;Nicole Murphy, Head of Pharmaceutical Operations & Technology, explains that most of a company’s environmental impact comes from its supply chain. In our quest to go fossil fuel free, we are partne...;165.02999877929688;;178.47000122070312;;142.1999969482422;;346.010009765625;;2.609999895095825;A look at the shareholders of Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) can tell us which group is most powerful...;83.1500015258789;BioMarin (BMRN) receives a positive CHMP opinion for Roctavian, its gene therapy for treating adults with hemophilia A. The European Commission's decision is expected by the third quarter of 2022.;46.880001068115234;;75.62999725341797;;41.11000061035156;Yahoo Finance’s Alexandra Semenova joins the Live show to discuss ARKK ETF seeing is longest inflow streak in over one year as inflation continues.;51.060001373291016;;52.029998779296875;;96.93000030517578;;74.66999816894531;;68.5;;32.470001220703125;The experimental Arrowhead Pharmaceuticals drug fazirsiran can reduce the accumulation of a mutant protein by 83% among people with alpha1-antitrypsin deficiency (AAT) disease, according to results from an open-label phase 2 trial involving 16 volunteers.  The condition is a rare genetic liver disease wherein a mutant protein, known as Z-AAT, accumulates in the liver and can lead to fibrosis, then cirrhosis or portal hypertension, and eventually hepatic decompensation or hepatocellular carcinoma.  There is no approved treatment.;53.459999084472656;;63.279998779296875;Yahoo Finance’s Alexandra Semenova joins the Live show to discuss ARKK ETF seeing is longest inflow streak in over one year as inflation continues.In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $66.90, marking a -0.09% move from the previous day.;34.459999084472656;;24.75;ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration Expanded Partnership Enables Development of both CAR NK and CAR T-cell Collaboration Candidates for Solid Tumors SAN DIEGO, June 28, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that it has expanded its off-the-shelf, iPSC-derived, c;20.940000534057617;;8.699999809265137;;40.400001525878906;;29.299999237060547;;58.72999954223633;;45.779998779296875;;;;25.729999542236328;;14.5600004196167;;8.020000457763672;;4.860000133514404;MENLO PARK, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 50,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity;37.970001220703125;;42.68000030517578;;55.22999954223633;;10.260000228881836;;36.06999969482422;;14.0;;30.389999389648438;Shares of Kezar (KZR) surge more than 100% during after-hour trading on Jun 27, following a promising data readout from a mid-stage study evaluating zetomipzomib in patients with active lupus nephritis.GSK announced positive results in a late-stage study on a new Covid-19 vaccine targeted to combat the omicron variant.Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.We’re committed to listening to mental health providers and learning how we can better help them support individuals with bipolar 1 disorder.Investors are optimistic about CVS Health's (CVS) robust revenue growth across its operating segments.
2022-06-29;245.42999267578125;In the latest trading session, Amgen (AMGN) closed at $243.51, marking a -0.55% move from the previous day.;62.47999954223633;Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.Gilead Sciences (GILD) closed at $62.21 in the latest trading session, marking a -0.99% move from the prior day.;597.6199951171875;Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the EYLEA® (aflibercept) Injection supplemental Biologics License Application (sBLA) for an every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with diabetic retinopathy (DR). The target action date for the FDA decision is February 28, 2023.;141.97999572753906;"Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's vote to update its COVID-19 boosters.Germany's BioNTech, Pfizer's partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.  In presentation slides posted on BioNTech's website for its investor day, the German biotech firm said its aim was to ""provide durable variant protection"".  As part of a push to further boost its infectious disease business, BioNTech said it was independently working on precision antibiotics that kill superbugs that have grown resistant to currently available anti-infectives.The FDA's VRBPAC committee recommends updated COVID-19 vaccine boosters that target the Omicron variant to improve vaccine effectiveness.Germany's BioNTech, Pfizer's partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.  The two partners, makers of the Western world's most widely used COVID-19 shot, are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its sublineages.The FDA will need to make a final decision soon on the composition of the shots if they are to be ready for a vaccination drive planned to start in October.A new COVID-19 booster strategy should focus on developing new shots that better protect against omicron and its subvariants.Johnson & Johnson does not plan to update its COVID-19 vaccine, though other vaccine makers like Moderna Inc. , BioNTech SE and Pfizer Inc. , and Novavax Inc. are already working on new versions that aim to better protection against the currently circulating strains of the virus. ""The company will focus on supplying its COVID-19 vaccine in parts of the world where the pandemic remains an emergency and there is acute need,"" a J&J spokesperson told MarketWatch in an email on Tuesday. ""To date, two";186.42999267578125;Investment from LifeArc, Illumina, and Illumina Ventures will fund genomics startups for Illumina Accelerator Cambridge graduates;280.3500061035156;Dow Jones futures rose slightly Wednesday morning, along with S&P 500 futures and Nasdaq futures. The stock market rally suffered sharp losses Tuesday, with the Nasdaq and S&P 500 breaking below a key level.No stock should even be a contender as the best biotech stock on the market right now if it isn't at least delivering positive returns, in my view.  Vertex is a big winner in the midst of a lot of losers.  At a minimum, the company should have growing sales and profits.;205.22999572753906;;162.2899932861328;;179.05999755859375;;145.42999267578125;When Dr. Shehnaaz Suliman joined ReCode Therapeutics Inc. in December as CEO, she knew of the oversubscribed $80 million Series B round the Menlo Park company raised two months before.  The Series B extension was co-led by Leaps by Bayer, the venture capital arm of German drug giant Bayer AG, and Matrix Capital Management affiliate AyurMaya with participation from Amgen Ventures.  ReCode already plans to file an investigational drug application with the Food and Drug Administration — launching the process of clinical trials — in the fourth quarter for an experimental treatment of primary ciliary dyskinesia and in second-quarter 2023 against cystic fibrosis.;348.5;Bio-Techne Corporation ( NASDAQ:TECH ) shareholders might be concerned after seeing the share price drop 22% in the...;2.5;;83.91999816894531;;46.20000076293945;;75.88999938964844;Ideally, your overall portfolio should beat the market average. But even the best stock picker will only win with some...;40.58000183105469;;51.849998474121094;"Taiwan will take delivery of its first doses of the Novavax Inc COVID-19 vaccine this week, received under the COVAX sharing scheme, the government said on Wednesday.  Taiwan's Central Epidemic Command Centre said the 504,000 doses would arrive on Thursday at Taipei's main international airport.  Taiwan is scheduled to receive 2.268 million doses of the Novavax vaccine in batches this year through the COVAX mechanism, it added.The pandemic-era bull market drove the values of many companies to lofty heights. Here's how those star performers are faring during a much more turbulent 2022.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today participated in the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee's (VRBPAC) meeting which resulted in a 19-2 vote to recommend inclusion of a SARS-CoV-2 Omicron component for COVID-19 booster vaccines in the U.S. beginning this fall.A new COVID-19 booster strategy should focus on developing new shots that better protect against omicron and its subvariants.Johnson & Johnson does not plan to update its COVID-19 vaccine, though other vaccine makers like Moderna Inc. , BioNTech SE and Pfizer Inc. , and Novavax Inc. are already working on new versions that aim to better protection against the currently circulating strains of the virus. ""The company will focus on supplying its COVID-19 vaccine in parts of the world where the pandemic remains an emergency and there is acute need,"" a J&J spokesperson told MarketWatch in an email on Tuesday. ""To date, two";52.43000030517578;;98.45999908447266;;77.06999969482422;;67.23999786376953;;34.560001373291016;;52.209999084472656;;63.0;Vaxart (NASDAQ: VXRT) is working on a coronavirus vaccine candidate.  Recently, Vaxart said its omicron-specific candidate and its original candidate both protected against the variant in preclinical tests.  Of course, even if Vaxart is successful, the company will make it to market much later than bigger rivals.Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.;34.54999923706055;;24.8799991607666;;20.790000915527344;;8.84000015258789;;40.41999816894531;;28.979999542236328;;60.2400016784668;;45.279998779296875;;;;26.010000228881836;;14.369999885559082;;7.920000076293945;;4.570000171661377;;37.560001373291016;;43.63999938964844;;58.310001373291016;;10.109999656677246;VANCOUVER, British Columbia, June 29, 2022--AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCellera’s collaboration with Lilly, for approximately $275 million. The existing U.S. government supply of bebtelovimab, including the new purchase, is expected to meet present demand through late August 2022. Del;34.77000045776367;;14.220000267028809;;30.290000915527344;
2022-06-30;243.3000030517578;;61.810001373291016;FOSTER CITY, Calif., June 29, 2022 /3BL Media/ - The U.S. Supreme Court delivered a decision in Dobbs v. Jackson Women’s Health Organization, which overturned the landmark 1973 Roe v. Wade ruling. ...;591.1300048828125;FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.;149.10000610351562;"The Food and Drug Administration on Thursday told COVID-19 vaccine makers that plan to update their boosters to add a BA.4 and BA.5 spike protein component to the new shots that are in development. These ""bivalent"" boosters should equally target the two subvariants of omicron as well as the original strain of the virus and are expected to be rolled out to Americans in the fall or winter. Earlier this week, the FDA's advisory committee on vaccines voted 19-2 that the COVID-19 boosters need to bePfizer (PFE) and partner BioNTech (BNTX) enter into an agreement with the government of the United States to supply 105 million doses of its mRNA-based COVID-19 vaccine.The price increase is another signal that investors may be underestimating the durability of the drug company's revenue from the vaccine.The Chef's Warehouse and AZEK are part of as Zacks Bull and Bear of the Day article.Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced a new vaccine supply agreement with the U.S. government. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult omicron-adapted COVID-19 vaccines, subject to the FDA authorization. The doses are planned to be delivered as soon as late summer 2022 and continue into Q4 of 2022. Related: Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response AgUnder the deal, the U.S. government will get 105 million doses and have the option to purchase more. The doses would be for a fall booster drive.Pfizer Inc. and BioNTech SE said late Wednesday they have inked a new agreement with the U.S. government to supply 105 million doses of their COVID-19 vaccines, including a formulation adapted to target omicron variants, pending approval from the FDA. The two pharma companies said the doses are expected to be delivered as soon as late summer, and continue into the end of the year. Under the agreement, the U.S. has the option to buy up to 195 million additional doses, which would bring the total105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses NEW YORK and MAINZ, GERMANY, JUNE 29, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult Omi";184.36000061035156;Illumina's (ILMN) division GRAIL will offer the Galleri MCED blood test to eligible patients across the Community Health Network's care sites.;281.7900085449219;The stock market rally searched for direction Wednesday. Jobless claims and inflation data are on tap.In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $280.35, marking a +1.51% move from the previous day.These are the healthcare stocks with the best value, fastest growth, and most momentum for July 2022.;203.94000244140625;In the immediate aftermath of the Supreme Court's decision to overturn nationwide protections for abortion, Cambridge-based Biogen Inc. says it will begin paying for travel for its employees to access abortion services.;161.85000610351562;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, June 30, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced new data from RATIONALE 306, a global Phase 3 trial evaluating tislelizumab plus chemotherapy in adult patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) without prior syst";176.94000244140625;;145.85000610351562;;346.6400146484375;;2.380000114440918;;82.87000274658203;;45.25;In this article, we discuss the 10 stocks billionaire Ken Griffin is selling in 2022. If you want to skip our detailed analysis of Griffon’s investment philosophy, hedge fund returns, and history, go directly to Billionaire Ken Griffin is Selling These 5 Stocks in 2022. Kenneth C. Griffin is the founder and Chief Executive Officer […];75.97000122070312;;39.38999938964844;Exact Sciences' (EXAS) legacy Screening business is growing on impressive Cologuard volume growth and revenue contributions from the PreventionGenetics acquisition.;51.43000030517578;"A couple of stocks that I would be very cautious with right now are Novavax (NASDAQ: NVAX) and Rivian Automotive (NASDAQ: RIVN).  Novavax's COVID-19 vaccine is approved for use in many countries, with Taiwan being the latest (on June 23) to grant it Emergency Use Authorization (EUA).The Food and Drug Administration on Thursday told COVID-19 vaccine makers that plan to update their boosters to add a BA.4 and BA.5 spike protein component to the new shots that are in development. These ""bivalent"" boosters should equally target the two subvariants of omicron as well as the original strain of the virus and are expected to be rolled out to Americans in the fall or winter. Earlier this week, the FDA's advisory committee on vaccines voted 19-2 that the COVID-19 boosters need to be(Bloomberg) -- Whether it’s commendable courage or a refusal to face reality, a receding stock market tide has left Wall Street analysts sitting with price predictions that will take more than a little luck to come true.Most Read from BloombergTrump’s Final Scene Didn’t Go According to ScriptDemocrats Weigh Paring Biden Tax Hike to Win Over ManchinVenice Plans to Start Weeding Out Cheap TouristsFauci Suffers Covid Symptom Rebound After Course of Pfizer’s PaxlovidDisquiet Over the Housing MarketVaccine stocks rose Wednesday after a experts recommended including an omicron-fighting component in updated Covid boosters this fall.Is Novavax stock a buy after the company's omicron data impressed two FDA experts at a recent meeting? Is NVAX stock a buy right now?The experimental shot played a front-and-center role during this week’s debate about how best to update the COVID-19 vaccines to better protect against omicron.";51.7599983215332;;97.4800033569336;;74.95999908447266;The FDA has placed a clinical hold on a Duchenne muscular dystrophy drug made by Sarepta Therapeutics Inc.;67.12999725341797;;35.209999084472656;;50.5099983215332;Shares of Blueprint Medicines Corp. gained 3.3% in premarket trading on Thursday after the company announced a deal with investment firm Sixth Street and Royalty Pharma , which acquires pharmaceutical royalties, worth up to $1.2 billion. Sixth Street will pay $250 million upfront for future royalties for two products, up to $400 million in a senior secured credit facility, and $260 million in a potential credit facility to support any buy-side business opportunities. Royalty Pharma will pay $175Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based mBlueprint Medicines Corporation (NASDAQ: BPMC) today announced strategic financing collaborations with Sixth Street and Royalty Pharma (NASDAQ: RPRX) for up to $1.25 billion, bringing significant non-dilutive, low-cost capital to drive innovation and growth.;60.77000045776367;;34.68000030517578;;24.780000686645508;;20.81999969482422;;9.079999923706055;;38.709999084472656;;29.43000030517578;;59.65999984741211;;44.0;;;;25.469999313354492;;14.460000038146973;;7.639999866485596;;4.420000076293945;;37.02000045776367;;42.09000015258789;;57.08000183105469;;10.649999618530273;;34.959999084472656;SOUTH SAN FRANCISCO, Calif. & SEOUL, South Korea, June 30, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ildong Pharmaceutical, today announced an agreement under which Ildong will license a suite of Twist VHH antibody libraries to use to discover and develop antibodies for applications in immuno-oncology.;14.09000015258789;;29.790000915527344;
2022-07-01;245.5500030517578;A blockbuster could be on the way next year -- but if you wait that long to invest, could it be too late?The big shareholder groups in Amgen Inc. ( NASDAQ:AMGN ) have power over the company. Institutions often own shares in...Chevron is well off its June peak, but is still the top Dow Jones stock performer so far in 2022 amid a brutal market sell-off.;62.36000061035156;;595.4000244140625;Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the acquisition of Sanofi's stake in Libtayo® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.Regeneron (REGN) closed at $591.13 in the latest trading session, marking a -1.09% move from the prior day.;157.5;;191.0399932861328;Illumina and Cold Spring Harbor Asia DNA Learning Center reach more than 1,000 STEM learners through a new program;287.32000732421875;"If you hold on to a promising growth stock for five years, you should expect to accumulate some decent gains over that time.  Investing in just the S&P 500 would have resulted in a nearly 60% increase in value -- and that's even after factoring in this year's bearish market.  Five years ago, Vertex Pharmaceuticals (NASDAQ: VRTX) was coming off a year when its revenue soared by 65% to $1.7 billion.Is a recession coming? Ark Invest CEO Cathie Wood thinks that one has already arrived. Economists surveyed by The Wall Street Journal put the odds of a recession over the next 12 months at 44%. Federal Reserve chairman Jerome Powell recently said that a recession is ""a possibility,"" although the Fed is trying to avoid causing one with its interest rate hikes.";210.6300048828125;;166.9499969482422;;180.11000061035156;The  (ticker: XBI), which tracks small- and mid-cap biotech stocks, fell 33.7% in the first half of the year, which ended on Thursday.  The  (IBB), which tracks larger biotech names, fell 22.8%.  In a note out early Friday, analysts with  Cowen  biotechnology team noted that June represented the XBI’s first positive month since last August.Does Seattle Genetics (SGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.;148.25;A little competition can greatly benefit patients. Shareholders may have a more difficult path to navigate.;353.17999267578125;;2.380000114440918;;84.9800033569336;;46.86000061035156;;77.66999816894531;;41.130001068115234;;57.150001525878906;;54.0099983215332;;99.25;;75.70999908447266;CAMBRIDGE, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 40 individuals hired by Sarepta in June 2022. The equity awards were approved in accordance with Nasdaq Listing Rule 5;71.18000030517578;"Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' ""short squeeze"" and investors' bargain hunting.";35.959999084472656;;49.93000030517578;"Blueprint Medicines Corp. has struck deals with Sixth Street and Royalty Pharma plc to bring in up to $1.25 billion.Today Blueprint Medicines Corp (NASDAQ: BPMC) announced strategic financing agreements with Sixth Street and Royalty Pharma Plc (NASDAQ: RPRX) for up to $1.25 billion, including $575 million upfront upon deal closure. SVB Securities thinks the terms of the deals are fairly valued on the Sixth Street portion and favorable for Blueprint Medicines on the Royalty Pharma portion. ""In addition, these deals provide non-dilutive capital and independent validation by sophisticated investors, although we";63.790000915527344;The leading gene editing company  CRISPR Therapeutics  is looking better to technically oriented traders. Let's take a look. In this daily bar chart of CRSP, below, we can see that following a downtrend that prices have turned sideways since January.;38.540000915527344;;25.139999389648438;SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Brian T. Powl has been appointed Chief Commercial Officer. Mr. Powl brings to Fate Therapeutics extensive commercial leadership experience in hematologic malignancies and solid tumors, having previously served as the Global Commercial CAR T lead at Celgene Corporation wh;21.56999969482422;The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.;9.920000076293945;;39.790000915527344;;31.239999771118164;;62.650001525878906;;44.47999954223633;;;;25.8700008392334;;14.680000305175781;;7.75;;4.46999979019165;;38.060001373291016;;42.58000183105469;;55.16999816894531;;10.640000343322754;;37.08000183105469;;14.369999885559082;;30.530000686645508;
2022-07-05;246.72999572753906;Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.;62.34000015258789;;596.5599975585938;;161.02999877929688;"CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development. CureVac has filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE (NASDAQ: BNTX) and two of its subsidiaries, seeking fair compensation for infringement of a portfolio of CureVac’s intellectual property rights utilized in Comirnaty, BioNTech and Pfizer Inc’s (NYSE: PFE) mRNBERLIN (Reuters) -CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus.  The German-based biotech company is seeking ""fair compensation"" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday.  When asked in a media call, Chief Executive Franz-Werner Haas did not rule out further legal action against BioNTech partner Pfizer or mRNA vaccine maker Moderna.Shares of BioNTech SE fell 0.9% in premarket trading Tuesday, after CureVac N.V. filed in Germany a patent infringement suit against the biotechnology company. CureVac said there were certain of its patents that were utilized in the manufacture and sale of BioNTech and Pfizer Inc.'s COVID-19 vaccine, Comirnaty. CureVac said while it doesn't seek an injunction, and won't take legal action to impede the production or sale of Comirnaty, it is seeking ""fair compensation"" for infringement of its pateCureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus.  The German-based biotech company is seeking ""fair compensation"" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday.CureVac has filed a lawsuit in Germany against BioNTech, seeking compensation for what it said was infringement of its intellectual property rights, the vaccine maker said on Tuesday.  CureVac said that it claimed intellectual property rights based on more than two decades of work on mRNA technology that helped contribute to the development of COVID-19 vaccines.  The Germany-based company said it was not seeking an injunction, nor does it intend to take legal action that would impede the production, sale or distribution of the coronavirus vaccine made by BioNTech and Pfizer.";193.02000427246094;;288.9800109863281;The FDA has lifted the clinical hold placed on Vertex Pharmaceuticals Inc's (NASDAQ: VRTX) Phase 1/2 trial of VX-880 for people with type 1 diabetes (T1D) with severe hypoglycemia. VX-880 is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy. The FDA instituted a clinical hold on the study due to a determination of insufficient information to support dose escalation with the product. As a result, the Phase 1/2 trial will be reopened for screeningBOSTON, July 05, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia. As a result, the Phase 1/2 trial will be reopened for screening, enrollment and dOne particular example is Vertex Pharmaceuticals (NASDAQ: VRTX).  The biotech company's shares have climbed about 25% so far this year.  Investors might not like Vertex's total dependence on one therapeutic area.;212.5800018310547;;194.47999572753906;;176.77000427246094;;150.72999572753906;;362.29998779296875;Bio-Techne Corporation (NASDAQ:TECH), today announced it has completed the acquisition of Namocell, Inc. The Namocell acquisition adds easy-to-use single cell sorting and dispensing platforms that are gentle to cells and preserve cell viability and integrity. Namocell's instruments and consumables are critical technologies in various workflows in both biotherapeutics and diagnostics, including cell and gene therapy development and commercialization, cell engineering, cell line development, singl;2.700000047683716;;86.36000061035156;;49.9900016784668;;79.25;;44.400001525878906;;64.29000091552734;;63.18000030517578;;98.30000305175781;;75.73999786376953;;71.95999908447266;;39.15999984741211;PASADENA, Calif., July 05, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in two Phase 1/2a clinical trials of ARO-MUC5AC and ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutics designed to reduce production the of mucin 5AC (MUC5AC) and the receptor for advanced glycation end products (RAGE), respectively, as potential treatments for various muco-obstructive and inflammatory pulmonary diseases.;54.40999984741211;;70.5999984741211;;41.40999984741211;;29.100000381469727;;22.270000457763672;Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.;10.789999961853027;;46.4900016784668;Protracted drawdowns in the stock market are unnerving, to say the least.  Two of my personal favorites in this buyer's market are AMC Entertainment Holdings (NYSE: AMC) and Beam Therapeutics (NASDAQ: BEAM).  AMC Entertainment Holdings' underlying fundamentals and near-term growth prospects aren't going to win over many classic value investors.;31.68000030517578;;63.79999923706055;;46.33000183105469;;;;27.809999465942383;China-based biotechnology company Brii Biosciences Limited exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology Inc (NASDAQ: VIR) VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting HBV in Phase 2 development. This is Brii Bio's second option exercise for a Vir infectious disease program, with two remaining options still available to the co;15.210000038146973;;8.029999732971191;;5.199999809265137;;37.849998474121094;A look at the shareholders of Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) can tell us which group is most powerful...;46.689998626708984;;57.09000015258789;;10.380000114440918;;41.09000015258789;;15.270000457763672;;31.43000030517578;
2022-07-06;245.25;In this article, we discuss the Dow 30 stocks and their rank according to the 2022 hedge fund bullishness index. If you want to skip our review of these stocks and the latest market situation, go directly to 15 Dow Stocks Listed and Ranked By 2022 Hedge Fund Bullishness Index. The Dow Jones Industrial Average, […]Amgen (AMGN) closed the most recent trading day at $246.73, moving +0.48% from the previous trading session.;62.72999954223633;;594.9000244140625;;160.1999969482422;"Pfizer stock crashed into its 50-day line Tuesday after Germany's CureVac sued its Covid vaccine partner, BioNTech, for patent infringement.BioNTech is looking into taking legal steps against CureVac after the latter filed a patent lawsuit against it over its use of mRNA technology, BioNTech said on Wednesday, confirming a report by daily Welt.  ""We are looking at all legal options,"" said a BioNTech spokesperson.  CureVac is seeking ""fair compensation"" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday.Pfizer (NYSE: PFE) is already the leader in the coronavirus vaccine space.  Rival Moderna (NASDAQ: MRNA) has a significant position in the market.  Latecomer Novavax (NASDAQ: NVAX) could also take market share in the months to come.The team behind Britain’s most-used Covid booster vaccine is being sued by a German pharmaceutical firm which has accused it of stealing the technology behind the jab.While the daily average of new COVID-19 cases have settled back into a low-100K range that has lasted for about seven weeks, hospitalizations took their first dip since mid-April and deaths ticked up to a 2 1/2-month high.CureVac says its intellectual property portfolio protects multiple inventions that are considered essential to Pfizer and BioNTech's Covid-19 vaccine.";195.38999938964844;Biotech stocks have been brought low over the past 18 months. Both the iShares Biotechnology ETF (NASDAQ:IBB) and S&P Biotech ETF (NYSEARCA:XBI), Wall Street’s two most popular funds that track the industry, dropped 33% and 57% since peaking last February. But the losses were worse two weeks ago. Many biotechs rallied back, and both ETFs are sporting double bottom formations. Unfortunately, some components still have broken trends and remain vulnerable to further downside. I scoured the top hold;291.1600036621094;The FDA lifts clinical hold on Vertex's (VRTX) study on VX-880, its stem-cell-derived, fully differentiated islet replacement therapy that could offer a functional cure for type 1 diabetes patients.If a company's business model is durable and proven to be all-weather by years of strong performance, it won't be at risk for as many problems when things get dicey.  In this vein, there are three such companies that investors should know about and consider buying today.  Vertex Pharmaceuticals (NASDAQ: VRTX) is one of the world's largest biopharma companies, and its long-standing focus on developing and commercializing medicines for cystic fibrosis (CF), a rare hereditary pulmonary disease, is what makes it so formidable.The plunging stock market has wiped out billions of dollars in market capitalization for major public companies across Massachusetts.;215.97999572753906;"Shares of biotech giant Biogen (NASDAQ: BIIB) have dropped by 40% in the past year, easily underperforming the broader market over this period.  The drugmaker has encountered many headwinds related to its controversial Alzheimer's disease drug, Aduhelm.  Recapping the entire Aduhelm saga would take far more space than we have here.The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).The FDA will decide whether to approve lecanemab on the basis of early-stage data showing that it can clear brain plaques.Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, ""Biogen"") announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due tThe U.S. Food and Drug Administration will expedite its review of Eisai Co Ltd's and Biogen Inc's experimental Alzheimer's drug lecanemab, with a decision due by Jan 6, 2023, the companies said on Tuesday.  Lecanemab, like the partners' previous drug Aduhelm, is an antibody designed to remove sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer’s, a disease that leads to memory loss and the inability to care for oneself.  The FDA controversially approved Aduhelm in June last year, although only one of two late-stage trials showed it helped slow cognitive decline.Biotech stocks have been brought low over the past 18 months. Both the iShares Biotechnology ETF (NASDAQ:IBB) and S&P Biotech ETF (NYSEARCA:XBI), Wall Street’s two most popular funds that track the industry, dropped 33% and 57% since peaking last February. But the losses were worse two weeks ago. Many biotechs rallied back, and both ETFs are sporting double bottom formations. Unfortunately, some components still have broken trends and remain vulnerable to further downside. I scoured the top hold";181.0500030517578;CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, July 06, 2022--BeiGene announced it entered into a worldwide strategic collaboration with InnoRNA to develop mRNA-based therapeutics.;175.1300048828125;There’s no doubt about it, the tech sector, which powered so much of the market’s success in the last decade, has led the declines in the past six months. Since the start of the year, the tech-heavy NASDAQ index is down nearly 28%, even after some recent bounces. But while the index is beaten down, not every component stock is suffering right now. Some stocks, in fact, have been outperforming their peers, and haven’t been touched by the general collapse in tech. Jim Cramer, the well-known host o;150.0;;362.7799987792969;Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced the European launch of the CE-IVD marked RNAscope ISH Probe High Risk HPV, intended for use in patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC) to aid in the identification of high-risk human papillomavirus (HPV).;2.990000009536743;;86.41000366210938;;49.58000183105469;;79.72000122070312;;43.290000915527344;;63.540000915527344;;60.5099983215332;;95.19999694824219;;75.97000122070312;Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy under development in partnership with Roche Holdings AG (OTC: RHHBY). Results from Cohort 1 demonstrated a 3.8-point improvement and 3.2-point improvement on the Duchenne functional scale 52 weeks after treatment compared to a propensity-score weighted external control. RelaSarepta and its partner Roche present new results and analyses at the International Congress on Neuromuscular Diseases (ICNMD), which demonstrate that SRP-9001 shows consistent, statistically significant functional benefits in individuals with Duchenne versus a propensity-weighted external control that continue to positively diverge from natural history disease course In the 20-patient Cohort 1 of SRP-9001-103 (ENDEAVOR), SRP-9001-treated participants improved 4 points from their pre-therapy basSarepta will update investors Thursday on the data it hopes will persuade U.S. regulators to accelerate approval of its gene therapy treatment for muscular dystrophy.CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wednesday, July 6, 2022 at 8:30am Eastern Time, the Company will host a webcast and conference call to share new functional data across multiple studies from the clinical development program for SRP-9001 (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy. The Company also plans to present an;69.83000183105469;;39.9900016784668;;54.279998779296875;;72.69999694824219;;37.2400016784668;(Bloomberg) -- Hong Kong is likely to see more dual-traded companies shift toward primary listings in the financial hub as they seek inclusion in trading links with mainland China, according to the city’s exchange chief.Most Read from BloombergElon’s OutWho Shot Shinzo Abe and Why? Everything We Know So FarBiden’s Quest for Saudi Oil Faces Reality-Check of Slim CapacityTrump Lashes Out at Elon Musk and ‘Rotten’ Twitter DealPutin’s New Weapon of Mass Disruption: Kazakh OilIn a wide-ranging interv;28.6299991607666;;21.530000686645508;ALAMEDA, Calif., July 05, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand beginning Monday, July 11, 2022.;10.600000381469727;;45.560001373291016;;32.72999954223633;;63.380001068115234;;46.75;Apple and other techs led a big rally off morning lows as oil prices and bond yields dived. Markets see Fed rate hikes ending this year.;;;27.299999237060547;;15.09000015258789;;8.149999618530273;;5.150000095367432;;36.810001373291016;;48.5;;56.16999816894531;;10.579999923706055;;40.689998626708984;SOUTH SAN FRANCISCO, Calif., July 06, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the opening of its new Twist Boston location in Quincy, Massachusetts.;15.119999885559082;;31.8700008392334;"GREENWICH, Conn., July 06, 2022--Sarissa Capital Management LP (""Sarissa"") today made the following statement on Alkermes PLC (NASDAQ: ALKS) regarding how it intends to vote at the upcoming Alkermes annual meeting and the reasons therefor:Financials are one of the few sectors that are well-positioned to succeed and grow in this inflationary environment.  In IBD's Global Leaders screen, there are various insurance stocks that make the list, as well as a top biotech stock.  IBD's Insurance and Property Casualty group has outperformed recently, ranking 10th out of 197 industries."
2022-07-07;247.4199981689453;;62.720001220703125;In this article, we discuss 10 dividend stocks to buy according to John Allison’s Unio Capital. You can skip our detailed analysis of the hedge fund’s investment philosophy and Allison’s investment career, and go directly to read John Allison’s Unio Capital Portfolio: 5 Dividend Stocks. John A. Allison founded Unio Capital, a New York-based hedge […]ExxonMobil, Chevron, Philip Morris International, Gilead Sciences and General Mills are part of Zacks Market Edge blog.Expectations are low for this earnings season. Will companies surprise the Street?;607.4500122070312;Regeneron (REGN) closed at $594.90 in the latest trading session, marking a -0.28% move from the prior day.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2022 financial and operating results on Wednesday, August 3, 2022, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.;167.97000122070312;Governments and manufacturers are tossing out doses by the millions because of waning demand, a sharp reversal from the rollout of Covid-19 vaccines.Yahoo Finance health reporter Anjalee Khemlani outlines the events surrounding the FDA's ban on Juul products and e-cigarettes, as well as Pfizer's Paxlovid COVID-19 treatment pill receiving an Emergency Use Authorization from the FDA.;202.1999969482422;At Illumina, we are driven by the power of genomics to positively impact the world and shape a more sustainable and equitable future for all.;294.1700134277344;Here, I'll talk about a vaccine stock on the rise, a biotech company with a catalyst on the horizon, and a surgical company that leads the market.  Novavax (NASDAQ: NVAX) has reached an exciting moment.  The company has brought its coronavirus vaccine to market in various countries and in the first quarter began generating revenue and profit.The FDA has given priority review to lecanemab, the second Alzheimer's disease drug made by Biogen and Japanese pharmaceutical firm Eisai, under the accelerated approval pathway — the same regulatory route used by the companies for Aduhelm.The FDA cleared Vertex to restart testing a diabetes treatment, and VRTX stock jumped to a fresh high Wednesday.As the market regroups, 25 names — including Vertex, WWE, Li Auto and KO stock — make the IBD Breakout Stocks Index.;217.9600067138672;The FDA has given priority review to lecanemab, the second Alzheimer's disease drug made by Biogen and Japanese pharmaceutical firm Eisai, under the accelerated approval pathway — the same regulatory route used by the companies for Aduhelm.;191.41000366210938;;177.9499969482422;Yahoo Finance Live anchors discuss reports of an acquisition deal between Merck and Seagen.The two companies are discussing a price for Seagen above $200-a-share, The Wall Street Journal reported.;153.4199981689453;;368.239990234375;;3.240000009536743;;88.3499984741211;;52.59000015258789;;80.77999877929688;The difference is that many investors don't recognize the opportunities that major pullbacks provide.  Here are three that the world's smartest investors are buying hand over fist right now.  Warren Buffett certainly deserves a spot high on the list of the most successful investors of all time.;45.75;In this article, we discuss 10 stocks that Cathie Wood and Steve Cohen love. If you want to see more favorite stocks of the prominent hedge fund managers, click Cathie Wood and Steve Cohen Love These 5 Stocks. Cathie Wood, the chief of ARK Investment Management, and Steve Cohen of Point72 Asset Management are perhaps […];73.13999938964844;;64.04000091552734;;96.45999908447266;;79.69999694824219;;66.02999877929688;;42.16999816894531;;54.810001373291016;;78.19999694824219;;38.08000183105469;;30.93000030517578;;21.709999084472656;"Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.ALAMEDA, Calif. & KRAKOW, Poland, July 07, 2022--Exelixis, Inc. (Nasdaq: EXEL) and Ryvu Therapeutics S.A. (""Ryvu"") (Warsaw Stock Exchange: RVU) today announced that the companies have entered into an exclusive license agreement focused on the development of novel targeted therapies utilizing Ryvu’s STING (STimulator of INterferon Genes) technology. The agreement expands Exelixis’ portfolio of biotherapeutics by combining Ryvu’s proprietary small molecule STING agonists and STING biology know-how";10.520000457763672;;51.66999816894531;Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ: BEAM), which amended the agreement initially announced in April 2019. The original agreement provided Verve with an exclusive, worldwide, sublicensable license under certain of Beam’s base editing, gene editing, and delivery technologies for applications against four liver-mediated cardiovascular disease targets and two undisclosed gene targets. Under;34.150001525878906;;63.83000183105469;;50.16999816894531;;;;28.989999771118164;Vir Biotechnology (NASDAQ:VIR) has had a great run on the share market with its stock up by a significant 25% over the...;14.970000267028809;;10.050000190734863;;5.599999904632568;;36.77000045776367;;52.36000061035156;What goes down must come up — or at least that's been the recent case for biotech stocks, which continued going gangbusters Wednesday.;58.0099983215332;Here is how HealthEquity (HQY) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...;11.489999771118164;;43.25;;15.710000038146973;;31.479999542236328;
2022-07-08;248.47999572753906;I’ve written before about how biotech is the biggest technology trend of our kids’ generation. Naturally, that means many people are looking for the best biotech stocks to buy. But as with the PC industry of my time, finding long-term winners is difficult. Back in the early 1980s, dozens of companies entered the PC market, many of them huge for their time. IBM (NYSE:IBM) was the bet everyone made. But the BUNCH — Burroughs, Univac, NCR (NYSE:NCR), Control Data and Honeywell (NASDAQ:HON), were alIn the latest trading session, Amgen (AMGN) closed at $247.42, marking a +0.88% move from the previous day.The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.;62.84000015258789;As we continue to celebrate Pride Month, we feature Cristina Herrera of Translatinx Network, a Gilead grantee. Learn more about how she continues to fulfill her dream of leading a trans-led, immigr...;621.5700073242188;The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.;170.1300048828125;FDA's advisory committee supports granting authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. The vaccine also receives authorization for use in adolescents in Europe.;197.0399932861328;;294.2900085449219;Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) is an excellent example.  Although Vertex Pharmaceuticals is firing on all cylinders, the future could be even brighter.  Let's consider why this biotech company is still worth investing in.The bear market has sent plenty of great companies into the doldrums.  Once economic pressures ease, our favorite companies have a great chance of rebounding -- and gaining over time.  Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) are both gaining so far this year -- even as the S&P 500 declines.Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -1% and 13.36%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.Vertex Pharmaceuticals Incorporated (Canada) (Nasdaq: VRTX) today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA), which represents an agreement in principle regarding the public reimbursement of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for patients ages 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.In this article we present the list of Disney (DIS) and 9 Other Stocks Billionaire Phill Gross Was Buying Up in Q1. Click to skip ahead and check out Disney (DIS) and 4 Other Stocks Billionaire Phill Gross Was Buying Up in Q1. Walt Disney Co (NYSE:DIS), Dollar Tree, Inc. (NASDAQ:DLTR), and Vertex Pharmaceuticals Incorporated […];218.8000030517578;Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.;188.74000549316406;;177.4499969482422;BOTHELL, Wash., July 08, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2022 financial results on Thursday, July 28, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.CORRECTIONS The drug Adcetris accounted for $706 million of Seagen $1.4 billion in sales last year. A Page One article on Thursday about Merck & Co.’s talks to acquire Seagen incorrectly said Adcetris alone had $1.The sector is positioned well to outperform for a variety of fundamental reasons. Biotechs are largely recession-resistant. And they're down almost 40% from last year's high.Yahoo Finance Live looks at several of today's trending stocks, including Merck as it continues its negotiations to acquire SeaGen.A deal, potentially worth $40 billion or more, would help Merck broaden its lineup of cancer drugs, currently led by Keytruda.;152.49000549316406;;369.92999267578125;;3.2300000190734863;Even after some recent positive trading sessions, the stock markets are still registering heavy losses this year. The S&P is down 18%, and the NASDAQ remains in bear territory with a 26% year-to-date loss. But these broad-based market losses have also opened up opportunities, as many stocks have fallen for no fault of their own. Some of the Street’s most legendary investors are not shying away from buying in, even in this bearish environment. Andreas Halvorsen, a former Tiger Cub and the billion;89.0199966430664;;51.70000076293945;;80.4800033569336;;46.58000183105469;Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2022 financial results after the close of the U.S. financial markets on August 2, 2022. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.;76.12000274658203;;63.38999938964844;;95.56999969482422;;80.47000122070312;;67.69999694824219;;41.72999954223633;;56.58000183105469;Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on July 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 18,434 shares of its common stock and an aggregate of 9,214 restricted stock units (RSUs) to fifteen new employees under Blueprint Medicines' 2020 Inducement Pla;76.69999694824219;Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs well, when investors win, they can win big...Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot.  Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by 17% over the holiday-shortened week as of Thursday's closing bell, according to data provided by S&P Global Market Intelligence.  What's more, shares of CRISPR Therapeutics (NASDAQ: CRSP) have gained 22.6% over the same period, and fellow gene editor Editas Medicine (NASDAQ: EDIT) also saw its equity rise in price by a healthy 20.7% this week.The major indexes rallied Thursday right to where they've struggled this year. Here are 5 stocks triggering buy signals.I’ve written before about how biotech is the biggest technology trend of our kids’ generation. Naturally, that means many people are looking for the best biotech stocks to buy. But as with the PC industry of my time, finding long-term winners is difficult. Back in the early 1980s, dozens of companies entered the PC market, many of them huge for their time. IBM (NYSE:IBM) was the bet everyone made. But the BUNCH — Burroughs, Univac, NCR (NYSE:NCR), Control Data and Honeywell (NASDAQ:HON), were al;38.5;;30.010000228881836;;22.010000228881836;;10.079999923706055;;52.0099983215332;;34.06999969482422;;66.13999938964844;;51.779998779296875;Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.;;;29.760000228881836;;14.789999961853027;;9.380000114440918;;5.449999809265137;;37.150001525878906;;52.209999084472656;;57.56999969482422;;11.579999923706055;;42.27000045776367;;15.739999771118164;The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.;31.850000381469727;"Alkermes plc (Nasdaq: ALKS) today announced the results of its 2022 Annual General Meeting of Shareholders (the ""Annual Meeting"") held July 7, 2022."
2022-07-11;247.77999877929688;;62.65999984741211;;614.4600219726562;Stock splits are big news these days. That's because some of the most popular companies have announced or completed them this year. For example, Amazon split its stock in June. And Tesla shareholders are set to vote on a potential split during their meeting in August.;166.47000122070312;A new, highly infectious subvariant of omicron is raising concerns among scientists and health experts as it spreads in India and other countries, including the U.S.The U.S. government purchased 3.2 million doses of Novavax Inc.'s still-investigational COVID-19 vaccine. Novavax's recombinant protein-based vaccine uses different technology than the mRNA shots developed by Moderna Inc. and BioNTech SE . The vaccine still has to receive authorization from the Food and Drug Administration and the OK from the Centers for Disease Control and Prevention, though an FDA advisory committee has already recommended authorization of the two-dose vaccine. Novavax's stock;190.32000732421875;;294.07000732421875;Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has agreed to acquire ViaCyte, a privately held biotechnology, for $320 million in cash. ViaCyte is focused on delivering stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D). Vertex's VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy for T1D. Related: FDA Lifts Clinical Hold On Vertex Pharma's Stem Cell-Derived Diabetes Treatment Trial. ThBOSTON, July 11, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.;215.25999450683594;;177.02000427246094;;177.30999755859375;Expectations that Merck will buy Seagen in a $40 billion deal have lifted stocks across the sector, but little else has changed.;150.91000366210938;;363.0400085449219;;2.990000009536743;;87.83000183105469;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it presented four oral presentations and two poster presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 World Congress from July 9-12 in London.;47.04999923706055;;80.95999908447266;Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.;45.380001068115234;;67.1500015258789;;60.29999923706055;;95.88999938964844;;80.12000274658203;;62.63999938964844;;40.29999923706055;;53.810001373291016;;73.70999908447266;;38.43000030517578;Qiming Venture Partners announced today the closing of its latest funds totaling US$3.2 billion, including USD Fund VIII at US$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million).;28.510000228881836;;20.6299991607666;ALAMEDA, Calif., July 11, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that COSMIC-313 met its primary endpoint, demonstrating significant improvement in progression-free survival (PFS) at the primary analysis. COSMIC-313 is an ongoing phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX®), nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma (RCC).;9.149999618530273;;50.45000076293945;;32.86000061035156;;65.87000274658203;;50.0;;;;30.09000015258789;;14.489999771118164;;8.720000267028809;;4.880000114440918;;36.540000915527344;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that its long-standing partner, Roche, will license and advance IONIS-FB-LRx, an investigational antisense medicine, into a Phase 3 clinical study in patients with immunoglobulin A nephropathy (IgAN). IgAN is a rare and serious condition that often leads to chronic kidney disease and renal failure. Roche's decision to advance the program comes after positive data from a Phase 2 clinical study in which IONIS-FB-LRx met its primary endpoi;49.310001373291016;;55.400001525878906;;11.109999656677246;AbCellera Biologics (NASDAQ:ABCL) has had a great run on the share market with its stock up by a significant 39% over...;38.56999969482422;;15.920000076293945;;30.899999618530273;
2022-07-12;246.97000122070312;A handful of pharmaceutical stocks — including Pfizer and Amgen — are either eyeing buy points or have broken out after diving in June.;62.34000015258789;FOSTER CITY, Calif., July 12, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Deborah Telman will join the company as Executive Vice President, Corporate Affairs and General Counsel, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day. Ms. Telman will assume responsibility for Gilead’s legal and corporate affairs function, which includes government and policy, and public affairs. Ms. Telman will start inRegional Court of Dusseldorf has ruled in favor of NuCana plc (NASDAQ: NCNA), stating that Gilead Sciences Ireland UC and Gilead Sciences GmbH infringed NuCana's composition of matter claims in European Patent 2955190 through their sales of Sovaldi, Harvoni, Vosevi and Epclusa in Germany. This judgment follows Gilead's unsuccessful challenge to the validity of NuCana's ‘190 patent at the Opposition Division of the European Patent Office in 2021. Gilead also attempted to challenge the validity of;610.0900268554688;Ultima Genomics, Inc. (the Company) has signed an agreement with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) to further advance Ultima Genomics' sequencing architecture. Under the terms of the agreement, Regeneron will collaborate with Ultima on the development and testing of Ultima's second-generation sequencing platform, which will build upon the advances of the Company's first instrument, the UG100™ anticipated to launch in 2023. In conjunction with the agreement, Regeneron, who is currentToday we'll do a simple run through of a valuation method used to estimate the attractiveness of Regeneron...;161.4199981689453;The average of price targets set by Wall Street analysts indicates a potential upside of 47.9% in BioNTech SE Sponsored ADR (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.Children's Hospital of Philadelphia Dr. Paul Offit sits down with Yahoo Finance Live to talk about the U.S. government's move to purchase additional booster shots ahead of the fall season, the prominence of new Omicron subvariants, and the efficacy of vaccines on these newer COVID-19 strains.;187.99000549316406;Today we're going to take a look at the well-established Illumina, Inc. ( NASDAQ:ILMN ). The company's stock saw...;290.010009765625;Vertex (VRTX) will acquire ViaCyte for $320 million in cash.Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $294.07, moving -0.07% from the previous trading session.;215.5800018310547;;178.66000366210938;"Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and acc688235ess for patients worldwide, today announced the initiation of Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap's anti-SSEDickkopf 1 (DKK1) antibody";179.0;IPO Edge and the Palm Beach Hedge Fund Association will host a fireside chat with the Director of Research at Sentieo and Stream along with the Vice President of Sales, […];145.85000610351562;Ionis (IONS) states that its partner Roche will advance IONIS-FB-L Rx into a phase III study for the treatment of IgAN after announcing positive data from a phase II study.;352.79998779296875;Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has launched the innovative Maurice™ Turbo CE-SDS cartridge. As the name suggests, Turbo enables high speed and high resolution analysis of protein size and purity on Maurice, the flagship capillary electrophoresis (CE) instrument of the iCE family. By providing protein purity results in as few as 5.5 minutes, Turbo meets the demand for fast and high throughput sample analysis during discovery, cell cul;2.990000009536743;;87.8499984741211;Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.The stock market closed lower Monday, led down by the Nasdaq as fears of inflation and the upcoming earnings season put pressure on stocks. The Dow Jones Industrial Average was the least affected. Technology, communications services and consumer discretionary sectors led the declines, with Tesla and Amazon.A handful of pharmaceutical stocks — including Pfizer and Amgen — are either eyeing buy points or have broken out after diving in June.;47.68000030517578;;80.41999816894531;WILMINGTON, Del., July 12, 2022--Incyte to Report Second Quarter Financial ResultsA handful of pharmaceutical stocks — including Pfizer and Amgen — are either eyeing buy points or have broken out after diving in June.In this daily bar chart of INCY, below, we can see that prices have made some wide up and down swings the past year.  The On-Balance-Volume (OBV) line has moved up and down with the price action but with a firmer tone - the June OBV line is higher than the June price low.;46.66999816894531;;69.76000213623047;;62.970001220703125;;95.30000305175781;Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022. The analyst notes that though NBI-827104 lags behind its competitors, the market opportunity will be attractive given the total addressable market estimated at ~$13 billion, with no recently approved drugs in ET. The following data readout for Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) and Praxis Precision Medicines In;79.11000061035156;;60.959999084472656;;41.5;;55.11000061035156;;79.05000305175781;;37.689998626708984;;29.780000686645508;;21.06999969482422;Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.;9.59000015258789;BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) shareholders will doubtless be very grateful to see the share price up 37% in...;52.880001068115234;;33.099998474121094;;65.86000061035156;;49.45000076293945;;;;30.690000534057617;My two favorites are Novavax (NASDAQ: NVAX) and Vir Bio (NASDAQ: VIR).  The cheap stock I'm seeing in this area is Coinbase Global (NASDAQ: COIN).  Novavax has been a wild ride for investors, and it continues to surprise.;14.130000114440918;;9.279999732971191;;5.099999904632568;;37.0;Ionis (IONS) states that its partner Roche will advance IONIS-FB-L Rx into a phase III study for the treatment of IgAN after announcing positive data from a phase II study.;48.7400016784668;;54.470001220703125;;11.390000343322754;;40.619998931884766;;15.529999732971191;;30.729999542236328;
2022-07-13;247.08999633789062;Early trial data on Amgen Inc's Lumakras was released on Tuesday by the World Conference on Lung Cancer (WCLC), but meeting organizers decided to hold until Aug. 7 results from a highly anticipated study in combination with drugs that help the immune system attack cancer.  The study, which will be the first report of how well Lumakras works in combination with immunotherapies - Merck & Co's Keytruda and Roche Holding AG's Tecentriq - was selected to be part of the press program at the organization's Vienna meeting, WCLC spokesman Chris Martin said.Trial data on Amgen Inc's Lumakras will be released later on Tuesday by the World Conference on Lung Cancer (WCLC), but meeting organizers decided to hold until Aug. 7 results from a study in combination with drugs that help the immune system attack cancer.  The study, which will be the first report of how well Lumakras works in combination with immunotherapies - Merck & Co's Keytruda and Roche Holding AG's Tecentriq - was selected to be part of the press program at the organization's Vienna meeting, WCLC spokesman Chris Martin said on Tuesday.;62.459999084472656;The World Health Organization said Tuesday the coronavirus pandemic remains a public health emergency, and warned that a reduction in surveillance, including testing and sequencing, is making it difficult to assess the impact of new variants.Shares of Humanigen Inc. plunged 67.9% in premarket trading on Wednesday, the day after the company said a National Institutes of Health clinical trial testing lenzilumab and Gilead Sciences Inc.'s Veklury in hospitalized COVID-19 patients did not produce the same benefit as it did in previous studies. Humanigen's stock is down 19.6% this year, while the S&P 500 has declined 19.9%.In the latest trading session, Gilead Sciences (GILD) closed at $62.34, marking a -0.51% move from the previous day.FOSTER CITY, Calif., July 12, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2022 financial results will be released on Tuesday, August 2, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2022 financial results and will provide a business update.;602.02001953125;In the latest trading session, Regeneron (REGN) closed at $610.09, marking a -0.71% move from the previous day.;166.6199951171875;Novavax (NVAX) inks a deal with the US government to supply 3.2 million doses of COVID shot. But the deal will be effective only if the vaccine gets EUA from the FDA. It also needs CDC recommendation.Moderna's (MRNA) bivalent COVID booster candidate exhibits a higher antibody response against all-tested COVID-19 variants, including the Omicron subvariants BA.4 and BA.5.;181.17999267578125;"Ruling allows European probe of Illumina’s $8bn Grail takeover and sets precedent for deeper oversight of dealsDeals that wouldn’t normally be subject to review because of a company’s low revenue can now be scrutinized, a top EU court ruled, in a blow to U.S. life-sciences company Illumina’s acquisition of Grail.Illumina on Wednesday lost its challenge in Europe's second-highest court against the European Union having scrutiny over its $8 billion cash-and-stock takeover of fellow U.S. life sciences firm Grail .  The case is important for EU antitrust chief Margrethe Vestager who wants to expand the European Commission's power to examine acquisitions of startups by big companies that could seek to shut nascent rivals, particularly in tech and pharmaceuticals deals.  Her critics see it as a power grab that has triggered alarm bells at some national competition agencies.LUXEMBOURG (Reuters) -U.S. life sciences company Illumina on Wednesday lost its challenge against European Union scrutiny of its $8 billion cash-and-stock takeover of Grail, as a top European court agreed the EU antitrust watchdog had the right to do so.  The case is important for EU antitrust chief Margrethe Vestager who wants to expand the European Commission's power to examine acquisitions of startups by big companies that could seek to shut nascent rivals, particularly in tech and pharmaceuticals deals.  Illumina said it would appeal the ruling to the Court of Justice of the European Union, Europe's highest.U.S. life sciences company Illumina said on Wednesday that it will appeal an EU court decision affirming EU antitrust regulators' right to examine its acquisition of Grail.  The General Court, Europe's second-highest, said the European Commission has the competence to scrutinise the deal following a request from EU countries.  ""We will appeal today's decision to the EU Court of Justice,"" Illumina said in an email.EU antitrust regulators can scrutinise U.S. life sciences company Illumina's $8 billion cash-and-stock takeover of Grail following a request from France and other EU countries, Europe's second-top court said on Wednesday.  The case is important for EU antitrust chief Margrethe Vestager who wants to expand the European Commission's power to examine big companies' acquisitions of start-ups aimed at shutting down nascent rivals, particularly in tech and pharma deals.  ""The Commission has the competence to examine that concentration which did not have a European dimension or fall within the scope of the national merger control rules of member states of the European Union or states party to the agreement on the European Economic Area,"" the General Court said.By Peter Nurse";288.7300109863281;Come, thou long-expected M&A.  On Monday, Vertex Pharmaceuticals Inc. and Innoviva Inc. both announced that they were making acquisitions.  Vertex (Nasdaq: VRTX) is set to buy ViaCyte, a cell therapy startup specializing in diabetes, for $320 million cash, while Innoviva will pay about $149 million for infectious diseases firm La Jolla Pharmaceutical Company (Nasdaq: LJPC).;214.52999877929688;Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;169.74000549316406;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, July 13, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Chan Lee as General Counsel, effective July 18, 2022.Longleaf Partners Fund, a Memphis-based fund under Southeastern Asset Management, published its “Longleaf Partners Asia Pacific UCITS Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. Longleaf Partners Asia Pacific UCITS Fund returned -7.48% in the first quarter, trailing the MSCI AC Asia Pacific Index. There is an immense opportunity […]";177.44000244140625;Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?;142.6999969482422;;348.95001220703125;;3.190000057220459;;88.11000061035156;;46.91999816894531;Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.;79.41000366210938;;46.790000915527344;If you need some inspiration, here are two cancer-focused companies that could provide excellent returns in the coming years: Exact Sciences (NASDAQ: EXAS) and Guardant Health (NASDAQ: GH).  Shares of Exact Sciences could skyrocket by 102% if it lives up to its average price target of $94.18, according to Yahoo!  Can the company pull it off?A colonoscopy is the most accurate way to screen for colon cancer, which is recommended for all individuals once they reach age 45.  It involves, well, you know, an invasive procedure to check for cancerous and precancerous lesions in your colon.  The convenience helped it become the first diagnostic test ever to reach $1 billion in annual revenue in 2021.;69.94999694824219;;63.380001068115234;;94.8499984741211;;81.16999816894531;Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.;62.06999969482422;;42.880001068115234;;55.400001525878906;;80.69999694824219;The Ark Innovation ETF (NYSEMKT: ARKK) has been performing dreadfully this year, down 53% thus far.  The fund's focus has been on growth-oriented companies, many of which aren't posting strong and consistent profits.  The three stocks that are the Ark's best holdings right now are CRISPR Therapeutics (NASDAQ: CRSP), Cerus (NASDAQ: CERS), and Signify Health (NYSE: SGFY).Crispr Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Wednesday before the open, rising from 74 to 81. If you were tuned in to IBD Live this morning, you would have heard the team chatting about this particular stock.Come, thou long-expected M&A.  On Monday, Vertex Pharmaceuticals Inc. and Innoviva Inc. both announced that they were making acquisitions.  Vertex (Nasdaq: VRTX) is set to buy ViaCyte, a cell therapy startup specializing in diabetes, for $320 million cash, while Innoviva will pay about $149 million for infectious diseases firm La Jolla Pharmaceutical Company (Nasdaq: LJPC).;38.029998779296875;"Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist for gMG patients in ChinaSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for efgartigimod alfa injection, a first-in-clas";31.290000915527344;"BMO Capital Market upgraded Fate Therapeutics Inc (NASDAQ: FATE) to Outperform from Market Perform. The analyst believes Fate's iPSC platform is uniquely positioned in the cell therapy space. But, the analyst wants to focus on the debate on whether engineered NK cells provide CAR-T-like efficacy and convenience, and safety. ""Early data for lead programs have been encouraging, particularly in safety concerns. For DLBCL, the median duration of response is misleading since it could reflect only a f";21.6299991607666;;9.930000305175781;;55.59000015258789;;34.33000183105469;;65.83000183105469;;48.38999938964844;The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...;;;31.100000381469727;;14.039999961853027;It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...;9.140000343322754;;5.119999885559082;;37.650001525878906;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a virtual fireside chat at the H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference on Wednesday, July 20, 2022.;49.22999954223633;;53.38999938964844;;11.319999694824219;VANCOUVER, British Columbia, July 12, 2022--AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022;42.40999984741211;MOUNTAIN VIEW, Calif. & SOUTH SAN FRANCISCO, Calif., July 13, 2022--DNAnexus and Twist Bioscience collaboration aims to reduce time to design, validate, and commercialize new, high-quality, NGS-based diagnostic tests;15.989999771118164;;30.549999237060547;Here is how Glaukos (GKOS) and Alkermes (ALKS) have performed compared to their sector so far this year.
2022-07-14;245.58999633789062;"BMO Capital Markets says that while Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) + PD1i data was delayed to the August 7 presentation, it did get data on the Lumakras + SHP2 inhibitor combination. ""While these data (n=21) showed clinical activity and safety, additional data could validate whether the combination can tackle ""adaptive resistance,"" the next challenge in KRAS-targeted therapy,"" BMO said. The Lumakras + SHP2 inhibitor combo showed clinical activity, but additional data will be nee";61.810001373291016;;598.8599853515625;Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Phase 3 trial of Dupixent (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE) met its primary endpoint of histological disease remission at 16 weeks. EoE is a chronic inflammatory disease that damages the esophagus and prevents it from working correctly. 68% of children on a higher dose and 58% of patients on a lower dose of Dupixent achieved histological disease remission compared to 3% of chilRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 trial assessing the investigational use of Dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE) met its primary endpoint of histological disease remission at 16 weeks with both higher and lower dose weight-tiered regimens. There are no approved treatments for children with EoE under 12 years of age.;154.4600067138672;"U.S. health regulators authorized the use of Novavax Inc.'s COVID-19 vaccine, providing a new option that works differently than the two leading vaccines based on mRNA technology, but the move comes at a time when uptake of shots and boosters is low.Following the grant of emergency use authorization by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in the United States.BioNTech snagged an upgrade Wednesday with an analyst saying ""Covid fatigue"" has obscured its non-pandemic efforts.";177.22999572753906;Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.;286.1499938964844;Have these scorching-hot stocks peaked, or could there still be more gains ahead for investors who buy today?Vertex Pharmaceuticals is part of the Zacks Investment Ideas article.Most stocks fall when the major market indexes sink. That makes sense. But there are exceptions.  Some of the outliers will only be able to outperform the market on a temporary basis. However, some are also great picks for the long term.Today's reaction to a high CPI print is the opposite of what we saw last month.;214.27000427246094;;175.92999267578125;"The Food and Drug Administration delayed a decision on a proposed new esophageal-cancer treatment from Novartis and BeiGene until the agency can complete inspections in China.China-based drug developer BeiGene said on Thursday the U.S. Food and Drug Administration (FDA) has delayed a decision on its cancer drug as COVID-19 curbs in the country prevented the regulator from conducting inspections.  The FDA was expected to decide on the drug, tislelizumab, by July 12 but has now delayed its move until the inspections are complete, the company said.  The delay makes BeiGene the latest China-based company for which the FDA has cited pandemic travel restrictions as an issue following similar problems with Hutchmed Ltd, as well as U.S.-based Coherus BioSciences Inc and its Chinese partner Shanghai Junshi Biosciences Co Ltd.CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING, July 14, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has deferred action on the Biologics License Application (BLA) for tislelizumab as a second-line (2L) treatment for patients with unresectable or metastatic";176.19000244140625;;138.5399932861328;;341.3900146484375;Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, August 4, 2022, at 8:00 a.m. CDT to review fourth quarter 2022 financial results.;3.0899999141693115;"Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today published its inaugural Sustainability Report. The report highlights the company's vision for and approach to sustainability, includes case studies across its ecosystem, and reports data according to leading environmental, social, and governance (""ESG"") frameworks.";86.70999908447266;;43.290000915527344;;79.62999725341797;;46.02000045776367;Today I want to discuss several Cathie Wood stocks to buy on the dip. They are big holdings in her portfolios and are likely to see big gains once the market shakes out of its current downtrend. Sometimes it’s easier to simply piggyback on top of popular mutual funds’ holdings and simply buy them for the long term. That’s because mutual funds have lots of restrictions. Moreover, they have to constantly honor the inflows and outflows of their funds. That means you can’t really copy the weightingsCathie Wood had an amazing run in 2020.  Wood added to her existing positions in Unity Software (NYSE: U), Exact Sciences (NASDAQ: EXAS), and Twilio (NYSE: TWLO) on Wednesday.  Unity Software stock was plunging on Wednesday after the company announced a poorly received acquisition, and Wood has made the mistake of chasing many of her holdings lower as she tries to buy the dip.;51.619998931884766;;63.77000045776367;In this article, we discuss 10 stocks to watch as Cathie Wood’s fund starts to rebound. If you want to read about some more stocks in the Wood portfolio, go directly to Cathie Wood’s Fund Starts to Rebound: 5 Stocks to Watch. Growth investors who profited from the tech-led disruption of the market at the […];94.23999786376953;;82.25;;60.189998626708984;;41.65999984741211;;52.220001220703125;;81.91000366210938;Today I want to discuss several Cathie Wood stocks to buy on the dip. They are big holdings in her portfolios and are likely to see big gains once the market shakes out of its current downtrend. Sometimes it’s easier to simply piggyback on top of popular mutual funds’ holdings and simply buy them for the long term. That’s because mutual funds have lots of restrictions. Moreover, they have to constantly honor the inflows and outflows of their funds. That means you can’t really copy the weightingsIn this article, we discuss 10 stocks to watch as Cathie Wood’s fund starts to rebound. If you want to read about some more stocks in the Wood portfolio, go directly to Cathie Wood’s Fund Starts to Rebound: 5 Stocks to Watch. Growth investors who profited from the tech-led disruption of the market at the […];37.65999984741211;;31.510000228881836;;21.350000381469727;;9.479999542236328;Market forces rained on the parade of BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) shareholders today, when the analysts...;56.119998931884766;;33.70000076293945;;64.56999969482422;Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) announced the sale of 30% of its royalty interest from Kyowa Kirin Co Ltd on the future sales of Crysvita (burosumab) in the U.S. and Canada to OMERS for $500 million. In Q1 FY22, Crysvita in Ultragenyx territories generated sales of $54.6 million, and EU royalty revenue was $4.8 million. The company expects 2022 revenue for Crysvita in Ultragenyx territories of $250 million - $260 million. OMERS' right to receive royalty payments is based on net prodStrengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the Ultragenyx royalty interest, subject to a 1.45x cap Proceeds to fund planned clinical and commercial activities NOVATO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced th;47.15999984741211;;;;28.6200008392334;SAN FRANCISCO, July 14, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Herbert “Skip” Virgin, M.D., Ph.D., Vir’s executive vice president, research and chief scientific officer, will step down effective August 31, 2022 to pursue a new position as chief medical officer and head of the Altos Institute of Medicine. He will remain a member of Vir’s Scientific Advisory Board. Phil Pang, M.D., Ph.D., Vir’s executive vice president and chief medical officer, will ta;13.779999732971191;;9.100000381469727;;4.630000114440918;;37.11000061035156;;49.09000015258789;;55.95000076293945;;11.100000381469727;;41.02000045776367;Twist Bioscience Corp (NASDAQ: TWST) launched two human monkeypox virus synthetic DNA controls. Positive controls provide quality control measures for developing, verifying, and validating both next-generation sequencing (NGS) and polymerase chain reaction (PCR) assays. The Twist synthetic DNA controls include known clades of the monkeypox virus, currently named the Congo Basin (Central African) clade and the West African clade. The latter has been identified as the predominant clade in the currSOUTH SAN FRANCISCO, Calif., July 14, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today launched two human monkeypox virus synthetic DNA controls1.;15.739999771118164;;29.68000030517578;Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.Does Alkermes (ALKS) have what it takes to be a top stock pick for momentum investors? Let's find out.
2022-07-15;248.69000244140625;While biotechs have played a vital role in the fight against COVID-19, the sector seems to be struggling in the stock market, as measured by the performance of the SPDR S&P Biotech Index.  Amgen has been in business since the 1980s and has consistently developed and marketed innovative medicines.  True, Amgen has faced increased competition for some of its products in recent years, in addition to patent cliffs.2022 is likely to go down as one of the most challenging years for investors since 2008. Year-to-date, the S&P 500 is down more than 20%, while there is equal pain in the bond market due to inflation and a hawkish Federal Reserve. However, there are a handful of sectors outperforming over the past few weeks due to longer-term rates turning lower as recession odds spike higher. Out of these sectors, biotech stocks are the most attractive from a valuation and growth perspective. Additionally, biotIn the latest trading session, Amgen (AMGN) closed at $245.59, marking a -0.61% move from the previous day.;62.599998474121094;Over Gilead’s 35-year history, bold ambitions were set and achieved in the company’s fight against devastating diseases. The journey to fulfill Gilead’s purpose of making the world a healthier plac...Pfizer (NYSE: PFE) is one of the top pharmaceutical businesses in the world, and it's the undisputed champion of coronavirus medicines.  Between its antiviral pill Paxlovid and its vaccine called Comirnaty, it's on track to make around $54 billion in sales of its coronaviral mitigation products before 2022 ends.  On July 6, regulators at the FDA said that they were expanding the Emergency Use Authorization (EUA) issued for Pfizer's antiviral drug Paxlovid for coronavirus infections so that it could be prescribed by pharmacists.;607.5399780273438;2022 is likely to go down as one of the most challenging years for investors since 2008. Year-to-date, the S&P 500 is down more than 20%, while there is equal pain in the bond market due to inflation and a hawkish Federal Reserve. However, there are a handful of sectors outperforming over the past few weeks due to longer-term rates turning lower as recession odds spike higher. Out of these sectors, biotech stocks are the most attractive from a valuation and growth perspective. Additionally, biot;161.44000244140625;The administration of Novavax's (NVAX) COVID-19 vaccine leads to some cases of severe allergic reactions as well as skin problems, per a safety update issued by the EMA.;189.2100067138672;Shares of Illumina (NASDAQ: ILMN) were tumbling 10.1% lower this week as of the market close on Thursday, according to data from S&P Global Intelligence.  Most of the decline came after a European Union court ruled on Wednesday that an antitrust investigation into Illumina's acquisition of Grail can move forward.  EU regulators opposed Illumina's $8 billion buyout of Grail due to concerns that it would give Illumina too much control of the genetic-sequencing testing market.Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2022 following the close of market on Thursday, August 11, 2022.The Science Based Targets initiative has validated Illumina’s targets to reach Net-Zero greenhouse gas emissions by 2050;292.8399963378906;While biotechs have played a vital role in the fight against COVID-19, the sector seems to be struggling in the stock market, as measured by the performance of the SPDR S&P Biotech Index.  Amgen has been in business since the 1980s and has consistently developed and marketed innovative medicines.  True, Amgen has faced increased competition for some of its products in recent years, in addition to patent cliffs.;217.00999450683594;;177.14999389648438;Beigene Limited (NASDAQ: BGNE) provided a regulatory update on the anticipated US approval decision for the Biological License Application for tislelizumab in 2L metastatic esophageal squamous cell carcinoma (ESCC). With the BLA filing initially having a PDUFA date of July 12, the FDA deferred action on the decision, as they have been unable to conduct required inspections in China due to recent COVID-19 travel restrictions. SVB Leerink notes that BGNE did not receive a Complete Response Letter;178.7100067138672;;145.38999938964844;Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) added one more patent infringement lawsuit against Moderna Inc (NASDAQ: MRNA), claiming it violated a newly obtained patent. The claim is over mRNA technology Moderna used in developing its COVID-19 vaccine, Alnylam says. In the lawsuits filed in U.S. district court in Delaware, Alnylam said its newly granted patent covers the vaccine's messenger-RNA delivery systems and violates an Alnylam patent on lipid nanoparticle (LNP) technology for delivering ge;344.3500061035156;;3.0;;87.08000183105469;;35.900001525878906;"Shares of 10x Genomics Inc. plunged 22.3% in active morning trading Friday, putting them on track to suffer a record one-day drop to a record low Friday, after the biotechnology company's revenue warning prompted BofA Securities analyst Derik de Bruin to turn bearish. Trading volume was 3.9 million shares, already about triple the full-day average of about 1.3 million shares. 10x's rating was cut by de Bruin to underperform from neutral, and the stock price target was slashed to $35 from $80. ""W10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenue is expected to be ~$114.5 million, a decrease of 1% year-over-year, below the consensus of $127.7 million. The company sees America's revenue of ~$70.9 million (+8% Y/Y), EMEA ~$25.6 million (-11% Y/Y), and APAC of ~$18.1 million (-15% Y/Y). Separately, 10x Genomics announced the appointment of Jim Wilbur, Ph.D., as Chief Commercial Officer, effective July 27. Mr. Wilbur brings nearly 30 years of experience building businShares of 10x Genomics Inc.  (TXG)  fell in the extended session Thursday after the biotech company said it expects second-quarter revenue to come in below Wall Street expectations.  10x Genomics shares dropped 15% after hours, following a 7.7% drop in the regular session to close at $43.29.Following a comprehensive search process, 10x Genomics, Inc. (Nasdaq: TXG), today announced the hiring of Jim Wilbur, Ph.D., as Chief Commercial Officer, effective July 27. In this role, Wilbur will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that its preliminary revenue is expected to be approximately $114.5 million for the second quarter ended June 30, 2022. This represents an approximate 1% decrease from $115.8 million for the prior year period, and flat revenue sequentially.";80.02999877929688;;46.900001525878906;;54.43000030517578;There’s a gap between what’s happening with the transmissible variant and the U.S. response, says Rick Bright.The administration of Novavax's (NVAX) COVID-19 vaccine leads to some cases of severe allergic reactions as well as skin problems, per a safety update issued by the EMA.;63.279998779296875;;95.16999816894531;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2022 financial results after the Nasdaq market closes on Thursday, August 4, 2022. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).;83.58999633789062;;60.02000045776367;;42.79999923706055;;53.54999923706055;Blueprint Medicines Corporation (NASDAQ: BPMC) today published its first Corporate Responsibility Report, highlighting its long-standing commitment to deliver sustainable value to patients with cancer and blood disorders, as well as the communities in which it operates. The report, which formalizes the company's efforts to track and report environmental, social and governance (ESG) standards and initiatives, includes summaries and performance metrics that demonstrate its purpose-driven culture a;83.38999938964844;In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $81.91, marking a +1.5% move from the previous day.;39.0;;31.700000762939453;;21.34000015258789;;8.989999771118164;;57.619998931884766;;34.70000076293945;;64.75;Ultragenyx (RARE) sells 30% of the royalty interest receivable on future North America sales of Crysvita for $500 million. The total payments are capped at 1.45 times the purchase price.Companies with interests in approved drugs or late-stage drugs can draw cash immediately by selling their sales-based royalty streams.;49.15999984741211;;;;29.020000457763672;;13.670000076293945;;9.100000381469727;;4.239999771118164;;39.310001373291016;;49.849998474121094;;55.25;;10.539999961853027;;42.5;;15.279999732971191;;29.93000030517578;NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.The top five biotech stocks today have several commonalities: strong ratings, promising charts and membership on the IBD Tech Leaders list.Organizations supporting people living with addiction, serious mental illness and cancer have faced unique needs and challenges during the COVID pandemic. The 2020 Alkermes Inspiration Grants ident...
2022-07-18;243.83999633789062;;60.900001525878906;Want to learn how to trade stocks successfully? First examine fundamentals. And keep these seven key words on Wall Street in mind.;586.7000122070312;;161.02999877929688;The European Medicines Agency on Monday started reviewing a low-dose version of BioNTech and Pfizer’s COVID-19 vaccine for use in children between the age of six months and four years.  Last month the U.S Centers for Disease Control and Prevention cleared the way for use of the shot in children of that age group in the United States.  Pfizer and BioNTech filed for approval in Europe in the age group on July 8, proposing a three-shot course with a 3 microgram dosage, which is a fraction of the 30 micrograms used on adults.;187.2899932861328;;286.05999755859375;;214.33999633789062;Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.It's the first glimpse into how the drugmaker's operations have changed in the Bay State amid extreme cost-cutting measures.The stakes are high on Wall Street this week as quarterly results from names including Netflix, Tesla, and Twitter kick the earnings season into full swing.;172.74000549316406;;168.47000122070312;Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...;140.63999938964844;CAMBRIDGE, Mass., July 18, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2022 on Thursday, July 28, 2022, before the U.S. financial markets open.;336.239990234375;;2.9800000190734863;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of a new cell programming project as part of a broader collaboration with Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies. Through this partnership, Sumitomo Chemical will leverage Ginkgo's extensive codebase and expertise in organism engineering to produce molecules in a sustainable fashion that are used in products across a broad range of industries. Th;85.5;;35.36000061035156;;78.86000061035156;;45.310001373291016;;51.970001220703125;Some stocks have been really hammered, and are down 70%, 80%, or even 90% off their highs. If you want to buy a stock in that scenario, how should you approach it?Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.The U.S. Food and Drug Administration (FDA) granted Novavax's (NASDAQ: NVAX) coronavirus vaccine Emergency Use Authorization (EUA) last week.  Originally, Novavax had hoped to win access to the U.S. market last year.  Meanwhile, Novavax has gained authorization in nearly 40 other countries over the past several months -- and started to generate revenue and profit from its vaccine.;60.20000076293945;Biotech stocks were among the first group of equities to head southward late last year.  The closely watched iShares Biotechnology ETF and SPDR S&P Biotech ETF are up by 2.56% and 7.62%, respectively, since July 1.  Which beaten-down biotech stocks might come roaring back in the second half of 2022?;93.9000015258789;;84.43000030517578;;59.5;;41.27000045776367;;52.459999084472656;;79.36000061035156;EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;41.560001373291016;"Inclusion of Zai Lab shares in Shanghai-Hong Kong Stock Connect is effective today Zai Lab has been dual-primary listed on Nasdaq and the Hong Kong Stock Exchange, and its shares included in the Shenzhen-Hong Kong Stock Connect since June 2022Zai Lab’s inclusion in two Stock Connect Programs provides additional opportunity for investors in mainland China to invest in the Company SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., July 17, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX:";30.68000030517578;;21.56999969482422;;8.760000228881836;;58.0099983215332;;34.619998931884766;;61.02000045776367;;48.20000076293945;;;;27.729999542236328;;13.359999656677246;;9.130000114440918;;3.930000066757202;;38.7400016784668;;47.5;;54.189998626708984;;10.449999809265137;;40.400001525878906;SOUTH SAN FRANCISCO, Calif., July 18, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 third quarter ended June 30, 2022, before the opening of the market on Aug. 5, 2022. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss;15.010000228881836;;29.3799991607666;
2022-07-19;247.32000732421875;Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.;62.119998931884766;FOSTER CITY, Calif., July 19, 2022--Gilead Sciences and the European Commission today signed a new joint procurement agreement (JPA) that will ensure continued rapid and equitable access to Veklury® (remdesivir) for participating Member States across the European Union (EU) and European Economic Area (EEA).The European Commission has signed a joint procurement contract for an antiviral treatment for patients with COVID-19 with Gilead Sciences Inc , it said on Tuesday.  This is the second contract for the drug, branded as Veklury, which is approved in Europe to treat COVID patients who are at high risk of experiencing a severe case of the disease, as well as  patients who have pneumonia and require supplemental oxygen.  Altogether, 22 EU member states and countries are participating in the joint procurement, under which they can purchase up to 2,250,000 vials.The European Commission said on Tuesday that it had signed a joint procurement contract for an antiviral treatment for patients with COVID-19 with Gilead Sciences Inc.  The European Union executive said it was the second contract for this therapeutic, the first having ended in April.  It added in a statement that 22 EU member states and countries are participating in the joint procurement, under which they can purchase up to 2,250,000 vials.;595.72998046875;;164.72999572753906;Johnson & Johnson CFO Joe Wolk sits down with Yahoo Finance's Anjalee Khemlani to discuss company earnings and COVID-19 vaccine demand.An advisory panel to the Centers for Disease Control and Prevention will meet later Tuesday to discuss the Novavax [s:nvax] vaccine that recently won authorization from the Food and Drug Administration for use in adults over 18. The CDC panel's decision is expected to lift the final regulatory hurdle for the vaccine, which is based on more conventional technology than the ones developed by Moderna , Pfizer and BioNTech , amid hopes it will appeal to more people who have not yet been vaccinated.;194.63999938964844;BRUSSELS (Reuters) -U.S. life sciences firm Illumina risks a hefty fine for jumping the gun and closing its takeover of Grail without waiting for official approval, EU antitrust chief Margrethe Vestager said on Tuesday.  Illumina angered the European Commission when it completed the acquisition of Grail, a U.S.-based biotechnology company, in August last year amid the ongoing EU investigation into the deal.  The EU competition watchdog subsequently ordered the company to keep Grail separate and to have independent managers run the company until an EU decision.The European Commission said on Tuesday it had sent a statement of objections to U.S. life sciences firms Illumina and GRAIL alleging they breached EU merger rules by implementing the merger while the Commission's in-depth investigation into the proposed transaction was still ongoing.Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today it is among the first group of companies worldwide to receive approval of its net-zero targets by the Science Based Targets initiative (SBTi). This includes validation of Illumina's corporate greenhouse gas (GHG) emissions reduction targets by the organization.Global conference to focus on advancing the transformative impacts of genomic health;289.6000061035156;"The Nasdaq Composite (NASDAQINDEX: ^IXIC) feigned a recovery effort in the latter half of June, but in the wake of its 5% slide from its early-July high point, the index now sits 30% below the all-time peak it touched in November.  While Tesla may be the centerpiece of most discussions about the electric vehicle (EV) market, it's not the only major player in the game.  It's just the biggest name in the U.S. In China, Li Auto (NASDAQ: LI) is making a splash with its all-electric, six-seat, luxury SUVs.BOSTON, July 18, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2022 financial results on Thursday, August 4, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1 (412) 902-6510 (International) and reference the ""Vertex Pharmaceuticals Second Quarter 2022 Earnings Call"".";220.25999450683594;Shares of Biogen  , a  biotechnology company that makes advanced drugs to treat patients with diseases like multiple sclerosis and Alzheimer's disease, have been quietly basing the past five months following a big price decline.  Bottom-line strategy: I have no special knowledge of what BIIB is going to report to shareholders and analysts Wednesday morning but the charts have improved and we could see prices advance.;178.36000061035156;;172.8300018310547;;145.72000122070312;;350.239990234375;;3.2200000286102295;;86.08999633789062;;36.66999816894531;;81.36000061035156;Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.Incyte Corp. said Monday that the Food and Drug Administration approved Opzelura as a topical repigmentation treatment for patients with nonsegmental vitiligo. Vitiligo is an autoimmune disease that can cause patients to lose color in patches on their hair and skin. Opzelura's wholesale acquisition cost is $1,950 for a 60-gram tube, according to a spokesperson for the company. The therapy last year received FDA approval as a treatment for mild to moderate atopic dermatitis, generating $12.7 millWILMINGTON, Del., July 19, 2022--Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo;46.81999969482422;;58.0;Johnson & Johnson CFO Joe Wolk sits down with Yahoo Finance's Anjalee Khemlani to discuss company earnings and COVID-19 vaccine demand.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, has signed agreements with its partner, SK bioscience, for the manufacturing and supply of a version of the Novavax COVID-19 vaccine (NVX-CoV2373) containing Omicron variant and for the manufacture of the vaccine in prefilled syringes.An advisory panel to the Centers for Disease Control and Prevention will meet later Tuesday to discuss the Novavax [s:nvax] vaccine that recently won authorization from the Food and Drug Administration for use in adults over 18. The CDC panel's decision is expected to lift the final regulatory hurdle for the vaccine, which is based on more conventional technology than the ones developed by Moderna , Pfizer and BioNTech , amid hopes it will appeal to more people who have not yet been vaccinated.Gaithersburg’s Novavax Inc. is on the cusp of rolling out its Covid-19 vaccine to the public.  It’s a necessary step before Novavax's Covid shot can go into any arms.  As part of its regular review of such vaccines, the CDC committee provides recommendations for how the products should be administered, including the timing, dosage and any reason certain patients shouldn't receive it based on their health conditions.;65.33000183105469;;96.41000366210938;;84.69999694824219;Sarepta is building a base as this biotech stock tries to convince regulators to approve its gene therapy.;62.15999984741211;;42.66999816894531;;55.52000045776367;;83.77999877929688;;43.209999084472656;"Company to Host Conference Call and Webcast on August 10, 2022, at 8:00 a.m. ETSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the three months ended June 30, 2022, after the closing of the U.S. equity markets on August 9, 2022. The Company will host a live";32.5;Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.;21.84000015258789;;9.579999923706055;;64.61000061035156;Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.BMO Capital Markets has raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $61 from $41, with a Market Perform rating unchanged. The model changes include updated collaboration revenues for Verve Therapeutics Inc's (NASDAQ: VERV) VERVE-101 program and the incorporation of the Alpha-1 antitrypsin deficiency (AATD) program, modeled at ~$1 billion peak risk-adjusted sales in 2035E. Related: Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics. BMO says that the key poi;36.2599983215332;;52.88999938964844;Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and GeneTx Biotherapeutics LLC announced interim data from the Phase 1/2 study in pediatric patients with a genetically confirmed diagnosis of full maternal UBE3A gene deletion. Interim results demonstrate a meaningful improvement in clinical disease and an acceptable safety profile. 7/9 patients showed improvement on the disease scale from Baseline in at least 3 of 5 domains and the overall score. Six patients exhibited a decrease in severity in at lThe deal includes a $75 million upfront payment and the promise of $115 million to GeneTx shareholders if the Angelman Syndrome therapy hits late-stage clinical and commercial milestones.Doses up to 10 mg show good tolerability and meaningful clinical activity in multiple domains U.K. and Canadian health authorities approved escalation to higher doses Ultragenyx exercises option to acquire GeneTx for $75 million upfront payment Conference call to discuss update planned for 5 p.m. Eastern Time NOVATO, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and GeneTx Biotherapeutics LLC today provided a program update on GTX-102 for the treatment o;50.060001373291016;;;;29.299999237060547;;13.729999542236328;;9.739999771118164;;4.239999771118164;PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2022 financial results on Wednesday, August 3, 2022, at 5:00 pm Eastern Time.;39.279998779296875;;51.91999816894531;;55.93000030517578;;10.649999618530273;;43.459999084472656;;15.470000267028809;Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.SAN DIEGO, July 18, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older.;29.760000228881836;Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
2022-07-20;246.6300048828125;Two excellent examples right now are Amgen (NASDAQ: AMGN) and Apple (NASDAQ: AAPL).  Both businesses generate plenty of cash flow, have been raising their dividend payments in recent years, and investors shouldn't expect those trends to end anytime soon.  Drugmaker Amgen currently pays a dividend yield of 3.1%, which is easily more than the S&P 500 average of 1.7%.;61.54999923706055;As a physician who specializes in sexual health and HIV, David Malebranche treats one patient at a time in the clinic. As an activist and a writer embedded in the intersection of Black, LBGTQ+ and ...Gilead Sciences Inc (NASDAQ: GILD) and the European Commission signed a joint procurement agreement for rapid and equitable access to the COVID-19 therapeutic Veklury (remdesivir). This is the second contract for the drug, which is approved in Europe to treat COVID patients at high risk of experiencing a severe case of the disease and patients who have pneumonia and require supplemental oxygen. The agreement covers purchases of Veklury over the next twelve months and has the option to be extende;594.5900268554688;A business that has high margins has much more of a buffer to handle adversity and rising costs.  If a company's cost of revenue is significant and leaves little of the top line left to cover overhead and other operating expenses, it can be difficult to consistently stay in the black.  Three companies that don't have that problem and that enjoy gross profit margins of at least 80% or better include Regeneron Pharmaceuticals (NASDAQ: REGN), Adobe (NASDAQ: ADBE), and Visa (NYSE: V).Regeneron (REGN) closed at $595.73 in the latest trading session, marking a +1.54% move from the prior day.;164.0800018310547;"AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.Following the endorsement by the U.S. CDC, Novavax (NVAX) can now start immunizations with its COVID-19 vaccine as a primary two-dose regimen for use in adults in the United States.Pfizer (PFE) and BioNTech (BNTX) complete a regulatory filing for their Omicron-specific bivalent COVID-19 vaccine in the EU. The bivalent vaccine has been developed to target the Omicron BA.1 subvariant.The U.S. Centers for Disease Control and Prevention authorized the Novavax vaccine for adults late Tuesday, clearing the final obstacle to the use of a fourth alternative and one that is based on more traditional technology than earlier shots.The Centers for Disease Control and Prevention authorized the Novavax [s:nvax] vaccine late Tuesday, lifting the final regulatory hurdle for the nation's fourth vaccine, which is based on more conventional technology than the ones developed by Moderna , Pfizer and BioNTech . Experts are hoping it will appeal to more people who have not yet been vaccinated. ""If you have been waiting for a COVID-19 vaccine built on a different technology than those previously available, now is the time to join theThe CDC has unanimously recommends Novavax's latest COVID-19 booster vaccine for adults, awaiting the director's final approvalJ&J is winding down its COVID-19 vaccine manufacturing as demand wanes globally and as the company sits on excess supply.Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.";200.66000366210938;If the preliminary second-quarter 2022 earnings from 10x Genomics  are any guide, then investors are in for a decent amount of pain this earnings season.  10x Genomics expects to report a 1% decline in Q2 revenue compared with the year-earlier period.;285.5;Vertex Pharmaceuticals (NASDAQ: VRTX) is one of the stocks that's defying this bear market.  It's best to hold onto stocks you buy for at least five years, and if a company's growth prospects look good, you'll probably want to keep it in your portfolio a lot longer.  In July 2017, you could have picked up Vertex for $129 a share, so an outlay of about $5,000 ($5,031, to be precise) would have purchased 39 shares.Vertex Pharmaceuticals (VRTX) closed at $289.60 in the latest trading session, marking a +1.24% move from the prior day.;207.49000549316406;Yahoo Finance Live anchors discuss second-quarter earnings for Biogen.Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Biogen Inc (NASDAQ: BIIB) has posted Q2 sales of $2.59 billion, beating the consensus of $2.48 billion, down 7% Y/Y and 5% at constant currency (CC). Multiple sclerosis revenue, including royalties on sales of Ocrevus, of $1.72 billion decreased by 4% (down 3% CC). Spinraza's revenue of $431 million decreased by 14% at actual currency (by 11% at CC). Aduhelm generated sales of a mere $0.1 million in Q2. Biosimilars' revenue of $194 million decreased 4% versus the prior year at actual currency anNetflix lost 970,000 global subscribers in the second quarter, much better than its projection for a loss of 2 million. The stock is rising Wednesday.Shares of Biogen Inc. were down 2.8% in premarket trading on Wednesday after the company missed on revenue in the second quarter of the year. Revenue for three of Biogen's top-selling therapies ⁠- muscular-atrophy therapy Spinraza and multiple-sclerosis drugs Tecfidera and Tysabri ⁠- was lower this quarter than in the same three months of last year. Biogen reported earnings of $1.0 billion, or $7.24, in the second quarter of 2022, compared with $448.5 million, or $2.99, in the same quarter a yeaBiogen Inc on Wednesday tried to assuage investor worries by laying out a plan for its Alzheimer's disease drug being developed with Eisai Co Ltd and promising to draw lessons from the setbacks to its treatment Aduhelm.  Biogen also disclosed that it had agreed to pay $900 million to resolve a whistleblower lawsuit accusing it of paying doctors kickbacks to prescribe multiple sclerosis drugs.  Biogen's experimental Alzheimer's drug, lecanemab, is crucial for the growth of the drugmaker as it faces competition for several of its blockbuster drugs, including multiple sclerosis treatment Tecfidera.(Reuters) -Biogen Inc on Wednesday tried to assuage investor worries by laying out a plan for its Alzheimer's disease drug being developed with Eisai Co Ltd and promising to draw lessons from the setbacks to its treatment Aduhelm.  Biogen also disclosed that it had agreed to pay $900 million to resolve a whistleblower lawsuit accusing it of paying doctors kickbacks to prescribe multiple sclerosis drugs.  Biogen's experimental Alzheimer's drug, lecanemab, is crucial for the growth of the drugmaker as it faces competition for several of its blockbuster drugs, including multiple sclerosis treatment Tecfidera.What to watch in markets on Wednesday, July 20, 2022.By Peter Nurse;186.0;;172.6199951171875;;146.55999755859375;;356.57000732421875;;3.1600000858306885;;84.91000366210938;;34.650001525878906;If the preliminary second-quarter 2022 earnings from 10x Genomics  are any guide, then investors are in for a decent amount of pain this earnings season.  10x Genomics expects to report a 1% decline in Q2 revenue compared with the year-earlier period.;82.48999786376953;'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.INCY vs. TECH: Which Stock Is the Better Value Option?Biopharmaceutical company Incyte Corp.  is poised to make an upside breakout on the charts.  Let's check out our favorite indicators and plot a trading strategy.  The On-Balance-Volume (OBV) line is leading the price action and has already made a new high for the move up.IBD Stock Of The Day Incyte just won U.S. approval for a new skin treatment, leading Incyte stock to flirt with a breakout.;48.0;;59.56999969482422;"'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.With Novavax (NASDAQ: NVAX) shares down by more than 70% in the past 12 months, investors are probably feeling a bit devastated right now.  The shares even crashed on July 13, when its vaccine candidate for COVID-19 got an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA).  Unlike coronavirus vaccine competitors Pfizer and Moderna, Novavax's Nuvaxovid jab isn't yet approved for use as a booster shot in the U.S. That means it's missing out on government purchasing orders intended to secure booster doses for the public -- but that probably won't be won't be the case for long.What happened Shares of Novavax (NASDAQ: NVAX) were jumping 5% higher as of 10:33 a.m. ET on Wednesday after rising as much as 11.2% earlier in the day. The gain came after the U.S. Centers for Disease Control and Prevention (CDC) cleared the way on Tuesday for Novavax's COVID-19 vaccine (NVX-CoV2373) to be used as a two-dose primary series in individuals ages 18 and older.On the other hand, Novavax finally cleared one of its most important (and long overdue) regulatory milestones.  Let's discuss Novavax's recent regulatory win and what it means for the company's future.  On July 13, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Novavax's coronavirus vaccine, Nuvaxovid.Following the endorsement by the U.S. CDC, Novavax (NVAX) can now start immunizations with its COVID-19 vaccine as a primary two-dose regimen for use in adults in the United States.The vaccine from Novavax is the fourth approved for use in the United States. It's administered as two doses given three weeks apart.The U.S. Centers for Disease Control and Prevention authorized the Novavax vaccine for adults late Tuesday, clearing the final obstacle to the use of a fourth alternative and one that is based on more traditional technology than earlier shots.Last week, Novavax finally received news from the Food and Drug Administration that its COVID-19 vaccine obtained Emergency Use Authorization for people who are 18 years of age and older.  It took months of waiting before Novavax's authorization came in.The U.S. Centers for Disease Control and Prevention's (CDC) advisory committee recommended using Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine as a two-dose primary series for individuals aged 18 and above. The committee will submit its recommendation to the Director of the CDC for review and endorsement. CDC director Rochelle Walensky said the decision ""expanded the options available"" to U.S. adults for vaccinations. ""If you have been waiting for a COVID-19 vaccine built on a different technoloThe Centers for Disease Control and Prevention authorized the Novavax [s:nvax] vaccine late Tuesday, lifting the final regulatory hurdle for the nation's fourth vaccine, which is based on more conventional technology than the ones developed by Moderna , Pfizer and BioNTech . Experts are hoping it will appeal to more people who have not yet been vaccinated. ""If you have been waiting for a COVID-19 vaccine built on a different technology than those previously available, now is the time to join theInstead of rising, though, Novavax's shares plunged 27%.  There are several reasons behind this surprising sell-off, some of which have nothing to do with the FDA's EUA decision.  Despite going in the wrong direction lately, it's still possible for Novavax to be a monster comeback stock.The CDC approved Novavax's COVID vaccine on Tuesday, and investors sent Novavax's stock up 11.5%U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax -- a more traditional kind of vaccine, health officials said Tuesday.The two-dose, protein-based shot offers an alternative to gene technology from Moderna and the Pfizer-BioNTech partnership.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend the use of the Novavax COVID-19 Vaccine, Adjuvanted as a two-dose primary series in individuals aged 18 and older.Vaccine maker Novavax on Tuesday said that the U.S. Food and Drug Administration had cleared a lot of its COVID vaccine for release in the United States, and it plans to ship doses to be distributed by the U.S. government in the coming days.  The FDA authorized the vaccine last week, but the manufactured doses were still awaiting quality testing before they could be released.  Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Tuesday voted unanimously to recommend use of the vaccine, and rollout of the shots can begin once the agency's director signs off on that recommendation.The recommendation puts the Gaithersburg company in the homestretch to roll out its vaccine to the public.The CDC has unanimously recommends Novavax's latest COVID-19 booster vaccine for adults, awaiting the director's final approvalShares of Novavax Inc. jumped 11.9% in trading on Tuesday after the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted in favor of the company's COVID-19 vaccine. The next step is for CDC director Rochelle Walensky to decide whether to sign off on the decision; if she does, the vaccine will then be made available to adults in the U.S. The Food and Drug Administration granted emergency authorization to the two-dose, protein vaccine last week. Novavax'sThe U.S. Centers for Disease Control and Prevention (CDC) on Tuesday recommended use of Novavax Inc's COVID-19 vaccine for individuals aged 18 and above.  CDC director Rochelle Walensky said the decision ""expanded the options available"" to U.S. adults for vaccinations.  The recommendation came after the CDC's Advisory Committee on Immunization Practices (ACIP) unanimously backed the shot, a week after the U.S. Food and Drug Administration authorized the vaccine as two-dose primary vaccination series.U.S. CDC advisers back Novavax COVID vaccine for adults";68.19999694824219;;97.29000091552734;;85.44999694824219;;64.55000305175781;;44.13999938964844;;55.150001525878906;;82.33999633789062;;44.060001373291016;;32.63999938964844;;21.959999084472656;;9.8100004196167;;67.91000366210938;;36.83000183105469;;54.72999954223633;Shareholders aren't happy with the biotech's decision to acquire an early-stage asset for Angelman syndrome.;50.529998779296875;;;;30.170000076293945;;14.5600004196167;"Abcam plc (""Abcam"", ""Company"", ""Group"") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following trading update for the six-month period ending 30 June 2022. The Company will release its full results for the six-month period on 12 September 2022.";9.9399995803833;;4.460000038146973;;39.0099983215332;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Novartis has completed patient enrollment of the pivotal Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen, with 8,325 study participants. Lp(a) HORIZON is evaluating the safety and efficacy of pelacarsen in reducing cardiovascular events in patients with cardiovascular disease and elevated levels of Lp(a). Topline data from the study are expected in 2025. Novartis licensed pelacarsen from Ionis in 2019.;54.560001373291016;;56.5;;10.649999618530273;;46.34000015258789;If the preliminary second-quarter 2022 earnings from 10x Genomics  are any guide, then investors are in for a decent amount of pain this earnings season.  10x Genomics expects to report a 1% decline in Q2 revenue compared with the year-earlier period.;15.09000015258789;;29.350000381469727;Research shows that societal stigmas associated with substance use disorders like alcohol and opioid dependence can have a direct impact on people’s ability to receive a diagnosis and treatment. Le...Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2022-07-21;245.77999877929688;The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.These two dividend-paying pharmaceutical titans ought to keep crushing the broader markets for the foreseeable future.Big pharma stocks gained impressively during the pandemic years for obvious reasons. However, with the pandemic in the rear-view mirror, the best pharmaceutical stocks continue to perform remarkably well. This is a welcome surprise, considering how the equities and other risky assets have taken a beating of late. Inflation, interest rate hikes and geopolitical tensions have weighed down market returns, but Big pharma seems to be an anomaly. Regardless of the pandemic, the pharmaceutical industryAmgen (AMGN) closed the most recent trading day at $246.63, moving -0.28% from the previous trading session.;61.0099983215332;FOSTER CITY, Calif., July 21, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 24th International AIDS Conference (AIDS 2022). AIDS 2022 will be a hybrid conference, taking place in person in Montreal, Canada, as well as virtually, from July 29-August 2, 2022. As the leader in HIV innovation, the company will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs aGilead Sciences (GILD) closed at $61.55 in the latest trading session, marking a -0.92% move from the prior day.FOSTER CITY, Calif., July 20, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an $85 million contribution to the Gilead Foundation to further the company's vision of creating a healthier world for all people. This donation builds on the endowment Gilead announced last year to recapitalize the Gilead Foundation, with a new vision and mission to create impact in the community and society by encouraging a culture of giving, engaging in local communities and exploring innovative approache;592.4400024414062;;165.8699951171875;Vascular Biogenics' (VBLT) phase III OVAL study, evaluating ofra-vec in patients with platinum-resistant ovarian cancer, fails to meet the primary endpoint.;207.0;Ensemble Capital recently published its 2022 Q2 investor letter, a copy of which can be downloaded here. The fund lost nearly a third of its value this year and trails the S&P 500 Index. However, it posted positive annualized returns of 7% and 10% respectively over the last 3 and 5 years. One of the […]Illumina is proud to be a top-scoring company on Disability:IN and American Association of People with Disabilities' Disability Equality Index and recognized as a Best Place To Work for Disability ...;283.1099853515625;Now is a great time for long-term investors to load up on some quality growth stocks.  Although the bear market may be a frightening time to buy shares, there are many quality businesses that are safe to hang on to for the long haul.  A couple of top growth stocks you can buy today include Vertex Pharmaceuticals (NASDAQ: VRTX) and Alphabet (NASDAQ: GOOG).Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Verve Therapeutics Inc (NASDAQ: VERV) announced an exclusive, four-year global research collaboration to discover and develop an in vivo gene editing program for undisclosed liver disease. Under the terms of the collaboration, Verve will advance the discovery, research, and certain preclinical development, with all program costs funded by Vertex. Vertex will be responsible for subsequent development, manufacturing, and commercialization of aVerve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and RoyaltiesBOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Verve Therapeutics, Inc. (Nasdaq: VERV) today announced an exclusive, four-year global research collaboration focused on discovering and developing an in vivo gene editing program for a single undisclosed liver disease. Under the terms of the collaboration,;214.05999755859375;"Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 2025.The latest housing data showed existing home sales fell again in June as home prices kept rising.U.S. stock indexes were higher Wednesday, as investors await more corporate earnings, with Tesla due to report after the market closes.Biogen's second-quarter report was ""fine,"" one analyst said. But without an update on its strategy for life after Aduhelm, Biogen stock fell.Stocks finished Wednesday's trading session higher, with tech stocks leading the way once again.At this time, I'd like to welcome everyone to the Biogen second quarter earnings call and financial update.  As a reminder, during the Q&A portion of the call, we kindly ask that you limit yourself to one question.The Cambridge drugmaker is facing generic competition, continued fallout from Aduhelm and the weakening of currencies in international markets.";188.52999877929688;;173.16000366210938;;147.1999969482422;;370.1099853515625;;3.200000047683716;;85.70999908447266;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 3rd, at 4:30 p.m. ET to discuss second quarter 2022 financial results and provide a general business update.;36.689998626708984;;82.86000061035156;;47.810001373291016;;58.95000076293945;It's easy to see why investors might be wondering whether it's too late to buy shares of Novavax (NASDAQ: NVAX).  After all, the vaccine manufacturer's Nuvaxovid jab is already cleared for sale in many countries around the world and endorsed by the World Health Organization (WHO).  If it can successfully compete in a few key coronavirus vaccine segments over the next few years, it could well provide robust returns for people who buy shares of it today.President Joe Biden has tested positive for Covid-19, the White House said on Thursday.  The president was feeling “very mild symptoms” and has begun taking Paxlovid, Press Secretary Karine Jean-Pierre said in a statement.  Biden will isolate at the White House until testing negative, Jean-Pierre added, and will continue to carry out all duties fully during that time.The appetite for meme stocks that swept Wall Street in early 2021 may have lost its steam but the phenomenon is still alive and kicking. The likes of AMC (NYSE:AMC) and GameStop (NYSE:GME) became the poster children for the meme phenomenon – one which was driven by retail investors. This social-media-driven buying was well supported by discount brokerages, which offer the convenience of trading from anywhere on a mobile phone and allow zero-commission trades. For investors, meme stocks provided;68.19999694824219;As investors scramble to insulate their portfolios from the chaotic global economy, inflation, and a falling market, biotech stocks might seem a safe harbor.  After all, these companies don't need to procure much in the way of raw materials to operate, and the medicines they develop are priced to get a healthy margin and recoup the costs of development, both of which make inflation and other macroeconomic issues less concerning.  Let's examine why biotechs are underperforming and determine whether there's a path to recovery.;97.5999984741211;;84.66000366210938;;69.63999938964844;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the second quarter of 2022 along with recent corporate updates on August 3, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on August 3, company executives will provide company updates and review financial results.;44.38999938964844;PASADENA, Calif., July 20, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022.;55.2400016784668;;79.94999694824219;;45.47999954223633;;33.34000015258789;;21.3799991607666;;9.890000343322754;PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a new collaboration with Baylor College of Medicine to identify and translate cutting-edge research into potential therapies for patients with genetic diseases. “In these challenging times we believe it is more important than ever to be a stalwart partner to academic institutions working to serve patientPALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced its founding affiliation with Bakar Labs, the incubator at UC Berkeley’s Bakar BioEnginuity Hub. Bakar Labs was established by the University of California (UC), Berkeley and QB3, UC’s research institute for innovation and entrepreneurship in the life sciences and is open to academic researchers from arou;68.4800033569336;;37.130001068115234;;54.220001220703125;NOVATO, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 10,240 shares of common stock of the company and 5,120 restricted stock units of the company’s common stock to one newly hired non-executive officer of the company. The awards were approved;50.189998626708984;;;;30.15999984741211;;14.760000228881836;;9.899999618530273;;4.800000190734863;Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Jeff Eidel as Chief Commercial Officer, effective August 16, 2022. In this role, Mr. Eidel will have global responsibility for all commercial activity including sales, marketing, and customer support.;39.0;Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 2025.;54.79999923706055;;55.810001373291016;;10.470000267028809;;47.7400016784668;;14.979999542236328;;29.049999237060547;Vascular Biogenics' (VBLT) phase III OVAL study, evaluating ofra-vec in patients with platinum-resistant ovarian cancer, fails to meet the primary endpoint.Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 27, 2022 to discuss the company's second quarter financial results. Management will also provide an update on the company.
2022-07-22;245.9499969482422;Amgen is forming a base showing a 258.55 buy point with its next quarterly report expected on Aug. 4. The pattern is a first-stage flat base. on a weekly chart from MarketSmith. It is a follow-on to a cup with handle base with the same entry point.;60.79999923706055;SANTA MONICA, Calif., July 22, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (ALL). If approved, Tecartus will be the first and only Chimeric Antigen Receptor (CAR) T-cell ther“At the time I was diagnosed, I decided to push everything about hepatitis B to a place in my mind where it wasn’t real anymore. I didn’t want to deal with it.”FOSTER CITY, Calif., July 22, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Commission (EC) adopted a positive opinion on the fulfillment of the last specific obligation and recommended the granting of Marketing Authorization (MA) for Veklury® (remdesivir) that is no longer subject to specific obligations. Veklury was initially granted a conditional marketing authorization in July 2020 for the treatment o;586.1099853515625;;160.16000366210938;Novavax passed the finish line to gain authorization for its COVID-19 vaccine, and its first commercial product. But the company is still working on younger age group eligibility and boosters with the FDA.The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions.  Many biotech companies have shifted their focus entirely or added COVID-19 vaccines and treatments to their product pipeline.  Early-stage biotech companies are prone to wild swings in revenue due to going from nearly no revenue to having a significant revenue stream once a drug is approved or a partnership with another company is reached.Novavax CEO Stan Erck joins Yahoo Finance Live to discuss the CDC recommending Novavax’s COVID-19 vaccine for adults, COVID vaccine distribution, the vaccine demand, and the outlook for an Omicron vaccine.;201.69000244140625;Applications for the Illumina/SD2 STEM Scholars Award opened in the Fall, and closed in January with a total of 36 student applications. The scholarship was open to all 10th through 12th grade stud...;280.2900085449219;BOSTON, July 22, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that following the positive Phase 2 results earlier this year and having reached agreement on the design of the pivotal development program with the U.S. Food and Drug Administration (FDA), Vertex plans to advance the selective NaV1.8 inhibitor VX-548 into Phase 3 clinical trials in the fourth quarter of 2022. Vertex also intends to initiate a Phase 2 dose-ranging study of VX-548 in neuropathic pain by theJohnson & Johnson, Cigna, Vertex Pharmaceuticals, Xcel Energy and Illumina have been included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Cigna Corporation (CI), and Vertex Pharmaceuticals Incorporated (VRTX).;206.25;In this article, we will discuss the 10 companies that just raised their guidance despite global economic headwinds. To skip the detailed analysis and outlook for 2022, you can go directly to These 5 Companies Upped Guidance Despite Global Economic Headwinds. Since the pandemic-induced recession, the global financial outlook looked bleak due to lockdowns and […]In this article, we discuss 10 companies that recently raised their guidance. If you want to read about some more companies that recently raised their guidance, go directly to 5 Companies that Recently Raised Guidance. Inflation risks continue to weigh heavily on the US economy, with the International Monetary Fund (IMF) recently revising growth projections […]Yesterday, Biogen Inc (NASDAQ: BIIB) reported Q2 earnings. Needham writes that while operational performance looked good, uncertainty looms over the company's growth potential. Lecanemab Phase 3 readout this fall should provide some clarity. The high-risk, high-reward event will impact the company's medium-term growth prospects. Needham still sees the base business plus risk-adjusted value of lecanemab as providing upside vs. current stock levels. It maintains the Buy rating but lowered the pric;180.57000732421875;;171.6199951171875;;143.2100067138672;CAMBRIDGE, Mass., July 22, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of vutrisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. If approved by the European Commission (EC);363.25;;2.9200000762939453;;85.2300033569336;;35.11000061035156;;80.9000015258789;"For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...JMP Securities reiterated its Market Outperform rating and increased the price target to $113 from $108 for Incyte Corporation (NASDAQ: INCY) based on multiple discounted earnings per share and revenue analyses. Recently, Incyte's Opzelura (ruxolitinib cream) in vitiligo received FDA approval. JMP says, ""despite the generic boxed warning of oral JAK inhibitors, we expect the vitiligo approval to usher in a new avenue of growth given the large unmet need and lack of competition."" With two recent";45.38999938964844;;54.849998474121094;Two years after the onset of COVID-19 in the U.S., a new vaccine is coming to market -- who will it help?Novavax passed the finish line to gain authorization for its COVID-19 vaccine, and its first commercial product. But the company is still working on younger age group eligibility and boosters with the FDA.Novavax (NVAX) closed the most recent trading day at $58.95, moving -1.04% from the previous trading session.Novavax CEO Stan Erck joins Yahoo Finance Live to discuss the CDC recommending Novavax’s COVID-19 vaccine for adults, COVID vaccine distribution, the vaccine demand, and the outlook for an Omicron vaccine.;65.1500015258789;;95.29000091552734;Tesla led the market rally Thursday, with a few more stocks setting up. But the Snap crash highlights this big risk.Neurocrine is the IBD Stock Of The Day. The biotech stock is approaching two potential entries as the movement disorder space heats up.;83.98999786376953;;67.91999816894531;;42.66999816894531;;51.880001068115234;Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;75.81999969482422;Exelixis (NASDAQ: EXEL) and CRISPR Therapeutics (NASDAQ: CRSP) have been able to parlay their specialized knowledge of genetic therapies into share-price growth.  While the Fidelity Select Biotech ETF is down more than 22% for the year, these two biotechs have been able to buck that downward trend.  Exelixis is a biotech that focuses on genetic therapies to fight difficult-to-treat cancers.;43.869998931884766;;31.040000915527344;;20.860000610351562;Exelixis (NASDAQ: EXEL) and CRISPR Therapeutics (NASDAQ: CRSP) have been able to parlay their specialized knowledge of genetic therapies into share-price growth.  While the Fidelity Select Biotech ETF is down more than 22% for the year, these two biotechs have been able to buck that downward trend.  Exelixis is a biotech that focuses on genetic therapies to fight difficult-to-treat cancers.Biotech company Exelixis (NASDAQ: EXEL) is not the most famous name in the industry.  If Exelixis can continue beating the market, investors would do well to purchase its shares now.  Exelixis' crown jewel, cancer drug Cabometyx, continues to be successful.The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions.  Many biotech companies have shifted their focus entirely or added COVID-19 vaccines and treatments to their product pipeline.  Early-stage biotech companies are prone to wild swings in revenue due to going from nearly no revenue to having a significant revenue stream once a drug is approved or a partnership with another company is reached.;10.149999618530273;;62.880001068115234;The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions.  Many biotech companies have shifted their focus entirely or added COVID-19 vaccines and treatments to their product pipeline.  Early-stage biotech companies are prone to wild swings in revenue due to going from nearly no revenue to having a significant revenue stream once a drug is approved or a partnership with another company is reached.;36.220001220703125;;51.4900016784668;;49.5;;;;28.969999313354492;SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2022, on Thursday, August 4, 2022. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir BiotechnologyVir Biotechnology is a co;14.420000076293945;;9.539999961853027;;4.46999979019165;;38.099998474121094;;50.31999969482422;;55.66999816894531;;10.069999694824219;;43.52000045776367;;14.420000076293945;;28.81999969482422;West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.
2022-07-25;248.72000122070312;;60.75;;587.280029296875;;162.3699951171875;Mainz, Germany, July 25, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2022 on Monday, August 8th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter 2022. To access the live conference call via telephon;199.50999450683594;Illumina is thrilled to announce that Kathryne Reeves, Illumina's Chief Marketing Officer, has been featured among Savoy's 2022 Most Influential Black Executives in Corporate America. It's rewardin...BIIB vs. ILMN: Which Stock Is the Better Value Option?;283.67999267578125;It's been a big year for Vertex Pharmaceuticals (NASDAQ: VRTX) so far.  The biotech company has grown its main cystic fibrosis (CF) business -- reporting billions of dollars in revenue from its portfolio of products.  Vertex plans to launch a phase 3 trial of its non-opioid pain candidate by the end of the year.;207.57000732421875;BIIB vs. ILMN: Which Stock Is the Better Value Option?;182.58999633789062;;172.83999633789062;;141.1999969482422;Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;361.1000061035156;;2.7799999713897705;Today, Ginkgo Bioworks (NYSE: DNA) — the leading horizontal platform for cell programming — and the biotechnology company Zymergen (Nasdaq: ZY) announced they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization. Under the terms of the agreement, which have been unanimously approved by the boards of directors of both companies, Zymergen stockholders will receive aGinkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the signing of a definitive agreement for the previously announced transaction with Bayer to expand Ginkgo's platform capabilities in agricultural biologicals. These capabilities will be built pursuant to a transaction in which Ginkgo will acquire Bayer's 175,000-square-foot West Sacramento Biologics Research & Development site, team, and internal discovery and lead optimization platform for approx;85.3499984741211;Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.;35.41999816894531;;80.62000274658203;;45.630001068115234;;55.5099983215332;;65.47000122070312;;95.25;;83.19999694824219;;66.91000366210938;;41.689998626708984;;51.040000915527344;;76.5;;43.36000061035156;"Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the ""STAR Market"") of the Shanghai Stock Exchange. The issue price is CNY 18.12 per share, representing a market cap of CNY 10.419 billion.";30.739999771118164;;21.010000228881836;;11.029999732971191;- CHMP recommendation for approval of NULIBRY in the European Union (EU) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A is based on the efficacy and safety data collected to date compared to data from a natural history study - Under an accelerated assessment pathway, a decision by the European Commission (EC), which authorizes marketing approval in the European Union (EU), is expected on the NULIBRY application later this year - If approved by the EC, NULIBRY wou;63.970001220703125;;35.34000015258789;;50.93000030517578;Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;50.470001220703125;;;;29.360000610351562;;14.609999656677246;;9.239999771118164;;4.360000133514404;;38.31999969482422;;49.790000915527344;;53.02000045776367;;10.100000381469727;;42.029998779296875;;14.229999542236328;;29.040000915527344;
2022-07-26;251.13999938964844;;60.619998931884766;Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Gilead (GILD) receives positive CHMP opinion for full marketing authorization of its COVID-19 Jab, Veklury, and for using its CAR-T cell therapy Tecartus to treat relapsed or refractory B-cell precursor ALL in adults.;582.5599975585938;"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 10th annual Regeneron Prize for Creative Innovation, a competition designed to recognize excellence and creativity in biomedical research conducted by postdoctoral fellows and graduate students. Each year, Regeneron invites the country's leading research universities to nominate early career scientists. Applicants present their ""dream projects"" within the field of biomedical science to a committee of Regeneron scieRegeneron (REGN) closed the most recent trading day at $587.28, moving +0.2% from the previous trading session.SVB has cut the price target from $738 to $630 and downgraded from Outperform to Market Perform to reflect Regeneron Pharmaceutical Inc's (NASDAQ: REGN) acquisition of Libtayo ex-US rights from Sanofi SA (NASDAQ: SNY) and more conservative long-term Eylea forecasts. SVB Leerink said it is moving to the sidelines because of low confidence that both (Q12W and Q16W) high dose Eylea arms will succeed in the upcoming phase 3 readouts and anticipated competitive pressure from Roche Holding AG's (OTC:";159.72000122070312;COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.  The lawsuit https://tmsnrt.rs/3PAjBo7, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.  The lawsuit, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.Gilead (GILD) receives positive CHMP opinion for full marketing authorization of its COVID-19 Jab, Veklury, and for using its CAR-T cell therapy Tecartus to treat relapsed or refractory B-cell precursor ALL in adults.;199.2899932861328;;288.2200012207031;Vertex Pharmaceuticals (NASDAQ: VRTX) is an evergreen stock because it has proven that it's an expert at consistently extracting wild growth from a tiny niche.  Of the 83,000 estimated patients living with the rare hereditary disease cystic fibrosis (CF) in the Western World, Vertex treats more than half of them with its portfolio of drugs, and it's doing a significant amount of research and development work to treat everyone that's left.  What's more, Vertex is starting to diversify into developing therapies for other illnesses, ranging from type 1 diabetes to pain and Duchenne muscular dystrophy.Vertex Pharmaceuticals (VRTX) closed at $283.68 in the latest trading session, marking a +1.21% move from the prior day.As UnitedHealth tops the list of new buys by the best mutual funds, UNH stock finds its way back into a buy zone.Among the top stocks to buy and watch, biotech leader Vertex Pharmaceuticals and ELF Beauty are in or near new buy zones in today's action.;210.85000610351562;"Biogen Inc. said Tuesdsay that its experimental treatment for a type of amyotrophic lateral sclerosis (ALS), which is often referred to as Lou Gehrig's disease, has been granted Priority Review by the Food and Drug Administration. The regulator is expected to make a decision whether to approve tofersen by Jan. 25. An advisory committee meeting date has not yet been set. ""If approved, tofersen will be the first treatment to target a genetic cause of ALS and we hope this will pave the way for furtThe biotech's share price fell 4.1% in a single day last fall, when the company disclosed disappointing results from the Phase 3 trial of the drug.Biogen Inc's treatment for a rare type of amyotrophic lateral sclerosis (ALS) was accepted for review by the U.S. health regulator, weeks after follow-up analyses of data from a failed late-stage study suggested the drug was likely to work.  The company said the U.S. Food and Drug Administration's decision on its treatment, tofersen, which will go through a priority review, is expected by Jan. 25, 2023.  The FDA also plans to hold a meeting of its outside experts to discuss the application.SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads to the loss of everyday functions and is uniformly fatalIf approved, tofersen would be the first treatment to target a genetic cause of ALS12-month data included in the filing show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of life CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NasBiogen Inc. (BIIB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).";177.3000030517578;;177.50999450683594;"From the FDA crackdown on Altria Group Inc.’s JUUL to RH’s recent decision to cut guidance due to a weak housing market outlook, experts can often make smart predictions about […]Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Shares of Seagen Inc. gained 2.5% in premarket trading on Tuesday after the company said an early-stage clinical trial evaluating its investigational treatment for urothelial cancer in combination with Merck & Co. Inc.'s Keytruda met its primary endpoint. Seagen is developing the therapy, enfortumab vedotin, with Astellas Pharma Inc. ; it received a Breakthrough Therapy designation in early 2020. The company said in a news release that the combination therapy generated a 64.5% confirmed objectivAstellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas"") and Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K evaluating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible to receive cisplBOTHELL, Wash. & TOKYO, July 26, 2022--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas"") today announced positive topline results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K evaluating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (la/m";140.0;;370.6300048828125;;2.609999895095825;Boston-based Ginkgo Bioworks Holdings Inc. has agreed to pay $83 million to acquire Bayer’s 175,000-square-foot West Sacramento biologics research and development site, along with its employees there and discovery technology platforms.The merger brings nearly to an end a year-long journey since Zymergen, once with 800 employees and the promise to change the world of petroleum-based products with materials-producing microbes.Wag Labs Inc. plans to give away 300,000 shares of its stock to pet caregivers and nonprofit organizations as part of its plans to go public.  The San Francisco startup, which offers dog walking and pet care services, intends to hit Wall Street soon via a merger with a blank-check company.  Robinhood Financial LLC, the Menlo Park based online brokerage, and DonateStock, a Houston-based startup that specializes in philanthropic giving, will administer Wag's stock donations.The synthetic biology firm Ginkgo Bioworks Holdings Inc. will acquire a California company in an all-stock transaction valued at $300 million.;85.26000213623047;;35.91999816894531;;79.83999633789062;Incyte's (INCY) top line is likely to have been driven by sales of its lead drug, Jakafi, in the second quarter.;45.11000061035156;In this article, we discuss 10 stocks that Cathie Wood is not letting go of despite losses. If you want to see more stocks in this selection, click Cathie Wood is Not Letting Go of These 5 Stocks Despite Losses. Cathie Wood, the CEO of ARK Investment Management, has been in hot water so far […]Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.;56.54999923706055;President Joe Biden is making good progress in his recovery from COVID, he told reporters on Monday, and expects to be back to working in person by the end of the week.As the hottest vaccine stock du jour, Novavax (NASDAQ: NVAX) has a long and bright future ahead. Thanks to its coronavirus jab, which was recently awarded an Emergency Use Authorization (EUA) by regulators in the U.Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval in Japan for adolescents aged 12 through 17. Novavax has partnered with Takeda Pharmaceutical Co Ltd (NYSE: TAK) to develop, manufacture, and distribute Nuvaxovid in Japan. The Australian Therapeutic Goods Agency has granted expanded approval for provisional registration of Nuvaxovid for adolescents aged 12 through 17. Also Read: Novavax's COVID-19 Vaccine For Adults GetsNovavax Inc. said Tuesday that its COVID-19 vaccine received authorization in Australia and Japan for teens. Both authorizations are for adolescents between the ages of 12 and 17 years old. In Japan, Novavax is partnering with Takeda Pharmaceutical Co. to manufacture and distribute the shots there. Novavax's stock is up 3.5% this year, while the S&P 500 is down 16.7%.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for primary immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents ageNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the Australian Therapeutic Goods Agency (TGA) has granted expanded approval for provisional registration of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine▼ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to adolescents aged 12 throughChoosing between Novavax (NASDAQ: NVAX) and Moderna (NASDAQ: MRNA) might seem like a slam dunk in Moderna's favor.  Based on market cap, Moderna is more than 16 times larger than Novavax.  Moderna is generating a lot more revenue and earnings than Novavax is.;65.3499984741211;;94.5999984741211;;82.54000091552734;CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2022 financial results after the Nasdaq Global Market closes on Tuesday, August 2, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2022 financial results and to provide a corporate update. The event will be webcast live under the investor relations section o;66.91999816894531;;41.84000015258789;;50.66999816894531;Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 2, 2022 to report its second quarter 2022 financial results and provide a corporate update.;77.12000274658203;CRISPR Therapeutics AG (CRSP) closed at $76.50 in the latest trading session, marking a +0.9% move from the prior day.;43.0099983215332;(Bloomberg) -- Alibaba Group Holding Ltd. will seek a primary listing in Hong Kong, entrenching the financial hub’s status as an alternative to US markets ahead of a potential exodus of Chinese companies from New York.Most Read from BloombergBiden Considers New Pause on Paying Back Student Loans, $10,000 ReliefStar Wars Knights of the Old Republic Game Paused Amid Studio ShakeupBiden Will Speak With Xi on Thursday as US-China Ties WorsenMajor Philippine Earthquake Kills 4, Triggers LandslidesCoi;31.3799991607666;There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 3, 2022 at 5:00 PM ET to report its second quarter 2022 financial results and provide a corporate update. In order to participate in t;21.329999923706055;;9.289999961853027;"BridgeBio Pharma Inc (NASDAQ: BBIO) has announced interim results from PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia, the most common form of short-limbed dwarfism. At the highest dose level (0.128 mg/kg once daily), the mean increase in annualized height velocity (AHV) was 1.52 cm/yr over baseline in children five years and older. Earlier cohorts in PROPEL 2 did not achieve the target efficacious exposure as suggested by preclinical data, and no dose-response was observ- At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) was +1.52 cm/yr (p=0.02, n=11) and the responder rate was 64% in children 5 years and older1 - Infigratinib was well-tolerated with no serious adverse events (SAE) and no discontinuations due to adverse events (AE) including in Cohort 5 (dose: 0.25 mg/kg once daily) participants dosed to date, with a median duration of follow-up of 48.1 weeks; only a";64.13999938964844;;35.939998626708984;;50.15999984741211;Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NOVATO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, July 28, 2022, at 5:00pm ET to discuss its financial results and corporate update for the quarter ended June 30, 2022. The live and replayed webcast of the call will be available through the co;50.91999816894531;"Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today announced it will release its second quarter 2022 financial and operating results on Tuesday, August 9, 2022, following the close of trading.";;;28.950000762939453;;14.569999694824219;;9.399999618530273;;4.269999980926514;;38.04999923706055;The biotech's share price fell 4.1% in a single day last fall, when the company disclosed disappointing results from the Phase 3 trial of the drug.Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for tofersen, an investigational antisense medicine for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS). The NDA was submitted by Biogen, which licensed tofersen from Ionis in 2018. The application has been granted priority review and given a Prescription Drug User Fee Act action date of Jan. 25, 2023. The FDA has noted t;51.400001525878906;;53.25;;10.1899995803833;;40.88999938964844;;14.15999984741211;SAN DIEGO, July 25, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 8, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.;29.389999389648438;Koninklijke Philips' (PHG) Q2 top and bottom-line results reflect the negative impact of supply chain constraints and COVID lockdowns in China.Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVAAlthough Black Americans have the same rate of bipolar disorder as other racial and ethnic groups, they are less likely to receive a diagnosis due to lack of access and cultural stigma. Check out t...Alkermes' (ALKS) second-quarter 2022 results set to report earnings and revenues figures and provide updates on its portfolio of marketed drugs.
2022-07-27;251.72000122070312;Yahoo Finance’s Ines Ferre joins the Live show to break down how stocks are moving in early trading.Merck, Novartis and others are seeking to revive the $48 billion market, which had shrunk after top-selling cholesterol and other drugs lost patent protection.;60.900001525878906;Gilead Sciences (GILD) closed the most recent trading day at $60.62, moving -0.21% from the previous trading session.(Bloomberg) -- Groundbreaking drugs that prevent HIV infection may be harder to get in the US if a prominent Texas lawyer wins a lawsuit that pits his clients’ religious beliefs against free nationwide access to the medicines.Most Read from BloombergRockstar Games Cleaned Up Its Frat-Boy Culture — and Grand Theft Auto, TooBiden Considers New Pause on Paying Back Student Loans, $10,000 ReliefStar Wars Knights of the Old Republic Game Paused Amid Studio ShakeupWalmart’s Mega Sale Is More Bad News;587.9099731445312;Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;155.8800048828125;Research published Tuesday by the journal Science offers more evidence that the coronavirus pandemic that has caused the deaths of more than six million people globally originated in a wet market in Wuhan, China, and not from a Chinese lab.If a company's profit margin is slim, then a surge in expenses can easily put its bottom line into the red.  Two companies with significant buffers on that front are BioNTech (NASDAQ: BNTX) and Public Storage (NYSE: PSA).  BioNTech has been reporting strong sales and profit numbers thanks to the COVID-19 vaccine that it developed with Pfizer.Pfizer Inc. and German partner BioNTech SE said Wednesday they have started a Phase 2 study to evaluate an enhanced COVID-19 vaccine aimed at the original strain of the virus and the omicron variant that seeks to create a more robust and longer-lasting immune response. The new bivalent vaccine called BNT162b5 will be tested in a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response. The study will be U.S.-based and involve about 200NEW YORK and MAINZ, Germany, July 27, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestrA new generation of vaccines is needed to continue fighting COVID-19, according to experts at the White House Tuesday.Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe patents related to the COVID-19 vaccine held by CureVac N.V. (NASDAQ: CVAC). CureVac, earlier this month, filed a lawsuit in Germany against BioNTech over its use of mRNA technology. Related: CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech. It did not rule out further legal action against BioNTech's p;207.1699981689453;Illumina has offered rivals royalty-free global licences for some of its patents and a three-year patent truce with Chinese rival BGI in Europe in a bid to address EU antitrust concerns over its acquisition of Grail, people familiar with the matter said.  The U.S. life sciences company submitted the concessions to the European Commission last week.  They consist of royalty-free global licences to rivals of next-generation sequencing technology and equipment and a pledge not to pursue any patent litigation against BGI in Europe, the sources said.Illumina's acquisition of biotechnology company Grail will likely be blocked by EU antitrust regulators because of concerns about concessions offered by the U.S. life sciences firm, people familiar with the matter said on Wednesday.  There are doubts whether the concessions offered last week to address the European Commission's concerns about the $8 billion cash-and-stock deal will boost competition, the people said.  Illumina has offered rivals royalty-free global licences for some of its patents and a three-year patent truce with Chinese rival BGI in Europe in a bid to address EU antitrust concerns over its acquisition of Grail, other people familiar with the matter said.Illumina has offered rivals royalty-free global licences for some of its patents and a three-year patent truce with Chinese rival BGI in Europe in a bid to address EU antitrust concerns over its acquisition of Grail, people familiar with the matter said.  The U.S. life sciences company submitted the concessions to the European Commission last week.  They consist of royalty-free global licences to rivals of next-generation sequencing technology and equipment and a pledge not to pursue any patent litigation against BGI in Europe, the sources said.Illumina (ILMN) closed at $199.29 in the latest trading session, marking a -0.11% move from the prior day.;286.989990234375;Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $288.22, moving +1.6% from the previous trading session.;212.9199981689453;Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.Wall Street has heated up in July following June’s gloomy market behavior. But if you thought it’s too late to act now or even too early to buy, there are undervalued S&P 500 stocks which smartly dictate otherwise and demand going long today. As the clock ticks down on July and a solid monthly gain of 5% in the large-cap, broad-based S&P 500, the seeds of doubt for some investors persists. And it’s easy to see why. The Federal Reserve is set to raise interest rates once again this week as it att;177.61000061035156;;176.8000030517578;;141.97000122070312;CAMBRIDGE, Mass., July 27, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company and collaborators have identified mutations in the INHBE gene associated with protection against abdominal obesity and metabolic syndrome – a condition impacting more than 20 percent of adults worldwide. The discovery leveraged sequencing data from more than 360,000 individuals in UK Biobank, and was published in the 13th issue of Nature Communica;374.44000244140625;;2.7899999618530273;;87.0199966430664;BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;38.40999984741211;;80.68000030517578;;46.29999923706055;;56.40999984741211;What happened Biotechnology company Novavax, Inc. (NASDAQ: NVAX) surged higher on Tuesday on what was an all-around bad day for the markets. The share price was up 5.8% from the previous day's close at around 12:35 p.Is Novavax stock a buy after officials in Japan and Australia approved its Covid vaccine for teens? Is NVAX stock a buy now?;67.52999877929688;CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its second quarter 2022 financial results and operational highlights in a conference call on August 4, 2022, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately fCathie Wood stocks trading at a discount is our topic for today. The prominent fund manager and her team focus on disruptive innovation, considered by many to be a new paradigm in investing. However, after skyrocketing in 2020, Cathie Wood stocks have had a dismal first-half in 2022. As Bloomberg recently reported, “Wood and her firm ARK Investment Management have been among the highest-profile victims of a stock selloff that has swept Wall Street as inflation takes off and the Federal Reserve r;95.55000305175781;Here is how Lyra Therapeutics, Inc. (LYRA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.;85.86000061035156;;68.0199966430664;;44.310001373291016;;51.709999084472656;Denali Therapeutics Inc. (DNLI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;78.93000030517578;;43.25;The mean of analysts' price targets for Zai Lab Limited Unsponsored ADR (ZLAB) points to a 144.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.;33.16999816894531;Cathie Wood stocks trading at a discount is our topic for today. The prominent fund manager and her team focus on disruptive innovation, considered by many to be a new paradigm in investing. However, after skyrocketing in 2020, Cathie Wood stocks have had a dismal first-half in 2022. As Bloomberg recently reported, “Wood and her firm ARK Investment Management have been among the highest-profile victims of a stock selloff that has swept Wall Street as inflation takes off and the Federal Reserve r;21.290000915527344;ALAMEDA, Calif., July 26, 2022--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.;10.079999923706055;;67.80999755859375;;36.83000183105469;Denali Therapeutics Inc. (DNLI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;50.810001373291016;;51.70000076293945;;;;29.6200008392334;;14.869999885559082;;9.789999961853027;;4.489999771118164;;38.63999938964844;Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, August 9th at 11:30 a.m. Eastern Time to discuss its second quarter financial results and report on pipeline and business progress.;53.029998779296875;While Arvinas, Inc. ( NASDAQ:ARVN ) shareholders are probably generally happy, the stock hasn't had particularly good...;53.4900016784668;;10.510000228881836;Abcellera Biologics Inc shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 89.VANCOUVER, British Columbia & SAN FRANCISCO, July 27, 2022--AbCellera (Nasdaq: ABCL) and Versant Ventures today announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm’s stealth-stage companies under previous partnerships.;42.97999954223633;;14.770000457763672;Generally speaking long term investing is the way to go. But no-one is immune from buying too high. To wit, the ACADIA...;27.829999923706055;BIPOC mental health month is a time to raise awareness around the barriers that keep many communities from receiving proper mental health care. Learn more and stay tuned as we share facts and resou...Alkermes (ALKS) delivered earnings and revenue surprises of 50% and 1.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2022 and provided updated financial expectations for full-year 2022.
2022-07-28;249.75;Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;60.400001525878906;Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) second-quarter 2022 results.;582.3699951171875;Mergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come.Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that scientists from the Regeneron Genetics Center® (RGC) have uncovered rare genetic loss-of-function mutations in the CIDEB gene that are associated with substantial protection from liver disease, including serious diseases such as nonalcoholic steatohepatitis (NASH) and cirrhosis. The new discovery has been published today in The New England Journal of Medicine.;164.9199981689453;Pfizer (PFE) beats estimates for Q2 earnings and sales. It maintains the sales forecast for COVID products, Comirnaty and Paxlovid.Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant. Related: BioNTech, Pfizer File For Clear;213.75;Three stocks that are trading near their four-year lows that you may want to keep a close eye on right now are Illumina (NASDAQ: ILMN), PayPal Holdings (NASDAQ: PYPL), and Unilever (NYSE: UL).  Genomic-sequencing company Illumina has fallen 48% year to date while the S&P 500 has declined by just 17%.  Illumina is a promising growth stock with lots of potential in revolutionizing healthcare, by making it easier to run genetic tests and identify rare diseases that people may otherwise not notice until later on in life.Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Illumina, Inc...DRAGEN™ v4.0 brings greater accuracy, comprehensiveness, and efficiency to genomic analysis than ever before, unlocking the full potential of genomics to improve human health;280.82000732421875;Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.In this article, we shall be going through the top 10 stock picks of Efrem Kamen’s Pura Vida Investments. To skip our detailed analysis of Kamen’s history, his investment strategy, and hedge fund performance, go directly and see Top 5 Stock Picks of Efrem Kamen’s Pura Vida Investments. Efrem Kamen currently serves as Managing Member […]AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate exa-cel.;214.1999969482422;The FDA has granted priority review to tofersen, a drug for a certain genetic form of amyotrophic lateral sclerosis.In this article, we shall be going through the top 10 stock picks of Efrem Kamen’s Pura Vida Investments. To skip our detailed analysis of Kamen’s history, his investment strategy, and hedge fund performance, go directly and see Top 5 Stock Picks of Efrem Kamen’s Pura Vida Investments. Efrem Kamen currently serves as Managing Member […]Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary endpointBiogen is also evaluating litifilimab in systemic lupus erythematosus through the Phase 3 TOPAZ studies and plans to initiate a pivotal study in CLE later this yearBiogen is advancing two lupus therapies in Phase 3 trials to address this chronic autoimmune disease CAMBRIDGE, Mass., July 28, 2022 (;174.8699951171875;Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.;177.42999267578125;;143.52000427246094;Alnylam (ALNY) delivered earnings and revenue surprises of -41.36% and 13.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?CAMBRIDGE, Mass., July 28, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2022 and reviewed recent business highlights.Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Jul 28.;380.760009765625;Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of an exclusive licensing agreement to commercialize The University of Dundee's BromoTAG® system and fund the recruitment of postdoctoral researchers at the University's Centre for Targeted Protein Degradation (CeTPD). CeTPD researchers will create new chemical tools that will be commercialized by Tocris, a Bio-Techne brand, for use by the biopharmaceutical research community.;2.8399999141693115;Mergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come.Today we will run through one way of estimating the intrinsic value of Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) by...;87.08000183105469;Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;39.900001525878906;;78.81999969482422;;46.2599983215332;;57.11000061035156;On Novavax's (NVAX) second-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.In the latest trading session, Novavax (NVAX) closed at $56.41, marking a -0.25% move from the previous day.;65.66000366210938;Mergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come.;93.9000015258789;Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;85.93000030517578;Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;66.58999633789062;;43.7599983215332;;51.970001220703125;;75.9000015258789;On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate exa-cel.;42.099998474121094;;32.150001525878906;;20.729999542236328;The market volatility has made investors skeptical right now.  Diversifying one's portfolio with quality stocks from high-growth industries would be a smart move now.  Oncology drug maker Exelixis (NASDAQ: EXEL) could have a shining future.;9.119999885559082;;65.68000030517578;;35.66999816894531;Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;51.880001068115234;;50.52000045776367;;;;28.950000762939453;Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;15.029999732971191;;9.890000343322754;;4.489999771118164;;38.9900016784668;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced positive topline results of the Phase 2b RE-THINC ESRD study of fesomersen, formerly IONIS-FXI-LRx, in patients with end-stage renal disease (ESRD) on hemodialysis. In the study, fesomersen achieved its primary outcome measure of no increase in incidence of major bleeding and clinically relevant non-major bleeding as compared to placebo. Data from the study show that fesomersen, administered monthly at 40 mg, 80 mg and 120 mg for up to;52.869998931884766;;54.209999084472656;;10.430000305175781;;43.939998626708984;;14.579999923706055;;26.549999237060547;Baxter's (BAX) second-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. However, the company expects softer demand for its products and services in the second half of 2022.CONMED's (CNMD) adjusted second-quarter earnings reflect strong segmental performance. However, unfavorable currency movement hurt sales growth. Inflationary or supply chain challenges hurt gross margin.Good morning and welcome to the Alkermes plc conference call to discuss our financial results and business update for the quarter ended June 30, 2022.  Before we begin, I encourage everyone to go to the Investors section of alkermes.com to find our press release, related financial tables, and reconciliations of the GAAP to non-GAAP financial measures that we'll discuss today.
2022-07-29;247.47000122070312;In the latest trading session, Amgen (AMGN) closed at $249.75, marking a -0.78% move from the previous day.Gilead Sciences  is a biotechnology company that operates with a focus on antiviral medication and treatments.  Its main products include treatments for HIV, Hepatitis B, and Hepatitis C (HBV/HCV), but Gilead has also ventured into other areas such as oncology.  The company generated revenues of $6.6 billion during the first quarter, which was above the analyst consensus estimate.;59.75;After a journey across the country, two pieces of the AIDS Memorial Quilt have now found their permanent home at Gilead’s Foster City campus.Gilead Sciences  is a biotechnology company that operates with a focus on antiviral medication and treatments.  Its main products include treatments for HIV, Hepatitis B, and Hepatitis C (HBV/HCV), but Gilead has also ventured into other areas such as oncology.  The company generated revenues of $6.6 billion during the first quarter, which was above the analyst consensus estimate.Gilead Sciences Inc (NASDAQ: GILD) announced results reinforcing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) as a highly efficacious treatment option for HIV, including individuals with HIV/hepatitis B (HBV) coinfection. Interim data from the ALLIANCE trial evaluating Biktarvy in adults with HIV/HBV coinfection who were initiating therapy show potential HBV and HIV suppression comparable to an alternative HIV regimen. Related: Gilead Again Seeks HIV Drug Approval From FDA After AdFOSTER CITY, Calif., July 28, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results reinforcing Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a highly efficacious treatment option for a broad range of people with HIV, including individuals with HIV/hepatitis B (HBV) coinfection. Interim data from the ALLIANCE trial evaluating Biktarvy in adults with HIV/HBV coinfection who were initiating therapy show potential suppression of HBV;581.6900024414062;Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.;165.14999389648438;The Biden administration said it would spend $1.74 billion to buy 66 million doses of  Moderna  updated Covid-19 vaccine, as well as the option to purchase up to 234 million additional doses, as part of a fall booster campaign.  The deal Friday, which follows an agreement to buy 105 million doses of updated vaccines from  Pfizer  and partner  BioNTech SE  is expected to give the federal government enough shots for a booster push as early as September.  Under the latest deal, the U.S. government has the option to buy up to an additional 234 million doses from Moderna.Strong quarterly sales of Pfizer’s Covid-19 products helped offset mixed results from other products, and the drugmaker sees full-year revenue gains being offset by unfavorable currency effects.;216.67999267578125;Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today it is among the first group of companies worldwide to receive approval of its net-zero targets by the Science Based Targets initiative (SBTi). This includes validation of Illumina's corporate greenhouse gas (GHG) emissions reduction targets by the organization.On National Intern Day, Illumina’s interns share their advice and experiences;280.4100036621094;The Dow Jones Industrial Average reversed higher Friday on a hot inflation report. Amazon and Apple rallied on strong results.;215.05999755859375;The company had said it was in talks with the FDA about seeking early approval, but Wall Street analysts thought the agency would make it wait to apply.;168.0800018310547;;179.97999572753906;Seattle Genetics (SGEN) delivered earnings and revenue surprises of 10.98% and 12.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?CLICK HERE TO REGISTER FOR FREE 14 DAY STREAM TRIAL From the FDA crackdown on Altria Group Inc.’s JUUL to RH’s recent decision to cut guidance due to a […]BOTHELL, Wash., July 28, 2022--Seagen Inc. (Nasdaq:SGEN) reported financial results today for the second quarter ended June 30, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline.From the FDA crackdown on Altria Group Inc.’s JUUL to RH’s recent decision to cut guidance due to a weak housing market outlook, experts can often make smart predictions about listed companies. With Stream, investors can find such expert insights quickly and efficiently. IPO Edge and the Palm Beach Hedge Fund Association will host a […] The post Predicting the Next FDA Juul Crackdown and More: Join Stream and Sentieo Thursday in Fireside to Discuss Expert Call Platform appeared first on CorpGov.The drug giant reports second-quarter adjusted earnings of $1.87 a share, which is above analysts' estimates.;142.0399932861328;Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.We analyzed the 100 largest public companies in Mass. by both stock price performance in 2021 and CEO compensation.;385.2799987792969;;2.859999895095825;We analyzed the 100 largest public companies in Mass. by both stock price performance in 2021 and CEO compensation.The company’s top two executives also happen to be founders, leading to massive compensation packages for both last year.;86.05000305175781;;40.150001525878906;10x Genomics, Inc. (NASDAQ: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.In this article, we discuss Cathie Wood’s top 10 buys in July. If you want to see more stocks that Cathie Wood bought this month, click Cathie Wood’s Top 5 Buys in July. In the beginning of July, Cathie Wood of ARK Investment Management admitted that while her predictions about inflation were wrong, the US […];77.68000030517578;Amid the ongoing stock market volatility, investors should be on the hunt for high-quality growth stocks approaching potential buy points.  The bulk of trading in the stock market is done by institutions: mutual funds, hedge funds and other major investors with billions of capital to invest.  This activity will be reflected in IBD's Accumulation/Distribution Rating, which analyzes a stock's price and volume trends over the prior 13 weeks.;45.099998474121094;In this article, we discuss Cathie Wood’s top 10 buys in July. If you want to see more stocks that Cathie Wood bought this month, click Cathie Wood’s Top 5 Buys in July. In the beginning of July, Cathie Wood of ARK Investment Management admitted that while her predictions about inflation were wrong, the US […];54.5099983215332;Yahoo Finance's Julie Hyman breaks down leading headlines including the Biden administration planning to offer updated COVID-19 booster shots in September, Euro Zone inflation, Instacart going public, and Shakira potentially facing jail time after being accused of tax fraud.;64.76000213623047;;94.12999725341797;It's make-or-break time for Neurocrine Biosciences' essential tremors treatment, analysts say, as NBIX stock trends sideways.;92.94999694824219;The company had said it was in talks with the FDA about seeking early approval, but Wall Street analysts thought the agency would make it wait to apply.CAMBRIDGE, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced its intent to submit a Biologics License Application (BLA) seeking accelerated approval for SRP-9001 (delandistrogene moxeparvovec) to treat ambulant individuals with Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche. “We are delighted to confirm that;64.4000015258789;;42.529998779296875;;51.060001373291016;;75.0;;40.529998779296875;;30.530000686645508;Needham initiated coverage on Fate Therapeutics Inc (NASDAQ: FATE) with a Hold rating without a price target. The company is working on induced pluripotent stem cell (iPSC) derived cancer therapeutics, primarily NK cells. Needham says that Fate's platform has several appealing qualities: NK cells are natively allogeneic. Using iPSCs allows for improved scalability and controlled COGS while achieving efficacies in line with the most advanced therapeutics. Early proof of concept was achieved in B-;20.920000076293945;The Alameda, California, biotechnology company is establishing a major East Coast hub that will eventually have more than 600 employees.;8.65999984741211;;62.97999954223633;;34.02000045776367;;53.279998779296875;Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Q2 sales reached $89.3 million, up from $86.97 million a year ago, beating the consensus of $87.51 million. The company recognized $64.0 million in Crysvita (burosumab) revenue in the Ultragenyx territories, including $51.6 million in collaboration revenue in the North American profit share territory and net product sales in other territories regions of $12.4 million. Yoyalty revenue related to European Crysvita sales was $5.4 million. Dojolvi's (trUltragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Second quarter 2022 total revenue of $89.3 million and Crysvita® revenue in Ultragenyx territories1 of $64.0 million Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million Expanded clinical pipeline through acquisition of GeneTx and global rights to UX111 for Sanfilippo syndrome Completed $500.0 million sale of a capped 30% of royalty interest on the future sales of Crysvita in the United States and Cana;48.900001525878906;;;;27.809999465942383;;14.9399995803833;;9.949999809265137;;4.369999885559082;;37.560001373291016;;53.11000061035156;;54.119998931884766;;10.039999961853027;;43.7400016784668;;14.6899995803833;;25.600000381469727;Despite the top line missing estimates, DexCom's (DXCM) second-quarter results reflected strong domestic and international revenue growth.Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales besides strength in the majority of product lines.Here is how Corcept Therapeutics (CORT) and Alkermes (ALKS) have performed compared to their sector so far this year.Alkermes (ALKS) beat estimates for both earnings and sales in the second quarter of 2022. The company narrows sales guidance for Vivitrol and Aristada. Stock down.
2022-08-01;245.63999938964844;Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.Amgen Inc (NASDAQ: AMGN) will fight Internal Revenue Service over the company’s international tax strategy and $10.7 billion in back taxes and penalties, Wall Street Journal reported. The IRS agency says that Amgen underreported its taxable income by nearly $24 billion from 2010 to 2015 by inappropriately attributing its U.S. profits to a Puerto Rico subsidiary. According to FactSet data, Amgen has long had one of the lowest tax rates in the pharmaceutical industry, reporting a median 12.5% effeAmgen is fighting a $10.7 billion tax bill from the IRS, which says the biotech improperly shifted nearly $24 billion in profits to a Puerto Rico subsidiary to reduce its tax burden.;59.599998474121094;Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;576.6799926757812;Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.;163.47999572753906;Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.;215.61000061035156;Dr. Ranjana Bhattacharjee is using whole-genome sequencing to understand the crop’s evolution and generate improved varietiesIllumina and Best Buy are part of Zacks Bull and Bear of the Day article.Leader in genomic sequencing still growing sales over 15% as lifescience labs crunch more genetic data;273.8299865722656;Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.;209.25999450683594;Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.;162.49000549316406;;175.47000122070312;;139.9499969482422;;383.260009765625;;2.869999885559082;;85.41000366210938;;39.84000015258789;10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;77.4000015258789;;47.209999084472656;Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.;53.91999816894531;Yahoo Finance health care reporter Anjalee Khemlani discusses President Biden testing positive for COVID-19 after taking Paxlovid as well as the latest developments in the monkeypox outbreak.;62.7400016784668;;92.02999877929688;;91.55000305175781;Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) is possibly approaching a major achievement in its business, so we would...;65.79000091552734;;41.77000045776367;;50.599998474121094;;74.01000213623047;;38.880001068115234;;30.040000915527344;;20.959999084472656;;8.460000038146973;;58.84000015258789;CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that on Friday, July 29, 2022, the company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) that the BEAM-201 Investigational New Drug (IND) application for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T cell lymphoblastic lymphoma (T;32.77000045776367;;50.630001068115234;;48.529998779296875;;;;27.43000030517578;Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;14.9399995803833;;9.550000190734863;;4.46999979019165;Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.;37.4900016784668;;50.380001068115234;NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of Chief Commercial Officer (CCO). “John is an excellent addition to the Arvinas leadership team, and I am confident that his experience and impressive product development and commercialization track record will play an imp;51.720001220703125;Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;10.145000457763672;;44.61000061035156;SOUTH SAN FRANCISCO, Calif., August 01, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Jim Thorburn, CFO of Twist Bioscience, and Patrick Finn, Ph.D., CCO of Twist Bioscience, will host a fireside chat and one-on-one meetings at the UBS Genomics 2.0 and Medtech Innovations Summit on Tuesday, August 9th, at 2:00 p.m. Pacific Time in Dana Point, California;14.109999656677246;Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;25.170000076293945;PerkinElmer's (PKI) second-quarter results benefit from a solid performance at Discover & Analytics Solutions business.For UroLift, Teleflex (TFX) witnesses revenue declines in all sites of service, including hospital, ASC and physician's office.Alkermes (ALKS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
2022-08-02;243.91000366210938;Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 4, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.;59.540000915527344;Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.;574.9600219726562;;165.77000427246094;On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.Pfizer and BioNTech appear to be beating Moderna in this market -- at least, so far.  The U.S. government has finalized supply agreements with Pfizer-BioNTech and Moderna that include the companies' respective omicron boosters.  First, Pfizer and BioNTech received a much larger initial order than Moderna.;219.13999938964844;Illumina (ILMN) closed the most recent trading day at $215.61, moving -0.49% from the previous trading session.A Medical Stock with a Solid Earnings Outlook and a Retailer with a Compelling Growth Story.;273.8599853515625;Dow Jones futures dropped 200 points Tuesday on rising U.S.-China tensions, as House Speaker Nancy Pelosi heads to Taiwan.Dow Jones futures fell 130 points early Tuesday. Seven stocks to buy and watch include energy giants Chevron and Exxon.With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones.;209.14999389648438;;165.85000610351562;In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Eli Casdin founded Casdin Capital in 2011 and currently he serves as the hedge […];176.72000122070312;;141.97000122070312;In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Eli Casdin founded Casdin Capital in 2011 and currently he serves as the hedge […]CAMBRIDGE, Mass., August 02, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has ranked #1 on Fast Company’s fourth annual list of Best Workplaces for Innovators.;387.010009765625;;3.0;;86.69000244140625;;40.79999923706055;Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;72.58000183105469;Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.Incyte Corporation's (NASDAQ: INCY) Q2 adjusted EPS reached $1.01, compared to $0.8067 posted a year ago. Analysts had estimated $0.75. Sales increased 29% Y/Y to $911.39 million, beating the consensus of $815.17 million. The company reported an operating income of $254.43 million, compared to $140.84 million posted a year ago. Jakafi net product revenues increased 13% Y/Y to $597.67 million, primarily driven by volume growth. The company said that the launch of Opzelura in atopic dermatitis conIncyte (INCY) delivered earnings and revenue surprises of 27.85% and 11.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?WILMINGTON, Del., August 02, 2022--Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsLet's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.;47.93000030517578;In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Eli Casdin founded Casdin Capital in 2011 and currently he serves as the hedge […];57.459999084472656;The biotech's results and what management has to say about its plans will help to determine whether a rally will continue.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2022 financial results and operational highlights on Monday, August 8, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows:;64.05999755859375;;92.68000030517578;;94.01000213623047;In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Eli Casdin founded Casdin Capital in 2011 and currently he serves as the hedge […]Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.;70.05000305175781;;42.02000045776367;;56.290000915527344;In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Eli Casdin founded Casdin Capital in 2011 and currently he serves as the hedge […]Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -20.18% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2022.Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.;76.33999633789062;;38.45000076293945;(Bloomberg) -- The US’s top auditor watchdog is throwing cold water on a workaround that’s been floated as a way to avoid the delisting of nearly 200 Chinese companies from American stock exchanges.Most Read from BloombergSneakerhead Accused of Running Huge Air Jordan Ponzi SchemeThis Is How China Could Hit Back Over Pelosi’s Taiwan VisitChina Warns Airlines to Avoid ‘Danger Zones’ Around TaiwanA company’s decision to leave the New York Stock Exchange or Nasdaq voluntarily might not keep the Pub;30.6299991607666;;21.489999771118164;Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.;9.0;;59.13999938964844;CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a panel titled, “So Let it Be (Re)Written - Updates in Gene Modulation” during the 2022 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 9, 2022 at 9:45 a.m. ET. A live webcast will be available in the investor section of the compThe Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday, leading Beam stock to topple.Beam Therapeutics (NASDAQ: BEAM), a pre-clinical gene-editing company, saw its shares dip by as much as 9.8% in early morning trading Monday.  Ahead of the opening bell, Beam announced that the Food and Drug Administration (FDA) placed a clinical hold on its relapsed/refractory T-cell acute lymphoblastic leukemia candidate known as BEAM-201.  Beam didn't provide a reason for the clinical hold in its early morning press release.;33.119998931884766;;51.279998779296875;;47.93000030517578;"Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today announced that Roche's Phase III IMscin001 study evaluating a subcutaneous (SC) formulation of Tecentriq® (atezolizumab) with Halozyme's ENHANZE® technology met its co-primary endpoints.";;;27.920000076293945;;15.029999732971191;;8.3100004196167;;4.849999904632568;;37.18000030517578;Most businesses don't have the special sauce that it takes to reassure shareholders in times of economic uncertainty, and the few that do are likely to have looming catalysts for higher earnings or access to cash-cow market segments that competitors don't -- or both.  In that vein, below are two biomedical growth stocks that are crushing the bear market.  Buoyed by a slew of favorable clinical trial data readouts and success with regulators, Ionis Pharmaceuticals (NASDAQ: IONS) is up by 16% this year in comparison to the market's decline of more than 13%.Fusion Pharmaceuticals Inc. (FUSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;51.369998931884766;;55.2599983215332;NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, August 9, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2022. To access the li;10.720000267028809;AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;44.93000030517578;SOUTH SAN FRANCISCO, Calif., August 02, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today shared a new white paper from Furthur Market Research1 highlighting the dramatic need for new enterprise storage technologies that can be deployed more cost effectively at massive scale with minimal power consumption, such as DNA data storage.SOUTH SAN FRANCISCO, Calif. & NEW YORK, August 02, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today received expanded Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay for the;15.010000228881836;;25.6299991607666;DaVita (DVA) records an overall solid Q2 performance owing to strength in its Other segment's revenues and uptick in total U.S. dialysis treatments.The contraction in Zimmer Biomet's (ZBH) gross margin is concerning.IDEXX's (IDXX) Q2 top-line benefits from strong sales at the CAG and Water businesses.Avantor's (AVTR) robust performance across majority of its segments drives its Q2 sales, despite business challenges.
2022-08-03;247.13999938964844;Some employers match employees' 401(k) contributions up to a limit. Learn what the average employer match is and about some of the biggest employer matches.Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) at 12:00 p.m. ET on Monday, Aug. 8, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will discuss the data being presented on LUMAKRAS® (sotorasib) in combination with immunotherapy and in combin;62.27000045776367;"Shares of Gilead Sciences (NASDAQ: GILD) are jumping today, up by 6.5% as of 11:23 a.m. ET.  Gilead reported Q2 revenue of $6.3 billion, up 1% year over year and better than what Wall Street expected.  While this reflected a 13% year-over-year decline, it was higher than the consensus estimate of $1.51 per share.By Yasin EbrahimGilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.Gilead Sciences Inc (NASDAQ: GILD) reported Q2 sales of $6.26 billion, +1% Y/Y, beating the consensus of $5.86 billion, driven by increased sales of HIV and oncology products, partially offset by decreased sales of Veklury (remdesivir) and hepatitis C virus products. Q2 product sales were $6.1 billion, flat Y/Y and excluding Veklury, increased 7% to $5.7 billion. HIV product sales increased 7% to $4.2 billion, reflecting a higher average realized price and demand for treatment and pre-exposure pThe speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.  Before we get started, let me remind you that we will be making forward-looking statements, including those related to the impact of the COVID-19 pandemic on Gilead's business; financial condition and results of operations; plans and expectations with respect to products, product candidates, corporate strategy, business and operations; financial projections and use of capital; and 2022 financial guidance, all of which involve certain assumptions, risks, and uncertainties that are beyond our control and could cause actual results to differ materially from these statements.Gilead (GILD) delivered earnings and revenue surprises of 4.64% and 6.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Gilead Sciences Inc. raised its full-year guidance on Tuesday for total product sales and adjusted earnings per share, while it cut its outlook for earnings per share.FOSTER CITY, Calif., August 02, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2022.";608.77001953125;"Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.77 per share for Q2 FY22, down 62% Y/Y, beating the $9.54 estimate. Sales decreased 44% to $2.85 billion, surpassing the analysts' consensus of $2.79 billion. Total revenues excluding REGEN-COV and Ronapreve revenues increased by 20%. No REGEN-COV sales were recorded as the company had completed its final deliveries under its agreements with the U.S. government. Q2 U.S. Eylea sales increased 14% Y/Y to $1.62 billion. The company obtained theRegeneron Pharmaceuticals Inc.  reported better-than-anticipated earnings and revenue numbers Wednesday morning.  The daily On-Balance-Volume (OBV) line made a new low for the move down, telling us that sellers of REGN are still more aggressive than buyers.  The weekly OBV line has been rolling over the past four months.Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.Pre-markets Green on Strong Earnings Numbers.Regeneron (REGN) delivered earnings and revenue surprises of 14.54% and 3.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Regeneron Pharmaceuticals Inc. topped expectations with its second-quarter financial results Wednesday morning, though revenue and profits both fell from a year earlier. The company logged net income of $852 million, or $7.47 a share, down from $3.1 billion, or $27.97 a share, in the year-earlier quarter, a decline that the company said largely reflected a lack of sales of its REGEN-COV monoclonal antibody treatment for COVID-19 during the period. On an adjusted basis, Regeneron saw earnings perRegeneron Pharmaceuticals said on Wednesday it expects demand for blockbuster eye drug Eylea to remain strong in the third quarter even in the face of emerging competition from rival drugs, sending the company's shares up nearly 8%.  Analysts earlier this year flagged competition concerns for Eylea from newly launched Roche Holding AG's Vabysmo, as both belong to the same class of drugs, called anti-VEGF.  ""Despite new competition, Eylea's share was approximately half of the anti-VEGF category, affirming its status as the gold standard,"" Regeneron Chief Executive Officer Leonard Schleifer said.(Reuters) -Regeneron Pharmaceuticals said on Wednesday it expects demand for blockbuster eye drug Eylea to remain strong in the third quarter even in the face of emerging competition from rival drugs, sending the company's shares up nearly 8%.  Analysts earlier this year flagged competition concerns for Eylea from newly launched Roche Holding AG's Vabysmo, as both belong to the same class of drugs, called anti-VEGF.  ""Despite new competition, Eylea's share was approximately half of the anti-VEGF category, affirming its status as the gold standard,"" Regeneron Chief Executive Officer Leonard Schleifer said.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2022 and provided a business update.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2 trial investigating REGN5678, a novel PSMAxCD28 costimulatory bispecific antibody, in combination with the company's PD-1 inhibitor Libtayo® (cemiplimab) in advanced metastatic castration-resistant prostate cancer (mCRPC). REGN5678 is one of Regeneron's three clinical-stage costimulatory bispecifics, all of which are designed to bridge T cells to cancer cells and augment CD28 signaliBy Peter Nurse";178.22999572753906;;223.10000610351562;Illumina is honored to be included in JUST Capital 's list of top companies in the US supporting healthy families and communities. The health of our employees, communities, and the planet is vital ...;275.0299987792969;The Dow Jones Industrial Average climbed Wednesday ahead of new economic data, while AMD stock dived 6% on a weak sales outlook.Let us look at four large drug and biotech companies, AMGN, VRTX, LLY, NVO, which are gearing up for their earnings release.Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.;213.60000610351562;;169.72000122070312;BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;174.99000549316406;;212.00999450683594;"Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are poised to post a new all-time high upon market open Wednesday.  The RNA interference (RNAi) drug specialist's stock price rose by as much as 53% in premarket action this morning.  Ahead of the opening bell, Alnylam announced that its closely watched phase 3 Apollo-B study of the RNAi therapy, patisiran, in patients with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy met its primary endpoint of change in baseline in the 6-minute walk test at 12 months compared to placebo.Alnylam Pharmaceuticals Inc. said Wednesday morning that a 12-month trial of one of its RNA-blocking drugs met its primary goal, propelling its stock up more than 50% as of 10 a.m. The Cambridge-based drugmaker said the late-stage study of patisiran showed it did significantly better than a placebo in treating patients with an increasingly common heart condition.The data seem likely to open a far larger market for a drug called Onpattro, which was responsible for $475 million of revenue last year.Shares of Alnylam Pharmaceuticals Inc. soared 57.0% in premarket trading on Wednesday after the company said its investigational RNAi therapeutic for a type of heart failure met the primary endpoint in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled study enrolled 360 adult patients in 21 countries. ""We are encouraged to see the potential of patisiran to improve the functional capacity and quality of life of patients living with this fatal, multi-system disease,"" Dr. PAlnylam Pharmaceuticals Inc (NASDAQ: ALNY) shares are rallying after upbeat data from APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. Clumps of irregular proteins called fibrils build up in the heart harder for the heart to pump blood. The trial met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo. The study also met the first secondary endpoint of change from baseline in qualityCAMBRIDGE, Mass., August 03, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo (p-value 0.0162). The study also met the first secondary endpoint o";391.8500061035156;;3.059999942779541;;88.4000015258789;;42.400001525878906;;72.54000091552734;Incyte stock tumbled below its 200-day line Tuesday after sales of the company's new skin treatment lagged second-quarter expectations.;47.59000015258789;On the call today are Kevin Conroy, the company's chairman and CEO, and Jeff Elliott, our chief financial officer and chief operating officer.  Everett Cunningham, our chief commercial officer, will also be available for questions.  Exact Sciences issued a news release earlier this afternoon detailing our second quarter financial results.Exact Sciences (EXAS) delivered earnings and revenue surprises of 12.15% and 5.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, announced today that it has entered a collaboration agreement with the West German Study Group (WSG), an international research institution that focuses on practice-changing clinical studies in breast cancer. Together, Exact Sciences and WSG plan to conduct a prospective, multicenter validation study in hormone receptor (HR)-positive, HER2-negative early breast cancer patients. The study is intended to demonstrate the abExact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $521.6 million for the second quarter ended June 30, 2022, compared to $434.8 million for the same period of 2021.Exact Sciences has the world's first $1 billion diagnostic test: Cologuard, the colon-cancer-screening system.;61.11000061035156;Moderna CEO Stéphane Bancel speaks with Yahoo Finance’s Anjalee Khemlani about earnings, COVID-19 vaccine demand, the biotech company’s pipeline, and monkeypox vaccine development.Esperion Therapeutics (ESPR) reports dismal second-quarter results, missing estimates for earnings and sales. However, shares rose on the back of ESPR's progress with its cardiovascular outcome study.The European Medicines Agency (EMA) is recommending Novavax's COVID-19 vaccine carry a warning of the possibility of two types of heart inflammation, an added burden for a shot that has so far failed to win wide uptake.  The heart conditions - myocarditis and pericarditis - should be listed as new side effects in the product information for the vaccine, Nuvaxovid, based on a small number of reported cases, the EMA said on Wednesday.The European Medicines Agency (EMA) is recommending Novavax's COVID-19 vaccine carry a warning of two inflammatory conditions of the heart, based on a small number of reported cases.  The conditions - myocarditis and pericarditis - should be listed as new side effects in the product information for the vaccine, Nuvaxovid, the EMA said on Wednesday.;71.69999694824219;;94.05999755859375;;96.11000061035156;Good day, ladies and gentlemen, thank you for standing by, and welcome to Sarepta Therapeutics second quarter 2022 earnings conference call.  Actual results could materially differ from these forward-looking statements, and any such risks can materially and adversely affect the business, the results of operations, and trading prices for Sarepta's common stock.Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?- Total revenues, which consist of net product revenues and collaboration revenues, for the second quarter 2022 totaled $233.5 million - Net product revenues for the second quarter 2022 totaled $211.2 million, a 49% increase over the same quarter of prior year - Increased full-year total revenue and net product revenue guidance to a range of $905-$920 million and $825-$840 million, respectively CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the lead;71.77999877929688;;44.36000061035156;;59.70000076293945;Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.Massachusetts-based IDRx emerged from stealth on Tuesday armed with $122 million in Series A funding to bring combination therapies to the forefront of cancer treatment.;78.58000183105469;;37.77000045776367;;32.810001373291016;;21.399999618530273;;7.940000057220459;;63.0099983215332;;33.209999084472656;;53.599998474121094;;47.47999954223633;;;;29.010000228881836;;15.449999809265137;;8.619999885559082;Shares of the clinical-stage eye disease specialist Kodiak Sciences (NASDAQ: KOD) are trending lower on higher-than-normal volume today.  Specifically, the biotech's stock price fell by as much as 10% in early morning action on Tuesday, and it was still down by a noteworthy 8.8% as of 10:52 a.m. ET.  Kodiak's stock is under pressure this morning in response to a downgrade from an analyst at Citigroup.;5.210000038146973;;41.02000045776367;;53.40999984741211;;56.20000076293945;;10.979999542236328;VANCOUVER, British Columbia & CAMBRIDGE, Mass., August 03, 2022--AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients;46.0099983215332;SOUTH SAN FRANCISCO, Calif., August 03, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Flash Memory Summit taking place August 2-4, 2022 at the Santa Clara Convention Center in Santa Clara, CA. Mr. Hellmold will present on Thursday, August 4 from 8:30-9:45;14.970000267028809;;25.31999969482422;While 28 million Americans live with alcohol use disorder, less than 8% receive treatment for their disease. Board-certified addiction specialist Sarah Akerman shares her expertise on the barriers ...
2022-08-04;246.97999572753906;"With the acquisition, the biotech company adds a newly approved drug for an autoimmune disorder to its lineup.The deal could signal more M&A activity by Bay Area biotech companies, faced with a pullout by generalist investors and the need to cut costs, ditch programs or seek deals of some sort.Shares of ChemoCentryx (NASDAQ: CCXI) skyrocketed by as much as 110% in premarket trading Thursday morning.  The company's stock bolted higher following the news that biotech heavyweight Amgen (NASDAQ: AMGN) offered $3.7 billion in cash to acquire the rare-disease specialist.  The deal represents a whopping 116% premium relative to where ChemoCentryx's shares closed on Wednesday.Amgen Inc (NASDAQ: AMGN) has agreed to acquire ChemoCentryx Inc (NASDAQ: CCXI) for $52 per share in cash, representing an enterprise value of approximately $3.7 billion. ""The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with Tavneos (avacopan), a transformative, first-in-class treatment for ANCA-associated vasculitis,"" said Robert Bradway, chairman & CEO of Amgen. U.S. sales of Tavneos in Q1 of 2022Amgen Inc. said Thursday it plans to buy ChemoCentryx Inc. for $3.7 billion in cash. The deal will give Amgen access to Tavneos, a treatment for ANCA-associated vasculitis that received approval from the Food and Drug Administration in October. ""The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with Tavneos, a transformative, first-in-class treatment for ANCA-associated vasculitis,"" Amgen CEO Robert(Reuters) -Amgen Inc on Thursday agreed to buy ChemoCentryx Inc for $3.7 billion to gain access to a potential blockbuster treatment for inflammatory disorders and beat quarterly revenue estimates on demand for its bone disease drug.  The deal, announced before markets opened, will also hand the company control of at least two experimental therapies for immune disorders, a field in the spotlight following AstraZeneca's 2020 purchase of Alexion Pharmaceuticals for $39 billion.  Amgen has been facing stiff competition for its top-selling arthritis drug, Enbrel, from newer branded treatments and patents for the therapy are expected to expire in 2029.Amgen Inc on Thursday agreed to buy ChemoCentryx Inc for $3.7 billion to gain access to a potential blockbuster treatment for inflammatory disorders and beat quarterly revenue estimates on demand for its bone disease drug.  The deal, announced before markets opened, will also hand the company control of at least two experimental therapies for immune disorders, a field in the spotlight following AstraZeneca's 2020 purchase of Alexion Pharmaceuticals for $39 billion.  Amgen has been facing stiff competition for its top-selling arthritis drug, Enbrel, from newer branded treatments and patents for the therapy are expected to expire in 2029.The all-cash deal would give biotech Amgen a company launching a new drug for a rare immune-system disease.Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.Amgen (NASDAQ: AMGN) today announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately. Dr. Drake will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Governance and Nominating Committee. Following the appointment of Dr. Drake, the Board will be composed of 13 directors, 12 of whom are independent.";61.90999984741211;By Joydeep GangulyEvery investor in Gilead Sciences, Inc. ( NASDAQ:GILD ) should be aware of the most powerful shareholder groups...FOSTER CITY, Calif. & OXFORD, England, August 04, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.The pandemic isn’t over. These stocks could pop again.Gilead now expects $2.5 billion from its Covid treatment, Veklury, vs. prior views for $2 billion. And GILD stock rocketed Wednesday.In this article, we will take a look at the top 10 gainers on Wednesday. If you want to see some more stocks rallying today, go directly to Top 5 Gainers on Wednesday. The three key U.S. indices, including S&P 500, Dow Jones Industrial Average and Nasdaq Composite, rose on Wednesday morning following better-than-expected Q2 […]By Yasin Ebrahim;614.9600219726562;Companies in The News Are: MRNA, REGN, HZNP, EXCRegeneron Pharmaceuticals outplayed its competition in eye diseases Wednesday, reporting Eylea sales that beat, leading REGN stock to soar.;180.44000244140625;;225.27999877929688;SAN FRANCISCO, August 04, 2022--Illumina Ventures, a healthcare-focused venture firm partnered with Illumina, announces the addition of four new members to its European team.;274.8500061035156;The Dow Jones Industrial Average fell Thursday after jobless claims data. Next, investors await Friday's highly anticipated jobs report.;217.3000030517578;"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, ""Biogen"") announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401) and the modeling simulation of the impact of ApoE4 genotype on the incidence of amyloid-related imaging abnormalities – edema/effusion (ARIA-E) – in subjects treated with lecanemab, an investigational anti-amyloid beta (Aβ)";191.0800018310547;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, August 04, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today reported financial results for the second quarter of 2022, recent business highlights, and anticipated upcoming milestones.";175.86000061035156;From the FDA crackdown on Altria Group Inc.’s JUUL to RH’s recent decision to cut guidance due to a weak housing market outlook, experts can often make smart predictions about […];224.0500030517578;"Alnylam stock hit a record high Wednesday after the company reported a ""clean hit"" for its Pfizer rival cardiomyopathy drug.The biotech said one of its drugs helped improve heart-disease patients’ capacity for physical exertion in a study, opening the door to an expanded regulatory approval that could add billions of dollars in sales.";390.8999938964844;Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ended June 30, 2022.Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2022. The quarterly dividend will be payable August 29, 2022, to all common shareholders of record on August 15, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis.Bio-Teche Corporation (NASDAQ: TECH) today announced Chuck Kummeth's planned two-year transition from his position as Bio-Techne's Chief Executive Officer (CEO) effective June 30, 2024. The Company's Board of Directors has begun its search for Mr. Kummeth's replacement, evaluating both internal and external candidates to assume the CEO position upon Kummeth's retirement at the end of its fiscal 2024. It is anticipated that Mr. Kummeth will continue to serve on Bio-Techne's Board of Directors upo;3.009999990463257;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Kathy Hopinkah Hannan, PhD, CPA has joined its Board of Directors, effective August 2, 2022. Dr. Hannan brings over thirty years of experience as a senior C-Suite executive, corporate advisor, independent board director and strategist leading significant operations and high priority initiatives.;92.9800033569336;"BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Q2 sales reached $533.8 million, up 6% Y/Y, beating the consensus of $521.47 million. BioMarin said the increase was achieved ""despite continued erosion of the U.S. Kuvan market."" Total revenues grew 13% Y/Y, excluding Kuvan. The company reported EPS of $0.15 compared to $0.07 a year ago, beating the consensus of $0.11. Voxzogo for achondroplasia (dwarfism) reported sales of $34.4 million. An estimated 446 children were being treated with commercial VBiomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (BioMarin or the Company) today announced financial results for the second quarter ended June 30, 2022.";42.560001373291016;;71.91000366210938;;49.369998931884766;Cancer diagnostics powerhouse Exact Sciences  appears on track to easily beat full-year 2022 revenue guidance.  Exact Sciences is focused on profitable growth, rather than growth for the sake of growth.  Exact Sciences easily beat its own revenue guidance for the quarter.June quarter sales were $522 million, representing 26% growth if one backs out last year's sales bump from Covid-19 testsExact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.;61.93000030517578;;65.43000030517578;"Shares of Intellia Therapeutics (NASDAQ: NTLA) are sinking today, down by 13.3% as of 11:01 a.m. ET.  The decline came after the biotech company provided its second-quarter update earlier in the morning.  This result was slightly worse than the consensus estimate for net loss of $1.31 per share.Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -1.53% and 21.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Completed dose-escalation portion of the ongoing Phase 1 study of NTLA-2001 in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy; expects to present interim safety and serum TTR reduction data in 2H 2022 Presented updated interim data from the dose-escalation portion of the polyneuropathy arm, establishing deep reductions of disease-causing protein were sustained through 12 months following a single dose of NTLA-2001 Plans to present interim data for second in vivo CRISPR clinic";95.93000030517578;;101.44999694824219;Sarepta Therapeutics Inc (NASDAQ: SRPT) reported above-consensus 2Q FY22 product sales of $211 million and provided more details on the path forward for SRP-9001 gene therapy for Duchenne muscular dystrophy. Last week, the company announced that it would seek accelerated approval for gene therapy. RBC Capital continues to see substantial share appreciation potential even on approval following Phase 3. The potential for accelerated approval provides additional upside optionality to expedite the dStrong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.;77.9000015258789;Mirati (MRTX) delivered earnings and revenue surprises of 9.92% and 143.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter of 2022 and recent corporate updates.;46.130001068115234;;64.72000122070312;;78.91000366210938;;40.83000183105469;;32.54999923706055;"FATE reports a narrower loss and higher collaboration revenues in the second quarter.Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL FT516 RMAT Meeting Scheduled with FDA for 3Q22 to Discuss Registrational Pathways for R/R BCL First Patient Treated with FT536 iPSC-derived CAR MICA/B NK Cell Product Candidate for Solid Tumors Commercial Option Exercised by Janssen for First Antigen Program; First IND Submission for CAR NK Cell Collaboration Product";21.440000534057617;;9.979999542236328;BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 11.96% and 146.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?- Reported positive interim Phase 2 data for infigratinib in achondroplasia demonstrating a mean increase in annualized height velocity (AHV) of 1.52 cm/year among all Cohort 4 children 5 years of age and older, and announced addition of a 5th cohort to the trial - Reported positive Phase 2 data for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) and announced design of the Phase 3 pivotal study, which is expected to begin later this year - Selected a next-generation KRAS G12C dual in;62.880001068115234;Flagship Pioneering spinout Axcella Therapeutics Inc. has promising results from a small Phase 2a study investigating a drug for long Covid.;33.400001525878906;;55.77000045776367;;45.38999938964844;;;;29.25;;15.520000457763672;;9.15999984741211;;5.809999942779541;"The consensus price target hints at a 261.4% upside potential for Pacific Biosciences (PACB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.With me today are Christian Henry, president and chief executive officer; and Susan Kim, chief financial officer.  Before we begin, I would like to remind you that on today's call, we will be making forward-looking statements, including statements regarding predictions, progress, estimates, plans, expectations, intentions, guidance, and others, including expectations with respect to collaborations, cash flow, and product and technology launches.  You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results.Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2022.";43.290000915527344;For many investors, the main point of stock picking is to generate higher returns than the overall market. But its...;51.40999984741211;Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?NEW HAVEN, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “This is an exciting time at Arvinas as we remain on track to initiate two pivotal programs with ARV-471 in metastatic breast cancer in the second half of this year, have a clear development pathway fo;58.77000045776367;;11.329999923706055;Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;46.83000183105469;;15.619999885559082;;25.899999618530273;Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.McKesson's (MCK) fiscal first-quarter 2023 results benefit from segmental growth.Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
2022-08-05;246.25;Amgen (AMGN) beats Q2 estimates for earnings and sales. It offers to buy ChemoCentryx (CCXI) for $3.7 billion.Amgen Inc (NASDAQ: AMGN) posted Q2 revenues of $6.59 billion, +1% Y/Y, slightly beating the consensus of $6.53 billion. The increase resulted from a 3% growth in global product sales partially offset by lower Other Revenue from COVID-19 manufacturing collaboration. Unit volumes grew 10%, offset by a 6% lower net selling price and a 2% negative impact from foreign exchange. Adjusted EPS increased from $1.77 to $4.65, ahead of the consensus of $4.40. Yesterday, Amgen agreed to acquire ChemoCentryxThe indexes were quiet before the July jobs report tests the Fed's soft landing. Tesla shareholders OK'd a 3-for-1 stock split.Included in the deal is Tavneos, which is expected to generate $1 billion in revenue by 2027Amgen (AMGN) delivered earnings and revenue surprises of 5.68% and 0.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Amgen Inc. has agreed to buy ChemoCentryx Inc., a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $3.7 billion in cash.  Thousand Oaks, California-based Amgen (Nasdaq: AMGN) said it will pay $52 per share for ChemoCentryx (Nasdaq: CCXI), more than double the company’s closing stock price of $24.11 a share on Wednesday.Amgen agreed to buy ChemoCentryx for $3.7 billion on Thursday, leading CCXI stock to rocket by a triple-digit percentage.Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include:;61.09000015258789;Gilead Sciences Inc (NASDAQ: GILD) has agreed to acquire MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors. Gilead will pay approximately $405 million in cash. The acquisition will provide Gilead with MiroBio's proprietary discovery platform and the entire portfolio of immune inhibitory receptor agonists. Related: Gilead Sciences' Q2 Beats Street View On Robust Oncology, HIV Product Sales. MiroBio's;613.6099853515625;Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.;183.11000061035156;;223.77000427246094;New laboratory automation technology will advance marine biomedical research, preparing students for biotech workforceRecently, Zacks.com users have been paying close attention to Illumina (ILMN). This makes it worthwhile to examine what the stock has in store.;288.0299987792969;The indexes were quiet before the July jobs report tests the Fed's soft landing. Tesla shareholders OK'd a 3-for-1 stock split.Image source: The Motley Fool.  Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2022 Earnings CallAug 04, 2022, 4:30 p.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  OperatorGood day, and welcome to the Vertex Pharmaceuticals second quarter 2022 earnings call.Vertex (VRTX) delivered earnings and revenue surprises of 3.45% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?BOSTON, August 04, 2022--Vertex Reports Second Quarter 2022 Financial ResultsIn this piece, we will take a look at the twelve best healthcare stocks to buy now. If you want to skip the details and head on to the top stocks in this list, then take a look at 5 Best Healthcare Stocks To Buy Now. Healthcare stocks are proving to be resilient in the […];218.1999969482422;Trying to find a good bargain seems tough these days, but there are certainly opportunities for savvy investors. Looking for cheap blue-chip stocks to buy before they rebound is a smart strategy right now. As anyone that has been grocery shopping, to the gas pump or out for a night on the town can attest, the world has gotten a great deal more expensive in 2022 due to price hikes inexorably linked to Covid-19 and the Russia-Ukraine war. But that’s just on Main Street. Within the financial market;194.47000122070312;;175.80999755859375;;218.5800018310547;A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple.;382.9700012207031;;3.069999933242798;;95.81999969482422;;42.619998931884766;;72.16000366210938;;47.04999923706055;;60.27000045776367;;63.31999969482422;A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple.Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.;104.04000091552734;"Tucked in its Q2 earning release, Neurocrine Biosciences Inc (NASDAQ: NBIX) said that in August, the Phase 2a study of NBI-827104 in essential tremor did not meet specified endpoints. Based on the totality of data from the Phase 2a study, at this time, the company will not proceed further with the clinical development of NBI-827104 in essential tremors. The FDA has signed off Neurocrine's Investigational New Drug (IND) Application for a Phase 2 trial of NBI-1117568 for schizophrenia. The achieveThe indexes were quiet before the July jobs report tests the Fed's soft landing. Tesla shareholders OK'd a 3-for-1 stock split.With me are Kevin Gorman, our chief executive officer; Matthew Abernethy, our chief financial officer; Eiry Roberts, our chief medical officer; Eric Benevich, our chief commercial officer; and Kyle Gano, our chief business development and strategy officer.  During a call, we will be making forward-looking statements.Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia Clinical development milestone triggers payment of US$30 million to Sosei Heptares from NeurocrineNBI-1117568 is the most advanced candidate under the multi-program muscarinic receptor agonist collaboration between Sosei Heptares and Neurocrine TOKYO and CAMBRIDGE, United Kingdom, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the CoNeurocrine (NBIX) delivered earnings and revenue surprises of -132.14% and 11.03%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2022 and raised net sales guidance for INGREZZA in 2022.Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.";106.0199966430664;;86.55999755859375;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 56 new employees with a grant date of August 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).Mirati Therapeutics' (MRTX) Q2 earnings and sales beat the mark. The company plans to start early-stage clinical studies for a SOS1 inhibitor by year-end.;45.959999084472656;"Thank you for joining us today to discuss Arrowhead's results for its fiscal 2022 third quarter ended June 30, 2022.  With us today from management are president and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr.  Javier San Martin, our chief medical officer, who will provide an update on our mid-and later-stage clinical pipeline; Dr. James Hamilton, our senior vice president of Discovery and Translational Medicine, who will provide an update on our earlier stage programs; and Ken Myszkowski, our chief financial officer, who will give a review of the financials.PASADENA, Calif., August 04, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022. The company is hosting a conference call today, August 4, 2022, at 4:30 p.m. ET to discuss the results.";68.13999938964844;Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective August 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 29,359 shares of its common stock and an aggregate of 14,675 restricted stock units (RSUs) to fourteen new employees under Blueprint Medicines' 2020 Inducement Pl;81.4000015258789;;45.27000045776367;;33.41999816894531;;21.520000457763672;;11.1899995803833;;63.43000030517578;Faced with conflicting signs from all sides of the biotech economy, executives are left sorting out how to plan for growth.;35.75;;55.599998474121094;;45.130001068115234;;;;30.170000076293945;;14.989999771118164;;9.739999771118164;;6.059999942779541;PacBio (NASDAQ: PACB) announced today that it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.;45.70000076293945;The IBD SmartSelect Composite Rating for Ionis Pharmaceuticals rose from 94 to 96 Friday.  The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.  Ionis Pharmaceuticals is currently forming a cup without handle, with a 44.52 entry.Five companies are slated to beat earnings estimates next week. These are: TTWO, IONS, CELH, LMND and GO.;55.43000030517578;;59.9900016784668;;11.319999694824219;;52.77000045776367;Twist Bioscience Corporation (NASDAQ: TWST) has reported a 60% Y/Y increase in its Q3 FY22 revenues to $56.1 million, beating the Wall Street estimate of $51.45. The company shipped products to approximately 1,900 customers versus about 1,800 a year ago. Twist Bioscience shipped approximately 163,000 genes during the quarter, compared with about 107,000 in Q3 FY21. The company received total orders of $59.7 million compared to $39.1 million a year ago. The company posted an EPS loss of $(1.08) pTwist Bioscience (TWST) delivered earnings and revenue surprises of 16.92% and 9.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?SOUTH SAN FRANCISCO, Calif., August 05, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2022 ended June 30, 2022.;16.440000534057617;The FDA has issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals Inc (NASDAQ: ACAD) regarding its supplemental marketing application for pimavanserin in hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The CRL recommended that Acadia conduct an additional trial in ADP. The advisory committee voted 9-3 that Acadia's pimavanserin doesn't appear effective in treating ADP patients. While the FDA stated that Study 019 demonstrated a statistically significThe U.S. Food and Drug Administration declined to approve expanded use of Acadia Pharmaceuticals Inc's antipsychotic drug for treating psychosis related to Alzheimer's disease, the company said on Thursday.  The health regulator concluded there were limitations in the interpretability of Acadia's antipsychotic drug study and an additional study would be required, according to the company.  The U.S. regulator's decision comes roughly a month after its panel of outside advisors voted 9-3 that available data does not support conclusion that the drug, pimavanserin, was effective for treatment of hallucinations and delusions in Alzheimer's disease.SAN DIEGO, August 05, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).;25.770000457763672;bluebird (BLUE) posts a narrower-than-expected loss in the second quarter. However, sales miss estimates.Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.LHC Group's (LHCG) second-quarter results benefit from organic growth in hospice admissions. However, home health admissions decline organically.Eli Lilly's (LLY) earnings and sales miss second-quarter estimates. The company lowers its earnings outlook for 2022. The stock falls in pre-market trading.PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.The majority of BD's (BDX) core units witness strong revenue growth in the fiscal third quarter.Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
2022-08-08;247.2899932861328;Amgen Inc (NASDAQ: AMGN) announced new data sets from its thoracic oncology portfolio, including new combination study results, including Lumakras (sotorasib) with pembrolizumab or atezolizumab and Lumakras with RMC-4630. Treatment with Lumakras alongside either Merck & Co Inc’s (NYSE: MRK) Keytruda (pembrolizumab) or Roche Holdings AG’s (OTC: RHHBY) Tecentriq in KRAS G12C-mutated non-small cell lung cancer led to a marked increase in liver toxicities. There was a roughly 50% rate of severe live;61.599998474121094;;630.6300048828125;Kodiak Sciences Inc's (NASDAQ: KOD) BEACON Phase 3 study of tarcocimab tedromer met the primary endpoint of non-inferior change from baseline in visual acuity in macular edema due to retinal vein occlusion (RVO). Tarcocimab also demonstrated robust anatomic responses and a favorable safety profile. After two initial monthly loading doses, tarcocimab was dosed every two months compared to consistent monthly dosing for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept). The non-inf;169.3000030517578;;222.97999572753906;;293.95001220703125;It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Vertex Pharmaceuticals is showing is showing green check marks across the board, and today we will look at a bullish option strategy.;217.55999755859375;;202.24000549316406;In this article, we will take a look at the 10 healthcare stocks making moves after earnings. If you want to see some more healthcare companies moving on quarterly results, go directly to 5 Healthcare Stocks Making Moves After Earnings. The Healthcare sector is usually considered defensive. That’s because pharmaceutical companies, hospitals, medical device makers […];178.3300018310547;;230.74000549316406;Analysts said the results were strong enough that the drug could be the go-to treatment once it is approved.;375.1499938964844;;3.240000009536743;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2022, on Monday, August 15, 2022, beginning at 4:30 p.m. ET.;95.69999694824219;;43.4900016784668;;74.0;;46.810001373291016;;57.25;;63.4900016784668;;104.58999633789062;;111.47000122070312;-Following internal corroboration of published results on the MyoAAV platform, Sarepta secures exclusive license for Duchenne muscular dystrophy, plus four additional neuromuscular and cardiac indications -The MyoAAV platform is a potential breakthrough in genetic medicine delivery, with early research showing significantly greater gene expression at lower doses compared to natural serotype capsids CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the;86.69999694824219;Mirati Therapeutics, Inc. ( NASDAQ:MRTX ) shareholders will have a reason to smile today, with the analysts making...;47.02000045776367;;71.08999633789062;;81.38999938964844;"Gene editing company CRISPR Therapeutics  made a basing pattern in the January-July time frame and the indicators support the potential for further price gains.  In this daily bar chart of CRSP, below, we can see that prices declined to a low in May but the base pattern looks like it has been evolving from February.  The daily On-Balance-Volume (OBV) line bottomed in February and turned higher in March telling us of a shift from aggressive selling to aggressive buying.CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -7.62% and 96.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA); discussions with the U.S. Food and Drug Administration (FDA) ongoing- -Initiated two additional Phase 3 clinical trials of exa-cel for the treatment of transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) in pediatric pati";47.08000183105469;Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary endpoints, demonstrating statistically significant reductions in positive and negative symptoms of schizophrenia, as measured by the PANSS positive, PANSS negative and PANSS negative Marder factor subscales KarXT was generally well tolerated, with a side effect profile substantially consistent with prior tr;34.13999938964844;Small-cap stocks with lower market capitalizations ranging from $300 million to $2 billion have taken quite a hit since January. These stocks typically belong to smaller companies with massive long-term growth potential. However, they are sensitive to rising inflation and interest rate hikes due to tighter profits and weak balance sheets. Therefore these stocks have taken a bigger hit compared to the broader market. The Russell 2000’s performance is a testament to that, so it’s best to pick up s;21.549999237060547;Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.;11.930000305175781;;63.689998626708984;;37.25;;52.630001068115234;;45.040000915527344;;;;30.059999465942383;;14.949999809265137;;11.109999656677246;"Kodiak Sciences Inc's (NASDAQ: KOD) BEACON Phase 3 study of tarcocimab tedromer met the primary endpoint of non-inferior change from baseline in visual acuity in macular edema due to retinal vein occlusion (RVO). Tarcocimab also demonstrated robust anatomic responses and a favorable safety profile. After two initial monthly loading doses, tarcocimab was dosed every two months compared to consistent monthly dosing for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept). The non-infKodiak Sciences Inc. (Nasdaq: KOD) today announced that its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab), its novel antibody biopolymer conjugate, met the primary endpoint of non-inferior change from baseline in visual acuity at week 24 compared to aflibercept in patients with macular edema due to retinal vein occlusion. Tarcocimab also demonstrated robust anatomic responses and a favorable safety profile. After two initial monthly loading doses, tarcocimab was dosed every t";6.900000095367432;Market forces rained on the parade of Pacific Biosciences of California, Inc. ( NASDAQ:PACB ) shareholders today, when...;45.709999084472656;Take-Two Interactive Software, Ionis Pharmaceuticals, Celsius Holdings, Grocery Outlet Holding and Lemonade are part of Zacks top Analyst Blog.Ionis Pharmaceuticals (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;55.83000183105469;;58.849998474121094;;11.760000228881836;;56.560001373291016;In this article, we will take a look at the 10 healthcare stocks making moves after earnings. If you want to see some more healthcare companies moving on quarterly results, go directly to 5 Healthcare Stocks Making Moves After Earnings. The Healthcare sector is usually considered defensive. That’s because pharmaceutical companies, hospitals, medical device makers […];16.6200008392334;;25.75;According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.
2022-08-09;248.36000061035156;Amgen (NASDAQ: AMGN) today announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the safety and efficacy of investigational tarlatamab, a potential first-in-class half-life extended bispecific T-cell engager (HLE BiTE®) molecule targeting delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). Updated data from the ongoing Phase 1 study were presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World;62.0;Drugmaker Gilead Sciences plans to announce on Tuesday that it will provide up to $5 million in grants to help a coalition of LGBTQ+ and human rights advocacy groups craft public health responses to monkeypox outbreaks, the company said.  The World Health Organization and the United States have declared monkeypox a public health emergency.  The Human Rights Campaign (HRC), GLAAD, the National Black Justice Coalition, and the National Center for Lesbian Rights are each receiving $350,000 from Gilead for public education toward preventing and treating the virus.ClearBridge Investments, an investment management company, released its “ClearBridge Sustainability Leaders Strategy” second quarter 2022 investor letter. A copy of the same can be downloaded here. The fund’s portfolio outperformed the Russell 3000 benchmark Index in the second quarter of 2022. Stock selection and sector allocation contributed to the fund’s performance. For more information on […];622.1500244140625;;157.2100067138672;;214.8000030517578;Each summer, our Illumina interns put our culture of giving back into action by completing a social impact project. The application of skills-based volunteering is just another way we aim to embed ...;298.8299865722656;The Dow Jones Industrial Average fell Tuesday ahead of Wednesday's key inflation report. Vaccine maker Novavax crashed on earnings results.CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.Dow Jones futures were lower after Monday's stock market action ahead of Wednesday's inflation report — the consumer price index.;217.58999633789062;Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.Biogen Inc. is looking to exit one of its buildings in Kendall Square and to sublease a sizable chunk of its space in Weston. The moves come as the Cambridge-based biotech company cuts costs amid struggles related to its Alzheimer's drug.;197.6199951171875;"CAMBRIDGE, U.S. & BASEL, Switzerland & BEIJING, August 09, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the global Phase 3 RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior Overall Survival (OS) versus sorafenib as a first-line treatment in adult patients with unresectable he";175.60000610351562;;223.3699951171875;;361.1199951171875;;3.130000114440918;;95.69999694824219;ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2022 investor letter. A copy of the same can be downloaded here. The second quarter was difficult for growth funds, and the fund underperformed the benchmark index. Only the consumer staples sector contributed positively to the fund’s performance. To know […];44.939998626708984;"10x Genomics (TXG) delivered earnings and revenue surprises of -42.50% and 0.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?""Lingering macro headwinds"" have slowed international orders for a company that books about 45% of its revenue from outside the United States.10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2022.";73.7300033569336;;43.04999923706055;;40.279998779296875;;60.40999984741211;;107.66000366210938;;109.0999984741211;Sarepta Therapeutics Inc (NASDAQ: SRPT) will license a new group of adeno-associated viruses from the institute for undisclosed upfront payment and milestone promises. Under the agreement, Sarepta will have the rights to five neuromuscular and cardiac indications, including Duchenne muscular dystrophy. According to Sarepta, the deal covers the MyoAAV program that aims to deliver more efficient gene therapies and at lower doses using modified capsids. Also Read: Sarepta's Duchenne Gene Therapy Up;82.08999633789062;;45.45000076293945;By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO-MUC5AC, which are the company’s investigational candidates designed as potential treatments;68.16999816894531;Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...;75.12999725341797;CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.Shareholders in CRISPR Therapeutics AG ( NASDAQ:CRSP ) may be thrilled to learn that the analysts have just delivered a...;45.209999084472656;Zai Lab (ZLAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;32.84000015258789;TCR-CAR+ iPSC-derived CD8αβ T Cells Induced Complete and Durable Responses In Vivo in Systemic Leukemia Model Cell-surface Markers, Gene Transcription Profile, and In Vivo Anti-tumor Activity of TCR-CAR+ iPSC-derived CD8αβ T Cells Compared Favorably with Healthy-donor Peripheral Blood CAR T Cells Phase 1 Study Ongoing of First-ever iPSC-derived T-cell Product Candidate FT819 for Off-the-shelf Treatment of Patients with Relapsed / Refractory B-cell Malignancies SAN DIEGO, Aug. 09, 2022 (GLOBE NEW;21.059999465942383;;11.09000015258789;;60.959999084472656;"Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders will doubtless be very grateful to see the share price up 78% in...Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 On-track for Second Half of 2022 BEAM-201 IND Submitted to FDA; Currently on Clinical Hold BEAM-102 IND Submission and BEAM-301 IND-enabling Studies On-track for Second Half of 2022 John Lo, Ph.D., Appointed as Chief Commercial Officer Ended Second Quarter 2022 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities to Support Advancement of Broad Precision Genetic Medicines Portfolio CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE";37.40999984741211;Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2022, and provided business highlights. “The Phase 1 study of DNL919 (ATV:TREM2) is now underway, making this our third BBB Transport Vehicle (TV)-enabled program,;51.369998931884766;;43.33000183105469;;;;28.84000015258789;;14.680000305175781;;10.920000076293945;;6.659999847412109;;44.2599983215332;Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -21.31% and 9.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the second quarter of 2022 and recent business achievements.;55.79999923706055;;56.33000183105469;Intra-Cellular (ITCI) delivered earnings and revenue surprises of -16.46% and 12.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase CAPLYTA net product revenues for the second quarter 2022 were $55.1 million, representing a 190% increase over the same period in 2021 and a 58% increase over the first quarter 2022 Second quarter 2022 CAPLYTA new and total prescriptions increased 225% and 191%, respectively, versus the same period in 2021 Second quarter 2022 CAPLYTA new and total pre;11.109999656677246;;48.529998779296875;;16.219999313354492;Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?SAN DIEGO, August 08, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.;25.600000381469727;Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and expansion in gross margin.Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.DENTSPLY SIRONA's (XRAY) preliminary second-quarter 2022 results reflect the normalizing business, aided by product launches and pricing adjustments. Shares rise.
2022-08-10;252.08999633789062;Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is the latest sign that cash-flush drug makers are ready to make some deals.;63.13999938964844;If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.;641.489990234375;;160.9199981689453;;227.3000030517578;Al Jalila Children’s Specialty Hospital is on a mission to diagnose critically ill infants—and serve underrepresented patient populations;295.7699890136719;The Dow Jones Industrial Average surged 460 points on cool CPI inflation data. Elon Musk sold nearly $7 billion worth of Tesla stock.Among the top stocks to buy and watch, biotech leader Vertex Pharmaceuticals is in a buy area following last week's strong earnings results.Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) non-opioid painkiller. The company scrapped the ACP-044 program after evaluating the final phase 2 data on bunion removal patients. Initial data announced in April showed that the primary endpoint of pain intensity was not met. Rival Vertex boasted a mid-phase win for a similar candidate. Acadia has also discontinued ACP-319, which w;221.0399932861328;Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.Apple is growing its Triangle footprint by filling an entire office building in Durham as the tech giant awaits the build out of a technology hub expected to one day house 3,000 employees in Research Triangle Park.;191.3800048828125;;175.64999389648438;;232.0;;379.95001220703125;Bio-Techne CEO Charles Kummeth has started a two-year transition plan that will see him leave the top executive role, but maintain his position on the company’s board of directors, the manufacturer of biotechnology products said.;3.130000114440918;;96.0;;46.939998626708984;;74.12999725341797;;45.130001068115234;;41.36000061035156;A more than 30% peak decline in the Nasdaq Composite is allowing investors to buy these phenomenal stocks at bargain-basement prices.(Bloomberg) -- The selloff in Novavax Inc. shares deepened on Tuesday, to erase $17 billion in market value from last year’s record high, after the Covid-19 vaccine maker slashed its revenue guidance.Most Read from BloombergMusk Sells $6.9 Billion of Tesla to Avoid Twitter Fire SaleUK Plans for Blackouts in January in Emergency Energy PlanTrump Under Intense Legal Scrutiny After FBI Searches Mar-a-LagoRussia Is Scouring the Globe for Weapons to Use Against UkraineTrump Search Was Unprecedented,Novavax widely missed second-quarter forecasts Tuesday, leading the Covid vaccine maker to slash its guidance and NVAX stock to crash.The Nasdaq closed down on Tuesday after a dismal forecast from Micron Technology pulled chip makers and tech stocks lower as investors await U.S. inflation data that could lead the Federal Reserve to further tighten its efforts to curb inflation.  High inflation numbers on Wednesday, following last week's blowout jobs report, would likely stop the Fed from easing interest rates hikes anytime soon and halt the market's rally off mid-June lows.Pfizer is pursuing M&A with its profits from selling Covid-19 vaccines. Rival Moderna is developing its own pipeline of drugs.;66.54000091552734;Celebrations may be in order for Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders, with the analysts delivering...;106.79000091552734;;113.06999969482422;;83.05000305175781;;46.959999084472656;;70.9800033569336;;78.87000274658203;Barclays says that CRISPR Therapeutics AG's (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the goal of on-track regulatory submissions for CTX001 in SCD/BT by YE22 and CTA submission for VCTX211 (next generation) for Type 1 Diabetes (T1D) in 2H22. Though investors are focused on BLA submission for CTX001, the analyst expects a high probability of approval even with some delay. But Barclays has moved to the sidel;44.72999954223633;"Key pipeline milestones achieved including the BLA acceptance of efgartigimod by China’s NMPA and positive topline results for the KarXT Phase 3 EMERGENT-2 trial Continued revenue growth led by ZEJULA; strong balance sheet with a cash position of $1.26 billion Company to host a conference call and webcast on August 10, 2022, at 8:00 a.m. ET SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative,";32.41999816894531;;19.5;"Thank you, Sarah, and thank you all for joining us for the Exelixis second quarter 2022 financial results conference call.  Joining me on today's call are Mike Morrissey, our president and CEO; Chris Senner, our chief financial officer; P.J. Haley, our executive vice president of commercial; Vicki Goodman, our chief medical officer; and Peter Lamb, our chief scientific officer, who will together review our progress for the second quarter 2022 ended June 30th, 2022.Exelixis (EXEL) delivered earnings and revenue surprises of 10% and 7.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?ALAMEDA, Calif., August 09, 2022--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.";11.989999771118164;- NULIBRY is the first and only approved therapy in the United States (U.S.) and in Israel to treat patients with MoCD Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years - NULIBRY received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in July 2022 recommending approval by the European Commission (EC) in the European Union (EU) - NULIBRY was approved by the U.SCelebrations may be in order for BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) shareholders, with the analysts delivering a...;65.7300033569336;;38.529998779296875;;52.15999984741211;;44.099998474121094;"Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q2 revenue of $152.4 million, +12% Y/Y, surpassing the consensus of $138.78 million. The increase was primarily driven by an increase in royalty revenue primarily attributable to subcutaneous Darzalex (daratumumab) and the addition of product sales due to the Antares Pharma acquisition. Revenue for Q2 included $85.3 million in royalties. Adjusted EPS of $0.53 was down from $0.66 a year ago and better than the consensus of $0.50. The Company reporHalozyme Therapeutics (HALO) delivered earnings and revenue surprises of 6% and 15.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today reported its financial and operating results for the second quarter ended June 30, 2022 and provided an update on its full year 2022 financial guidance and recent corporate activities.";;;30.649999618530273;In its Q2 earnings release, Vir Biotechnology Inc (NASDAQ: VIR) and its partner GSK plc (NYSE: GSK) said that they do not plan to file a marketing application for sotrovimab for COVID-19 at this time. The company also said it does not intend to pursue the US-based Phase 3 COMET-STAR prophylaxis trial, citing evolving COVID-19 landscape and FDA discussions. Discussions with the FDA remain ongoing regarding the appropriate path forward for sotrovimab in the U.S. Related: Why Did FDA Pull AuthorizaVir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -241.18% and 129.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing operations and liabilities for up to five years – – Company provides update on COVID-19 development program and outlines multiple anticipated value drivers from its robust pipeline – SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the seco;15.25;;12.5;Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases.Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended June 30, 2022.;7.690000057220459;;46.11000061035156;Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.Ionis Pharmaceuticals kept its 2022 outlook intact Tuesday despite a broad second-quarter miss. But IONS stock tumbled.;57.9900016784668;;59.189998626708984;;13.34000015258789;Image source: The Motley Fool.  AbCellera Biologics Inc. (NASDAQ: ABCL)Q2 2022 Earnings CallAug 09, 2022, 5:00 p.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  OperatorGood afternoon, and welcome to AbCellera's second quarter 2022 business update and conference call.AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -150% and 40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?VANCOUVER, British Columbia, August 09, 2022--AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the second quarter of 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.;52.63999938964844;;16.149999618530273;Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) non-opioid painkiller. The company scrapped the ACP-044 program after evaluating the final phase 2 data on bunion removal patients. Initial data announced in April showed that the primary endpoint of pain intensity was not met. Rival Vertex boasted a mid-phase win for a similar candidate. Acadia has also discontinued ACP-319, which w;25.649999618530273;CONMED (CNMD) acquires privately-held Biorez, Inc. for $85 million. The deal is set to boost CONMED's sports medicine portfolio with the addition of Biorez's proprietary BioBrace Implant technology.Perrigo (PRGO) delivers mixed second-quarter 2022 results. Higher demand for cough/cold products continues during the reported quarter. Unfavorable currency movements hurt sales and earnings.Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
2022-08-11;248.35000610351562;Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.;62.45000076293945;When Pip Petersen heard the name of his team announced as the winner of Gilead’s Hacks for HIV Prevention contest, his jaw dropped open in surprise. Pip, a PhD student in physics at Case Western Re...;623.9000244140625;Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...;158.58999633789062;;227.44000244140625;Illumina, Inc. ( NASDAQ:ILMN ) shareholders should be happy to see the share price up 19% in the last month. But that's...Just in its latest quarter, ILMN registered a solid 23% bottom-line beat.;292.1600036621094;The Dow Jones Industrial Average rallied Thursday after a key inflation report. Disney stock soared almost 10% on strong earnings results.There's a lot in this legislation, including a provision that will allow Medicare to directly negotiate the prices of the costliest drugs.  The U.S. House of Representatives is expected to vote in favor of the bill later this week.  President Joe Biden has already stated that he's ready to sign it into law.;218.22000122070312;;196.63999938964844;;174.0399932861328;;229.38999938964844;Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce;374.42999267578125;;3.4000000953674316;"Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming. The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collabGinkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Rwanda Development Board (""RDB""), representing the government of the Republic of Rwanda, today announced that they have entered into a Memorandum of Understanding (""MOU"") with the intent of developing and implementing new biosecurity capabilities in Rwanda.";95.06999969482422;;48.31999969482422;;73.76000213623047;;42.36000061035156;;40.34000015258789;The latest analyst coverage could presage a bad day for Novavax, Inc. ( NASDAQ:NVAX ), with the analysts making...Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.This year hasn't been an easy one for Novavax (NASDAQ: NVAX) investors. After a series of stumbles culminating in its disastrous earnings report on Aug. 8, its shares are down by 60% so far in 2022. And with management slashing its full-year revenue guidance by roughly half, there isn't much hope for smoother sailing for at least a few quarters.;65.5999984741211;;104.87999725341797;;109.26000213623047;;80.44999694824219;;45.630001068115234;;69.72000122070312;;77.45999908447266;;45.0;;32.650001525878906;;19.229999542236328;Exelixis easily beat second-quarter expectations, but kept its 2022 outlook and EXEL stock crumbled Wednesday.In this article, we will take a look at the top 10 gainers on Wednesday. If you want to see some more stocks moving higher today, go directly to Top 5 Gainers on Wednesday. Notable stocks from the tech and industrials sectors, including The Trade Desk, Inc. (NASDAQ:TTD), Unity Software Inc. (NYSE:U) and Plug Power […]Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.;10.880000114440918;;66.08999633789062;Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce;38.47999954223633;;51.25;;43.36000061035156;Halozyme's (HALO) second-quarter earnings and sales beat estimates. Following the completion of the acquisition of Antares Pharma, the company raises its financial guidance for 2022.;;;27.850000381469727;;15.329999923706055;;11.770000457763672;;7.940000057220459;;43.439998626708984;;54.540000915527344;;57.02000045776367;;13.359999656677246;The contract drug developer's stock is finally shaking off the froth of its initial public offering.;49.08000183105469;Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.;15.739999771118164;;25.469999313354492;Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.Cardinal Health's (CAH) fiscal fourth-quarter results benefit from a solid performance in the Pharmaceutical segment.Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.
2022-08-12;248.38999938964844;Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.The U.S. Senate Finance Committee is widening its investigation into the tax practices of U.S. drugmakers to include Amgen Inc, according to a letter sent on Thursday by the committee's chairman, Senator Ron Wyden.  Amgen is already in the crosshairs of the U.S. Internal Revenue Service over its tax practices, particularly how it allocates profits between the U.S. and Puerto Rico.  The IRS is after more than $10 billion in back taxes and penalties the California-based biotech firm, although Amgen has said it believes the proposed adjustments and penalties are without merit.;62.959999084472656;;628.7100219726562;;160.35000610351562;;208.3300018310547;"By Yasin EbrahimThe San Diego company slashed its forecast for revenue growth in 2022 to between 4% and 5% from 14% to 16%.DNA-sequencing leader Illumina swung to a loss in Q2 2022. Contributions from Grail didn't help.By Liz MoyerIllumina was named as one of the 50 Smartest Companies in China 2021 by MIT Technology Review. This is the sixth consecutive time Illumina has been included on the list.Gene-sequencing company Illumina cuts its earnings guidance for the full year; Toast boosts its fiscal-year forecast.By Peter NurseIllumina (ILMN) delivered earnings and revenue surprises of -9.52% and 4.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Illumina Inc. shares sank more than 22% after hours Thursday after the gene-sequencing company swung to a loss in the second quarter, fell short of revenue expectations and revised its full-year outlook downward.Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the second quarter of fiscal year 2022, which include consolidated financial results for GRAIL.";294.5199890136719;The Dow Jones Industrial Average rose Friday, looking to cap off a week of solid gains. Apple stock is closing in on a new buy point.Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.;220.99000549316406;;193.97000122070312;;170.13999938964844;;233.85000610351562;Alnylam Pharmaceuticals' (NASDAQ: ALNY) stock went vertical in the past month -- up over 50% -- and there might be even more growth on the way.  Sales of its top-earning medicines are booming, and breakthroughs in clinical trials have added to the enthusiasm.  Alnylam has a small handful of medicines on the market, led by its drugs Onpattro and Amvuttra, which are intended to treat peripheral neuropathy caused by hereditary transthyretin amyloidosis (ATTR), which is a rare but deadly and progressively worsening heart disease.;379.6499938964844;Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.;3.630000114440918;Ginkgo is teaming up with Synlogic to launch a new gout drug, moving shares of both stocks higher.;95.06999969482422;Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks declineRoche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.;48.2400016784668;;73.98999786376953;Some businesses are just bigger than any economic headwind and don't run the risk of obsolescence.;42.709999084472656;;41.470001220703125;Commission-free trading platform Robinhood Markets grew in prominence helping newer investors participate in what remains one of the best ways to accumulate wealth over time.  One example is Ocugen (NASDAQ: OCGN).  Can Ocugen succeed in the COVID-19 vaccine market?Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner, SK bioscience, has received a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-A hugely disappointing quarter and new bear takes on the company by analysts made for a very bad set of trading days.Pick your favorite of these adjectives, and it will definitely apply to Novavax's (NASDAQ: NVAX) second-quarter update.  What's more, Novavax slashed its full-year revenue guidance.  Unsurprisingly, Novavax stock crashed on the atrocious, bad, dismal, horrible news.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the SVB Securities Virtual Vaccine Forum. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.;67.73999786376953;Generally, Wall Street stock price predictions are hardly the best source of investing ideas that have the most upside. Investors should interpret stocks that analysts claim have the most upside carefully. Often, either the analyst is too optimistic about the company’s fair value or the stock market is wrong. Investors may pick stocks with the most promising price predictions by reviewing their stock scores. As difficult as it is to make stock price predictions based on the numbers alone, someti;105.62999725341797;;109.0;;86.37000274658203;;47.290000915527344;;72.22000122070312;;78.66000366210938;Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.;44.16999816894531;;33.81999969482422;;19.479999542236328;Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...;11.600000381469727;;69.08000183105469;;38.11000061035156;;51.56999969482422;;43.13999938964844;;;;28.600000381469727;;15.6899995803833;;12.199999809265137;;8.789999961853027;;44.099998474121094;;54.459999084472656;;53.56999969482422;;13.680000305175781;;52.970001220703125;;16.399999618530273;;26.149999618530273;Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
2022-08-15;251.0800018310547;"A run of good news this summer is what touched off a run-up for the sector, says Jefferies analyst Michael Yee.Rating Action: Moody's assigns Baa1 rating to Amgen's notes; stable outlookGlobal Credit Research - 15 Aug 2022New York, August 15, 2022 -- Moody's Investors Service (""Moody's"") assigned a Baa1 rating to the new senior unsecured notes offering of Amgen Inc. (""Amgen"").  There are no changes to Amgen's existing ratings including the Baa1 senior unsecured long-term rating and the Prime-2 short-term rating, and the outlook remains stable.Proceeds from the offering are for general corporate purposes.  Amgen recently announced that it will acquire ChemoCentryx, Inc. for approximately $3.7 billion, expected to close in the fourth quarter of 2022.";66.20999908447266;Yahoo Finance Live’s Brad Smith breaks down how stocks are moving in early trading.FOSTER CITY, Calif., August 15, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced statistically significant and clinically meaningful results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. Detailed OS results will be presGrowth stocks typically generate above-average returns compared to the stock market and their peers. We often find growth stocks in an innovative sector or in a new market that grows faster than conventional industries. In the past decade, software, semiconductor, financial technology (fintech), online shopping, biotech, and clean energy have, at least occasionally, been viewed by investors as good spaces in which to find excellent growth stocks to buy. Unlike value stocks, growth stocks trade a;643.2899780273438;;162.47999572753906;;226.58999633789062;PacBio  is one of those companies.  Trading volumes this August have been topped only once before in the company's history -- when it was the target of a takeover by fellow DNA sequencing peer Illumina .  The most successful companies don't necessarily sell the most instruments, but instead sell the most chemicals and kits needed to operate the installed base of instruments.Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.Companies In The News Are: ILMN, FLO, VIAV, AQN.Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature Dr. Karen Knudsen, CEO of the American Cancer Society, at its inaugural Illumina Genomics Forum (IGF) on October 1. Dr. Knudsen will participate in an on-stage conversation with Dr. Phil Febbo, Illumina's Chief Medical Officer, about the landscape of cancer treatment and research, including what is currently being done to support the prevention, detection, and treat;305.5299987792969;The Dow Jones Industrial Average fell Monday, kicking off a busy week of economic data. Tesla rival Li Auto skidded on earnings.All eyes were on the Bureau of Labor Statistics (BLS) last week.  On Aug. 10, BLS announced that the July Consumer Price Index for All Urban Consumers (CPI-U), arguably the most important measure of inflation, remained unchanged from the previous month at 8.5%.  One day later, the agency reported that the Producer Price Index (PPI) fell by 0.5% in July.;222.3800048828125;;197.16000366210938;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, August 15, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today announced a strategic agreement with Ontada®, a McKesson business with leading provider technology and actionable real-world research, education, and evidence in oncology, to improve U.S. c";168.52999877929688;"As Seagen Inc (NASDAQ: SGEN) awaits a final buyout offer from Merck & Co Inc (NYSE: MRK), Seagen lost an arbitration dispute with Daiichi Sankyo (OTC: DSKNY) relating to the companies' 2008 collaboration around the use of antibody-drug conjugate (ADC) technology. An arbitrator gave the win to Japan's Daiichi in the clash over an antibody-drug conjugate technology-sharing pact that stretches back to 2008. ""While we are disappointed with the arbitration decision, it was important for us to pursue";231.00999450683594;;378.0799865722656;;3.490000009536743;Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurityBOSTON and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expec;96.94000244140625;;47.58000183105469;;75.27999877929688;;44.2400016784668;;42.29999923706055;"Gaithersburg’s Novavax Inc. (NASDAQ: NVAX) is seeking U.S. regulators’ green light to make its Covid-19 vaccine available to adults as a booster, an important step toward ensuring the shot’s viability in the market — where, so far, it’s seen underwhelming demand.  The biotech said Monday it has submitted its application to the Food and Drug Administration for emergency use authorization for its protein-based shot to boost immunity in adults already immunized with any of the Covid vaccines.  Novavax told us Monday it’s unable to confirm a time frame in which it could expect an FDA response.The U.K. regulator has become the first to authorize Moderna's bivalent COVID vaccine booster for use in adults aged 18 and older.Novavax Inc (NASDAQ: NVAX) has submitted an application to the FDA for Emergency Use Authorization (EUA) for its protein-based COVID-19 vaccine as a homologous and heterologous booster in adults aged 18 and older. This application is supported by data from Novavax's Phase 3 PREVENT-19 trial conducted in the U.S. and Mexico and from the UK-sponsored COV-BOOST Phase 2 trial. As part of an open-label booster phase of the PREVENT-19 trial, a single booster dose of the Novavax COVID-19 Vaccine was adCurrently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.Novavax Inc said on Monday it had filed for U.S. authorization for use of its COVID-19 vaccine as a booster dose in people who had either received its shots or a different vaccine.  The application to the U.S. Food and Drug Administration comes in the face of a slow rollout in the United States, where the Novavax vaccine was authorized in July, despite expectations that it would convince vaccine skeptics to get inoculated.  ""It's important for people to have a choice as they evaluate how to stay protected against COVID-19,"" Chief Executive Officer Stanley Erck said in a statement, referring to the Novavax vaccine that uses a traditional technology.Novavax Inc. said Monday that it asked the Food and Drug Administration to authorize its COVID-19 booster for adults. The company's primary series of protein-based shots received FDA authorization in July. ""We believe our vaccine offers a broad, long-lasting immune response against a range of variants,"" Novavax CEO Stanley Erck said in a news release. Novavax said giving a third shot of its vaccine to adults six months after getting the first two Novavax shots boosted antibody levels that were cNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologou";68.41999816894531;;107.38999938964844;;109.04000091552734;In the last month, both the S&P and the NASDAQ climbed back out of bear territory, and are registering 10% and 13% gains respectively. It’s enough to make investors' heads spin. Let's not forget, the markets presented investors with a bearish challenge in 1H22, with 6 straight months of losses. Headwinds, in the form of supply chain problems, Russia’s invasion of Ukraine, inflation at generational high levels, rising interest rates, all combined to give investors the shivers. For the retail inve;86.31999969482422;;48.310001373291016;;69.94999694824219;;80.13999938964844;;45.779998779296875;;36.060001373291016;;19.399999618530273;;11.5600004196167;;70.30999755859375;;37.61000061035156;;51.20000076293945;;43.09000015258789;"Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"" or the ""Company""), a leader in converting IV biologics to subcutaneous delivery and autoinjector devices, today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2028 (the ""Convertible Notes""). The Convertible Notes are to be offered and sold to ""qualified institutional buyers"" pursuant to Rule 144A under the Securities Act of 1933, as a";;;27.899999618530273;;15.609999656677246;;12.050000190734863;;8.359999656677246;;44.40999984741211;;54.119998931884766;In this article, we discuss 15 small company stocks you should own now for the next decade. If you want to read about some more stocks, go directly to 5 Small Company Stocks You Should Own Now for the Next Decade. Small company stocks were heavily impacted by the recent market downturn. The Russell 2000 […]NEW HAVEN, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Lisa Sinclair has joined the company as Senior Vice President, Corporate Operations. “Lisa’s extensive experience in strategic operations, portfolio management, and new product development planning, will be very valuable as Arvinas continues on an incredible growth trajectory and exciting;52.529998779296875;;13.539999961853027;;53.90999984741211;;16.600000381469727;;26.600000381469727;Here is how Alkermes (ALKS) and Elevance Health (ELV) have performed compared to their sector so far this year.
2022-08-16;253.14999389648438;Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.Since their PCSK9 drugs to lower bad cholesterol won FDA approvals in 2015, Amgen Inc (NASDAQ: AMGN) sued Regeneron Pharmaceuticals Inc (NASDAQ: REGN) regarding intellectual property in crafting an antibody that blocks the protein PCSK9 that helps the body clear LDL cholesterol. Drugs in the lawsuit are Regeneron's Praluent (alirocumab) and Amgen's Repatha (evolocumab). In May, Regeneron filed an antitrust suit that alleged Amgen conducted a bundling scheme that allowed the company to charge low;66.33000183105469;"Gilead Will Provide up to $5 Million in Global Grant Funding to Immediately Support Public Education and Vaccine Hesitancy Communications, a Public Policy Response and a Global Outbreak Emergency F...FOSTER CITY, Calif., August 15, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.Gilead Sciences (NASDAQ: GILD) stock was off to a good start this week, rising by more than 5% on Monday against the modest (0.4%) gain of the S&P 500 index.  The prominent pharmaceutical company had some good news to impart about an important cancer drug.  Gilead announced that morning that its breast cancer treatment Trodelvy recorded ""statistically significant and clinically meaningful"" results in a phase 3 clinical trial.AstraZeneca is the IBD Stock Of The Day amid growing enthusiasm for its cancer drug, Enhertu. But AZN stock hit resistance Monday.Yahoo Finance's Jared Blikre takes a look at how the Nasdaq 100 and major sectors are performing into the close.Shares of Gilead Sciences Inc. were up 4.9% in trading on Monday after the company said in a news release that Trodelvy improved overall survival rates in people with HR+/HER2- metastatic breast cancer. Gilead said it already filed an application with the Food and Drug Administration asking the regulator to approve the Trodelvy for this group of patients. It also said it expects to soon share full data from this clinical trial, which will help Wall Street analysts understand how Trodelvy will co";648.7000122070312;Since their PCSK9 drugs to lower bad cholesterol won FDA approvals in 2015, Amgen Inc (NASDAQ: AMGN) sued Regeneron Pharmaceuticals Inc (NASDAQ: REGN) regarding intellectual property in crafting an antibody that blocks the protein PCSK9 that helps the body clear LDL cholesterol. Drugs in the lawsuit are Regeneron's Praluent (alirocumab) and Amgen's Repatha (evolocumab). In May, Regeneron filed an antitrust suit that alleged Amgen conducted a bundling scheme that allowed the company to charge low;160.3699951171875;;219.8300018310547;Basepaws uses DNA sequencing and DRAGEN to give cat owners information about their pet’s breed, traits, and health risks;303.0;It the new Nasdaq bull market gains momentum, these stocks will likely soar even higher than they already have.Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended June 30, 2022, Baron Health Care Fund (the “Fund”) declined 10.00% (Institutional Shares), compared with the 7.43% decline for the Russell 3000 Health Care Index […]The stock market extended gains Monday, shrugging of weak economic data out of China and a sell-off in oil and gas stocks.SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quarter ended June 30, 2022. “We were very pleased to have completed the sale of our complement portfolio during the second quarter to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (“Vertex”) for $60.0 million in cash with up to $5.0 million of that amount due in May 2023. This transaction was the;219.63999938964844;;188.25;The big question on investors’ minds right now is, where will inflation go? And the related follow-up question, for everyone, is, how far will the Fed hike rates in response? The potential answers cover the full range of possibilities, from President Biden’s happy talk about ‘zero percent inflation,’ to the market bears predicting a full-blown economic depression. Count JPMorgan’s chief asset management strategist David Kelly among the bulls. He’s not convinced by the doomsayers, and sees the re;170.52000427246094;The decision comes after Seagen won a $41.8 million patent infringement case against Daiichi Sankyo in April.;228.14999389648438;;370.05999755859375;Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended June 30, 2022, Baron Health Care Fund (the “Fund”) declined 10.00% (Institutional Shares), compared with the 7.43% decline for the Russell 3000 Health Care Index […];3.740000009536743;"Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) (""Ginkgo""), the leading horizontal platform for cell programming, today announced its results for the second quarter ended June 30, 2022. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.";95.02999877929688;;46.369998931884766;;74.95999908447266;;41.11000061035156;;42.880001068115234;The coronavirus might not pose the threat it once was, and Novavax (NASDAQ: NVAX) can be considered a laggard in the Great COVID-19 Vaccine Race, but the stock certainly has plenty of believers.  The more important of these two filings was with the U.S. Food and Drug Administration (FDA).  Novavax's money product of the moment, its coronavirus vaccine Nuvaxovid, won emergency use authorization (EUA) from the American regulator last month.;64.16999816894531;;106.11000061035156;;107.83000183105469;;85.37999725341797;;47.630001068115234;;68.55000305175781;;75.8499984741211;;45.560001373291016;;32.900001525878906;;19.510000228881836;;11.079999923706055;;63.560001373291016;;36.22999954223633;;49.310001373291016;;44.47999954223633;"Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"" or the ""Company""), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $625.0 million aggregate principal amount of convertible senior notes due 2028 (the ""Convertible Notes""). The Convertible Notes are being offered and sold to ""qualified institutional buyers"" pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). The offering was upsized from an originally announc";;;26.75;;15.329999923706055;;11.8100004196167;;8.0;;44.31999969482422;;52.47999954223633;;53.810001373291016;;12.75;;51.06999969482422;;16.959999084472656;;26.450000762939453;FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
2022-08-17;250.5800018310547;Today's Research Daily features update on the Q2 earnings season and new research reports on The Coca-Cola Company (KO), Oracle (ORCL) and Morgan Stanley (MS).;66.0199966430664;Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.Gilead announced Monday that the overall survival rate for patients taking the drug had achieved statistical significance.;636.3400268554688;;152.0399932861328;;213.02000427246094;;299.2300109863281;;217.5800018310547;;179.82000732421875;;170.7899932861328;;223.1300048828125;;362.7699890136719;;3.259999990463257;;94.83999633789062;;42.88999938964844;;73.86000061035156;;39.560001373291016;;39.369998931884766;Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a heterologous and homologous booster dose in adults aged 18 andNovavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.;59.560001373291016;;104.94000244140625;;109.0;;80.22000122070312;;45.880001068115234;PASADENA, Calif., August 17, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).;61.16999816894531;"Blueprint Medicines Corporation (NASDAQ: BPMC) announced topline results from the registrational Part 2 of the PIONEER trial of Ayvakit (avapritinib) for non-advanced systemic mastocytosis (SM). SM is a rare disorder that results in too many mast cells (type of mast cells) building up in the body. Blueprint Medicines plans to submit a supplemental marketing application to the FDA for Ayvakitin in Q4 of 2022, with European submission in 2023. Related: This Analyst Thinks Blueprint Medicines' Non-Shares of Blueprint Medicines Corp. tumbled 11.7% in premarket trading on Tuesday after the company said a Phase 2 clinical trial evaluating Ayvakit in patients with non-advanced systemic mastocytosis, a rare disorder, met the primary and secondary endpoints. However, one Wall Street analyst said he is concerned about the change in the symptom score in the Phase 2 study, compared with the Phase 1 trial. ""While we think these data are approvable, they do represent a deterioration in the absoluteBlueprint Medicines Corporation (NASDAQ: BPMC) today announced positive top-line results from the registrational Part 2 of the PIONEER clinical trial of AYVAKIT® (avapritinib) in patients with non-advanced systemic mastocytosis (SM) demonstrating clinically meaningful and highly significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms and objective measures of mast cell burden. Based on these top-line data, Blueprint Medicines plans to subm";71.73999786376953;;43.52000045776367;;30.209999084472656;;19.309999465942383;;10.600000381469727;;59.560001373291016;;35.189998626708984;;47.25;;43.40999984741211;;;;25.90999984741211;;15.239999771118164;;11.59000015258789;;7.610000133514404;;43.880001068115234;;46.70000076293945;;51.5;;13.010000228881836;;48.290000915527344;The South San Francisco-based maker of synthetic DNA plans to be in operation in the Portland area by January.;17.059999465942383;;25.610000610351562;LHC Group (LHCG) is set to acquire Georgia-based Three Rivers Home Health that will expand its service footprint in 36 counties in the state of Georgia.The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.For the all the working parents at Alkermes, we recognize that there is no greater responsibility than being present for your family. That’s why we’re so proud to be listed as one of The Best Place...
2022-08-18;249.6999969482422;he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.;65.18000030517578;FOSTER CITY, Calif., ATLANTA and NEW ORLEANS, August 18, 2022 /3BL Media/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new health equity collaboration with the Satcher Health Leadership...Regulatory and pipeline updates from Gilead (GILD) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.;624.8300170898438;;147.61000061035156;;209.05999755859375;Its sequencing devices are among the most widely distributed in global hospitals and laboratories of all stripes, and its ongoing years-long efforts to develop new technologies place it at the cutting edge of the field, with few notable competitors anywhere in sight.  Illumina is currently facing some serious legal trouble in the E.U. to the point where it constitutes a red flag for its near-term performance.  To prepare for the possible fine, Illumina is setting aside $453 million.Zacks.com users have recently been watching Illumina (ILMN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended June 30, 2022, Baron Health Care Fund (the “Fund”) declined 10.00% (Institutional Shares), compared with the 7.43% decline for the Russell 3000 Health Care Index (the […]New partnership will use the power of high-throughput sequencing to measure and understand marine life in our oceans at a rate that eclipses traditional research methods;294.2900085449219;;216.33999633789062;;177.8300018310547;;169.08999633789062;;223.4499969482422;CAMBRIDGE, Mass., August 18, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, during a late-breaker session at the 18th International Symposium on Amyloidosis (ISA) on September 8, 2022. The Company announced positive topline;361.45001220703125;Bio-Techne Corporation (NASDAQ: TECH) today announced that R&D Systems®, a Bio-Techne brand, has released its new Quantist Luminex® data analysis software. Compatible with all available Luminex xMAP® instruments, Quantist software provides fast, reliable analysis of Luminex multiplex assay data, helping researchers extract valuable insights from complex data.;3.25;;92.95999908447266;;39.369998931884766;In this article, we discuss 10 Cathie Wood stocks to buy before the bull run starts. If you want to see more stocks preferred by Cathie Wood to load up on before the bull run begins, click 5 Cathie Wood Stocks to Buy Before the Bull Run Starts. Cathie Wood, the founder and CIO of […];73.62000274658203;;38.47999954223633;;37.18000030517578;Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.Chasing best-known favorites may not be the best way to score on Meme stocks, analysts say. Meme stock ETFs can help.Vaccines, treatments and tests will soon all be commercially available. But what that means for consumers' out-of-pocket costs is unclear.;59.470001220703125;;106.76000213623047;;108.6500015258789;As one of the leading genetic medicine companies on the planet, Sarepta Therapeutics is on the forefront of many nerdy advances.  It was the first drug developer to earn U.S. Food and Drug Administration (FDA) approval for products treating Duchenne muscular dystrophy (DMD), a rare genetic disorder impacting muscle development.  Meanwhile, Sarepta Therapeutics currently boasts over 37 pipeline programs, including 21 assets in gene therapy alone.;79.08000183105469;;44.0099983215332;;64.08999633789062;"Blueprint Medicines (BPMC) posts top-line data from part 2 of the PIONEER study evaluating Ayvakit in patients with non-advanced systemic mastocytosis. Shares down.Blueprint unveiled the ""long-awaited"" results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed.Earlier today, Blueprint Medicines Corporation (NASDAQ: BPMC) released the long-awaited pivotal PIONEER dataset in Indolent Systemic Mastocytosis (ISM). The topline data indicates that the trial met all primary and key secondary endpoints with statistical significance and that there were no intracranial bleeds. SVB Leerink thinks that though these data are approvable, they represent a deterioration in the absolute improvement in the symptom score (TSS), which was 15.6 points in this trial versus";72.1500015258789;;43.18000030517578;;30.290000915527344;;19.219999313354492;;10.699999809265137;BridgeBio Pharma Inc (NASDAQ: BBIO) has dosed the first patient in its Phase 1 trial of BBP-671, an investigational oral therapy for conditions caused by coenzyme A (CoA) deficiencies, including propionic acidemia (PA), methylmalonic acidemia (MMA), and pantothenate kinase-associated neurodegeneration (PKAN). PA and MMA are rare metabolic disorders in which the body cannot properly break down certain proteins and lipids (fats). BBP-671 is an investigational oral therapy intended to increase CoA- Initial data readout for patients with PA and MMA expected in the first half of 2023 - Interim data from healthy individuals, reported earlier this year, showed that BBP-671 was detected in plasma and cerebrospinal fluid (CSF) at concentrations above predicted therapeutic thresholds, suggesting the compound has the potential to impact key systemic and neurological complications of PA and MMA - BridgeBio is in active discussions with regulators and expects to launch a pivotal Phase 2/3 clinical;57.58000183105469;;34.5099983215332;;48.66999816894531;NOVATO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 19,020 shares of common stock of the company and 12,910 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company. The awards were approv;43.11000061035156;;;;24.8799991607666;;15.350000381469727;;11.390000343322754;;7.170000076293945;;44.040000915527344;;46.119998931884766;;50.7400016784668;;12.449999809265137;Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.;46.9900016784668;In this article, we discuss 10 Cathie Wood stocks to buy before the bull run starts. If you want to see more stocks preferred by Cathie Wood to load up on before the bull run begins, click 5 Cathie Wood Stocks to Buy Before the Bull Run Starts. Cathie Wood, the founder and CIO of […];17.3700008392334;;25.239999771118164;GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
2022-08-19;250.86000061035156;;65.33999633789062;Ashley InnesRegional Director;618.3599853515625;"The World Health Organization (WHO) on Friday recommended two monoclonal antibody treatments against Ebola, saying the use of such drugs combined with better care had ""revolutionised"" the treatment of a disease once seen as a near-certain killer.  The drugs - Regeneron's Inmazeb (REGN-EB3) and Ridgeback Bio's Ebanga (mAb114) - use laboratory-made monoclonal antibodies that mimic natural antibodies in fighting off infections.  Ebola virus disease used to be perceived as a near certain killer.";147.9199981689453;;202.75;Speakers will outline critical steps needed to achieve health equity;299.0400085449219;"Dow Jones futures fell as the market rally pulls back with Bitcoin tumbling. BBBY stock dived in a ""reversion to the meme.""";214.08999633789062;Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.One could write a book (or two) about everything that's happened to Biogen (NASDAQ: BIIB) in the past three years.  The company's controversial approval of Alzheimer's disease (AD) medicine Aduhelm makes for a fascinating story, as does the fallout from this approval and the fact that Aduhelm is nowhere close to living up to its lofty potential on the market.  With the issues surrounding Aduhelm and Biogen's loss of exclusivity for multiple sclerosis medicine Tecfidera -- which was one of its top-selling products -- the biotech isn't doing too well.;174.83999633789062;;171.6699981689453;;215.97000122070312;;354.8299865722656;;2.8499999046325684;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation. Under the terms of the deal, Ginkgo will assume ownership of proprietary datasets, modeling and analytic tools, and a software platform with the capabilities to track, model, and forecast epidemics and associated risks and impacts. Ginkgo also expects to integrate sever;92.83999633789062;;36.34000015258789;;74.54000091552734;;36.83000183105469;;36.220001220703125;A couple of stocks that I wouldn't consider investing in right now -- even if money did fall from the sky -- are Novavax (NASDAQ: NVAX) and fuboTV (NYSE: FUBO).  Novavax stock has been a volatile investment over the past few years.  What was concerning is that from a previous forecast that called for revenue between $4 billion and $5 billion, Novavax slashed that down to a range of $2 billion and $2.3 billion.New Zealand's Medsafe has granted expanded provisional approval for Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in adolescents aged 12 through 17. The provisional approval was based on data from the ongoing pediatric expansion of the Phase 3 PREVENT-19 trial of 2,247 adolescents aged 12 through 17. In the pediatric expansion, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% overall clinical efficacy when the Delta variant was predominant. Relat;56.29999923706055;;107.0;;107.86000061035156;;77.4000015258789;;42.61000061035156;;69.66000366210938;HC Wainwright has cut the price target on Blueprint Medicines Corporation (NASDAQ: BPMC) from $100 to $80 and reiterated the Buy rating. The analyst attributes the stock's downward momentum to investor pushback from only a 6.4 difference between the mean change in TSS at 24 weeks compared to the control arm. HC Wainwright notes that Ayvakit did show a superior mean change in total symptom score compared to placebo plus best available care but says that investors hoped for a difference between 7-;68.5999984741211;The first drug to make use of technology discovered only a decade ago will be with regulators by the end of the year;42.81999969482422;;29.030000686645508;;19.329999923706055;;10.369999885559082;;53.290000915527344;;33.150001525878906;;49.029998779296875;;42.2599983215332;;;;24.649999618530273;;15.489999771118164;;10.460000038146973;Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that results from the Phase 3 BEACON study in Retinal Vein Occlusion (RVO) of its investigational therapy tarcocimab tedromer (KSI-301) will be presented at two upcoming ophthalmology conferences: the 22nd EURETINA Congress in Hamburg, Germany, and the 2022 American Academy of Ophthalmology;6.400000095367432;;44.0;;45.63999938964844;NEW HAVEN, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Liam Ratcliffe, M.D., Ph.D. has stepped down from the company’s Board and John Young has been appointed to join. “Since joining our board in 2015, Liam has been a valuable member of our team, providing expert guidance, especially as a member of our Compensation Committee,” said John Houst;51.41999816894531;;11.4399995803833;;42.810001373291016;;16.90999984741211;;25.260000228881836;
2022-08-22;246.89999389648438;Amgen (NASDAQ:AMGN) today announced the presentation of eight cardiovascular (CV) scientific research abstracts, including long-term and real-world evidence studies that add to the robust body of evidence demonstrating the efficacy and safety profile of Repatha® (evolocumab). Notable abstracts include data from the open label extension (OLE) studies to the Phase 3 FOURIER cardiovascular outcomes study, which will be presented as a late-breaking Hot Line Oral Presentation. The data will be presen;64.36000061035156;Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.FOSTER CITY, Calif., August 22, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted Marketing Authorization for Sunlenca® (lenacapavir) injection and tablets for the treatment of HIV infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. Lenacapavir is a first-in-class capsid inhibitor with a multi-stage mecha;612.0999755859375;;148.3000030517578;Pfizer Inc. and BioNTech SE said Monday that they formally completed an application asking the Food and Drug Administration to authorize their experimental bivalent COVID-19 booster in those who are 12 years old or older. The new shot equally targets the original strain of the virus and the BA.4 and BA.5 strains. BA.5 is the most dominant strain of SARS-CoV-2 in the U.S. right now. Moderna Inc. is also developing a bivalent COVID-19 booster. So far this year, Pfizer's stock is down 16.9%, while;195.5800018310547;"Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature Anne Wojcicki, co-founder and CEO of personal genomics company 23andMe, at its inaugural Illumina Genomics Forum (IGF) on October 1. In a spotlight session titled ""Disruption Ahead,"" Wojcicki will speak with biotechnology journalist Luke Timmerman about putting the consumer at the center of health care, drawing from her personal experience disrupting the health care";293.8399963378906;Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.;207.6999969482422;;172.99000549316406;;166.36000061035156;;217.91000366210938;Speaking to this point, Pfizer recently doled out $5.4 billion to acquire Global Blood Therapeutics for its sickle cell disease assets.  A buyer, therefore, would probably have to be willing to pay up to around 20 times 2023 estimated sales (roughly $32.6 billion or about $272 a share) to win over Alnylam's key stakeholders.;345.6499938964844;;2.690000057220459;;92.44999694824219;;35.0099983215332;;73.58999633789062;;35.959999084472656;;35.470001220703125;The U.S. Centers for Disease Control and Prevention (CDC) on Monday signed off on the use of Novavax Inc's COVID-19 vaccine for adolescents aged 12 through 17.  The protein-based vaccine received emergency use authorization in July for use among adults in the United States, with health officials hoping it would drive uptake among those skeptical of messenger RNA shots from Moderna Inc and Pfizer Inc.  However, Novavax earlier this month halved its full-year revenue forecast, saying it does not expect further sales of its COVID-19 shot in the United States this year.First Lady Jill Biden left isolation on Sunday, after testing negative for COVID twice and was able to join her husband, President Joe Biden, in Delaware.Biotech company Novavax (NASDAQ: NVAX) achieved an important milestone in July when it earned emergency use authorization (EUA) for its COVID-19 vaccine, Nuvaxovid, in the U.S. However, since that momentous event, the company's shares have lagged the market.  The vaccine maker has encountered some headwinds related to Nuvaxovid.  Since many people are still hesitant to get the jab, and some of that hesitancy may be because some otherwise popular vaccines are mRNA-based, it isn't crazy to think that a protein-based vaccine such as Nuvaxovid would attract mRNA skeptics.The FDA has granted expanded use authorization for Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine in adolescents aged 12 through 17. The move comes immediately after New Zealand approved the shot for the same group. The FDA EUA decision was based on data from the ongoing pediatric expansion of the Phase 3 PREVENT-19 trial of 2,247 adolescents. In pediatric expansion, the vaccine achieved its primary efficacy endpoint with clinical efficacy of 78.29% overall when the Delta variant was the predominThe Food and Drug Administration granted similar emergency use authorization for Novavax's adult vaccine in July.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received expanded emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus;54.25;;106.20999908447266;;107.7300033569336;;75.16000366210938;;41.11000061035156;;71.5;;66.3499984741211;;42.029998779296875;;28.889999389648438;;19.149999618530273;;10.25;;51.40999984741211;;31.989999771118164;;48.150001525878906;;41.900001525878906;;;;24.309999465942383;;15.170000076293945;;10.319999694824219;;5.650000095367432;;44.02000045776367;;44.95000076293945;;49.13999938964844;;11.010000228881836;;39.5;;16.75;;24.989999771118164;
2022-08-23;244.47000122070312;Amgen Inc (NASDAQ: AMGN) has announced topline results from the DAHLIA study crossover Phase 3 study of ABP 959, a biosimilar candidate to Soliris (eculizumab) in paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare blood disorder characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function. Soliris was a centerpiece for Alexion's $39 billion takeover by AstraZeneca Plc (NASDAQ: AZN). The study demonstrated no clinically meaningful differences between AThe Dow Jones Industrial Average fell Tuesday, adding to Monday's stock market plunge. Zoom Video stock dived on earnings.Amgen (NASDAQ: AMGN) today announced positive top-line results from the DAHLIA study, a randomized, double-blind, active-controlled, two-period crossover Phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS® (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).;63.68000030517578;;602.530029296875;;147.25;The efficacy rate disclosed Tuesday is down slightly from the figure of 80.3% the company had presented earlier.Pfizer and German partner BioNTech on Tuesday offered updated COVID vaccine data supporting efficacy in children aged 6 months through 4 years of age.Pfizer Inc and BioNTech's vaccine was 73.2% effective in preventing COVID-19 among children aged 6 months through 4 years, new data from the companies showed on Tuesday, two months after the U.S. rollout of the shots began for that age group.  The Pfizer-BioNTech  vaccine was authorized for children under 5 years of age in June, based on data that showed the vaccine generated a similar immune response as in older age groups.  An early analysis based on 10 symptomatic COVID-19 cases in the study had suggested a vaccine efficacy of 80.3%.Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccine contains mRNA encoding the spike protein present in the original vaccine as well as mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant.Pfizer Inc. and German partner BioNTech SE on Tuesday announced updated COVID vaccine data supporting efficacy in children aged 6 months through 4 years of age. The companies said updated analysis from 34 cases occurring at least seven days after a three-dose regimen showed 73.2% vaccine efficacy among children in that age group. The vaccine efficacy remained consistently above 70% in both children aged six months through 23 months and the 2 through 4 years age groups. Sequencing of the cases coPfizer Inc's COVID-19 vaccine was 73.2% effective in children aged between 6 months and 4 years, the company's data showed on Tuesday, two months after the U.S. rollout of the shots began for that age group.  Pfizer and BioNTech's vaccine was authorized for children under 5 years of age in June, based on data that showed the vaccine generated a similar immune response to those seen in older age groups.  An early analysis based on 10 symptomatic COVID-19 cases in the study had suggested a vaccine efficacy of 80.3% in this group, but experts had warned that the data was preliminary due to the low number of symptomatic cases.NEW YORK & MAINZ, Germany, August 23, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported interim vaccine efficacy data collected in March and April 2022. Emergency Use Authorization (EUA) of this vaccine was granted by the U.S. Food and Drug Administration (FDA) for this aPfizer and BioNTech have formally completed an application asking the Food and Drug Administration to authorize their experimental bivalent COVID-19 booster in those who are 12 years old or older. The new shot equally targets the original strain of the virus and the BA.4 and BA.5 strains, the latter of which is now the dominant strain of SARS-CoV-2 in the U.S. The news comes as U.S. known cases of COVID are continuing to ease, although the true tally is likely higher given how many people are teThe updated shot, which targets the latest Omicron subvariants as well as the original virus, would be used in a fall booster campaign.Post the label expansion by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in individuals aged 12 years and older in the United States.Pfizer and BioNTech have applied to US regulatory authorities for emergency authorisation of a Covid-19 vaccine specifically tailored to target the most dominant strain of the Omicron coronavirus variant ahead of a nationwide booster programme planned for the autumn.  The companies said on Monday they had rapidly increased production of the newly developed shot targeting the fast spreading BA.4/BA.5 sub-variants and stand ready to deliver doses from September.  Shipping could begin immediately if regulators authorised the new “bivalent” vaccine, which contains the original Covid strain and the genetic code for the now dominant sub-variants, they added.;194.83999633789062;;286.25;Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) is gaining momentum.  The drugmaker has substantially outperformed the broader market in the past year, and it is showing few signs of slowing down.  Vertex's performance is especially commendable considering the world's economic issues such as inflation.Mastercard, Cisco, PayPal, Vertex Pharmaceuticals and ICICI Bank are included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Cisco Systems, Inc. (CSCO) and PayPal Holdings, Inc. (PYPL).;202.80999755859375;;173.02000427246094;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, August 23, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for tislelizumab";163.55999755859375;;216.88999938964844;;342.1300048828125;;2.690000057220459;;91.58999633789062;;35.43000030517578;;72.98999786376953;WILMINGTON, Del., August 23, 2022--Incyte (Nasdaq:INCY) announced today that it will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 12:30 p.m. (EDT) in New York.In this article, we will take a look at the 10 stocks that were recently downgraded by analysts. If you want to see some other stocks receiving downgrades, go directly to Analysts Are Downgrading These 5 Stocks. Despite a strong upswing seen recently in late-July, U.S. stocks were subdued at the start of August, amid […];35.91999816894531;;36.54999923706055;It comes just a few days after the Gaithersburg biotech scored an emergency use authorization from the FDA.Novavax's (NASDAQ: NVAX) Nuvaxovid vaccine against COVID-19 continues to rack up regulatory victories, but you'd never know that from the stock's performance on Monday.  It fell by 2%, more or less matching the slump of the S&P 500 index on the day, despite a highly encouraging development on the regulatory front for the company and its jab.  In contrast to the vaccines that have been available on the U.S. market for quite some time, Nuvaxovid is a protein-based formulation, as opposed to one built on newer mRNA-based technology.The updated shot, which targets the latest Omicron subvariants as well as the original virus, would be used in a fall booster campaign.Post the label expansion by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in individuals aged 12 years and older in the United States.;60.560001373291016;First clinical data on safety and activity of NTLA-2002, Intellia’s second systemically administered in vivo CRISPR candidate CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract featuring interim clinical data from the Phase 1/2 study of NTLA-2002 has been selected for an oral pres;105.62000274658203;;109.08999633789062;;76.30999755859375;;41.220001220703125;;71.68000030517578;;68.69999694824219;Cathie Wood is well-known in the investment world as the face of ARK Invest, the firm she founded in 2014. ARK itself stands for Active Research Knowledge. She became something of a cult figure during the speculative tech boom that thrived throughout 2021. Her representative ARK Innovation ETF (NYSEARCA:ARKK) was a particular standout at the time, rising as much as 10% in a single day. 2022 hasn’t been as kind. ARKK stock has lost more than 50% of its value year-to-date (YTD). The value of the a;42.18000030517578;"SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in September: 5th HKEX Biotech Summit 2022Panel Discussion: Thursday, September 1, 2022, 3:10 p.m. HKTLocation: Hong Kong Citi’s 17th Annual BioPharma ConferenceFireside Chat: Thursday, Sept";29.84000015258789;;19.110000610351562;;10.949999809265137;;54.2400016784668;This article is excerpted from Tom Yeung’s Profit & Protection newsletter dated Aug. 16, 2022. To make sure you don’t miss any of Tom’s picks, subscribe to his mailing list here. When I recommended shares of CRISPR Therapeutics (NASDAQ:CRSP) and Beam Therapeutics (NASDAQ:BEAM) in July, biotech’s future seemed dim at best. Fed Chairman Jerome Powell had just raised rates by 75 basis points the month before, and the age of easy money seemed to be long gone. Shares of CRISPR and Beam had both falle;32.02000045776367;;48.689998626708984;;42.439998626708984;;;;25.0;;14.630000114440918;;10.630000114440918;;6.010000228881836;;43.86000061035156;World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers as potential diagnostic and therapeutic targetsProvisional patent applications have been filed in the United States (US) to seek protection for these new inventionsA potential therapeutic marker known to be modulated by ATL1102 in DMD patients has been identified as suggestive of its therapeutic potential as a treatment for Long COVID-19Collabo;45.2400016784668;;49.84000015258789;;11.470000267028809;;41.689998626708984;;16.8799991607666;;24.90999984741211;Coping with a schizophrenia diagnosis may not be easy, but there are ways to make this serious mental illness more manageable – including treatment prescribed by your provider. Check out this list ...
2022-08-24;244.49000549316406;The Dow Jones Industrial Average fell Wednesday, extending a losing streak. Tesla stock climbed ahead of Thursday's 3:1 stock split.Biotech giants Amgen (NASDAQ: AMGN) and AstraZeneca (NASDAQ: AZN) are great options.  In the second quarter, Amgen's revenue increased by an unimpressive 1% year over year to $6.6 billion.  What's to blame for the company's seemingly poor performance?;63.619998931884766;Regulatory updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.;602.7899780273438;;146.24000549316406;Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day, according to a new report.Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day, according to a new report. The New York Times reported Tuesday night that the Biden administration is eager to approve the new boosters as soon as possible, and is close to authorizing the updated shots. On Tuesday, Moderna Inc. said it had submitted an emergency-use application to the Food and Drug Administration for its experimental bivalent COVID-19 booster for those 18 and older. On MondayThe New York Times reported Tuesday night that the Biden administration is eager to approve the new boosters as soon as possible, and is close to authorizing the updated shots.Moderna stock inched higher late Tuesday just before announcing it asked the FDA to sign off on its updated Covid booster shot.Moderna Inc. said late Tuesday it has completed its submission to the U.S. Food and Drug Administration for the emergency-use authorization for its experimental bivalent COVID-19 booster for those who are 18 years old or older. The new shot targets the original strain of the virus as well as the BA.4 and BA.5 strains, thought to be the prevalent ones in the U.S. and other countries. Pfizer Inc. and BioNTech SE said Monday they had completed their submission for a booster available for people 12Some 175 million doses of updated vaccines would be available in the U.S. if health regulators give the green light.Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.;210.75;;291.0299987792969;;201.77999877929688;;176.2100067138672;;164.1199951171875;While investors are eagerly awaiting news on a Seagen tie-up, Merck offers upside even if the deal doesn’t materialize.;221.0;;346.9800109863281;Bio-Techne Corporation (NASDAQ: TECH) today announced that it has been included in the Forbes list of Best-in-State Employers 2022. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list can currently be viewed on the Forbes website.;2.8399999141693115;Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, today announced the appointment of Frank Jaksch as the company's chief executive officer. Jaksch founded, was the longtime CEO and presently serves as Board Chair of health and wellness company ChromaDex, manufacturer of popular NAD product, Tru Niagen (Nasdaq: CDXC).;92.9000015258789;;38.029998779296875;;72.97000122070312;WILMINGTON, Del., August 24, 2022--Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress;37.38999938964844;The growth investor that became a rock star after a market-thumping run in 2020 as the co-founder and CEO of the Ark Invest exchange-traded funds (ETFs) has seen many of her key investments falter over the past year and change.  Exact Sciences was a market darling for Wood in 2020, but it's been largely downhill since the stock peaked early last year.The synthetic biology pioneer has underpromised and over-delivered on biosecurity revenue in 2022. Here's what comes next.;37.06999969482422;Is Novavax stock a sell after its second-quarter disappointment led to a guidance cut? NVAX stock ranks low among biotechs.;62.380001068115234;;106.58999633789062;;114.75;;78.52999877929688;;42.75;;74.87999725341797;Blueprint Medicines Corporation (NASDAQ: BPMC) today announced two publications in the medical journal CANCER describing results from the TouchStone patient and healthcare provider (HCP) study designed to characterize the burden and needs of patients living with systemic mastocytosis (SM). Patient-reported results indicated that SM is associated with severe and burdensome symptoms including anaphylactic events, frequent emergency department visits, use of multiple symptom-directed medications, r;71.97000122070312;;43.369998931884766;;30.6200008392334;In this article, we discuss 10 Cathie Wood stocks that can rebound in Q4. If you want to see more stocks in this selection, check out 5 Cathie Wood Stocks that Can Rebound in Q4. Cathie Wood, the CEO of ARK Investment Management, is often the talk of Wall Street due to her bold market […];19.010000228881836;;11.470000267028809;;59.84000015258789;;31.010000228881836;;52.08000183105469;;42.38999938964844;;;;25.15999984741211;;15.029999732971191;;11.270000457763672;;6.570000171661377;;44.75;;46.5099983215332;;50.290000915527344;;11.850000381469727;Those following along with AbCellera Biologics Inc. ( NASDAQ:ABCL ) will no doubt be intrigued by the recent purchase...;43.91999816894531;;17.139999389648438;;25.209999084472656;
2022-08-25;245.67999267578125;The Dow Jones Industrial Average fell Thursday after key economic data. Peloton dived 18% on earnings, while Tesla stock rallied post-split.Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.;63.59000015258789;One way to boost your income is by investing in dividend stocks.  If you put that money into shares of Gilead Sciences (NASDAQ: GILD) and Enbridge (NYSE: ENB), that would be enough to earn you a little over $1,100 per year -- and that amount would likely increase over time.  Healthcare company Gilead Sciences is a stable investment, with its focus on developing medicine and treatment options for HIV.;603.7999877929688;;148.55999755859375;Pfizer, BioNTech, Moderna and Morphic are included in this Analyst Blog.Lower and middle income countries have faced severe vaccine inequity during the pandemic. Increased interest in manufacturing could be the key to equity.Pfizer (PFE) and BioNTech (BNTX) report updated data, showing that their three-dose COVID-19 vaccine is 73.2% effective in children under five years.Moderna's (MRNA) bivalent COVID-19 booster vaccine, mRNA-1273.222, is designed to target the Omicron BA.4 and BA.5 subvariants. The vaccine has been developed specifically for the U.S. market.;217.52000427246094;;291.2200012207031;;204.8300018310547;;175.9499969482422;;164.3699951171875;;213.9199981689453;CAMBRIDGE, Mass., August 24, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M.D., Ph.D., to its Board of Directors. Dr. Sigal brings decades of senior leadership and board experience at biopharmaceutical companies. He served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb (BMS) and as a director on the company’s board. During his tenure at BMS, he was instrumental in building th;358.6000061035156;Bio-Techne Corporation (NASDAQ: TECH) announced the publication of a study in the Green Analytical Chemistry journal, titled Establishment of a Platform Imaged Capillary Isoelectric Focusing (icIEF) Characterization Method for Adeno-Associated Virus (AAV) Capsid Proteins. The study, led by Jiaqi Wu, Ph.D., and Chris Heger, Ph.D., describes an icIEF method on Maurice, the flagship CE (capillary electrophoresis) instrument by ProteinSimple (a Bio-Techne brand) for the development, platform suitabi;2.930000066757202;;93.30000305175781;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization (CMA) to ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5). The EC also endorsed EMA's recommendation for Roctavian to maintain orphan dru;38.68000030517578;;72.68000030517578;;39.900001525878906;Investors are optimistic about Exact Sciences' (EXAS) better-than-expected results and robust Cologuard volumes.;37.25;Lower and middle income countries have faced severe vaccine inequity during the pandemic. Increased interest in manufacturing could be the key to equity.;63.5;;104.30000305175781;;113.80999755859375;Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shareholders (or potential shareholders) will be happy to see that insider...;78.2699966430664;;42.61000061035156;;73.68000030517578;;72.44000244140625;;44.59000015258789;;30.8700008392334;;18.809999465942383;;11.039999961853027;;62.150001525878906;;31.25;;51.459999084472656;;42.310001373291016;;;;25.399999618530273;;15.5;;11.279999732971191;;6.900000095367432;;43.95000076293945;;46.68000030517578;;49.310001373291016;;12.180000305175781;;46.34000015258789;;16.84000015258789;;24.940000534057617;
2022-08-26;240.64999389648438;Amgen is showing very low implied volatility compared to recent history. That could mean it’s a good time to buy an option strangle.;62.369998931884766;;596.1799926757812;Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:;142.60000610351562;"(Bloomberg) -- Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their Covid-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans.Most Read from BloombergNearly 60,000 Sneakers in $85 Million Ponzi Scheme to Go on SaleGOP Fury Over ESG Triggers Backlash With US Pensions at RiskWorld’s Most Popular Password Manager Says It Was HackedA 129-Foot Superyacht Worth Millions Sinks Off the Italian CoastTrump’s Stash atSome 16 million Americans of working age have long-term COVID and about 2 to 4 million are not working as they struggle with their symptoms, according to a new report from the Brookings Institution.NEW YORK & MAINZ, Germany, August 26, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older. This application for a variation of the conditional marketing authorization (cMA) follows guidance from the EMA and International Coalition of Medicines Regulatory Authorities (ICMRA) to work tThe Cambridge company (Nasdaq: MRNA) alleged in a complaint filed in the U.S. District Court of Massachusetts Friday that Pfizer (NYSE: PFE) and BioNTech's vaccine, Comirnaty, violates three patents Moderna filed between 2010 and 2016.Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss Moderna’s decision to sue rival vaccine maker Pfizer over the delivery technology used in COVID-19 vaccines.Moderna Inc (NASDAQ: MRNA) has filed patent infringement lawsuits against Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) in the U.S. and Germany. Moderna believes that Pfizer/BioNTech's COVID-19 vaccine infringes patents filed between 2010 and 2016 covering foundational mRNA technology, critical in creating Moderna's mRNA COVID-19 vaccine. In July, Pfizer and BioNTech filed a complaint seeking a judgment that they did not infringe patents related to the COVID-19 vaccine held by CureVac N.By Liz MoyerNovartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.""We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission,"" Moderna said.Moderna Inc. said Friday it is suing Pfizer Inc. and German partner BioNTech SE for infringing patents relating to its mRNA platform, the source of the COVID vaccines developed by the three parties. The suit is to be filed Friday in the U.S. District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany. ""This groundbreaking technology was critical to the development of Moderna's own mRNA COVID-19 vaccine, Spikevax,"" the company said in a statement. ""Pfizer and(Reuters) -Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.  The suit also would be filed also in the Regional Court of Duesseldorf in Germany, Moderna said in a news release.  ""We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic,"" Moderna Chief Executive Stephane Bancel said in the news release.US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic";205.3699951171875;;281.67999267578125;2020 will probably go down in history as the year of COVID-19. 2021 could be known as the year of the reopening. How will 2022 be remembered? Perhaps as the year of sky-high inflation. Prices of goods and services are at levels not seen in four decades.;198.58999633789062;Biogen Inc. (BIIB) closed the most recent trading day at $204.83, moving +1.51% from the previous trading session.;181.08999633789062;;155.00999450683594;;210.94000244140625;;338.739990234375;;2.7799999713897705;;91.01000213623047;BioMarin's (BMRN) Roctavian is the first gene therapy to get approval for hemophilia A in the European Union. The therapy has also been granted a 10-year market exclusivity.;34.88999938964844;;71.4800033569336;WILMINGTON, Del., August 26, 2022--Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement;36.90999984741211;;35.20000076293945;Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has granted expanded conditional marketing authorization (CMA) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine▼ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coro;58.75;;104.87000274658203;;111.88999938964844;;76.2300033569336;;40.060001373291016;;72.2300033569336;;67.37000274658203;;46.58000183105469;;27.530000686645508;;18.229999542236328;Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.;10.479999542236328;;56.2599983215332;Shares of the clinical-stage base-editing company Beam Therapeutics (NASDAQ: BEAM) stormed higher through the first four days of trading this week.  Beam's sizable uptick seems to simply be a rebound following last week's 23% drop in its share price.  Clinical-stage biotech stocks have been extremely volatile this year, thanks to rising interest rates, geopolitical turmoil, and investors' general aversion to risk right now.;29.34000015258789;;49.5;;40.290000915527344;;;;24.399999618530273;;15.239999771118164;;11.149999618530273;;5.96999979019165;;42.349998474121094;;44.220001220703125;;49.70000076293945;;11.260000228881836;;43.099998474121094;;16.530000686645508;;24.540000915527344;
2022-08-29;239.3800048828125;Amgen Inc (NASDAQ: AMGN) presented new data from the Phase 3 FOURIER open-label extension (OLE) studies of Repatha (evolocumab) in adults with atherosclerotic cardiovascular disease (ASCVD) for a median follow-up of up to five years and a maximum exposure to Repatha of more than eight years. No new long-term safety findings were observed. Repatha delivered medically significant and sustained reduction in low-density lipoprotein cholesterol (LDL-C) levels, with 80% of patients achieving low-densiUnsurprisingly, dividend stocks tend to attract a lot of money.  As popular as dividend stocks already are, though, they could soon become even more attractive.  President Biden signed the Inflation Reduction Act into law on Aug. 19.Amgen (NASDAQ:AMGN) today presented new compelling data from the Phase 3 FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in adults with atherosclerotic cardiovascular disease (ASCVD) during the Aug. 29 late-breaking Hot Line Session of the European Society of Cardiology (ESC) Annual Meeting being held in Barcelona, Spain, and online. These data were simultaneously published in Circulation. Repatha is the first and only proprotein convertase subtilisin/kexin type 9 inhibitor (;62.45000076293945;FOSTER CITY, Calif., August 29, 2022--Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022;592.77001953125;Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced results from a Phase 2 study of cemdisiran for immunoglobulin A nephropathy (IgAN). Cemdisiran is an investigational RNAi therapeutic targeting the C5 component of the complement pathway and is under development in collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN). New results demonstrated a 36% reduction in 24-hour urine total protein and a higher proportion, 32% versus 13%, of patients treated with cemdisiran as compared to tho;144.6300048828125;Moderna (MRNA) sues Pfizer and BioNTech, alleging that Comirnaty infringes on patents that Moderna filed from 2010 to 2016 related to its mRNA technology.Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.;210.17999267578125;Canada’s STREAM project uses genomics to advance watershed health monitoringA sell side firm has named the life science firm Illumina a new top pick (overweight) with a $320 price target. Let's check out the charts of ILMN to see if the charts are in gear with the fundamental story.Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature International Tennis Hall of Fame member Chris Evert as a special guest at its inaugural Illumina Genomics Forum (IGF) on October 1. Evert, who was diagnosed with stage 1C ovarian cancer earlier this year, will participate in a fireside chat discussing how genomics can improve early cancer detection, lead to more proactive, effective treatment of cancer, and help sa;281.6000061035156;Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.With its stock down 5.8% over the past week, it is easy to disregard Vertex Pharmaceuticals (NASDAQ:VRTX). However...Most investors consider stocks to be in a bear market when they're down at least 20% from the most recent high.  Are we in a new bull market or just a bear market bounce?  Prior to this year's sell-off, the most recent bear market occurred in 2020 with the COVID-19 pandemic.;197.11000061035156;;167.3000030517578;;157.3699951171875;;209.02999877929688;Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced results from a Phase 2 study of cemdisiran for immunoglobulin A nephropathy (IgAN). Cemdisiran is an investigational RNAi therapeutic targeting the C5 component of the complement pathway and is under development in collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN). New results demonstrated a 36% reduction in 24-hour urine total protein and a higher proportion, 32% versus 13%, of patients treated with cemdisiran as compared to thoCAMBRIDGE, Mass., August 29, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced positive results from a Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway, in development in collaboration with Regeneron Pharmaceuticals for the treatment of adult patients with immunoglobulin A nephropathy (IgAN). The results were presented at the 18th European Meeting on Complement in Human Disease (EMCHD) being held in Bern, Switz;333.3900146484375;Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 9:10 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;2.6700000762939453;;90.33000183105469;;33.81999969482422;;70.51000213623047;Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.;35.70000076293945;;36.27000045776367;Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.;59.060001373291016;In this article, we will be taking a look at the top 12 from Cathie Wood’s Q2 portfolio. To skip our detailed analysis of the first seven stocks and Wood’s investment history and strategy, you can go directly to the Top 5 From Cathie Wood’s Q2 Portfolio. This August on Bloomberg ETF IQ, ARK Investment […];105.31999969482422;;110.27999877929688;Investing in biotech stocks can be a leap of faith.  Many of those in the sector with the most promising therapies aren't profitable, and some have taken a drubbing so far this year.  If you're investing for the long term, however, biotech companies can provide huge potential.;75.16000366210938;;39.220001220703125;;72.16000366210938;;65.7699966430664;Investing in biotech stocks can be a leap of faith.  Many of those in the sector with the most promising therapies aren't profitable, and some have taken a drubbing so far this year.  If you're investing for the long term, however, biotech companies can provide huge potential.In this article, we will be taking a look at the top 12 from Cathie Wood’s Q2 portfolio. To skip our detailed analysis of the first seven stocks and Wood’s investment history and strategy, you can go directly to the Top 5 From Cathie Wood’s Q2 Portfolio. This August on Bloomberg ETF IQ, ARK Investment […];43.86000061035156;;26.940000534057617;;18.0;;10.520000457763672;;55.040000915527344;;28.700000762939453;;49.11000061035156;;40.529998779296875;;;;24.25;;14.989999771118164;;10.84000015258789;;5.829999923706055;;42.0;;41.959999084472656;;49.54999923706055;;10.630000114440918;;40.22999954223633;;16.469999313354492;;24.1200008392334;
2022-09-01;245.5;Amgen stock jumped Wednesday after outperforming expectations in a lung-cancer study. It brought rival Mirati along for the ride.Amgen's (AMGN) phase III CodeBreaK 200 study evaluating once-daily oral, Lumakras, for treating KRAS G12C-mutated non-small cell lung cancer meets its primary endpoint.;64.94999694824219;;600.6300048828125;;147.80999755859375;The U.S. is getting closer to offering a new generation of COVID-19 booster shots that can better protect against omicron and its subvariants to Americans.Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) develop the Omicron BA.4/BA.5-adapted bivalent vaccines at the FDA's recommendation.FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.The first potential problem for Pfizer is that its antiviral pill for coronavirus infections, Paxlovid, may not be performing as well as one might hope.  For infected people between 40 and 64 who were at high risk of developing severe COVID-19 and who were treated with Paxlovid, researchers found a hospitalization rate of 15.2 cases per 100,000 person-days.  While these findings still need confirmation from third-party researchers before they can be considered as ironclad facts, it's hard to overstate the possible significance of these results for Pfizer.NEW YORK & MAINZ, Germany, September 01, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a 30-µg booster dose of their Omicron BA.1 Bivalent COVID-19 Vaccine (COMIRNATY® Original/Omicron BA.1 15/15 µg) has been recommended for conditional marketing authorization (cMA) by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for individuals 12 years and older. The European Commission will review the CHMP recommendation and is expeVaccine makers' stocks sank Wednesday despite Food and Drug Administration authorization for their updated Covid booster shots.The Food and Drug Administration authorized newly modified Covid-19 booster shots to target the latest versions of the Omicron variant. The authorization, however, comes without a key part of the decision-making process. WSJ’s Daniela Hernandez explains what’s changed with these new booster shots. Photo: Laura KammermannThe FDA cleared updated Pfizer-BioNTech and Moderna vaccines against the BA.4 and BA.5 Omicron subvariants, in preparation for a fall booster campaign that could start within days.New booster shots could be rolled out within days to bolster people’s protection against Omicron subvariants BA.4 and BA.5.;200.6199951171875;;290.20001220703125;;199.7899932861328;;171.10000610351562;;155.9600067138672;;211.25;;332.8399963378906;"Bio-Techne Corporation (NASDAQ: TECH) today announced its plan to request shareholder approval during its upcoming 2022 Annual Meeting of Shareholders (the ""Annual Meeting"") for an increase in the total number of authorized shares of common stock through an amendment to the Company's Articles of Incorporation to implement a four-for-one forward stock split in the form of a stock dividend. The proposed amendment to the Company's Articles of Incorporation will be voted on by shareholders during BiThe recent 4.4% drop in Bio-Techne Corporation's ( NASDAQ:TECH ) stock could come as a blow to insiders who purchased...";2.740000009536743;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Behzad Mahdavi, Ph.D., MBA, has joined as senior vice president of biopharma manufacturing and life sciences tools. In this new role, Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities. Dr. Mahdavi brings more than 20 years of experience in developing and leading innovative patient-centric growth;90.87000274658203;;32.2599983215332;;71.3499984741211;Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.;36.2400016784668;Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.;31.950000762939453;;59.970001220703125;;105.62999725341797;Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...Neurocrine is shrugging off market woes, buoyed by movement drug Ingrezza and NBIX stock investors' hope for its pipeline.;110.08000183105469;Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;82.04000091552734;Amgen stock jumped Wednesday after outperforming expectations in a lung-cancer study. It brought rival Mirati along for the ride.Amgen's (AMGN) phase III CodeBreaK 200 study evaluating once-daily oral, Lumakras, for treating KRAS G12C-mutated non-small cell lung cancer meets its primary endpoint.;41.290000915527344;PASADENA, Calif., September 01, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:;73.83000183105469;Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;65.5999984741211;;46.290000915527344;;27.030000686645508;;18.219999313354492;;10.220000267028809;;55.58000183105469;CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the Wells Fargo 2022 Healthcare Conference on Thursday, September 8, 2022 at 9:45 a.m. ET in Boston. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the;27.979999542236328;;48.470001220703125;;40.58000183105469;"Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the 2022 Wells Fargo Healthcare Conference being held in Boston, MA on September 7-9, 2022.";;;24.34000015258789;;14.130000114440918;;10.59000015258789;;5.889999866485596;;43.459999084472656;;43.560001373291016;;50.52000045776367;;11.069999694824219;;40.459999084472656;;16.8700008392334;SAN DIEGO, September 01, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:;24.360000610351562;
2022-09-02;242.3699951171875;;63.81999969482422;Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;580.6199951171875;;147.89999389648438;Pfizer and its German partner BioNTech have filed proceedings at the High Court of England and Wales,  seeking a judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac's European patents, according to a regulatory filing on Friday.  In July, CureVac had filed a patent lawsuit against BioNTech over its use of mRNA technology, seeking fair compensation from the company and two subsidiaries for infringement of its intellectual properly rights.  Pfizer and BioNTech later filed a complaint with a U.S. district court, seeking a judgment that they did not infringe U.S. patents held by CureVac.Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.Pfizer /BioNTec and Moderna are part of The Zacks top Analyst Blog.The latest booster shots, which health authorities have been counting on to protect people once the weather turns colder and cases often rise, will be widely available in the coming days.Canada on Thursday authorized Moderna Inc's bivalent COVID-19 shots for adults, adding the first Omicron-adapted vaccine to its arsenal just as falling temperatures are poised to force people indoors where the risk of infection is higher.  COVID vaccines were originally developed to target the coronavirus strain first detected in China in 2019.  Several new variants have since been detected, with Omicron considered one of the most contagious.;196.07000732421875;Illumina's top line is going to be under more pressure in the short term as well as in the medium term.As Warren Buffett says, it's best to be greedy when others are fearful, and right now we're in fearful times.  Over the last 10 years, Illumina's (NASDAQ: ILMN) return of 380% absolutely smashed the market's gain of 246.1%.  To accomplish that feat, it sold, installed, and serviced more than 20,000 of its gene sequencer devices, which hospitals and biomedical researchers use to analyze genetic information.Global conference to focus on advancing the life-saving impacts of genomic health care;281.0400085449219;;196.02999877929688;;166.8800048828125;;152.33999633789062;;205.4499969482422;;330.0299987792969;;2.509999990463257;;89.63999938964844;BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;30.760000228881836;;70.20999908447266;;36.09000015258789;;30.389999389648438;;56.0099983215332;NTLA-2002, an in vivo genome editing candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) after a single dose, is currently being evaluated in a Phase 1/2 study CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA;103.01000213623047;;109.37999725341797;Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;81.02999877929688;Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;39.41999816894531;;72.91999816894531;Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;63.7400016784668;;46.209999084472656;;26.719999313354492;Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 2022 in Boston, Massachusetts Hosting 1x1 investor meetings only Wells Far;17.90999984741211;;10.0600004196167;;52.68000030517578;;27.829999923706055;;47.75;NOVATO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Eric Crombez, Chief Medical Officer, Gene Therapy, will participate in a Rare Disease Panel at Citi's 17th Annual BioPharma Conference on Wednesday, September 7, 2022, at 11:20 AM ET. The live and archived webcast of the presentation w;38.91999816894531;;;;23.700000762939453;;14.180000305175781;;10.149999618530273;;5.320000171661377;;43.2400016784668;;43.119998931884766;;51.61000061035156;;10.84000015258789;;38.77000045776367;;16.729999542236328;;24.510000228881836;
2022-09-06;242.22000122070312;;63.38999938964844;Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.;573.969970703125;;138.5800018310547;Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.;201.02000427246094;"The European Commission says Illumina's acquisition of Grail ""would have stifled innovation and reduced choice in the emerging market for blood-based early cancer detection tests.""Notable business headlines include Irish data privacy regulators fining Instagram over teen data use, the European Union blocking life sciences firm Illumina's acquisition of Grail, and China’s city of Chengdu remaining on lockdown following an earthquake.The European Commission has prohibited Illumina Inc's (NASDAQ: ILMN) acquisition of GRAIL. The company is reviewing the Commission's order and intends to appeal the decision. The company said the ""merger of Illumina and GRAIL would usher in a transformational phase in the detection and treatment of cancer by facilitating equal and affordable access to the life-saving early cancer detection Galleri test."" The EC decision follows last week's U.S. Federal Trade Commission judge ruling in favor of IIllumina, Inc. (NASDAQ:ILMN), today received a decision from the European Commission prohibiting the company's acquisition of GRAIL. The company is reviewing the Commission's order and intends to appeal the decision. The EC decision follows last week's ruling by US Federal Trade Commission judge in favor of Illumina's acquisition of GRAIL.U.S. life sciences firm Illumina will have to divest biotechnology company Grail after an EU veto of the $7.1 billion acquisition over concerns it would hurt competition and stifle innovation.  The European Commission, which acts as the competition enforcer in the 27-country bloc, said on Tuesday that Illumina's remedies did not adequately address its concerns, confirming a Reuters story in July.  Illumina completed the deal in August last year ahead of EU regulatory approval, resulting in an EU order to keep Grail separate and appoint independent managers to run the company until the investigation's conclusion.By Peter NurseBy Geoffrey Smith";279.17999267578125;;194.69000244140625;;163.4499969482422;;149.02000427246094;;201.25999450683594;CAMBRIDGE, Mass., September 06, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 11:10 am ET at the Sheraton New York Hotel.;329.0400085449219;Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 12:50 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;2.4100000858306885;;88.8499984741211;;31.190000534057617;;69.11000061035156;;35.369998931884766;;28.530000686645508;Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.;55.369998931884766;;103.0199966430664;Futures rose modestly. Oil prices erased gains despite OPEC+ cut production while natgas fell despite Russia cutting off European natural gas.;108.68000030517578;The FDA has removed the clinical hold on Sarepta Therapeutics Inc's (NASDAQ: SRPT) SRP-5051 (vesleteplirsen) for Duchenne muscular dystrophy who are amenable to exon 51 skipping. After discussions with FDA and as part of the lift, Sarepta will adjust the global trial protocol to include expanded monitoring of urine biomarkers. ​ Also Read: Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial. The hold in Part B of Study 5051-201, also known as MOMENTUM, followed a serious aCAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 12:30 p.m. E.T. The fireside chat will be held at the Sheraton New York. The presentation will be webcast live under the Events & Presentations section of the investor relatiCAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on SRP-5051 (vesleteplirsen), the Company’s investigational, next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. After discussions w;78.04000091552734;;37.220001220703125;;70.66000366210938;;62.7599983215332;While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.Biotech is undoubtedly in a bear market.  Vertex Pharmaceuticals (NASDAQ: VRTX), for example, has had little trouble shrugging off this bear market.  Vertex's stock has been booming of late mainly because of its high-growth cystic fibrosis franchise.;48.349998474121094;;25.299999237060547;;17.3700008392334;;9.8100004196167;PALO ALTO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: Citi’s 17th Annual BioPharma Conference, Boston, MA: September 7th at 8:50 am ET Morgan Stanley Global Healthcare Conference, New York, NY: September 13th at 7:20 am ET Bair;52.93000030517578;;27.170000076293945;;47.0;;38.529998779296875;;;;22.1200008392334;;14.130000114440918;;9.399999618530273;;5.480000019073486;;41.650001525878906;;42.83000183105469;;50.779998779296875;;10.460000038146973;;38.11000061035156;SOUTH SAN FRANCISCO, Calif., September 06, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience will present at the Baird 2022 Global Healthcare Conference on Tuesday, September 13th, at 2:35 p.m. Eastern Time in New York, NY.;16.1299991607666;;23.950000762939453;
2022-09-07;244.7899932861328;Today I’m writing about Dow stocks to buy. Seasoned investors are realizing that many of the 30 members of the Dow Jones Industrial Average (DJIA) are now trading at low valuation levels and prices. The index serves as a bellwether that tracks investors’ sentiment. These large-cap, well-known companies are widely regarded as safe havens from market volatility. With their remarkable longevity and solid fundamentals, these companies tend to be among the first businesses to recover from economic un;64.79000091552734;Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.In February 2019, Eleonora was preparing to go out with a friend when she suddenly fainted. She woke up in the hospital near her home in Italy and didn’t remember a thing. But she will never forget...SANTA MONICA, Calif., September 06, 2022--KITE’S CAR T-CELL THERAPY TECARTUS® GRANTED EUROPEAN MARKETING AUTHORIZATION FOR ADULT RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIAGilead Sciences Inc (NASDAQ: GILD) outlined new data for the antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) ahead of their presentation at the European Society of Medical Oncology. The results come from a post hoc subgroup analysis from the Phase III TROPiCS-02 study, which examines the impact of the therapy in the later-line treatment of breast cancer. Progression-free survival (PFS) analysis showed that Trodelvy improved median PFS compared to the prescriber’s choice of ch;596.4400024414062;;144.11000061035156;JERUSALEM, Israel, and MAINZ, Germany, September 7, 2022 —BioNTech SE (Nasdaq: BNTX) announced today that Prof. Ugur Sahin, CEO and Co-founder of BioNTech, visited Israel to meet with the Minister of Economy and Industry, Major General (res.) Orna Barbivay, the Accountant General, Mr. Yali Rothenberg, and other government officials. The visit was set to promote the potential cooperation between the State of Israel, its academic institutions and BioNTech on pandemic preparedness and discuss potenHealth authorities expect to recommend that people get boosters once a year, starting with the new shots now rolling out, a shift from their current practice of issuing new advice every several months.;205.75;Companies In The News Are: BBBY, SGFY, CVS, LOW, ILMN.Presentations will include evidence on how genomic signatures and next-generation sequencing can improve the care of patients with cancerThe European Union’s antitrust regulator says the acquisition of Grail would stifle innovation and reduce choice in the blood-test market, putting a $7.1 billion merger into jeopardy after a U.S. judge allowed it to proceed.Illumina stock jumped Tuesday after the EC blocked its acquisition of Grail — another step in a battle over the early cancer-detection outfit.;284.44000244140625;;200.6699981689453;;164.24000549316406;;152.42999267578125;BOTHELL, Wash., September 07, 2022--Seagen Inc. (Nasdaq:SGEN) today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 12:55 p.m. Eastern Time. The presentation will be webcast live and available for replay from the investor section of Seagen’s website at investor.seagen.com.;208.86000061035156;;334.1300048828125;;2.630000114440918;;91.20999908447266;;32.38999938964844;;71.41000366210938;;37.369998931884766;;30.6200008392334;Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Shares of beaten-down biotech Novavax (NASDAQ: NVAX) are under pressure yet again.  For the year, Novavax's stock has now lost a staggering 79% of its value, and on Tuesday, it hit a fresh 52-week low.  The stock has been locked in a downward spiral over concerns that its COVID-19 vaccine Nuvaxovid may fail to live up to expectations from a commercial standpoint.;57.61000061035156;;105.56999969482422;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 10:35 a.m. Eastern Time on Tuesday, September 13, 2022 in New York. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.;112.9000015258789;The FDA lifts the clinical hold placed on Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, being evaluated in the ongoing phase II MOMENTUM study.- Recipients include 15 individuals living with Duchenne and five siblings in Duchenne families CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced twenty recipients of Route 79, The Duchenne Scholarship Program for the 2022-2023 academic year. The Program was created in 2018 to recognize exceptional individuals living with Duchenne muscular dystrophy as they pursue their post-s;80.30000305175781;;39.16999816894531;Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders have seen the share price descend 19% over the month. But...;75.87000274658203;Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective September 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 18,170 shares of its common stock and an aggregate of 9,083 restricted stock units (RSUs) to thirteen new employees under Blueprint Medicines' 2020 Inducement;65.01000213623047;CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;46.119998931884766;;27.309999465942383;;17.780000686645508;ALAMEDA, Calif., September 06, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in September:;10.640000343322754;;55.810001373291016;;29.489999771118164;Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;47.0;;39.40999984741211;;;;22.020000457763672;SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, at 4:05 p.m. ET. A live webcast of the fire side chat can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About Vir BiotechnologyVir Biotechnology is a commercial;14.279999732971191;;9.529999732971191;;5.860000133514404;;43.45000076293945;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a planned 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). In the study, eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for its co-primary and secondary efficacy endpoints compared to the external placebo group. Eplontersen dem;45.36000061035156;;52.209999084472656;;10.859999656677246;;40.02000045776367;;16.850000381469727;Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;24.139999389648438;
2022-09-08;245.4499969482422;Amgen (NASDAQ:AMGN) today announced results from two significant Phase 3 clinical studies of oral Otezla® (apremilast), demonstrating efficacy in pediatric patients with moderate to severe plaque psoriasis and in adults with moderate to severe genital psoriasis, at the 31st European Academy of Dermatology and Venereology (EADV) Congress, taking place in Milan, Italy, Sept. 7-10, 2022.Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congress (ESMO) at 1:30 p.m. ET on Monday, Sept. 12, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will discuss the data being presented from the LUMAKRAS® (sotorasib) CodeBreaK 200 confirmatory Phase 3 study in non-small cell lung cancer and data from th;65.0999984741211;Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.Gilead Sciences Inc's Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ahead of a presentation at a European cancer meeting on Friday.  Put another way, the Gilead drug reduced the risk of death by 21% in the Phase III trial.  The study being presented at the European Society for Medical Oncology's annual meeting in Paris compares Trodelvy to chemotherapy in 543 patients with hormone-sensitive tumors that test negative for a receptor called HER2 and who had stopped responding to at least two earlier courses of therapy.FOSTER CITY, Calif., September 07, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the positive overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In the study, Trodelvy demonstrated a statistically significant and clinically meaThe European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.Regulatory and acquisition updates from Gilead (GILD) and Forma (FMTX) are key highlights from the biotech sector during the past week.;708.8499755859375;"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented detailed positive results from the second of two Phase 3 trials (PRIME) evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis in a late-breaking session at the European Academy of Dermatology and Venereology (EADV) 2022 Congress. These data, which were consistent with the detailed data from the first Phase 3 trial (PRIME2) in prurigo nodularis, show Dupixent significantly reduced itch and skin lesiBayer said on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron, has been shown to work as well when given at a higher dose at a longer interval between injections.  Two late-stage trials showed that Eylea, which is normally given in doses of 2 milligrams every eight weeks, was as effective when given at 8 mg at longer intervals, without any additional safety issues, the German company said in a statement.  The results will help Bayer compete with Roche, whose rival drug Vabysmo was launched this year.Yahoo Finance's Ines Ferré discusses how markets are moving in early trading.Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) two pivotal trials evaluating aflibercept 8 mg with 12- and 16-week dosing regimens met the primary endpoints in diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The PHOTON trial in DME and the PULSAR trial in wAMD achieved non-inferiority in vision gains compared to the currently-approved 2 mg Eylea 8-week dosing regimen. Also Read: Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product. 91% and 89%Regeneron Pharmaceuticals Inc. said Thursday that an 8-milligram dose of aflibercept successfully treated patients with diabetic macular edema and wet age-related macular degeneration in a pair of pivotal trials. Regeneron's stock was halted ahead of the announcement. The studies ""demonstrated that nearly 90% of patients with diabetic macular edema and almost 80% of patients with wet age-related macular degeneration were able to maintain a 16-week dosing regimen,"" Dr. David Brown, director of reBayer said on Thursday that its anti-blindness treatment Eylea, jointly developed with Regeneron, was shown to work as well when given at a higher dose at a longer interval between injections.  Eylea, which is normally given at 2 milligrams every eight weeks, was shown in two late-stage trials to be as effective when given at 8 mg at longer intervals, without any additional safety issues, the German company said in a statement.  The results will help Bayer compete with Roche, while rival drug Vabysmo was launched this year.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The PHOTON trial in DME and the PULSAR trial in wAMD both demonstrated that aflibercept 8 mg 12- and 16-week dosing regimens achieved non-inferiority in vision gains compared to the EYLEA 8-week dosing regimen.";147.1999969482422;;207.30999755859375;Illumina, Inc. (NASDAQ:ILMN) today announced that investors, analysts, and other interested parties may view a live webcast of the Innovation Roadmap session of the Illumina Genomics Forum, which will be hosted by Francis deSouza, Chief Executive Officer, and Alex Aravanis, Chief Technology Officer. The session will be held from 9:00-10:00am Pacific Time (12:00-1:00pm Eastern Time), Thursday, Sept. 29, 2022.The DNA-sequencing titan in November 2018 proposed to acquire smaller peer PacBio .  The deal would've given Illumina the tools it needed to keep up-and-coming challenger Oxford Nanopore Technologies  at bay - at least for a little while longer.  Trade regulators in the UK, where Oxford Nanopore is based, stepped in to block the acquisition and protect one of its homegrown technological gems.;288.989990234375;;207.97999572753906;;167.2100067138672;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 07, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, 2022 with a fireside chat at 9:10 a.m. ET.";152.63999938964844;BOTHELL, Wash., September 07, 2022--Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2022, to be held September 9-13 in Paris, France. One of two late-breaking oral presentations will feature results from Cohort K of EV-103 (also known as KEYNOTE-869), a phase 1b/2 clinical trial conducted in partnership with Astellas. Cohort K is evaluating PADCEV® (enfortumab vedotin-;226.3000030517578;Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The company previously announced topline results from the APOLLO-B study in August 2022. The 12-month study achieved its primary endpoint, with patisiran demonstrating a statistically significant and clinically meaningful benefit on functional capacity, as measured by the 6-Minute Walk Test (6-MWT), compared to placeCAMBRIDGE, Mass., September 08, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The results were presented today in a late-breaker session at the 18th International Symposium on Amyloidosis (ISA). The Company previously announced positive topl;342.67999267578125;Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, will present initial data on their novel non-invasive saliva profiling assay for Sjögren's Syndrome diagnosis and monitoring at the 15th International Symposium on Sjögren's Syndrome in Rome, Italy on Friday Sept 9. Exosome Diagnostics' novel Sjögren's Syndrome diagnostic and monitoring tool leverages extracellular vesicles (EVs) to monitor the RNA transcriptome from a small saliva sample.;2.880000114440918;;93.01000213623047;;34.0;;71.72000122070312;;38.939998626708984;;30.280000686645508;Investors are also scaling back the premiums they're willing to pay for stocks.  As a result, many high-priced growth stocks have come down in valuation.  Three Nasdaq stocks that took a beating last month are Novavax (NASDAQ: NVAX), Tandem Diabetes Care (NASDAQ: TNDM), and Bumble (NASDAQ: BMBL).Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.;61.33000183105469;;106.68000030517578;"Neurocrine Biosciences, Inc.  is a biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.  The company reported strong second-quarter revenue numbers last month and raised their sales target for Ingrezza, their tardive dyskinesia medicine.  Prices made a ""neckline"" around $100 and the upside breakout over $100 is clear and trading volume surged for ""confirmation.""";119.23999786376953;;84.3499984741211;Mirati Therapeutics Inc (NASDAQ: MRTX) announced results from the KRYSTAL-1 Phase 1/2 study of adagrasib with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation. The data will be presented at the European Society for Medical Oncology (ESMO) Congress 2022. In this analysis, 44 patients received adagrasib monotherapy, and 32 received the combination of adagrasib + cetuximab, with a follow-up of 20.1 months and 17.5 months, respectively. Related: MiMirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from KRYSTAL-1, a multicohort Phase 1/2 study, evaluating adagrasib with or without cetuximab in patients with advanced CRC harboring a KRASG12C mutation.;39.16999816894531;;77.69999694824219;Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;66.2699966430664;;43.33000183105469;;28.260000228881836;;17.809999465942383;Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.ALAMEDA, Calif., September 07, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from COSMIC-313, an ongoing phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX®), nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma (RCC). The data, including detailed results of the primary endpoint of progression-free survival (PFS), are being presente;11.289999961853027;;57.06999969482422;;31.8700008392334;;47.72999954223633;;39.66999816894531;Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;;;22.260000228881836;;14.619999885559082;;9.869999885559082;Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 2022 Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 14, 2022, at 1:05 p.m. Pacific Time (4:05 p.m. Eastern Time).;6.190000057220459;PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.;44.27000045776367;Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;48.41999816894531;;52.25;;11.300000190734863;;41.9900016784668;;17.420000076293945;;24.059999465942383;
2022-09-09;247.69000244140625;Amgen's biosimilar drug is close to stealing away sales from AstraZeneca's rare disease drug called Soliris.T-Mobile US, NextEra Energy, Amgen, 3M and Itau Unibanco Holding are part of The Zacks top Analyst Blog .Amgen's Lumakras extends duration before cancer worsens in certain cases of genetic mutation in small cell lung cancer patients.Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), NextEra Energy, Inc. (NEE) and Amgen Inc. (AMGN).Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 2022 Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 13, 2022. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.;65.27999877929688;The Relative Strength (RS) Rating for Gilead Sciences entered a new percentile Friday, with a rise from 78 to 84.  Over 100 years of market history shows that the top-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves.  Gilead Sciences is working on a long consolidation with a 74.22 buy point.Gilead Sciences Inc (NASDAQ: GILD) announced the overall survival (OS) results from the Phase 3 TROPiCS-02 study of Trodelvy (sacituzumab govitecan-hziy) versus comparator chemotherapy (TPC) in HR+/HER2- metastatic breast cancer patients who received endocrine-based therapies and at least two chemotherapies. The TROPiCS-02 study met its primary endpoint of progression-free survival earlier this year. Related: Gilead's Breast Cancer Drug Improves Progression-Free Survival in HR+/HER2- Metastatic;724.3200073242188;"Morgan Stanley upgraded Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) to Overweight from Equal Weight with a price target of $851, up from $625. The analyst says Eylea's ""tail risk is removed"" following yesterday's aflibercept 8 mg data, and Regeneron is now a ""key large-cap biotech growth story."" The analysts still see a ""significant upside"" despite yesterday's rally, driven by a ""clear growth trajectory at the company,"" as High-dose Eylea now becomes the agent of choice for front-line patientRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to share updates on the company's oncology portfolio in conjunction with the European Society for Medical Oncology (ESMO) Annual Congress on Monday, September 12, 2022. The webcast is scheduled for 8:00 AM ET (2:00 PM CEST) and may be accessed from the ""Investors & Media"" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. To participate via telephone, please reCompanies in The News Are: REGN, JPM, CASY, GMERegeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.FEATURE  Stock futures were rising to end the week as traders remained focused on monetary policy and inflation. Futures for the  were up 0.8% and    futures gained 0.9%. Futures for the tech-heavy   were rising 1.By Peter NurseStudies ""support aflibercept 8 mg as a potential new standard-of-care,"" Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.Yahoo Finance's Jared Blikre looks at how markets closed on Thursday, with meme stocks and financials leading the way.Wall Street's main indexes posted gains on Thursday mainly lifted by financial institutions and healthcare companies, as investors digested hawkish remarks from policymakers that cemented bets of a large interest rate hike later this month.  Indexes bounced back and forth in a choppy trading as concerns over Federal Reserve's next steps to tame a surging inflation remain.  ""There's just a lot of uncertainty and I think people aren't going to really make up their minds for longer than five minutes or five seconds, you know, until there's a little bit more clarity or light at the end of the tunnel,"" said Grace Lee, an equity income senior portfolio manager at Boston-based Columbia Threadneedle Investments.Yahoo Finance Live examines Regeneron Pharmaceuticals' stock following reports of positive results in its eye treatment drug trials.Regeneron announces promising results from late-stage clinical trials on its signature eye drug medication, Eylea.Biotechnology giant Regeneron Pharmaceuticals is up approximately 18% in trading Thursday on the heels of positive news on their new blockbuster drug for eyes -- Eylea. Traders could look at buying REGN but the risk/reward profile is problematic to me.Shares of the large-cap biotech Regeneron Pharmaceuticals (NASDAQ: REGN) were up by a healthy 19.2% on exceptionally heavy volume as of 1:46 p.m. ET Thursday afternoon.  Earlier today, Regeneron and Bayer announced that their jointly developed anti-blindness medication Eylea (generic name: aflibercept) met the primary endpoint in two late-stage trials.  The big deal is that these positive trial results support the use of Eylea at higher dosages (8 mg compared to 2 mg) at longer dosing intervals (16 weeks versus 8 weeks).Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) presented detailed results from the second of two Phase 3 trials (PRIME) evaluating Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis. Prurigo nodularis patients experience intense, persistent itch with thick skin lesions (nodules) that can cover most of the body. Related: Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids. These data, consistent withPer the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.";150.91000366210938;"Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and tolerability profile, building on the positive interim data presented at AACR in AprilStrongest responses seen in testicular cancer patients treated at dose level 2 after lymphodepletion with overall response rate of 57% and a disease control rate of 85%; product candidate recently received Priority Medicines designation by the European Medicines Agency for this indication MAINZ, Germ";210.35000610351562;At ECP 2022, Illumina presents new validation for TSO ComprehensiveThe gene-sequencing giant spent $8 billion for a cancer-screening pioneer. But antitrust regulators in Europe and the U.S. have come out against the deal, and the takeoff has yet to come.;292.1099853515625;;211.83999633789062;;170.7100067138672;;155.47000122070312;;223.27000427246094;Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;346.7799987792969;;2.940000057220459;;92.93000030517578;;35.900001525878906;;72.19999694824219;;40.650001525878906;;31.719999313354492;COVID-19 vaccine stocks came under enormous pressure last month.  Over the course of August, Moderna's (NASDAQ: MRNA) shares dipped by a hefty 19.3%, Pfizer's (NYSE: PFE) stock ticked lower by a notable 10.4%, and Novavax's (NASDAQ: NVAX) equity lost an eye-catching 39.4% of its value, according to data from S&P Global Market Intelligence.  What caused investors to hit the exits on these top three coronavirus vaccine stocks?;64.44000244140625;Review of first clinical data from ongoing Phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema (HAE) presented at the 2022 Bradykinin Symposium Event to include interim safety and serum TTR reduction data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis CAMBRIDGE, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on deve;106.51000213623047;The market rally was up and down, but closed near Thursday's highs, just below 50-day line resistance. Zscaler and DocuSign jumped.;118.44000244140625;"Morgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating. The analyst notes concerns regarding the Phase 3 EMBARK study, with a modest probability of success (60%) for that study. He also acknowledges that the option value associated with an early filing is not yet fully reflected in SRPT. ""We see a likely October filing and thus December acceptance as the key catalyst for SRPT into year-end,"" writes the analyst. The question looms whether the";84.7699966430664;;38.56999969482422;;76.06999969482422;;66.95999908447266;CRISPR Therapeutics AG (CRSP) closed at $66.27 in the latest trading session, marking a +1.94% move from the prior day.;48.79999923706055;;28.100000381469727;;17.899999618530273;Exelixis Inc (NASDAQ: EXEL) announced detailed results from the COSMIC-313 Phase 3 trial cabozantinib (Cabometyx), nivolumab, and ipilimumab combo in untreated advanced renal cell carcinoma (RCC) patients. The data are being presented at the 2022 European Society of Medical Oncology (ESMO) Congress. As previously announced, the cabozantinib combination significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab. The cabozantinib combin;11.8100004196167;;57.5099983215332;;31.350000381469727;;49.2400016784668;;41.400001525878906;;;;22.3799991607666;;15.119999885559082;;10.239999771118164;;6.690000057220459;;46.84000015258789;Morgan Stanley has assumed coverage on Ionis Pharmaceuticals Inc (NASDAQ: IONS) with an Overweight (previously Underweight) rating and a price target of $57 from $30 to capture the optionality in these near-term readouts. The analyst has added estimates for Ionis's near-term pipeline products (donidalorsen, fesomersen, IONIS-AGT-LRx, IONIS-FBLRx, and cimdelirsen) as well as associated increases in operating expenses to fund these programs. Related: AstraZeneca - Ionis Eplontersen Achieves Positi;48.970001220703125;;52.0;;11.199999809265137;;44.040000915527344;;17.3799991607666;;24.010000228881836;
2022-09-12;237.6199951171875;"Marc Lichtenfeld, an expert in biotech and income stocks, notes that a lot of Wall Street money moves into companies that issue positive Phase 2 clinical trial data.Amgen Inc (NASDAQ: AMGN) announced detailed results from the global Phase 3 CodeBreaK 200 trial. These data will be presented at the European Society for Medical Oncology (ESMO) Congress 2022 The data showed that oral Lumakras/Lumykras (sotorasib) led to significantly superior progression-free survival (PFS) and higher objective response rate (ORR), in KRAS G12C-mutated non-small cell lung cancer (NSCLC), compared with intravenous chemotherapy, docetaxel. Lumakras reduced the risk of disease proBristol Myers Squibb shares rose 7% in premarket trade after the company said the U.S. Food and Drug Administration approved Sotyktu, which the drugmaker said was the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years. Bristol Myers Squibb said the approval came after Phase 3 trials found it was more effective compared to placebo and twice-daily Otezla, made by Amgen . Analysts at Mizuho Securities said Sotyku was approved without a so-called black boxAmgen (NASDAQ: AMGN) today announced updated data from its Phase 1b CodeBreaK 101 study, one of the most comprehensive global clinical development programs in patients with KRAS G12C-mutated colorectal cancer (CRC). These data show that combining LUMAKRAS®/LUMYKRAS® (sotorasib) with Vectibix® (panitumumab), Amgen's monoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody, demonstrated encouraging efficacy and safety. Overall, the confirmed objective response rate (ORR) was 30% in paAmgen Inc's Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said on Sunday.  The company is also testing whether the drug could be effective against lung cancer earlier in the disease, and said last month a small study of Lumakras combined with immunotherapy found high rates of liver toxicity and that further study was needed.  More detailed results from the 345-patient study, including median progression-free survival - the length of time until the cancer begins to worsen - will be presented on Monday at the annual meeting of the European Society for Medical Oncology (ESMO) in Paris.Amgen (NASDAQ: AMGN) today announced detailed results from the global Phase 3 CodeBreaK 200 trial, which showed once-daily oral LUMAKRAS®/LUMYKRAS® (sotorasib) led to significantly superior progression-free survival (PFS; primary endpoint) and a significantly higher objective response rate (ORR; a key secondary endpoint) in patients with KRAS G12C-mutated non small cell lung cancer (NSCLC), compared with intravenous chemotherapy, docetaxel. These data will be presented today, Monday, Sept. 12 at";68.01000213623047;Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise. The drug cited in the case is tenofovir alafenamide, which is included in the formulation of several Gilead therapies, including Biktarvy and Truvada. Gilead said it agreed to a non-exclusive license with several generic drug manufacturers - Cipla Ltd. , Lupin Ltd. , Apotex Inc., Macleods Pharmace;710.739990234375;Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced early data for ubamatamab in recurrent ovarian cancer and REGN5093 in MET-altered advanced non-small cell lung cancer (NSCLC). Within 42 patients who received full doses of ubamatamab, a 14% (6 of 42 patients) overall response rate (ORR) was achieved across dose levels. The ORR increased to 21% in those without visceral metastases and 31% in those with high MUC16-expressing tumors. Across dose levels, the disease control rate was 57%, and thRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo® (cemiplimab) as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma (CSCC). The data, from the primary analysis of a confirmatory Phase 2 trial, were presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris and concurrently published in the New England Journal of Medicine (Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive data from multiple expansion cohorts of an initial Phase 1 trial for an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo® (cemiplimab) in advanced melanoma. The results were shared in a mini-oral session at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.;148.27000427246094;NEW YORK & MAINZ, Germany, September 12, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 Vaccine (COMIRNATY® Original/Omicron BA.4/BA.5 15/15 µg) has been recommended for conditional marketing authorization (cMA) by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for individuals ages 12 years and older. The European Commission will review the CHMP rec;212.49000549316406;"Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will convene a panel of leading visionaries, titled ""Architecting Health's Radically New Infrastructure,"" as part of its inaugural Illumina Genomics Forum being held in San Diego from September 28 through October 1. This main-stage session, taking place on Friday, September 30, will feature renowned experts addressing the cornerstone challenges and opportunities facing the healtFull agenda now available for September 28–October 1 event";293.4800109863281;;212.8800048828125;;173.75;BeiGene Limited (NASDAQ: BGNE) shared updates from its solid tumor development program for tislelizumab at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. The Phase 3 RATIONALE 301 trial of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma met its primary endpoint of overall survival (OS) non-inferiority. The median OS was 15.9 months for tislelizumab compared to 14.1 months for Bayer AG (OTC: BAYRY) Nexavar (sorafenib). Rela;150.10000610351562;"BOTHELL, Wash. & TOKYO & RAHWAY, N.J., September 12, 2022--Seagen Inc. (Nasdaq:SGEN), Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas"") and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K investigating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and PADCEV alone as first-liAstellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas""), Seagen Inc. (Nasdaq:SGEN) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K investigating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced";212.0;"CAMBRIDGE, Mass., September 12, 2022--Alnylam Pharmaceuticals, Inc. (""Alnylam"") (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $900 million aggregate principal amount of convertible senior notes due 2027 (the ""notes"") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). In connection with this offering, Alnylam expects to gr";344.80999755859375;;3.1700000762939453;The White House today announced that President Biden intends to appoint Renee Wegrzyn, PhD, as the first Director of the Advanced Research Projects Agency for Health (ARPA-H). Dr. Wegrzyn is currently the Vice President for Business Development at Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming. ARPA-H was established in March 2022 to drive transformative health breakthroughs that cannot readily be accomplished through traditional research or commercial activity;90.23999786376953;;36.86000061035156;Inspire (INSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.;70.52999877929688;;41.61000061035156;;33.0;The European Commission has approved the expanded conditional approval of Novavax Inc's (NASDAQ: NVAX) Nuvaxovid COVID-19 vaccine as a homologous and heterologous booster for adults aged 18 and older. The approval follows the recommendation made by the European Medicines Agency's Committee for Medicinal Products for Human Use earlier this month. The expanded approval was based on data from Novavax's Phase 2 trial conducted in Australia, a separate Phase 2 trial conducted in South Africa, and theShares of Novavax Inc. were up 2.4% in trading on Monday after the company said its COVID-19 booster has been authorized in Europe for adults. Novavax's stock has declined 77.3% so far this year, while the S&P 500 is down 14.6%.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) as a homologous and heterologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory synGood news from the Food and Drug Administration (FDA) can send biotech stocks into the stratosphere.  Patrick Bafuma (Mirati Therapeutics): One company that has to be champing at the bit to get FDA approval is Mirati Therapeutics, with its lead drug adagrasib.;65.19999694824219;;106.66000366210938;Parkinson & Movement Disorder (PMD) Alliance, in partnership with Neurocrine Biosciences (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company committed to meeting the needs of people with complex and debilitating disorders, today announced results from the Survey Assessment: Impact of OFF Time on People with Parkinson's Disease and Their Care Partners. Findings revealed that despite a majority of these people with Parkinson's disease (PD) and their care partners being signifiThe stock market rally is reviving, but is even stronger than the major indexes suggest. Tesla is among stocks in buy areas.;116.55000305175781;Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end;86.5999984741211;Good news from the Food and Drug Administration (FDA) can send biotech stocks into the stratosphere.  Patrick Bafuma (Mirati Therapeutics): One company that has to be champing at the bit to get FDA approval is Mirati Therapeutics, with its lead drug adagrasib.;39.599998474121094;;75.47000122070312;;69.81999969482422;;51.689998626708984;;29.1200008392334;;17.969999313354492;Exelixis Inc (NASDAQ: EXEL) announced results from the dose-escalation stage of STELLAR-001, an ongoing phase 1b trial evaluating XL092 as a single agent and in combination with atezolizumab for locally advanced or metastatic solid tumors. The maximum tolerated dose was determined to be 120 mg, and the recommended dose for the expansion phase is 100 mg for both single-agent XL092 and XL092 in combination with atezolizumab. Tumor reduction was seen in 71% of patients receiving single-agent XL092;12.359999656677246;;57.58000183105469;;31.329999923706055;;48.779998779296875;;42.0;;;;22.170000076293945;;15.699999809265137;Full Year 2022 Abcam PLC Earnings CallAbcam plc (NASDAQ: ABCM) (AIM: ABC) ('Abcam', the 'Group' or the 'Company'), a global leader in the supply of life science research tools, today announces its interim results for the six-month period ended 30 June 2022 (the 'period').;10.109999656677246;;6.949999809265137;;48.65999984741211;;50.0;;53.119998931884766;;11.079999923706055;;44.279998779296875;;17.90999984741211;SAN DIEGO, September 12, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The FDA has granted a priority review and assigned a PDUFA (Prescription Drug User Fee Act) action date of March 12, 2023. The FDA has also informed the company that at this time they are not planning to hold an Advisory Committee meeting.;24.219999313354492;Marc Lichtenfeld, an expert in biotech and income stocks, notes that a lot of Wall Street money moves into companies that issue positive Phase 2 clinical trial data.
2022-09-13;226.86000061035156;New data from the first of a new type of cancer drug suggest its benefits and limitations, while leaving room for other candidates seeking to enter the lucrative market.  Amgen lung-cancer pill Lumakras beat out a common chemotherapy in a late-stage study, helping patients survive without their tumors getting worse, though it failed to prove that it reduced overall deaths, the company said.  The Food and Drug Administration conditionally approved Lumakras last year based on encouraging early-stage study data but required Amgen to conduct a confirmatory study, which the company reported Sunday.Amgen (NASDAQ:AMGN) will present at Bank of America Merrill Lynch's 2022 Global Healthcare Conference at 4:55 a.m. ET on Thursday, Sept. 15, 2022. Peter H. Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.;65.0999984741211;FOSTER CITY, Calif., September 13, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Gilead Foundation’s Creating Possible Fund™ will provide a total of $20 million to 13 inaugural grantees. The Creating Possible Fund was launched to support creative and high-impact strategies that advance health through education equity, with a main focus on building a pipeline of Black health leaders. The work of these grantees aims to help increase social connections for underserved studentsBiopharmaceutical company Gilead Sciences  gapped higher Monday, but is likely to pull back Tuesday with weakness in the broader market due to the hotter-than expected CPI report.  Trading volume was heavy in March suggesting a change of hands from weak hands to stronger hands.  A firming OBV line tells us that buyers of GILD are being more aggressive than sellers.Companies in The News Are: AAPL, BMY, TWTR, GILDWhen it comes to finding a great dividend stock to add to your investment portfolio, there's a wide variety of stocks to choose from.  David Jagielski: In June, dividend stalwart Abbott Laboratories announced it was paying a dividend for the 394th quarter in a row.  At first glance, the healthcare company's dividend yield of 1.8% may look humdrum given that the S&P 500 average yield is 1.7%.;701.3900146484375;;141.0500030517578;Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.China’s government, and vigorous pharmaceutical industry, have set their minds to playing catch-up with more effective vaccines.;199.1199951171875;;280.6700134277344;Vertex Pharmaceuticals is the IBD Stock of the Day as the global biotech company climbs above its 50-day moving average.;203.91000366210938;;162.8699951171875;;144.42999267578125;;206.58999633789062;"CAMBRIDGE, Mass., September 13, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present additional data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, during an oral poster session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022, on September 30, 2022. ThCAMBRIDGE, Mass., September 13, 2022--Alnylam Pharmaceuticals, Inc. (""Alnylam"") (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 1.00% convertible senior notes due 2027 (the ""notes"") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). In addition, Alnylam granted the";323.8599853515625;;2.990000009536743;;86.54000091552734;In an SEC filing, BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that, in August, a participant in its valoctocogene roxaparvovec (BMN 270) phase 3 study was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). Based on BioMarin's assessment of the case to date, including initial genetic testing of the leukemic cells, BioMarin believes at this time that this cancer is unrelated to BMN 270. In August, the hemophilia A gene therapy received conditional European approval. The overall rate o;32.959999084472656;;68.13999938964844;;39.939998626708984;;30.780000686645508;Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the South African Health Products Regulatory Authority has granted full product registration with conditions for Novavax' protein-based vaccine, NVX-CoV2373, as a two-dose primary series for active immunization to prevent coro;63.150001525878906;;102.75;;105.16000366210938;– With current cash and projected revenue, offering is expected to fund operations to profitability CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it intends to offer, subject to market and other conditions, $1.0 billion aggregate principal amount of convertible senior unsecured notes that will mature on September 15, 2027, unless earlier redeemed, repurchased or conve;82.9800033569336;;35.900001525878906;;70.73999786376953;Blueprint Medicines' (BPMC) Ayvakit, approved for treating PDGFRA Exon 18 mutant gastrointestinal stromal tumors, is witnessing strong uptake. The drug's label expansion studies also hold promise.;67.55000305175781;;49.95000076293945;;25.59000015258789;;17.139999389648438;;11.109999656677246;;53.33000183105469;;29.90999984741211;;45.810001373291016;;41.29999923706055;;;;20.56999969482422;;15.720000267028809;Life sciences research tool supplier Abcam said it will seek to delist from the AIM on London’s stock exchange following a “positive shareholder response”.;9.350000381469727;;6.139999866485596;;46.25;;47.83000183105469;CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- hC Bioscience, Inc., a company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, today announced the appointment of industry veteran Brad Margus to its board of directors. “We are excited to welcome Brad to the company during this pivotal time of growth,” said Leslie Williams, co-founder, director and chief executive officer of hC Bioscience. “Brad has successfully established and;51.97999954223633;;10.739999771118164;;39.65999984741211;;16.899999618530273;The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.;23.610000610351562;
2022-09-14;228.1199951171875;Investing in a top dividend stock should involve more than just looking at which one has a high yield today.  With increasing yields, that means you will be collecting more in dividend income than you are right now, which gives you an incentive to buy and hold.  Three high-yielding dividend stocks that analysts believe could make significant increases to their payouts over the next two years are Amgen (NASDAQ: AMGN), Tapestry (NYSE: TPR), and Stanley Black & Decker (NYSE: SWK).;65.18000030517578;In Q2, HIV drugs generated more than two-thirds of its total revenue.  If you delve further into the details, you'll see that two drugs -- Biktarvy and, to a lesser extent, Descovy -- appear to be cannibalizing sales of Gilead's other HIV drugs.  Gilead is also partnering with Gritstone Bio to evaluate an experimental HIV therapeutic vaccine in an early-stage clinical study.Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.;697.6199951171875;;146.5500030517578;Pfizer Inc (NYSE: PFE) has dosed the first participants in the Phase 3 trial of its quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy U.S. adults. Influenza annually causes 140,000 to 710,000 hospitalizations, 12,000 to 52,000 deaths, and about $25 billion in economic loss in the U.S. The quadrivalent modRNA vaccine candidate will encode World Health Organization recommended strains for the Northern Hemisphere 2022-23 cell culture- or recombinant-basePfizer (PFE) and BioNTech (BNTX) get a positive recommendation from CHMP for Omicron BA.4 and BA.5-adapted bivalent vaccines.;196.86000061035156;;284.8599853515625;;204.11000061035156;;154.25;;143.6699981689453;;208.27999877929688;;319.6700134277344;;3.069999933242798;;86.86000061035156;;33.66999816894531;;68.41999816894531;;40.560001373291016;;32.54999923706055;;63.880001068115234;;104.31999969482422;;107.56999969482422;Sarepta Therapeutics Inc. said Wednesday it has priced $980 million of convertible senior unsecured notes that mature in September of 2027. The company will reduce the potential dilution of issuing new shares by entering capped call transactions with one or more dealers. Proceeds will be used to cover the cost of those transactions, as well as to repurchase convertible notes due in 2024, terminate a credit agreement, and fund general corporate purposes. The notes will bear cash interest at a ratWith current cash and projected revenue, offering is expected to fund operations to profitabilityCAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the pricing of $980.0 million aggregate principal amount of convertible senior unsecured notes that will mature on September 15, 2027, unless earlier redeemed, repurchased or converted. The notes are being offered and sold only to p;81.86000061035156;;35.27000045776367;;72.5199966430664;;72.19000244140625;;49.16999816894531;;26.079999923706055;;17.18000030517578;;11.569999694824219;;56.83000183105469;;30.43000030517578;;45.27000045776367;;42.5099983215332;;;;21.020000457763672;Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.;16.170000076293945;;9.229999542236328;;6.130000114440918;;47.40999984741211;;49.04999923706055;;50.150001525878906;;10.84000015258789;;39.54999923706055;;17.43000030517578;;23.760000228881836;Alcohol use disorder is a chronic brain condition marked by compulsive drinking and loss of control with alcohol use. Anyone can develop AUD, however, certain factors like biology and environment m...
2022-09-15;227.66000366210938;;65.0;When Angelina Namiba first learned she had HIV, she was in her early 20s and had graduated from college just six months earlier. Fear about her future quickly filled her mind.;705.8499755859375;Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced preliminary Phase 1 data supporting the clinical advancement of ALN-HSD for nonalcoholic steatohepatitis (NASH). ALN-HSD is an investigational RNAi therapeutic targeting HSD17B13. After single-dose evaluation in healthy adult volunteers (Part A), multiple doses of ALN-HSD are being studied in adult patients with NASH (Part B). Patients in the first two Part B cohorts (200 and 400 mg quarterly) hRegeneron Pharmaceuticals (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH).Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...;144.13999938964844;Pfizer (PFE) doses the first participants in the phase III study of its investigational mRNA-based influenza vaccine. The study will enroll nearly 25,000 participants.The so-called bivalent vaccines are expected to offer better protection against the BA.4 and BA.5 subvariants than previous shots.;201.97000122070312;Six startups from Indonesia, Ireland, Israel, South Africa, United Kingdom and the United States will receive seed investment and access to technology and expertise;287.6700134277344;As the bear market emerged, even some of the healthiest companies saw their shares drop or stagnate.  Shares of Axsome Therapeutics (NASDAQ: AXSM) have climbed 64% this year.  Most of the gains came in recent weeks after the company's great news: It won U.S. regulatory approval for Auvelity, its drug for major depressive disorder (MDD).It didn't help that on Tuesday of this week the major stock indexes experienced their biggest one-day decline since June 2020.  Many investors were already asking whether or not it was a new bull market or just a bear market bounce.  With the S&P again flirting with bear market territory and the Nasdaq Composite Index again firmly in a bear market, the answer to that question seems to be obvious.Vertex Pharmaceuticals (VRTX) closed at $284.86 in the latest trading session, marking a +1.49% move from the prior day.;206.72000122070312;;160.6300048828125;;141.30999755859375;;208.47999572753906;Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced preliminary Phase 1 data supporting the clinical advancement of ALN-HSD for nonalcoholic steatohepatitis (NASH). ALN-HSD is an investigational RNAi therapeutic targeting HSD17B13. After single-dose evaluation in healthy adult volunteers (Part A), multiple doses of ALN-HSD are being studied in adult patients with NASH (Part B). Patients in the first two Part B cohorts (200 and 400 mg quarterly) hRegeneron Pharmaceuticals (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH).CAMBRIDGE, Mass. & TARRYTOWN, N.Y., September 15, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH).;316.3699951171875;;3.130000114440918;;88.08999633789062;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report updating the previous Hemophilia A assessment of the comparative clinical effectiveness and value of ROCTAVIAN ™ (valoctocogene roxaparvovec).;33.4900016784668;;68.9800033569336;;40.88999938964844;;32.54999923706055;Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.;68.58000183105469;;106.93000030517578;Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the need for education on supportive evidence regarding best approaches to managing tardive dyskinesia (TD) symptoms while maintaining control of the underlying psychiatric disorder. These results (abstract #29) will be shared at the MDS International Congress of Parkinson's Disease and Movement Disorders® September 15-18 in Madrid, Spain.Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today will present data on the effects of ONGENTYS® (opicapone) capsules on soluble-catechol-O-methyltransferase (S-COMT) enzyme inhibition. These data (abstract #1025) are being shared at the MDS International Congress of Parkinson's Disease and Movement Disorders® September 15-18 in Madrid, Spain.;110.68000030517578;;82.48999786376953;;35.130001068115234;;72.58999633789062;;75.01000213623047;Crispr Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength RatingYou may not be in the mood for a stock market shopping spree right now.  And today, Amazon's cloud computing business -- Amazon Web Services -- continues to report double-digit increases in sales and operating income, in spite of the difficult economic context.;48.95000076293945;;27.049999237060547;While broader markets face continued pressure amid recession fears, small-cap stocks stand out as an undervalued segment of the stock market. The Russell 2000 index, the popular benchmark for small-cap stocks, is currently down 18% over the past year. Meanwhile, the S&P 500 index has declined less than 12% during the same period. Seasoned investors realize that a smaller company typically has more room for exponential growth in terms of both business operations and share price. In addition, many;17.1299991607666;Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results...;11.9399995803833;;60.4900016784668;;31.09000015258789;;47.279998779296875;;42.33000183105469;;;;20.309999465942383;SVB Leerink initiated coverage on Vir Biotechnology Inc (NASDAQ: VIR) with an Outperform rating and a price target of $40, with an investment thesis based on: With multiple clinic programs, Vir is well-positioned as a leading infectious disease & commercial-stage biopharma company. Vir developed and globally distributed its first generation COVID-19 antiviral, sotrovimab (Xevudy), and received repeat US government contracts. Xevudy generated around $2.6 billion in revenues that could provide rob;16.459999084472656;;9.470000267028809;;6.610000133514404;;47.4900016784668;;48.869998931884766;;50.529998779296875;;10.880000114440918;;40.43000030517578;;18.270000457763672;;23.770000457763672;
2022-09-16;231.13999938964844;The New York-based Initiative for Medicines, Access & Knowledge (I-MAK) said in a report that three of the top 10 selling drugs in the U.S. face no competition in the country and will cost Americans an estimated further $167 billion before they are expected to so.  I-MAK said cheaper generic and biosimilar versions of Bristol-Myers Squibb and Pfizer's  blood clot preventer Eliquis, AbbVie's Humira, and Amgen's Enbrel, both used to treat rheumatoid arthritis, will have been available in Europe for an average of 7.7 years before their expected U.S. launch.  AbbVie, Amgen, Bristol-Myers Squibb, and Pfizer, did not immediately respond to requests for comment.Amgen (AMGN) closed the most recent trading day at $227.66, moving -0.2% from the previous trading session.Lumakras had mixed results in a closely watched clinical trial comparing the drug to docetaxel. Analysts wonder if Mirati Therapeutics' drug will do better.;65.5999984741211;"Gilead Sciences Inc (NASDAQ: GILD) announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for severe COVID-19. WHO continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation is mainly driven by the final results of the WHO-sponsored SOLIDARITY study, which showed a statistically significant 17% loweSANTA MONICA, Calif., September 16, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Yescarta® (axicabtagene ciloleucel) for adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. If approved, Yescarta will be the fGilead Sciences Inc. said Friday the European regulator has adopted a positive opinion on extending the use of its COVID treatment Veklury for pediatric patients. The European Commission will review the recommendation, and if adopted, Veklury, also called remdesivir, could become the only authorized treatment for adolescents at high risk of developing severe disease and children with COVID who require supplemental oxygen. The positive opinion was based on a Phase 2/3 trial of Veklury among pediaFOSTER CITY, Calif., September 16, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion to extend the indication of Veklury® (remdesivir) for the treatment of pediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19 and pediatric patients (4 weeks of age and older and weighingGilead Sciences Inc. said late Thursday the World Health Organization expanded its recommended guide for the use of the biotech drug maker's COVID-19 treatment Veklury. In a statement, the company said WHO updated its guidelines to recommend the drug to treat patients with severe COVID, an expansion from simply ""those with non-severe COVID-19 at the highest risk of hospitalization."" In late July, European Commission regulators recommended that Veklury be used as an expanded COVID-19 treatment. VFOSTER CITY, Calif., September 15, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced updates to the World Health Organization’s (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury® (remdesivir) for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization.In the latest trading session, Gilead Sciences (GILD) closed at $65, marking a -0.28% move from the previous day.Gilead Sciences Inc (NASDAQ: GILD) disclosed agreements with generic manufacturers that delay the U.S. launch of generic TAF products from 2025 to 2031/2032. SVB Leerink said this is positive for Gilead's long-term HIV sales and total revenue trajectories. TAF products, Descovy, Vemlidy, and Odefsey, generated $2.8 billion in 2021, the U.S. sales that the analyst previously expected to erode to over $100 million by 2031E. SVB models $1.3 billion 2031E US revenue for these products based upon mor";710.2999877929688;"Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced positive interim results from an ongoing Phase 1 trial of NTLA-2001, a CRISPR/Cas9 genome editing therapy for transthyretin (ATTR) amyloidosis. The interim data include 12 ATTR amyloidosis adult patients with cardiomyopathy (ATTR-CM) with heart failure. Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions ofShares of Intellia Therapeutics Inc. gained 6.5% in premarket trading on Friday after the company and Regeneron Pharmaceuticals Inc. announced positive data from an ongoing Phase 1 clinical trial evaluating their investigational Crispr therapy as a treatment for transthyretin amyloidosis with cardiomyopathy, which can cause heart failure. The data demonstrated a reduction in serum transthyretin in 12 patients for up to six months. ""At these deep and consistent levels of protein reduction, we belIntellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis. The interim data include 12 adult patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I – III heart failure. Single dRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that The Lancet has published positive results from a Phase 3 Dupixent® (dupilumab) trial in children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis. These data were the basis for the U.S. Food and Drug Administration (FDA) approval of Dupixent in June 2022 and for a regulatory submission currently under review by the European Medicines Agency.";145.75999450683594;"Pfizer Inc. and BioNTech SE said Friday that the Committee for Medicinal Products for Human Use (CHMP) for the European Medicines Agency (EMA) has recommended the companies' COVID-19 vaccine Comirnaty be converted to standard, or ""full,"" Marketing Authorization (MA) from conditional MA for all indications and formulations. The companies said the European Commission (EC) will review the CHMP recommendation and is expected to make a decision ""soon."" The vaccine has been granted MA by the EC to preStandard marketing authorization recommendation applies to all indications and formulations in the European Union, including COMIRNATY® Original/Omicron BA.4-5 and COMIRNATY® Original/Omicron BA.1 bivalent vaccinesCHMP separately recommends approval of booster dose of COMIRNATY® in children 5 through 11 years of age in the European Union NEW YORK and MAINZ, GERMANY, September 16, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Committee for Medicinal ProducVaccine stocks Pfizer and Moderna could see some upside from their new Covid boosters, according to the September IBD/TIPP Poll.";199.8800048828125;;289.7099914550781;Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.Dow Jones futures: The stock market is still reeling from the Fed bull case turning into bigger rate hikes for longer. FedEx dived on earnings.;208.25999450683594;;157.08999633789062;;142.02999877929688;;213.0;Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?;307.5899963378906;;2.990000009536743;;88.20999908447266;Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?;30.68000030517578;;68.83000183105469;;39.25;;30.40999984741211;Novavax Inc. said Friday that Israel has granted an import and use permit for the company's COVID vaccine for use in people aged 12 and older. The vaccine is protein based, using a more traditional technology than the mRNA used in the vaccines developed by Pfizer Inc. and German partner BioNTech SE and Moderna Inc. . The vaccine has now received authorization for use in adults aged 18 and older from more than 40 markets, including the U.S. It has also won authorization from the World Health OrgaNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Taiwan Food and Drug Administration (TFDA) has granted expanded emergency use authorization (EUA) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 througNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Israel Ministry of Health has granted an import and use permit which provides individuals aged 12 and older access to the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primNovavax (NVAX) closed the most recent trading day at $32.55, making no change from the previous trading session.;65.70999908447266;"Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced positive interim results from an ongoing Phase 1 trial of NTLA-2001, a CRISPR/Cas9 genome editing therapy for transthyretin (ATTR) amyloidosis. The interim data include 12 ATTR amyloidosis adult patients with cardiomyopathy (ATTR-CM) with heart failure. Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions ofShares of Intellia Therapeutics Inc. gained 6.5% in premarket trading on Friday after the company and Regeneron Pharmaceuticals Inc. announced positive data from an ongoing Phase 1 clinical trial evaluating their investigational Crispr therapy as a treatment for transthyretin amyloidosis with cardiomyopathy, which can cause heart failure. The data demonstrated a reduction in serum transthyretin in 12 patients for up to six months. ""At these deep and consistent levels of protein reduction, we belIntellia Therapeutics Inc (NASDAQ: NTLA) announced interim results from an ongoing Phase 1/2 study of NTLA-2002, its second in vivo genome editing candidate. NTLA-2002 is a systemically administered CRISPR candidate being developed for hereditary angioedema (HAE) and is designed to knock out the KLKB1 gene in liver cells, thereby reducing the production of kallikrein protein. The uncontrolled activity of kallikrein is responsible for the overproduction of bradykinin, which leads to fatal swellinIntellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis. The interim data include 12 adult patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I – III heart failure. Single dPositive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of NTLA-2002 led to a 65% and 92% mean plasma kallikrein reduction at 25 mg and 75 mg doses, respectively, at week eightHAE attacks were reduced by 91% in the 25 mg dose cohort through week 16; two of three patients remain attack free since treatment with third patient attack free since week 10 through lateMarkets ended the day in the red, with the energy and utilities sectors among the biggest laggards, while ARKK components like Roku and Intellia moved to the upside.";106.08999633789062;Dow Jones futures: The stock market is still reeling from the Fed bull case turning into bigger rate hikes for longer. FedEx dived on earnings.;111.98999786376953;;79.56999969482422;Lumakras had mixed results in a closely watched clinical trial comparing the drug to docetaxel. Analysts wonder if Mirati Therapeutics' drug will do better.;34.59000015258789;;69.2300033569336;;70.52999877929688;;47.45000076293945;;25.0;;17.149999618530273;;11.140000343322754;;56.119998931884766;;29.829999923706055;;46.029998779296875;;41.970001220703125;;;;20.020000457763672;;16.68000030517578;;9.109999656677246;;6.019999980926514;;46.33000183105469;Esperion Therapeutics (ESPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.;47.40999984741211;;48.20000076293945;;10.350000381469727;;37.58000183105469;;18.020000457763672;;23.3700008392334;
2022-09-19;230.75999450683594;When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...;65.81999969482422;Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.;715.3400268554688;Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is up by a considerable 22% over the past three months. Since the market...;133.22000122070312;"Stocks of the three key vaccine makers fell sharply Monday, after President Joe Biden said the pandemic is over, in an interview with ""60 Minutes"" that aired on Sunday. Moderna Inc. fell 9.2%, Pfizer Inc. was down 1.7% and its German partner BioNTech SE was down 8.4%. Novavax Inc. , which had its protein-based vaccine authorized in July, was last down 9%. The SPDR S&P Biotech ETF was down 2.2%.";198.80999755859375;"Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will convene a panel titled ""Clinical Genomics Is Now. Are You Ready?"" at its inaugural Illumina Genomics Forum (IGF), moderated by Nobel laureate and chemical engineer Frances Arnold of the California Institute of Technology. The September 28 roundtable will focus on genomics' role in transforming human health and the next steps in bridging research and clinical genomics.";285.1400146484375;The Dow Jones Industrial Average fell Monday, as the 10-year Treasury yield surged to hit an 11-year high ahead of the Fed meeting.Futures fell and the 10-year Treasury yield hit a new high. The Fed meeting looms after rate hike reality slammed the stock market. Tesla, Enphase are among stocks that have held up, so far.;209.25999450683594;;154.82000732421875;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 19, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of BRUKINSA ® (zanubrutinib) for the treatment o";139.4199981689453;BOTHELL, Wash., September 19, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) seeking accelerated approval for TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with HER2-positive colorectal cancer who have received at least one prior treatment regimen for unresectable or metastatic disease.;216.0;"CAMBRIDGE, Mass., September 19, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 9th annual series of ""RNAi Roundtable"" webinars over the coming weeks. The series will offer presentations from Alnylam scientists and program leaders who will review recent progress in a selection of the Company’s pipeline programs and platform innovations, as well as medical thought leaders who will provide their perspectives on cl";303.9800109863281;Bio-Techne (NASDAQ:TECH) has had a rough month with its share price down 13%. But if you pay close attention, you might...Bio-Techne Corporation (NASDAQ: TECH) today issued its 2022 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values (Empowerment, Passion, Innovation and Collaboration) remain the backbone of our corporate culture and provide the foundation for;3.069999933242798;;87.69999694824219;;31.459999084472656;;68.80999755859375;;38.38999938964844;;28.43000030517578;"Stocks of the three key vaccine makers fell sharply Monday, after President Joe Biden said the pandemic is over, in an interview with ""60 Minutes"" that aired on Sunday. Moderna Inc. fell 9.2%, Pfizer Inc. was down 1.7% and its German partner BioNTech SE was down 8.4%. Novavax Inc. , which had its protein-based vaccine authorized in July, was last down 9%. The SPDR S&P Biotech ETF was down 2.2%.";63.470001220703125;Portfolio manager Cathie Wood is known for having an aggressive appetite for risk when it comes to the investments she makes in her exchange-traded fund, the ARK Innovation ETF (NYSEMKT: ARKK).  Between its stakes in biotech companies with no products on the market and in rising stars like Tesla, its holdings are often in long shots that have the potential to be transformative for their industries or for the world.  On that note, there are two promising -- but speculative -- biotechnology businesses in the ARK portfolio that investors might be interested in if they're patient enough to hold onto their shares for a few years before seeing major returns.;107.80999755859375;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data demonstrating sustained improvements with long-term INGREZZA® (valbenazine) capsules treatment in adults with tardive dyskinesia (TD) at the Psych Congress 2022 scientific meeting being held September 17-20.;115.25;;77.44999694824219;;34.29999923706055;;70.11000061035156;;68.81999969482422;Portfolio manager Cathie Wood is known for having an aggressive appetite for risk when it comes to the investments she makes in her exchange-traded fund, the ARK Innovation ETF (NYSEMKT: ARKK).  Between its stakes in biotech companies with no products on the market and in rising stars like Tesla, its holdings are often in long shots that have the potential to be transformative for their industries or for the world.  On that note, there are two promising -- but speculative -- biotechnology businesses in the ARK portfolio that investors might be interested in if they're patient enough to hold onto their shares for a few years before seeing major returns.;46.5;;25.309999465942383;;16.920000076293945;;11.279999732971191;;53.790000915527344;Beam Therapeutics Inc (NASDAQ: BEAM) announced new preclinical data demonstrating the potential of its multiplex base editing approach to reduce hepatitis B surface antigen (HBsAg) expression and prevent viral rebound of hepatitis B virus (HBV) in vivo models. Base editors are designed to enable direct and irreversible conversion of a specific DNA base into another without inducing double-stranded breaks. In HBV-infected cells, cytosine base editors (CBEs) can target both integrated HBV DNA andCAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical data demonstrating the potential of the company’s multiplex base editing approach to both reduce viral markers – including hepatitis B surface antigen (HBsAg) expression – and prevent viral rebound of hepatitis B virus (HBV) in in vivo models. The data will be presented today, September 19,;30.0;;45.790000915527344;;40.90999984741211;;;;19.809999465942383;;16.75;;9.260000228881836;;6.090000152587891;;46.7400016784668;;46.650001525878906;;47.16999816894531;;10.420000076293945;;38.029998779296875;;17.8700008392334;;22.899999618530273;
2022-09-20;227.7100067138672;Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.;64.58000183105469;If you want to know who really controls Gilead Sciences, Inc. ( NASDAQ:GILD ), then you'll have to look at the makeup...;704.219970703125;;133.4600067138672;BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) stocks decline 8.6%, 7.1% and 6.5%, respectively.Whether the pandemic is over or not, plenty of people are still looking for protection against COVID-19.;194.6999969482422;Cancer detection test maker Grail, acquired by Illumina Inc last year despite ongoing antitrust challenges, on Tuesday said it would expand use of its flagship Galleri test through a new agreement with life insurer John Hancock, a division of Manulife Financial.  The test, designed to detect more than 50 types of cancer before symptoms appear, looks at the DNA in a patient's blood to determine whether any come from cancer cells.  Data have shown that, across the 50 cancer types, including early-stage to late-stage, the Galleri test correctly identified the presence of cancer in 51.5% of cases.Cancer detection test maker Grail, acquired by Illumina Inc last year despite ongoing antitrust challenges, on Tuesday said it would expand use of its flagship Galleri cancer diagnostic test through a new agreement with life insurer John Hancock, a division of Manulife Financial .  The test, designed to detect more than 50 types of cancer before symptoms appear, looks at the DNA in a patient's blood to determine if any come from cancer cells.  Data have shown that, across the 50 cancer types, including early-stage to late-stage, the Galleri test correctly identified the presence of cancer in 51.5% of cases.Today, John Hancock, the US division of Toronto-based Manulife (NYSE: MFC), announced it is offering access to GRAIL's Galleri® multi-cancer early detection test to a pilot group of existing customers through the John Hancock Vitality Program, in collaboration with reinsurer Munich Re Life US. As the first life insurance carrier to make this breakthrough screening technology available, John Hancock is enabling eligible customers to take proactive steps to better understand and make more informedIllumina, Inc. (Nasdaq: ILMN) will host its 2022 Investor Day on Monday, October 3rd starting at 8:00am Pacific Time in San Diego, CA. The event will feature presentations by members of Illumina's executive team and conclude with a Q&A session.;286.94000244140625;The Dow Jones Industrial Average sold off 350 points Tuesday ahead of the Federal Reserve's two-day policy meeting.Dow Jones futures dropped after Monday's stock market rally ahead of the Federal Reserve's two-day policy meeting.With the S&P 500 again near bear market territory, the thought of buying stocks could be scary.  The other is driven by the knowledge that, historically, buying stocks after the market has fallen significantly has often led to handsome returns over the long run.  Among your financial priorities, it's much more important to pay your bills and lower your debt.;204.1999969482422;;153.74000549316406;"England's National Institute for Health and Care Excellence (NICE) has recommended BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for Waldenström's Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable. This decision from NICE marks Brukinsa as the first and only treatment for WM to be recommended for routine use in England and Wales. Also Read: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In LeukemiaCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 19, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing oncology medicines, today announced that England’s health technology assessment institute, the National Institute for Health and Care Excellence (NICE), has issued a final appraisal document (FAD) recommending BRUKINSA (zanubrutinib) for the treatment of Waldenström’s Macroglobulinemia (WM) in adults who have";141.99000549316406;;212.00999450683594;CAMBRIDGE, Mass., September 20, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the European Commission (EC) has granted marketing authorization for AMVUTTRA® (vutrisiran), an RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. The EC approval is based on positive 18-month results from the HELIOS-A Phase 3 study, where AMVUTTRA signific;300.0899963378906;;2.940000057220459;;86.95999908447266;;31.979999542236328;;68.26000213623047;;37.88999938964844;Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.;27.459999084472656;Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.The latest pronouncements by the president aren't exactly doing the two healthcare companies any favors.;62.529998779296875;"Warren Buffett famously stated that it's smart to ""be fearful when others are greedy and be greedy when others are fearful.""  All of Wood's ARK Invest exchange-traded funds (ETFs) are down significantly this year.  Ginkgo Bioworks specializes in cell programming.Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).";107.08999633789062;Electric-vehicle giant Tesla stock and three other leaders are in or near buy zones in the current stock market correction.;113.9000015258789;;75.69000244140625;;33.84000015258789;;70.23999786376953;;70.12999725341797;How investors can approach investing in gene therapies.  To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.  Karl Thiel: We're used to the idea, honestly, of paying millions of dollars to treat people with the disease but we're not used to paying it to a drug company.;49.119998931884766;"New subgroup analysis of the Phase 3 PRIME study reveals improvement in efficacy outcomes for ZEJULA® (niraparib) maintenance treatment when started within 12 weeks after first-line platinum-based chemotherapy (1LCT)SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will present a poster featuring initiation timing analysis from the Phase";24.25;;16.899999618530273;;11.510000228881836;"- The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years. - European Commission (EC) decision is based on the efficacy and safety data collected to date compared to data from a natural history study. - NULIBRY was BridgeBio’s first FDA-approved therapeutic; Sentynl acquired global rights to NULIBRY inInsiders who bought US$2.5m worth of BridgeBio Pharma, Inc.'s ( NASDAQ:BBIO ) stock at an average buy price of US$13.63...";53.47999954223633;;28.850000381469727;;45.310001373291016;;40.279998779296875;;;;19.209999084472656;;16.1299991607666;;9.300000190734863;;5.829999923706055;;46.5;First use of Ciitizen platform as source of real-world data in regulatory filingSAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developm;47.13999938964844;;46.38999938964844;;10.289999961853027;;37.11000061035156;SOUTH SAN FRANCISCO, Calif. & SYDNEY, September 20, 2022--Twist Bioscience (Nasdaq: TWST) and the Australian Research Council (ARC) Centre of Excellence in Synthetic Biology (CoESB) today announced a partnership that will enable CoESB members and partners to order a wide range of Twist products that facilitate research and development.;18.15999984741211;;23.260000228881836;Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio at Psych Congress, which began on Sept. 17 and concludes today, Sept. 20 in New Orleans.A conversation with Craig Hopkinson
2022-09-21;224.4600067138672;I’ve written before about how biotech is the biggest technology trend of our kids’ generation. Naturally, that means many people are looking for the best biotech stocks to buy. But as with the PC industry of my time, finding long-term winners is difficult. Back in the early 1980s, dozens of companies entered the PC market, many of them huge for their time. IBM (NYSE:IBM) was the bet everyone made. But the BUNCH — Burroughs, Univac, NCR (NYSE:NCR), Control Data and Honeywell (NASDAQ:HON), were al;63.5;FOSTER CITY, Calif., September 20, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for approximately $405 million in cash. The acquisition provides Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lea;684.6300048828125;;128.24000549316406;Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.;198.1699981689453;A look at the shareholders of Illumina, Inc. ( NASDAQ:ILMN ) can tell us which group is most powerful. And the group...The gene-sequencing company is fighting antitrust regulators on two continents as it seeks to hold on to Grail, which it bought last year.;280.3999938964844;The Dow Jones Industrial Average rose Wednesday ahead of the Federal Reserve's interest rate decision and Fed chief Powell's press conference.Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.Vertex Pharmaceuticals' (NASDAQ:VRTX) stock is up by 5.4% over the past three months. Given its impressive performance...;199.33999633789062;;148.85000610351562;;141.5500030517578;;206.38999938964844;RBC Capital Markets raised the price target on Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) from $225 to $250. The analyst says that the company is confident that the recent APOLLO-B validates the therapeutic hypothesis. Subgroup analysis at the Heart Failure Society of America (HFSA) next week will be limited by a small number, but ALNY sees an approvable drug. Related: Alnylam Shares Detailed Patisiran Data From Rare Disease Study. The base business continues to perform, and POC for Alzheimer's;296.25;Bio-Techne Corporation (NASDAQ: TECH) today announced data demonstrating icIEF fractionation from their soon to be launched Maurice Flex™ instrument was presented at the 2022 CE Pharm conference. Data generated using customer and National Institute of Standards and Technology (NIST) samples have been presented at multiple conferences in the last 20 months and the presentation at CE Pharm is a continuation of this work.;2.869999885559082;;85.12000274658203;;30.229999542236328;;66.83000183105469;;36.29999923706055;The gene-sequencing company is fighting antitrust regulators on two continents as it seeks to hold on to Grail, which it bought last year.;25.8700008392334;;59.470001220703125;;105.62999725341797;At least the stock market isn't rallying into the Fed meeting. Expect another 75-basis-point rate hike, with more to come. Tesla stock flirted with buy points.The Dow Jones fell as the Federal Reserve meeting kicked off. Apple stock climbed. Coinbase stock dipped as Bitcoin fell. Ford stock nose-dived.;110.13999938964844;;71.69999694824219;;32.47999954223633;;68.08999633789062;;66.6500015258789;I’ve written before about how biotech is the biggest technology trend of our kids’ generation. Naturally, that means many people are looking for the best biotech stocks to buy. But as with the PC industry of my time, finding long-term winners is difficult. Back in the early 1980s, dozens of companies entered the PC market, many of them huge for their time. IBM (NYSE:IBM) was the bet everyone made. But the BUNCH — Burroughs, Univac, NCR (NYSE:NCR), Control Data and Honeywell (NASDAQ:HON), were al;42.88999938964844;;23.469999313354492;;16.5;Biotech stocks have performed relatively well compared to the broader market of late. The SPDR S&P Biotech ETF (NYSEARCA:XBI) is up 21% over the past three months compared with a 6% gain for the S&P 500. Biotech stocks have a reputation for being high-risk investments. The underlying firms spend a ton on research and development with no assurance that their products will reach market. As a whole, though, the segment’s growth is being driven by government initiatives “aimed at modernization of re;10.710000038146973;;51.619998931884766;;27.850000381469727;;44.08000183105469;;39.209999084472656;Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...;;;18.700000762939453;Biotech stocks have performed relatively well compared to the broader market of late. The SPDR S&P Biotech ETF (NYSEARCA:XBI) is up 21% over the past three months compared with a 6% gain for the S&P 500. Biotech stocks have a reputation for being high-risk investments. The underlying firms spend a ton on research and development with no assurance that their products will reach market. As a whole, though, the segment’s growth is being driven by government initiatives “aimed at modernization of re;15.579999923706055;;8.829999923706055;;5.71999979019165;PacBio's (PACB) strength in its Sequel system raises optimism about the stock.;45.06999969482422;;43.900001525878906;;44.25;;10.229999542236328;VANCOUVER, British Columbia, September 21, 2022--AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic;36.380001068115234;;17.06999969482422;;22.43000030517578;September is National Recovery Month. Together we can reduce stigma, increase awareness of substance use disorder and celebrate the journey of recovery. Educating ourselves about the components of ...
2022-09-22;227.75;AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.Amgen (AMGN) closed at $224.46 in the latest trading session, marking a -1.43% move from the prior day.;63.77000045776367;FOSTER CITY, Calif., September 22, 2022--Gilead Sciences, Inc. today announced a new public-private initiative with the Partnership for Health Advancement in Vietnam (HAIVN), a collaboration between Brigham and Women’s Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center. This multi-year initiative will have a phased approach to help address barriers that limit viral hepatitis diagnosis and care at primary healthcare facilities in Vietnam and the Philippines, two countries wGilead Sciences (GILD) closed at $63.50 in the latest trading session, marking a -1.67% move from the prior day.;688.260009765625;;130.0;;193.49000549316406;US nonprofit GRID Alternatives launches new projects to provide renewable energyHenry Ford Health, one of the nation's leading academic medical centers recognized for excellence in clinical care, research and education, and GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced Henry Ford Health as the first healthcare provider in Michigan to offer Galleri®, GRAIL's Multi-Cancer Early Detection (MCED) blood test. Henry Ford is among an early group of healthcare providers in the U.S. to offer this MCED test.;286.3399963378906;The Dow Jones Industrial Average dropped Thursday, threatening to add to Wednesday's Fed-fueled stock market sell-off.Vertex Pharmaceuticals (NASDAQ: VRTX) is a monster stock because it's the undisputed master of the market for cystic fibrosis (CF) therapies.  There are only about 25,000 CF patients in the Western world that are eligible but not currently enrolled in treatment with any of the company's six therapies for the condition.  Vertex is advancing with commercial efforts to access that untapped market, not to mention chasing an even smaller population of around 5,000 patients for whom wholly new medicines are being developed.;200.6199951171875;;144.02999877929688;;140.5500030517578;;202.7100067138672;The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.CAMBRIDGE, Mass., September 21, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of two new members to the management team – Piyush Sharma as Chief Ethics & Compliance Officer (CECO), and Evan Lippman in the newly created role of Chief Corporate Development and Strategy Officer (CDSO). Both executives will report to Chief Executive Officer, Yvonne Greenstreet.;290.2200012207031;;2.950000047683716;;84.91999816894531;;29.1200008392334;;67.41000366210938;;34.349998474121094;For a few months, I’ve believed that both inflation and stocks were bottoming. Now prominent JPMorgan analyst Marko Kolanovic is making the same call. Thanks to the bear market, shares of companies with good fundamentals and strong outlooks are drastically undervalued. Nowhere is this more evident than on the Nasdaq exchange, which has fallen much more than the other major indices over the past year. Therefore, I’ve put together a list of seven Nasdaq stocks to buy on the dip. Before I go throug;22.440000534057617;Shares of the recombinant-protein vaccine specialist Novavax (NASDAQ: NVAX) were down by a noteworthy 9.2% on heavy volume as of 9:55 a.m. ET on Thursday.  Yesterday, J.P. Morgan analyst Eric Joseph reportedly cut his 12-month price target on the stock from $132 to $27 a share, citing the company's recent downward revision for its 2022 revenue forecast as a key reason for the far lower price target.  This dramatic downward price revision is particularly interesting because it implies that Novavax won't even meet Wall Street's most-pessimistic 2023 revenue estimate of $1.25 billion.Yahoo Finance Live’s Julie Hyman discusses Novavax stock performance after JPMorgan downgrades its shares to Underweight from Neutral.Shares of Novavax Inc. slumped 7.1% in morning trading Thursday, to extend their recent plunge toward a near 2 1/2-year low, after J.P. Morgan threw in the towel on the maker of the COVID-19 vaccine Nuvaxovid, citing expectations of more cuts to revenue guidance. Analyst Eric Joseph cut his rating to underweight, after being at neutral since May 2021, and at overweight before that since August 2020. He cut his stock price target to $27 from $132. The stock has now dropped 26.0% amid a 5-day losiBy Liz MoyerJPMorgan analyst Eric Joseph slashed his price target on Novavax by more than $100, to $27 per share.By Peter Nurse;57.08000183105469;The founder and CEO of ARK Investment Management is buying up drugmaker stocks like they're going out of style.;103.33999633789062;Among the top stocks to watch today's stock market, biotech leader Neurocrine Biosciences is nearing a new buy point.;110.87000274658203;;69.94000244140625;;31.5;;67.0999984741211;;64.9000015258789;;37.33000183105469;;22.469999313354492;;16.56999969482422;;10.4399995803833;;48.150001525878906;;27.25;;43.13999938964844;;38.7400016784668;;;;18.6299991607666;– Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis – – Novel combination strategy designed toreduce HDV viremia and block viral entry – SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic hepatitis D virus;15.380000114440918;;8.529999732971191;If you want to know who really controls Kodiak Sciences Inc. ( NASDAQ:KOD ), then you'll have to look at the makeup of...;5.409999847412109;;44.970001220703125;;42.93000030517578;;45.709999084472656;;9.6899995803833;;33.63999938964844;;16.989999771118164;;22.469999313354492;
2022-09-23;226.97000122070312;If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...;62.86000061035156;NORTHAMPTON, MA / ACCESSWIRE / September 23, 2022 / Gilead Sciences For Dr. Javier Cortes, being a breast cancer researcher isn't just a profession - it's a calling. As the head of the International Breast Cancer Center (IBCC) in Madrid and Barcelona, ...Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).  AbbVie is one of the largest pharmaceutical companies around.  Like other drugmakers, AbbVie benefits from the fact that doctors do not stop prescribing lifesaving drugs even during challenging economic times, nor do patients stop taking them.Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.;697.3300170898438;;128.35000610351562;Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.A manufacturing-quality problem has led to some vaccine providers only offering the Pfizer-BioNTech booster shot.;190.3800048828125;;283.45001220703125;The Dow Jones Industrial Average sold off Friday ahead of Fed chief Powell's comments at a Federal Reserve event in Washington D.C.;197.77999877929688;;138.63999938964844;;139.1999969482422;;200.77999877929688;Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.;291.05999755859375;;2.799999952316284;;84.83999633789062;;28.90999984741211;We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...;66.88999938964844;;33.40999984741211;;21.0;Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.Novavax has some serious short-term challenges but could still have growth opportunities in the future.Novavax stock is trading at a two-year low amid slowly ramping use of its Covid vaccine, dubbed Nuvaxovid, in the U.S.Vaccine maker Novavax has sunk to a new low for the move down as fundamental analysts are publishing weaker ratings. President Biden's recent assessment of Covid has not helped, either.    Let's check the charts and indicators.J.P. Morgan analyst Eric Joseph downgrades vaccine maker Novavax to Underweight from Neutral, and slashes the price target to $27 from $132.;53.91999816894531;;103.5;;108.19000244140625;;68.18000030517578;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.;30.93000030517578;;65.56999969482422;;63.15999984741211;;37.0;;21.969999313354492;;16.280000686645508;;9.75;;47.09000015258789;;27.190000534057617;;41.5;;38.81999969482422;;;;18.59000015258789;;14.630000114440918;;7.980000019073486;;5.269999980926514;;43.22999954223633;"Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced topline data from the Phase 2b SOLANO study of ION449 (AZD8233) for hypercholesterolemia (high cholesterol levels). Ionis said that although the candidate met the primary endpoint, its partners at AstraZeneca Plc (NASDAQ: AZN) have decided not to move it into Phase III studies because the ""results did not achieve pre-specified efficacy criteria."" The trial showed that 60mg of ION449 (AZD8233) administered monthly achieved a statistically signifiIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 (AZD8233) administered monthly achieved a statistically significant 62.3% (p<0.001) reduction in low-density lipoprotein cholesterol (LDL-C) levels after 28 weeks compared to placebo, meeting the study's primary efficacy endpoint. ION449 was generally safe and well tolerated in this study. However, these results did";42.060001373291016;;43.5099983215332;;9.199999809265137;;33.439998626708984;;16.75;;22.31999969482422;
2022-09-26;226.8699951171875;Both the S&P 500 and the tech-heavy Nasdaq Index are in bear market while the Dow Jones in the only of the three main indexes not to have bear market status.;62.34000015258789;;686.0999755859375;;127.6500015258789;"Pfizer and BioNTech asked U.S. health regulators to clear use of their updated Covid-19 booster in children 5 years to 11 years, just as retooled shots for people 12 and older roll out.Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have completed an FDA submission seeking Emergency Use Authorization (EUA) for a 10-µg booster dose for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age. The emergency use request of the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is supported by safety and immunogenicity data from the companies' bivalent Omicron BA.1-adapted vaccine, non-clinical & manufacturing data, and pre-clPfizer Inc's (NYSE: PFE) CEO Albert Bourla said he had tested positive for COVID-19. ""I'm feeling well and symptom-free,"" 60-year-old Bourla said in a statement. In August, he contacted COVID and received one course of paxlovid, Pfizer's oral COVID-19 antiviral treatment. Bourla has received four doses of the COVID vaccine developed by Pfizer and BioNTech SE (NASDAQ: BNTX). Bourla said he has not yet taken the new bivalent booster. Developed by Moderna Inc (NASDAQ: MRNA) and Pfizer/BioNTech, thePfizer Inc and its German partner BioNTech on Monday sought the U.S. Food and Drug Administration's authorization for an Omicron-tailored COVID-19 vaccine booster for children aged 5 through 11 years.  The application comes just days after Moderna also applied for FDA authorization of its own Omicron-targeting shot in adolescents aged 12 to 17 years and children aged six to 11.  The applications represent a step towards getting children vaccinated by a so-called bivalent vaccine, which targets both the original strain of the virus and the circulating BA.4 and BA.5 subvariants of Omicron.Pfizer Inc. and German partner BioNTech SE said Monday they have submitted an application to the U.S. Food and Drug Administration seeking an emergency use authorization for their bivalent vaccine booster for use in children aged 5 to 11 years of age. The application is for a 10-ug booster dose of the vaccine targeting omicron BA.4 and BA.5 subvariants, which have become dominant in the U.S and around the world. The application ""is supported by safety and immunogenicity data from the companies'NEW YORK & MAINZ, Germany, September 26, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age. The request for Emergency Use Authorization of the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is sup";184.1199951171875;Illumina, Inc. (NASDAQ: ILMN) today announced that its inaugural Illumina Genomics Forum, being held in San Diego from September 28 through October 1, is sold out.;276.7799987792969;The Dow Jones Industrial Average dropped Monday, as the stock market correction worsened. The 10-year Treasury yield surged to new highs.;195.75;;131.8000030517578;;135.27000427246094;BOTHELL, Wash. & UTRECHT, Netherlands & PHILADELPHIA, September 26, 2022--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an;197.38999938964844;;290.0799865722656;Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the United Kingdom to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc.;2.799999952316284;;82.16000366210938;;28.75;;66.18000030517578;;32.34000015258789;;18.8700008392334;In the early days of the pandemic, if there was one coronavirus vaccine stock investors were betting on, it was Novavax (NASDAQ: NVAX).  The biotech stock soared more than 2,700% in 2020 as it developed its vaccine candidate.  In the same timeframe, Pfizer shares hardly budged.;54.20000076293945;CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be presenting at the following upcoming investor conferences in October: Chardan’s 6th Annual Genetic Medicines Conference, New YorkDate: Monday, October 3, 2022Time: 8:30 a.m. ETFormat: Fireside chat 2022;100.56999969482422;;106.1500015258789;;67.23999786376953;;29.6299991607666;;63.119998931884766;;61.099998474121094;;37.43000030517578;;21.040000915527344;;15.890000343322754;Axsome Therapeutics' solid gains of 42% this year came with the hope that its two new products would bring in plenty of revenue in the next few years.  Last month, the U.S. Food and Drug Administration (FDA) approved its drug Auvelity for treating major depressive disorder (MDD).;9.130000114440918;;46.560001373291016;;25.969999313354492;;39.959999084472656;;38.58000183105469;;;;18.260000228881836;;14.770000457763672;;7.570000171661377;;5.090000152587891;;41.75;;43.65999984741211;NEW HAVEN, Conn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Bank of America Securities Precision Oncology Conference taking place virtually on Monday, October 3 at 10:40 a.m. ET. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Co;42.70000076293945;;9.220000267028809;;33.86000061035156;;16.280000686645508;;22.0;
2022-09-27;225.99000549316406;Many Amgen Inc. ( NASDAQ:AMGN ) insiders ditched their stock over the past year, which may be of interest to the...;62.630001068115234;;695.010009765625;Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) stock price has dropped 4.1% in the previous week, but insiders who...;130.3000030517578;As people acclimatize to the new normal, it’s time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections. Once infected with the less fatal strain, Omicron, people would isolate themselves for a few days and then return to work. By shifting away from its reliance on drug companies, investors must recognize there are vaccine stocks that it’s time to sell. The government cut orders for vaccines and antivira;186.83999633789062;;284.739990234375;CRISPR Therapeutics Inc. and Vertex Pharmaceuticals Inc. said Tuesday that the Food and Drug Administration granted a rolling review to the exagamglogene autotemcel, the therapy the companies are developing to treat sickle cell disease and transfusion-dependent beta thalassemia. CRISPR's stock was up 3.1% in premarket trading on Tuesday, while Vertex shares gained 1.1%. Vertex said it plans to a submit an application to the FDA in November, with plans to complete the submission in the first quarBOSTON & ZUG, Switzerland, September 27, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that Vertex has concluded discussions with the U.S. Food and Drug Administration (FDA), and the FDA granted exagamglogene autotemcel (exa-cel) a rolling review for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Vertex will submit its biologics licensing application (BLA) for exa-cel for rolDow Jones futures were little changed ahead of Tuesday's open. The Dow Jones Industrial Average finished in a bear market Monday.After an all-too-short bounce, the S&P 500 is again in a bear market.  The Nasdaq Composite Index has been firmly in bear market territory for weeks.  Arguably the smartest place to park $10,000 right now is in the U.S. Treasury's Series I savings bonds.Hostess Brands, J.M. Smucker, Toro and Vertex Pharmaceuticals are stocks to watch, as the current stock market correction continues.;197.7899932861328;Notable business headlines include Hurricane Ian becoming a Category 4 hurricane before hitting Florida, Biogen settling a lawsuit that alleged the company paid doctors to prescribe drugs, and Ford asking for a new trial after rollover accident suit.Biogen Inc (NASDAQ: BIIB) has reached a $900 million settlement with a whistleblower who accused the firm of paying doctors bribes to encourage them to prescribe its multiple sclerosis drugs. The whistleblower behind the report, Michael Bawduniak, will receive about $250 million directly, according to a statement released Monday by the U.S. Justice Department. About $843 million will essentially go to the federal government and a smaller part-$56 million to 15 American states that had joined the;138.55999755859375;;135.35000610351562;"BOTHELL, Wash. & SHANGHAI & CAMBRIDGE, Mass., September 27, 2022--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage global biopharmaceutical company, today announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK® (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the";202.61000061035156;;282.5400085449219;;2.890000104904175;;83.44000244140625;;29.309999465942383;;66.44000244140625;Incyte (NASDAQ:INCY) has had a rough three months with its share price down 12%. However, stock prices are usually...;31.969999313354492;The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.;20.040000915527344;"Is Novavax stock a sell after its second-quarter disappointment led to a guidance cut? NVAX stock ranks low among biotechs.The Canadian government announced Monday it will no longer require people to wear masks on airplanes to guard against COVID-19, the Associated Press reported.An initial one million doses of the Novavax's Covid-19 vaccine are now available for use in the U.K.By Liz MoyerNovavax Inc. said Tuesday that one million doses of its protein-based COVID vaccine Nuvaxovid are now available in the U.K. ""With U.K. data showing that people infected with both COVID-19 and the flu are more than five times as likely to die compared to someone with no infection(1) , it is more important than ever to consider any vaccine offered to you by the National Health Service,"" said Stanley C. Erck, Novavax chief executive, in a statement. The Novavax vaccine uses more conventional technoNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that an initial one million doses of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine are now available for use in the United Kingdom (U.K.). Nuvaxovid is the first protein-based COVID-19 vaccine granted authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) and will be offered per the Joint Committee on VaAs people acclimatize to the new normal, it’s time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections. Once infected with the less fatal strain, Omicron, people would isolate themselves for a few days and then return to work. By shifting away from its reliance on drug companies, investors must recognize there are vaccine stocks that it’s time to sell. The government cut orders for vaccines and antivira";56.029998779296875;;101.36000061035156;Neurocrine Biosciences is the IBD Stock Of The Day as market uncertainty shakes plenty leading of equities — but not NBIX stock.;108.33000183105469;;67.55999755859375;;31.200000762939453;;66.33999633789062;;63.630001068115234;CRISPR Therapeutics Inc. and Vertex Pharmaceuticals Inc. said Tuesday that the Food and Drug Administration granted a rolling review to the exagamglogene autotemcel, the therapy the companies are developing to treat sickle cell disease and transfusion-dependent beta thalassemia. CRISPR's stock was up 3.1% in premarket trading on Tuesday, while Vertex shares gained 1.1%. Vertex said it plans to a submit an application to the FDA in November, with plans to complete the submission in the first quar;38.84000015258789;"Seagen Inc (NASDAQ: SGEN) and Zai Lab Limited (NASDAQ: ZLAB) have announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the first and only ADC approved in the U.S. for treating adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The collaboration supports regional patient enrollment for InnovaTV 301BOTHELL, Wash. & SHANGHAI & CAMBRIDGE, Mass., September 27, 2022--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage global biopharmaceutical company, today announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK® (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the";21.8799991607666;;15.899999618530273;Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.;9.930000305175781;;48.40999984741211;;27.290000915527344;;40.290000915527344;;38.63999938964844;;;;18.75;;14.479999542236328;;7.610000133514404;;5.25;"PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the availability of a new computational analysis method for profiling more than a million tandem repeats (TRs) across the human genome using PacBio's native long-read HiFi sequencing data. The Tandem Repeat Genotyping Tool (TRGT: pronounced as ""target"") is intended to provide scientists with the ability to obtain a full characterization of the sequence and methylation status of TRs g";42.27000045776367;Enhancing the depth of 5AM’s scientific and operational expertiseSAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, whi;43.2400016784668;;44.58000183105469;;9.430000305175781;;34.599998474121094;;16.729999542236328;;22.020000457763672;
2022-09-28;230.97999572753906;Several biotech stocks have outperformed the struggling market this year.  This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL), and Amgen (NASDAQ: AMGN).  Let's consider why these three biotechs are solid buys for the next decade.In the latest trading session, Amgen (AMGN) closed at $225.99, marking a -0.39% move from the previous day.;63.93000030517578;To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the...Gilead Sciences (GILD) closed the most recent trading day at $62.63, moving +0.47% from the previous trading session.;705.4199829101562;;133.7899932861328;Data is still scarce on latest COVID-19 boostersPfizer (PFE) and partner BioNTech seek authorization from the FDA for using their bivalent COVID-19 booster vaccine in kids. The vaccine is already authorized for use in adolescents and adults.;201.2899932861328;The firm's better-than-90% share of a booming market for gene-reading technology sent its stock to $525 last year. It now has an army of rivals.;292.4100036621094;The Dow Jones Industrial Average rose Wednesday, ahead of Fed chief Powell's speech, struggling to avoid a seventh straight decline.Several biotech stocks have outperformed the struggling market this year.  This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL), and Amgen (NASDAQ: AMGN).  Let's consider why these three biotechs are solid buys for the next decade.Between rumors of a recession, rising interest rates, and inflation, it's tough to find stocks that you're confident will keep growing instead of going to zero.  Vertex Pharmaceuticals (NASDAQ: VRTX) is worth a $2,500 investment because it's the world's largest public business devoted to curing rare diseases, and it's proven to be quite adept at that goal so far.Let's talk about two leaders in their markets and a well-diversified healthcare company with a track record of success.  Vertex Pharmaceuticals (NASDAQ: VRTX) has been generating returns for investors for quite a while.  Vertex is the global market leader in the treatment of cystic fibrosis (CF).The S&P 500 joined the Dow Jones in undercutting bear market lows as the 10-year Treasury yield races toward 4%. Here's what to do now.Vertex Pharmaceuticals (NASDAQ: VRTX), a commercial-stage biotech specializing in treatments for cystic fibrosis, saw its share price rise on Tuesday thanks to news about one of its pipeline programs.Crispr said Tuesday it will begin asking the FDA to approve its gene-editing blood diseases treatment in November, and CRSP stock jumped.Check the Stock Market Today column to spot changes in market trend and track the best stocks to buy and watch.;276.6099853515625;"Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.Data from Eisai and its partner Biogen are startling because their drug lecanemab slowed cognitive decline, and suggest that a theory that seemed all but disproved still has legs.Cambridge, Massachusetts-based biotech Biogen  and Japanese drug maker Eisai  reported on Wednesday morning that their experimental Alzheimer's disease treatment had met the main goal of a late-stage clinical trial.  The candidate, Lecanemab, reduced the pace of cognitive decline in patients diagnosed with early-stage disease by 27% over 18 months compared to those treated with a placebo.  This result could be a major accomplishment for researchers who have been trying for decades to find a way to treat Alzheimer's. The medicine, before Biogen and Eisai started trying to develop it, was licensed from Sweden's BioArctic.(Bloomberg) -- Biogen Inc. and partner Eisai Co. surged and led other drugmakers’ shares higher amid optimism about their breakthrough trial results on Alzheimer’s disease. Most Read from BloombergApple Ditches iPhone Production Increase After Demand FaltersGermany Suspects Sabotage Hit Russia’s Nord Stream PipelinesPutin’s Mobilization Hits Russia’s Economy in Its Weak SpotsRussia Declares Victory in Sham Ukraine ‘Referendums’US Housing Prices Fall for First Time Since 2012The two partners saidBiogen and Eisai announced a positive surprise for a closely-watched Alzheimer's drug candidate in a late-stage study.Mizuho analyst Salim Syed says there are enough data on the drug ""that likely allows for regulatory approval.By Liz MoyerYahoo Finance Live anchors discuss Biogen stock performance on promising Alzheimer’s drug trial data.Biotechnology firm Biogen and their Japan-based partner Eisai Co. Ltd reported better-than-expected results from a late-stage study of their developing Alzheimer's treatment. A successful treatment for Alzheimer's could be worth tens of billions in sales for Biogen.Investors on Wall Street continued to have doubts about when the stock market is likely to recover, as ongoing worries about inflation, interest rates, and the global financial system have everyone on edge.  Biotech stocks have been among those hit hardest by the bear market in 2022, but Biogen (NASDAQ: BIIB) announced good news in a key clinical trial that has huge implications for those suffering from a harsh and debilitating disease.  Biogen's favorable outcome also gave industry peer Eli Lilly (NYSE: LLY) a boost, on optimism that a new way of coming up with important treatments could spur further successes.Apple is curbing iPhone production. The 10-year yield hit 4%, until the Bank of England stepped in. A Biogen Alzheimer's drug shows promise.Here are 4 tickers trending on Yahoo Finance in premarket trading.Biogen stock rips higher on a promising new drug. Here's what Wall Street is saying.""Today's announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer's disease,"" said Biogen CEO Michel Vounatsos.Stock futures resume slump on rate hike, recession concerns; Apple shares slide on report of waning iPhone demand; Biogen shares soar after positive results from Alzheimer's trial; Elon musk seeks to overturn sec rule on Twitter vetting and Hurricane Ian to slam Florida coast as category 4 storm.(Reuters) -Biogen Inc was set to add more than $10 billion to its market capitalization on Wednesday, as a surprise trial success of the experimental Alzheimer's drug it developed with Eisai was hailed as an unequivocal win by analysts.  The trial results released on late Tuesday could mark a rare victory in the search for a treatment for the memory-robbing disease after years of clinical failures.  Biogen's stock surged 35.4% to $267.61 in early U.S. trading, putting it on track to erase all of its losses this year.By Peter NurseBy Geoffrey SmithEisai and Biogen BIIB said Wednesday that their drug, lecanemab, reduced cognitive and functional decline by 27%, compared with a placebo, over 18 months in a Phase 3 study of 1,800 patients with early-stage Alzheimer's.An experimental Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.  A breakthrough would be a major boost to similar studies being run by Roche and Eli Lilly.  Speaking of the Eisai-Biogen drug results announced late on Tuesday night, Ronald Petersen, director of the Mayo Clinic Alzheimer's Disease Research Center in Rochester, Minnesota said: ""It's not a huge effect, but it's a positive effect"".Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed diseaseAn experimental Alzheimer's drug developed by Eisai Co Ltd and Biogen Inc significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the companies said on Tuesday.  Eisai said the results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer's can delay advance of the debilitating disease.  Lecanemab, like the companies' previous drug Aduhelm, is an antibody designed to remove those amyloid deposits.Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, ""Biogen"") announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectiveQui Tam is perhaps better known as ""whistleblower litigation"" and it is included in the False Claims Act, which President Abraham Lincoln signed into law in 1863.  The False Claims Reform Act of 1985 changed the so-called ""Lincoln Law"", making it easier for the government to investigate False Claims Act cases and lowering the required burden of proof, as well as increasing the potential whistleblower's share to 15-30%, among other items.  Today, Qui Tam can translate into an awful lot of money changing hands .U.S. President Joe Biden claimed victory on Tuesday for a drop in costs for tens of millions of Americans covered by the Medicare health program, though it is primarily due to a decision to severely limit coverage of an expensive, new Alzheimer's drug.  Biden highlighted a drop in premiums next year for the first time in over a decade for Medicare Part B, which among other things covers doctor and hospital visits as well as drugs they administer.  ""It's going to be a godsend for many families,"" Biden told healthcare advocates in a White House Rose Garden event.U.S. President Joe Biden will claim victory on Tuesday for a drop in costs for tens of millions of Americans covered by the Medicare health program, though it is primarily due to a decision to severely limit coverage of an expensive, new Alzheimer's drug.  The White House said Biden would highlight a drop in premiums next year for the first time in over a decade for Medicare Part B, which among other things covers doctor and hospital visits as well as drugs they administer.  The government Medicare plan covers some 35 million Americans aged 65 and older or who are disabled.";142.42999267578125;;137.72000122070312;;210.75999450683594;;289.6499938964844;;3.4700000286102295;;85.83999633789062;;31.65999984741211;;67.66000366210938;;34.439998626708984;Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.;19.610000610351562;Novavax (NASDAQ:NVAX) stock hasn’t had a great 2022, down 86% since the beginning of the year. The company focuses on products to treat infectious diseases but is definitely best known for its Covid-19 vaccine NVX-CoV2373, also known as Nuvaxovid. There are plenty of other competing vaccines in this category, and Novavax’s shots haven’t been strong sellers in the company’s home market. A recent statement from President Joseph Biden certainly won’t buoy Novavax’s already dismal financial stats.InWhat happened Shares of Novavax (NASDAQ: NVAX) were bouncing back on Tuesday, rising 7.1% as of 12:50 p.m. ET after jumping as much as 14.7% earlier in the day. The gain came after an analyst's downgrade caused the stock to plunge last week.Novavax Inc (NASDAQ: NVAX) announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine are now available in the U.K. Nuvaxovid is the first protein-based COVID-19 vaccine granted authorization from the Medicines and Healthcare products Regulatory Agency (MHRA). It will be offered per the Joint Committee on Vaccination and Immunisation (JCVI) advice. Related: Europe Backs Approval Of Omicron-Adapted COVID-19 Vaccines. The MHRA granted Conditional Marketing Authorizatio;58.63999938964844;;102.83000183105469;;109.91000366210938;;70.51000213623047;;33.959999084472656;;67.91000366210938;;66.94000244140625;The stock market strengthened in the first 30 minutes of trading. Biotechs rallied on news of positive trials.ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130™, the Company’s wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS). “The RMATVertex Pharmaceuticals (NASDAQ: VRTX), a commercial-stage biotech specializing in treatments for cystic fibrosis, saw its share price rise on Tuesday thanks to news about one of its pipeline programs.Crispr said Tuesday it will begin asking the FDA to approve its gene-editing blood diseases treatment in November, and CRSP stock jumped.;38.04999923706055;;23.100000381469727;;16.190000534057617;Several biotech stocks have outperformed the struggling market this year.  This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL), and Amgen (NASDAQ: AMGN).  Let's consider why these three biotechs are solid buys for the next decade.;10.760000228881836;;51.02000045776367;;32.119998931884766;;41.27000045776367;;40.25;;;;19.0;;14.880000114440918;;8.039999961853027;;5.849999904632568;;44.41999816894531;;45.54999923706055;;45.36000061035156;;9.970000267028809;;37.790000915527344;;16.790000915527344;;22.93000030517578;"Alkermes plc (Nasdaq: ALKS) today announced that it is now accepting applications for its annual Alkermes Pathways Research Awards® program.65% of heavy drinkers responded ""yes"" when asked if they have ever been concerned about their drinking, yet only 26% have sought treatment. It's important to know that treatment and support are available. If you are concerned about your drinking, talk to your healthcare provider."
2022-09-29;228.41000366210938;;63.06999969482422;"U.S. District Judge Ann Donnelly has ordered to freeze several assets related to people and entities accused of operating a U.S. supply chain that distributes counterfeit bottles of Gilead Sciences Inc's (NASDAQ: GILD) HIV drugs. In a statement, Gilead has identified and named as defendants two individuals responsible for leading and orchestrating the counterfeit scheme. The company initiated this litigation in July 2021 to halt the distribution of counterfeits. A court filing uncovered an operaA federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc HIV drugs, including two alleged ""kingpins.""  Gilead, which has been pursuing alleged counterfeiters in a civil lawsuit since last year, said in a court filing unsealed on Wednesday it had uncovered an operation that was ""staggering in scope,"" responsible for sales of hundreds of millions of dollars of counterfeit bottles of its top sellers Descovy, Genvoya and Biktarvy, and other medicines.  U.S. District Judge Ann Donnelly's latest asset freeze order, also unsealed on Wednesday, targets more than 50 defendants newly added to Gilead's lawsuit.Gilead Sciences, Inc. (Nasdaq:GILD) today announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury® (remdesivir) for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization.";691.8200073242188;"The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent became the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation. The FDA evaluated the Dupixent application for prurigo nodularis under Priority Review. Related: RegeneronDow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent becomes the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest amongRegeneron Pharmaceuticals  soared sharply higher earlier this month and made a ""normal"" correction as prices pulled back to unwind overbought conditions.  The On-Balance-Volume (OBV) line shows gains in September and that is a positive development.  The weekly OBV line is pointed lower and suggests that sellers of REGN are more aggressive.";133.60000610351562;Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.;193.80999755859375;ROBO Global Head of Advisor Relations Lauren Hein joins Yahoo Finance Live to explain how more investors are shifting towards robotics and how increased automation could affect the job market.;292.79998779296875;Dow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks.When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...Concerns are mounting that a full-blown recession could be on the way.  Here are three stocks to buy if you're afraid of buying stocks.  The stock market's huge downturn so far this year hasn't impacted Vertex Pharmaceuticals (NASDAQ: VRTX) in the least.As biotech leaders Vertex and Crispr shoot for a gene-editing first, VRTX stock takes aim at a new breakout.Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.;264.2799987792969;"Mizuho Americas Senior Biotech Analyst Salim Syed joins Yahoo Finance Live to discuss encouraging Phase 3 data from Biogen’s Alzheimer’s treatment lecanemab, how many sales the drug could generate, and what this means for the pharmaceutical industry.The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.Dow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks.In this article we are going to estimate the intrinsic value of Biogen Inc. ( NASDAQ:BIIB ) by taking the forecast...New clinical trial results are great, but this company's Alzheimer's disease program has deeply disappointed investors in the past.For the 55 million people around the world who suffer from Alzheimer's and related dementias -- not to mention their loved ones -- Biogen's...Baird Senior Research Analyst Brian Skorney joins Yahoo Finance Live to discuss the breakthrough of Biogen's Alzheimer's drug, which is pushing the stock higher. (Bloomberg) -- Biogen Inc. rose the most since November 2020 after a key clinical trial with its partner Eisai Co. showed the therapy lecanemab slowed the progression of Alzheimer’s disease.Most Read from BloombergApple Ditches iPhone Production Increase After Demand FaltersMacKenzie Scott Files for Divorce From Science Teacher HusbandGermany Suspects Sabotage Hit Russia’s Nord Stream PipelinesNord Stream Gas Leaks May Be a New Disaster for the ClimateS&P 500 Roars Back From Six-Day Slide; BondsBiogen stock catapulted Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a test.Biogen stock is up almost 40% on Wednesday but is barely holding above a key level. Let's look at the chart.Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday.  The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease.  The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.";136.27999877929688;;135.6999969482422;;209.38999938964844;;285.6300048828125;;3.130000114440918;;85.05999755859375;;29.93000030517578;;66.61000061035156;;33.16999816894531;With inflation, rising interest rates, and fear of a recession weighing on investors' minds, even the best stocks have been in freefall.  Investment bank analysts on Wall Street have identified a handful of top growth stocks that have a lot more potential than their present market values would suggest.  Wall Street analysts who follow Exact Sciences think its best days are still to come.YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.;18.56999969482422;In the past two years, biotech companies Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) rose to fame thanks to their successful attempts to develop vaccines for COVID-19 and help us end the outbreak.  The pandemic isn't over yet, but Moderna and Novavax have given up substantial chunks of their value in the past year.  Where does that leave Moderna and Novavax?;55.290000915527344;;102.76000213623047;Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr. Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021.;109.62999725341797;CAMBRIDGE, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the accelerated approval of SRP-9001 (delandistrogene moxeparvovec) to treat ambulant patients with Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership wPepGen Inc (NASDAQ: PEPG) reported data from PGN-EDO51's SAD study in adult healthy volunteers that suggest best-in-class exon skipping capabilities. SVB notes that PGN-EDO51's safety profile was generally well-tolerated. However, the 15mg/kg dose saw mild hypomagnesemia and an SAE of transient kidney biomarker changes, both events commonly linked to the peptide conjugates that aid oligo delivery. It reiterates its Outperform rating with a price target of $6. On the other hand, the analyst views;69.9800033569336;;33.279998779296875;;65.86000061035156;;64.48999786376953;"ZUG, Switzerland and BOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the BMO Biopharma Spotlight Series: Gene Editing and Therapy on Thursday, October 6, 2022, at 9:00 a.m. ET. A live webcast of the events will be available on the ""Events & Presentations"" page in the InveVertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.MaxCyte Inc (NASDAQ: MXCT) has signed a strategic platform license with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Under the terms of the agreement, Vertex obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform in developing its CRISPR/Cas9-based gene-edited therapy (exa-cel, formerly known as CTX001). MaxCyte is entitled to receive platform licensing fees and program-related revenue. Exa-cel is an investigational ex viv";35.08000183105469;;22.34000015258789;;15.84000015258789;;10.199999809265137;;47.5;;29.290000915527344;Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.;40.54999923706055;;39.52000045776367;;;;19.110000610351562;;14.630000114440918;;7.599999904632568;;5.599999904632568;PacBio's (PACB) latest tool is expected to enable scientists to better understand the role of known TRs in human disease, which could also lead to the discovery of novel disease-causing TRs.;44.279998779296875;;44.79999923706055;;45.25;;9.850000381469727;;35.779998779296875;;16.139999389648438;;22.459999084472656;Check out Alkermes' Steve Schiavo, SVP of HR, in this BioSpace article discussing how to best support a multigenerational workforce.We released our 2022 Corporate Responsibility Report. Check it out to learn about Alkermes' efforts related to environmental sustainability, responsible corporate governance and social responsibility.The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
2022-09-30;225.39999389648438;;61.689998626708984;Kelly was getting ready to leave on a trip to celebrate her 25th wedding anniversary when she started experiencing pain in her abdomen and discovered a lump on her neck. When the pain progressed to the point where it got worse when she laid down, she asked her husband, an emergency room doctor, what he thought.;688.8699951171875;(Bloomberg) -- Illumina Inc. says it can read a person’s entire genetic code for as little as $200 with its new sequencing machine, bringing the company within reach of its long-promised goal of the $100 genome.Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurriRegulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.;134.8800048828125;Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday.  The 7.6 million figure represents only 3.5% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series.  The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people.The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.;190.7899932861328;llumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq™ X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing.The era of rapid and cheap genome sequencing is now here. Illumina, which has long lived at the cutting edge of the genome-sequencing race,...Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced multiple breakthrough sequencing innovations at its inaugural Illumina Genomics Forum:(Bloomberg) -- Illumina Inc. says it can read a person’s entire genetic code for as little as $200 with its new sequencing machine, bringing the company within reach of its long-promised goal of the $100 genome.Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurriIllumina, a leading maker of gene-sequencing systems, announced faster, cheaper gene-readers Thursday.Illumina introduced gene-sequencing machines that it says can more-than-double capacity and slash the cost of sequencing, as it faces competition and price pressures.Illumina Inc, the top maker of DNA sequencers used to speed drug development and other research, on Thursday announced the launch of its next-generation NovaSeq X systems, which it said can generate more than 20,000 whole genomes per year, or 2.5 times that of prior sequencers.  The larger-scale throughput will make the systems, the largest of which is priced at $1.25 million, more cost-effective for customers, Illumina Chief Commercial Officer Susan Tousi told Reuters.  She said the new sequencers will also for the first time allow for data to be processed directly on the instrument.;289.5400085449219;The Dow Jones Industrial Average dropped Friday on hot inflation data. Tesla stock fell ahead of the company's AI Day.If you're not familiar with Vertex Pharmaceuticals (NASDAQ: VRTX), this healthcare stock is certainly one to put on your radar.  The company develops and manufactures medicines that treat rare diseases.  As of right now, it has four approved products, and all of them treat cystic fibrosis.Vertex Pharmaceuticals (VRTX) closed at $292.80 in the latest trading session, marking a +0.13% move from the prior day.;267.0;The major indexes fell, with the S&P 500 breaking below bear market lows. Biogen soared on an Alzheimer's drug while Nike dived.CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody. RoACTEMRA® is indicated in Europe as an intravenous formulation for severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate, moderate toRegulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.;134.82000732421875;(Bloomberg) -- Chinese companies are flailing in a fresh bid to avoid being booted off US stock exchanges for shirking Washington’s oversight demands. Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurricaneTop Apple Executive Is Leaving After Making Crude Remark;136.8300018310547;;200.16000366210938;;284.0;;3.119999885559082;;84.7699966430664;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Company resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational AAV gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. The resubmission incorporates the Company's response to the FDA Complete Response (CR) Letter for valoctocogene roxaparvovec gene therapy issued on August 18, 2020, and subsequent feedback, including two-year outcomes f;28.479999542236328;;66.63999938964844;;32.4900016784668;;18.200000762939453;;55.959999084472656;;106.20999908447266;;110.54000091552734;;69.83999633789062;;33.04999923706055;;65.88999938964844;;65.3499984741211;;34.20000076293945;(Bloomberg) -- Chinese companies are flailing in a fresh bid to avoid being booted off US stock exchanges for shirking Washington’s oversight demands. Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurricaneTop Apple Executive Is Leaving After Making Crude Remark;22.40999984741211;;15.680000305175781;;9.9399995803833;;47.63999938964844;;30.690000534057617;;41.40999984741211;;39.540000915527344;;;;19.280000686645508;;14.989999771118164;;7.739999771118164;;5.809999942779541;;44.22999954223633;;44.4900016784668;NEW HAVEN, Conn., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the Company’s inaugural “Arvinas Impact Day,” a company-wide community service day benefiting organizations in the Greater New Haven area. “Giving back to the communities in which we work and live is an integral part of our values and who we are at Ar;46.529998779296875;;9.890000343322754;;35.2400016784668;;16.360000610351562;;22.329999923706055;
2022-10-03;230.44000244140625;On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia.  With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug.  Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.;62.31999969482422;SANTA MONICA, Calif., October 03, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production. Viral vectors are key components needed to manufacture Kite’s cell therapies to treat certain blood cancers. Kite is the only cell therapy company with in-house commercial and clinical trial viral vector manufacturing capabilities, au;735.1300048828125;Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Craig B. Thompson, M.D., has been elected to the Board of Directors, effective immediately. Dr. Thompson has also been appointed to serve on the Technology Committee of the Regeneron Board. Dr. Thompson is a renowned healthcare business leader with exceptional senior executive experience and scientific expertise in multiple therapeutic areas, including oncology. Regeneron's Board of Directors has been expanded from 12 to 13 memb;136.67999267578125;;187.24000549316406;September jobs numbers will be released on Friday, plus earnings from Lamb Weston, Conagra, McCormick, and Constellation. Also, September PMIs and August JOLTS.;297.42999267578125;;264.29998779296875;Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%.  The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab.  Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too.The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc subsidiary Mylan Pharmaceuticals Inc.  The justices turned away Biogen's appeal of a lower court's decision to invalidate the patent in a ruling that helped clear the way for Mylan's generic version of Tecfidera.  Biogen sued Mylan, now part of Canonsburg, Pennsylvania-based Viatris, in West Virginia in 2017, saying Mylan's proposed generic version of Tecfidera would infringe Biogen patents.AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc subsidiary Mylan Pharmaceuticals Inc.  The justices turned away Biogen's appeal of a lower court's decision to invalidate the patent in a ruling that helped clear the way for Mylan's generic version of Tecfidera.Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2LRRK2 mutations are one of the most common genetic drivers of Parkinson’s diseaseTargeting LRRK2 has the potential to impact the underlying biology and slow the progression of Parkinson’s disease CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that dosing has commenced in the;137.13999938964844;;137.6999969482422;;196.7899932861328;Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced results from exploratory endpoints and additional analyses from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The RNAi drug maintained “generally consistent” benefits in efficacy and quality of life across several prespecified subgroups at month 12, Alnylam announced. It also revealed more detail on a key miss, a composite secondary endpoint including all-cause mortality. The researc;293.07000732421875;;3.140000104904175;;86.69999694824219;;28.329999923706055;;68.83000183105469;Incyte Corp (NASDAQ: INCY) has agreed to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on developing novel antibody therapeutics for vitiligo, a condition in which the skin loses its pigment cells. Its lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023. Under the terms of the agreement, Incyte will acquire Villaris and the exclusive global rights to develop and commeWilmington biotech company Incyte has agreed to acquire Villaris Therapeutics in a deal valued at up to $1.36 billion.  The centerpiece of the deal is auremolimab, a monoclonal antibody that is under development to treat the skin disorder vitiligo — but has potential applications beyond dermatology.  Villaris, based in Cary, North Carolina, was founded in 2019 and is backed by Medicxi, a health care-focused investment firm based in London.WILMINGTON, Del., October 03, 2022--Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody;33.29999923706055;Social media is speculating about the idea that Exact Sciences would buy Invitae. Investors should pinch themselves out of the daydream.;18.600000381469727;REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise across his time with Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc. He currently serv;55.83000183105469;;106.72000122070312;;109.94000244140625;;68.36000061035156;;33.7400016784668;;66.41999816894531;;63.099998474121094;;34.279998779296875;;22.670000076293945;;16.350000381469727;;10.369999885559082;;47.88999938964844;;31.040000915527344;Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2LRRK2 mutations are one of the most common genetic drivers of Parkinson’s diseaseTargeting LRRK2 has the potential to impact the underlying biology and slow the progression of Parkinson’s disease CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that dosing has commenced in the;41.93000030517578;;40.060001373291016;;;;19.959999084472656;;15.680000305175781;;7.599999904632568;;5.829999923706055;;44.9900016784668;;42.79999923706055;NEW HAVEN, Conn., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Paul McInulty has joined the company as Senior Vice President, Regulatory Affairs. “We are delighted to welcome Paul to our leadership team in this crucial role as we enter the next phase of Arvinas – a late-stage development company,” said John Houston, Ph.D., Arvinas President and Chief;47.7599983215332;;10.25;Every investor in AbCellera Biologics Inc. ( NASDAQ:ABCL ) should be aware of the most powerful shareholder groups. And...;36.08000183105469;;17.040000915527344;;22.950000762939453;
2022-10-04;233.02000427246094;;65.30999755859375;"Shares of Gilead Sciences Inc. rallied 3.2% in premarket trading Tuesday, after the biopharmaceutical company was upgraded at J.P. Morgan, which cited greater clarity on the human immunodeficiency virus (HIV) IV franchise and an emerging and undervalued oncology, or cancer treatment franchise. Analyst Christopher Schott raised his rating to overweight, after being at neutral for at least the past 2 1/2 years, while raising his stock price target to $80 from $72. ""At current levels, we see GILD'sBy Peter Nurse";739.5399780273438;REGN vs. RGEN: Which Stock Is the Better Value Option?Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Biogen (NASDAQ: BIIB) are developing remarkable therapies that, instead of merely treating disorders, have the potential to cure them or at least make an impact that no other drug has to date.  The reason that's not a big cause for alarm is that the company's second-quarter revenue of $2.86 billion would be up 20% over the same period in 2021 if its COVID-19 therapy, REGEN-COV, was excluded from total revenue.  The company's sales of the treatment ended late last year when government contracts for the therapy ended.Should investors be excited or worried when a stock crosses above the 20-day simple moving average?Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.Holding on to popular or trending stocks for the long-term can make your portfolio a winner.;137.57000732421875;Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.;205.05999755859375;Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, announced multiple breakthrough sequencing innovations at its inaugural Illumina Genomics Forum:;300.6400146484375;;267.45001220703125;Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Biogen (NASDAQ: BIIB) are developing remarkable therapies that, instead of merely treating disorders, have the potential to cure them or at least make an impact that no other drug has to date.  The reason that's not a big cause for alarm is that the company's second-quarter revenue of $2.86 billion would be up 20% over the same period in 2021 if its COVID-19 therapy, REGEN-COV, was excluded from total revenue.  The company's sales of the treatment ended late last year when government contracts for the therapy ended.The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera. The ruling clears the way for Viatris Inc (NASDAQ: VTRS) to continue marketing its generic version of the drug, launched more than two years ago. The justices turned away Biogen's appeal of a lower court's decision to invalidate the patent. Related: These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win. Biogen sued Mylan, n;144.94000244140625;;139.1699981689453;;201.24000549316406;;308.55999755859375;;3.5199999809265137;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Circularis, a biotechnology company with a proprietary circular RNA and promoter screening platform. When circularized, RNA is much longer-lived in cells, improving its robustness as a potential therapeutic modality. The Circularis platform also allows ultra-high-throughput screening of promoters and other enhancers. Ginkgo is excited to welcome the Circularis team and plGinkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Altar, a French biotechnology company that has developed a proprietary adaptive evolution platform. A fleet of Altar's automated adaptive laboratory evolution (ALE) instruments will be integrated into Ginkgo's Foundry to serve customers across food and beverage, biofuels, biomaterials, cosmetics, animal health and human health applications, among others. Ginkgo has succes;87.91000366210938;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 26th, at 4:30 p.m. ET to discuss third quarter 2022 financial results and provide a general business update.;32.119998931884766;Twist Bioscience, 10x Genomics, and others with large international exposure could be squeezed by global currency selloffs.;69.55999755859375;WILMINGTON, Del., October 04, 2022--Incyte Names New Member to Its Board of Directors;36.15999984741211;;19.399999618530273;Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.;60.880001068115234;;109.23999786376953;As the market indexes work through a downturn, Vertex is among nine stocks to watch showing relative strength.;111.47000122070312;;67.98999786376953;;34.90999984741211;;66.4800033569336;;65.66999816894531;The two companies are collaborators, but they aren't equally likely to be a better purchase than Amazon.;36.599998474121094;;23.829999923706055;;16.40999984741211;ALAMEDA, Calif., October 04, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced the expansion of its June 2021 Clinical Trial Collaboration and Supply Agreement with Bristol-Myers Squibb Company (NYSE: BMY) to include the use of the fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial (NCT05176483), which is evaluating XL092 in combination with multiple immune checkpoint inhibitors (ICIs) in advanced solid tumors. Exelixis is sponsoring STELLAR-0;11.520000457763672;;51.599998474121094;;32.209999084472656;;42.65999984741211;;41.54999923706055;Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. Small-cap stocks overall posted rather disappointing returns in the second quarter of 2022. In what has become a common theme, the Russell 2000® Growth Index (down […];;;21.489999771118164;"Shares of Vir Biotechnology Inc. were up 10.2% in premarket trading on Tuesday after the company said it received a contract from the U.S. government that is worth up $1 billion to develop treatments for the flu and other ""infectious disease threats."" As part of the agreement, the Biomedical Advanced Research and Development Authority is investing $55 million into the development of a prophylactic monoclonal antibody against seasonal and pandemic flu. Vir's stock is down 52.3% this year, while tVir Biotechnology Inc said on Tuesday it had received $55 million in funding from the U.S. government to support its influenza-focused antibody drug that is expected to enter mid-stage trials this year.  The multi-year contract with Biomedical Advanced Research and Development Authority (BARDA) also allows for potential investment of up to $1 billion by the government for developing candidates against emerging infectious disease, including influenza.  The company developed a COVID-19 antibody drug, sotrovimab, along with GSK plc during the pandemic.– First award from the agency’s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza – – Initial investment of approximately $55 million from Biomedical Advanced Research and Development Authority to support development of VIR-2482, an investigational prophylactic monoclonal antibody for seasonal and pandemic influenza viruses – – Multi-year contract also allows for potential total investment of up to $1 billion in the development of influenza and other emerging infectious disea";16.25;;8.050000190734863;;6.510000228881836;;46.189998626708984;;44.13999938964844;;48.709999084472656;;11.239999771118164;;39.2599983215332;Twist Bioscience, 10x Genomics, and others with large international exposure could be squeezed by global currency selloffs.;18.059999465942383;SAN DIEGO, October 04, 2022--Acadia Pharmaceuticals today announced the launch of Rett Revealed, a new awareness campaign that will highlight the lives of Rett patients through a photo mosaic designed by Emily Shifflet, a 27-year-old eye-gaze artist living with Rett syndrome. In honor of Rett syndrome awareness month, this October members of the community are encouraged to submit their photos capturing meaningful moments in their lives to RettRevealed.com to be compiled into the unique mosaic ar;23.010000228881836;Did you know that 47% of heavy drinkers said they sought treatment because a family member expressed concerns? https://bit.ly/3Bt0qrz
2022-10-05;233.82000732421875;When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...;65.44999694824219;"In this article, we will be taking a look at the 10 healthcare stocks to watch in light of Biden’s 60 Minutes interview. To skip our detailed analysis of these stocks and Biden’s insights, you can go directly to see the 5 Healthcare Stocks to Watch in Light of Biden’s 60 Minutes Interview. On September […]Biopharmaceutical company Gilead Sciences  was raised to an ""overweight (buy)"" rating by a sell-side firm Tuesday.  In the daily bar chart of GILD, below, we can see that the shares have been working on a bottom pattern since February.  Trading volume has been improving since June.";745.6799926757812;The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.;137.19000244140625;;218.52000427246094;;302.0199890136719;;261.69000244140625;One of these stocks has significantly outperformed the other over the past year. Will that continue?;144.27000427246094;;136.8699951171875;;201.02000427246094;;308.54998779296875;;3.309999942779541;;89.52999877929688;;32.09000015258789;;69.5;;36.060001373291016;;18.700000762939453;;60.91999816894531;;108.6500015258789;The Dow Jones Industrial Average sold off 300 points Wednesday after a stronger-than-expected ADP employment report.;110.62000274658203;;70.11000061035156;;34.459999084472656;;65.0;Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.;64.62999725341797;Vertex Pharmaceuticals (NASDAQ: VRTX), a biopharmaceutical company that specializes in gene-editing therapies, saw its shares rise 2.8% in September, according to data provided by S&P Global Market Intelligence.  Vertex easily went against the tide, though.  Vertex, known for its franchise of therapies to treat cystic fibrosis (CF), a rare genetic disorder that affects the lungs, pancreas, liver, kidneys, and intestines, showed that it is about to expand its portfolio of marketed drugs.These stocks have significant upside and can make the most of your money -- but they do come with risks.ZUG, Switzerland and BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation and a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, MA or virtually from November 8 to 12, 2022. Title: CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in p;37.06999969482422;;23.559999465942383;SAN DIEGO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present clinical and preclinical data for the Company’s induced pluripotent stem cell (iPSC) product platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held in Boston, MA, and virtually, November 8-12, 2022;15.979999542236328;Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.In this article, we discuss the 11 cheap healthcare stocks to invest in. If you want to skip the detailed analysis of the healthcare industry, go directly to 5 Cheap Healthcare Stocks To Invest In. Healthcare is one of the biggest sectors in the world. According to a research report, the healthcare consumer market size was […];11.300000190734863;;50.95000076293945;Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, which have the potential to gain from their promising gene therapy pipeline candidates.;31.709999084472656;;40.540000915527344;NOVATO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 13,000 shares of common stock of the company and 6,500 restricted stock units of the company’s common stock to one newly hired non-executive officer of the company. The awards were approved;41.65999984741211;;;;22.25;The company has been without a product on the market since the FDA withdrew emergency use authorization in April of its Covid 19 treatment as the Covid virus mutated.With its COVID-19 monoclonal antibody sidelined in the U.S. since April and plans for full approval no longer in the cards, Vir Biotechnology Inc (NASDAQ: VIR) is focusing on influenza product. U.S. Department of Health and Human Services' BARDA has injected $55 million into the company's asset, dubbed VIR-2482, with the potential for up to $1 billion to advance the development across that program and others. As part of the multi-year contract, Vir could be on tap to create as many as ten candid;16.229999542236328;In this article, we discuss the 11 cheap healthcare stocks to invest in. If you want to skip the detailed analysis of the healthcare industry, go directly to 5 Cheap Healthcare Stocks To Invest In. Healthcare is one of the biggest sectors in the world. According to a research report, the healthcare consumer market size was […];7.989999771118164;;6.550000190734863;;45.97999954223633;;44.779998779296875;;47.459999084472656;;11.229999542236328;In this article, we discuss the 11 cheap healthcare stocks to invest in. If you want to skip the detailed analysis of the healthcare industry, go directly to 5 Cheap Healthcare Stocks To Invest In. Healthcare is one of the biggest sectors in the world. According to a research report, the healthcare consumer market size was […]VANCOUVER, British Columbia, October 05, 2022--AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022;38.5099983215332;SOUTH SAN FRANCISCO, Calif., October 05, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Joint School of Nanoscience and Nanoengineering (JSNN) NanoImpacts 2022: Semiconductor Synthetic Biology and Beyond taking place October 13-15, 2022 in Greensboro, NC.;18.049999237060547;The security could overcome a technical level of resistance, too;23.1299991607666;
2022-10-06;230.94000244140625;In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […](Oct. 6, 2022) – Amgen (NASDAQ:AMGN) today announced the opening of a new research and development site in San Francisco's Oyster Point, continuing the company's nearly two-decade presence in the region. The new site will constitute the company's second largest research and development facility, which focuses on discovering therapeutics for patients living with cancer, inflammatory disease and cardiometabolic disorders.;64.94999694824219;"In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […]Growing up in Oakland, Alonzo Henderson didn't have a lot of teachers that looked like him. As a young Black man, he says he felt isolated and thought the educators around him didn't understand his experiences or interests.With a price-to-earnings (or ""P/E"") ratio of 19.8x Gilead Sciences, Inc. ( NASDAQ:GILD ) may be sending bearish signals...";731.8599853515625;;137.52999877929688;In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […];212.72000122070312;In this article, we will take a look at the 10 stocks recently upgraded by analysts. If you want to see some more stocks on the list, go directly to Analysts are Upgrading These 5 Stocks. U.S. stocks turned red on Wednesday morning after staying in positive territory during the last two trading sessions. Meanwhile, […];298.6300048828125;;262.260009765625;"Biotech giant Biogen (NASDAQ: BIIB) was underperforming the market this year -- that is, until the company's shares soared by as much as 37% last week.  The drugmaker's major win in the stock market came after it reported positive top-line results from a phase 3 clinical trial for lecanemab, a potential therapy for Alzheimer's disease (AD).  Biogen is developing lecanemab in collaboration with Japan-based Esai.ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA are part of the Zacks Market Edge article.Biogen's patent battles over Tecfidera are over after SCOTUS decision; Ginkgo Bioworks delves into the RNA therapeutics; and Peter Thiel invests in Waltham startup creating ""humanized"" mice.Tracey and Kevin discuss the rocky 2022 stock market and the future of growth stocks.Reportedly, Biogen (NASDAQ:BIIB) and Japanese pharmaceutical company Eisai (OTCMKTS:ESALY) achieved positive test results for their Alzheimer’s disease treatment. As you might expect, BIIB stock exploded higher on this news. However, these are early-stage results and prospective investors should read the fine print. Besides, if the good news has already been priced in, then buying now is tantamount to chasing, which generally isn’t a recommended strategy. Just to provide the backstory, Biogen an";140.33999633789062;;136.27999877929688;BOTHELL, Wash., October 06, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.;202.3699951171875;;309.0799865722656;Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of new automated co-detection assays specifically designed for the Roche DISCOVERY ULTRA Platform, enabling simultaneous detection of RNA and protein on the same tissue section.;3.2300000190734863;;91.4800033569336;;31.350000381469727;;69.63999938964844;;36.31999969482422;;18.079999923706055;;62.689998626708984;;111.37999725341797;The Dow Jones Industrial Average fell Thursday after weekly jobless claims. The pivotal September payroll report is due out Friday morning.;114.81999969482422;CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.;72.4000015258789;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 22 new employees with a grant date of October 3, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).;33.56999969482422;;62.83000183105469;;65.26000213623047;CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.;35.470001220703125;;23.219999313354492;;15.600000381469727;Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.;10.850000381469727;;51.34000015258789;CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.;31.5;;39.939998626708984;;41.81999969482422;;;;21.34000015258789;;16.030000686645508;;7.869999885559082;;6.869999885559082;;45.599998474121094;;43.7599983215332;;47.150001525878906;We feel now is a pretty good time to analyse Intra-Cellular Therapies, Inc.'s ( NASDAQ:ITCI ) business as it appears...;11.40999984741211;;39.11000061035156;;18.6299991607666;;22.809999465942383;
2022-10-07;229.02999877929688;Amgen Inc. Chairman and CEO Bob Bradway acknowledges the company's move to a new R&D site in South San Francisco isn't a big deal — at least as far as geography — but as far as culture, recruitment, retention and the chance to deliver scientifically, it's huge.  Amgen officially opened its new research-and-development and office building Thursday in BioMed Realty's Gateway of Pacific complex.;64.29000091552734;;722.3699951171875;;134.7100067138672;Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Several big pharma stocks have held up quite well as the overall stock market fell this year.  At first glance, Wall Street might not seem all that optimistic about GSK.  This multiple looks even more impressive considering that analysts project the company will deliver average annual earnings growth of more than 10% over the next five years.BioNTech and Australia’s State of Victoria will establish an mRNA research and innovation center to strengthen translational research for innovative medicines from discovery to delivery As part of the partnership, BioNTech is committed to building a BioNTainer® facility for end-to-end clinical scale manufacturing of mRNA-based products and candidates in Melbourne BioNTech plans to further expand its clinical development capabilities in Australia and evaluate the testing of additional clinical caBioNTech SE, the German biotech that developed a widely used COVID-19 vaccine with Pfizer Inc, will set up research and manufacturing centres in Australia based on the same technology, the company and Australian lawmakers said on Friday.  The Nasdaq-listed company  and Australia's Victoria state said they signed a partnership to create a centre, which would run clinical research of experimental messenger ribonucleic acid, or mRNA, vaccines and therapies with the aim of attracting experts from around the world.  The partnership would also involve setting up mRNA manufacturing facilities in Melbourne, based on BioNTech's modular design, the company and the state government said.Around 3.9 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday.  The 11.5-million figure represents only 5.3% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series.  The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people.;206.17999267578125;Many corporations and companies have adopted employee resource groups, or ERGs, into their work cultures to help employees from minority and marginalized backgrounds feel welcome and to provide career support and development. These groups are completely voluntary and employee-led, and unite employees around a common cause or shared life experiences.Tests from Grail and others aim to help clinicians diagnose more cancers earlier, though data are limited.Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2022 following the close of market on Thursday, November 3, 2022.A historically bearish signal could keep a lid on shares;295.2300109863281;"The Dow Jones Industrial Average plunged 500 points Friday on the September jobs report. AMD lost 8% after a third-quarter revenue warning.Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) price-to-earnings (or ""P/E"") ratio of 24x might make it look like...Most investors would like to see their stock portfolio grow significantly, especially if they have quite a few years left until retirement.  Alphabet (NASDAQ: GOOG), Vertex Pharmaceuticals (NASDAQ: VRTX), Eli Lilly and Company (NYSE: LLY), and Meridian Bioscience (NASDAQ: VIVO) all show solid potential to grow your investments significantly.  Alphabet's stock has risen 105% over the past five years.Vertex Pharmaceuticals is approaching a buy point as this biotech stock expands into other markets, gains institutional investors.";257.8900146484375;;134.8699951171875;;131.25999450683594;Biohaven Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;195.80999755859375;The FDA approved a label expansion for Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) for Oxlumo (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate (UOx) and plasma oxalate (POx) levels in pediatric and adult patients. PH1 is an ultra-rare genetic disease characterized by oxalate overproduction in the liver. The approval is based on positive efficacy and safety results of the ILLUMCAMBRIDGE, Mass., October 07, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved a label expansion for OXLUMO® (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate (UOx) and plasma oxalate (POx) levels in pediatric and adult patients. The approval is based on positive e;296.0;These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2022.;3.0899999141693115;;88.1500015258789;BioMarin Pharmaceutical Inc (NASDAQ: BMRN) will redesign the organization to better focus investments that advance its R&D pipeline, maximize recent commercial launch success, prepare for a potential launch of Roctavian (valoctocogene roxaparvovec) in the U.S., and drive core infrastructure optimization. Biomarin is laying off about 120 employees (or roughly four percent of the global workforce) in a slim down that will save about $50 million annually beginning 2023. Related: BioMarin Says One PBioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced its decision to redesign the organization to better focus investments that advance its R&D pipeline, maximize recent commercial launch success, prepare for a potential launch of ROCTAVIAN™ (valoctocogene roxaparvovec) in the U.S., and drive core infrastructure optimization. This redesign simplifies the organization, creates efficiencies, reduces the average management layers across the organization and prioritizes and heightens the capab;28.56999969482422;Cathie Wood's ARK Innovation ETF (NYSEMKT: ARKK) is down by more than 56% this year, and it might have further to fall.  In that vein, two aspiring biomedical businesses are a bit worse for the wear of the bear market despite Cathie Wood's continued confidence in their success.  10X Genomics (NASDAQ: TXG) sells laboratory analyzer devices used to profile gene expression in cells.;68.41999816894531;"MONTREAL, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (""Knight"") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for tafasitamab in combination with lenalidomide to ANVISA, the Brazilian health regulatory agency, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for auto";33.81999969482422;Tests from Grail and others aim to help clinicians diagnose more cancers earlier, though data are limited.;16.299999237060547;;56.02000045776367;"Investors are facing a storm of headwinds right now – a genuine bear market, stubbornly high inflation, rising interest rates, and increased fears of a recession in the near-term. However, Mary Callahan Erdoes, CEO of JPMorgan's Asset & Wealth Management division, advises investors to stay invested. ""It's actually the easiest time in the world to find alpha — there is alpha everywhere... It's everywhere, because we are in such a state of change... While all the world is focused on all the black";108.25;The major indexes reversed from short-term levels Thursday with the September jobs report on tap. Twitter fell as Elon Musk made new demands. AMD warned late.;111.33999633789062;CAMBRIDGE, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will share new data from across its genetic medicine portfolio at the 27th International Hybrid Annual Congress of the World Muscle Society 2022 Congress (WMS 2022), taking place Oct. 11-15, 2022, in Halifax, Nova Scotia, Canada. Data includes a late-breaking real-world evidence presentation on eteplirsen in treated patients with Duchenne amena;66.88999938964844;For many, the main point of investing in the stock market is to achieve spectacular returns. While the best companies...;31.6200008392334;;59.0;Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective October 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 11,381 shares of its common stock and an aggregate of 5,688 restricted stock units (RSUs) to eight new employees under Blueprint Medicines' 2020 Inducement Plan.;61.650001525878906;;33.029998779296875;;21.469999313354492;;15.399999618530273;;10.40999984741211;- The conference will take place at the National Cancer Institute at Frederick, Maryland from October 17-19, 2022 - Presentation to include details from next-generation G12C dual inhibitor clinical candidate and characterization of advanced leads from the PI3Kα:RAS breaker program - BridgeBio will host an investor call on October 17, 2022 at 1:30 pm ET to discuss the data and next steps for its two lead RAS programs - RAS is the most common oncogenic driver with approximately 30% of all human ca;47.75;;30.75;;37.93000030517578;;41.5;;;;20.610000610351562;;15.34000015258789;;7.449999809265137;;6.110000133514404;;45.93000030517578;;41.439998626708984;;47.939998626708984;;10.75;;32.65999984741211;Cathie Wood's ARK Innovation ETF (NYSEMKT: ARKK) is down by more than 56% this year, and it might have further to fall.  In that vein, two aspiring biomedical businesses are a bit worse for the wear of the bear market despite Cathie Wood's continued confidence in their success.  10X Genomics (NASDAQ: TXG) sells laboratory analyzer devices used to profile gene expression in cells.;16.290000915527344;Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.;22.1299991607666;
2022-10-10;232.14999389648438;Aristotle Capital Management, LLC, an investment management company, released its “Aristotle Global Equity Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. In the second quarter, the fund returned -13.17% at NAV compared to a -15.66% return for the MSCI ACWI Index and -16.19% return for the MSCI World […];64.45999908447266;Gilead (GILD) is having a good run despite the volatility on a string of positive updates.To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the...;730.9199829101562;;135.2899932861328;In this article, we will look at the 12 best stocks for long-term growth. If you want to explore similar stocks, you can also take a look at 5 Best Stocks for Long-Term Growth. Growth stocks are taking a beating in 2022 due to higher borrowing costs that are delaying expansion plans and negatively impacting […];203.52999877929688;Illumina CEO Francis deSouza told analysts that the company can cut sequencing’s cost without crimping its 60%-plus gross margins.;294.5400085449219;Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.The Dow Jones Industrial Average reversed lower Monday ahead of earnings season. Tesla stock reported record China deliveries in September.Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure. This combination makes these companies attractive to value investors. In general, however, investing in biotech stocks is not for risk-averse investors. Many of these companies are smaller players. They may or may not be generating revenue, much less profit. But it’s usually at these compa;254.77999877929688;Although Biogen and Eisai’s lecanemab cleared plaque from patients’ brains, researchers say the benefits may be limited.Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure. This combination makes these companies attractive to value investors. In general, however, investing in biotech stocks is not for risk-averse investors. Many of these companies are smaller players. They may or may not be generating revenue, much less profit. But it’s usually at these compa;130.89999389648438;;130.9499969482422;;186.82000732421875;;284.489990234375;Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 1, 2022, at 8:00 a.m. CDT to review first quarter 2023 financial results.;2.890000104904175;;87.44999694824219;;26.90999984741211;;67.58000183105469;;32.79999923706055;Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2022 financial results after the close of the U.S. financial markets on November 3, 2022. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.;17.780000686645508;Swiss drugs regulator Swissmedic temporarily approved Pfizer Inc's (NYSE: PFE) COVID-19 booster shot targeting the original and BA.1 omicron coronavirus variants. Swissmedic added that the available data was not yet sufficient to decide on Pfizer's bivalent booster vaccine targeting the BA.4 and BA.5 Omicron variants. The bivalent vaccine contains mRNA for the spike protein of the Wuhan strain and that of the Omicron variant BA.1. The modified composition promises to be more effective against thShares of Novavax (NASDAQ: NVAX) were jumping 6.3% as of 10:44 a.m. ET on Monday.  The nice gain came after the company announced that Swiss regulators have recommended Novavax's COVID-19 vaccine Nuvaxovid as a booster in adults ages 18 and older.  Novavax also announced on Monday morning that its partner, SK bioscience, has filed for approval in South Korea for Nuvaxovid to be used as a booster in adults.A Triangle company is getting a big payout after its contract involving a Covid vaccine was canceled.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will present new safety and immunogenicity data from the first Phase 1/2 COVID-Influenza Combination (CIC) dose-finding trial evaluating its CIC vaccine candidate at the World Vaccine Congress (WVC) Europe, October 11 to 14, 2022. Data from the Phase 3 PREVENT-19 trial and from Study 307: Lot Consistency evaluating the protein-based Novavax C;54.310001373291016;;106.83999633789062;;108.69999694824219;;65.30000305175781;;30.489999771118164;;55.18000030517578;;60.81999969482422;;30.75;;21.31999969482422;;14.960000038146973;;10.380000114440918;;46.66999816894531;;30.670000076293945;One simple way to benefit from the stock market is to buy an index fund. But many of us dare to dream of bigger...;37.189998626708984;;41.2599983215332;;;;21.280000686645508;;14.770000457763672;;7.019999980926514;;5.739999771118164;;45.099998474121094;;38.790000915527344;;47.599998474121094;;10.920000076293945;Investors need to pay close attention to AbCellera Biologics (ABCL) stock based on the movements in the options market lately.;30.639999389648438;;16.1200008392334;;21.940000534057617;
2022-10-11;245.44000244140625;U.S. stocks fell on Tuesday in the run-up to third-quarter results from companies as profit expectations drop amid rising interest rates and stubborn inflation, while gains in drugmaker Amgen limited declines on the Dow.  Microsoft Corp, Twitter Inc, Amazon.com , Apple Inc, and Tesla Inc were down between 1% and 3.5%.MARKET PULSE Shares of Amgen Inc. (AMGN) leapt 5.2% in morning trading Tuesday, enough to pace the Dow Jones Industrial Average’s (DJIA) gainers, after Morgan Stanley turned bullish on the biotechnology company.The three main indexes have been on a loss-making streak in the past few sessions as recent data continues to point to more policy tightening by the U.S. Federal Reserve that could tip the economy into a recession.  Most rate-sensitive growth stocks such as Microsoft Corp , Twitter Inc, Amazon.com, Apple Inc , and Tesla Inc were down between 0.1% and 0.2% in premarket trading.  With recent economic indicators signaling persistent inflation going forward, money markets are pricing in a 92% chance of another 75-basis-point hike at the Fed's meeting in November.In this article, we will take a look at 12 best ethical stocks to buy now. If you want to see some more of the best ethical stocks to buy, go directly to 5 Best Ethical Stocks To Buy Now. Sometimes investing is more than about just making money. Investing can also be used to […]A year after emerging from stealth with what would ultimately be the fifth-largest fundraise among local life sciences companies in 2021, Neumora Therapeutics has raised another $112 million to propel its neuropsychiatric drugs forward.Amgen (AMGN) closed at $232.15 in the latest trading session, marking a +1.36% move from the prior day.;65.66999816894531;In this article, we will take a look at 12 best ethical stocks to buy now. If you want to see some more of the best ethical stocks to buy, go directly to 5 Best Ethical Stocks To Buy Now. Sometimes investing is more than about just making money. Investing can also be used to […]FOSTER CITY, Calif., October 11, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have receivGilead Sciences (GILD) closed at $64.46 in the latest trading session, marking a +0.26% move from the prior day.;737.4099731445312;Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) presented more positive data for their Dupixent product. The companies said new Dupixent data showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly. In May 2022, FDA approved Dupixent 300 mg weekly for EoE in people aged 12 years and older, weighing at lRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented late-breaking positive results from a Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) in children aged 1 to 11 years with active eosinophilic esophagitis (EoE). The data will be shared at United European Gastroenterology (UEG) Week 2022 and submitted to regulatory authorities around the world, starting with the U.S. Food and Drug Administration (FDA) next year. In May 2022, Dupixent 300 mg weekly;129.49000549316406;;199.16000366210938;;295.1600036621094;"The Dow Jones Industrial Average fell Tuesday, as the 10-year Treasury yield neared 4% after gains in recent sessions.With a price-to-earnings (or ""P/E"") ratio of 23.6x Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) may be sending...BOSTON, October 11, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the advancement of its investigational program targeting alpha-1 antitrypsin deficiency (AATD), a rare, genetic disease characterized by a protein folding defect that can lead to liver and lung disease.If there is, it's wrong too -- at least when applied to the stock market.  As a case in point, here are three top biotech stocks that are defying the bear market.  Few stocks in any sector have outperformed Vertex Pharmaceuticals (NASDAQ: VRTX) in 2022.Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Pfizer Inc. (PFE) and Citigroup Inc. (C).";254.07000732421875;In this article, we will take a look at 12 best ethical stocks to buy now. If you want to see some more of the best ethical stocks to buy, go directly to 5 Best Ethical Stocks To Buy Now. Sometimes investing is more than about just making money. Investing can also be used to […]Recently, Biogen Inc (NASDAQ: BIIB) and Eisai Co (OTC: ESALY) announced encouraging data from the most-watched Alzheimer's therapies in the clinic. Lecanemab cleared accumulations in the brain of beta-amyloid, sticky protein fragments that researchers have long suspected contribute to Alzheimer's. Citing physicians and neurology researchers, Wall Street Journal reported that the drug's benefit to patients might be limited. They said the reduction of cognitive decline that patients experienced wa;125.51000213623047;;133.17999267578125;;186.67999267578125;If there is, it's wrong too -- at least when applied to the stock market.  As a case in point, here are three top biotech stocks that are defying the bear market.  Few stocks in any sector have outperformed Vertex Pharmaceuticals (NASDAQ: VRTX) in 2022.;281.9800109863281;Bio-Techne Corporation (NASDAQ: TECH) and PROGEN announced today the release of three new Simple Plex™ Adeno-Associated Virus (AAV) viral titer assays for intact AAV capsid quantification. Featuring best-in-class AAV reagents from PROGEN—a leader in AAV antibodies, ELISAs, and controls—the new Simple Plex AAV1, AAV6, and AAV8 viral titer assays provide users with a fully automated and quantitative method of vector analysis.;2.9800000190734863;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Merck, known as MSD outside the United States and Canada, to engineer up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient (API) manufacturing efforts. Through this collaboration, Ginkgo will leverage its extensive experience in cell engineering and enzyme design, as well as its capabilities in automated high throughput screening, manufacturing;88.06999969482422;;26.719999313354492;;67.25;WILMINGTON, Del., October 11, 2022--Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, November 1, 2022.;32.15999984741211;;18.969999313354492;;53.47999954223633;The technical signals of the genome editing company are largely bearish and indicate its stock is poised to weaken.;107.5999984741211;If there is, it's wrong too -- at least when applied to the stock market.  As a case in point, here are three top biotech stocks that are defying the bear market.  Few stocks in any sector have outperformed Vertex Pharmaceuticals (NASDAQ: VRTX) in 2022.;108.9800033569336;;66.23999786376953;;31.25;PASADENA, Calif., October 11, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present interim clinical data from the ongoing SHASTA-2 Phase 2 study of ARO-APOC3 in patients with severe hypertriglyceridemia and the ongoing ARCHES-2 Phase 2 clinical study of ARO-ANG3 in patients with mixed dyslipidemia, in late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2022, being held in Chicago on November 5–7, 2022. The company will;52.349998474121094;;58.5099983215332;;28.760000228881836;;20.93000030517578;;15.510000228881836;EXEL vs. TECH: Which Stock Is the Better Value Option?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.;10.59000015258789;- BBP-398, an investigational SHP2 inhibitor, is a potentially optimal agent for use in combination therapies given its continuous, once-daily dosing in addition to synergistic activity with other agents to treat cancers driven by KRAS G12C mutations - The combination of investigational therapy BBP-398 and LUMAKRAS, if successful, has the potential to address the serious unmet need for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). - This combination trial is designed to tar;46.56999969482422;;30.940000534057617;;37.459999084472656;;42.20000076293945;;;;20.479999542236328;;14.819999694824219;;7.260000228881836;;5.670000076293945;;45.560001373291016;;39.5099983215332;;47.349998474121094;;10.9399995803833;A Relative Strength Rating upgrade for Abcellera Biologics Inc shows improving technical performance. Will it continue?;30.329999923706055;;15.880000114440918;;22.600000381469727;
2022-10-12;246.44000244140625;Amgen (AMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.Wall Street closed mixed on Tuesday after a choppy session.Amgen (NASDAQ:AMGN) today released the 9th edition of its Biosimilar Trends Report, which examines the current and future state of the U.S. marketplace with biosimilars. This year, in addition to examining important trends in the U.S., the Report also highlights key considerations and learnings from the global marketplace with biosimilars. To access the full Report, visit https://www.amgenbiosimilars.com/commitment/trends-report.Chevron, Amgen, HSBC, CVS Health and S&P Global are included in this Analyst Blog.U.S. stock indexes turned lower in the final hour of trading after remarks from Bank of England Gov. Andrew Bailey.The S&P 500 and Nasdaq ended lower on Tuesday, with indications from the Bank of England that it would support the country's bond market for just three more days adding to market jitters late in the session.  Trading was volatile, with investors cautious ahead of key U.S. inflation data and the start of third-quarter earnings later this week.Amgen stock surged Tuesday on a reportedly bullish call for its experimental obesity treatment — a potential rival to Novo and Lilly.Analyst Matthew Harrison upgraded shares of the biotechnology company to Overweight from Equal Weight.The Dow and S&P 500 were higher in late afternoon trading Tuesday as investors snapped up some beaten-down shares, but volatility was high ahead of U.S. inflation data and the start of third-quarter earnings later this week.  The Nasdaq was lower, extending recent declines.An upgrade highlights one of the more philosophical reasons you want to bet on this biopharma name right now.Today's Research Daily features new research reports on 12 major stocks, including Chevron Corporation (CVX), Amgen Inc. (AMGN) and HSBC Holdings plc (HSBC).The S&P 500 and the Nasdaq fell on Tuesday in the run-up to a key inflation reading and the start of third-quarter results from companies amid falling profit expectations, while gains in drugmaker Amgen helped boost the Dow.  With recent jobs and inflation data suggesting more big interest rate hikes by the Federal Reserve, Wall Street's main indexes have been clocking losses in the past few sessions on fears of the economy slipping into a recession.;65.38999938964844;Both drugmakers have been outperforming the market -- which may continue if they earn important regulatory approvals soon.Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.Before Rashad Burgess held the professional title of Vice President of Advancing Health and Equity at Gilead Sciences or the personal identification of husband and father, he witnessed the devastating effects of HIV in the early nineties as a gay teenager growing up on the south side of Chicago.These stocks pay at different intervals and collectively can ensure you're collecting a dividend payment each month.All four of these drugmakers are expecting important FDA approval decisions over the next few months.The FDA has accepted for review Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for unresectable locally advanced or metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. The supplemental application covers patients who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The target action date of the Prescription Drug User Fee Act (PDUFA) is February;728.0599975585938;Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants. The target action date for the FDA decision is February 11, 2023.;136.64999389648438;The FDA has granted Emergency Use Authorization for Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) 10-µg booster dose of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age. Pending recommendation from the Centers for Disease Control and Prevention, 10-µg doses will be shipped immediately. Clinical data from a Phase 2/3 trial showed a booster dose of 30-µg Omicron BA.1-adapted vaccine elicited a superior immune response compared to the companies' orShares of Pfizer Inc.  (PFE)  climbed 2.2% and BioNTech SE  (BNTX)  hiked up 5.5% in morning trading Wednesday, after the companies said the U.S. Food and Drug Administration has granted Emergency Use Authorization (EUA) for its omicron bivalent COVID-19 booster vaccine for children aged 5 through 11.  The drug makers said pending recommendation from the Centers for Disease Control and Prevention (CDC), the 10-ug booster doses, adapted for the BA.4 and BA.5 subvariants, will be shipped immediately.  Pfizer’s stock has lost 17.7% over the past three months and BioNTech shares have shed 15.2%, while the S&P 500  (SPX)  has lost 5.7%.NEW YORK and MAINZ, GERMANY, OCTOBER 12, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age. Pending recommendation from the Centers for Disease Control and Prevention (CDC), 10-µg doses will be shipped immediately. “As families across the country take partThe FDA authorizes the first bivalent COVID-19 booster for ages 5-11.In this article, we discuss 10 best international stocks to buy now. If you want to see more stocks in this selection, check out 5 Best International Stocks to Buy Now. Markets are swinging wildly, and the rally in the last week is already over, with major US indices running red for days on end. […];198.27000427246094;Illumina Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, announced a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise.Illumina Inc (NASDAQ: ILMN) entered a strategic research collaboration with AstraZeneca plc (NASDAQ: AZN) on drug target discovery. Financial and other details of the partnership were not disclosed. Under the terms of the agreement, the firms will join forces on artificial intelligence-based genome interpretation and genomic analysis and evaluate whether a combined framework can increase the yield of and confidence in target discovery. AstraZeneca's Center for Genomics Research will use the combGrowing up in Tijuana, Mexico, Olivia Graeve was interested in pursuing the sciences but didn't quite know how to make a career of it. To her knowledge, no cross-border student exchange programs for scientific research were available to her. She was able to attend college and graduate school in the US and eventually joined the University of California San Diego as a professor in the Department of Mechanical and Aerospace Engineering in 2012.;290.1300048828125;The Dow Jones Industrial Average fell Wednesday on hot inflation data. Minutes from Federal Reserve's policy meeting are due out today.These unstoppable stocks could be resilient choices to buy and hold in the next bear market and beyond.Futures pared gains as the 10-year Treasury yield in flux with big inflation reports due. The S&P 500 is at bear market lows.The stock market has left many investors uneasy lately.  With valuations of many once-high-flying stocks tumbling in recent months, as well as concerns about a global recession rising, businesses across a range of industries are facing unique challenges.  If you have $50,000 to put in the stock market right now, here are three powerhouse stocks to consider for at least part of that investment.Axsome Therapeutics wowed investors when it soared more than 80% this year through August.  Investors cheered Axsome's first steps in the world of product commercialization.  Vertex is best known for its leadership in the world of cystic fibrosis (CF) treatment.Vertex Pharmaceuticals Inc (NASDAQ: VRTX) has advanced its investigational program targeting alpha-1 antitrypsin deficiency (AATD), a rare genetic disease characterized by a protein folding defect that can lead to liver and lung disease. Vertex announced that the FDA had cleared the Investigational New Drug (IND) Application for VX-634, enabling the company to initiate a first-in-human clinical trial for this small molecule AAT corrector in healthy volunteers. Also see: Vertex Pharma's Flagship;253.6699981689453;Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Shares of Biogen (NASDAQ: BIIB) soared late last month after the company again received positive results around one of its Alzheimer's treatments.  It wasn't Aduhelm this time, but a new promising treatment called lecanemab, which the company is hoping can slow down the disease.  Does the price jump signal a turnaround for Biogen, and is now the time to buy shares of the healthcare company before its value rises even further?All four of these drugmakers are expecting important FDA approval decisions over the next few months.Biogen Inc. (BIIB) closed at $254.07 in the latest trading session, marking a -0.28% move from the prior day.;151.3000030517578;"BeiGene Limited (NASDAQ: BGNE) announced topline data from the Phase 3 ALPINE trial of Brukinsa (zanubrutinib) against ibrutinib in previously treated patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL). Brukinsa achieved superior Progression-Free Survival (PFS) versus Johnson & Johnson's (NYSE: JNJ) Imbruvica (ibrutinib) in a final analysis of the Phase 3 ALPINE trial. Related: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response RaCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, October 12, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) achieved superior Progression-Free Survival (PFS) versus IMBRUVICA® (ibrutinib) in a final analysis of the Phase 3 ALPINE trial, as assessed by an independent review committe";133.2899932861328;;185.11000061035156;;282.8699951171875;Bio-Techne Corporation (NASDAQ: TECH) today announced the introduction of 3 novel TSA Vivid Fluorophores for highly sensitive fluorescent detection of RNAs and proteins in cells and tissues. Optimized for use with proprietary RNAscope ISH technology, the TSA Vivid Fluorophores enable researchers to illuminate RNA biomarkers with industry leading sensitivity and clarity, accelerating cellular phenotyping and functional analysis at single-cell and subcellular resolution.;2.8499999046325684;;88.94999694824219;The mean of analysts' price targets for BioMarin (BMRN) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.;27.329999923706055;;67.51000213623047;;31.6200008392334;;20.239999771118164;"Novavax Inc (NASDAQ: NVAX) presented data from the Phase 3 PREVENT-19 trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022. PREVENT-19 data showed that the prototype Novavax COVID-19 vaccine (NVX-CoV2373) achieved its pre-specified immunologic endpoint. Immunoglobulin G (IgG; a type of antibody) levels increased significantly relative to pre-boost levels. Neutralizing antibodies against the prototype strain also increased by 34- to 27-fold compared to pre-boost levelsThe head of the World Health Organization made his strongest comments yet about the devastation being caused by long COVID and urged world leaders to launch immediate and ""sustained"" efforts to tackle the 'very serious' crisis.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today presented data from the Phase 3 PREVENT-19 trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022. PREVENT-19 data in both adults aged 18 and older and adolescents aged 12 through 17 showed the prototype Novavax COVID-19 vaccine (NVX-CoV2373) achieved its pre-specified immunologic endpoint. Study 307 (Lot ConsisNovavax Inc said on Wednesday data from studies in adults and adolescents showed that the booster dose of its COVID vaccine produced robust antibodies against several Omicron variants, including BA.1, BA.2 and BA.5.  The data was from two studies - a late-stage study evaluating the booster in adults and adolescents who had received Novavax primary vaccination and another study testing it in those aged 18 to 49 who had received primary series of Novavax vaccine or other authorized or approved vaccines.MARKET PULSE Shares of Novavax Inc. (NVAX) jumped 1.7% in premarket trading on Wednesday after the company said its COVID-19 vaccine boosted antibody levels when used as a booster. The data, from a Phase 3 clinical trial, tested a third shot in adults who had been vaccinated with Novavax’s initial series of shots 8 or 11 months prior.The Federal Office of Public Health in Switzerland recommends Novavax's (NVAX) COVID-19 vaccine, Nuvaxovid, as a booster for both heterologous and homologous use in adults aged 18 years and older.";54.86000061035156;;108.33999633789062;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on November 1, 2022.;112.12999725341797;;69.94999694824219;Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (Nasdaq: AADI), a commercial stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumiAll four of these drugmakers are expecting important FDA approval decisions over the next few months.;32.0;;53.0;;58.5099983215332;;29.1299991607666;;21.329999923706055;;15.319999694824219;;11.470000267028809;;48.220001220703125;;31.59000015258789;;38.470001220703125;;42.599998474121094;;;;20.860000610351562;SAN FRANCISCO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research, is scheduled to present at the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on Tuesday, October 18, at 10:30 a.m. PT / 1:30 p.m. ET. A live webcast of the fireside chat can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio;14.800000190734863;;6.960000038146973;;6.409999847412109;;46.02000045776367;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into an agreement with Sudberry Properties to develop and lease a new development chemistry and manufacturing site in Oceanside, Calif. Sudberry will develop and construct the shell for the approximately 217,000-square-foot building. Ionis will design and construct improvements to customize the facility. Under the terms of the agreement, Ionis will lease the property for 20 years, with two 10-year options to renew and;41.400001525878906;;47.88999938964844;;10.640000343322754;VANCOUVER, British Columbia, October 11, 2022--AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022;30.459999084472656;SOUTH SAN FRANCISCO, Calif., October 12, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has earned Great Place to Work® Certification™ in the U.S. for the second consecutive year, and for the first time in China, Germany, Singapore, and the United Kingdom.;15.649999618530273;Acadia's (ACAD) lead drug, Nuplazid, is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. Sole dependence on Nuplazid for growth remains an overhang.;22.18000030517578;
2022-10-13;251.66000366210938;Despite a 5.4% gain in Amgen Inc.'s ( NASDAQ:AMGN ) stock price this week, shareholders shouldn't let up. In spite of...On Wednesday, Amgen stock hit an important technical milestone, with its Relative Strength (RS) Rating entering into the 90-plus percentile with an upgrade to 90, a rise from 78 the day before.  When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.  IBD's unique RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.;66.45999908447266;Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.The established nature of Gilead's business allows the company to pay out a strong dividend, currently yielding 4.2%.;752.5599975585938;Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is up by a considerable 22% over the past three months. Given that the...Investors often favor that industry during tough times because its earnings are less at risk -- patients can't do without the products these companies sell.  Shares of Axsome Therapeutics (NASDAQ: AXSM), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX) have actually been climbing this year, and it doesn't look as if those trends will end any time soon.  Axsome Therapeutics attracted investors' attention as it moved closer to product commercialization.;140.00999450683594;A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support for the new bivalent boosters that target the most dominant virus strains and experts are hoping they will persuade more Americans to get the updated shot.The preliminary data results are the first from human testing of the shots in people at least 18 years old.FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.MARKET PULSE Pfizer Inc. (PFE) and German partner BioNTech SE (BNTX) said Thursday early data from a Phase 2/3 clinical trial of their omicron BA.4/BA.5-adapated bivalent booster showed positive results in treating individuals aged 18 and older.NEW YORK & MAINZ, Germany, October 13, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating the safety, tolerability, and immunogenicity of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)).MARKET PULSE The Centers for Disease Control and Prevention officially signed off on allowing children as young as 5 years old to get an updated COVID-19 booster shot. CDC Director Rochelle Walensky signed the decision memo on Wednesday afternoon, the same day that the Food and Drug Administration expanded the authorizations for Moderna Inc.The FDA’s decision broadens a campaign by health officials to bolster protection against the Omicron strains of the coronavirus.;202.63999938964844;;296.5400085449219;The Dow Jones Industrial Average dived Thursday on hot inflation data from the consumer price index. The 10-year Treasury yield topped 4%.Stocks were quiet Wednesday, as investors avoided rallying into the CPI inflation report. EV plays Albemarle and Aehr Test Systems dived.Investors often favor that industry during tough times because its earnings are less at risk -- patients can't do without the products these companies sell.  Shares of Axsome Therapeutics (NASDAQ: AXSM), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX) have actually been climbing this year, and it doesn't look as if those trends will end any time soon.  Axsome Therapeutics attracted investors' attention as it moved closer to product commercialization.Here's why I think that Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), MercadoLibre (NASDAQ: MELI), and Vertex Pharmaceuticals (NASDAQ: VRTX) are the top picks.  Thanks to its 20-for-1 stock split conducted in July, you can buy a lot more shares of Alphabet with less money than you could've in the past.  For one thing, Alphabet's share price has fallen more than 30% year to date.The FDA clears Vertex's (VRTX) Investigational New Drug application for VX-634, a small molecule AAT corrector, thereby allowing the company to initiate a first-in-human clinical study in healthy volunteers.;269.94000244140625;"NORTHAMPTON, MA / ACCESSWIRE / October 13, 2022 / Biogen ""I remember this one girl from Cambridge: she was filling out the survey we give to students on their last day,"" says Tracy Callahan, Biogen's first Community Lab teacher. ""She said to ...SANTA MONICA, Calif., October 13, 2022--GoodRx (NASDAQ: GDRX), a leading consumer-focused digital healthcare platform, today announced a collaboration with Biogen (NASDAQ: BIIB) that aims to improve the patient and healthcare provider (HCP) experience when initiating a new specialty therapy. HCPs who have decided to start patients with relapsing forms of multiple sclerosis (MS) on VUMERITY® (diroximel fumarate) may now find the enrollment form and submit to the specialty hub through Provider ModBy Peter NurseRegulatory and pipeline updates from DICE and RIGL are the key highlights from the biotech sector during the past week.";151.88999938964844;BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.Chinese biotech’s research chief calls decision ‘unfortunate’ as zero-Covid policy strangles economyBeiGene stock catapulted Wednesday after the company's leukemia treatment beat out a blockbuster drug from Johnson & Johnson.;133.52999877929688;;191.75999450683594;CAMBRIDGE, Mass., October 13, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2022 on Thursday, October 27, 2022, before the U.S. financial markets open.;288.95001220703125;;2.8399999141693115;;89.4000015258789;The FDA accepted BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) resubmission of the marketing application for its investigational AAV gene therapy, valoctocogene roxaparvovec, for severe hemophilia A. The Prescription Drug User Fee Act (PDUFA) target action date is March 31, 2023. At this time, the FDA has not communicated any plans to hold an advisory committee meeting. If approved, valoctocogene roxaparvovec would be the first gene therapy in the U.S. to treat severe hemophilia A. The European CBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S. Food and Drug Administration (FDA) accepted the Company's resubmission of the Biologics License Application (BLA) for its investigational AAV gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. The Prescription Drug User Fee Act (PDUFA) target action date is March 31, 2023. At this time, the FDA has not communicated any plans to hold an advisory committee meeting. If approved, valoctocogene roxap;27.420000076293945;10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 2, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.;68.41999816894531;;30.420000076293945;Investment bank analysts think these stocks will shoot through the roof once the rest of the market sees them in the same light.;21.280000686645508;A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support for the new bivalent boosters that target the most dominant virus strains and experts are hoping they will persuade more Americans to get the updated shot.Shares of Novavax Inc.  (NVAX)  were down 3.4% in premarket trading on Thursday after the company said its combination COVID-19 vaccine and flu shot candidate generated an immune response in a Phase 1/2 clinical trial.  Novavax also said that the safety and tolerability of the combination vaccine was consistent with getting a standalone COVID-19 vaccine or flu shot, and it plans to begin a confirmatory Phase 2 clinical trial this year.  Novavax’s stock has tumbled 85.8% this year, while the S&P 500  (SPX)  has declined 24.7%.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination (CIC) vaccine candidate. Data demonstrated the CIC vaccine's ability to generate immune responses, including both antibody and polyfunctional CD4+ T-cell (lymphocytes that help coordinate the immune response) responses against severe acute;55.11000061035156;Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.;111.51000213623047;;112.97000122070312;;69.48999786376953;;32.31999969482422;;52.09000015258789;;58.060001373291016;;28.5;;21.450000762939453;;15.65999984741211;;10.619999885559082;LianBio (NASDAQ: LIAN) reported that its partner BridgeBio Pharma Inc (NASDAQ: BBIO) informed LianBio that Helsinn Healthcare SA, which holds the Truseltiq (infigratinib) New Drug Application (NDA) in the U.S., is permanently discontinuing distribution of the drug. It also anticipates requesting the withdrawal of the NDA in the U.S. due to business reasons. Due to the planned withdrawal of the NDA, BridgeBio informed LianBio that it intends to close the ongoing global Phase 3 PROOF-301 clinical;49.0;;33.91999816894531;;39.650001525878906;;43.220001220703125;;;;21.43000030517578;It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...;15.0600004196167;;7.110000133514404;;6.539999961853027;;45.66999816894531;;42.86000061035156;;48.54999923706055;;10.729999542236328;;30.440000534057617;;16.15999984741211;SAN DIEGO, October 13, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Adora Ndu, Pharm.D., J.D. to its Board of Directors. Dr. Ndu is a biopharma executive with more than 15 years of experience in regulatory affairs and clinical development.;22.719999313354492;
2022-10-14;251.33999633789062;This health stock is up over 9% for the week and within 3% of a buy point on the chart. Shares soared on news of its obesity treatment.;66.16999816894531;In the latest trading session, Gilead Sciences (GILD) closed at $66.46, marking a +1.64% move from the previous day.The change represents Gilead's focus on research, now concentrated on the south section of its 72-acre Foster City campus.FOSTER CITY, Calif., October 13, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2022 financial results will be released on Thursday, October 27 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2022 financial results and will provide a business update.;736.0599975585938;Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo® (cemiplimab) as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The European Commission is expected to make a final decision on the application in the coming months.The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.;135.6199951171875;Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.Anticipating a surge of COVID-19 infections later this year, the FDA broadens the label of authorized Omicron-based BA.4/BA.5 adapted bivalent boosters to include children as young as five years.;199.32000732421875;NORTHAMPTON, MA / ACCESSWIRE / October 14, 2022 / Illumina: As a scientist on Illumina's Assay Research team in San Diego, Suzanne Rohrback works with colleagues to come up with new ways next-generation sequencing (NGS) can maximize insights from ...;293.2099914550781;"The Dow Jones Industrial Average reversed lower Friday on hot inflation data. JPMorgan and UnitedHealth rallied on earnings results.Unsurprisingly, Warren Buffett gave some excellent investing advice several years ago.  Let me begin by acknowledging that Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) faces some challenges.  Alphabet's shares have also fallen more than 30% year to date.BOSTON, October 13, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the ""Vertex Pharmaceuticals Third Quarter 2022 Earnings Call"".";264.6300048828125;Biogen could easily take on Roche and Eli Lilly in Alzheimer's treatment, an analyst said Thursday as he upgraded Biogen stock.Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's. It raised the price target from $223 to $299. The analyst worries about residual competitive/commercial risks, notwithstanding the uncertainty around Biogen's future CEO. Stifel views upcoming Roche Holding AG's (OTC: RHHBY) gantenerumab data are unlikely to live up to the high bar lecanemab recently set and thinks there's a meaningful commercial role for lecane;155.83999633789062;"European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of BeiGene Limited's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) in adults. The CHMP recommendation is based on two global head-to-head Phase 3 clinical trials in which Brukinsa demonstrated superior efficacy - ALPINE comparing Brukinsa to ibrutinib in patients with R/R CLL and SEQUOIA comparing Brukinsa to BR in patients with TNCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, October 14, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of BRUKINSA® (zanubrutinib) for the treatment of a";133.39999389648438;;185.52999877929688;Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.;282.8599853515625;;2.5899999141693115;;87.25;If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.;25.579999923706055;;69.0999984741211;A recent acquisition could pair nicely with the commercial infrastructure being built for the recently-approved Opzelura.;30.350000381469727;;19.670000076293945;Shares of Novavax (NASDAQ: NVAX) were skyrocketing 31.6% this week as of 3:18 p.m. ET on Thursday, according to data provided by S&P Global Market Intelligence.  On Monday, Swiss regulators recommended the use of Novavax's Nuvaxovid COVID-19 vaccine as a booster in adults ages 18 and older.  Novavax's partner, SK Bioscience, also filed for South Korean approval of Nuvaxovid as a booster.;52.369998931884766;;108.2300033569336;;112.44999694824219;;66.8499984741211;;32.02000045776367;"PASADENA, Calif., October 13, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 4, 2022, the Compensation Committee of the Company’s Board of Directors approved ""inducement"" grants to 39 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 117,500 restricted stock units, including 30,000 restricted stock units granted to Peter";51.97999954223633;;54.06999969482422;In this article, we discuss 10 best gene editing stocks to buy. If you want to see more stocks in this selection, check out 5 Best Gene Editing Stocks To Buy. A report by The Wall Street Journal dated September 16 suggests that Intellia Therapeutics, Inc. (NASDAQ:NTLA) revealed positive early-stage trial results for its CRISPR […];28.729999542236328;"Outlines Company’s ESG Strategy through its Trust for Life CommitmentsZai Lab is committed to earning your trust through our environmental, social, and governance (ESG) strategy, which we are calling Trust for LifeZai’s Trust for Life strategy includes three commitments to improve human health, create better outcomes, and act right nowZai’s goal is to reach one million patients by 2030 SHANGHAI and CAMBRIDGE, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a";20.360000610351562;;15.649999618530273;With the S&P 500 down more than 25% this year, the stock market has not been a very attractive place for investors to be lately.  If investors are still hesitant to put more money into the market, there are some attractive growth stocks available for as little as $20.  Investors do not need a bucket full of money to buy shares of healthcare specialist Exelixis (NASDAQ: EXEL) and rising cannabis company Tilray Brands (NASDAQ: TLRY).;9.880000114440918;BridgeBio Pharma Inc (NASDAQ: BBIO) presented pharmacodynamic, tolerability, and preliminary functional efficacy data from the first three participants dosed in the CANaspire Phase 1/2 trial of BBP-812. BBP-812 is an investigational intravenous gene therapy for Canavan disease, an ultra-rare neurodevelopmental disorder. The disease is caused by an inherited mutation of the ASPA gene that codes for aspartoacylase, a protein that breaks down a compound called N-acetylaspartate (NAA). At Month 3 poNovel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samplesIncrease in the ratio of glycosylated αDG to total αDG from baseline towards normal levels, suggesting that the investigational oral therapy, BBP-418, has the potential to address the root cause of LGMD2iLarge, sustained reduction in creatine kinase (CK) (>75%), a key marker of muscle breakdown, after 12 months of treatmentImprovements in key functional me- Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic data from the first three participants show sustained reductions in N-acetylaspartate (NAA) in the brain and urine, suggesting that the investigational therapy is producing functional ASPA enzyme - If successful, BridgeBio’s gene therapy could be the first therapeutic option for children born with Canavan disease, a devastating and fatal neurodevelopmental disorder PALO ALTO, Cal;45.470001220703125;In this article, we discuss 10 best gene editing stocks to buy. If you want to see more stocks in this selection, check out 5 Best Gene Editing Stocks To Buy. A report by The Wall Street Journal dated September 16 suggests that Intellia Therapeutics, Inc. (NASDAQ:NTLA) revealed positive early-stage trial results for its CRISPR […];32.56999969482422;;37.060001373291016;;44.16999816894531;;;;20.670000076293945;;15.029999732971191;;6.769999980926514;;6.099999904632568;;46.36000061035156;;42.47999954223633;;46.970001220703125;;10.34000015258789;;28.639999389648438;;15.720000267028809;;22.6200008392334;
2022-10-17;252.92999267578125;In this article, we shall discuss the 10 best weight loss stocks to buy now. To skip our detailed analysis of the obesity epidemic and its effects on the weight loss and fitness industry in 2022, go directly and see 5 Best Weight Loss Stocks To Buy Now. The 21st century has seen obesity emerge […]Despite a 9.7% gain in Amgen Inc.'s ( NASDAQ:AMGN ) stock price this week, shareholders shouldn't let up. Even though...;66.37999725341797;Gilead Sciences Inc (NASDAQ: GILD) and MacroGenics Inc (NASDAQ: MGNX) announced an exclusive option and collaboration agreement to develop MGD024 and two additional bispecific research programs. MGD024 is an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics' DART platform. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia and myelodysplastic syndromes. Also Read:FOSTER CITY, Calif. & ROCKVILLE, Md., October 17, 2022--Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid;735.9600219726562;Today we will run through one way of estimating the intrinsic value of Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN...;138.94000244140625;Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;207.11000061035156;Illumina and the Illumina Corporate Foundation have provided a grant to the Child Health Research Foundation (CHRF), a Bangladeshi nonprofit that promotes public health and STEM education.;297.0199890136719;The Dow Jones Industrial Average rallied Monday, as Bank of America jumped on strong earnings results. Apple stock was named a top pick.;269.54998779296875;The FDA extended the review period for Biogen Inc's (NASDAQ: BIIB) experimental Tofersen treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months. Biogen had submitted responses to the FDA's information requests, which the agency said would require additional time for review, and set a new target action date of April 25, 2023. The agency had accepted Biogen's application for the drug, tofersen, under its accelerated approval pathway in July, with an approval decisioSage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression (PPD). The SKYLARK Study, as previously reported, achieved the primary and all key secondary endpoints. Zuranolone 50 mg showed a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, compared to the placebo. In the presentation at the European College oShares of Biogen Inc. gained 1.4% in premarket trading on Monday after telling investors that the Food and Drug Administration extended the review period for its experimental treatment for amyotrophic lateral sclerosis (ALS) by three months. The new decision date is April 25. Biogen's stock is up 10.3% this year, while the S&P 500 is down 24.8%.The U.S. Food and Drug Administration has extended the review of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months, the company said on Monday.  Biogen said it had submitted responses to the FDA's information requests, which the agency said would require additional time for review and set a new target action date of April 25, 2023.  The agency had accepted Biogen's application for the drug, tofersen, under its accelerated approval pathway in July this year, with an approval decision expected by Jan. 25.The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is April 25, 2023 CAMBRIDGE, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for tofersen by three months. Tofersen is an investigational treatment for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The updated Prescription Drug User Fee Act (PDUFA) goal d;166.8300018310547;;135.99000549316406;;195.08999633789062;;296.1600036621094;;2.630000114440918;The Intelligence Advanced Research Projects Activity (IARPA), the research and development arm of the U.S. Intelligence community, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming and Draper, a nonprofit engineering innovation firm, today announced the completion of IARPA's Finding Engineering-Linked Indicators (FELIX) program. The program was created to augment and improve current biodetection and biosurveillance capabilities. Specifically, Ginkgo has developed;88.77999877929688;;26.809999465942383;;70.36000061035156;INCY vs. GMAB: Which Stock Is the Better Value Option?;33.88999938964844;;20.31999969482422;Moderna CEO Stephane Bancel on competing with traditional players in the drug and vaccine space.Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.;54.56999969482422;;111.05999755859375;;114.41000366210938;;68.5199966430664;;33.9900016784668;;53.810001373291016;;56.33000183105469;;29.459999084472656;Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...;21.079999923706055;;16.329999923706055;;10.550000190734863;;48.16999816894531;;33.70000076293945;;38.29999923706055;;44.689998626708984;;;;21.600000381469727;;15.300000190734863;"Abcam plc, (AIM: ABC) (Nasdaq: ABCM) (""Abcam"" or the ""Company""), a global leader in the supply of life science research tools, today announces:";7.090000152587891;;6.440000057220459;;46.52000045776367;;44.77000045776367;;47.36000061035156;Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.;10.640000343322754;;31.389999389648438;;15.960000038146973;;23.1200008392334;
2022-10-18;252.1199951171875;Amgen is more established and has a dividend, while Vertex is one of several companies looking for therapies using the CRISPR Cas/9 gene-editing technique, which won the Nobel Prize just two years ago.  Amgen helped pioneer biotechnology and sells its therapies in more than 100 countries.;66.87000274658203;The European Commission approved Kite Pharma's, a Gilead Sciences Inc (NASDAQ: GILD) Yescarta (axicabtagene ciloleucel) for diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). The approval covers patients who relapse within 12 months of completion or are refractory to first-line chemoimmunotherapy. The approval is based on results from the pivotal Phase 3 ZUMA-7 study, the largest and longest trial of a CAR T-cell therapy versus SOC in this patient population. Also Read:FOSTER CITY, Calif., October 18, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company’s upcoming new data from its HIV research and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022) in Glasgow, Scotland and virtually from October 23-26, 2022. Gilead will present data supporting its current and pipeline innovations in HIV treatment and the latest research from its ongoing cure development program, reflectiSANTA MONICA, Calif., October 17, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission (EC) has granted approval for the use of Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. The approval is based on results from the pivotal Phase 3 ZUMA-7 study, the largRockville’s MacroGenics Inc. just struck a deal with a major U.S. pharmaceutical company that could mean more than $1.7 billion for the local biotech.  MacroGenics (NASDAQ: MGNX) said Monday it has formed a collaboration agreement with Foster City, California-based Gilead Sciences Inc. (NASDAQ: GILD) — giving Gilead the green light to develop and exclusively license MacroGenics’ blood cancer treatment candidate, called MGD024.;722.7100219726562;"Regulators in the U.S. restricted the use of REGEN-COV because they deemed it unlikely to work against what has now become the most widespread variant in the country, omicron.  The company's two key assets, Eylea and Dupixent, continue to perform well; Regeneron shares the rights to these products with Bayer and Sanofi, respectively.  It's worth noting that Eylea's patents start expiring next year, meaning Regeneron could face generic competition soon.Regeneron (REGN) closed the most recent trading day at $735.96, moving -0.01% from the previous trading session.The sector has been tricky for investors. Regeneron Pharmaceuticals is an example, getting a downgrade to In Line from Outperform from Evercore ISI.Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.";133.67999267578125;Moderna CEO says not everyone will need an annual COVID booster.;208.67999267578125;Shares of Illumina (NASDAQ: ILMN) rose 8% last week and added another 4% on Monday, reaching the stock's highest point since mid-August, on news that the company has developed a speedier gene-sequencing machine.  Illumina stock is still down more than 45% this year and the company has had its share of headaches, but I see it as a great long-term bargain right now.  Shares of Illumina trade for roughly 40 times earnings and have a price-to-sales ratio of 6.6, both of which may seem high, until you consider that the biotech has huge growth potential and has increased revenue by 4,526% over the past 10 years.Illumina, Inc. (NASDAQ: ILMN) today announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time (12:30 pm Eastern Time), Friday, October 28, 2022.;300.1700134277344;Amgen is more established and has a dividend, while Vertex is one of several companies looking for therapies using the CRISPR Cas/9 gene-editing technique, which won the Nobel Prize just two years ago.  Amgen helped pioneer biotechnology and sells its therapies in more than 100 countries.;270.2799987792969;"The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.A Roche executive said on Tuesday that positive trial data on an Alzheimer's disease drug candidate by rival Biogen was encouraging for companies such as Roche also pursing amyloid beta proteins as a drug target.  ""Before that readout there was quite a raging debate, as to whether targeting a amyloid beta does anything whatsoever to clinical signs and symptoms of Alzheimer's. After that data that debate has to take on a different character and it reassures us in the validity of the pathway,"" the head of Roche's pharma unit Bill Anderson said in an analyst call.Biogen Inc. (BIIB) closed at $269.55 in the latest trading session, marking a +1.86% move from the prior day.";167.10000610351562;Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying...;134.83999633789062;;194.0500030517578;;302.6199951171875;Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 6.01% compared to a 4.72% decline for the Russell 3000 Health Care Index. The fund’s underperformance in the quarter was attributed to poor […]Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported results from a proof-of-concept study for a novel exosome-based platform that could monitor key biological changes in astronauts in space. The peer-reviewed publication was issued in npj Microgravity, a Nature publication.Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...;2.6600000858306885;;89.48999786376953;;26.75;;71.11000061035156;"SVB Leerink initiated coverage on CTI Biopharma Corp (NASDAQ: CTIC) with an Outperform rating and a $13 price target. CTIC is a commercial-stage biopharmaceutical company launching Vonjo — a differentiated, next-generation JAK inhibitor for myelofibrosis. SVB thinks Vonjo will transform the treatment paradigm and offer blockbuster sales potential. ""In contrast to other targeted oncology launches, we think Vonjo will surpass expectations based on results from our proprietary MEDACorp survey of myIncyte (INCY) is well positioned to outperform the market, as it exhibits above-average growth in financials.";35.290000915527344;;18.6200008392334;Since hitting their respective all-time highs within the past year, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite have plunged by as much as 22%, 28%, and 38%.  This means all three major U.S. stock indexes are now in a bear market.  There's little question that bear markets can be scary.;55.11000061035156;;112.69999694824219;;116.83000183105469;IBD Stock Of The Day Sarepta will lead the gene therapy market in treating a form of muscular dystrophy, an analyst said Monday.;68.41000366210938;;35.09000015258789;;52.27000045776367;;56.900001525878906;;29.579999923706055;"-- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ETSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the three months ended September 30, 2022, after the closing of the U.S. equity markets on November 9, 2022. The Company will";21.639999389648438;;16.530000686645508;;10.890000343322754;- BridgeBio to host investor call today (October 17, 2022) at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs – KRASG12C GTP/GDP dual inhibitor development candidate BBO-8520, and its novel PI3Kα:RAS breaker mechanism which is in late lead optimization - KRASG12C GTP/GDP dual inhibitor BBO-8520 has shown significantly greater potency in KRAS models than first-generation KRAS G12C GDP-only inhibitors as measured by its ability to bind and covalently modify KRASG12C, bl;48.04999923706055;;32.810001373291016;;39.45000076293945;;46.0099983215332;;;;21.450000762939453;Vir Biotechnology Inc. said Tuesday that it began dosing participants in a Phase 2 clinical trial evaluating its experimental monoclonal antibody to prevent illness from influenza A. The investigational therapy is an intramuscular dose that has been designed to prevent seasonal flu and influenza A, which has previously caused flu pandemics, including the H1N1 pandemic in 2009. The randomized, double-blind, placebo-controlled study will enroll 3,0000 healthy adults, and the first batch of data fr– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent U.S. government award from the Biomedical Advanced Research and Development Authority supporting development of VIR-2482 – SAN FRANCISCO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 PENINSULA (Prevention of Illness Due to Influenza A) trial evaluating VIR-2482 for the pre;15.5600004196167;;7.039999961853027;;6.46999979019165;PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the creation of the Consortium for Long Read Sequencing (CoLoRS) that aims to accelerate the utility of long-read human genome datasets. CoLoRS is an open coalition of international researchers focused on creating a comprehensive database of frequency information for all classes of human variation identified using long-read human whole-genome sequencing. High quality long-read data c;46.20000076293945;;46.4900016784668;;48.68000030517578;;10.640000343322754;;32.279998779296875;SOUTH SAN FRANCISCO, Calif., October 18, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the Twist Human Sample ID Kit to provide researchers with a solution to track samples throughout the lab workflow. The Twist Human Sample ID Kit can be easily integrated into Twist NGS workflows and enables tracking from whole blood or purified genomic DNA to;16.030000686645508;;22.8700008392334;
2022-10-19;248.19000244140625;In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […];66.19000244140625;Gilead Sciences, Inc. (Nasdaq:GILD) recently announced that the Gilead Foundation's Creating Possible Fund™ will provide a total of $20 million to 13 inaugural grantees. The Creating Possible Fund was launched to support creative and high-impact strategies that advance health through education equity, with a main focus on building a pipeline of Black health leaders.In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […]While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma.;709.3699951171875;;122.66000366210938;NEW YORK and MAINZ, Germany, October 19, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization (MA) for a 3-µg dose of COMIRNATY® (COVID-19 vaccine, mRNA), which is based on the wild-type spike protein of SARS-CoV-2, as a three-dose series for children ages 6 months to less than 5 years (also referred to as 6 months through 4 years of ag;204.72999572753906;Illumina Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics company, announced a partnership to accelerate progress to end tuberculosis (TB) worldwide. The partnership will expand capabilities for countries most impacted by tuberculosis to more effectively detect and combat multidrug-resistant TB (MDR-TB).When COVID-19 hit, most of The Ohio State University-home of the Buckeyes in the state capital of Columbus-shut down.;292.0199890136719;"The Dow Jones Industrial Average fell Wednesday, as Netflix soared on strong earnings results. Tesla earnings are due out after the close.With that said, let's examine two biotech stocks that could be excellent long-term bets: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).  CRISPR Therapeutics is a clinical-stage biotech.  The company's targets include several forms of cancer and two rare blood-related conditions called sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).Biotech company Vertex Pharmaceuticals is a top name in cystic fibrosis (CF), and that has been what's driving its sales growth today.  Last month, Vertex said it planned to submit a biologics licensing application for exa-cel to the Food and Drug Administration for a rolling review that will begin as early as November and will be complete early next year.  Shares of Vertex have soared 35% this year, eclipsing the S&P 500.With a price-to-earnings (or ""P/E"") ratio of 24.1x Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) may be sending...";264.45001220703125;In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […];154.8800048828125;;129.8300018310547;Seagen Inc. ( NASDAQ:SGEN ) shareholders might be concerned after seeing the share price drop 22% in the last quarter...;192.0;Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 6.01% compared to a 4.72% decline for the Russell 3000 Health Care Index. The fund’s underperformance in the quarter was attributed to poor […];290.0199890136719;;2.440000057220459;Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches.;88.3499984741211;Akouos (AKUS) is set to be acquired by Eli Lilly for an aggregate amount of $610 million. The deal is expected to close in the fourth quarter of 2022. Stock up.With all the vagaries in the market these days, investors may be better served considering undervalued biotech stocks to buy. At the most basic level, biotechnology firms aim to address critical vulnerabilities in the human condition. Therefore, while the sector certainly features a profit motivation, it generally falls under a feel-good framework. To be fair, this narrative does not mean that undervalued biotech stocks to buy feature no risk. Those companies tied to novel therapeutics necessari;25.579999923706055;;69.58999633789062;;32.689998626708984;;17.93000030517578;Shares of Novavax Inc. rallied 1.9% in morning trading Wednesday, after the biotechnology company said its protein-based COVID-19 vaccine booster was granted emergency use authorization (EUA) for adults. The booster shot is OK'd for people at least 18 years old who have completed primary vaccinations. The company said in trials, any local and systemic reactions from the booster had a median duration of about two days. Of those receiving the booster, 81.1% had pain/tenderness at the sight of theThe U.S. Food and Drug Administration on Wednesday authorized Novavax Inc's COVID-19 vaccine as a booster for adults.  The booster authorization applies to people who are unable to get updated Omicron-tailored boosters, or those who would choose not to receive any other booster dose of a vaccine.Teladoc Health (NYSE: TDOC) and Novavax (NASDAQ: NVAX) shares have traveled a similar road.  Investors bet on Teladoc winning more and more customers as people avoided crowds and turned to virtual medical visits.  Investors worried that Teladoc's successes wouldn't last beyond the pandemic.Is Novavax stock a buy or a sell as it adds new Covid vaccine authorizations? Is NVAX stock a buy or a sell right now?;52.70000076293945;In this article, we discuss the top 10 stock picks from the ARK Invest stock portfolio. If you want to see more stocks in this selection, check out ARK Invest Stock Portfolio: Top 5 Picks. ARK Investment Management’s Cathie Wood wrote an open letter to the central bank on October 10, saying that the Federal […]Cathie Wood's ARK Innovation ETF (NYSEMKT: ARKK) invests in companies that have massive potential to benefit from breakthroughs in disruptive innovation, specifically in fields like genomic sequencing, gene editing, and artificial intelligence.  Teladoc Health's (NYSE: TDOC) claim to fame is its flagship telehealth service, which uses its digital platform to connect subscribers to healthcare professionals like doctors via a phone call or video call.  While it's true that telehealth isn't a solution that's applicable to every health issue someone might have, the convenience of having a doctor one phone call away is tough to beat.;109.5;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced data on the real-world comorbidities, polypharmacy, and treatment patterns of patients on newly prescribed benztropine who were also being treated with antipsychotic medications. This research will be presented at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference being held October 19–22 both virtually and in Long Beach, CA.;112.25;With that said, let's examine two biotech stocks that could be excellent long-term bets: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).  CRISPR Therapeutics is a clinical-stage biotech.  The company's targets include several forms of cancer and two rare blood-related conditions called sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).;64.02999877929688;;32.380001068115234;;49.88999938964844;Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host an Investor Day for analysts and investors on Tuesday, November 1, 2022 beginning at 8:30 a.m. ET in New York City. In addition, the company will report its third quarter 2022 financial results on Tuesday, November 1, 2022.;54.06999969482422;With that said, let's examine two biotech stocks that could be excellent long-term bets: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).  CRISPR Therapeutics is a clinical-stage biotech.  The company's targets include several forms of cancer and two rare blood-related conditions called sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).In this article, we discuss the top 10 stock picks from the ARK Invest stock portfolio. If you want to see more stocks in this selection, check out ARK Invest Stock Portfolio: Top 5 Picks. ARK Investment Management’s Cathie Wood wrote an open letter to the central bank on October 10, saying that the Federal […]With all the vagaries in the market these days, investors may be better served considering undervalued biotech stocks to buy. At the most basic level, biotechnology firms aim to address critical vulnerabilities in the human condition. Therefore, while the sector certainly features a profit motivation, it generally falls under a feel-good framework. To be fair, this narrative does not mean that undervalued biotech stocks to buy feature no risk. Those companies tied to novel therapeutics necessari;27.010000228881836;;19.68000030517578;;16.25;Interest rates have been on the rise this year, and inflation still remains a big problem for the federal government.  Exelixis (NASDAQ: EXEL) and Shopify (NYSE: SHOP) are two stocks that don't have debt problems and possess plenty of upside, making them not just safe buys but also potentially bargain investments as well.  Exelixis is a healthcare company that develops treatments targeting multiple types of cancers.ALAMEDA, Calif., October 18, 2022--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.With all the vagaries in the market these days, investors may be better served considering undervalued biotech stocks to buy. At the most basic level, biotechnology firms aim to address critical vulnerabilities in the human condition. Therefore, while the sector certainly features a profit motivation, it generally falls under a feel-good framework. To be fair, this narrative does not mean that undervalued biotech stocks to buy feature no risk. Those companies tied to novel therapeutics necessari;10.0;;44.849998474121094;;27.8700008392334;SOUTH SAN FRANCISCO, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $250 million of shares of its common stock in an underwritten public offering. In addition, Denali Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered. The proposed offering is subject to market and other conditions, and there can be no assuran;37.97999954223633;;43.95000076293945;;;;20.5;With all the vagaries in the market these days, investors may be better served considering undervalued biotech stocks to buy. At the most basic level, biotechnology firms aim to address critical vulnerabilities in the human condition. Therefore, while the sector certainly features a profit motivation, it generally falls under a feel-good framework. To be fair, this narrative does not mean that undervalued biotech stocks to buy feature no risk. Those companies tied to novel therapeutics necessari;14.630000114440918;;6.519999980926514;;6.639999866485596;PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, and Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of an initial portfolio of off-the-shelf long-read gene panels. These fixed Twist Alliance panels are designed to capture target regions in a cost-effective and high throughput manner. Customers will also have the ab;44.470001220703125;;43.08000183105469;;46.880001068115234;;10.1899995803833;;30.280000686645508;Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...;15.600000381469727;;22.3799991607666;
2022-10-20;247.4499969482422;Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion.In this article, we discuss 10 best dividend stocks on Robinhood. If you want to read about some more dividend stocks on Robinhood, check out 5 Best Dividend Stocks on Robinhood. Stock trading applications like Robinhood Markets, Inc. (NASDAQ:HOOD) have taken the investing world by storm in the past few years, prompting a new generation […]Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.Shares of Amgen (NASDAQ: AMGN) have been rising of late after a recent analyst upgrade generated some bullishness around the biotech company.  Should you buy the stock as it is climbing, or is Amgen's valuation due to fall back down?  Morgan Stanley upgraded Amgen's stock last week, setting a price target of $279 for the company, noting that its weight-loss treatment, AMG 133, has been demonstrating positive results.;66.16000366210938;"Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.SANTA MONICA, Calif. & MENLO PARK, Calif., October 20, 2022--Kite, a Gilead Company (Nasdaq: GILD) and Refuge Biotechnologies, Inc. (""Refuge""), today announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize Refuge’s proprietary gene expression platform to develop potential treatments for blood cancers.Gilead Sciences (GILD) closed the most recent trading day at $66.19, moving -1.02% from the previous trading session.";705.8900146484375;;118.43000030517578;Novavax gets FDA nod for original formula as its booster differs from mRNA boosters.The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approving Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) 3-µg dose of COVID-19 vaccine for kids less than five years. The recommendation is based on data from a Phase 2/3 trial. Following the third dose in this age group, the companies' original COVID-19 vaccine was found to be 73.2% effective at preventing COVID-19, with a favorable safety profile similar to the placebo. Related:;208.63999938964844;Australia's Centre for Population Genomics (CPG), a collaboration between the Garvan Institute of Medical Research and the Murdoch Children's Research Institute, has launched a new initiative to engage diverse communities in genomic research.;290.1600036621094;Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;262.6499938964844;Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.Shares of Biogen (NASDAQ: BIIB) have been volatile in the past few years, largely hinging on success of the company's Alzheimer's treatments.  Sales in recent years have been declining, and the loss of patent protection for top-selling multiple sclerosis treatment Tecfidera is only exacerbating those concerns.  What will the company's business look like over the next five years, and is it promising enough for investors to buy shares of Biogen today?;160.3800048828125;;126.69999694824219;;192.97999572753906;Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;282.1300048828125;;2.4700000286102295;Bolt Threads, a biotechnology company creating the next generation of advanced materials, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a multi-project collaboration to increase the production efficiency and performance of Bolt's current portfolio as well as expand it by developing novel proteins for biomaterials. The first program in this collaboration aims to optimize the production efficiency of Bolt's Mylo™ material, a leather alternat;88.69999694824219;Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023. Stock up.;25.739999771118164;;68.95999908447266;WILMINGTON, Del., October 19, 2022--Pivotal Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in NEJM;32.029998779296875;This morning, analysts at investment bank Craig-Hallum announced a switch in their bets on cancer-screening biopsy companies, downgrading shares of Exact Sciences (NASDAQ: EXAS) from buy to hold -- and replacing them with a bet on Guardant Health -- initiated at buy.  Responding to the news, investors are selling off Exact Sciences stock by 6.5% today, as of 10:45 a.m. But here's the bad news: they're selling Guardant Health too -- it's down 5.5%.  In twin notes reported by StreetInsider this morning, Craig-Hallum notes that the Guardant ECLIPSE Shield study is nearing a conclusion.;17.18000030517578;Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.The WHO found that omicron subvariant XBB, which may be even more resistant to antibodies than other variants, spread to more countries in the week ending Oct. 16 from the previous week.Biotech company Novavax (NASDAQ: NVAX) has had a terrible year on the stock market, with its shares down by 86% year to date.  The company does still face some challenges.  The coronavirus vaccine market, where it plans to make its money for the next few years, could shrink substantially starting next year.With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu vaccinations.  With fewer shots needed, vaccine makers including Pfizer Inc, partner BioNTech SE, rival Moderna Inc and Novavax Inc could have to hike prices as much as three times current levels if they hope to meet Wall Street revenue forecasts for the shots for 2023 and beyond, several analysts said.  Last year, many on Wall Street were estimating the number of  COVID-19 shots would be in line with the annual flu vaccine, which is the vaccine market leader with more than 160 million shots per year in the United States and 600 million shots globally.What happened Shares of Moderna (NASDAQ: MRNA) fell 7.9% on Wednesday after health regulators authorized Novavax's (NASDAQ: NVAX) COVID-19 vaccine, Adjuvanted, as a booster for adults.  So what The Centers for Disease Control and Prevention (CDC) will allow Novavax's vaccine to be used as a first booster shot for people aged 18 and older who would rather take it than initial boosters offered by Moderna and Pfizer (NYSE: PFE).The Food and Drug Administration granted emergency authorization to  Novavax  Covid-19 shot as a booster for adults.  The shot targets the original strain of the virus, whereas the updated booster shots from  Moderna  and  Pfizer  and its partner  BioNTech SE  authorized in August by the FDA, target both the original strain and newer Omicron strains.  The Novavax shot also uses a protein platform, whereas the other two companies’ boosters use messenger RNA, a newer technology.Food and Drug Administration (FDA) authorization for a product typically delivers a nice stock price boost for the affected company.  This, however, wasn't the case with vaccine specialist Novavax (NASDAQ: NVAX) on Hump Day, as the latest FDA green light had the opposite effect, driving the shares down by almost 4% on the day.  The FDA has granted emergency use authorization (EUA) for Novavax's booster coronavirus shot, an adjuvanted version of its NVX-CoV2373.Novavax won Food and Drug Administration for its Covid booster on Wednesday, but NVAX stock dipped slightly in response.Novavax gets FDA nod for original formula as its booster differs from mRNA boosters.The FDA has granted emergency use authorization to Novavax Inc's (NASDAQ: NVAX) COVID-19 Vaccine to provide a first booster dose at least six months after completion of primary vaccination. The FDA EUA decision was based on data from the Phase 3 Prevent-19 clinical trial and the U.K.-sponsored COV-BOOST trial. Related: Novavax Prototype COVID-19 Vaccine Data Shows Benefit Against Variants. Following a booster dose, antibody levels increased significantly relative to pre-boost levels, rising abovGaithersburg’s Novavax Inc. (NASDAQ: NVAX) just got the regulatory go-ahead to make its Covid-19 vaccine available to adults as a booster.  The company said Wednesday that the Food and Drug Administration has granted emergency use authorization to administer its vaccine as a first booster dose at least six months after a person received a primary immunization series by any of the existing Covid vaccines.  The decision comes about two months after Novavax sought the agency’s authorization.;49.38999938964844;;110.68000030517578;;112.11000061035156;;62.959999084472656;;32.61000061035156;;49.04999923706055;;51.290000915527344;;28.309999465942383;;19.040000915527344;;16.1299991607666;With its stock down 24% over the past three months, it is easy to disregard Exelixis (NASDAQ:EXEL). However, the...;9.800000190734863;;43.849998474121094;;27.850000381469727;SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 10,377,359 shares of its common stock at a price to the public of $26.50 per share. All of the shares are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,556,603 shares of its common stock. Before deducting the underwriting discoun;37.810001373291016;;43.900001525878906;;;;20.3700008392334;;13.920000076293945;;6.769999980926514;;6.679999828338623;PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the launch of its Multiplexed Arrays Sequencing (MAS-Seq) kit in partnership with the Broad Institute of MIT and Harvard and 10x Genomics, Inc. The kit is a first-of-its-kind kitted solution leveraging 10x Genomics' Single Cell Gene Expression technology to enable cost-effective long-read single-cell RNA sequencing for a more complete interrogation of the transcriptome. Insights gene;44.83000183105469;;41.130001068115234;;44.709999084472656;;10.100000381469727;;28.860000610351562;;15.680000305175781;Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023. Stock up.;21.989999771118164;The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
2022-10-21;251.94000244140625;"Amgen Inc.'s ( NASDAQ:AMGN ) price-to-earnings (or ""P/E"") ratio of 20.1x might make it look like a sell right now...Smead Capital Management, an investment management company, released its Smead Value Fund third quarter 2022 investor letter. A copy of the same can be downloaded here. For the recent quarter, the Smead Value Fund (SMVLX) lost 1.82% versus a loss of 4.88% for the formerly formidable S&P 500 Index and 5.62% in the Russell 1000 […]In the latest trading session, Amgen (AMGN) closed at $247.45, marking a -0.3% move from the previous day.";67.79000091552734;;713.9099731445312;Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 20...Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for EYLEA® (aflibercept) Injection. This grant extends the period of U.S. market exclusivity for EYLEA by an additional six months through May 17, 2024.;131.63999938964844;The Centers for Disease Control and Prevention has refuted claims that it will add COVID-19 vaccine to immunization schedules for schoolchildren, noting authority for that decision lies with states and other local entities.BioNTech SE ( NASDAQ:BNTX ) shareholders might be concerned after seeing the share price drop 26% in the last quarter...The drugmaker laid out a potential price as it prepares to sell the shot commercially, perhaps early next year.If the Centers for Disease Control and Prevention follows the guidance of its advisory panel, the shots would be part of the agency’s lists of recommended inoculations for adults and children.The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.;220.00999450683594;;300.0;Vertex Pharmaceuticals is forming a base and near a possible buy point ahead of its next quarterly earnings report, expected on or around Oct. 27.Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $290.16, marking a -0.64% move from the previous day.;267.6199951171875;Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.Alzheimer's therapies are big news lately.  The disease is the leading cause of dementia and memory loss.  The Alzheimer's Association estimates that 6.5 million Americans 65 and older are living with Alzheimer's dementia (AD) and by 2050, the number of people 65 and older with AD is projected to reach 12.7 million.;169.3699951171875;;128.83999633789062;;198.8800048828125;;283.2900085449219;;2.569999933242798;;90.01000213623047;Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.;25.68000030517578;;70.58000183105469;;32.86000061035156;;19.34000015258789;The Gaithersburg vaccine maker has earned the Centers for Disease Control and Prevention’s recommendation to make its protein-based shot available as a booster to adults in the U.S., the last hurdle required before people can use it beyond a primary series.  The CDC said late Wednesday that its director, Dr. Rochelle Walensky, greenlit the decision — which gives initially vaccinated adults the choice to get Novavax’s jab as a booster instead of the updated Omicron-specific shots from Pfizer-BioNTech or Moderna.  Novavax’s vaccine instead uses a decades-old technology found in vaccines for viruses such as flu and whooping cough, which the company is hoping will spur demand from people unable to, or who choose not to, receive the newer mRNA vaccines.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will present new data from the Phase 3 PREVENT-19 trial evaluating its protein-based COVID-19 vaccine (NVX-CoV2373) as a booster in adults, including a breakdown by age and by booster dose interval (8 and 11 months) at IDWeek 2022, October 20 to 22, 2022. Novavax will also present data from the first Phase 1/2 COVID-19-Influenza Combination (Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.;50.220001220703125;Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments.;110.94000244140625;;112.69999694824219;;63.22999954223633;;33.38999938964844;;49.65999984741211;;50.84000015258789;Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments.;28.690000534057617;;19.290000915527344;;16.450000762939453;;10.430000305175781;;44.959999084472656;;28.31999969482422;;38.4900016784668;;46.060001373291016;;;;21.239999771118164;;14.319999694824219;;6.889999866485596;;7.769999980926514;;44.95000076293945;;44.0099983215332;;46.599998474121094;;10.3100004196167;The mean of analysts' price targets for AbCellera Biologics Inc. (ABCL) points to a 137.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.;29.350000381469727;;15.880000114440918;SAN DIEGO, October 20, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2022 financial results on Wednesday, November 2, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 2, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.;22.260000228881836;
2022-10-26;266.6600036621094;;70.81999969482422;;733.97998046875;In the latest trading session, Regeneron (REGN) closed at $747.33, marking a +1.38% move from the previous day.;137.08999633789062;;237.33999633789062;"Gene-sequencing company Pacific BioSciences of California Inc on Tuesday announced the launch of a new, more affordable, higher-throughput ""long-read"" sequencer as well as customer testing of its first ""short-read"" sequencer aimed at emerging markets such as multi-cancer early detection.  The Menlo, California-based company said its new Revio long-read sequencing system, with a list price of $779,000, offers a 15-fold increase in throughput, enabling customers to sequence up to 1,300 human whole genomes per year for less than $1,000 per genome.  PacBio said its trademark HiFi technology – used for large studies in human genetics, cancer research, agricultural genomics, and more – looks at 20,000 base pairs of DNA at a time.Illumina CEO, Francis deSouza received the award for 3BL Media's 2022 Responsible CEO of the Year: Innovation and ESG Integration. 3BL Media presents Responsible CEO of the Year awards to corporate executives who embody leadership in delivering on their environmental, social, and governance (ESG) commitments.";311.17999267578125;;280.42999267578125;"The companies said last month that their new experimental therapy, called lecanemab, slowed cognitive decline by 27% in a Phase 3 clinical trial.Data demonstrate potential of Manual Dexterity Test and Konectom™ smartphone-based technology in measuring MS disease progressionRetrospective analysis applying machine learning, artificial intelligence and radiomics identifies brain imaging patterns that may further the understanding of MS disease and lesion heterogeneityTwo-stage precision medicine models leveraging real-world data from MS PATHS network provide new insights on enabling more individualized predictions of treatment effect CAMBRIFinal safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY® (diroximel fumarate) consistent with previous assessmentsPatient-reported outcomes favored TYSABRI® (natalizumab) compared to Ocrevus® (ocrelizumab); new insights on subcutaneous administration one year after approval in GermanyData on interferon exposure during pregnancy showed that treatment with PLEGRIDY® (peginterferon beta-1a) or AVONEX® (inThe good news keeps coming in for Biogen (NASDAQ: BIIB). On Tuesday, the drugmaker reported its third-quarter results, and for the first time in a while, investors found something in one of its earnings updates to cheer about.Stock market gains despite slide in consumer confidence General Motors, Coca-Cola, Medpace and others posted earnings bumps.Biogen stock fell Tuesday despite a beat-and-raise quarter and continued enthusiasm for its experimental Alzheimer's treatment.The biotech raised its earnings per share estimate to $16.50 to $17.15 from the previously estimated $15.25 to $16.75 range.Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.";170.9600067138672;CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING, October 26, 2022--BeiGene announces significant progress in unlocking global opportunities for BRUKINSA with recent regulatory approvals in 6 Latin American countries;129.4600067138672;;201.02000427246094;;301.8900146484375;;2.7799999713897705;;92.0999984741211;;27.809999465942383;;73.62000274658203;Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.The Williams Companies, Interactive Brokers, Incyte, Hubbell and Lamb Weston Holdings are part of the Zacks top Analyst Blog.;35.06999969482422;;22.809999465942383;;52.560001373291016;;113.98999786376953;Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;114.30999755859375;Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, November 2, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2022 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://i;69.62999725341797;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2022 along with recent corporate updates on November 8, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on November 8, company executives will provide company updates and review financial results.;32.7599983215332;;49.93000030517578;Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;55.20000076293945;CRISPR Therapeutics AG (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.CRSIPR Therapeutics (CRSP) is expected to update its pipeline candidates, specifically exa-cel, its lead candidate, in its third-quarter earnings.;26.610000610351562;;20.850000381469727;;16.34000015258789;Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.ALAMEDA, Calif., October 26, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced promising initial results from the ongoing dose-escalation stage of JEWEL-101, a phase 1 study evaluating XB002, Exelixis’ next-generation tissue factor-targeting antibody-drug conjugate. The data are being presented on Friday, October 28 during the Antibody-drug Conjugates Poster Session (abstract 256) at 10:00 a.m. CEST at the 34th Symposium on Molecular Targets and Cancer Therapeutics hosted by the European Organ;10.880000114440918;;47.54999923706055;;27.950000762939453;;39.970001220703125;CRISPR Therapeutics AG (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;46.90999984741211;;;;22.299999237060547;;15.680000305175781;;7.260000228881836;;8.819999694824219;Pacific BioSciences of California Inc (NASDAQ: PACB) announced the launch of the Revio long-read sequencing system. The company said its new Revio long-read sequencing system, with a list price of $779,000, offers a 15-fold increase in throughput, enabling customers to sequence up to 1,300 whole human genomes per year for less than $1,000 per genome. PacBio said its HiFi technology could be used for large studies in human genetics, cancer research, agricultural genomics, and more. Revio will delPacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Revio™ long-read sequencing system, which will enable customers to dramatically scale their use of PacBio's celebrated HiFi sequencing technology. Revio is designed to provide customers with the ability to sequence up to 1,300 human whole genomes per year at 30-fold coverage for less than $1,000 per genome. With this scale and pricing, PacBio believes Revio will enable the use ofPacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the commencement of external beta testing of the Onso™ sequencing system. This innovative benchtop short-read DNA sequencing platform is expected to provide an extraordinary level of accuracy by utilizing PacBio's unique sequencing by binding (SBB) technology.PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, Nov. 7, 2022, at 5:00 p.m. Eastern Time.;44.349998474121094;Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Ionis Pharmaceuticals is a leader in discovering and developing RNA-targeted therapeutics. Cutting-edge stuff. Let's check out the charts and indicators and see what we discover there. In the daily bar chart of IONS, below, we can see that the shares have risen from early December.Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced a live webcast on Wednesday, November 9th at 11:30 a.m. Eastern Time to discuss its financial results for the third quarter of 2022.;49.439998626708984;;45.93000030517578;;10.819999694824219;In this article, we will look at the 12 best stocks to buy under $50. If you want to explore similar stocks, you can also take a look at 5 Best Stocks Under $50. Stocks have been sandwiched between inflation and an aggressive Fed. Equity investors are panicking and exiting positions in companies due to […];33.36000061035156;SOUTH SAN FRANCISCO, Calif., October 26, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Patrick Finn, Ph.D. to the newly created position of president and chief operating officer. Dr. Finn previously served as chief commercial officer of Twist Bioscience.;16.010000228881836;Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) is possibly approaching a major achievement in its business, so we would...;22.65999984741211;
2022-10-27;267.2300109863281;;70.19999694824219;;724.8800048828125;Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;135.5800018310547;;236.8699951171875;Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.For decades, cardiovascular disease has remained the number-one cause of death. In 2019 alone, nearly 18 million people around the world died from cardiovascular diseases (CVDs), which include disorders such as coronary heart disease, heart failure, and cerebrovascular disease.PacBio says its latest technology will halve the cost of sequencing using its products, which could expand its market.;287.8900146484375;;277.8699951171875;Earnings updates from BIIB and BMY are the key highlights from the biotech sector during the past week.;166.99000549316406;;131.25;;194.0;Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.Alnylam (ALNY) delivered earnings and revenue surprises of -78.49% and 7.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?CAMBRIDGE, Mass., October 27, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2022 and reviewed recent business highlights.Let's analyze how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Oct 27.;295.7699890136719;;2.630000114440918;;85.7300033569336;"Biomarin Pharmaceutical Inc (NASDAQ: BMRN) reported a Q3 loss of $(0.04) lower than $(0.20) a year ago but missing the consensus of $(0.01). The company's revenue rose 23.6% to $505.34 million from $408.74 million last year, missing the consensus of $518.91 million. Non-GAAP income increased to $82.7 million compared to $33.5 million a year ago, driven by higher gross profit due to increased sales volume. ""As anticipated, BioMarin is on track to deliver double-digit revenue growth and profitabilBioMarin (BMRN) delivered earnings and revenue surprises of 21.62% and 1.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (BioMarin or the Company) today announced financial results for the third quarter ended September 30, 2022.";26.770000457763672;;72.86000061035156;e.l.f. Beauty, Monarch Casino & Resort, Incyte and Hubbell are part of the Zacks Screen of the Week article.;33.849998474121094;Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;22.290000915527344;;52.15999984741211;Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its third quarter 2022 financial results and operational highlights in a conference call on November 3, 2022, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately;113.8499984741211;Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced the first patient has been randomized for its Phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound NBI-1117568 in adults with schizophrenia. NBI-1117568 is an investigational, muscarinic M4 selective acetylcholine receptor agonist believed to be a key regulator of neurotransmitters im;111.73999786376953;Fulcrum Therapeutics, Inc. (FULC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;66.37999725341797;;33.189998626708984;;50.560001373291016;;52.36000061035156;Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Gene editing refers to techniques that allow researchers to modify the DNA of various organisms.  Given that it offers the potential to help discover innovative therapies, it isn't surprising that more and more drugmakers are turning to the technology.  Two prominent biotechs that focus on gene editing are CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE).ZUG, Switzerland and BOSTON, Oct. 27, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Lawrence Klein, Ph.D., will be stepping down from the Company to pursue external opportunities. It is expected that he will remain with the Company through year end to help ensure a smooth transition. A search is underway to find a successor to;25.709999084472656;;20.649999618530273;Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;16.31999969482422;EXEL vs. TECH: Which Stock Is the Better Value Option?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.;10.520000457763672;BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;46.310001373291016;;27.780000686645508;;39.33000183105469;;47.0;;;;21.8799991607666;;15.739999771118164;;7.010000228881836;;7.670000076293945;;43.5099983215332;;48.56999969482422;Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.Katherine Donovan, Ph.D. of the Dana-Farber Cancer Institute has been awarded a $25,000 monetary prize recognizing her innovation in the field of targeted protein degradationNEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation (TPD), announced Katherine Donovan, Ph.D. of the Dana-Farber Cancer Institute/Harvard Medical School as the winner of the 2022 Arvinas Ea;44.83000183105469;NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, November 3, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2022. To atten;10.739999771118164;;33.470001220703125;;15.699999809265137;Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;22.739999771118164;Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Wednesday, Nov. 2, 2022 to discuss the company's third quarter financial results. Management will also provide an update on the company.
2022-10-28;273.80999755859375;;79.2699966430664;;750.760009765625;"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) has been recognized as the ""Best Biotechnology Product"" of 2022 by the Galien Foundation, which acknowledges extraordinary scientific innovations that improve the human condition. The Prix Galien USA Award was presented in a ceremony in New York City last night.French drugmaker Sanofi on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines, spurring a rise in its battered share price.  Sanofi said it now expects 2022 adjusted earnings per share to grow by about 16%, not taking into account an expected positive currency impact of between 9.5% and 10.5%.  It also reported a 26.5% rise in third-quarter business operating income, or adjusted earnings before interest and tax, to 4.5 billion euros ($4.5 billion), well ahead of an average analyst estimate of 4.17 billion.Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2022 investor letter. A copy of the same can be downloaded here. The fund lost 0.32% in the third quarter compared to a 0.17% gain for the MSCI ACWI (in $A). For September, the fund gained 6.68% compared to a 3.58% loss for the MSCI […]Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.";137.64999389648438;;233.0;"It’s true that the troika of Microsoft (NASDAQ:MSFT), Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL), and Meta (NASDAQ:META), much loved by the Street for the decade that ended in mid-2021, reported disappointing third-quarter results. Once viewed as beyond reproach by most, those three stocks are now being shunned and scorned by the “smart money.” But the Street is finally starting to realize, just because much of “Big Tech” is struggling doesn’t mean that there are no good tech stocks to buy. On the conEU antitrust regulators on Friday renewed interim measures ordering U.S. life sciences company Illumina to keep Grail as a separate entity pending an order to unwind the takeover completed before the deal had been approved.  The interim order, which was due to expire at the end of the month, was issued by the competition enforcer last year after Illumina jumped the gun and acquired Grail before securing the EU green light.  ""The European Commission has renewed and adjusted, under the EU Merger Regulation, the interim measures that ensure that Illumina and GRAIL remain separate following the Commission's decision to block the merger,"" the EU watchdog said in a statement.Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” third-quarter 2022 investor letter. A copy of the same can be downloaded here. The fund returned -5.47% net in the third quarter compared to -3.60% return for the Russell 1000 Growth Index and -4.88% return for the S&P 500 Index. Inflation and interest rate […]";313.8900146484375;;284.2900085449219;;166.1199951171875;;129.69000244140625;Seattle Genetics (SGEN) delivered earnings and revenue surprises of -11.96% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?BOTHELL, Wash., October 27, 2022--Seagen Inc. (Nasdaq:SGEN) reported financial results today for the third quarter ended September 30, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline.;204.50999450683594;CAMBRIDGE, Mass., October 27, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its second place ranking in Science Magazine’s 2022 Top Employer Survey. This marks the fourth year Alnylam was featured as one of the top three companies in the annual survey of more than 6,200 professionals across biotechnology, biopharmaceuticals and related industries.Tucked Away in the Q3 earnings release, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) revealed it would scrap plans to launch a Phase 3 trial for vutrisiran in the rare Stargardt disease as it continues to evaluate the impact of the Inflation Reduction Act. The Stargardt disease study was slated to begin before the end of the year. Additionally, Alnylam has decided not to perform an optional interim analysis of the closely watched Helios-B trial in transthyretin-mediated amyloidosis with cardiomyop;295.5;;2.690000057220459;;86.7699966430664;BioMarin Pharmaceuticals (NASDAQ: BMRN), a biopharmaceutical company that specializes in finding therapies for rare genetic diseases, saw its shares drop 6.9% on Thursday after falling as much as 9.8% earlier in the day.  The company reported third-quarter earnings after the market closed on Wednesday, and investors were not that impressed.  Earnings per share (EPS) for nine months came in at a loss of $0.04, compared to an EPS loss of $0.20 in the first nine months of 2021.BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.;27.3799991607666;;74.5999984741211;Incyte's (INCY) third-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.;34.58000183105469;;23.020000457763672;;54.029998779296875;;115.56999969482422;;115.27999877929688;;67.91000366210938;;35.869998931884766;;53.040000915527344;;54.290000915527344;;23.75;;21.799999237060547;;16.6299991607666;Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.;10.989999771118164;;48.7400016784668;;29.6200008392334;;40.7599983215332;NOVATO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Wednesday, November 2, 2022, at 5:00pm ET to discuss its financial results and corporate update for the quarter ended September 30, 2022. The live and replayed webcast of the call will be available throu;48.2400016784668;;;;22.649999618530273;;15.960000038146973;;7.269999980926514;;8.720000267028809;;44.61000061035156;;50.91999816894531;;46.36000061035156;;11.710000038146973;;33.380001068115234;;16.1299991607666;SAN DIEGO, October 27, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that its President, Srdjan (Serge) Stankovic, M.D., M.S.P.H., who is responsible for R&D, and Medical and Scientific functions, will retire at the end of the year. A search for a successor to Dr. Stankovic is ongoing. Following his retirement, Dr. Stankovic will provide consulting and advisory services for Acadia on a part-time basis.;23.329999923706055;We are honored to be recognized as an awardee of New England Employee Benefits Council (NEEBC)'s Best Practices Award for 2022! This award recognizes our competitive benefits offerings and demonstrates our continued commitment to making Alkermes a great place to work.Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2022-10-31;270.3500061035156;;78.45999908447266;To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the...Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.;748.75;Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent.;137.63999938964844;;228.82000732421875;;312.0;Today we will run through one way of estimating the intrinsic value of Vertex Pharmaceuticals Incorporated...In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Unprecedented inflation, increasing interest rates, and a worldwide recession pose risks to the 10-year upward […];283.44000244140625;;168.88999938964844;;127.16000366210938;;207.25999450683594;In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Unprecedented inflation, increasing interest rates, and a worldwide recession pose risks to the 10-year upward […];296.260009765625;Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, will present its diagnostic lab solutions at the upcoming annual meeting of the Association for Molecular Pathology (AMP), taking place November 1-5 in Phoenix, Ariz. The company also announced the commercial availability of new molecular controls for monkeypox and other non-variola Orthopoxvirus DNA viruses.;2.7300000190734863;;86.62999725341797;;27.18000030517578;;74.33999633789062;;34.779998779296875;;22.270000457763672;Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;52.779998779296875;- New data to include interim safety and kallikrein reduction data from 50 mg dose cohort, and additional safety, kallikrein reduction and attack rate data from 25 mg and 75 mg dose cohortsCAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract featuring new interim clinical data from;115.12000274658203;;114.0199966430664;In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Unprecedented inflation, increasing interest rates, and a worldwide recession pose risks to the 10-year upward […];67.31999969482422;;34.810001373291016;;51.84000015258789;In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Unprecedented inflation, increasing interest rates, and a worldwide recession pose risks to the 10-year upward […];52.34000015258789;;22.280000686645508;"SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in November: Goldman Sachs Asia Pacific Healthcare Forum 2022Panel discussion: Tuesday, November 15, 2022 at 9:30 a.m. HKT Morgan Stanley 21st Annual Asia Pacific SummitMeetings: Wednesday,";20.920000076293945;In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Unprecedented inflation, increasing interest rates, and a worldwide recession pose risks to the 10-year upward […];16.579999923706055;;10.430000305175781;Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;44.060001373291016;;28.68000030517578;;40.459999084472656;;47.810001373291016;;;;21.979999542236328;;15.5600004196167;;7.179999828338623;;8.4399995803833;;44.20000076293945;;49.709999084472656;;45.66999816894531;;11.829999923706055;;32.83000183105469;;16.030000686645508;;22.700000762939453;
2022-11-01;272.05999755859375;Tango Therapeutics, Inc. (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Thursday, Nov. 3, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.;79.33999633789062;In this article we present the list of 15 Best NASDAQ Dividend Stocks To Buy. Click to skip ahead and see the 5 Best NASDAQ Dividend Stocks To Buy. Starbucks Corporation (NASDAQ:SBUX), Gilead Sciences, Inc. (NASDAQ:GILD), and Intel Corporation (NASDAQ:INTC) are just a handful of the best NASDAQ dividend stocks to buy, which we’ll examine in […]FOSTER CITY, Calif., November 01, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that clinical and real-world data from more than 70 abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place from Nov. 4-8, 2022. Key presentations include Week 48 integrated efficacy and safety analyses from Phase 2 and Phase 3 studies of Hepcludex® (bulevirtide), Gilead’s first-in-class investigational treatment for chronic hepatit;759.9099731445312;;144.0800018310547;;219.1300048828125;Clene Inc. (CLNN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Advances in genomic studies have now permeated all aspects of our lives from agriculture to health and wellness. It is therefore becoming increasingly important to help the community understand these innovations so that they can navigate the increasingly complex realm of genomics. To this end, the outreach team at the Carl R.;314.20001220703125;These are the healthcare stocks with the best value, fastest growth, and most momentum for November 2022.;280.0400085449219;;169.42999267578125;;126.69000244140625;;213.1199951171875;;309.2900085449219;Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2022.Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2022. The quarterly dividend will be payable November 28, 2022, to all common shareholders of record on November 14, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis.These are the healthcare stocks with the best value, fastest growth, and most momentum for November 2022.;2.740000009536743;;86.5999984741211;While the market volatility of 2022 opened doors for intriguing discounts, investors may want to consider allocating some of their funds toward undervalued biotech stocks. Fundamentally, the underlying industry represents the cutting edge of scientific innovation. Should clinical trials lead to commercialization, individual biotechnology firms can deliver outstanding returns. Of course, when looking for undervalued biotech stocks to buy, investors must consider the reason for their market discou;28.219999313354492;10x Genomics (Nasdaq: TXG) today announced it will host an Investor Day on December 8, 2022 at the company's headquarters in Pleasanton, CA starting at 9:00 a.m. Pacific Time. The event will feature presentations by several members of the company's leadership team and will include Q&A discussion between the audience and 10x Genomics panel members.;76.94999694824219;Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?WILMINGTON, Del., November 01, 2022--Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical ProgramsLet's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.;34.79999923706055;Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.A look at the shareholders of Exact Sciences Corporation ( NASDAQ:EXAS ) can tell us which group is most powerful. We...;22.0;;53.209999084472656;AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;119.36000061035156;Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2022 and raised net sales guidance for INGREZZA in 2022.;114.08000183105469;CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 34 individuals hired by Sarepta in October 2022. The equity awards were approved in accordance with Nasdaq Listing;67.48999786376953;Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;35.52000045776367;;48.2400016784668;Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 11.16% and 51.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Blueprint Medicines (NASDAQ: BPMC) today announced its 2027 Blueprint to achieve precision medicine at scale, a five-year business strategy to expand the company's reach to broader patient populations by leveraging its scientific leadership, proven development capability and integrated business. The company plans to highlight this business strategy, including commercial plans to bring AYVAKIT to patients with non-advanced systemic mastocytosis (SM), at its Investor Day event today. In addition,Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.;52.02000045776367;While the market volatility of 2022 opened doors for intriguing discounts, investors may want to consider allocating some of their funds toward undervalued biotech stocks. Fundamentally, the underlying industry represents the cutting edge of scientific innovation. Should clinical trials lead to commercialization, individual biotechnology firms can deliver outstanding returns. Of course, when looking for undervalued biotech stocks to buy, investors must consider the reason for their market discou;25.020000457763672;;20.989999771118164;Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;16.799999237060547;While the market volatility of 2022 opened doors for intriguing discounts, investors may want to consider allocating some of their funds toward undervalued biotech stocks. Fundamentally, the underlying industry represents the cutting edge of scientific innovation. Should clinical trials lead to commercialization, individual biotechnology firms can deliver outstanding returns. Of course, when looking for undervalued biotech stocks to buy, investors must consider the reason for their market discouLet's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.;10.4399995803833;;44.36000061035156;;28.959999084472656;Interim results from Part A in healthy volunteers demonstrated dose-dependent increases in CSF progranulin levels, consistent with robust brain delivery of DNL593Single doses of DNL593 were generally well toleratedData support progression to enrolling participants with FTD-GRN in Part B of the Phase 1/2 study SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engine;41.93000030517578;;48.279998779296875;NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;;;22.520000457763672;While the market volatility of 2022 opened doors for intriguing discounts, investors may want to consider allocating some of their funds toward undervalued biotech stocks. Fundamentally, the underlying industry represents the cutting edge of scientific innovation. Should clinical trials lead to commercialization, individual biotechnology firms can deliver outstanding returns. Of course, when looking for undervalued biotech stocks to buy, investors must consider the reason for their market discouSAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical program have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Washington, D.C., from November 4-8, 2022. These include two poster presentations, one of which is a late-breaking poster, and two oral presentations, both of which;15.710000038146973;;7.090000152587891;;8.8100004196167;;44.83000183105469;;51.29999923706055;Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;45.93000030517578;;11.5;AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;33.77000045776367;;15.859999656677246;Acadia Pharmaceuticals (ACAD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;23.25;NORTHAMPTON, MA / ACCESSWIRE / November 1, 2022 / Alkermes The importance of corporate responsibility comes more sharply into focus with each passing year. The challenges we face as a global community are significant and growing as we grapple with ...
2022-11-02;269.010009765625;Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...AbbVie, Gilead Sciences, Cardinal Health, Merck, Bristol Myers, and Amgen are large-cap healthcare companies that have the capacity to grow their dividends.;77.87999725341797;"G1 Therapeutics Inc (NASDAQ: GTHX) described safety data from the first 18 patients enrolled in its ongoing Phase 2 study of trilaciclib administered before sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Sacituzumab govitecan is marketed as trodelvy by Gilead Sciences Inc (NASDAQ: GILD). ""We believe we are seeing on-target effects of trilaciclib in the expected reduction in the rate of myelosuppression and the rates oNORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ...CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today earning a $15.0 million clinical milestone payment from Gilead Sciences, Inc. (NASDAQ: GILD) under the exclusive license agreement for GS-1811, an anti-CCR8 antibody for which Gilead has exclusive rights to develop and commercialize. GS-1811 (formerly JTX-1811) isFOSTER CITY, Calif., November 02, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients 12 years of age and older with compensated liver disease.Eli Lilly's (LLY) earnings and sales surpass third-quarter estimates. The company lowers 2022 financial view for the third time this year. The stock falls in pre-market trading.";740.47998046875;Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.Does the November share price for Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) reflect what it's really worth...;141.52000427246094;;210.97999572753906;Anavasi Diagnostics ('Anavasi'), an NIH/RADx medical technology company focused on the development of novel molecular diagnostic testing, recently announced the election of three new outside members to its Board of Directors, Bryan Crane, PhD, Arthur Kirsch, and David Vied.Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.;310.010009765625;Lantheus Holdings' (LNTH) third-quarter results are likely to reflect solid top line results on the back of robust product adoption.The big biotech has a cash stockpile of nearly $10 billion. Here's how Vertex plans to use the money.;278.3699951171875;;178.42999267578125;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 02, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has granted marketing authorization of BRUKINSA® (zanubrutinib) for the treatment of adult patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. The approval is applicable to all 27 member states of the European Union (EU),";129.10000610351562;;214.35000610351562;The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...;297.95001220703125;Let's talk about the popular Bio-Techne Corporation ( NASDAQ:TECH ). The company's shares saw significant share price...;2.640000104904175;;84.16999816894531;;26.920000076293945;The lab hardware provider has been whacked by a strong U.S. dollar, which only grew stronger during the third quarter.;77.1500015258789;;33.0099983215332;;20.5;With the Fed signaling oversized rate hikes for longer is the likely trajectory moving forward, it is understandable why investors are looking for stocks to sell rather than stocks to buy. Consumer spending continues to rise, and inflation refuses to go down. Moreover, the jobs market is surprisingly strong despite recent rate hikes, with unemployment decreasing to 3.5% in September. Meanwhile, some sectors still face supply chain issues and worker shortages. A difficult but sensible solution isNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment of Richard Rodgers, MBA to its board as an independent director. Mr. Rodgers brings extensive experience in biopharmaceutical management to his role on the Novavax Board of Directors.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2022 financial results and operational highlights on Tuesday, November 8, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows:;51.099998474121094;;122.05999755859375;In this daily bar chart of NBIX, below, we can see that prices have been strong from late September.  The On-Balance-Volume (OBV) line has been strong all year and continues to gain and tell us that buyers of NBIX are more aggressive than sellers.  In this weekly Japanese candlestick chart of NBIX, below, we see a positive picture.IBD stock screens are regularly updated to add new stocks to watch, as well as weed out those that have started to show weakness. In the tables below, you'll see which stocks have been added to or removed from lists like the IBD 50, Sector Leaders and the IBD Big Cap 20. ANET stock, for example, is a new ticker on...Neurocrine Biosciences beat third-quarter forecasts and raised its Ingrezza outlook for 2022, leading NBIX stock to jump Tuesday.;113.41999816894531;;64.98999786376953;;34.61000061035156;;46.099998474121094;Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.;54.68000030517578;"CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 2.61% and 97.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?-Exagamglogene autotemcel (exa-cel), formerly known as CTX001™ submission to the U.S. Food and Drug Administration (FDA) for rolling review expected to begin in November, with completion of the U.S. submission package expected in Q1 2023; EMA and MHRA submissions are on track for Q4 2022- -Enrollment and dosing ongoing for CTX110®, targeting CD19+ B-cell malignancies; expecting to report additional data in 2022- -Enrollment and dosing ongoing for CTX130™, targeting CD70 for the treatment of both";27.43000030517578;;20.040000915527344;;17.010000228881836;"Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.Exelixis Inc (NASDAQ: EXEL) posted Q3 sales of $411.7 million, up 26% Y/Y, beating the consensus of $404.30 million. The company posted an adjusted EPS of $0.31, above the consensus of $0.20. Exelixis revised FY22 sales guidance from $1.525-$1.625 billion to $1.575-$1.600 billion. Exelixis and Cybrexa Therapeutics announced an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12, a peptide-drug conjugate (PDC) that utilizes Cybrexa's proprietary alphalex technology toThank you, Chuck, and thank you all for joining us for the Exelixis third quarter 2022 financial results conference call.  Joining me on today's call are Mike Morrissey, our president and CEO; Chris Senner, our chief financial officer; P.J. Haley, our executive vice president of commercial; Vicki Goodman, our chief medical officer; and Peter Lamb, our chief scientific officer, who together will review our progress for the third quarter 2022 ended June 30, 2022, and subsequent events, including the two business development announcements made today.Exelixis (EXEL) delivered earnings and revenue surprises of 24% and 1.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?ALAMEDA, Calif. & ROTTERDAM, The Netherlands, November 01, 2022--Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα. SIRPα expressed on myeloid cells interacts with CD47 present on the surface of cancer cells and blocks the ability of macrophages to clear tumor cells via phagocytosis and inhibits tumor aALAMEDA, Calif. & NEW HAVEN, Conn., November 01, 2022--Exelixis, Inc. (Nasdaq: EXEL) and Cybrexa Therapeutics (Cybrexa) today announced that the companies have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12 (alphalex™ exatecan), a clinical-stage, first-in-class peptide-drug conjugate (PDC) that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells. CBX-12 is designed to increase the efficacy and reduceALAMEDA, Calif., November 01, 2022--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.";9.949999809265137;;43.599998474121094;;30.729999542236328;;40.59000015258789;;47.380001068115234;;;;22.31999969482422;;15.140000343322754;;6.929999828338623;We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...;8.079999923706055;PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it is bringing together a group of scientific experts to form PacBio's Scientific Advisory Board (SAB). The SAB will provide guidance to the research and development efforts at PacBio, including critical feedback, advice, and expertise on future technological and scientific direction to inform PacBio's priorities and roadmaps for current and future products. The goal of the SAB is to;44.68000030517578;Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;48.779998779296875;NEW HAVEN, Conn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming conferences: Society for Neuroscience (SFN) Annual Meeting: Saturday, November 12, 4:00-5:00 p.m. PT. Angela Cacace, Ph.D., Senior Vice President of Neuroscience and Platform Biology, will deliver a poster presentation titled, “Orally Administered PROTA;45.83000183105469;;12.0;VANCOUVER, British Columbia, November 02, 2022--AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances into Late-Stage Preclinical Development;32.56999969482422;SOUTH SAN FRANCISCO, Calif., November 02, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a partnership to provide expanded customer access to the co-branded Twist Bioscience® for Illumina® Exome 2.0 Plus panel designed to advance disease research. The panel can;15.930000305175781;;24.059999465942383;Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.Alkermes (ALKS) delivered earnings and revenue surprises of 0% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2022 and updated certain financial expectations for full-year 2022. Alkermes today also announced its intent, as approved by its Board of Directors (the Board), to explore a separation of its commercial-stage neuroscience business and development-stage oncology business.Alkermes plc (Nasdaq: ALKS) today announced approval by its Board of Directors (the Board) to explore separating its commercial-stage neuroscience business and development-stage oncology business. The company, together with the Board and external financial and legal advisors, plans to explore a separation of the oncology business into an independent, publicly-traded company (Oncology Co.) as part of an ongoing review of strategic alternatives for the oncology business.
2022-11-03;265.8800048828125;If a recession does come, it won't be the first that these two companies will have survived one.Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the American Heart Association (AHA) Scientific Sessions at 6:00 p.m. ET on Monday, Nov. 7, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team and a clinical investigator, will discuss the Phase 2 data on olpasiran, an investigational small interfering RNA molecule designed to lower the body's production of apolipoprotein(a),;79.45999908447266;FOSTER CITY, Calif. & SANTA MONICA, Calif., November 03, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will support 30 data presentations, including seven oral presentations in large B-cell lymphoma (LBCL), and two oral presentations on investigator-sponsored studies in acute myeloid leukemia (AML) during the 64th Annual American Society of Hematology (ASH) Annual Meeting (December 10-13).Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.;738.6799926757812;Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new data across its hematology pipeline will be highlighted in 17 presentations at the 2022 American Society of Hematology (ASH) Annual Meeting from December 10-13 in New Orleans, LA.Regeneron (REGN) delivered earnings and revenue surprises of 14.85% and 5.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Regeneron Pharmaceuticals Inc. said Thursday its third-quarter net income fell 19% to $1.32 billion or $11.66 a share, from $1.63 billion or $14.33 a share, in the year-ago period. Adjusted net income fell to $11.14 a share from $15.37 a share. Revenue at the Tarrytown, N.Y., drug maker dropped 15% to $2.94 billion from $3.45 billion. Wall Street analysts expected Regeneron to earn $9.76 a share on revenue of $2.92 billion, according to a survey by FactSet. Regeneron CFO Robert Landry said the tRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2022 and provided a business update. The full press release can be accessed on Regeneron's media and investor relations website (http://newsroom.regeneron.com).;145.25;;211.92999267578125;;311.29998779296875;BOSTON, November 03, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts on the company’s portfolio of cystic fibrosis (CF) medicines will be presented in posters and oral presentations at this year’s North American Cystic Fibrosis Conference (NACFC), including studies demonstrating the clinical benefits and long-term safety of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor).Across industries, headwinds such as rising inflation and general economic woes are weighing on companies and stock performance.  Now, the question is: Should you hop on the bandwagon and buy shares of some of the top performers?  Vertex Pharmaceuticals (NASDAQ: VRTX) has climbed more than 40% since the start of the year, and for good reason.The innovation-driven Nasdaq Composite and Nasdaq 100 -- the Nasdaq 100 is comprised of the 100-largest non-financial Nasdaq-listed companies -- have both lost over a third of their value on a peak-to-trough basis.  What follows are three Nasdaq 100 stocks investors can confidently buy hand over fist in November.  The first Nasdaq 100 stock that's an absolute screaming buy in November is fintech-giant PayPal Holdings (NASDAQ: PYPL).;280.25;Biogen (NASDAQ: BIIB) has been a volatile investment in recent years and its outlook still remains cloudy at best.  Meanwhile, its Alzheimer's treatment Aduhelm went from a hero to a zero within a span of just months as questions were raised about its efficacy.  Now, however, there's renewed hope around Biogen.;185.11000061035156;"BeiGene (NASDAQ: BGNE), is a Chinese biopharmaceutical company with offices in Cambridge, Massachusetts; Basel, Switzerland; and Beijing.  It focuses on unique therapies to treat cancer, specializing in B-cell malignancies and solid tumors in lung and gastrointestinal cancers.  Amid delisting concerns, a lot of Chinese stocks have fallen this year.CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING, November 03, 2022--BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced clinical and real-world data accepted at the 64th American Society of Hematology (ASH) Annual Meeting, scheduled for December 10-14, 2022, in New Orleans. BeiGene is focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide.";127.80000305175781;;215.72000122070312;;305.20001220703125;Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 8:35 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;2.5799999237060547;;84.87999725341797;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at two upcoming investor conferences. To access the live webcasts, please visit: https://investors.biomarin.com/. An archived version of the presentations will also be available through the Company's website for a limited time following the conference.;31.899999618530273;10x Genomics (TXG) delivered earnings and revenue surprises of 17.78% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2022.;76.9000015258789;WILMINGTON, Del., November 03, 2022--More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting;32.34000015258789;;20.170000076293945;;51.61000061035156;"Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -13.74% and 2.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Presented interim data from the cardiomyopathy arm of NTLA-2001 Phase 1 study demonstrating deep and sustained mean serum TTR reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28; additional data to be presented in late-breaking, oral presentation at AHA on November 5Initiated dosing at 55 mg in Part 2 of the Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosisPresented interim data from the ongoing Phase 1/2 study of NTLA-2002, demonstrRepligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022";124.11000061035156;Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from a study on INGREZZA® (valbenazine) capsules evaluating in vitro dissolution performance of whole intact or crushed capsule contents in 40 mg and 80 mg strength. These data (Poster #27, Complete In Vitro Dissolution of Valbenazine as Either Whole Capsule or Crushed Content) are being shared at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting being held on November 3-6 in San Antonio, TexNeurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the Phase 3 KINECT-HD study investigating valbenazine for the treatment of chorea associated with Huntington Disease (HD). In December 2021, Neurocrine previously reported that once-daily administration of valbenazine was well tolerated with a statistically significant improvement in chorea associated with HD compared with placebo, along with substantial c;105.01000213623047;Futures fell after the stock market sold off Wednesday on Fed chief Jerome Powell hinting at slower rate hikes but also a higher peak rate.Earlier today, we released our financial results for the third quarter of 2022.  Joining us on the call today are Doug Ingram, Ian Estepan, Dallan Murray and Dr.  After our formal remarks, we'll open the call for Q&A. I'd like to note that during this call, we will be making a number of forward-looking statements.Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -142.98% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Total revenues, which consist of net product revenues and collaboration revenues, for the third quarter 2022 totaled $230.3 million Net product revenues for the third quarter 2022 totaled $207.8 million, a 24% increase over the same quarter of prior year CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2022. “The third quarter was an enor;63.369998931884766;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 13 new employees with a grant date of November 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).;34.15999984741211;;43.970001220703125;Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of abstracts highlighting long-term clinical outcomes and impact on overall survival of AYVAKIT® (avapritinib) in patients with advanced systemic mastocytosis (SM), as well as real-world evidence characterizing the burden of SM, for presentation at the 2022 American Society of Hematology (ASH) Annual Meeting in December. These abstracts were submitted by the regular abstract deadline and posted online by ASH today.HC Wainwright lowered the price target on Blueprint Medicines Corp (NASDAQ: BPMC), keeping the Buy rating. Blueprint expects to submit a supplemental application for Ayvakit in non-advanced systemic mastocytosis (non-ADvSM) in 4Q22 (expected launch in mid-2023), with the longer-term value being driven by an expanding suite of precision medicines aimed at NSCLC and beyond. The analyst has long believed that Ayvakit will gain approval in non-ADvSM but concurrently believe that the elucidation and;53.2400016784668;ZUG, Switzerland and BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster on CTX110®, its wholly-owned allogeneic CAR-T cell investigational therapy targeting CD19+ B-cell malignancies, at the American Society of Hematology (ASH) 2022 Annual Meeting, taking place December 10-13, 2022, virtually and at the Ernest N. MorialCRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.;28.34000015258789;;19.450000762939453;Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate for Multiple Myeloma and FT819 CD19-targeted CAR T-cell Product Candidate for B-cell Lymphoma Preclinical Data of FT555 GPRC5D-targeted CAR NK Cell Collaboration Candidate for Multiple Myeloma to be Jointly Presented with Janssen Novel Approaches to Eliminate Patient Conditioning and Promote Functional Persistence of Off-the-shelf, iPSC-derived Cell Therapies to be Highlighted SAN DIEGO,;16.239999771118164;ALAMEDA, Calif. & SOMERSET, N.J., November 03, 2022--Exelixis, Inc. (Nasdaq: EXEL) and Catalent, Inc. (NYSE: CTLT) today announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with lead antibody and/or ADC candidates. The ADC candidates have been developed using Catalent’s proprietary SMARTag® technology, and each of the licensed antibodies has potential for development as an ADC or other biologic tPresident and CEO Michael Morrissey said the deals tap the company's balance sheet and share risks with its partners.;9.859999656677246;BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 8.82% and 94.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?- Reported positive preclinical data for its next-generation KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization - Reported positive updated 12-month Phase 2 data for BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i - Enrolled Cohort 5 of Phase 2 trial of infigratinib in achondroplasia, with no serious adverse events (SAEs), and no adverse events that required dose modifications reported to date - Reported dosi;44.0099983215332;CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new data supporting the advancement of its Engineered Stem Cell Antibody Paired Evasion (ESCAPE) conditioning approach will be presented during poster sessions at the 64th Annual American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting is being held December 10-13, 2022, in New O;30.6299991607666;Denali Therapeutics (NASDAQ: DNLI), a biopharmaceutical company that focuses on therapies to treat neurodegenerative disorders, had a bit of a seesaw day on Wednesday.  Denali doesn't have any marketed therapies, but it does have a large pipeline.  The stock was buoyed when the company, on Tuesday, released interim phase 1/2 results from a study in which TAK-594/DNL593, a therapy it is developing with Takeda Pharmaceutical (NYSE: TAK), showed good safety results in healthy subjects while increasing the progranulin levels in their brains.;38.16999816894531;Ultragenyx (RARE) delivered earnings and revenue surprises of -6.11% and 8.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Third quarter 2022 total revenue of $90.7 million and Crysvita® revenue in Ultragenyx territories1 of $64.5 million Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million Enrollment completion of DTX401 Phase 3, UX143 Phase 2, and GTX-102 dose escalation cohorts anticipated around the end of the year NOVATO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopha;47.040000915527344;;;;21.799999237060547;;14.760000228881836;;7.010000228881836;;7.920000076293945;;44.4900016784668;;48.97999954223633;;51.880001068115234;Intra-Cellular (ITCI) delivered earnings and revenue surprises of 33.72% and 10.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?CAPLYTA net product revenues for the third quarter 2022 were $71.9 million, compared to $21.6 million for the same period in 2021, representing a 233% increase over the same period in 2021 and a 30% increase over the second quarter 2022 Third quarter 2022 CAPLYTA total prescriptions increased 220%, versus the same period in 2021 and 26% sequentially versus the second quarter 2022 NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical compan;12.109999656677246;;32.54999923706055;;14.819999694824219;Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?SAN DIEGO, November 02, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022.;24.139999389648438;This Hispanic Heritage Month, we celebrated the contributions of Hispanic Americans to the field of mental health.Alkermes plc (NASDAQ: ALKS) is exploring separating its commercial-stage neuroscience and development-stage oncology business as part of an ongoing review of strategic alternatives for the oncology business. Alkermes will retain its focus on neuroscience and drive its proprietary commercial product growth. The company will also focus on advancing the development of pipeline programs focused on neurological disorders, including ALKS 2680, an orexin 2 receptor agonist for narcolepsy. The oncology
2022-11-04;269.0400085449219;"Amgen (AMGN) beats Q3 estimates for earnings and sales. It tightens previously issued revenue and adjusted earnings guidance ranges.Amgen Inc's (NASDAQ: AMGN) Q3 revenue reached $6.65 billion, down 1% Y/Y, due to 8% volume growth offset primarily by a 5% lower net selling price and a 2% negative impact from foreign exchange. Analysts estimated sales of $6.56 billion. Excluding the 2% negative impact of foreign exchange, total revenues increased by 2%. The company reported Q3 adjusted EPS of $4.70, up 15%, beating the consensus of $4.44. Related: Amgen's Lumakras Cuts Risk Of Progression By 34% In KRAS-Mutated Lung Cancer PatAmgen (AMGN) delivered earnings and revenue surprises of 6.09% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Biotechnology company Amgen Inc on Thursday said its third-quarter revenue rose 1% as higher volume growth for its cancer, rheumatology and cardiovascular products was offset by lower prices and foreign exchange losses.  The company also said data from a Phase I study of its potential obesity treatment AMG133 will be presented at the World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease conference in early December.  ""Our medicines generated 8% volume growth in the quarter globally, with 11 products achieving record quarterly sales,"" Amgen Chief Executive Robert Bradway said in a statement.(Reuters) -Biotechnology company Amgen Inc on Thursday said its third-quarter revenue rose 1% as higher volume growth for its cancer, rheumatology and cardiovascular products was offset by lower prices and foreign exchange losses.  The company also said data from a Phase I study of its potential obesity treatment AMG133 will be presented at the World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease conference in early December.  AMG133, which has garnered increased attention following strong sales for similar drugs launched recently by Eli Lilly and Co and Novo Nordisk, is designed to block a hormone and a protein involved in blood sugar control.Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022. Key results include:By Liz Moyer";80.33999633789062;Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States.TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Gilead Sciences, Inc...Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.;740.2100219726562;Regeneron Pharma topped third-quarter expectations Thursday, reporting less of a decline than expected. But REGN stock was down early.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:The stock market fell Thursday despite weaker-than-expected labor costs. Qualcomm and Roku dragged stocks lower.;154.30999755859375;"Pfizer Inc. and Germany-based partner BioNTech said updated trial data for their omicron BA.4/BA.5-adapted bivalent booster showed a ""substantially higher"" immune response in adults than the original COVID-19 vaccine.China agreed to approve BioNTech’s Covid-19 vaccines for foreign residents, German Chancellor Olaf Scholz said, in what would mark the first mRNA vaccine for Covid-19 approved for use in China.German Chancellor Olaf Scholz agreed to allow expatriates in China to use BioNTech SE (NASDAQ: BNTX) made COVID-19 vaccine. BioNTech would be the first non-Chinese coronavirus vaccine in China, as Beijing has insisted on administering domestically produced vaccines. BioNTech partners on COVID vaccines with Pfizer Inc (NYSE: PFE) in regions outside Greater China. Also Read: Pfizer/BioNTech Updated Omicron Adapted COVID-19 Vaccine Shows 4-Fold Higher Neutralizing Activity. In October, Moderna Inc'German Chancellor Olaf Scholz announced an agreement on Friday to let expatriates in China use the COVID-19 vaccine from Germany's BioNTech and pressed for Beijing to allow the shot to be made freely available to Chinese citizens.  On his first visit to China since becoming chancellor and the first by a G7 leader since the pandemic, Scholz said China and Germany had different approaches to fighting the virus but had a joint responsibility to eliminate it.Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced updated data from a Phase 2/3 trial demonstrating a robust neutralizing immune response one month after a 30-µg booster dose of omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine. Immune responses against BA.4/BA.5 sublineages were substantially higher for those who received the bivalent vaccine compared to the companies' original COVID-19 vaccine, with a similar safety and tolerability profile between both vaccines. These results";224.36000061035156;"Delays in instruments and consumables purchases, negative foreign exchange impact and consumables inventory deleveraging are expected to impede growth in the rest of 2022 for Illumina (ILMN).Illumina Inc (NASDAQ: ILMN) posted Q2 revenue of $1.12 billion, up 1% Y/Y and up 3% on a constant currency basis, almost in line with the consensus. Non-GAAP diluted earnings per share of $0.34 compared to $1.45 a year ago, beating the consensus of $0.30. ""Our second quarter results did not meet our expectations as challenges in a complex macroeconomic environment more than offset the growth we continue to see in sequencing runs on our platforms,"" said Francis deSouza, CEO. During the quarter, GIllumina (ILMN) delivered earnings and revenue surprises of 17.24% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the third quarter of fiscal year 2022, which include consolidated financial results for GRAIL.Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, announced a new research test for genitourinary pathogen and antimicrobial resistance (AMR) identification.";308.82000732421875;"Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States.TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.Equity markets are deep in the red for the year, and so is the broader biotech industry.  Vertex Pharmaceuticals is living proof that drugmakers do not necessarily need a diversified and deep lineup to be successful.  Here's the catch: Vertex holds a monopoly in this area.How far off is Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) from its intrinsic value? Using the most recent...BOSTON, November 04, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball Hall-of-Famer Alonzo Mourning to launch ""Power Forward"" (www.PowerForwardTogether.com), an educational initiative aimed at raising awareness of APOL1-mediated kidney disease (AMKD), highlighting the importance of early diagnosis and genetic testing.";281.82000732421875;;185.42999267578125;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 04, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences:";127.22000122070312;;208.33999633789062;;303.57000732421875;;2.5;;82.48999786376953;;31.90999984741211;Does the November share price for 10x Genomics, Inc. ( NASDAQ:TXG ) reflect what it's really worth? Today, we will...;77.30000305175781;Equity markets are deep in the red for the year, and so is the broader biotech industry.  Vertex Pharmaceuticals is living proof that drugmakers do not necessarily need a diversified and deep lineup to be successful.  Here's the catch: Vertex holds a monopoly in this area.;37.56999969482422;"Shares of Exact Sciences (NASDAQ: EXAS) were soaring 17.3% higher as of 11 a.m. ET on Friday.  Exact Sciences reported Q3 revenue of $523.1 million, up 15% year over year.  In addition, Exact Sciences raised its full-year revenue guidance.Exact Sciences (EXAS) registers robust revenues from the Screening and Precision Oncology segments in Q3.At this time, I would like to welcome everyone to the Exact Sciences third quarter 2022 earnings call.  Thanks, Colby, and I thank all of you for joining us for Exact Sciences third quarter 2022 conference call.  On the call today are Kevin Conroy, the company's chairman and CEO; and Jeff Elliott, our chief financial officer and chief operating officer.Exact Sciences (EXAS) delivered earnings and revenue surprises of 23.64% and 4.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021.";19.399999618530273;In the latest trading session, Novavax (NVAX) closed at $20.17, marking a -1.61% move from the previous day.;50.939998626708984;Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.;121.81999969482422;;103.62999725341797;Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.;63.13999938964844;;33.959999084472656;;42.02000045776367;;51.18000030517578;CRISPR Therapeutics (NASDAQ: CRSP) is submitting what may become its first commercialized gene-editing treatment to regulators this month.  Axsome Therapeutics (NASDAQ: AXSM) just started selling a potential blockbuster antidepressant.  The gene-editing specialist, along with its partner Vertex Pharmaceuticals, begins a regulatory submission this month.;30.93000030517578;Zai Lab, Li Auto, Dingdong (Cayman), Autohome and JD.com are part of the Zacks top Analyst Blog.;19.84000015258789;"Fate Therapeutics (FATE) delivered earnings and revenue surprises of 7.53% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?FT596+R Enrollment Ongoing in Three-dose Escalation Cohort for R/R BCL; Activating Community Sites for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL Positive Feedback Received from FDA under FT516 RMAT Designation for Derivation of Clonal Engineered Master iPSC Bank and for Potential Registrational Study Design Preclinical Data of FT555 GPRC5D-targeted CAR NK Cell Product Candidate for R/R MM under Janssen Collaboration to be Presented at ASH; Commercial Option Ex";16.459999084472656;;9.84000015258789;;42.79999923706055;;28.31999969482422;Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders will have a reason to smile today, with the analysts making...Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -1.20% and 64.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2022, and provided business highlights. “This is an exciting time in neuroscience and rare disease drug development,” said Ryan Watts, Ph.D., Denali's Chief Exe;35.27000045776367;Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.;46.59000015258789;;;;25.65999984741211;"Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 12,900% and 143.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?- Biomedical Advanced Research and Development Authority (BARDA) awarded contract to support pandemic preparedness for influenza and other infectious diseases; initial investment of ~$55.0 million with potential total of up to $1.0 billion - - Phase 2 data from three of the Company’s most advanced development programs – hepatitis B, hepatitis D and influenza A – expected in 2023 - - Strong balance sheet with approximately $2.7 billion in cash, cash equivalents, investments and profit-share payme";14.640000343322754;;7.0;;8.25;;41.54999923706055;Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced results from the Phase 2b RE-THINC ESRD study of fesomersen to reduce the production of Factor XI (FXI) for the prevention of thrombosis. Ionis to regain rights to fesomersen from Bayer AG (OTC: BAYRY). The RE-THINC ESRD study evaluated fesomersen in patients with end-stage renal disease (ESRD) on hemodialysis. In the study, fesomersen achieved its primary endpoint, demonstrating no increase in the incidence of the composite of major bleeding anIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the Phase 2b RE-THINC ESRD study of fesomersen (formerly IONIS-FXI-LRx), an investigational antisense medicine designed to reduce the production of Factor XI (FXI) for the prevention of thrombosis, were presented by Bayer at the American Society of Nephrology's (ASN) Kidney Week 2022. The RE-THINC ESRD study evaluated fesomersen in patients with end-stage renal disease (ESRD) on hemodialysis.;45.5;;51.220001220703125;;11.90999984741211;A Relative Strength Rating upgrade for Abcellera Biologics Inc shows improving technical performance.;32.5;SOUTH SAN FRANCISCO, Calif., November 03, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 fourth quarter and full year ended September 30, 2022, before the opening of the market on Friday, November 18, 2022. The company plans to hold a conference call and live audio webcast for analysts and investors;14.670000076293945;Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.;23.979999542236328;
2022-11-07;277.0199890136719;Amgen Inc (NASDAQ: AMGN) presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of olpasiran (formerly AMG 890) in adults with elevated lipoprotein levels and a history of atherosclerotic cardiovascular disease (ASCVD). These data were presented during the Nov. 6 Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions. Patients who received 75 mg or higher every 12 weeks had a 95% or greater reduction in lipoprotein levels compared to placebo at weThe U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc subsidiary Kite Pharma Inc over a lymphoma drug.  The justices turned away Juno's appeal of a lower court's ruling throwing out the award in the litigation over Kite's biologic drug Yescarta, in a case that could have repercussions for the cutting-edge biologic drug industry.Amgen (NASDAQ:AMGN) today announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR), taking place in Philadelphia on Nov. 10-14, 2022.Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of investigational olpasiran (formerly AMG 890) in adults with elevated lipoprotein(a) [Lp(a)] levels (>150 nmol/L) and a history of atherosclerotic cardiovascular disease (ASCVD). The study was designed to assess safety, tolerability and optimal dose of olpasiran in adults with established ASCVD to reduce Lp(a).1 These data were presented during the Nov. 6 Late-Breaking Science Session of the American;81.45999908447266;;750.9299926757812;;160.72000122070312;"A BioNTech executive on Monday confirmed that the company is in discussions with Chinese authorities over regulatory approval of the German biotech firm's COVID-19 vaccine for use by expatriates in China but the outcome was uncertain.  He added it was too early to predict the extent or the timing of such an approval for foreigners working in China.  BioNTech shares rose on Friday after German Chancellor Olaf Scholz announced an agreement to let expatriates in China use the vaccine and he pressed for Beijing to allow the shot to be made freely available to Chinese citizens.Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss third-quarter earnings for BioNTech and news that the biotechnology company is raising the lower end of its full-year outlook for 2022.Wall Street Journal After Musk's Mass Twitter Layoffs, Zuckerberg Reportedly Planning Similar Cuts At Meta This Week Meta Platforms Inc (NASDAQ: META) is reportedly planning to lay off thousands of workers in the coming week, similar to what Elon Musk did at Twitter just days ago. The Mark Zuckerberg-led company, which has more than 87,000 employees as of September-end, could lay off thousands and has asked its staff to cancel nonessential travel beginning this week. ""In aggregate, we expect toBy Liz MoyerBioNTech said it now expects full-year Covid-vaccine revenue of €16 billion-€17 billion, from €13 billion-€17 billion previously.BioNTech SE (NASDAQ: BNTX) has reported Q3 FY22 revenues of €3.46 billion, down from €6.09 billion a year ago, blaming the dynamic course of the pandemic leading to fluctuations in quarterly revenues. The company posted diluted EPS of €6.98, down from €12.35 a year ago. The company has invoiced approximately 300 million doses of the original/omicron BA.1- and BA.4/BA.5-adapted bivalent vaccines as of mid-October 2022. Ugur Sahin, BioNTech's co-founder & CEO, said, ""The next chapter of BioNTech'sCOVID-19 vaccine maker BioNTech on Monday raised the lower bound of its 2022 COVID-19 vaccine revenue guidance for the full year, citing demand for its adapted shots and higher prices.  The German biotech firm, the vaccines partner of U.S. pharma giant Pfizer, said in a statement that it is now targeting 16 to 17 billion euros ($16-$17 billion) in vaccine sales, compared with a previous range of 13-17 billion but down from 19 billion euros reported for last year.  ""The updated guidance reflects the shipment of the Omicron adapted bivalent vaccine boosters, which started early in September and is expected to continue throughout the fourth quarter of 2022 as well as higher prices and a positive foreign currency effect,"" the company said.BioNTech SE said Monday it had net income of $1.784 billion euros, or EUR6.98 a share, in the third quarter, down from EUR6.087 billion, or EUR12.35 a share, in the year-earlier period. Revenue fell to EUR3.461 billion from EUR6.087 billion a year ago. The FactSet consensus was for EPS of EUR3.42 and revenue of EUR2.065 billion. The Mainz, Germany-based biotech said it had invoiced about 300 million doses of its bivalent vaccines that target both the omicron variant and the original virus as ofBioNTech and Pfizer continue to build on global COVID-19 vaccine leadership with first-to-market Original/Omicron BA.4/BA.5-adapted bivalent vaccine launches across multiple countries and regions worldwide Approximately 300 million doses of the Original/Omicron BA.1- and BA.4/BA.5-adapted bivalent vaccines invoiced as of mid-October 2022 In infectious diseases, Phase 1 trial initiated with a combination vaccine candidate, incorporating the Pfizer-BioNTech Omicron BA.4/BA.5-adapted bivalent COVIDCOVID-19 vaccine maker BioNTech on Monday raised the lower bound of its 2022 COVID-19 vaccine revenue guidance for the full year, citing demand for its adapted shots and higher prices.  The German biotech firm, the vaccines partner of U.S. pharma giant Pfizer, said in a statement that it is now targeting 16 to 17 billion euros ($16-$17 billion) in vaccine sales, compared with a previous range of 13-17 billion but down from 19 billion euros reported for last year.  ""The updated guidance reflects the shipment of the Omicron adapted bivalent vaccine boosters, which started early in September and is expected to continue throughout the fourth quarter of 2022 as well as higher prices and a positive foreign currency effect,"" the company said.By Scott KanowskyBy Peter Nurse";217.19000244140625;San Francisco Bay Area residents Jainu and Shruti Jogani had their newborn daughter, Reyna, at home for nearly three weeks when they noticed her exhibiting seizure-like symptoms-episodes so quick they weren't able to capture them on video. Standard blood work, MRI scans, and EKGs all came back normal, except for a gene panel for epilepsy.;303.2300109863281;;284.6199951171875;;192.77999877929688;;129.7899932861328;;204.92999267578125;;314.7799987792969;;2.390000104904175;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2022, on Monday, November 14, 2022, beginning at 4:30 p.m. ET.;81.33000183105469;;30.899999618530273;;75.9000015258789;WILMINGTON, Del. & SAN DIEGO, Calif., November 07, 2022--Incyte and Mirati Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in KRASG12C-Mutated Solid TumorsWILMINGTON, Del., November 07, 2022--Data from Incyte’s Oncology Portfolio to be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting;38.15999984741211;;19.43000030517578;;48.529998779296875;;121.05000305175781;;100.38999938964844;;59.91999816894531;WILMINGTON, Del. & SAN DIEGO, Calif., November 07, 2022--Incyte and Mirati Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in KRASG12C-Mutated Solid Tumors;34.310001373291016;;42.77000045776367;;49.70000076293945;;32.029998779296875;;19.68000030517578;Multiplexed-engineered, iPSC-derived CAR T-cell Product Candidate Demonstrated Broad, Potent and Specific CAR Activity Across Multiple Preclinical Solid Tumor Models Fate and ONO to Jointly Develop and Commercialize FT825/ONO-8250 in U.S. and Europe with ONO having Exclusive Rights in Rest of World SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for;16.350000381469727;;9.170000076293945;;37.90999984741211;"Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -20% and 51.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution IND-enabling Studies Underway for BEAM-301 for Treatment of GSDIa BEAM-302 Nominated as Development Candidate for Treatment of Alpha-1 Antitrypsin Deficiency; Targeting Durable Gene Correction Designed to Address Both Lung and Liver Disease New Data Highlighting Enhanced Conditioning Approach for Hematologic Transplant (ESCAPE) to be Presented at ASH Ended T";27.75;;35.06999969482422;;46.279998779296875;;;;27.239999771118164;Vir Biotechnology Inc (NASDAQ: VIR) announced new data from its hepatitis B virus (HBV) portfolio aimed at achieving a functional cure. New preliminary data from an ongoing Phase 2 trial demonstrated that 30.8% of participants receiving 48 weeks of VIR-2218 combined with pegylated interferon alpha (PEG-IFN-α) achieved HBsAg seroclearance with anti-HBs seroconversion. Additionally, 48 weeks of VIR-2218 plus PEG-IFN-α provided greater reductions in hepatitis B surface antigen (HBsAg) compared to V;14.899999618530273;;7.03000020980835;;8.420000076293945;;41.61000061035156;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 clinical study of IONIS-FB-LRx in patients with immunoglobulin A nephropathy (IgAN). Results from the study were presented in a poster session at the American Society of Nephrology's (ASN) Kidney Week 2022.;42.470001220703125;;52.34000015258789;The consensus price target hints at a 33.5% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.;12.010000228881836;;30.610000610351562;;14.489999771118164;;23.31999969482422;
2022-11-08;292.3900146484375;U.S. stock indexes rose for the third straight session on Tuesday as voting began in the crucial midterm election that will determine control of Congress, with investors hoping for a political gridlock that could prevent radical policy changes.  Nonpartisan forecasters and opinion polls suggested a strong chance of Republicans winning a House majority and a tight race for Senate control.Amgen ( NASDAQ:AMGN ) Third Quarter 2022 Results Key Financial Results Revenue: US$6.65b (flat on 3Q 2021). Net income...Amgen (NASDAQ:AMGN) today presented a new analysis from the Phase 3 FOURIER and FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in adults with atherosclerotic cardiovascular disease (ASCVD) during the Nov. 7 Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2022 in Chicago, Illinois. These data demonstrated that achieving and sustaining a low-density lipoprotein cholesterol (LDL-C) level of <20 mg/dL was associated with improved cardiov;82.2300033569336;"Gilead Sciences ( NASDAQ:GILD ) Third Quarter 2022 Results Key Financial Results Revenue: US$7.04b (down 5.1% from 3Q...The U.S. Supreme Court turned away an appeal made by rebuffed efforts made by Bristol Myers Squibb Co's (NYSE: BMY) Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc's (NASDAQ: GILD) Kite Pharma Inc over Yescarts, a lymphoma drug. Juno and Sloan Kettering Institute for Cancer Research sued Kite in 2017 in a federal court in Los Angeles, accusing it of copying technology the institute licenses to Juno. A jury awarded the plaintiffs $778 miGilead Sciences Inc said on Monday the company and its unit Kite were in the ""process of pausing advertising"" on Twitter, after Elon Musk completed his takeover of the social media company.  In a statement to Reuters, Gilead said it was monitoring its advertising spend and waiting to better understand how community standards and content moderation will be handled on Twitter now.  Gilead joins a growing list of U.S. companies, including General Motors and General Mills, who have either paused or are in the process of re-evaluating advertising on the social media platform.";751.9500122070312;Regeneron Pharmaceuticals ( NASDAQ:REGN ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.94b (down 15...;160.94000244140625;BioNTech is in an exciting phase of its corporate development, and we are delighted to share our progress with you.  Taking a first look at Slide 2, I would like to remind you that during today's presentation, we will make several forward-looking statements.BioNTech doubled third-quarter profit expectations Monday and raised its full-year outlook for Covid vaccine sales — and BNTX stock jumped.If you want to know who really controls BioNTech SE ( NASDAQ:BNTX ), then you'll have to look at the makeup of its...(Bloomberg) -- BioNTech SE said some deliveries of the Covid-19 vaccine it sells with Pfizer Inc. have shifted into next year, adding to concerns about future revenue for its only marketed product.Most Read from BloombergTwitter Now Asks Some Fired Workers to Please Come BackElon Musk Tells Twitter Followers to Vote for a Republican CongressElon Musk Walks Back on Twitter Job Cuts, Blue Checks in Second WeekBillions in Capital Calls Threaten to Wreak Havoc on Global Stocks, BondsHouston Mogul’s;218.0399932861328;NORTHAMPTON, MA / ACCESSWIRE / November 8, 2022 / Illumina: At the Phoenix Convention Center in Arizona, representatives from Illumina, a global leader in DNA sequencing and array-based technologies, joined approximately 2000 molecular diagnostic ...;306.5;ClearBridge Investments, an investment management company, released its “ClearBridge Aggressive Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark index, Russell 3000 Growth Index, in the third quarter. The healthcare sector was the primary contributor to the strategy’s performance, while communication services detracted from […]When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...;286.1600036621094;ClearBridge Investments, an investment management company, released its “ClearBridge Aggressive Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark index, Russell 3000 Growth Index, in the third quarter. The healthcare sector was the primary contributor to the strategy’s performance, while communication services detracted from […]Biogen ( NASDAQ:BIIB ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.51b (down 9.7% from 3Q 2021). Net...BIIB vs. RGEN: Which Stock Is the Better Value Option?;189.1300048828125;;131.5399932861328;;204.75999450683594;;310.3900146484375;Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022, at 2:25 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;2.5399999618530273;;81.25;America goes to the only poll that counts, and tomorrow morning we’ll have a better picture of the next Congress. All indications point toward a hefty GOP win, and a consequent legislative check on the Democratic Administration. As for the stock market, if we look back at the past 70 years or so, we find reason for hope no matter the results of the vote. That’s because stocks have rallied after every single mid-term election since the Second World War. It’s no flash-in-the-pan effect either. AccBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today a progress update on its Biologics License Application (BLA) for valoctocogene roxaparvovec AAV gene therapy for adults with severe Hemophilia A that is currently under review by the U.S. Food and Drug Administration (FDA). As part of their review of the BLA, the FDA has scheduled its Pre-Licensure Inspection (PLI) of BioMarin's gene therapy manufacturing facility, located in Novato, CA. As anticipated, the FDA also has requested that t;32.380001068115234;;76.69000244140625;;40.90999984741211;The mean of analysts' price targets for Exact Sciences (EXAS) points to an 84.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.;19.649999618530273;"Novavax Inc. said Tuesday a late-stage trial of its vaccine targeting the COVID variant omicron supports its continued and future use as a booster. The company said the Phase 3 trial met its main strain-change endpoint. ""The data demonstrate that the BA.1 vaccine candidate neutralizing responses in those not previously exposed to COVID-19 were greater than those of the prototype vaccine (NVX-CoV2373), enabling a shift to a new variant vaccine, if necessary,"" the company said in a statement. TheData showed the shot, NVX-CoV2515, produced 1.6 times the amount of neutralizing antibodies in people who had previously not been exposed to COVID-19 compared to Novavax's original coronavirus vaccine.  The trial included Novavax's so-called bivalent vaccine, the BA.1-tailored shot and its prototype vaccine.  Novavax says the results from the study showed its Omicron-tailored shot can be changed to target a new variant vaccine if necessary.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS Variant Vaccines (COVID-19) showing that the Company's BA.1 vaccine candidate (NVX-CoV2515) met the primary strain-change endpoint. The data demonstrate that the BA.1 vaccine candidate neutralizing responses in those not previously exposed to COVID-19 were gAlthough an uncomfortable subject based on financial sensitivities, the topic of Nasdaq stocks to avoid cannot be avoided much longer. To be clear, it’s not so much about the companies specifically. Rather, with the Federal Reserve committed to its hawkish monetary policy, borrowing costs will rise. With that, the incentive for expansion-driven protocols will likely significantly diminish. Domestically, what’s incredibly problematic is that the Fed will probably push interest rates consistently";49.529998779296875;Intellia Therapeutics ( NASDAQ:NTLA ) Third Quarter 2022 Results Key Financial Results Revenue: US$13.3m (up 84% from...;123.9000015258789;;105.16000366210938;;59.439998626708984;;33.29999923706055;PASADENA, Calif., November 07, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of new clinical data on its pipeline of investigational RNAi-based cardiometabolic medicines, ARO-APOC3, ARO-ANG3, and olpasiran, which is being developed by Amgen, in three late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2022, being held in Chicago. The company will also host a virtual analyst and investor event on November 9, 2022, at;42.7599983215332;Blueprint Medicines ( NASDAQ:BPMC ) Third Quarter 2022 Results Key Financial Results Revenue: US$66.0m (up 173% from 3Q...;50.72999954223633;CRISPR Therapeutics AG (NASDAQ: CRSP), a gene-editing clinical-stage biotech company, saw its shares fall 19.9% in November, according to data from S&P Global Intelligence.  It opened October at $66.02 and then fell steadily throughout the month, dropping to a monthly low of $48.49 on Oct. 24.  The stock concluded the month at $52.34 and is down more than 33% so far this year, with a 52-week low of $42.51 and a 52-week high of $95.;29.829999923706055;"Poster presentations will highlight Zai’s key internal pipeline programs, ZL-1211 (anti-CLDN18.2 antibody) for gastric cancer and ZL-1218 (anti-CCR8 antibody) for solid tumorsSHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will present new data from its internal immuno-oncology pipeline at the upcoming Society for Immunotherapy of Cancer (SITC) Annual MeSHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Dr. Peter Huang as its Chief Scientific Officer (CSO), effective immediately. Dr. Huang brings an extensive scientific background and strong leadership and research and development experience, including over 16 years working within the biopharmaceutical industry, to Zai Lab";19.610000610351562;;16.559999465942383;;9.25;;38.38999938964844;Last November, the FDA signed off Beam Therapeutics Inc's (NASDAQ: BEAM) Investigational New Drug (IND) application for Phase 1/2 trial for BEAM-101 gene therapy for sickle cell disease. In the most recent earnings release, the company said it is still working on enrolling its first patient for the trial, dubbed BEACON-101, by year-end. The company announced in its Q3 update that it's pushing back plans to file an IND in 2022 for BEAM-102, another sickle cell gene therapy candidate. To speed upBeam's decision not to move forward with sickle cell treatment BEAM-102 isn't sitting well with investors today.;27.549999237060547;;34.7400016784668;;45.83000183105469;Halozyme Therapeutics (HALO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;;;26.84000015258789;The average of price targets set by Wall Street analysts indicates a potential upside of 107.4% in Vir Biotechnology, Inc. (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.;15.029999732971191;;6.849999904632568;;9.029999732971191;PacBio (PACB) witnesses strength in Service and other revenues, along with robust consumable sales, in the third quarter.Pacific Biosciences (PACB) delivered earnings and revenue surprises of 8.57% and 8.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2022.;42.25;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense oligonucleotide treatment for patients with chronic hepatitis B virus (CHB). The results showed that treatment with bepirovirsen resulted in sustained clearance of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA for 24 weeks after end of bepirovirsen treatment in people witIonis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;44.52000045776367;Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.53% and 31.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?– On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer – – Enrolling multiple clinical trials and initiating enrollment activity across estrogen receptor (ER) and androgen receptor (AR) franchises – NEW HAVEN, Conn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results;52.47999954223633;;12.239999771118164;;31.110000610351562;;15.300000190734863;;23.190000534057617;- Alkermes plc (Nasdaq:ALKS) announced the 2022 recipients of the Alkermes Inspiration Grants® program. Grants were awarded to nine nonprofit organizations working to address the needs of people living with alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and cancer.
2022-11-09;289.6499938964844;Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.U.S. stock indexes rose for the third straight session on Tuesday as voting began in the crucial midterm election that will determine control of Congress, with investors hoping for a political gridlock which could prevent radical policy changes.  Helping the blue-chip Dow outperform its Wall Street peers, shares of drugmaker Amgen Inc climbed 6.5% to a record high after reporting positive data related to its cholesterol drug and obesity treatment.  Nonpartisan forecasts and opinion polls suggested a strong chance of Republicans winning a House majority and a tight race for Senate control.With the shares trading around $295 Tuesday morning another look seems like a good idea.  The trading volume has increased from late September and the On-Balance-Volume (OBV) line has risen from early October telling us that buyers of AMGN have been more aggressive the past month.  The weekly OBV line is bullish and so is the MACD oscillator .;82.31999969482422;"We reviewed the charts of Gilead Sciences on Oct. 4 and wrote that we ""like the current look of the charts and indicators. Traders could go long GILD on strength above $68 and above $72. Our price target is $81 for now.In this article, we will discuss Goldman Sachs’ cheap dividend stocks. You can skip our detailed analysis of dividend investing and the firm’s outlook on dividend stocks, and go directly to read Goldman Sachs’ 5 Cheap Dividend Stocks. Growth tech stocks have dominated the market for years due to their innovative products and services. However, […]Perrigo (PRGO) reports dismal third-quarter 2022 results. Unfavorable currency movements force management to lower earnings outlook for 2022. Shares down.Gilead Sciences (NASDAQ: GILD) saw its shares rise 27.20% in October, according to data from S&P Global Intelligence.  The biotech stock ended September at $61.69.  Gilead, a biopharmaceutical company that focuses on oncology and HIV therapies, showed it has a strong future even as sales of its COVID-19 therapy, Veklury (remdesivir), have begun to ebb.";742.9500122070312;Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy, irrespective of PD-L1 expression levels.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation. Patie;159.5800018310547;Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.Britain's health regulator on Wednesday approved the country's first two-pronged COVID-19 booster targeting the Omicron BA.4 and BA.5 sub-variants and the original coronavirus strain.  The Medicines and Healthcare products Regulatory Agency (MHRA) said the vaccine from Pfizer and partner BioNTech was approved for use as a booster in people 12 years and older after it was found to meet safety, quality and effectiveness standards.With the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry could be worth nearly $1.6 trillion, according to Acumen Research and Consulting. Two, the best pharma stocks are still ranked as some of the safest, recession-resistant investments to own. After all, we can’t stop people from aging. Three, we can’t forget about secular tailwinds, such as population aging and growth. In fact, according to the Popul;215.85000610351562;Illumina ( NASDAQ:ILMN ) Third Quarter 2022 Results Key Financial Results Revenue: US$1.12b (flat on 3Q 2021). Net...While visiting her grandparents in Florida, 17-year-old Kate frequented a pond near their house and spent time observing the various species of fish living there.;309.3399963378906;BOSTON, November 09, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its participation in the following upcoming investor conferences:Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.Perrigo (PRGO) reports dismal third-quarter 2022 results. Unfavorable currency movements force management to lower earnings outlook for 2022. Shares down.;282.30999755859375;;176.22999572753906;CAMBRIDGE, Mass., BASEL, Switzerland & BEIJING, November 09, 2022--BeiGene today reported financial results for the third quarter of 2022, recent business highlights, and anticipated upcoming milestones.;137.9600067138672;;197.94000244140625;CAMBRIDGE, Mass., November 09, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:;313.05999755859375;;2.299999952316284;Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it will be presenting a poster on November 11 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The poster highlights Foundry-enabled methods for large-scale, combinatorial library design and screening of Chimeric Antigen Receptor (CAR) domains for improved persistence. The ability to screen hundreds of thousands of CAR designs in primary human T cells can enable di;80.93000030517578;;30.40999984741211;10x Genomics ( NASDAQ:TXG ) Third Quarter 2022 Results Key Financial Results Revenue: US$131.1m (up 4.6% from 3Q 2021...;77.22000122070312;;40.2599983215332;Exact Sciences ( NASDAQ:EXAS ) Third Quarter 2022 Results Key Financial Results Revenue: US$523.1m (up 15% from 3Q...;18.6299991607666;"Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.The southern Chinese manufacturing city of Guangzhou is the latest to see lockdowns amid a surge in COVID cases, as the government presses ahead with the strict zero-COVID policy that has frustrated citizens.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has expanded the conditional marketing authorization (CMA)i for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine▼ as a homologous and heterologous booster dose after the primary series of Nuvaxovid (six months) or of an mRNA or adenoviralNovavax Inc (NASDAQ: NVAX) revised its FY22 sales forecast for the second time in three months amid waning demand for COVID-19 vaccines. The company now expects annual revenue to be approximately $2.0 billion, the low end of its prior forecast range of $2 billion - $2.3 billion. In August, Novavax halved its full-year revenue forecast from $4-5 billion. Novavax reported a Q3 net loss of $168.6 million compared to a loss of $(322.4) million in the same period last year. EPS loss came in at $(2.15Gaithersburg’s Novavax Inc. has lowered its full-year revenue guidance for the second time in 2022, but its stock crept up in after-hours trading Tuesday after the company reported significant revenue for the quarter.  Novavax (NASDAQ: NVAX) executives said on a third-quarter earnings call Tuesday that it now projects to reach about $2 billion in 2022 revenue, the low end of its previous range of $2 billion to $2.3 billion.  Its third-quarter revenue this year included $626 million from sales of 35 million doses of its Covid vaccine, Novavax reported Tuesday.Top trending stocks after hours on Tuesday, November 8, 2022.Novavax (NVAX) delivered earnings and revenue surprises of -197.29% and 33.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Yahoo Finance Live anchor Seana Smith highlights which tickers are making moves in after-hours trading.Novavax Inc cut its full-year revenue forecast on Tuesday for the second time in three months, hurt by a global supply glut in COVID-19 vaccine and waning demand.  The company now expects annual revenue to be near the low end of its prior forecast range of between $2 billion and $2.3 billion.  In August, Novavax halved its full-year revenue forecast as it did not expect further sales of its COVID-19 shot this year in the United States.Shares of Novavax Inc. rallied after hours Tuesday, after the COVID-19 vaccine maker reported third-quarter results that were far better than expected.The company now expects annual revenue to be near the low end of its prior forecast range of between $2 billion and $2.3 billion.  In August, Novavax halved its full-year revenue forecast as it did not expect further sales of its COVID-19 shot this year in the United States.  The company is now ""pushing forward"" on developing a vaccine targeting Omicron subvariants BQ.1 and BQ.1.1 which they would also formulate as a bivalent vaccine with another coronavirus strain, Filip Dubovsky, Novavax's chief medical officer, said on a conference call with investors.Novavax Inc cut its full-year revenue forecast on Tuesday, hurt by a global supply glut in COVID-19 vaccine and waning demand.  The company now expects annual revenue to be about $2 billion, the lower end of its prior forecast range of between $2 billion and $2.3 billion.  In August, Novavax halved its full-year revenue forecast as it did not expect further sales of its COVID-19 shot this year in the United States.Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2022.Protests in northeastern China against the government's zero-COVID policy became violent, as seven people have been arrested after a clash between residents and police enforcing quarantine restrictions, as the Associated Press reported.Novavax Inc (NASDAQ: NVAX) announced topline results from its Phase 3 trial of updated COVID-19 shot against BA.1 strain meeting the primary strain-change endpoint. The data demonstrate that the BA.1 vaccine candidate neutralizing responses in those not previously exposed to COVID-19 were greater than those of the prototype vaccine. Immunoglobulin G (IgG) antibody responses against BA.1 and prototype strains showed similar responses across the three vaccine groups. Related: FDA Gives Emergency NThe findings come within three weeks after Novavax earned two critical green lights from regulators.";48.29999923706055;;122.38999938964844;Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:;103.94000244140625;;61.939998626708984;Mirati Therapeutics (MRTX) reports narrower-than-expected Q3 loss. Revenues also beat the mark. Stock rises in after-hours trading.Mirati (MRTX) delivered earnings and revenue surprises of 10.69% and 15.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates.Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D., to the position of executive vice president and chief medical officer. In his role, Dr. Sandler will provide leadership and direction over clinical development and operations, regulatory affairs, drug safety and asset development strategy and report to David Meek, chief executive officer. As part of the transition, Dr. James Christensen, executive vice pres;30.459999084472656;Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (NasdPASADENA, Calif. & NEW YORK, November 09, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.;41.060001373291016;;48.93000030517578;Often, healthcare stocks outperform because investors know people can't avoid buying their medications or undergoing a medical procedure.  Today, though, many healthcare stocks are heading for an annual decline.  Instead of avoiding these players, investors should give them a second look.;28.56999969482422;;18.780000686645508;;16.389999389648438;I believe this divergence between the performance in growth and value stocks is likely to continue, at least until the Fed 'pivots'.Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter.;8.470000267028809;PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: Jefferies Health Care Conference, London, UK: November 15th at 9:40 am ETEvercore ISI HealthCONx Conference, Virtual: November 30th at 10:05 am ET To access the live webcastBridgeBio Pharma ( NASDAQ:BBIO ) Third Quarter 2022 Results Key Financial Results Revenue: US$338.0k (down 86% from 3Q...;37.880001068115234;"CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences: 2022 Jefferies London Healthcare Conference (fireside chat) on Tuesday, November 15, 2022, at 8:00 a.m. GMT; and,Evercore ISI Virtual HealthCONx Conference 2022 (fireside chat) on Thursday, December 1, 2022, at 8:50 a.m. ET. LiBeam Therapeutics ( NASDAQ:BEAM ) Third Quarter 2022 Results Key Financial Results Revenue: US$15.8m (up by US$15.0m...";26.84000015258789;Denali Therapeutics ( NASDAQ:DNLI ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.56m (down 33% from...;33.720001220703125;;49.709999084472656;"Halozyme's (HALO) earnings and revenues beat estimates for the third quarter of 2022.Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today announced that members of its management team are scheduled to present and host investor meetings at the following investor conferences:Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 42.31% and 11.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Halozyme Therapeutics, Inc. (NASDAQ: HALO) (""Halozyme"") today reported its financial and operating results for the third quarter ended September 30, 2022 and provided an update on its recent corporate activities and outlook.";;;25.959999084472656;Vir Biotechnology ( NASDAQ:VIR ) Third Quarter 2022 Results Key Financial Results Revenue: US$374.6m (up 262% from 3Q...;14.989999771118164;"SEATTLE & CAMBRIDGE, United Kingdom, November 09, 2022--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, and Abcam (AIM: ABC; NASDAQ: ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString’s high-plex spatial multiomic s";6.730000019073486;;8.34000015258789;;43.060001373291016;"Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 55.41% and 7.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the ""Company"") today reported financial results for the third quarter of 2022. Financial results are summarized below:";40.77000045776367;;50.0099983215332;;11.8100004196167;Image source: The Motley Fool.  AbCellera Biologics Inc. (NASDAQ: ABCL)Q3 2022 Earnings CallNov 08, 2022, 5:00 p.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  OperatorGood afternoon, and welcome to AbCellera's third quarter 2022 business update conference call.AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?VANCOUVER, British Columbia, November 08, 2022--AbCellera Reports Q3 2022 Business Results;28.420000076293945;;14.960000038146973;SAN DIEGO, November 08, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:;23.68000030517578;Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, Nov. 15, 2022 at 8:00 a.m. ET (1:00 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
2022-11-10;291.010009765625;Loading up on passive income stocks is a great way to ride out a bear market.  Reliable cash distributions are a proven way to minimize losses, and elite dividend stocks tend to be among the first to recover following marketwide downturns.  Which top-tier passive income stocks should investors consider buying right now?Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.;82.5999984741211;"NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. ""We relied on traditional Latino ...One of the hottest healthcare stocks on the markets of late has been HIV-focused drugmaker Gilead Sciences (NASDAQ: GILD).  Shares of Gilead are up a whopping 33% over just the past three months, dwarfing the S&P 500 and its 8% losses during that stretch.  Here's a closer look at what's been behind Gilead's recent rally and whether or not its shares could still go higher.";741.0800170898438;Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.;156.9199981689453;"Pfizer Inc. and Germany-based partner BioNTech SE said Thursday that their booster dose of the omicron BA.4/BA.5-adapted bivalent COVID vaccine for 5-to-11 year olds was recommended for marketing authorization in the the European Union. The EU will review the recommendation from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), and is expected to make a decision ""soon."" The companies' bivalent booster is already authorized in the EU for people at least 12NEW YORK and MAINZ, GERMANY, November 10, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron BA.4/BA.5 5/5-µg) has been recommended for marketing authorization by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) for children 5 through 11 years of age. The European Commission will review the CHMP recommendation and is expected";240.08999633789062;;311.0299987792969;"AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged.Many healthcare stocks' earnings reports lately include the phrases ""inflationary pressures,"" ""labor shortages,"" ""supply chain issues,"" and ""short-term macroeconomic conditions"" to describe why earnings are flat or down.  UnitedHealth Group (NYSE: UNH), AbbVie (NYSE: ABBV), and Vertex Pharmaceuticals (NASDAQ: VRTX) are all up 8.5% or more this year despite the headwinds affecting so many companies.  It's easy to see why UnitedHealth Group's shares are up more than 8.5% so far this year.";290.70001220703125;Biogen Inc. has finally announced a new CEO, six months after Michel Vounatsos said he would be stepping down.Biogen Inc. stock rose 1% in premarket trades on Thursday after Christopher A. Viehbacher was named president and chief executive officer and a member of the board, effective Nov. 14. Viehbacher succeeds CEO Michel Vounatsos, who has led the company since 2017. Biogen Chairman Stelios Papadopoulos said Viehbacher's innovation and understanding of the complexities of the pharma business enabled him to turn around Sanfoi when he was CEO and leave it a much better company. Vounatsos will be leavingBiogen Inc on Thursday tapped pharmaceutical industry veteran Christopher Viehbacher as its new chief executive, after a months-long search for a successor to Michel Vounatsos.  The appointment comes at a crucial time for the U.S. drugmaker as it grapples with intense competition for top-selling drugs and a rocky launch of its highly anticipated Alzheimer's disease drug Aduhelm.  Investors and analysts are now pinning hopes on the second Alzheimer's drug the company is developing with Japan's Eisai Co Ltd after it slowed the progress of the memory-robbing disease by 27% in a trial.(Reuters) -Biogen Inc on Thursday tapped former Sanofi boss Christopher Viehbacher as its new chief executive, betting on an industry veteran to help the U.S. drugmaker put behind it a series of setbacks for Alzheimer's drug Aduhelm.  The appointment of Viehbacher, who founded private equity firm Gurnet Point Capital after being ousted from French drugmaker Sanofi in 2014, concludes a months-long search for a successor to Michel Vounatsos.Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies Christopher A. Viehbacher Christopher A. Viehbacher CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that its Board of Directors has appointed Christopher A. Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Viehbacher succeeds Michel Vounatsos, who has lThe Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.  Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.  Inhibikase slapped with clinical hold  The U.S. Food and Drug Administration has ordered a stop to a Phase 1 trial of a drug made by Inhibikase Therapeutics Inc. (Nasdaq: IKT), which has offices in Lexington.;188.8000030517578;"CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING, November 10, 2022--BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology, today announced BRUKINSA (zanubrutinib) has been approved in Brazil for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) and adult patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. BRUKINSA was previously approved as a treatment in Brazil for adult patient";131.05999755859375;BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that data from the company’s diverse pipeline of targeted cancer therapy candidates will be presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting being held November 8-12 in Boston. The presentations highlight data from multiple ongoing clinical and preclinical research studies that employ Seagen’s proprietary antibody-drug conjugate (ADC) technology, as well as other novel cancer targeting approBOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that Sandra M. Swain, M.D., has been appointed to the company’s Board of Directors. Dr. Swain has more than 30 years of breast cancer clinical research experience. She currently serves as Associate Dean for Research Development and Professor of Medicine at Georgetown University Medical Center and is the Vice President of Genetic Medicine for MedStar Health. She is also on the Conquer Cancer Foundation Board of AmericanBOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors. Mr. Epstein brings more than 30 years of experience in the biopharmaceutical industry, including more than 25 years at Novartis where he built its oncology business unit from initiation to second largest in the world and then served as CEO of Novartis Pharmaceuticals, a division of Novarti;212.4499969482422;;337.0899963378906;Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stephens Annual Investment Conference on Thursday, November 17, 2022, at 10:00 a.m. CST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;2.640000104904175;;83.31999969482422;;37.81999969482422;10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the commercial availability of BEAM (Barcode Enabled Antigen Mapping), a kitted solution for antibody and T-cell receptor (TCR) discovery. Built on top of 10x's industry-leading Chromium Single Cell Immune Profiling product, BEAM's proprietary antigen screening approach is fast and robust, delivering hundreds of antigen-receptor pairs with single cell gene expression. Th;77.77999877929688;;43.959999084472656;In this article, we discuss the 9 cheap stocks to buy according to Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to 4 Cheap Stocks to Buy According to Cathie Wood. Cathie Wood’s hedge fund ARK Investment Management has been battered this year as investors exit growth stocks […]In this article, we will discuss 15 stocks that will double in 2023. If you are short on time, you can skip our discussion and go straight to 5 Stocks That Will Double In 2023. We are almost through the nerve-racking year that 2022 was for equities. Inflation reached record highs, interest rates followed suit, […];22.139999389648438;Novavax ( NASDAQ:NVAX ) Third Quarter 2022 Results Key Financial Results Revenue: US$734.6m (up 311% from 3Q 2021). Net...These amazing deals are ripe for the picking and poised to deliver triple-digit returns in five years.Novavax posted an unexpected third-quarter loss, and NVAX stock yo-yoed Wednesday despite better-than-expected sales.;52.75;;123.22000122070312;;106.87999725341797;;70.43000030517578;;34.72999954223633;;43.470001220703125;Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation the following upcoming investor conferences:;54.689998626708984;;30.389999389648438;"Revenue of $57.5 million for the third quarter of 2022, representing a 33% increase y-o-y and a 19% increase q-o-q; continued revenue growth led by ZEJULA Regional strategic collaboration for TIVDAK® (tisotumab vedotin) strengthens Zai Lab’s leadership in developing and providing access to medicine to treat women’s cancer in ChinaStrong balance sheet with a cash position of $1.12 billionCompany to host a conference call and webcast on November 10, 2022, at 8:00 a.m. ET SHANGHAI and CAMBRIDGE, Ma";20.969999313354492;In this article, we discuss the 9 cheap stocks to buy according to Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to 4 Cheap Stocks to Buy According to Cathie Wood. Cathie Wood’s hedge fund ARK Investment Management has been battered this year as investors exit growth stocks […];16.90999984741211;;10.170000076293945;;44.15999984741211;;30.469999313354492;;37.58000183105469;NOVATO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the following upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 15, 2022, at 1:50 PM EST in New YorkJefferi;53.33000183105469;Halozyme Therapeutics ( NASDAQ:HALO ) Third Quarter 2022 Results Key Financial Results Revenue: US$209.0m (up 80% from...IBD Stock Of The Day Halozyme is entering a new wave of development — leading HALO stock to surge into a breakout Wednesday.;;;27.43000030517578;;16.34000015258789;;7.119999885559082;Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended September 30, 2022.;10.020000457763672;;45.470001220703125;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:;45.52000045776367;;50.66999816894531;NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate at two upcoming investor conferences: J.P. Morgan Equity Opportunities ForumMonday, November 14 – Tuesday, November 15, 2022 in Miami, FL Evercore ISI 5th Annual HealthCONx Virtual Conference Tuesday, November 29, 2022 at 12:35 pm;12.90999984741211;VANCOUVER, British Columbia, November 10, 2022--AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022;33.900001525878906;;16.420000076293945;;24.290000915527344;Our employees are the foundation upon which our business is built. Their expertise, intelligence and creativity drive our innovation, and their passion and commitment to excellence are the cornerstone of our success.
2022-11-11;285.0199890136719;Drug stocks have been outperforming the market all year since their sales are unaffected by changes in economic demand.Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Amgen Inc...;81.81999969482422;Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.;734.4500122070312;Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. In Septembe;154.50999450683594;;242.74000549316406;;303.260009765625;Vertex Pharmaceuticals (NASDAQ: VRTX) is something of a unicorn in the world of stocks right now.  While the S&P 500 has slid by nearly 20% over the past 12 months, Vertex is up by around 60% in that same period.  While it's true that healthcare stocks tend to outperform when the market is down, this is far from the only tailwind driving Vertex's precipitous growth in such a volatile market.Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.;289.45001220703125;Here's a few things to know about Christopher Viehbacher, the former Sanofi CEO who will soon step into the corner office at Biogen.Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements.The veteran pharmaceutical executive takes charge after the failed launch of Biogen’s once-promising Alzheimer’s disease drug Aduhelm.Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.Biogen's new CEO is Christopher Viehbacher, former head of French pharma giant Sanofi. Biogen faces challenges after the commercial failure of Alzheimer’s disease therapy Aduhelm.;197.9499969482422;;132.91000366210938;David Epstein spent more than 25 years at the Swiss pharmaceutical giant Novartis, where he helped build its oncology business.BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS® (brentuximab vedotin) for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide. The approval is based on data from a phase 3 study (AHOD1331) conducted by the Children's Oncology Group (COG;216.3699951171875;;349.9700012207031;;2.8499999046325684;Lygos, Inc., a vertically integrated provider of sustainable specialty ingredients, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a multi-product research and development collaboration designed to optimize and scale production of sustainable specialty ingredients that can replace toxic petrochemistry, reclaim local manufacturing, and advance industrial bio-innovation.;82.16000366210938;;41.29999923706055;;77.52999877929688;;46.33000183105469;;25.040000915527344;;54.95000076293945;;121.44000244140625;;106.9000015258789;;73.11000061035156;;34.4900016784668;;43.63999938964844;;60.349998474121094;ZUG, Switzerland and BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today presented data for CTX130™ for the treatment of relapsed or refractory renal cell carcinoma (RCC) as an oral presentation delivered by City of Hope’s Sumanta Pal, M.D. Additionally, together with collaborators at the Moffitt Cancer Center, the Company presented preclinical data in a poste;37.7599983215332;;22.959999084472656;;16.799999237060547;Exelixis, which announced it would move its headquarters to Alameda in 2017, now leases more than a half-million square feet there.In 2014, he was forced to lead a now-or-never meeting with the whole company. Here's what's happened since.ALAMEDA, Calif., November 10, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in November:;11.359999656677246;;50.93000030517578;;31.799999237060547;;36.54999923706055;NOVATO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Mardi Dier, Chief Financial Officer (CFO) and Executive Vice President, is leaving the company, effective November 15, 2022, to assume the dual role of CFO and Chief Business Development Officer at privately held ACELYRIN, INC. Ted Huizenga, Chief Accounting Officer, and Aaron Olsen, Senior Vice President of Corporate Strategy and Finance, will lead ongoing finance activities during the;53.970001220703125;The biotechnology company is seeing heavier trading volume in its stock on days when its shares trade higher.;;;27.350000381469727;;16.84000015258789;"Abcam plc (AIM: ABCM) (ABC: ABCM) (Nasdaq: ABCM) (""Abcam"" or the ""Company""), a global leader in the supply of life science research tools, today announces that the resolution put to its General Meeting held today for the cancellation of the admission of its Ordinary Shares to trading on AIM was passed.";7.559999942779541;Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.;10.300000190734863;;43.25;While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.;50.060001373291016;;52.880001068115234;;13.579999923706055;;39.369998931884766;;16.389999389648438;;23.59000015258789;
2022-11-14;285.29998779296875;Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.;82.8499984741211;;742.010009765625;Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.;160.3699951171875;BioNTech SE (NASDAQ: BNTX) said that its first mRNA manufacturing facility in Singapore will be operational in late 2023, with the facility also serving as the German company's regional headquarters. BioNTech has agreed to acquire a plant located in Tuas Biomedical Park, which is currently owned by Novartis AG (NYSE: NVS). Deal terms were not disclosed. The acquisition is part of BioNTech's expansion strategy to strengthen its footprint in Asia and will be its first such facility in the region.BioNTech SE, the German biotech that developed a widely used COVID-19 vaccine with Pfizer Inc, acquired a manufacturing facility in Singapore, its first in Asia, the company said on Monday.  The facility, bought from a Novartis unit, will be its first messenger ribonucleic acid, or mRNA, facility in Singapore and support its vaccines production for the Asia Pacific region, BioNTech said in a statement, without disclosing financial details.First mRNA manufacturing facility in Singapore will create regional manufacturing capacities in support of BioNTech’s growing pipeline of mRNA-based vaccines and therapeutics across Asia Pacific region for both clinical and commercial scale State-of-the art facility is expected to be fully operational in late 2023, and to create more than 100 jobsAcquisition marks the next step in BioNTech’s plans to establish a regional hub in the Asia Pacific Region MAINZ, GERMANY, and SINGAPORE, November 14,;234.57000732421875;Before next-generation sequencing (NGS) came along, children and families with rare and undiagnosed genetic diseases often faced years-long diagnostic odysseys.;306.0299987792969;Vertex Pharmaceuticals  is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.  Trading volume has been stable but an increasing pattern would be preferred.  The On-Balance-Volume (OBV) line shows a rise over the past year telling me that buyers of VRTX have been more aggressive than sellers.Vertex Pharmaceuticals (NASDAQ: VRTX) has a lot going on these days.  The biotech company is developing two candidates that could make it even stronger in the billion-dollar cystic fibrosis (CF) treatment market.  Vertex already is a leader in the market.;299.05999755859375;"Swiss pharmaceutical company Roche said the drug failed to slow patients' clinical decline, in contrast to positive results from Biogen earlier this year.By Yasin Ebrahim""While the (trial) results are not what we hoped, we are proud to have delivered a high quality, clear and comprehensive Alzheimer's dataset to the field,"" Roche said.Biogen Inc. shares rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer's disease failed to meet its main goal. German-listed shares of MorphoSys fell 30% on the news, while Roche was down 4% in Zurich as the company said Phase 3 studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia did not meet their primary endpoint of slowing clinical decline. Biogen, which lasBy Liz Moyer(Reuters) -Roche's Alzheimer's drug candidate could not be shown to slow dementia progression in two drug trials, leaving rivals Biogen and Eisai as leaders in a high-stakes race to launch a treatment for the memory-robbing disease.  Roche said in a statement on Monday that twin studies known as Graduate 1 and 2 had not reached their main goal of showing that the drug gantenerumab could preserve abilities such as remembering, solving problems, orientation and personal care in patients suffering from early stages of Alzheimer's disease.  Within each study, volunteers were randomly assigned to receive either the injectable antibody drug gantenerumab or a placebo.";202.97999572753906;;130.9499969482422;;213.47999572753906;;345.1300048828125;;2.680000066757202;;84.38999938964844;;38.939998626708984;;77.08999633789062;;44.810001373291016;;23.079999923706055;Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.;53.29999923706055;Intellia Therapeutics Inc (NASDAQ: NTLA) announced updated data from an ongoing Phase 1/2 study of NTLA-2002 for hereditary angioedema (HAE). Single doses of 25 mg (n=3), 50 mg (n=4), and 75 mg (n=3) of NTLA-2002 were administered via intravenous infusion. Administration of NTLA-2002 led to deep, dose-dependent reductions in plasma kallikrein. For the 25 mg and 75 mg cohorts, these deep reductions in plasma kallikrein were sustained through the observation period, which ranged from week 16 to we;118.05000305175781;;108.2300033569336;;73.81999969482422;;33.06999969482422;;41.83000183105469;;59.779998779296875;;36.95000076293945;;22.15999984741211;;16.709999084472656;;10.739999771118164;;49.7400016784668;BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United StatesCAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the first patient has been enrolled in the company’s BEACON trial. BEACON is an open-label, single-arm, multicenter, Phase 1/2 clinical trial designed to evaluate the safety and efficacy of BEAM-101 in adult;31.0;;35.25;;53.90999984741211;;;;26.850000381469727;;16.790000915527344;;7.25;The consensus price target hints at a 72% upside potential for Kodiak Sciences Inc. (KOD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.;10.130000114440918;;44.040000915527344;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Metagenomi today announced that the companies have entered a collaboration that will leverage Ionis' extensive expertise in RNA-targeted therapeutics and Metagenomi's versatile next-generation gene editing systems to pursue a mix of validated and novel genetic targets that have potential to expand therapeutic options for patients. The companies will jointly conduct research aimed initially at delivering investigational medicines for up to four genetIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 open-label extension (OLE) study evaluating the safety and efficacy of its investigational antisense medicine, donidalorsen, in patients with hereditary angioedema (HAE), a rare and devastating inflammatory disease. Interim data after all patients completed 1 year of treatment in the study showed a sustained reduction in HAE attacks and no new safety signals following treatment with donidalorsen. Treatment;52.02000045776367;;51.209999084472656;;14.270000457763672;;38.0;Twist Bioscience (TWST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;15.920000076293945;;22.790000915527344;
2022-11-15;283.6000061035156;;83.0;;728.72998046875;;163.72999572753906;Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTMX returned -2.43%, Advisor Class fund APDMX posted a return of -2.42%, and Institutional Class fund APHMX returned -2.41%, compared to a […]Moderna stock popped Monday after the company said its bivalent Covid booster led to a 15-fold jump in omicron-blocking antibodies.;238.49000549316406;Illumina Inc (NASDAQ: ILMN) is cutting 5% of its global workforce to realign its operating expenses to reflect the current macroeconomic environment. The company expects to take a restructuring charge, including expenses associated with optimizing facilities, in the fourth quarter of 2022 This charge will be excluded from non-GAAP financial metrics, the company said in its SEC filing. Illumina posted Q2 revenue of $1.12 billion, up 1% Y/Y and up 3% on a constant currency basis, almost in line wiIllumina Inc said on Monday it was cutting 5% of its global workforce to realign its operating expenses as stubborn inflation and a strong dollar weigh on the genetic sequencing equipment maker's business.  The company, which is in the process of launching its next-generation NovaSeq X DNA sequencing systems, has over 9,100 employees globally, according to its website.Illumina  is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function.  The shares are down sharply from its 2021 zenith but the charts have improved in recent months.;305.2799987792969;The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.Crispr Therapeutics (NASDAQ: CRSP) may be about to prove the strength of its gene-editing technology.  The biotech company is submitting its candidate to treat blood disorders to regulators in the U.S., Europe, and the U.K. this month.  If regulators give Crispr the nod, it may soon reach the major milestone of product commercialization.Amazon (NASDAQ: AMZN) is a leader in two markets set to grow in the double-digits this decade: e-commerce and cloud computing.  As a result, Amazon's reported declines in operating income.  Amazon has the market position and financial resources to weather these times.The stock could hit fresh highs, if past is prologue;299.7799987792969;Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA.Amazon.com is reportedly planning to cut about 10,000 workers, Berkshire Hathaway buys shares of Taiwan Semiconductor, Biden-Xi meeting adds to Chinese market optimism, crypto firms rush to calm fears, and other news to start your day.Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled.Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease.Earlier today, MorphoSys AG (NASDAQ: MOR) and its partner Roche Holdings AG (OTC: RHHBY) reported disappointing results from gantenerumab studies in mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia. Needham writes that with both GRADUATE studies failing to meet the primary endpoint, it removes a potential competitor for Eisai Ltd (OTC: ESALY) and Biogen Inc's (NASDAQ: BIIB) lecanemab. Roche's data was much awaited after Biogen and Eisai said the global Phase 3 conBy Yasin Ebrahim;207.7100067138672;CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 15, 2022--BeiGene today announced the launch of a new program, Talk About It: Cancer and Mental Health.;133.74000549316406;;214.2899932861328;;352.2900085449219;Bio-Techne Corporation (NASDAQ: TECH) today announced the opening of its new 52,000 square foot state-of-the-art product innovation and manufacturing facility. The expansion more than doubles the operational footprint at Bio-Techne's Wallingford, Connecticut site and provides a five-fold increase in Ella™ immunoassay cartridge production capacity. Ella is an automated multiplexing immunoassay system, that enables rapid and hands-free precision biomarker detection.;2.6700000762939453;"Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, ""Ginkgo""), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2022. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.";86.18000030517578;;40.5;;76.62000274658203;;44.279998779296875;;23.219999313354492;"Let's look at two examples investors should consider: Novavax (NASDAQ: NVAX) and Netflix (NASDAQ: NFLX).  Can a company that isn't yet profitable be considered ""cheap?"" In my view, the answer is yes, and Novavax is a good example.  Although there is still red on the bottom line, the biotech is generating revenue from its coronavirus vaccine, Nuvaxovid.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the Jefferies London Healthcare Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.";52.91999816894531;In this piece, we will take a look at the ten most promising gene therapy companies to watch. For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a revolutionary new technology that has followed the growing advances in computing power. The human body is estimated to […];114.7699966430664;;109.68000030517578;;72.5;;33.65999984741211;PASADENA, Calif., November 14, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 28, 2022, at 4:30 p.m. ET to discuss its financial results for the 2022 fiscal year ended September 30, 2022.;43.630001068115234;;61.0099983215332;Crispr Therapeutics (NASDAQ: CRSP) may be about to prove the strength of its gene-editing technology.  The biotech company is submitting its candidate to treat blood disorders to regulators in the U.S., Europe, and the U.K. this month.  If regulators give Crispr the nod, it may soon reach the major milestone of product commercialization.In this piece, we will take a look at the ten most promising gene therapy companies to watch. For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a revolutionary new technology that has followed the growing advances in computing power. The human body is estimated to […];38.709999084472656;;22.280000686645508;;16.799999237060547;;10.449999809265137;;49.18000030517578;In this piece, we will take a look at the ten most promising gene therapy companies to watch. For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a revolutionary new technology that has followed the growing advances in computing power. The human body is estimated to […];31.209999084472656;;35.459999084472656;;54.02000045776367;Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned 3.23%, Advisor Class fund APDSX posted a return of 3.27%, and Institutional Class fund APHSX returned 3.27%, compared to a […];;;27.350000381469727;;16.899999618530273;;8.010000228881836;;11.199999809265137;;43.52000045776367;It is the second drug-target deal disclosed by the four-year-old UC Berkeley spinout in the past five months.;57.2400016784668;;50.65999984741211;;14.489999771118164;;30.43000030517578;Shares of Twist Bioscience Corp. plunged 18.7% in premarket trading on Tuesday after Scorpion Capital, an activist short seller,;15.6899995803833;;22.579999923706055;
2022-11-16;283.7699890136719;The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.Today we will run through one way of estimating the intrinsic value of Amgen Inc. ( NASDAQ:AMGN ) by taking the...;82.87999725341797;FOSTER CITY, Calif., November 15, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:;735.6699829101562;;164.89999389648438;Moderna's (MRNA) Omicron-targeting bivalent COVID vaccines exhibit substantial antibody response compared with an original booster dose of Spikevax.;231.7899932861328;Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences:;305.44000244140625;Artisan Partners, an investment management company, released its “Artisan Value Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund underperformed its benchmark index. Its Investor Class fund ARTLX returned -7.04%, Advisor Class fund APDLX posted a return of -7.07%, and Institutional Class fund APHLX […]Two of the hottest stocks on the markets this year are Vertex Pharmaceuticals (NASDAQ: VRTX) and Occidental Petroleum (NYSE: OXY).  Vertex is up almost 37% so far in 2022 and Occidental is up an amazing 156%!  Here's why these two hot growth stocks could continue to do well in 2023.Moderna's (MRNA) Omicron-targeting bivalent COVID vaccines exhibit substantial antibody response compared with an original booster dose of Spikevax.;300.010009765625;Biogen had been a sinking ship following its Alzheimer’s flop, but positive results in September have changed the company’s trajectory.;205.77000427246094;;131.55999755859375;;211.99000549316406;;348.4800109863281;;2.319999933242798;"Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) (""Ginkgo""), which is building the leading platform for cell programing and biosecurity, today announced the sale of shares of its Class A common stock for gross proceeds of approximately $100 million to BTIG, LLC, as the underwriter in the registered public offering of those shares. In connection with this offering, Ginkgo has granted the underwriter a 30-day option to purchase up to an additional $15 million of shares of Class A common stock.Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) (""Ginkgo""),which is building the leading platform for cell programing and biosecurity, today announced that it intends to offer and sell $100 million of its Class A common stock in an underwritten public offering. As part of this offering, Ginkgo intends to grant the underwriter a 30-day option to purchase up to an additional $15 million of the shares of Class A common stock. All of the shares in the proposed offering are to be sold by Ginkgo.";85.83999633789062;;39.7400016784668;;76.70999908447266;;43.61000061035156;;21.469999313354492;;50.540000915527344;;112.66999816894531;;109.2699966430664;;72.33000183105469;;31.670000076293945;;42.54999923706055;;58.7599983215332;;35.380001068115234;;20.610000610351562;;16.850000381469727;"Regardless of whether you're new to investing or have experienced your fair share of bear market declines, this has proved to be an exceptionally challenging year.  Each of the three major U.S. stock indexes has eventually recouped their losses following sizable declines; and I have little doubt the same will prove true of the current bear market downturn at some point in the future.  The first genius stock you can buy with just $20 is telecom company AT&T (NYSE: T).";9.640000343322754;;47.790000915527344;;30.6299991607666;;35.220001220703125;;53.27000045776367;Halozyme's under-the-skin technology helps deliver some of the biggest moneymaking injections, fueling booming growth and prospects for much more. HALO stock is surging.;;;27.309999465942383;SAN FRANCISCO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first on the 2022 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. The ranking was based on Vir’s revenue growth of 125,138% between fiscal years 2018 and 2021. This is the second year in a row that Vir has been ranked for substantial growth, landing at number 70 in 20;16.610000610351562;;7.679999828338623;;10.960000038146973;;42.689998626708984;Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.;54.36000061035156;;49.90999984741211;;14.520000457763672;;28.290000915527344;"A day after synthetic biology and genomics company Twist Bioscience (NASDAQ: TWST) saw its shares rise 16.1%, they did a U-turn, falling 19.92% on Tuesday.  A report issued Tuesday by Scorpion Capital sent Twist's shares plummeting.  In its third-quarter report, released Aug. 5, Twist said it had $56.1 million in revenue, up 60.2%, year over year and 37.4% sequentially.SOUTH SAN FRANCISCO, Calif., November 15, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today addressed a misleading short-seller report issued by Scorpion Capital.Twist Bioscience Corp. stock slid 20% Tuesday, after a damning short seller report compared the company to the failed blood-testing startup Theranos, calling it a ""cash-burning inferno"" and a ""'synthetic biology' swindle.""";15.1899995803833;;22.3799991607666;OUR APPROACH TO CORPORATE RESPONSIBILITY
2022-11-17;287.29998779296875;Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works are included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Amgen Inc. (AMGN) and Automatic Data Processing, Inc. (ADP).;83.62000274658203;Here is how Gilead Sciences (GILD) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.For nearly 30 years, Dr. Amelie Ramirez has sought to move the needle on health disparities in the Latino community through a mix of education, research and community-based care.;739.0800170898438;- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - - CytomX to receive $30 million upfront payment with the potential for up to $2 billion in research, development, regulatory and sales-based milestones - SOUTH SAN FRANCISCO, Calif. and TARRYTOWN, N.Y., Nov. 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) toRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX) today announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX's Probody® therapeutic platform and Regeneron's Veloci-Bi® bispecific antibody development platform.;166.25999450683594;Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have initiated a Phase 1 study to evaluate the safety, tolerability, and immunogenicity of a next-generation COVID-19 vaccine candidate. The next-gen vaccine candidate aims to enhance SARS-CoV-2 T cell responses and potentially broaden protection against COVID-19. The candidate, dubbed BNT162b4, includes T cell antigen mRNA encoding for SARS-CoV-2 non-spike proteins and will be evaluated in combination with the companies' omicron BA.4/BA.5-adNEW YORK and MAINZ, GERMANY, NOVEMBER 16, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a Phase 1 study to evaluate the safety, tolerability and immunogenicity of a next generation COVID-19 vaccine candidate that aims to enhance SARS-CoV-2 T cell responses and potentially broaden protection against COVID-19. This candidate, BNT162b4, is composed of a T cell antigen mRNA encoding for SARS-CoV-2 non-spike proteins that are highly co;224.67999267578125;Access to cutting edge genomics technology is expanding beyond the walls of industry and the conventional classroom. Illumina and The Illumina Corporate Foundation have granted Genspace in-kind product donations and a cash grant totalling over $100,000 to build capacity for authentic genomics research and project-based learning for New York City youth.;309.8999938964844;Investing in biotech companies, especially relatively small ones, can be a double-edged sword.  With that in mind, let's look at two gene-editing-focused biotechs that could perform substantially better next year: CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE).  Right now, CRISPR Therapeutics is a clinical-stage biotech.;302.04998779296875;Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.;200.57000732421875;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 17, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has approved BRUKINSA® (zanubrutinib) for the treatment of adult patients with treatment-naïve (TN) or relapsed/refractory (R/R) CLL.";131.52999877929688;To get a sense of who is truly in control of Seagen Inc. ( NASDAQ:SGEN ), it is important to understand the ownership...;209.1199951171875;;331.6700134277344;Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell™ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamines, and trans-ISRIB (CEPT) cocktail. This publication outlines a robust and scalable workflow for cloning human pluripotent stem cells (hPSCs) that maximizes the viability of the cells using the Namocell Single Cell;2.1500000953674316;;87.43000030517578;;37.54999923706055;;77.95999908447266;WILMINGTON, Del., November 17, 2022--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November and December:;43.0099983215332;;20.790000915527344;;48.9900016784668;;115.05999755859375;;109.95999908447266;;72.47000122070312;;30.56999969482422;;42.54999923706055;In this article, we discuss the 10 biggest small-cap stocks in the Ken Fisher portfolio. If you want to see more stocks in this selection, check out Ken Fisher Super Stocks: 5 Biggest Small-Cap Stocks. US stocks have been beaten down by inflation recently. Jim Paulsen, chief investment strategist at The Leuthold Group, noted that […];57.63999938964844;Investing in biotech companies, especially relatively small ones, can be a double-edged sword.  With that in mind, let's look at two gene-editing-focused biotechs that could perform substantially better next year: CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE).  Right now, CRISPR Therapeutics is a clinical-stage biotech.;35.529998779296875;;20.110000610351562;;16.920000076293945;;9.649999618530273;;47.34000015258789;;28.959999084472656;;35.119998931884766;;52.7599983215332;;;;27.25;Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.;16.59000015258789;A great 'pick and shovel' play within the biotechnology sector;7.610000133514404;Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present virtually at the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022, at 9:10am Pacific Time (12:10pm Eastern Time).;10.630000114440918;;43.040000915527344;;53.029998779296875;;50.61000061035156;;14.079999923706055;;25.399999618530273;;14.979999542236328;;22.56999969482422;
2022-11-18;287.2900085449219;In a market like this, you always can find dividend stocks to buy. If you’re like most investors, you probably can’t wait for 2023. History books will show that 2022 was a huge disappointment for the stock market, although it did create some compelling opportunities for top-tier dividend stocks. First of all, dividend stocks are a huge benefit in any portfolio. Dividend stocks pay a quarterly or monthly payment to shareholders, who can use the money for income (a great idea for retirees). Or for;83.62000274658203;;736.72998046875;It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...CytomX Therapeutics Inc (NASDAQ: CTMX) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a collaboration and licensing agreement to create conditionally-activated bispecific cancer therapies. The collaboration will utilize CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi bispecific antibody development platform. Under the agreement, Regeneron and CytomX will collaborate on the discovery activities to identify and validate conditionally active bispecific antibodies. RegeneThe deal is the company's third to help larger pharmaceutical companies power up their bispecific antibodies while getting those drugs closer to cancer cells instead of healthy tissue.;166.38999938964844;Pfizer Inc. and German partner BioNTech SE said Friday a new analysis of data reviewing the immune response created by the omicron BA.4/BA.5 adapted bivalent COVID vaccine showed strong results against newer omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1. The data, which has been posted on the preprint server bioRxiv, show that the booster induces a greater increase in neutralizing antibody titers than the companies' original COVID-19 vaccine against these emerging omicron suPfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine.  Antibody levels against the subvariant rose nearly nine-fold in older adults, aged 55 and above, who received the Omicron shot compared to a roughly two-fold increase in participants with the original shot, according to data posted on online archive bioRxiv.One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron sublineages increased 3.2- to 4.8-fold compared to the companies’ original COVID-19 vaccineNeutralizing antibody titers against Omicron sublineages BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 increased 4.8- to 11.1-fold from pre-booster levels, following a 30-µg booster dose of the bivalent vaccineOmicron BA.5 continues to be the most prevalent sublineagPfizer and BioNTech said Thursday they've started testing a next-generation Covid shot, and both vaccine stocks reversed early declines.;220.55999755859375;"MENLO PARK, Calif., November 17, 2022--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced findings from a fundamental substudy of the Circulating Cell-free Genome Atlas (CCGA; NCT02889978) study, demonstrating that methylation had the most promising combination of cancer detection and prediction of cancer signal origin when compared with other evaluated approaches. This is the first rigorous and systematic comparison of various genomicIn this article, we discuss the top 15 companies in Alphabet Inc (GOOGL)’s investment portfolio. If you want to see more names in this portfolio, check out Alphabet Inc (GOOGL) Investment Portfolio: Top 5 Companies. GV, previously named Google Ventures, is the venture capital investment arm of Alphabet Inc. (NASDAQ:GOOG), which was founded in 2009 […]";314.6300048828125;Today we will run through one way of estimating the intrinsic value of Vertex Pharmaceuticals Incorporated...If you want some great investing advice, just listen to The Rolling Stones: You can't always get what you want, but time is on your side.  The biggest knock against MongoDB is that it isn't profitable yet.VRTX vs. TECH: Which Stock Is the Better Value Option?;302.8900146484375;;203.1300048828125;;131.75999450683594;;217.36000061035156;;328.6099853515625;;2.190000057220459;;88.30999755859375;;35.310001373291016;;77.44999694824219;;42.529998779296875;2022 has undoubtedly been a rough one for investors. Even accounting for the recent gains, all the major indexes are still down for the year and the backdrop of economic uncertainty still hovers menacingly. Such an environment makes it difficult to find the stocks which are primed to charge ahead, but one way to sort the wheat from the chaff is to follow in the footsteps of legendary stock pickers. And few are as well-versed in the investing game as billionaire Steve Cohen. Famous for his high-r;19.65999984741211;Shares of Novavax Inc. were up 2.4% in premarket trading on Friday after the company said its COVID-19 booster was authorized for adults in Canada who were previously immunized with Novavax's protein-based vaccine. The company's stock is down 85.4% this year, while the S&P 500 has declined 17.2%.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous booster in adults aged 18 and;48.779998779296875;;120.16000366210938;;112.0;;76.75;;30.719999313354492;;42.470001220703125;;57.7400016784668;;34.959999084472656;;19.8700008392334;;16.90999984741211;;9.510000228881836;;46.880001068115234;In this article, we discuss the top 15 companies in Alphabet Inc (GOOGL)’s investment portfolio. If you want to see more names in this portfolio, check out Alphabet Inc (GOOGL) Investment Portfolio: Top 5 Companies. GV, previously named Google Ventures, is the venture capital investment arm of Alphabet Inc. (NASDAQ:GOOG), which was founded in 2009 […];30.0;;35.9900016784668;;52.939998626708984;;;;27.020000457763672;"The Bay Area is heartily represented in Deloitte's annual list of fastest growing technology companies in North America. Nearly one-fifth of the companies on the firm's ""Technology Fast 500"" are based here — the top region in this year's rankings, followed by the Tri-State area (New York, New Jersey and Connecticut) at 12% of the list, New England at 6%, and Washington State, Texas and the Washington, D.";16.3799991607666;;7.579999923706055;;10.609999656677246;;43.09000015258789;;51.310001373291016;;51.939998626708984;;14.15999984741211;;24.809999465942383;"Twist Bioscience (TWST) delivered earnings and revenue surprises of 28.91% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?SOUTH SAN FRANCISCO, Calif., November 18, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2022 ended September 30, 2022.Shares of Twist Bioscience (NASDAQ: TWST) were crashing this week, plunging 37.2% as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.  The steep decline came after Scorpion Capital announced on Tuesday that it was short-selling the stock and released a scathing online report about the synthetic DNA maker.  Scorpion accused Twist Bioscience of being ""a cash-burning inferno that is not a going concern.""";15.149999618530273;;23.440000534057617;Health Literacy Month is about improving disease education and knowledge of available health resources. This month, we're starting with substance use disorder: a widely misunderstood but treatable condition.
2022-11-21;288.1600036621094;Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.;84.3499984741211;Lowe's, Gilead Sciences, Intuitive Surgical, Valero Energy and MercadoLibre are part of the Zacks top Analyst Blog.Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Gilead Sciences, Inc...;738.97998046875;;158.41000366210938;Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.;224.4199981689453;NORTHAMPTON, MA / ACCESSWIRE / November 21, 2022 / Illumina: Nearly everyone is a carrier for some kind of genetic disorder.1 (Probably even you.) Being a carrier means you inherited an abnormal copy of a gene from one parent, but you show no symptoms ...;316.20001220703125;The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.Dow Jones futures: The market rally found support but new buys struggled. Here are seven investing rules to follow. Tesla stock hit fresh bear-market lows.;301.6300048828125;;194.64999389648438;;123.4800033569336;;206.64999389648438;;332.05999755859375;;2.0899999141693115;;88.51000213623047;;35.29999923706055;;78.41000366210938;;42.33000183105469;;18.950000762939453;;48.40999984741211;;118.30999755859375;;110.55000305175781;;74.54000091552734;;29.84000015258789;;43.20000076293945;;55.540000915527344;;34.880001068115234;;19.639999389648438;;16.81999969482422;;8.789999961853027;;45.40999984741211;;29.360000610351562;;34.369998931884766;The nature of investing is that you win some, and you lose some. Unfortunately, shareholders of Ultragenyx...;53.290000915527344;;;;26.700000762939453;;16.190000534057617;;7.409999847412109;;10.399999618530273;;42.459999084472656;;43.08000183105469;;52.08000183105469;;14.0600004196167;;25.610000610351562;;14.779999732971191;;23.739999771118164;
2022-11-22;287.04998779296875;;85.2300033569336;Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.;749.22998046875;"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of...";158.72999572753906;;222.1699981689453;;321.4800109863281;The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.Today we will run through one way of estimating the intrinsic value of Vertex Pharmaceuticals Incorporated...;306.7200012207031;;176.5399932861328;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 22, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation session at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans. ALPINE is a global Phase 3 trial comparing BRUKINSA (zanubrutinib) with IMBRUVICA® (ibrutinib) in pat";124.52999877929688;;209.41000366210938;;332.4700012207031;;2.0;;91.18000030517578;;35.15999984741211;;78.2699966430664;;42.22999954223633;;16.920000076293945;"Novavax said on Monday that it had issued a notice to Gavi for terminating the agreement with immediate effect, citing the alliance's failure to procure the doses it had agreed to buy in May last year for the COVAX facility, a global vaccine distribution program.  ""It is clear that Novavax will not be able to meet its commitment to manufacture"" the doses under the agreement for COVAX before the end of 2022, a Gavi spokesperson told Reuters.Global vaccine alliance Gavi said on Tuesday it was not in breach of a deal to buy Novavax's COVID-19 vaccine and that it reserved all rights, including the recovery of advance payments to the company.  Novavax said on Monday it delivered a notice to Gavi to terminate the COVID-19 vaccine sale agreement with immediate effect, citing the alliance's failure to procure the 350 million doses it had agreed to buy in May last year for the COVAX facility, a global vaccine distribution program.  ""It is clear that Novavax will not be able to meet its commitment to manufacture"" the doses under the agreement for COVAX before the end of 2022, a Gavi spokesperson told Reuters.Reuters China To Reportedly Impose Over $1B Fine On Jack Ma's Ant Group Ending 2-Year Long Regulatory Overhaul Ending Jack Ma's Ant Group's two-year-long regulatory feud, Chinese authorities will reportedly impose a fine of more than $1 billion on the billionaire's fintech company. China's central bank – which has been driving the revamp at Ant after the Xi Jinping-led administration scuttled the company's $37 billion IPO at the last minute in 2020 – is the regulator readying the fine. Warren BuNovavax Inc (NASDAQ: NVAX) delivered a written notice to Gavi, the Vaccine Alliance, terminating with immediate effect an agreement for the sale of its COVID-19 vaccine to low- and middle-income countries. The company cited Gavi's failure to procure the 350 million doses it had agreed to buy in May last year for the COVAX facility. The termination has not resulted in any penalties, the company said in its regulatory filing. Related: Canada Approves Novavax's COVID-19 Vaccine As Booster In AdultsIt's been an especially difficult year for the growth-focused Nasdaq Composite (NASDAQINDEX: ^IXIC).  Innovative businesses that offer industry-changing potential can deliver big gains when the next bull market inevitably arrives.  What follows are three remarkable growth stocks beaten down more than 90% from their respective all-time highs that can double your money by 2025.Novavax Inc said on Monday it had delivered a written notice to Gavi, the Vaccine Alliance, terminating with immediate effect an agreement for the sale of the company's COVID-19 vaccine to low- and middle-income countries.  The company cited Gavi's failure to procure the 350 million doses it had agreed to buy in May last year for the COVAX facility.  The COVAX facility is a joint program between Gavi, the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations for the equitable distribution of COVID vaccines in poorer countries.";48.90999984741211;;120.80000305175781;;111.9800033569336;;86.11000061035156;;29.549999237060547;PASADENA, Calif., November 21, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:;43.56999969482422;;55.459999084472656;;33.38999938964844;;19.549999237060547;;17.1200008392334;;8.529999732971191;;45.41999816894531;;30.329999923706055;;34.650001525878906;;53.630001068115234;;;;27.40999984741211;Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.;15.75;;7.510000228881836;;10.619999885559082;;42.20000076293945;;40.70000076293945;ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all patients and 5.7 months in patients with ESR1 mutant tumors support the initiation of two Phase 3 registrational trials NEW HAVEN, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced initial results from the Phase 2 cohort expansion portion (VERITAC) of a phase 1/2 study with ARV-471,;52.869998931884766;;13.979999542236328;;25.209999084472656;;15.039999961853027;;24.5;National Family Caregivers Month begins today. Supporting a loved one with a serious mental illness is important, but it is also critical for caregivers to make time to prioritize their own wellbeing.
2022-11-23;283.3999938964844;;85.41999816894531;Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Jacquie's journey with cancer began with non-Hodgkin lymphoma when she was just 15 years old.Gilead Sciences' first-in-class cancer drug and GILD stock are finally hitting their stride. The oncology business is growing bullishly.Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.GILD vs. HALO: Which Stock Is the Better Value Option?;735.3599853515625;Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.;156.22999572753906;In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […];222.0800018310547;;316.1600036621094;GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.;303.45001220703125;Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.Here is how AMN Healthcare Services (AMN) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.;181.7899932861328;;123.95999908447266;;208.49000549316406;;336.32000732421875;;1.9800000190734863;;97.79000091552734;BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced advancements in the U.S. Food and Drug Administration (FDA) review of the Biologics License Application (BLA) of ROCTAVIAN™ (valoctocogene roxaparvovec AAV gene therapy) for adults with severe hemophilia A. The Company was recently notified by the FDA that after further consideration, at this time, the Agency no longer plans to hold an advisory committee meeting to discuss the BLA for ROCTAVIAN that is currently under review. Previously, the;36.439998626708984;;77.76000213623047;;43.09000015258789;;17.030000686645508;"Novavax (NASDAQ: NVAX) shares were down more than 16% in late-afternoon trading.  On Tuesday, a dispute between the biotech maker of vaccines to treat infectious diseases and global nonprofit Gavi sent Novavax's shares dropping.  On Monday, Novavax canceled its contract with Gavi,  saying the nonprofit had breached an agreement to purchase, in advance, 350 million doses of Nuvaxovid, Novavax's COVID-19 vaccine.Each side is claiming that the other breached an agreement for Novavax to supply 350 million doses by the end of 2022.Global vaccine alliance Gavi on Tuesday rejected Novavax's  claim that the group had breached an advance purchase agreement to procure 350 million doses of the company's COVID-19 vaccine.  Novavax said on Monday that it had issued a notice to Gavi for terminating the agreement with immediate effect, citing the alliance's failure to procure the doses it had agreed to buy in May last year for the COVAX facility, a global vaccine distribution program.  ""It is clear that Novavax will not be able to meet its commitment to manufacture"" the doses under the agreement for COVAX before the end of 2022, a Gavi spokesperson told Reuters.Is Novavax stock a buy after the Covid vaccine maker handily beat third-quarter sales estimates? Is NVAX stock a buy right now?";49.88999938964844;;118.97000122070312;;114.73999786376953;CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 2:15 p.m. E.T. The fireside chat will be held virtually. The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s we;95.8499984741211;Mirati Therapeutics Inc (NASDAQ: MRTX) is reportedly amid fresh takeover interest from large pharmaceutical companies ahead of updates on its drug pipeline. For some time, the cancer-focused company has been weighing strategic options, including a potential sale. Related: Mirati's Adagrasib Shows Promising Efficacy In KRAS Mutated Colorectal Cancer. Mirati is working with an adviser, and larger drugmakers have been studying the merits of a transaction, Bloomberg reported. But currently, no forma(Bloomberg) -- Cancer drugmaker Mirati Therapeutics Inc. is attracting fresh takeover interest from large pharmaceutical companies ahead of updates on its drug pipeline, people with knowledge of the matter said. The stock rose as much as 16% on the news. Most Read from BloombergViolent Protests Erupt at Apple’s Main iPhone Plant in ChinaHow Bad Will Housing Get? The Chill Gripping a Once-Hot Market Offers a TestTrump Had Losses of $900 Million in Two Years, Jury ToldMalaysia Latest: Muhyiddin Tu;29.399999618530273;We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...;44.83000183105469;Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM). AYVAKIT was designed to potently and selectively inhibit D816V mutant KIT, the underlying cause of SM in about 95 percent of cases.;55.029998779296875;;33.380001068115234;;19.649999618530273;;16.860000610351562;;8.789999961853027;;45.70000076293945;;30.420000076293945;;34.59000015258789;NOVATO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Piper Sandler Annual Healthcare Conference on Tuesday, November 29, 2022, at 10:00 AM ET in New York. The live and archived webcast of;54.349998474121094;GILD vs. HALO: Which Stock Is the Better Value Option?;;;27.25;;16.079999923706055;;7.389999866485596;;10.350000381469727;;41.25;;39.560001373291016;Arvinas Inc (NASDAQ: ARVN) announced initial results from the Phase 2 cohort expansion portion of a phase 1/2 study with ARV-471 in collaboration with Pfizer Inc (NYSE: PFE) for locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. This disclosure was initially planned for December 8. However, the 2022 San Antonio Breast Cancer Symposium (SABCS) incorrectly published the abstract, omitting a key safety data table, and inadv;51.189998626708984;The consensus price target hints at a 32.7% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.;14.0;;25.530000686645508;SOUTH SAN FRANCISCO, Calif., November 23, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will host a fireside chat and one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 4:20 p.m. Eastern Time.;15.0;;24.270000457763672;Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 29, 2022 at 2:40 p.m. ET (7:40 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.At Alkermes, we strive to foster a culture of respect, inclusion and equality, supported by our Code of Business Conduct and Ethics and our other corporate policies and programs.
2022-11-25;283.739990234375;;86.26000213623047;Thanks in no small measure to Vanguard founder Jack Bogle, it's easy buy a low cost index fund, which should provide...;736.22998046875;Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.;154.85000610351562;;218.99000549316406;;312.9800109863281;Cathie Wood remains optimistic. Her ARK Invest exchange-traded funds (ETFs) have continued to scoop up stocks during the steep downturn this year. But she's apparently not optimistic about all of her ARK holdings.The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.;305.1499938964844;Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;174.97000122070312;;123.44000244140625;;212.72000122070312;;338.9700012207031;;1.9900000095367432;;96.91999816894531;The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.;35.84000015258789;;78.26000213623047;Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.;42.650001525878906;;16.540000915527344;Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.;49.68000030517578;;122.1500015258789;The S&P 500 still faces its 200-day line with key economic data looming. Tesla FSD Beta gets a wide release after TSLA stock jumped from bear market lows.;114.56999969482422;;98.62000274658203;;29.5;;44.88999938964844;;54.9900016784668;;31.719999313354492;;19.829999923706055;;16.940000534057617;;8.579999923706055;;44.279998779296875;;29.969999313354492;;35.720001220703125;;54.66999816894531;Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.;;;27.229999542236328;;15.859999656677246;;7.539999961853027;;10.109999656677246;;41.560001373291016;;40.34000015258789;"As the year winds toward its close, it’s time once again to engage in the age-old practice of picking out the changes that lie waiting in the year ahead. Wall Street’s stock pros are hardly immune from this; every year, they tag their top picks from the equity markets for the calendar change, and this year is no exception. The analysts are looking ahead toward the post-New Year market landscape, and picking out potential winners for investors to consider. We've opened up the database at TipRanks";52.22999954223633;;13.520000457763672;;25.440000534057617;;15.109999656677246;;24.200000762939453;
2022-11-28;282.6199951171875;;85.20999908447266;;741.47998046875;;161.49000549316406;;216.91000366210938;;315.29998779296875;;291.8999938964844;;179.2899932861328;;121.22000122070312;;209.1999969482422;;82.5999984741211;Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Fifth Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 8:50 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;1.840000033378601;;98.66000366210938;;34.720001220703125;;77.83000183105469;;41.5;;16.639999389648438;;48.2599983215332;;121.66000366210938;;118.12999725341797;Shares of Sarepta Therapeutics Inc. were up 4.6% in premarket trading on Monday after the company said U.S. regulators accepted its application for accelerated approval of SRP-9001, its experimental treatment for Duchenne muscular dystrophy. The Food and Drug Administration is expected to make a decision whether to approve SRP-9001 by May 29. Sarepta's stock has gained 27.2% so far this year, while the S&P 500 has declined 15.5%.– Regulatory action date of May 29, 2023 – SRP-9001 would be the first gene therapy for Duchenne, a one-time treatment designed to treat the underlying cause of DMD by delivering a functional shortened dystrophin to muscle CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Biologics License Application (;95.66999816894531;Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced a late-breaking presentation of concurrent combination results of adagrasib and pembrolizumab in first line advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Findings will be presented on December 7 at the 2022 European Society of Medical Oncology Immuno-Oncology (ESMO IO) Annual Congress as an oral presentation from 2:15 p.m.-2:25 p.m. CET / 8:15 a.m.-8:25 a.m;28.0;;45.22999954223633;;53.34000015258789;;31.049999237060547;;19.260000228881836;;16.790000915527344;;8.100000381469727;;43.18000030517578;;28.829999923706055;;35.400001525878906;;56.470001220703125;In this article, we discuss 11 best diabetes stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Diabetes Stocks To Buy Now. The global diabetes market is segmented based on the type, drug class, and devices used to treat the condition. Based on the type, the […];;;26.950000762939453;;16.8700008392334;;7.150000095367432;;9.720000267028809;;40.33000183105469;;38.97999954223633;;52.15999984741211;;13.5600004196167;;25.040000915527344;;14.770000457763672;;23.969999313354492;
2022-11-29;281.989990234375;;85.76000213623047;Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).;736.0800170898438;;163.61000061035156;Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.;208.57000732421875;;316.3299865722656;;291.4100036621094;;179.86000061035156;;117.37000274658203;;204.7899932861328;;81.76750183105469;;1.850000023841858;;97.12000274658203;;34.9900016784668;;77.80000305175781;;41.189998626708984;;16.829999923706055;Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an updated Emergency Use Listing (EUL) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series of two doses in adolescenNovavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.;48.0;;121.73999786376953;;117.0999984741211;The FDA said Monday it will perform a speedy review of Sarepta Therapeutics' muscular dystrophy gene therapy, and SRPT stock jumped.;88.76000213623047;;29.989999771118164;Q4 2022 Arrowhead Pharmaceuticals Inc Earnings CallPASADENA, Calif., November 28, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022. The company is hosting a conference call today, November 28, 2022, at 4:30 p.m. ET to discuss the results.;46.599998474121094;;52.880001068115234;;33.689998626708984;;19.84000015258789;;16.440000534057617;;8.710000038146973;;43.61000061035156;;30.18000030517578;;35.66999816894531;;57.04999923706055;;;;27.260000228881836;;15.329999923706055;;7.139999866485596;;9.449999809265137;;38.7599983215332;;38.290000915527344;;52.849998474121094;;13.359999656677246;;24.600000381469727;;14.670000076293945;;24.020000457763672;Alkermes respects the culture, customs and values of the people in the communities in which we operate.
2022-11-30;286.3999938964844;;87.83000183105469;Biotech giant Gilead Sciences (NASDAQ: GILD) is a member of this elite club, having seen its shares rise by 15% year to date.  Let's consider two reasons why Gilead Sciences is worth serious consideration heading into the new year.  Gilead Sciences' most important unit by some margin remains its HIV business.Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.;751.7000122070312;"The FDA has accepted Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) supplemental marketing application seeking approval for Evkeeza (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies for children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). The FDA target action date is March 30, 2023. HoFH is an ultra-rare inherited condition that occurs when two copies of the FH-causing genes are inherited, resulting in dangerously high levels of low-density lipoproteThe UK's Medicines and Healthcare Regulatory Agency (MHRA) warned of some new and severe eye-related side effects following the use of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) atopic dermatitis and asthma treatment Dupixent (dupilumab). Dupixent is already associated with cases of conjunctivitis and allergic conjunctivitis, dry eye, and infrequent cases of keratitis and ulcerative keratitis. The MHRA added that health professionals should look for any of these eRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Evkeeza® (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). The FDA target action date is March 30, 2023.It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of...A couple of stocks that have been hot buys this year are Regeneron Pharmaceuticals (NASDAQ: REGN) and T-Mobile US (NASDAQ: TMUS).  Unlike the S&P 500, which is down about 17% this year, these two stocks have generated positive returns of 15% or more.  Here's a closer look at why both of these stocks can still soar higher in 2023.";167.02000427246094;The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.BioNTech SE (NASDAQ: BNTX) and Ryvu Therapeutics S.A. have entered into a multi-target research collaboration consisting of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvu's STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations. In addition, BioNTech and Ryvu will jointly undertake drug discovery and research projects to develop multiple small molecule programs directed at exclusive targets sThe companies enter a multi-target research collaboration to develop multiple small molecule programs targeting immune modulation in cancer and potentially other disease areas based on targets selected by BioNTech In addition to these programs, BioNTech will receive a global, exclusive license to develop and commercialize Ryvu’s STING agonist portfolio as standalone small moleculesRyvu will receive €40 million from BioNTech, comprised of a €20 million upfront payment and an equity investment ofIn this article, we will discuss the 12 best falling stocks to buy now. If you want to explore similar stocks, you can read 5 Best Falling Stocks to Buy Now. We are approaching the end of the year which has been terrible for the markets. Fears of recession, the Ukraine war, supply chain woes, […];218.0800018310547;Emirati scientists, clinicians, and dignitaries attended the opening of the Illumina Solutions Center in Dubai on November 8.;316.3999938964844;;305.1700134277344;"""These peer-reviewed, published results show lecanemab will provide patients more time to participate in daily life and live independently,"" the Alzheimer's Association said.Japan's Eisai presented full data on a new Alzheimer's drug, but without mentioning the U.S. pharmaceutical company, its partner on the treatment.According to detailed data, Eisai Limited (OTC: ESALY) and Biogen Inc's (NASDAQ: BIIB) closely watched trial of an experimental Alzheimer's drug slowed cognitive decline but may carry a risk of side effects for certain patients. Lecanemab was associated with a type of brain swelling in 12.6% of trial patients, a side effect previously seen with similar drugs. 17.3% of patients had microhemorrhages in the brain— a symptom linked to two recent deaths of people receiving lecanemab in a follow-on stDetailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adverse events like brain hemorrhage.Trading volume has picked up in the past three months to help confirm the price gains.  The math-driven On-Balance-Volume (OBV) line shows a rising pattern from June telling us that buyers of the stock have been more aggressive than sellers.  Yes, the OBV line can lead prices!Shares in pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of the lecanemab drug.U.S. stock index futures edged higher on Wednesday, with those of the Nasdaq rising the most on gains in Tesla shares, while investors treaded cautiously ahead of comments from Federal Reserve Chair Jerome Powell later in day.  Powell's speech will be closely watched for signs of a slowdown in the pace of interest rate hikes by the central bank as well as to assess the general health of the U.S. economy.  ""Fed Chair Powell is speaking, but past comments have done little other than chant 'hike, hike, hike',"" said Paul Donovan, chief economist, UBS Global Wealth Management.Biogen Inc. stock rose 3% in premarket trade Wednesday, after a new study was unveiled late Tuesday that showed the company's experimental Alzheimer's drug being developed with Japan's Eisai moderately reduced cognitive decline after a year and a half. The study assessing lecanemab as a treatment for people with early forms of Alzheimer's disease was published Tuesday night by the New England Journal of Medicine. Eisai also presented the full findings from the trial on Tuesday night at the CliniStock futures nudge higher will Powell, jobs data in focus; Powell speech may challenge Fed's new rate hike outlook; Sam Bankman-Fried set for DealBook summit appearance after FTC collapse; Biogen shares jump after promising Alzheimer's treatment data and HPE shares surge after Q4 earnings beat, solid near-term outlook.Japan's Eisai, which is developing the treatment with the U.S. pharmaceutical company, said in a September press release that the therapy worked surprisingly well.By Peter NurseAn experimental Alzheimer's drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of serious side effects for certain patients, according to detailed data presented on Tuesday.  The drug, lecanemab, was associated with a dangerous type of brain swelling in nearly 13% of patients in the trial that spanned 18 months and enrolled nearly 1,800 participants with early-stage Alzheimer's.  Some patients also experienced bleeding in the brain, with five suffering macrohemorrhages and 14% suffering microhemorrhages - a symptom linked to two deaths of people receiving the drug in a follow-on study.The new Alzheimer's disease drug made by Eisai Inc. and Biogen Inc. is capable of slowing cognitive decline by 27%, as confirmed by a peer-reviewed study.";191.61000061035156;;121.38999938964844;;220.58999633789062;;84.98999786376953;;1.9900000095367432;;100.9800033569336;;38.65999984741211;;79.66999816894531;;44.95000076293945;;16.489999771118164;The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.;51.459999084472656;;127.05999755859375;;122.80999755859375;The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.;91.37999725341797;;32.20000076293945;By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Sells Royalty Interest in Olpasiran for $250 Million On November 9, 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that Royalty Pharma had acquired a royalty interest in Amgen’s olpasiran for $250 million in cash upfront and up to $160 million in additional potential clinical, regulatory, and salesArrowhead provided a bullish update for its midstage liver disease treatment on Monday, pushing ARWR stock to rocket Tuesday.;47.790000915527344;;54.790000915527344;;38.560001373291016;;20.81999969482422;;17.079999923706055;Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks.;9.369999885559082;;46.189998626708984;CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the BofA Securities 2022 Virtual Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 2:55 p.m. ET. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days follow;31.90999984741211;;36.29999923706055;;57.2599983215332;By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Third Quarter 2022 Financial and Operational Results On November 9, 2022 Lipocine (NASDAQ:LPCN) filed its third quarter 2022 Form 10-Q and posted its earnings release for the quarter ending September 30, 2022. In addition to the events listed below, the company attended several investor and scientific conferences since our;;;28.219999313354492;;16.040000915527344;;7.380000114440918;The consensus price target hints at an 87.4% upside potential for Kodiak Sciences Inc. (KOD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.;10.75;;40.790000915527344;;41.040000915527344;;54.220001220703125;Intra-Cellular-Therapies develops treatments for people with neuropsychiatric and neurologic disorders like their medicine for bipolar disease. Let's check out the charts and indicators.     In this daily bar chart of ITCI, below, we can see an improving picture.Here is how DICE Therapeutics, Inc. (DICE) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.;12.869999885559082;Antibody machine AbCellera Biologics is the IBD Stock Of The Day as ABCL stock eyes a potential entry following a brief pullback.;27.350000381469727;;15.579999923706055;;24.780000686645508;
2022-12-01;285.94000244140625;;87.9000015258789;Dancing has always been a part of Shadae McDaniel's life.Although hard, it's not impossible, there are healthcare companies with solid earnings and dividend growth that can be had for less than a bill with Ben Franklin's picture on it.  Gilead Sciences (NASDAQ: GILD) and Bristol Myers Squibb (NYSE: BMY) have posted triple-digit percentage gains over the past 10 years in revenue, earnings per share (EPS), and total return price.  On top of that, shares of Gilead and Bristol can both be bought for less than $90 a share, at least for the time being.;761.239990234375;The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data across its oncology pipeline will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) Congress 2022 from December 7 to 9 in Geneva, Switzerland. Presentation highlights include first clinical results and new exploratory analyses from trials investigating LAG-3 inhibitor fianlimab and/or PD-1 inhibitor Libtayo® (cemiplimab) in non-small cell lung cancer (NSCLC), melanoma and cervica;169.47000122070312;BioNTech (BNTX) signs a research collaboration agreement with Ryvu Therapeutics to develop small molecule programs targeting immune modulation in cancer and other diseases. Stock up.;220.86000061035156;;320.760009765625;;301.8500061035156;"After a year of more frequent climate-induced extreme weather, the Center for Climate, Health, and the Global Environment at Harvard T.H.Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six months.Biogen stock surged Wednesday after partner Eisai unveiled Alzheimer's treatment test results that two doctors reportedly described as ""magnificent.""Positive study results for Eisai-Biogen lifted the prospects for its medication and one from Eli Lilly—although regulators will have to weigh risks.Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD). William Blair analyst says that overall the data is robust and of high impact to both the AD clinician community and regulators and CMS as the next three to nine months carry critical regulatory and reimbursement milestones for the anti-amyloid therapy drug class. Related: Open Questions On Safety Lingers After Eisai-BResults of clinical trial point to a stable future for Eisai and Biogen's lecanemab once the therapy is approved by the Food and Drug Administration.";194.57000732421875;"Shares of Chinese pharmaceutical BeiGene (NASDAQ: BGNE) rose as high as 12.8% in early trading on Wednesday.  BeiGene didn't make any big announcements, and its earnings report was back on Nov. 9, so the move was curious.  Most likely, it was just a little bit of a return to normalcy after the stock took a beating when there were protests in China regarding the country's strict lockdown ""zero tolerance"" provisions regarding COVID-19.";121.0199966430664;BOTHELL, Wash., December 01, 2022--Seagen Inc. (Nasdaq: SGEN) today announced new data for ADCETRIS® (brentuximab vedotin) will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 10-13, 2022. The abstracts, including five oral presentations, highlight updated and interim efficacy and safety clinical trial results for ADCETRIS in both early- and advanced stage settings of classical Hodgkin lymphoma (cHL), and in patients with;220.25;"CAMBRIDGE, Mass., December 01, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2022 Top Places to Work in the ""Largest Employer"" category. This marks the second year in a row Alnylam’s takes the top spot in the Largest Employer category (> 1,000 employees).";86.41000366210938;Asuragen, a Bio-Techne brand (NASDAQ: TECH) and Oxford Nanopore Technologies plc (Oxford Nanopore) (LSE: ONT), today announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening. Asuragen will leverage its gold-standard PCR technology with Oxford Nanopore's any-read-length DNA sequencing capabilities to develop the first sequencing system to identify the most challenging yet high prevalence carrier genes in a singThe top healthcare stocks include Azenta Inc. for best value, McKesson Corp. for fastest growth, and Signify Health Inc. for most momentum.;1.9800000190734863;;103.0199966430664;;39.56999969482422;10x Genomics, Inc. ( NASDAQ:TXG ), might not be a large cap stock, but it saw a significant share price rise of over...;80.68000030517578;;46.0;Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?;16.850000381469727;;45.79999923706055;CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share. Intellia also granted the underwriter a 30-day option to purchase up to an additional 982,532 shares of its commonCAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that it has commenced an underwritten public offering of $250 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock o;126.30999755859375;;122.9800033569336;CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 42 individuals hired by Sarepta in November 2022. The equity awards were approved in accordance with Nasdaq Listin;91.5;;32.02000045776367;;47.4900016784668;;54.34000015258789;"ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 2022 BMO Growth & ESG Conference on Wednesday, December 7, 2022, at 1:00 p.m. ET. A replay of the webcast will be archived for 14 days following the presentation on the ""Events & Pr";36.150001525878906;;20.34000015258789;;17.040000915527344;ALAMEDA, Calif., November 30, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the virtual JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022 at 12:00 pm ET / 9:00 am PT.;9.229999542236328;;45.83000183105469;;31.200000762939453;;37.810001373291016;;57.400001525878906;;;;27.030000686645508;;16.75;;7.289999961853027;;11.079999923706055;;40.20000076293945;;39.75;;53.45000076293945;;13.180000305175781;VANCOUVER, British Columbia & NEW HAVEN, Conn., December 01, 2022--AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera’s antibody discovery engine with Rallybio’s clinical and commercial expertise in rare diseases to identify optimal clinical candidates and ulti;27.860000610351562;;15.34000015258789;;25.200000762939453;Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference on Wednesday, Dec. 7, 2022 at 8:00 a.m. ET (1:00 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.Our Wilmington, Ohio site was named to the 2022 Healthiest Employers of Ohio list! We are proud to receive this award that reflects our commitment to our employees' well-being and ensuring Alkermes is a great place to work.
2022-12-02;285.510009765625;;89.02999877929688;Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;766.3900146484375;;169.74000549316406;But a bigger problem for Beijing may be the number of elderly Chinese who have yet to get their booster shots.;218.75999450683594;"The business communications company and the biotechnology business said they are responding to ""challenging"" economic conditions.";321.3699951171875;;298.8999938964844;Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity.Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;201.86000061035156;;122.41000366210938;;234.39999389648438;Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;84.69000244140625;;1.9900000095367432;"Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) (""Ginkgo""), which is building the leading platform for cell programming and biosecurity, today announced that in connection with its transaction with Bayer CropScience LP (""Bayer"") on October 17, 2022, Ginkgo granted 9,868,143 restricted stock units to 139 new employees, and in connection with its acquisition of Zymergen Inc. (""Zymergen"") on October 19, 2022, Ginkgo granted 8,305,110 restricted stock units to 179 new employees. The restricted stock unit";105.55999755859375;Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;38.970001220703125;;83.12999725341797;WILMINGTON, Del. & HONG KONG, December 02, 2022--Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast AsiaIncyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;46.36000061035156;;16.520000457763672;Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.;46.119998931884766;;126.80999755859375;Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A-related epilepsies. Data was collected from more than 17,000 patients through Invitae Corporation's Behind the Seizure® Program, of which Neurocrine Biosciences is a sponsor. The clinical characteristics of patients with pathogenic or likely pathogenic SCN8A variants were evaWith analysts expecting a whopping 3,755% Q4 growth, HF Sinclair leads this list of 24 of today's fastest-growing stocks.;126.25;;96.25;Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that based on the results of an interim analysis on overall survival, the registrational Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 in patients with second or third line non-squamous non-small cell lung cancer (NSQ-NSCLC) who have acquired resistance to prior therapy with chemotherapy and immune checkpoint inhibitor therapy (SAPPHIRE) will continue to the stud;33.93000030517578;;48.93000030517578;Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;54.5;CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;36.59000015258789;;20.90999984741211;;17.389999389648438;Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;9.470000267028809;;46.81999969482422;CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared the Investigational New Drug (IND) application for BEAM-201 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LL). BEAM-201 is a potent and specific anti-C;32.630001068115234;;40.16999816894531;;59.439998626708984;;;;27.610000610351562;Vir Biotechnology (NASDAQ: VIR) and Axonics (NASDAQ: AXNX) are two of the fastest-growing healthcare companies in terms of revenue.  Vir raised $142.9 million when it went public with an initial public offering (IPO) in 2019, while Axonics raised $120 million with its IPO in 2018.  The key to both companies' success has been impressive innovation, which should serve them well beyond this year's success.;17.0;;7.460000038146973;;10.65999984741211;;40.31999969482422;;41.38999938964844;;54.08000183105469;;12.710000038146973;;28.5;;15.760000228881836;;26.09000015258789;This Giving Tuesday, we are thankful for the employees who take time to support people in our communities who are in need.
2022-12-05;284.9100036621094;;87.9800033569336;Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.;755.4500122070312;;166.7100067138672;Pfizer Inc and its German partner BioNTech SE said on Monday they have submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization of their Omicron-adapted COVID-19 vaccine booster  for children aged 6 months through 4 years.  If authorized, children would receive the primary series consisting of two doses of the original Pfizer-BioNTech COVID vaccine and one shot of the Omicron-adapted bivalent vaccine, the company said.  The bivalent COVID-19 vaccine, which targets the original strain and the BA.4/BA.5 Omicron subvariants, is currently authorized as a booster dose for ages 5 years and older in the United States and the European Union (EU).;213.86000061035156;EU antitrust regulators on Monday sent a charge sheet to U.S. life sciences company Illumina outlining proposed measures to unwind its acquisition of Grail, three months after they blocked the deal on concerns that it would hurt competition.  Illumina completed the deal in August last year without first waiting for EU regulatory approval.  The European Commission in its September decision said the company failed to offer adequate remedies to allay its worries.;317.6000061035156;GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.;292.75;SOD1-ALS is a rare, genetic form of ALS,1 comprising approximately 2% of people with ALS2If approved, tofersen would be the first treatment to target a genetic cause of ALS CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for review of tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-AL;188.7100067138672;;121.22000122070312;;226.1999969482422;;82.5999984741211;Bio-Techne Corporation (NASDAQ: TECH) today announced the introduction of MitoBrilliant™ probes. These novel probes enable the fluorescent labeling and tracking of mitochondria in live and fixed cells.;1.7999999523162842;;103.52999877929688;;36.56999969482422;;84.08000183105469;Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced that results from the Phase 1/2 trial of axatilimab, Syndax's anti-CSF-1R antibody, in patients with recurrent or refractory chronic graft-versus-host disease (cGVHD) following two or more prior lines of therapy, were published in the Journal of Clinical Oncology.;45.54999923706055;;17.610000610351562;;42.0099983215332;;124.0;;122.95999908447266;;92.75;;31.81999969482422;;50.189998626708984;;52.11000061035156;;33.72999954223633;;20.399999618530273;;17.219999313354492;;9.170000076293945;;44.369998931884766;;30.940000534057617;DNL343 demonstrated extensive blood-brain barrier penetration and robustly inhibited the integrated stress response pathway implicated in ALSOnce-daily oral dosing with DNL343 for 28 days was generally well tolerated in participants with ALSThe design phase for entry of DNL343 into a Phase 2/3 trial in the HEALEY ALS Platform Trial is underway SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad por;39.83000183105469;;55.939998626708984;;;;26.56999969482422;;16.1299991607666;;7.260000228881836;;10.029999732971191;;38.97999954223633;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for review of tofersen, an investigational medicine for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a progressive and uniformly fatal disease that affects fewer than 1,000 people across Europe.2;39.5099983215332;;54.25;;11.90999984741211;;27.739999771118164;;15.239999771118164;;25.510000228881836;
2022-12-06;283.2900085449219;;87.95999908447266;As U.S. stocks stumble on concerns of further rate hikes, investing in dividend players like Exxon Mobil (XOM), Gilead Sciences (GILD) and Conagra Brands (CAG) for a steady stream of income seems prudent.Ariel Investments, an investment management company, released its “Ariel Global Fund” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined -10.05%, underperforming the MSCI ACWI Index and the MSCI ACWI Value Index, which returned -6.82% and -7.66%, respectively. Multiple headwinds from all over the world affected […];747.469970703125;;161.6199951171875;"Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.Pfizer Inc (NYSE: PFE) and its partner, BioNTech SE (NASDAQ: BNTX), said that they developed their vaccine independently, refuting Moderna Inc's (NASDAQ: MRNA) patent claims. In August, Moderna filed patent infringement lawsuits saying Pfizer/BioNTech's COVID-19 vaccine infringes patents filed between 2010 and 2016 covering foundational mRNA technology critical in creating Moderna's mRNA COVID-19 vaccine. Pfizer called Moderna's lawsuit ""revisionist history"" and argued its patents ""far exceed itBritain's health regulator on Tuesday authorised a COVID-19 vaccine for infants as young as six months, opening the door for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees.  The Medicines and Healthcare products Regulatory Agency (MHRA) authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants.  Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme.Pfizer Inc and its German partner, BioNTech SE, fired back at Moderna Inc on Monday in a patent lawsuit over their rival COVID-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed.  Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the COVID-19 pandemic.  Moderna has also filed a related lawsuit against Pfizer and BioNTech in Germany.(Reuters) -Pfizer Inc and its German partner, BioNTech SE, fired back at Moderna Inc on Monday in a patent lawsuit over their rival COVID-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed.  Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the COVID-19 pandemic.  Moderna has also filed a related lawsuit against Pfizer and BioNTech in Germany.Pfizer Inc. and BioNTech SE said Monday that they asked the Food and Drug Administration to authorize their updated COVID-19 vaccine as the third dose for children between the ages of 6 months and 5 years old. Children in this age group receive three doses as their primary series of shots. (Older children, teens, and adults get two shots for their primary series.) If the FDA authorizes the new request, children in this age group would receive two of the original shots, and the third shot would b";205.97999572753906;The European Commission said Illumina will have to restore Grail’s independence and return it to the same level that existed before the acquisition.EU antitrust regulators on Monday proposed measures for U.S. life sciences company Illumina to unwind its acquisition of biotech firm Grail , three months after blocking the deal on concerns that it would hurt competition.  Illumina completed the takeover of Grail in August 2021, without securing European Union regulatory approval.  The European Commission said in a September veto decision that the company failed to offer adequate remedies to allay its worries and opened a separate case to force Illumina to unravel the deal.;311.80999755859375;Given all the market uncertainty this year and the downward trend of the major indices, it's no surprise that some investors are hesitant to buy right now.  Knowing the right time to pull the trigger on a stock purchase (or a sale) is often one of the hardest parts of being an investor.  Three such buy-now opportunities are Vertex Pharmaceuticals (NASDAQ: VRTX), Mattel (NASDAQ: MAT), and Nvidia (NASDAQ: NVDA).Take Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech that has delivered market-beating returns over the past decade.  The drugmaker is still at it even amid the market downturn and currently sits near its 52-week high.  Vertex has certainly been impressive, but are the company's best days already in the rearview mirror?;291.4700012207031;Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.The data presented for Eisai and Biogen’s drug wasn’t convincing enough to settle a debate among experts, but investors are betting on commercial success anyway.CAMBRIDGE, Mass., December 06, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a rapid-acting, once-daily, 14-day oral short course treatment in adults with MDD and PPD. The submission;187.5800018310547;;117.91000366210938;;219.63999938964844;;80.66999816894531;;1.7100000381469727;;102.22000122070312;;35.029998779296875;;82.54000091552734;The simplest way to invest in stocks is to buy exchange traded funds. But investors can boost returns by picking...;46.18000030517578;;16.780000686645508;The first fast-paced company with serious upside is hydrogen fuel-cell solution provider Plug Power (NASDAQ: PLUG).  According to analyst Amit Dayal of H.C. Wainwright, Plug Power can reach $78.  For those of you keeping score at home, this would work out to a near-quintupling in the company's share price in 2023.;38.97999954223633;;120.20999908447266;;120.0999984741211;;71.5199966430664;Mirati Therapeutics Inc (NASDAQ: MRTX) announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort of adagrasib combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in previously untreated metastatic lung cancer patients, harboring a KRASG12C mutation. Early data shows that a combination treatment demonstrated promising preliminary clinical activity across all PD-L1 subgroups with an objective response rate (ORR) of 49%, with a manageable safety prEarly trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co's immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.  The company expects the largest advantage in patients with lower levels of PDL1, the protein targeted by Keytruda, and plans to launch a phase-three trial enrolling only those patients soon, Mirati chief executive officer David Meek told Reuters.Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company today announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib (400mg twice daily) concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation across all PD-L1 subgroups. These data are the first to demonstrate the tolerability and feasibility of a concurrent combination regimen of a KRASG12C inhibitor anEarly trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co's immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.  The company expects the largest advantage in patients with lower levels of PDL1, the protein targeted by Keytruda, and plans to launch a Phase 3 trial enrolling only those patients by the end of this year, Mirati Chief Executive Officer David Meek told Reuters.  The trial will compare the adagrasib combination with the current standard of care, which is chemotherapy plus Keytruda, also known as pembrolizumab.;32.0099983215332;;48.5099983215332;Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective December 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 23,604 shares of its common stock and an aggregate of 11,800 restricted stock units (RSUs) to sixteen new employees under Blueprint Medicines' 2020 Inducement PIn this article, we discuss the 13 best genomics stocks to buy now. If you want to read about some more genomics stocks, go directly to 5 Best Genomics Stocks To Buy Now. Before talking about the best genomics stocks, it is important to understand what the term actually means. Genomics is the branch of […];50.779998779296875;Three good examples are Teladoc Health (NYSE: TDOC), Nike (NYSE: NKE), and Crispr Therapeutics (NASDAQ: CRSP).  Two billion-dollar noncash goodwill impairment charges hurt Teladoc's earnings this year -- and investor sentiment.  More than half of Fortune 500 companies are clients.In this article, we discuss the 13 best genomics stocks to buy now. If you want to read about some more genomics stocks, go directly to 5 Best Genomics Stocks To Buy Now. Before talking about the best genomics stocks, it is important to understand what the term actually means. Genomics is the branch of […];34.0;Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRASG12C mutationFindings will be presented on December 7 at the 2022 ESMO Immuno-Oncology Annual Congress, as an oral presentation from 2:05 p.m.-2:15 p.m. CET / 8:05 a.m.-8:15 a.m. ET (Presentation #LBA4) during the “Proffered Paper session 1” session SHANGHAI and CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) --;19.139999389648438;;16.670000076293945;;9.350000381469727;;43.18000030517578;The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. Stock up.;30.459999084472656;There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...;39.220001220703125;;56.380001068115234;;;;25.6200008392334;If you want to know who really controls Vir Biotechnology, Inc. ( NASDAQ:VIR ), then you'll have to look at the makeup...;15.8100004196167;;7.28000020980835;;9.100000381469727;"Pacific Biosciences of California Inc.  is a biotechnology company that develops and manufactures systems for gene sequencing and biological observation.  In this daily bar chart of PACB, below, we can see a ""classic"" saucer bottom formation.  A bullish golden cross buy signal can be seen in November with the 50-day line crossing above the 200-day line.PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced its HiFi sequencing technology will be used in a pilot project for the Children's Rare Disease Cohorts Initiative (CRDC) at Boston Children's Hospital. Boston Children's Hospital researchers will use HiFi whole-genome sequencing (HiFi WGS) for the purpose of investigating genetic and epigenetic variants associated with rare pediatric diseases. Samples from individuals enrolled in multiple rare diseIn this article, we discuss the 13 best genomics stocks to buy now. If you want to read about some more genomics stocks, go directly to 5 Best Genomics Stocks To Buy Now. Before talking about the best genomics stocks, it is important to understand what the term actually means. Genomics is the branch of […]";38.029998779296875;Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.;36.75;;53.220001220703125;;11.510000228881836;;25.889999389648438;;14.899999618530273;;25.0;
2022-12-07;285.760009765625;;87.79000091552734;"The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands are included in this Analyst Blog.FOSTER CITY, Calif., December 06, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies. In the analysis, Trodelvy improved progression-free survival (PFS), overall surviva";764.27001953125;;162.6300048828125;The Medicines and Healthcare products Regulatory Agency (MHRA) authorized the vaccine - made by Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for children aged six months to four years old. This decision was endorsed after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants. The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. Related: Pfizer/BioNTech's Omicron TailIn its response to a lawsuit brought by Covid-19 vaccine competitor Moderna Inc., Pfizer Inc. does not mince words: Pfizer did not copy Moderna's patented technology, it says, and Moderna is rewriting history by claiming otherwise.;208.52000427246094;"The stock of the provider of genetic analysis products is pulling back more than expected, so here's what may be next.The European Commission amped up its calls for Illumina Inc. to unwind early cancer detection company Grail Inc., which the giant life sciences tools maker bought with antitrust regulators' approval more than a year ago for a potential $8 billion.  It is the latest salvo in a long battle between San Diego-based Illumina (NASDAQ: ILMN), which has major operations in Foster City, and regulators on both sides of the Atlantic.  Grail and Illumina can formally respond to the EC's ""statement of objections,"" but the commission could make the ""transitional measures"" binding early next year.";317.5799865722656;Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.As 2023 approaches, it marks the end of what can be called a turbulent year for the stock market.  In a volatile market, it is smart to own stocks that have high growth prospects.  Thanks to its rising top and bottom line, Vertex Pharmaceuticals (NASDAQ: VRTX) shares have surged 46% so far this year.We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.;292.1499938964844;Biogen (NASDAQ: BIIB) is a business that generates more than $10 billion in revenue each year, with its multiple sclerosis treatments bringing in the bulk of its sales.  With the company's sales declining in recent years, Biogen needs a catalyst to turn things around and help inject some bullishness behind the business, and having an effective treatment for Alzheimer's could play a huge role in that objective.  Next year could prove to be a pivotal one for Biogen as investors can finally get some much-needed answers about whether lecanemab, a promising Alzheimer's treatment, could be the game changer the healthcare company is hoping that it will be for the business.Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.NORTHAMPTON, MA / ACCESSWIRE / December 7, 2022 / Biogen: Thousands of U.S. community health centers that care for uninsured or underinsured patients around the U.S. face an increasing number of systemic challenges due to extreme weather as a result ...Atai, Biogen, and Sage are working to develop new treatments for mental illness.;193.3800048828125;;119.36000061035156;;231.3300018310547;;80.66999816894531;When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...;1.75;;103.69000244140625;;34.2599983215332;The founding team spent the past several years at 10x Genomics, a pioneer in single-cell sequencing technology that could unlock new insights into using actual human antibodies as therapeutics.;84.02999877929688;;45.900001525878906;Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that new data presentations supporting the clinical value of its Precision Oncology portfolio will be shared in ten abstracts and three presentations at the 2022 San Antonio Breast Cancer Symposium® (SABCS®). The data presented highlight the Oncotype DX Breast Recurrence Score test, Oncomap™ ExTra test, a new investigational test to predict radiation therapy benefit, and an initial l;17.219999313354492;Novavax Inc said on Wednesday it will manufacture its COVID-19 vaccine in Canada after the country's health regulator allowed its use in children aged between 12 and 17 years as a primary series of shots.  Production of test batches of the protein-based vaccine, Nuvaxovid, will begin at the Montreal manufacturing center by early 2023, the company said.  The agency's approval was based on a late-stage study which showed the vaccine was effective against COVID-19 in children aged between 12 and 17 years.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has approved a supplement to a New Drug Submission (sNDS) for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series ofWith the business potentially at an important milestone, we thought we'd take a closer look at Novavax, Inc.'s...;38.04999923706055;;121.51000213623047;Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT study compared to placebo in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS). The primary endpoint was a reduction from baseline in the spike-wave index (SWI) ratio when measured after six weeks of study treatment. Related: Neurocrine Biosciences Buys UK-Based Hormone Therapy Player. The SWI measures the percentage of sleep affecNeurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that investigational NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT™ study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 compared to placebo in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS). NBI-827104 was generally well tolerated.;119.76000213623047;;49.59000015258789;Mirati Therapeutics' (MRTX) preliminary data from the first-line NSCLC study showed that adagrasib plus Merck's Keytruda achieved an objective response rate of 49%.Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity.Investors and analysts were unimpressed by trial results on the company's combination therapy to treat non-small cell lung cancer.;32.86000061035156;;46.849998474121094;;50.61000061035156;;32.9900016784668;;19.100000381469727;;16.350000381469727;;9.25;A new startup is spinning out of Waltham-based antibody discovery company Paragon Therapeutics to develop new approaches to treating immunological and inflammatory diseases.;44.099998474121094;;30.100000381469727;;39.5099983215332;;57.7400016784668;Today we will run through one way of estimating the intrinsic value of Halozyme Therapeutics, Inc. ( NASDAQ:HALO ) by...;;;25.59000015258789;;15.4399995803833;;7.199999809265137;;9.300000190734863;;38.20000076293945;;37.0099983215332;;54.09000015258789;;11.140000343322754;;25.31999969482422;;14.65999984741211;;25.270000457763672;NORTHAMPTON, MA / ACCESSWIRE / December 6, 2022 / Alkermes Originally published in Alkermes 2021 Corporate Responsibility We have developed and now manufacture and commercialize proprietary medicines for the treatment of alcohol dependence, opioid ...
2022-12-08;285.57000732421875;;89.47000122070312;Gilead Sciences (NASDAQ: GILD) is a top healthcare company that generates the bulk of its revenue from medicine that treats HIV.  Lenacapavir is an HIV treatment that would require patients to receive an injection just twice a year.  It's a significant change from the daily pills many HIV patients are accustomed to taking today.Marcus arrived home to Mississippi from his military assignment overseas, excited to see his 20-month-old son, when he realized something was wrong.Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going.SANTA MONICA, Calif. & TOKYO, December 08, 2022--Kite Pharma, Inc., a Gilead Company, (hereafter Kite) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) today jointly announced the revision of their 2017 partnership agreement, which gave Daiichi Sankyo exclusive rights to develop, manufacture and commercialize Yescarta (axicabtagene ciloleucel) in Japan. Kite was acquired by Gilead Sciences, Inc. later in 2017 after the Daiichi Sankyo partnership agreement. Daiichi Sankyo and Kite have no;765.4199829101562;"It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of...";171.80999755859375;NEW YORK & MAINZ, Germany, December 08, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. Children in this age group can receive a primary series consisting of two 3-µg doses of the original Pfizer-BioNTech COVID-19 VaccineThe Food and Drug Administration on Thursday authorized the bivalent COVID-19 boosters made by Moderna Inc. and BioNTech SE /Pfizer Inc. for children as young as 6 months old. The regulator said children between the ages of 6 months and 6 years old who first received Moderna's two-dose vaccine can now get Moderna's updated booster shot. The authorization for BioNTech and Pfizer's vaccine is slightly different. Children who are 6 months through 4 years can now get the companies' bivalent booster;210.4199981689453;;321.32000732421875;Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Entrada Therapeutics Inc (NASDAQ: TRDA) announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada's program for DM1, ENTR-701, which is in late-stage preclinical development. Under the terms of the agreement, Entrada will receive an upfront payment of $224 million and an equity investment of $26 milliBased on the average brokerage recommendation (ABR), Vertex (VRTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?Vertex Pharmaceuticals' (NASDAQ:VRTX) stock up by 9.9% over the past three months. Given that the market rewards strong...BOSTON, December 08, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage preclinical development.Two biotech companies are great examples of this: giant Vertex Pharmaceuticals (NASDAQ: VRTX) and up-and-coming player Axsome Therapeutics (NASDAQ: AXSM).  Vertex shares have climbed about 40% so far this year.  Vertex may be about to show that it can expand beyond its specialty of cystic fibrosis (CF) treatment -- and with a potential blockbuster product.Centene (CNC) collaborates with CHDI to establish a new community center in Texas, reflecting efforts to expand its Managed Care business across the state.;289.1000061035156;Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.;200.77999877929688;;125.23999786376953;Does the December share price for Seagen Inc. ( NASDAQ:SGEN ) reflect what it's really worth? Today, we will estimate...;238.00999450683594;CAMBRIDGE, Mass., December 08, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on December 15, 2022 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event.;81.94999694824219;;1.7999999523162842;Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the launch of Ginkgo Enzyme Services. Ginkgo Enzyme Services is powered by ultra high throughput screening and machine learning-guided protein design, as well as optimized proprietary bacterial and fungal host strains. Ginkgo Enzyme Services solves challenges for R&D teams developing enzymes, from discovery of novel enzyme activity through optimization of enzyme function and;104.38999938964844;;36.75;;84.11000061035156;Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;45.959999084472656;;17.31999969482422;;38.349998474121094;;120.38999938964844;;119.33999633789062;;43.849998474121094;Shares of Mirati Therapeutics (NASDAQ: MRTX) slumped more than 28% on Wednesday.  On Monday, the company released early phase 2 data on Adagrasib to treat non-small cell lung cancer (NSCLC), along with Keytruda, which is sold by Merck (NYSE: MRK).  On Wednesday, Mirati presented the data from its Krystal 7 and Krystal 1 trials with Adagrasib, at the 2022 ESMO Immuno-Oncology Annual Congress.;31.559999465942383;PASADENA, Calif., December 08, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million milestone payment, in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457, previously known as ARO-XDH. HZN-457 is a small interfering RNA (siRNA) candidate designed to treat gout b;46.779998779296875;Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;50.5;Eli Lilly (NYSE: LLY), CRISPR Therapeutics (NASDAQ: CRSP), and Johnson & Johnson (NYSE: JNJ) have all been doing so.  Eli Lilly and CRISPR are developing radical new therapies, while Johnson & Johnson is going all-in on using artificial intelligence to bring new therapies to market more quickly.  It's hard to see Eli Lilly as a revolutionary stock.CRISPR Therapeutics (NASDAQ: CRSP) is a compelling investment because of the potential it has as it works on developing gene-editing therapies that could be game changers and revolutionize the healthcare industry.  Shares of the healthcare stock are down 31% this year because a lot of the hype surrounding CRISPR has faded.  The excitement around CRISPR is due to the potential for one of its gene-editing treatments, exa-cel, to obtain Food and Drug Administration approval in the not-too-distant future.;35.22999954223633;;19.1200008392334;;16.520000457763672;ALAMEDA, Calif., December 08, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from the ongoing dose-escalation stage of QUARTZ-101, a phase 1 clinical trial evaluating XL102, a potent, selective, irreversible and orally bioavailable small molecule cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with advanced solid tumors. The data are being presented on Thursday, December 8 during the poster session (abstract P4-01-35) at 7:00 a.m. CST at the 2022 San Antonio Breast C;9.539999961853027;Led by a veteran of BridgeBio, the virtual company isn't saying much about the targets of its drugs, which were spun over to it by Paragon Therapeutics.;44.689998626708984;;30.260000228881836;;41.209999084472656;;57.849998474121094;;;;25.799999237060547;;15.510000228881836;;7.190000057220459;;9.949999809265137;;38.0;;37.18000030517578;;51.810001373291016;NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced four data presentations at the American College of Neuropsychopharmacology (ACNP) 61st Annual Meeting highlighting the therapeutic use of CAPLYTA for the treatment of bipolar I and II depression. “At ACNP, we presented new analyses from our bipolar depress;11.140000343322754;;26.329999923706055;Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).;14.630000114440918;;25.479999542236328;
2022-12-09;278.6499938964844;;87.97000122070312;Gilead Sciences Inc. said Friday that it will co-develop and co-commercialize Arcellx Inc.'s multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcellx $225 million upfront, plus make a $100 million equity investment in the company. The deal, which will reduce Gilead's GAAP and non-GAAP earnings per share next year by 16 cents, is expected to close in the first quarter. Gilead's stock is up 37.0% over the past three months, while Arcellx shares hSANTA MONICA, Calif. & REDWOOD CITY, Calif., December 09, 2022--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.It looks like Gilead Sciences, Inc. ( NASDAQ:GILD ) is about to go ex-dividend in the next four days. The ex-dividend...;750.0599975585938;Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union.;170.3000030517578;A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.STOCKSTOWATCHTODAY BLOG   Pfizer and BioNTech SE announced Friday an FDA fast track designation for a single-dose Covid and flu vaccine candidate.  The companies earlier began a Phase 1 trial to determine the safety of the candidate in healthy adults.Pfizer Inc. and German partner BioNTech SE said Friday they have received fast track designation from the U.S. Food and Drug Administration for a single-dose-mRNA-based vaccine candidate targeting both COVID and flu. The companies already announced that they are in early-stage trials to review the safety and immunogenicity of their combined vaccine among healthy adults. The vaccine will target the BA.4 and BA.5 omicron sublineages, which have become dominant globally, as well as four different fNEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for their mRNA-based combination vaccine candidate for influenza and COVID-19, which aims to help prevent two respiratory diseases with a single injection. Fast Track is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended toUnder the decision, certain children 6 months through 5 years can get the updated boosters, which target two Omicron offshoots as well as the original strain of the coronavirus.The FDA has authorized COVID-19 shots from Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)/ BioNTech SE (NASDAQ: BNTX) targeting the original coronavirus and Omicron sub-variants for use in children as young as six months of age. The amended authorization allows the use of Moderna's bivalent shot as a booster in children six months through 5 years of age, two months after their initial vaccination. Pfizer/BioNTech's updated shot can now be given as a third dose to those aged six months thrFoxconn urged looser COVID restrictions in China.  The founder of Foxconn Technology Group  (FXCOF)  reportedly wrote a letter attempting to persuade the Chinese government to relax its zero-COVID policy, saying China’s position in the global supply chain was under threat, people familiar with the matter told The Wall Street Journal.  Apple  (AAPL)   said last month that shipments of the iPhone 14 Pro and iPhone 14 Pro Max could be delayed because of COVID restrictions in China.;205.6199951171875;Emissions from industrial plants worldwide have been driving global warming for decades. Waste and gases from facilities like steel mills are rich in carbon and constitute about 21% of humanity's carbon footprint.;312.2200012207031;The market has taken growth investors for a bumpy ride over the past year.  Vertex Pharmaceuticals (NASDAQ: VRTX) is one of them.  Not only does the company have an incredible history of delivering favorable revenue growth and profits, but its stock has been a high performer for investors even in the volatility of the past year.Entrada Therapeutics inked a $250 million deal with Vertex Pharmaceuticals to develop a muscular dystrophy drug, and the biotech stock surged.Vertex (VRTX) could produce exceptional returns because of its solid growth attributes.;285.3699951171875;CAMBRIDGE, Mass., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced that the U.S. Food and Drug Administration (FDA) has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody. ACTEMRA® is indicated for several indications, including moderate to severe rheumatoid arthritis in adults as well as juvenile idiopathic polyarthritis and syMirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;197.0;CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, December 09, 2022--BeiGene, a global biotechnology company, is convening diverse stakeholders to amplify the mental health needs of the cancer community during an event hosted for patient advocates and scientists attending the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans. In collaboration with Cancer Support Community (CSC), the company will preview new national survey findings1, including that 60 percent of inBeiGene stock cleared that benchmark Thursday, with a jump from 77 to 82 Thursday.  Is BeiGene Stock A Buy?  BeiGene stock broke out earlier, but has fallen back below the prior 207.37 entry from a cup without handle.Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) to evaluate the safety and efficacy of Phanes' PT199, a differentiated anti-CD73 monoclonal antibody in combination with BeiGene's tislelizumab, an anti-PD-1 monoclonal antibody in the Phase I clinical study (NCT05431270) for the treatment of multiple advanced solid tumors.;124.0;;231.3300018310547;CAMBRIDGE, Mass., December 08, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. Patisiran is the established name for ONPATTRO®, which is currently approved by the U.S. FDA for the t;80.7300033569336;;1.8200000524520874;;102.33000183105469;;34.93000030517578;10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the first commercial shipments of its Xenium platform for in situ analysis. Xenium is the next generation of targeted spatial profiling of genes and proteins at subcellular resolution. The platform includes a versatile and easy-to-use instrument, a diverse menu of curated, customizable and high-quality panels, and Xenium Explorer, intuitive software for interactive data;82.33999633789062;;44.599998474121094;Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today shared initial clinical validation data for its breast cancer radiation signature, Profile for the Omission of Local Adjuvant Radiotherapy (POLAR), at the 2022 San Antonio Breast Cancer Symposium® (SABCS®). The meta-analysis of three independent, randomized clinical trials identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.;16.510000228881836;Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;37.939998626708984;;117.23999786376953;;118.36000061035156;There are many such corporations to consider on the market, but let's examine two: Guardant Health (NASDAQ: GH) and Sarepta Therapeutics (NASDAQ: SRPT).  Progress in cancer research is always important as cancer is a leading cause of death worldwide.  Guardant Health focuses on developing liquid biopsies -- tests that help detect signs of cancer from blood samples.;41.75;The analysts covering Mirati Therapeutics, Inc. ( NASDAQ:MRTX ) delivered a dose of negativity to shareholders today...Mirati Therapeutics' pain continued Thursday amid a series of analyst downgrades after MRTX stock lost about half of its value in three days.;30.239999771118164;;47.2400016784668;;48.9900016784668;CRISPR Therapeutics AG ( NASDAQ:CRSP ) shareholders might be concerned after seeing the share price drop 25% in the...With the financial media starting to discuss rumblings of a new bull market on the way, investors owe it to themselves to prepare.  Bull markets see a rising tide of share prices that buoys both conservative investments and more speculative ones.  If you think there's a bull market on the horizon, it could make sense to buy shares of companies that are likely to be buoyed more strongly as you might have to pay more if you wait.;35.400001525878906;;18.899999618530273;;15.770000457763672;A logistics giant and a small biotech have seen their shares struggle this year, but they are producing solid cash flow and look undervalued.Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) versus docetaxel in metastatic non-small cell lung cancer (NSCLC) without actionable mutations who experienced disease progression on or after treatment. Related: Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney CALAMEDA, Calif., December 08, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) versus docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) without actionable mutations who experienced disease progression on or after treatment with an immune checkpoint inhibitor;8.890000343322754;;42.119998931884766;;28.360000610351562;;40.650001525878906;;56.93000030517578;Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;;;25.420000076293945;;15.520000457763672;;6.840000152587891;;9.119999885559082;;37.5;;36.540000915527344;;51.77000045776367;;10.470000267028809;;24.420000076293945;;14.489999771118164;;24.700000762939453;NORTHAMPTON, MA / ACCESSWIRE / December 8, 2022 / Alkermes: For some people living with alcohol dependence, families play a support role. In fact, 47% of adults who sought treatment did so because a family member expressed concern. If someone you ...
2022-12-12;276.7799987792969;Horizon built its commercial drug portfolio with the help of two key Bay Area acquisitions. Now Amgen, which has R&D operations in South San Francisco and has been an opportunistic buyer of Bay Area drug developers, has emerged as the winner of a competition to buy Horizon.Wall Street Awaits Key Fed FOMC DecisionAmgen Inc. announced on Monday that it will acquire Horizon Therapeutics for $26 billion to further grow the company’s medical legacy. Horizon's best-selling drug is Tepezza.The $27.8 billion deal is by far the largest biotech acquisition of a year that has seen less M&A activity than many investors had anticipated.Consensus is currently for a 50 basis point (bps) hike mid-week, which will bring the Fed funds rate over +4% for the first time in 15 years.Horizon Therapeutics  closed on Friday at $97.29, which works out to 20.5 times forward looking earnings.  For Horizon's third quarter, the firm posted GAAP and adjusted EPS that beat Wall Street on about $925M in revenue.  On Monday morning, news broke that Amgen  had agreed to acquire Horizon for $116.50 per share, which is a 20% premium to Friday's closing price.Notable business headlines include Amgen’s $26.4 billion acquisition of Horizon Therapeutics, Shein considering becoming an online marketplace, and expectations that the U.S. Department of Energy will announce a nuclear fusion breakthrough.Shares of Horizon Therapeutics jumped in early Monday trading after Amgen [agreed to acquire the company](https://www.wsj.com/articles/amgen-in-advanced-talks-to-buy-horizon-therapeutics-11670785882), which develops medicines to treat rare autoimmune and severe inflammatory diseases. Horizon's shares were recently up more than 14%. Amgen's were off about 1% as [broader markets edged higher](https://www.wsj.com/articles/global-stocks-markets-dow-update-12-12-2022-11670845873).The U.S. biotech company’s deal for the drugmaker, which develops medicines to treat autoimmune and inflammatory diseases, is the year’s largest healthcare merger.The stock market has gotten locked in a holding pattern lately, and many investors anticipated that would likely continue on Monday.  With the Federal Open Market Committee scheduled to meet on Tuesday and Wednesday to discuss monetary policy and a potential interest rate increase, market participants aren't sure whether the central bank will slow its pace of monetary tightening or double down on its fight against inflation.  Below, you'll learn more about what has Coupa Software (NASDAQ: COUP) and Horizon Therapeutics (NASDAQ: HZNP) leading the Nasdaq higher.Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.By Liz MoyerAmgen Inc (NASDAQ: AMGN) has agreed to buy Horizon Therapeutics plc (NASDAQ: HZNP), implying an enterprise value of approximately $28.3 billion, marking the largest healthcare merger of the year. The Wall Street Journal was the first to report on Sunday that Amgen is in advanced talks to buy Horizon. Horizon confirmed its takeover talks with three large pharma companies in late November. Last week, Johnson & Johnson's (NYSE: JNJ) unit, Janssen, pulled out of the talks. Sunday, Sanofi SA (NASDAQ:;88.54000091552734;The Dow Jones Industrial Average is an index of 30 of the largest companies in the U.S. and it serves as a popular (if somewhat flawed) indicator of how the broader stock market is doing, and it has averaged an annual return of 8% since the 1980s.  Pharmaceutical company Gilead Sciences (NASDAQ: GILD) is one possible answer.  The company pays a solid dividend and could have the growth prospects to deliver market-beating returns over the next several years.SANTA MONICA, Calif., December 12, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced three-year follow-up data from the pivotal ZUMA-5 study for Yescarta® (axicabtagene ciloleucel) in relapsed or refractory (r/r) indolent non-Hodgkin lymphoma (iNHL), showing continued response in 52% of all enrolled patients, and prolonged duration of progression-free survival (PFS) in the Phase 2 study, presented at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract #SANTA MONICA, Calif., December 12, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from follow-up analyses of two pivotal studies (ZUMA-2 and ZUMA-3) of the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel). A comparison of two-year follow-up from ZUMA-3 and SCHOLAR-3, a retrospective historical control study, evaluating Tecartus versus standard of care (SOC) in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), was presented iA company that is capable of generating earnings well above its interest expense can withstand financial hardship. Sprouts Farmers (SFM), Fortinet (FTNT), O'Reilly Automotive (ORLY) and Gilead Sciences (GILD) are strong enough to meet financial obligations.SANTA MONICA, Calif., December 11, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta® (axicabtagene ciloleucel), the largest and longest follow-up of a CAR T-cell therapy versus standard of care (SOC) in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). These results include an analysis of outcomes for patients who received subsequent treatment for their lymphoma following second-line Yescarta;742.47998046875;Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive initial data from a pivotal Phase 2 expansion cohort evaluating investigational linvoseltamab (formerly REGN5458) at the 200 mg dose recommended for further development in patients with heavily pre-treated, relapsed/refractory (R/R) multiple myeloma. The results were part of a broader presentation of new and updated data from a Phase 1/2 trial and were shared at the 64th American Society of Hematology (ASH) Annual Meeting anToday we'll do a simple run through of a valuation method used to estimate the attractiveness of Regeneron...Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company has been included on the Dow Jones Sustainability World Index (DJSI World) for the fourth consecutive year and on the Dow Jones Sustainability North America Index (DJSI North America) for the third year. These indices recognize Regeneron's enduring leadership in supporting its patients, colleagues, communities and planet.Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced updated data from a Phase 1 and Phase 2 trial (ELM-1 and ELM-2) evaluating investigational odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). These included first data from a Phase 2 cohort of CAR-T naïve patients and updated data from a dose expansion cohort of a Phase 1 trial in patients who had progressed on CAR-T therapy. In the first look at the Phase 2 portion, Regeneron said the objective re;166.6199951171875;The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19.Beijing’s uneasy relationship with mRNA vaccines is all the more relevant as it begins to relax COVID restrictions.;208.52000427246094;;314.19000244140625;Though energy companies have been among the best-performing stocks in the S&P 500 index, here we discuss some top-performing non-energy S&P 500 stocks like MRK, VRTX and MCK.BOSTON, December 12, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF) lung disease for the approximately 5,000 people with CF who cannot benefit from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Vertex plans to initiate a sin;290.5899963378906;;204.3000030517578;;131.83999633789062;BOTHELL, Wash., December 12, 2022--Seagen Inc. (Nasdaq: SGEN) today announced results from two parts of a phase 2 trial (SGN35-027) evaluating ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) for the frontline treatment of patients with classical Hodgkin lymphoma (cHL). Part B of the trial evaluated patients with advanced-stage disease and was presented as an oral presentation, and Part C evaluat;235.86000061035156;;82.9800033569336;;1.8799999952316284;;106.26000213623047;;35.099998474121094;;82.36000061035156;WILMINGTON, Del., December 11, 2022--Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session;45.43000030517578;;16.3700008392334;The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19.;40.040000915527344;;119.4800033569336;;121.51000213623047;;41.40999984741211;;31.850000381469727;;45.41999816894531;;51.060001373291016;"-Update provided for both Part A (single dose with optional re-dosing) and Part B (consolidation dosing) of the Phase 1 CARBON™ clinical trial- -Part A data presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition confirm that CTX110® can lead to long-term durable complete remissions (CRs) for heavily pre-treated Large B-cell Lymphoma (LBCL) patients; three patients remain in CR beyond two years- -Emerging data from Part B demonstrate the benefits of consolidation";35.18000030517578;;16.200000762939453;Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity of AML BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at the American Society of Hematology's 64th Annual Meeting (ASH 2022). The presentation highlights the potential of a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (;16.079999923706055;;9.130000114440918;;44.29999923706055;;29.799999237060547;;42.779998779296875;;58.04999923706055;;;;25.5;;15.260000228881836;"In this article, we discuss 10 best medical stocks under $20. If you want to see more stocks in this selection, check out 5 Best Medical Stocks Under $20. The healthcare industry has undergone a significant restructuring in the wake of the COVID-19 pandemic. There were multiple new healthcare trends in 2022 that have a […]Abcam plc, (AIM: ABC) and (NASDAQ: ABCM) (""Abcam"" or the ""Company""), a global leader in the supply of life science research tools, today provides a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM (the ""AIM Delisting""), as originally announced on 17 October 2022.";7.059999942779541;;9.510000228881836;In this article, we discuss 10 best medical stocks under $20. If you want to see more stocks in this selection, check out 5 Best Medical Stocks Under $20. The healthcare industry has undergone a significant restructuring in the wake of the COVID-19 pandemic. There were multiple new healthcare trends in 2022 that have a […];38.2599983215332;;36.849998474121094;;52.689998626708984;Wasatch Global Investors, an asset management company, released its “Wasatch Small Cap Ultra Strategy” third-quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy underperformed its benchmark index, the Russell 2000 Growth Index, in the third quarter. News of continuous interest rate hikes from the federal reserve negatively impacted growth companies’ […];10.489999771118164;Investors need to pay close attention to AbCellera Biologics (ABCL) stock based on the movements in the options market lately.;25.56999969482422;;15.510000228881836;;25.280000686645508;
2022-12-13;272.260009765625;Here we have shortlisted five stocks - CVX, MRK, AMGN, TRV and IBM- that have fared better than the Dow Jones Index this year and have more upside potential for investment consideration.Companies in The News Are: COUP,HZNP,AMGN,RIVN,BAThe Food and Drug Administration approved Mirati's rival to Amgen's lung cancer drug, sending MRTX stock higher on Tuesday.Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the first quarter of 2023. The dividend will be paid on March 8, 2023, to all stockholders of record as of the close of business on February 15, 2023. This represents a 10% increase from that paid in each of the previous four quarters.The purchase of Horizon Therapeutics is the biggest this year by a major drugmaker seeking new sources of revenue to offset impending patent expiries.Amgen announced a $28.3 billion plan to acquire Horizon Therapeutics on Monday, leading HZNP stock to soar higher.Amgen will acquire Horizon Therapeutics for more than $26 billion as the company dives deeper into rare disease treatment.Amgen Inc. is acquiring Dublin-based Horizon Therapeutics in a roughly $28 billion deal that is the biggest in the healthcare sector in 2022.The company is buying Ireland-based drugmaker Horizon Therapeutics for more than $28bn, including debt. The $116.50 all-cash offer represents a 67 per cent premium to the three-month average of where Horizon’s shares were trading at before news last month that the company was in sale talks.  The strategic logic of buying Horizon is hard to fault.  Amgen needs to bolster its pipeline for new drugs as pressure on its legacy products grows.(Bloomberg) -- Amgen Inc. agreed to buy Horizon Therapeutics Plc for about $27.8 billion in its biggest-ever acquisition, deepening its commitment to treatments for autoimmune, inflammatory and rare diseases.Most Read from BloombergElon Musk Is Ruining Trump’s Presidential CampaignChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeUS Says Scientists Make Breakthrough in Nuclear Fusion EnergySam Bankman-Fried Arrested in Bahamas as US Files FTX ChargesKeystone Has Leaked More Oil Than AnyTwo major deals in the biotech and software industry were inked this weekend.Sales of Horizon’s thyroid eye-disease drug Tepezza have plateaued, a challenge its new owner will need to contend with.Amgen (AMGN) wins the race to buy Horizon Therapeutics and makes an acquisition offer of $27.8 billion.Yahoo Finance's Anjalee Khemlani explains news of a major biotech merger as Amgen is set to acquire Horizon Therapeutics.(Bloomberg) -- Amgen Inc. secured a $28.5 billion bridge loan to fund its purchase of Horizon Therapeutics Plc, joining ranks with Broadcom Inc. and AT&T Inc. in receiving some of the biggest debt commitments for mergers and acquisitions in nearly two years.Most Read from BloombergElon Musk Is Ruining Trump’s Presidential CampaignChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeUS Says Scientists Make Breakthrough in Nuclear Fusion EnergyUS Stocks Start Fed Week Higher as CPI Data LoomShares of Horizon Therapeutics (NASDAQ: HZNP) were soaring 14.8% higher as of 10:51 a.m. ET on Monday.  The nice gain came after the company announced that Amgen (NASDAQ: AMGN) plans to acquire Horizon in a deal that values the smaller drugmaker at $27.8 billion.  Horizon revealed a couple of weeks ago that it was in preliminary discussions with Amgen, Johnson & Johnson, and Sanofi about potentially being acquired.;88.75;A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. With 83...FOSTER CITY, Calif., December 12, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World). This ranking is based on an in-depth analysis of Gilead’s sustainability performance and highlights the company’s longstanding sustainable business practices and transparency on environmental, social and governance (ESG) issues.;747.5599975585938;In this article, we will be taking a look at the 15 best S&P 500 stocks that don’t pay dividends. To skip our detailed analysis of these stocks and the performance of the S&P 500 so far this year, you can go directly to see the 5 Best S&P 500 Stocks That Don’t Pay Dividends. […]Regeneron Pharmaceuticals Inc (NASDAQ: REGN) gave the first look at interim results from its Phase 2 study of odronextamab, a CD20xCD3 bispecific antibody in patients with relapsed/refractory follicular lymphoma. Trial investigators said 82% of 121 patients with the disease responded to Regeneron’s drug odronextamab, and 75% had a complete response. Related: Regeneron Highlights Its First Phase 2 Data To Build Case In CD20xC3 Bispecific Space. The median duration of complete response was 20.5 moRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive first data from a cohort of a pivotal Phase 2 trial evaluating investigational odronextamab in patients with heavily pre-treated, relapsed/refractory (R/R) follicular lymphoma (FL) grades 1 to 3a. The data were presented in an oral session at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA, and follow the first Phase 2 results for odronextamab in R/R diffuse large B-cell lymphom;178.24000549316406;The mean of analysts' price targets for BioNTech SE Sponsored ADR (BNTX) points to a 30.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.;210.75999450683594;;307.0899963378906;Racking up a five-bagger investment -- when one of your holdings grows by 5x -- is quite the accomplishment, and finding potential five-baggers is a great way to set your portfolio up for success.  On that note, powerful pharmaceutical businesses like Johnson & Johnson (NYSE: JNJ) and Vertex Pharmaceuticals (NASDAQ: VRTX) are stable enough and profitable enough to 5x, and they've both done it before.  Johnson & Johnson's market capitalization is around $461 billion, making it one of the largest businesses in the world.Citigroup CEO Jane Fraser expects a recession in 2023.  Here are three high-flying stocks to buy and hold if a recession is on the way.  Biotech stocks often soar, regardless of what's going on with the economy.;291.239990234375;In this article, we will be taking a look at the 15 best S&P 500 stocks that don’t pay dividends. To skip our detailed analysis of these stocks and the performance of the S&P 500 so far this year, you can go directly to see the 5 Best S&P 500 Stocks That Don’t Pay Dividends. […];208.07000732421875;"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, December 13, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia";134.05999755859375;;236.97999572753906;How far off is Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) from its intrinsic value? Using the most recent financial...;86.9800033569336;;1.7400000095367432;;107.08000183105469;;35.209999084472656;;82.91000366210938;;45.2400016784668;The consensus price target hints at a 34.5% upside potential for Exact Sciences (EXAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.;17.209999084472656;A peak 38% decline in the Nasdaq Composite has set these innovative growth stocks up for a bounce-back year.;40.029998779296875;;119.0;;122.87999725341797;;41.970001220703125;"Shares of Mirati Therapeutics Inc. were up about 3% in premarket trading on Tuesday, the day after the company said it received an accelerated approval from the Food and Drug Administration for a treatment for some people with advanced or metastatic non-small cell lung cancer. The drug, Krazati, can be used in patients who have a KRAS mutation; Agilent Technologies Inc. and Qiagen both have FDA-approved companion diagnostics that can test for the mutation. Krazati has a list price of $19,750 forThe Food and Drug Administration approved Mirati's rival to Amgen's lung cancer drug, sending MRTX stock higher on Tuesday.The FDA granted accelerated approval to Mirati Therapeutics Inc (NASDAQ: MRTX) Krazati (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). The approval covers patients who have received at least one prior systemic therapy. Related: Mirati Experimental Lung Cancer Drug Shows Favorable Tolerability, Promising Efficacy. This indication is approved under accelerated approval based on objective response rThe accelerated approval of Mirati Therapeutics' (MRTX) Krazati is based on ORR and DOR data from the phase II registration-enabling cohort of the KRYSTAL-1 study.Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI™ (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.";32.849998474121094;;46.599998474121094;;50.70000076293945;;36.060001373291016;;16.3700008392334;Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic ModelsSAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, presented preclinical data of several novel strategies designed to enable administration of off;16.049999237060547;;9.34000015258789;;45.7400016784668;;31.40999984741211;The charts of the biopharmaceutical company that focuses on neurodegenerative diseases indicate short-term caution but long-term promise.;44.93000030517578;;58.939998626708984;;;;26.239999771118164;;15.819999694824219;;7.28000020980835;;9.520000457763672;;38.130001068115234;;37.599998474121094;;54.45000076293945;;10.079999923706055;;26.459999084472656;Twist Bioscience Corp.’s $100 million “factory of the future” in Wilsonville is up and running 24/7 and is poised to expand the South San Francisco company’s DNA synthesizing operations.  The lab equipment is in and 177 employees are working at the site, some on shifts that run from 7 a.m. to 7 p.m. and others from 7 p.m. to 7 a.m., said CEO Emily Leproust.  Twist (Nasdaq: TWST) is looking to hire manufacturing associates in Wilsonville and eventually expects to employ 400 people there.;15.819999694824219;;25.540000915527344;Meet Michele, an Alkermes employee who uses her past experience as an oncology nurse to aid in her personal mission of helping to improve patients' lives through research.
2022-12-14;271.1300048828125;Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.In this article, we will take a look at 12 best blue chip stocks that outperformed in 2022. If you want to see more best blue chip stocks that outperformed in 2022, go directly to 5 Best Blue Chip Stocks That Outperformed in 2022. 2022 has been a challenging year for the markets as the […]In this article, we will be taking a look at the 15 biggest diet/weight loss companies in the world. To skip our detailed analysis of these companies, you can go directly to see the 5 Biggest Diet/Weight Loss Companies in the World. Over the years, there has been a growth in popularity when it comes to […]In the latest trading session, Amgen (AMGN) closed at $272.26, marking a -1.63% move from the previous day.Eli Lilly said Tuesday it plans to advance its next-generation obesity treatment into final-phase testing, but LLY stock dipped on guidance.Amgen (NASDAQ: AMGN) today announced the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present results from the E1910 randomized Phase 3 trial. This is the first study to demonstrate superior overall survival (OS) with BLINCYTO added to consolidation chemotherapy over current standard of care (multiagent consolidation chemotherapy) in newly diagnosed adult patients with Philadelphia chromosome-negative B-ALL who were measurable residual disease (MRD)-negative following induction and intensiRisk reversal option trades combine a short out-of-the-money put and a long out-of-the-money call. Here's how it works.Horizon Therapeutics PLC’s planned $27.8 billion sale to Thousand Oaks, California’s Amgen Inc. would put the West Coast biopharmaceutical giant in Montgomery County for the first time, though it’s not yet clear what the deal would mean for the combined company’s local real estate.  The agreement, announced Monday, comes as Dublin-based Horizon builds a research and development hub in Rockville and roughly two years after it acquired Gaithersburg’s Viela Bio Inc. for $3 billion.  The deal, first reported by the Wall Street Journal, would mark the industry's largest merger this year.Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.;88.4000015258789;Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.In this article, we discuss the 22 most charitable companies in 2022. If you want to skip the details about corporate and individual charitable practices and global charity statistics, go directly to the 5 Most Charitable Companies in 2022. According to the Charities Aid Foundation World Giving Index 2022, 40% of the global population took […];750.0;Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.;186.0500030517578;BioNTech SE Sponsored ADR (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).;209.97999572753906;Investors use a lot of different multiples to figure out if a stock is cheap or expensive. Sometimes that can just create confusion. Take Illumina (NASDAQ: ILMN), for example. The stock is down 60% from its peak to just above $200 per share -- a level it first reached in early 2018.U.S. life sciences company Illumina Inc on Tuesday defended its $7.1 billion acquisition of biotech firm Grail Inc , pledging to keep selling its DNA sequencing services to other firms, as it seeks to head off a potential vote by U.S. antitrust regulators to kill the deal.  The Federal Trade Commission, which enforces antitrust law, filed a complaint in March 2021 to stop Illumina's bid for its former subsidiary Grail.  The agency cited concerns that Illumina, the dominant provider of DNA sequencing for multi-cancer early detection tests, might raise prices or refuse to keep selling to rivals of Grail, which is seeking to market a powerful test to diagnose many kinds of cancer from a single blood test.U.S. life sciences company Illumina Inc on Tuesday defended its $7.1 billion acquisition of biotech firm Grail Inc , pledging to keep selling its DNA sequencing services to other firms, as it seeks to head off a potential vote by U.S. antitrust regulators to kill the deal.  The Federal Trade Commission, which enforces antitrust law, filed a complaint in March 2021 to stop Illumina's bid for its former subsidiary Grail.  The agency cited concerns that Illumina, the dominant provider of DNA sequencing for multi-cancer early detection tests, might raise prices or refuse to keep selling to rivals of Grail, which is seeking to market a powerful test to diagnose many kinds of cancer from a single blood test.;312.0899963378906;The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.Following clearance of the IND application by the FDA, Vertex (VRTX) intends to start a clinical study evaluating a single ascending dose of VX-522 in cystic fibrosis patients in the coming weeks.;289.04998779296875;;209.24000549316406;;132.0500030517578;;233.91000366210938;;86.80999755859375;;1.6799999475479126;;108.37999725341797;;34.959999084472656;;82.66999816894531;;45.540000915527344;;17.229999542236328;Is Novavax stock a buy after vaccine stocks surged on bullish news from Moderna? Is NVAX stock a buy right now?;38.79999923706055;The next big things for investors are always around the corner. As investors say goodbye to the 2022 bear market, we look forward to what could be an excellent 2023. Indeed, while this coming year will likely provide investors with just as many fears, bearish market sentiment is nothing new. The stock market perpetually swings between bullish and bearish sentiment. However, investors who search for the next big things will start 2023 on strong footing. There are several thematic investment areas;119.23999786376953;;126.31999969482422;;43.72999954223633;Adding Moderna's experimental messenger RNA-based cancer vaccine to a standard regimen of Merck's Keytruda in high-risk melanoma patients meaningfully reduced the risk of death or recurrence of cancer in a Phase 2 trial.Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 11 new employees with a grant date of December 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).;32.849998474121094;;46.72999954223633;;50.189998626708984;;35.08000183105469;;15.369999885559082;;16.190000534057617;;9.550000190734863;;44.880001068115234;The next big things for investors are always around the corner. As investors say goodbye to the 2022 bear market, we look forward to what could be an excellent 2023. Indeed, while this coming year will likely provide investors with just as many fears, bearish market sentiment is nothing new. The stock market perpetually swings between bullish and bearish sentiment. However, investors who search for the next big things will start 2023 on strong footing. There are several thematic investment areas;30.770000457763672;;45.459999084472656;;58.52000045776367;;;;25.899999618530273;;15.899999618530273;;7.289999961853027;;9.430000305175781;;38.29999923706055;;37.63999938964844;;52.77000045776367;Just because a business does not make any money, does not mean that the stock will go down. For example, although...;10.130000114440918;Does the December share price for AbCellera Biologics Inc. ( NASDAQ:ABCL ) reflect what it's really worth? Today, we...;26.489999771118164;;15.779999732971191;;25.6200008392334;
2022-12-15;266.1400146484375;Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Investors may keep a tab on LW, NUE, PWRr, TTC, and AMGN which have lately hiked their dividend payments to reward investors.Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...In this article, we discuss 10 best Dogs of the Dow stocks ranked by hedge fund sentiment. You can skip our detailed analysis of the Dogs’ performance over the years, and go directly to read 5 Best Dogs of the Dow Stocks Ranked By Hedge Fund Sentiment. ‘Dogs of the Dow’ is an investment strategy […];86.58000183105469;When Darcie Green's dad got sick, she thought she was prepared to help him navigate the healthcare system. She'd spent her entire career in healthcare policy.Gilead Sciences (GILD) closed at $88.40 in the latest trading session, marking a -0.39% move from the prior day.;731.27001953125;The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.The European Commission (EC) has expanded the marketing authorization of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent (dupilumab) for moderate-to-severe prurigo nodularis. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation. With this approval, Dupixent is the first and only targeted medicine specifically indicated to treat prurigo nodularis in Europe and the U.S. Related: UK Drug Regulator Warns Of Severe Eye ReactRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent® (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest among inflammatory skin diseases. With this approval,;182.0399932861328;Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets;207.4600067138672;Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced its achievement of the highest score out of 72 companies in its industry in the S&P Global Corporate Sustainability Assessment, also known as the Dow Jones Sustainability Index (DJSI).;308.3999938964844;While it's true that growth stocks don't make investors jump for joy like they used to, companies in this investment category that can win over the long term are still to be found.  Vertex Pharmaceuticals (NASDAQ: VRTX) is a bit of a rarity in the world of healthcare stocks, boasting a business that tends to generate revenue and earnings growth at a clip well beyond that of the average stock in this space.  Case in point: The company has seen its annual revenue and earnings surge by respective amounts of 204% and 789% in the past five years.Vertex Pharmaceuticals (VRTX) closed at $312.09 in the latest trading session, marking a +1.63% move from the prior day.;283.44000244140625;Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our model estimates. The company plans to launch four new drugs next year.;207.9199981689453;;128.41000366210938;;229.3699951171875;CAMBRIDGE, Mass., December 15, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2023 focused on continued commercial execution of four RNAi therapeutic products, and advancement of early-, mid-, and late-stage investigational programs.;84.19000244140625;;1.6299999952316284;;108.61000061035156;;35.779998779296875;;82.2300033569336;WILMINGTON, Del., December 15, 2022--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January:;44.61000061035156;;11.319999694824219;"Yahoo Finance Live's Julie Hyman discusses the decline in stock for Novavax.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027 (the ""notes""). The notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In connection with the offering of thThe Biden administration is urging Americans to take steps to avoid getting COVID this holiday season.By Liz MoyerTeladoc Health (NYSE: TDOC), Novavax (NASDAQ: NVAX), and Disney (NYSE: DIS) are good examples.  Teladoc disappointed investors when it reported two billion-dollar, non-cash goodwill impairment charges earlier this year.  This was linked to the purchase of chronic-care specialist, Livongo.By Peter NurseThe Gaithersburg biotech, which also detailed changes to a U.K. sales agreement for its Covid vaccine, saw its share price drop in after-hours trading.Shares of COVID-19 vaccine maker Novavax Inc. on Wednesday sank 11% after the company announced a proposed offering to sell millions of its debt and stock. The company said the proceeds could go toward the global launch of its Nuvaxovid COVID vaccine and the repayment or repurchase of some of the $325 million of its convertible debt due in February. Novavax announced a proposed sale of up to $125 million in stock, and said it expects to grant the underwriters a 30-day option to buy up to an addiYahoo Finance Live anchor Seana Smith highlights which stock tickers are making moves in after-hours trading.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its common stock. In connection with the common stock offering, Novavax expects to grant to the underwriters a 30-day option to purchase up to an additional $18.75 million of its common stock at the public offering price, less underwriting discounts and comm";36.529998779296875;;116.69000244140625;;124.6500015258789;;42.540000915527344;;31.440000534057617;;45.11000061035156;;47.5;;32.880001068115234;;14.210000038146973;;15.800000190734863;;8.90999984741211;;42.310001373291016;;29.030000686645508;;45.56999969482422;;57.029998779296875;;;;25.190000534057617;;15.630000114440918;;7.03000020980835;;9.0600004196167;;38.20000076293945;;37.150001525878906;;51.83000183105469;;10.399999618530273;VANCOUVER, British Columbia, December 15, 2022--AbCellera and AbbVie Partner to Advance New Antibody Therapies;25.3799991607666;;15.069999694824219;;25.09000015258789;NORTHAMPTON, MA / ACCESSWIRE / December 14, 2022 / Alkermes Environmental Protection and Sustainability We strive to conduct our business activities in a manner that minimizes the environmental impacts of our operations and promotes effective ...The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
2022-12-16;267.4100036621094;The global population is growing with each passing year.  The pharmaceutical industry has been at the forefront, with the launch of game-changing medicines and vaccines in recent decades.  With the global population expected to rise from around 8 billion now to 9.7 billion by 2050, rising demand for medical treatments is practically built into the business model of big pharma.Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 8th of March to $2.13...;86.76000213623047;;723.1699829101562;Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the...Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults and adolescents with eosinophilic esophagitis (EoE). This positive opinion covers those who are 12 years and older, weighing at least 40 kg, and inadequately controlled by, are intolerant to or who are not can;175.25;Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss China’s reopening challenges as COVID cases rise as well as the latest surrounding Pfizer and BioNTech’s combined COVID and flu vaccine.Bank of America analysts upgraded BioNTech SE stock to buy from hold on Thursday, citing excitement about its mRNA technology and the outlook for a combined flu/COVID vaccine and oncology vaccines that are currently in various stages of development.  Analysts led by Tazeen Ahmad reiterated their $239 price target on the stock  (BNTX)  which is 28.5% above its current price, and said the German company’s roughly 16 billion euros in cash is a positive.  Positive data this week from Moderna Inc.  (MRNA)  and Merck  (MRK)  in a trial of Merck’s Keytruda and a Moderna mRNA vaccine in treating patients with late-stage melanoma are positives for BioNTech’s NeST platform, which also aims to treat melanoma and other solid tumors, said the note.BofA Securities has upgraded BioNTech SE (NASDAQ: BNTX) and maintains a $239 price target. The analyst views the current valuation as an attractive entry opportunity citing several near-term opportunities, including an expanded opportunity for the COVID vaccine and de-risking of the growing oncology pipeline. Recent update on Moderna Inc (NASDAQ: MRNA) / Merck & Co Inc (NYSE: MRK) on personalized cancer vaccine for melanoma might provide POC validation ahead of BNT122’s readout in combo with Key;199.5399932861328;U.S. and European antitrust enforcers want to unwind gene sequencing leader Illumina Inc's purchase of cancer test company Grail, saying the two would stifle competition in a critical area of medicine, but some cancer researchers say it's far too early to make that assessment.  Illumina is the leading maker of high-speed genomic sequencing systems that can examine fragments of DNA found in blood or other samples for use in everything from solving crimes to drug research.  Antitrust regulators argue that Illumina, whose sequencers are being used by companies, hospitals and research centers, could unfairly prioritize Grail in the race to create tests for the early detection of multiple types of cancer.U.S. and European antitrust enforcers want to unwind gene sequencing leader Illumina Inc's purchase of cancer test company Grail, saying the two would stifle competition in a critical area of medicine, but some cancer researchers say it's far too early to make that assessment.  Illumina is the leading maker of high-speed genomic sequencing systems that can examine fragments of DNA found in blood or other samples for use in everything from solving crimes to drug research.  Antitrust regulators argue that Illumina, whose sequencers are being used by companies, hospitals and research centers, could unfairly prioritize Grail in the race to create tests for the early detection of multiple types of cancer.U.S. and European antitrust enforcers want to unwind gene sequencing leader Illumina Inc's purchase of cancer test company Grail, saying the two would stifle competition in a critical area of medicine, but some cancer researchers say it's far too early to make that assessment.  Illumina is the leading maker of high-speed genomic sequencing systems that can examine fragments of DNA found in blood or other samples for use in everything from solving crimes to drug research.  Antitrust regulators argue that Illumina, whose sequencers are being used by companies, hospitals and research centers, could unfairly prioritize Grail in the race to create tests for the early detection of multiple types of cancer.;304.79998779296875;"Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) price-to-earnings (or ""P/E"") ratio of 24.2x might make it look...In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $308.40, marking a -1.18% move from the previous day.Vertex is the IBD Stock Of The Day. The FDA signed off on its newest study in cystic fibrosis, but VRTX stock is trading sideways.";284.9800109863281;Biogen Inc. (BIIB) closed at $283.44 in the latest trading session, marking a -1.94% move from the prior day.;205.0;;129.61000061035156;;236.9199981689453;;82.37999725341797;;1.7300000190734863;;108.62999725341797;;35.599998474121094;;82.02999877929688;;51.91999816894531;"By Liz MoyerShares of Guardant Health Inc. tanked 40% and shares of Exact Sciences Corp. rallied more than 25% in the extended session Thursday after Guardant announced results from a study using its blood test to screen for colorectal cancer that didn't appear to surpass Exact Sciences' stool-sample screening test. Guardant said that the results ""pave the way for first potential FDA-approved and Medicare-reimbursed blood test for colorectal cancer screening,"" and that it plans to ask for U.S. Food and Drug";11.029999732971191;"Companies in The News Are: NFLX,WBD,NVAX,METATwo drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of shares of its common stock. In connection with the common stock offering, Novavax granted the underwriters a 30-day option to purchase up to an additional 975,000 sNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027 (the ""notes""). The notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In connection withThursday was a bad day for the stock market, as investors had a delayed reaction to the Federal Reserve's Wednesday decision to increase interest rates.  Popular video game company Roblox (NYSE: RBLX) and vaccine manufacturer Novavax (NASDAQ: NVAX) were hit particularly hard on Thursday, and investors are looking closely at the two stocks to see if more damage might be coming.  Shares of Roblox dropped 16% on Thursday as investors had the chance to react to the video game platform provider's latest financial metrics for the month of November.(Bloomberg) -- Novavax Inc. shares fell the most in almost four years on Thursday after the company announced it had cut its vaccine supply to the UK and was seeking additional equity and debt.Most Read from BloombergTrump Hawks Superhero NFT Trading Cards as Crypto Universe ImplodesIs Putin Finally Getting Smart About His Ukraine Disaster?Elon Musk’s Tesla Share Sales Approach the $40 Billion MarkUS Stocks Drop for a Second Day; Oil Snaps Rally: Markets WrapThe biotech company, which makes vaccShares of Novavax tumble as the vaccine maker plans to sell up to $125 million in stock, and offer $125 million of convertible senior notes.";36.86000061035156;;117.19000244140625;;123.55999755859375;;43.619998931884766;;31.770000457763672;"PASADENA, Calif., December 15, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 9, 2022, the Compensation Committee of the Company’s Board of Directors approved ""inducement"" grants to 35 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 84,000 restricted stock units. The grants are outside the Company’s stockholder-approveArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2022 Earnings Call Transcript November 28, 2022 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.81 EPS, expectations were $-0.16. Operator: Ladies and gentlemen, welcome to Arrowhead Pharmaceuticals Conference Call. Throughout today’s recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be […]";45.220001220703125;;46.40999984741211;;32.59000015258789;"- Median overall survival (mOS) was numerically longer for patients receiving ZEJULA regardless of biomarker status, at 46.3 months compared to 43.4 months in the placebo group- No new safety issues were identified SHANGHAI, China and CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today presented new interim overall survival (OS) data in Chinese patients with platin";13.079999923706055;;15.9399995803833;Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.;9.260000228881836;;42.540000915527344;;28.690000534057617;;45.630001068115234;Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline. However, pipeline setbacks remain concerning.;56.86000061035156;;;;26.670000076293945;;15.529999732971191;;6.920000076293945;;9.579999923706055;;38.65999984741211;;36.040000915527344;NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Brad Margus, M.B.A., has stepped down from the company’s Board and Everett Cunningham has been appointed to join. “We are very appreciative of Brad’s contributions to the development and success of Arvinas, particularly in his role as a member of our Audit Committee,” said John Houston, P;51.04999923706055;;10.210000038146973;AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.;25.25;;15.390000343322754;;25.520000457763672;
2022-12-19;265.70001220703125;;86.41999816894531;;721.0999755859375;;168.55999755859375;The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.;191.58999633789062;;291.5899963378906;Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.;284.3800048828125;Glofitamab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other blood cancers CAMBRIDGE, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that it has reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab. Under the terms of the agreement, Biogen will have no payment obligations and will receive tie;201.08999633789062;;127.62999725341797;;234.07000732421875;;80.79000091552734;Conestoga Capital Advisors, an asset management company, released its “Conestoga Mid Cap Growth Fund” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the Mid Cap composite returned -4.84% net of fees compared to a -0.65% return for the Russell Mid Cap Growth Index. Negative stock selection and allocation effects […];1.7000000476837158;;106.61000061035156;;35.150001525878906;;80.58999633789062;;50.0;When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?Should investors be excited or worried when a stock crosses above the 200-day simple moving average?;10.319999694824219;;35.939998626708984;Every investor in Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) should be aware of the most powerful shareholder groups...;117.93000030517578;Insulet, Medpace, Universal Health Services, Neurocrine Biosciences and UnitedHealth are all worth watching.  PODD stock, Medpace, Neurocrine Biosciences and UnitedHealth are all in bases, trying to hold key support levels.  NBIX stock is on IBD Leaderboard, with Medpace on the Leaderboard watchlist.;123.0;;41.43000030517578;;31.06999969482422;;42.970001220703125;;44.060001373291016;ZUG, Switzerland and BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023. Dr. Harding brings extensive leadership experience in biopharma business development and corporate strategy and joins CRISPR Therapeutics to lead;30.06999969482422;In this article, we will look at the top 15 Chinese companies listen on the Nasdaq. If you want to explore similar companies, you can also take a look at Top 5 Chinese Companies on NASDAQ. China is the world‘s most populous country and the second largest economy in terms of nominal Gross Domestic Product (GDP). […];12.75;;15.4399995803833;;8.539999961853027;;40.099998474121094;;26.280000686645508;;41.70000076293945;;56.20000076293945;;;;25.170000076293945;;15.25;;6.679999828338623;;8.680000305175781;;37.959999084472656;;34.310001373291016;;50.119998931884766;;9.9399995803833;;23.790000915527344;;15.100000381469727;;25.239999771118164;
2022-12-20;264.75;In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...In the latest trading session, Amgen (AMGN) closed at $265.70, marking a -0.64% move from the previous day.;84.7699966430664;"The Philadelphia cell therapy developer suffered a major setback last year when two patients died in a clinical trial testing the company's prostate cancer cell therapy.Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NASDAQ: RCUS) announced results from the fourth interim analysis of the ARC-7 Phase 2 study for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations. The study evaluates the combinations of domvanalimab + zimberelimab (doublet) and domvanalimab + zimberelimab + etrumadenant (triplet) versus zimberelimab monotherapy. Related: Gileadbluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.Shares of Arcus Biosciences Inc. were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that it's developing with Gilead Sciences Inc. improved progression-free survival and overall response rate [ORR] in a Phase 2 clinical study. ""The data clearly show that the program is viable, keeping hope alive for active building blocks within the large lung cancer space, but numerical ORR may be disappointing toSANTA MONICA, Calif. & PHILADELPHIA, December 20, 2022--Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets, platform capabilities, and a straFOSTER CITY, Calif. & HAYWARD, Calif., December 19, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is a Phase 2, multicenter, three-arm, randomized, open-label";733.530029296875;"Even though Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) has fallen by 3.5% over the past week , insiders who sold...Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023. The presentation is scheduled for 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) and may be accessed from the ""Investors & Media"" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. An archived version of the presentation will be available for at least 30 days.The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.";172.6999969482422;China and Germany should work together to foster good relations between Beijing and the European Union without any interference by a third party, President Xi Jinping told Germany's president  in a phone call on Tuesday, state media reported.  Xi was also quoted by state broadcaster CCTV as telling Frank-Walter Steinmeier that China hopes Germany can provide a fair, transparent and non-discriminatory operating environment for Chinese enterprises in Germany, the EU's largest market.;191.4600067138672;Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:;293.2300109863281;"Entrada (TRDA) plunges on clinical hold notice from the FDA regarding its Investigational New Drug Application (IND) for Duchenne muscular dystrophy (DMD) candidate.Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) price-to-earnings (or ""P/E"") ratio of 22.9x might make it look...";287.510009765625;;208.64999389648438;;133.02000427246094;"BOTHELL, Wash., December 20, 2022--Seagen Inc. (Nasdaq:SGEN) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:00 p.m. Pacific Time. The presentation will be webcast live and available for replay from the investor section of Seagen’s website at investor.seagen.com.BOTHELL, Wash. & TOKYO & RAHWAY, N.J., December 20, 2022--Seagen Inc. (Nasdaq: SGEN), Astellas Pharma Inc. (TSE:4503) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review supplemental Biologics License Applications (sBLAs) for PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) for use of these two agents in combination for the treatment of patients with locally advancAstellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas""), Seagen Inc. (Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review supplemental Biologics License Applications (sBLAs) for PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) for use of these two agents in combination for the treatment of patients with locally advanced o";237.5500030517578;;81.02999877929688;;1.649999976158142;"Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Ministry of Health (""MoH""), representing the Government of the Republic of Botswana, today announced that they have entered into a Memorandum of Understanding (""MoU"") with the intent of developing and implementing new biosecurity capabilities in Botswana.";106.30000305175781;;35.689998626708984;;81.06999969482422;;51.09000015258789;Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business and product launches.Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, supports recent policy changes that help increase access to recommended non-invasive colorectal cancer screening tests. These policy changes require Medicare and most commercial insurers to pay for colonoscopy after a positive Cologuard® test without cost to the patient. For most patients, these financial protections take effect starting January 1, 2023.;10.520000457763672;;36.029998779296875;;119.16000366210938;;127.44000244140625;;41.27000045776367;;32.939998626708984;PASADENA, Calif., December 20, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of olpasiran. Arrowhead is further eligible to receive up to an additional $535 million in aggregate development, regulatory, and sales milestone payments from Amgen and Royalty Pharma plc (NASDAQ: RPRX).;43.790000915527344;;44.310001373291016;;30.31999969482422;"SHANGHAI, China and CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that senior management from Zai Lab will participate in the following investor conferences in January 2023: Morgan Stanley Virtual China Opportunity ConferenceMeetings: Wednesday, January 4, 2023 - Friday, January 6, 2023 J.P. Morgan 41st Annual Healthcare ConferencePresentation: Tues";12.630000114440918;;15.6899995803833;;8.260000228881836;It's not possible to invest over long periods without making some bad investments. But really big losses can really...;41.59000015258789;Biotechnology firm Beam Therapeutics was raised to an outperform rating (buy) by a sell-side firm Tuesday. Let's check on the charts and indicators to see if technical analysis and fundamental analysis are ready to work together.Every investor in Beam Therapeutics Inc. ( NASDAQ:BEAM ) should be aware of the most powerful shareholder groups. The...;27.600000381469727;;43.900001525878906;;56.689998626708984;;;;25.520000457763672;;15.0600004196167;;6.989999771118164;;8.949999809265137;;38.91999816894531;;34.52000045776367;;51.380001068115234;TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the strategy outperformed the Russell 2000 Growth Index and returned 3.28% (net), and the index return was 0.24%. Strength in Industrials, Consumer Staples, Consumer Discretionary, […];10.40999984741211;;23.6299991607666;;15.449999809265137;;25.719999313354492;
2022-12-21;266.260009765625;The Dow Jones rallied 375 points Wednesday after consumer and housing data, as Nike stock surged 15% on strong earnings results.Broadcom, United Parcel Service, Amgen, America Movil and Manulife Financial are part of the Zacks top Analyst Blog.Today's Research Daily features update on the Q4 earnings season and new research reports on Broadcom (AVGO), UPS (UPS), Amgen (AMGN) and 16 other stocks.;85.2699966430664;Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.When Tatiana Williams was growing up as a young Trans woman in Florida, she faced many challenges and hardships - but she didn't find many resources available to her.One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...Gilead Sciences (GILD) closed at $84.77 in the latest trading session, marking a -1.91% move from the prior day.Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.;736.1900024414062;;178.14999389648438;BioNtech has dosed the first patient with its BNT163 herpes vaccine candidate designed to prevent genital lesions as part of a first-in-human Phase 1 clinical research study, the German vaccine maker said on Wednesday.  The vaccine candidate is meant to prevent HSV-2, the herpes simplex virus that causes genital herpes, and potentially HSV-1, which causes oral herpes and can lead to genital herpes.MAINZ, GERMANY, December 21, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) reached the next milestone in the establishment of scalable mRNA vaccine production in Africa. The six ISO-sized shipping containers for the first BioNTainer have finished construction in Europe, underwent quality checks by BioNTech experts and are being prepared for shipment to Kigali, Rwanda, where they are expected to arrive in the first quarter of 2023. Media material from the preparation is now available here. In parBerlin has sent its first batch of BioNTech COVID-19 vaccines to China to be administered initially to German expatriates, a German government spokesperson said on Wednesday, the first foreign coronavirus vaccine to be delivered to the country.  No details were available on the timing and size of the delivery, although the spokesperson said Berlin is pushing for foreigners other than German nationals, estimated at about 20,000, to be allowed access to the shot if they want it.First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine collaboration with the University of Pennsylvania to enter the clinic The program is part of BioNTech’s strategy to address diseases with high unmet medical need, as no vaccine has been approved for prevention of genital lesions caused by HSV MAINZ, Germany, December 21, 2022 – BioNTech SE (Nasdaq:;197.4600067138672;When Gloucester Marine Genomics Institute (GMGI) was founded in 2013, it already had an Illumina connection-it was created with help from Illumina co-founder David Walt.;290.54998779296875;For many investors, now would be an opportune time to take advantage of great stocks trading at a discount.Despite the short-term impact that $10 billion worth of write-downs had on Teladoc Health's (NYSE: TDOC) balance sheet in the first half of 2022, the company remains an undefeated leader in the global telehealth market.  While more companies are expanding into the telehealth space, few are doing so at Teladoc's scale.  In the most recent quarter, Teladoc's revenue surged 17% from the year-ago period to $611 million.If you have the cash to invest right now and are looking to add some powerhouse growth stocks to your portfolio before year's end, here are three notable contenders to consider.  Vertex Pharmaceuticals (NASDAQ: VRTX) isn't a household name like some healthcare stocks, but this biopharmaceutical company has grown into a giant in the rare disease drug market over the more than three decades since its founding.  In fact, its cystic fibrosis products generated $7.6 billion in revenue for all of 2021, in a market that was valued at around $9 billion as of 2020.If you have $20,000 to invest in the stock market right now, you're likely searching for durable businesses with a strong track record of growth that can generate consistent returns in a wide variety of markets.  Despite increased competition through the years, Johnson & Johnson (NYSE: JNJ) remains a giant in each of the three key markets in which it operates: consumer health, pharmaceuticals, and medical devices.  The company's consumer health business, which it is about to spin off into a stand-alone company called Kenvue, sells some of the world's most well-known daily use brands like Band-Aid, Tylenol, and Listerine.;286.8599853515625;;216.24000549316406;;132.32000732421875;;241.30999755859375;CAMBRIDGE, Mass., December 21, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic targeting ketohexokinase (KHK) for the treatment of Type 2 diabetes mellitus (T2DM). Pending regulatory authority and ethic committee approvals, the Company plans to be;83.16999816894531;Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 8:15 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.;1.75;;104.62000274658203;;36.939998626708984;;80.5199966430664;;52.380001068115234;NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for AML.It is doubtless a positive to see that the Exact Sciences Corporation ( NASDAQ:EXAS ) share price has gained some 38...;10.380000114440918;;36.209999084472656;;120.33999633789062;;131.41000366210938;;41.310001373291016;;37.099998474121094;PASADENA, Calif., December 21, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023, at 8:30 a.m. ET, it will present topline data from the SEQUOIA Phase 2 study evaluating fazirsiran and provide an outline of a Phase 3 study that was co-developed with and will be run by Takeda. Fazirsiran is a potential first-in-class investigational RNA interference (RNAi) therapy designed to reduce production of the mutant alpha-1 antitrypsin protein (Z-AAT) as a potenti;44.540000915527344;;45.41999816894531;;31.1299991607666;;12.25;;15.760000228881836;One thing I'm confident about is that at their reduced valuations, both Meta Platforms (NASDAQ: META) and Exelixis (NASDAQ: EXEL) are investments worth loading up on right now.  Meta Platforms, the social media giant that owns Instagram, WhatsApp, and Facebook, has seen its share price take a beating this year, falling 64% while the S&P 500 is down just 19%.;8.260000228881836;;43.22999954223633;BMO Capital Markets has upgraded Beam Therapeutics Inc (NASDAQ: BEAM) from Market Perform to Outperform and raised the price target from $61 to $66. The analyst writes that it remained on the sidelines due to a lack of near-term stock-moving catalysts. In the most recent earnings release, Beam said it is still working on enrolling its first patient for the trial, dubbed BEACON-101, by year-end. The company announced in its Q3 update that it's pushing back plans to file an IND in 2022 for BEAM-10;28.25;;44.11000061035156;;58.349998474121094;;;;26.260000228881836;– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 –SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of illness due to influenza A. PENINSULA is the first Phase 2 outpatient trial to evaluate the role of a;15.880000114440918;;7.159999847412109;;9.1899995803833;;38.81999969482422;;33.75;;52.40999984741211;;10.600000381469727;;24.170000076293945;;15.3100004196167;;25.979999542236328;
